<SEC-DOCUMENT>0001493152-25-010136.txt : 20250313
<SEC-HEADER>0001493152-25-010136.hdr.sgml : 20250313
<ACCEPTANCE-DATETIME>20250313073040
ACCESSION NUMBER:		0001493152-25-010136
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		76
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250313
DATE AS OF CHANGE:		20250313

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Indaptus Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001857044
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				863158720
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40652
		FILM NUMBER:		25733840

	BUSINESS ADDRESS:	
		STREET 1:		3 COLUMBUS CIRCLE
		STREET 2:		15TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		(646) 427-2727

	MAIL ADDRESS:	
		STREET 1:		3 COLUMBUS CIRCLE
		STREET 2:		15TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Intec Parent Inc.
		DATE OF NAME CHANGE:	20210414
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:INDP="http://indaptusrx.com/20241231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2024%2D(with%2DECD%2Dand%2DCYD) -->
<!-- Field: Set; Name: xdx; ID: xdx_034_INDP_indaptusrx.com_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20240101_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_05C_edei%2D%2DEntityCentralIndexKey_0001857044 -->
<!-- Field: Set; Name: xdx; ID: xdx_076_XDX_Z%2D%2D\2025 OPERATIONS\EDGAR\03 MARCH\INDAPTUS THERAPEUTICS, INC\03%2D02%2D2025\Form 10%2DK__December 31, 2024\Draft\Production\form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_065_EUR_0_iso4217%2D%2DEUR -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_sqft_0_utr%2D%2Dsqft -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_061_Integer_0_Integer -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000004" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000005" name="dei:EntityCentralIndexKey">0001857044</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0037" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0038" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0039" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0040" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl0084" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl0117" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl0120" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2024-12-31" id="xdx2ixbrl0126" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-12-31" id="xdx2ixbrl0127" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31" id="xdx2ixbrl0151" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31" id="xdx2ixbrl0152" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0225" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0228" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0242" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0244" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0245" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0248" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0249" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0250" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0254" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0255" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0256" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0260" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0261" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0263" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0269" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0277" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0282" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0284" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0285" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0290" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0291" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="INDP:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="INDP:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0299" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="INDP:StockIssuedDuringPeriodValueNewIssuesTwo" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="INDP:StockIssuedDuringPeriodValueNewIssuesTwo" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0307" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0312" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0321" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0329" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="INDP:InterestEarnedOnMarketableSecurities" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0349" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0370" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0373" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0376" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0386" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="INDP:LeaseRenewalOptionExercise" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="INDP:TransactionCostsInAccountsPayableAndOtherCurrentLiabilities" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0407" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="INDP:ChangeInAccumulatedOtherComprehensiveIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0409" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="INDP:DelawareFranchiseTaxesPayableCurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl0514" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0539" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0543" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-12-31" id="xdx2ixbrl0551" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2024-12-31" id="xdx2ixbrl0559" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="AsOf2024-12-31" id="xdx2ixbrl0567" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl0770" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl0840" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl0841" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0867" decimals="INF" unitRef="Integer">1</ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="indp-20241231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-01-01to2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-01-31_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-012025-02-28_custom_EquityPurchaseAgreementsMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">INDP:EquityPurchaseAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-01</xbrli:startDate>
        <xbrli:endDate>2025-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PropertyPlantAndEquipmentMember_custom_ComputersAndOtherOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">INDP:ComputersAndOtherOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PropertyPlantAndEquipmentMember_custom_FurnitureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">INDP:FurnitureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExercisePriceRangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">INDP:ExercisePriceRangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExercisePriceRangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">INDP:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExercisePriceRangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">INDP:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ExercisePriceRangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">INDP:ExercisePriceRangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ExercisePriceRangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">INDP:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ExercisePriceRangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">INDP:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember9626531">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-01_custom_AtTheMarketOfferingAgreementMember_custom_HCWainwrightAndCoLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">INDP:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">INDP:HCWainwrightAndCoLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_AtTheMarketOfferingAgreementMember_custom_HCWainwrightAndCoLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">INDP:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">INDP:HCWainwrightAndCoLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-06_custom_AtTheMarketOfferingAgreementMember_custom_HCWainwrightAndCoLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">INDP:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">INDP:HCWainwrightAndCoLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-08_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-08_us-gaap_WarrantMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-08_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-082024-08-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-08</xbrli:startDate>
        <xbrli:endDate>2024-08-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-22_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-22_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-222024-11-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-22</xbrli:startDate>
        <xbrli:endDate>2024-11-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-16_us-gaap_InvestorMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-16_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-16_us-gaap_WarrantMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-162025-01-16_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-16</xbrli:startDate>
        <xbrli:endDate>2025-01-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-11_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-122025-02-12_custom_YorkvilleMember_custom_StandbyEquityPurchaseAgreementsMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">INDP:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">INDP:StandbyEquityPurchaseAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-12</xbrli:startDate>
        <xbrli:endDate>2025-02-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-122025-02-12_custom_YorkvilleMember_custom_StandbyEquityPurchaseAgreementsMember_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">INDP:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">INDP:StandbyEquityPurchaseAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-12</xbrli:startDate>
        <xbrli:endDate>2025-02-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-122025-02-12_custom_ExchangeCapMember_custom_YorkvilleMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">INDP:ExchangeCapMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">INDP:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-12</xbrli:startDate>
        <xbrli:endDate>2025-02-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-12_custom_StandbyEquityPurchaseAgreementsMember_custom_YorkvilleMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">INDP:StandbyEquityPurchaseAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">INDP:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-122025-02-12_custom_YorkvilleMember_custom_StandbyEquityPurchaseAgreementsMember_srt_MaximumMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">INDP:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">INDP:StandbyEquityPurchaseAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-12</xbrli:startDate>
        <xbrli:endDate>2025-02-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-10-01_stpr_CA_custom_TwoYearLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">INDP:TwoYearLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-10-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-10-01_stpr_CA_custom_TwoYearLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">INDP:TwoYearLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-192023-04-19">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-19</xbrli:startDate>
        <xbrli:endDate>2023-04-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-19">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_FederalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">INDP:FederalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_StateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">INDP:StateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExpireInTwoThousandThirtySixMember_custom_FederalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">INDP:ExpireInTwoThousandThirtySixMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">INDP:FederalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_IndefinitePeriodMember_custom_FederalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">INDP:IndefinitePeriodMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">INDP:FederalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExpireInTwoThousandThirtyFiveMember_custom_StateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">INDP:ExpireInTwoThousandThirtyFiveMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">INDP:StateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_country_IL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ExternalResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">INDP:ExternalResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ExternalResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">INDP:ExternalResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_InternalPersonnelCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">INDP:InternalPersonnelCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_InternalPersonnelCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">INDP:InternalPersonnelCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001857044</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="EUR">
      <xbrli:measure>iso4217:EUR</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="sqft">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Integer">
      <xbrli:measure>INDP:Integer</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_900_edei--DocumentType_c20240101__20241231_zoyZY2Pa8bGf"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000014" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Mark
One)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--DocumentAnnualReport_c20240101__20241231_zV0YzBWxJDp1"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000015" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span>
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fiscal year ended <span id="xdx_90A_edei--DocumentPeriodEndDate_c20240101__20241231_zhRHBGHwfar3"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayyearen" id="Fact000016" name="dei:DocumentPeriodEndDate"><span id="xdx_909_edei--CurrentFiscalYearEndDate_c20240101__20241231_zKxnthubQe99"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayen" id="Fact000017" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, <span id="xdx_90E_edei--DocumentFiscalYearFocus_c20240101__20241231_zJhBnVaVzrS1"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000018" name="dei:DocumentFiscalYearFocus">2024</ix:nonNumeric></span></ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OR</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--DocumentTransitionReport_c20240101__20241231_zfpHArjkYdNb"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000019" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the transition period from to</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
File Number <span id="xdx_90B_edei--EntityFileNumber_c20240101__20241231_zWcKkER0SNEk"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000020" name="dei:EntityFileNumber">001-40652</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_902_edei--EntityRegistrantName_c20240101__20241231_zy2ioflsQpV1"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000021" name="dei:EntityRegistrantName">INDAPTUS
THERAPEUTICS, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of Registrant as specified in its Charter)</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 12pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityIncorporationStateCountryCode_c20240101__20241231_zwc7gQ1LvQ51"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:stateprovnameen" id="Fact000022" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 12pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 12pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityTaxIdentificationNumber_c20240101__20241231_ztqkvgwNmcf2"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000023" name="dei:EntityTaxIdentificationNumber">86-3158720</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
        or other jurisdiction</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
    incorporation or organization)</b></span></p></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(I.R.S.
        Employer</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification
    No.)</b></span></p></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; width: 49%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--EntityAddressAddressLine1_c20240101__20241231_z8S6iKSymMfb"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000024" name="dei:EntityAddressAddressLine1">3
Columbus Circle</ix:nonNumeric></span> <span id="xdx_902_edei--EntityAddressAddressLine2_c20240101__20241231_zvjFPnngBYb6"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000025" name="dei:EntityAddressAddressLine2">15th Floor</ix:nonNumeric></span> <span id="xdx_90D_edei--EntityAddressCityOrTown_c20240101__20241231_znGksMoXCLF2"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000026" name="dei:EntityAddressCityOrTown">New York</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressStateOrProvince_c20240101__20241231_zDFIpOL5dzBb"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000027" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span></b></span></p></td>
    <td style="font: 12pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 12pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--EntityAddressPostalZipCode_c20240101__20241231_z2RdHa9U2MAa"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000028" name="dei:EntityAddressPostalZipCode">10019</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address
    of principal executive offices)</b></span></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Zip
    Code)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>Registrant&#8217;s
telephone number, including area code: +<span id="xdx_905_edei--CityAreaCode_c20240101__20241231_zhNWlfUBoA3j"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000029" name="dei:CityAreaCode">(646)</ix:nonNumeric></span> <span id="xdx_90A_edei--LocalPhoneNumber_c20240101__20241231_zMT6ex0ZogPj"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000030" name="dei:LocalPhoneNumber">427-2727</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered pursuant to Section 12(b) of the Act:</b></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--Security12bTitle_c20240101__20241231_zr4xrIWuIJxe" title="Title of 12(b) Security"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000032" name="dei:Security12bTitle">Common
    stock, par value $0.01</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--TradingSymbol_c20240101__20241231_z6niGo0A5E6g" title="Trading Symbol"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000034" name="dei:TradingSymbol">INDP</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--SecurityExchangeName_c20240101__20241231_zCizqBJ1aVrh" title="Security Exchange Name"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:exchnameen" id="Fact000036" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    Capital Market</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Title of each class)</b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Name of each exchange
    on which registered)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered pursuant to Section 12(g) of the Act:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>None</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES &#9744; <span id="xdx_908_edei--EntityWellKnownSeasonedIssuer_c20240101__20241231_zFEst5TRC72h"><span style="-sec-ix-hidden: xdx2ixbrl0037">NO</span></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. YES &#9744; <span id="xdx_90C_edei--EntityVoluntaryFilers_c20240101__20241231_zgqgztvyXvSb"><span style="-sec-ix-hidden: xdx2ixbrl0038">NO</span></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_902_edei--EntityCurrentReportingStatus_c20240101__20241231_zn7STVGnW6V8"><span style="-sec-ix-hidden: xdx2ixbrl0039">YES</span></span> &#9746; NO &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the Registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant
was required to submit such files). <span id="xdx_907_edei--EntityInteractiveDataCurrent_c20240101__20241231_zYejRN1G2j2"><span style="-sec-ix-hidden: xdx2ixbrl0040">YES</span></span> &#9746; NO &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,
or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller
reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</span></td>
    <td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td>
    <td style="width: 15%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--EntityFilerCategory_c20240101__20241231_zUN6R4vkJ2Yb"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000041" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--EntitySmallBusiness_c20240101__20241231_zVoB1aKl84gc"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000042" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--EntityEmergingGrowthCompany_c20240101__20241231_zYZ3qENU0Z74"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000043" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <span id="xdx_903_edei--IcfrAuditorAttestationFlag_c20240101__20241231_zT3ezWD2t8J"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000044" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. <span id="xdx_905_edei--DocumentFinStmtErrorCorrectionFlag_c20240101__20241231_zP5VSk7mJCoa"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000045" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b). &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES &#9744; <span id="xdx_908_edei--EntityShellCompany_c20240101__20241231_zJldQRQcDDah"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000046" name="dei:EntityShellCompany">NO</ix:nonNumeric></span> <span id="xdx_906_edei--EntityShellCompany_dbF_c20240101__20241231_zXI6E7P0pgdh"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000047" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2024, the last business day of the Registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value
of the voting and non-voting common equity held by non-affiliates of the Registrant was $<span id="xdx_909_edei--EntityPublicFloat_iI_c20240630_zyyq5gMb1Jpb"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2024-06-30" id="Fact000048" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,039,986</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of Registrant&#8217;s common stock outstanding as of March 12, 2025 was <span id="xdx_902_edei--EntityCommonStockSharesOutstanding_iI_c20250312_z6TrABYYYDUh"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-03-12" id="Fact000049" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,429,244</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">DOCUMENTS
INCORPORATED BY REFERENCE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--DocumentsIncorporatedByReferenceTextBlock_c20240101__20241231_z0upxjkQ1rj2" title="Documents Incorporated by Reference"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000051" name="dei:DocumentsIncorporatedByReferenceTextBlock">None.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Table
    of Contents</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">PART
    I</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001">Business</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#v_001">Risk
    Factors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_001">Unresolved
    Staff Comments</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_002">Cybersecurity</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_003">Properties</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_004">Legal
    Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_005">Mine
    Safety Disclosures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_006">PART
    II</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_007">Market
    for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_008">[Reserved]</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_009">Management&#8217;s
    Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_010">Quantitative
    and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_011">Financial
    Statements and Supplementary Data</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_012">Changes
    in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_013">Controls
    and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_014">Other
    Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">72<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_015">Disclosure
    Regarding Foreign Jurisdictions that Prevent Inspections</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_016">PART
    III</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_017">Directors,
    Executive Officers and Corporate Governance</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    11.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#aj_001">Executive
    Compensation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#aj_002">Security
    Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">91</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#aj_003">Certain
    Relationships and Related Transactions, and Director Independence</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">93</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#aj_004">Principal
    Accountant Fees and Services</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#aj_005">PART
    IV</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#aj_006">Exhibits
    and Financial Statement Schedules</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#aj_007">Form
    10-K Summary</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ABOUT
THIS ANNUAL REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Indaptus Therapeutics&#8221;, &#8220;Indaptus&#8221;, &#8220;the
Company&#8221; and &#8220;our company&#8221;, in this Annual Report on Form 10- K, or our Annual Report, are to Indaptus Therapeutics,
Inc. (formerly Intec Parent, Inc.) and, where appropriate, its consolidated subsidiaries, Intec Pharma Ltd. and Decoy Biosystems, Inc.
All references to &#8220;common stock&#8221; and &#8220;share capital&#8221; refer to common stock and share capital of Indaptus. Our
historical results do not necessarily indicate our expected results for any future periods. Any discrepancies in any table between totals
and sums of the amounts listed are due to rounding. Unless otherwise indicated, or the context otherwise requires, references in this
Annual Report to financial and operational data for a particular year refer to the fiscal year of our Company ended December 31 of that
year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXPLANATORY
NOTE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
data and certain industry data and forecasts used throughout this Annual Report were obtained from market research databases, consultant
surveys commissioned by us, publicly available information, reports of governmental agencies and industry publications and surveys. Industry
surveys, publications, consultant surveys commissioned by us and forecasts generally state that the information contained therein has
been obtained from sources believed to be reliable. We have relied on certain data from third-party sources, including internal surveys,
industry forecasts and market research, which we believe to be reliable based on our management&#8217;s knowledge of the industry. Statements
as to our market position are based on the most currently available data. While we are not aware of any misstatements regarding the industry
data presented in this Annual Report, our estimates involve risks and uncertainties and are subject to change based on various factors,
including those discussed under Part I. Item 1A. &#8220;Risk Factors&#8221; in this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report contains, and management may make, certain forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements other than statements of historical facts contained in this Annual Report on Form 10-K are forward-looking
statements. In some cases, forward-looking statements can be identified by the use of terms such as &#8220;believe,&#8221; &#8220;expect,&#8221;
&#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;might,&#8221;
&#8220;seek,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;project,&#8221; &#8220;forecast,&#8221; &#8220;continue&#8221; or
their negatives or variations of these words or other comparable words. These statements include, without limitation, our statements
about: our product candidates&#8217; development, including the timing and design of the Phase 1 clinical trial of Decoy20; our expectations
regarding the recommended Phase 2 dose for subsequent multi-dosing and combination studies and related timing; the anticipated effects
of our product candidates; our plans to develop and commercialize our product candidates; the market potential and treatment potential
of our product candidates, including Decoy20; our commercialization, marketing and manufacturing capabilities and strategy; our expectations
about the willingness of healthcare professionals to use our product candidates; our general business strategy and the plans and objectives
of management for future operations; our research and development activities and costs; our future results of operations and condition;
the sufficiency of our cash and cash equivalents to fund our ongoing activities; the impact of current macroeconomic conditions on our
operations, ability to access capital, and liquidity; and any impact of a pandemic, epidemic or other future health crisis on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
forward-looking statements in this Annual Report are only predictions and are based largely on our current expectations and projections
about future events and financial trends that we believe may affect our business, financial condition and results of operations. These
forward-looking statements speak only as of the date of this Annual Report and are subject to a number of known and unknown risks, uncertainties
and assumptions, including those described under the sections in this Annual Report entitled &#8220;Summary Risk Factors,&#8221; Part
I. Item 1A. &#8220;Risk Factors&#8221; and Part II. Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition
and Results of Operations&#8221; and elsewhere in this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Because
forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some
of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events
and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially
from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties
may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Except
as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as
a result of any new information, future events, changed circumstances or otherwise. We intend the forward-looking statements contained
in this Annual Report to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities
Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Summary
Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal factors and uncertainties that make investing in our common stock risky, include, among others:</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are a clinical-stage
    company with a limited operating history. We are not currently profitable, do not expect to become profitable in the near future
    and may never become profitable.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have identified conditions
    and events that raise substantial doubt regarding our ability to continue as going concern.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given our lack of current
    cash flow, we will need to raise additional capital. If we are unable to raise a sufficient amount of capital when needed on acceptable
    terms or at all, we may be forced to delay, limit or eliminate some or all of our research programs, product development activities
    and commercialization efforts.</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raising additional capital
    would cause dilution to our existing shareholders and may restrict our operations or require us to relinquish rights to our technologies
    or product candidates.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical and preclinical
    development involves lengthy and expensive processes with uncertain outcomes. Any difficulties or delays in the commencement or completion,
    or the termination or suspension, of our current or planned clinical trials could result in increased costs to us, delay or limit
    our ability to generate revenue or adversely affect our commercial prospects.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We expect to continue to
    incur significant research and development expenses and other operating expenses, which may make it difficult for us to attain profitability.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may expend our limited
    resources to pursue a limited number of research programs, product candidates and specific indications and fail to capitalize on
    product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our product candidates
    may cause undesirable side effects that could delay or prevent their regulatory approval or commercialization or have other significant
    adverse implications on our business, financial condition and results of operations.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The commercial success
    of our product candidates depends upon their market acceptance among physicians, patients, healthcare payors and the medical community.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We rely on third parties
    to conduct our preclinical studies and clinical trials and perform other tasks. If these third parties do not successfully carry
    out their contractual duties, meet expected deadlines, or comply with regulatory requirements, we may not be able to obtain regulatory
    approval for or commercialize our product candidates and our business, financial condition and results of operations could be substantially
    harmed.</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We currently rely on third
    parties for the manufacture of our product candidates during clinical development, and expect to continue to rely on third parties
    for the foreseeable future. This reliance on third parties increases the risk that we will not have sufficient quantities of our
    product candidates, or such quantities at an acceptable cost, which could delay, prevent or impair our development or potential commercialization
    efforts.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The successful commercialization
    of Decoy20 or any future product candidates, if approved, will depend in part on the extent to which governmental authorities and
    health insurers establish coverage, adequate reimbursement levels and favorable pricing policies. Failure to obtain or maintain coverage
    and adequate reimbursement for our products could limit our ability to market those products and decrease our ability to generate
    revenue.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently enacted legislation,
    future legislation and healthcare reform measures may increase the difficulty and cost for us to obtain marketing approval for and
    commercialize Decoy20 and any future product candidates and may affect the prices we may set.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If our competitors have
    product candidates that are approved faster, marketed more effectively, are better tolerated, have a more favorable safety profile
    or are demonstrated to be more effective than our product candidates, our commercial opportunity may be adversely affected.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any product candidates
    for which we intend to seek approval as biologic products may face competition sooner than anticipated.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be able to adequately
    protect our proprietary or licensed technology in the marketplace.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be successful
    in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are subject to various
    U.S. federal, state and foreign healthcare laws and regulations, which could increase compliance costs, and our failure to comply
    with these laws and regulations could harm our results of operations and financial condition.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actual or perceived failures
    to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely
    affect our business, results of operations, and financial condition.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our business and operations
    may suffer in the event of information technology system failures, cyberattacks or deficiencies in our cybersecurity.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maintaining and improving
    our financial controls and the requirements of being a public company may strain our resources, divert management&#8217;s attention
    and affect our ability to attract and retain qualified board members.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unfavorable global economic
    conditions could adversely affect our business, financial condition or results of operations.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The market price of our
    common stock is volatile and you may sustain a complete loss of your investment.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="a_002"></span>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_001"></span>Item
1. Business.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Overview</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical biotechnology company developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy.
We have evolved from more than a century of immunotherapy advances. Our approach is based on the hypothesis that efficient activation
of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package
of immune system activating signals that can be administered safely intravenously. Our patented technology is composed of single strains
of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability
to prime or activate many of the cellular components of innate and adaptive immunity. This approach has led to broad anti-tumor and anti-viral
activity in preclinical models, including durable anti-tumor response synergy observed with each of four different classes of existing
agents, including NSAIDs, checkpoint therapy, targeted antibody therapy and low-dose chemotherapy. Tumor eradication by our technology
was associated with induction of both innate and adaptive immunological memory and, importantly, did not require provision of or targeting
a tumor antigen in preclinical models. We have carried out successful current Good Manufacturing Practice (cGMP) manufacturing of our
lead clinical candidate, Decoy20.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2022, the U.S. Food and Drug Administration, or the FDA, allowed us to proceed under our IND for a Phase 1 clinical trial in patients
with advanced solid tumors where currently approved therapies have failed. In December 2022, we initiated an open label, multi-center,
dose escalation and expansion, single arm (monotherapy) Phase 1 study conducted in 2 parts. The Phase 1 study began with single dose
administration and has now been followed with continuous weekly dosing of Decoy20 in tumor-specific expansion cohorts. The study is enrolling
patients with any one of six advanced/metastatic solid tumors, who have exhausted approved treatment options. The study&#8217;s objectives
are to assess the safety and tolerability of Decoy20, to determine the maximum tolerated dose, the optimal biologically active and recommended
Phase 2 dose, as well as to assess Decoy20 pharmacokinetics (PK), pharmacodynamics and clinical activity. The primary endpoints of the
study are incidence, relatedness and severity of adverse events and treatment-emergent adverse events and determining the number of subjects
per cohort with dose limiting toxicity-based adverse events. Secondary endpoints include the incidence of anti-drug antibodies and neutralizing
antibodies pre- and post-treatment, change in Decoy20 PK parameters over time, objective response rate and duration of response.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2023, we evaluated the first four patients who received a single dose of 7 x 10&#x5E;7 Decoy20 in Part 1 of the Phase 1 clinical trial.
All four patients who enrolled were evaluable in the first cohort. These patients experienced generally anticipated transient adverse
events including hemodynamic changes such as changes in pulse or blood pressure that resolved within 30 minutes and laboratory abnormalities
such as grade 1-3 elevations in transaminases (liver function tests) and grade 4 reductions in lymphocytes that generally resolved within
three days. One patient had a dose-limiting toxicity of grade 3 bradycardia (slow heart rate) and grade 2 hypotension (low blood pressure)
which resolved within approximately 90 minutes with i.v. fluids. Patients also experienced transient induction of over 50 different biomarkers
associated with innate and adaptive anti-tumor immune responses. After the end of infusion, Decoy20 was cleared from the blood within
30 to 120 minutes. Peak cytokine and chemokine induction occurred within ~4 to 24 hours and most cytokine/chemokines returned to the
patient&#8217;s respective baseline by 24-72 hours. This rapid clearance and associated transient cytokine/chemokine induction are desired
to avoid prolonged toxicity, often associated with longer term cytokine exposure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2023, we began the second cohort of the Phase 1 clinical trial after receiving authorization from the Safety Review Committee.
The second cohort dose was a reduction from 7 x 10&#x5E;7 Decoy20 dose to 3 x 10&#x5E;7 Decoy20. In March 2024, we completed the second cohort
of patients who received a single dose of 3 x 10&#x5E;7 Decoy20 in Part 1 of the clinical trial Patients on the second (lower dose) cohort
experienced adverse events similar in frequency and severity to the higher dose cohort with one dose-limiting toxicity of grade 3 ALT
elevation that required one week to resolve. Pharmacodynamic effects included transient induction of multiple biomarkers. Clearance of
Decoy20 was similarly rapid. Following authorization from the Safety Review Committee, we advanced into the weekly dosing part of the
trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May and June 2024, we enrolled two additional patients in the first cohort who received a single dose of 7 x 10&#x5E;7 Decoy20, and in August
2024 we received the authorization from the Safety Review Committee to initiate the weekly dosing with 7 x 10&#x5E;7 Decoy20.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of October 2024, we completed one month of the weekly dosing part in the first six patients at the 3 x 10&#x5E;7 Decoy20 dose and following
the review of the safety data by the Safety Review Committee we received the authorization to initiate unrestricted enrollment of patients
at the 3 x 10&#x5E;7 Decoy20 dose. As of March 12, 2025, we have enrolled more than 20 patients in the weekly dosing among the two Decoy20 dose levels
and we have observed early signs of potential benefits emerging with some patients with stable disease. We are working to increase the
number of trial sites to accelerate patient enrollment and data collection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2024, we entered into a clinical supply agreement, or the Supply Agreement, with BeiGene Switzerland GmbH, or BeiGene, to advance
clinical evaluation of Decoy20 in combination with BeiGene&#8217;s anti-PD-1 antibody, tislelizumab, or the BeiGene Product, for the
treatment of patients with advanced solid tumors, or the Combination Study. This Combination Study builds on preclinical results where
Decoy20, combined with a PD-1 inhibitor, demonstrated high tumor eradication rates and established immunological memory. We intend to
seek approval from the FDA to initiate the Combination Study, which is anticipated to begin in 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the Supply Agreement, we will pay for all costs associated with the Combination Study (other than the cost of the BeiGene
Product), BeiGene will supply the BeiGene Product to us for the purposes of the study, and we will supply Decoy20 for the purposes of
the Combination Study. The Supply Agreement will terminate upon the earlier of (i) the one-year anniversary of the date that we provide
BeiGene with the Combination Study&#8217;s final clinical study report or (ii) the date of termination of the Combination Study, subject
to early termination in certain circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2025, we announced that we received clinical trial authorization from Health Canada to initiate a clinical trial for Decoy20
which allows us to expand our ongoing U.S. clinical trial to Canadian sites. The trial will enroll patients in Canada under the current
protocol, which involves weekly dosing of Decoy20. We also plan to submit an amendment to Health Canada to initiate the Combination Study
in Canada.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unlike
many competitor products, our technology does not depend on targeting with or to a specific antigen, providing broad potential across
multiple indications. Our products are designed to have a much shorter half-life and produce less systemic exposure than small molecule,
antibody or human cell-based therapies, potentially reducing the risk of non-specific auto-immune reactions. Our technology has produced
single agent activity and/or combination therapy-based durable responses in lymphoma, hepatocellular, colorectal and pancreatic tumors
and has also showed activity against hepatitis B virus (HBV) and HIV infection in standard preclinical models. Our target indications
include, but are not limited to, colorectal, hepatocellular (&#177; HBV), bladder, cervical and pancreatic carcinoma, which according
to GLOBOCAN 2020, account in the aggregate for 23% of yearly cancer cases and over 28% of yearly cancer deaths world-wide.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
we have operated virtually with a team of highly experienced consultants and advisors, carrying out research and development at contract
research organizations (CROs). We have developed patented treatment methods (and associated patented compositions) for attenuation and
killing of non-pathogenic, Gram-negative bacteria (34 issued or granted patents). Since our inception, we have funded our operations
primarily through public and private offerings of our equity securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recent
Developments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>February
2025 Equity Line</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
February 12, 2025, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we <span style="background-color: white">entered
into a Standby Equity Purchase </span>Agreement, or the SEPA with YA II PN, LTD., a Cayman Islands exempt limited company, or
Yorkville. Pursuant to the SEPA, we have the right, but not the obligation, to sell to Yorkville from time to time up to $20.0
million of our <span style="color: #212529; background-color: white">common stock, </span>during the 36 months following the
execution of the Purchase Agreement, subject to the restrictions and satisfaction of the conditions in the SEPA. At our option, the
shares of common stock would be purchased by Yorkville from time to time at a price equal to 97% of the lowest of the three daily
VWAPs during a three consecutive trading day period commencing on the date that we, subject to certain limitations, deliver a notice
to Yorkville that the Company is committing Yorkville to purchase such shares of common stock. We may also specify a certain minimum
acceptable price per share in each Advance. As consideration for Yorkville&#8217;s irrevocable commitment to purchase our shares, we
issued to Yorkville 305,960 shares of common stock. Under the applicable rules of Nasdaq and pursuant to the SEPA, in no event may
we issue or sell to Yorkville more than 2,823,244 shares of common stock, or the Exchange Cap, which is 19.99% of the shares of
common stock outstanding immediately prior to the execution of the SEPA, unless (i) we obtain stockholder approval to issue shares
of common stock in excess of the Exchange Cap or (ii) the average price of all applicable sales of common stock under the SEPA
equals or exceeds $0.81722 per share (which represents the lower of (i) the Nasdaq Official Closing Price (as reflected on
Nasdaq.com) on the trading day immediately preceding the effective date or (ii) the average Nasdaq Official Closing Price of the
common stock (as reflected on Nasdaq.com) for the five trading days immediately preceding the effective date). In addition,
effective February 12, 2025, we terminated the purchase agreement that we entered into with Lincoln Park Capital Fund, LLC in
December 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>January
2025 Financing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 12, 2025, we entered into securities purchase agreements, or the January 2025 Purchase Agreements, with certain institutional
and accredited investors, or the January 2025 Purchasers. The January 2025 Purchase Agreements provide for the sale and issuance by us
of an aggregate of: (i) 2,109,383 shares of our common stock and (ii) warrants to purchase 2,109,383 shares of common stock in a private
placement, or the January 2025 Warrants. The shares and January 2025 Warrants were sold on a combined basis for consideration of $1.065
for one share and a January 2025 Warrant. The exercise price of the January 2025 Warrants is $0.94 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
January 2025 Warrants were immediately exercisable upon issuance and will expire five years following the date of issuance. The January
2025 Warrants contain standard adjustments to the exercise price including for stock splits, stock dividends and reorganizations. In
lieu of making the cash payment otherwise contemplated to be made upon exercise in payment of the aggregate exercise price, the holder
may, in the event the shares underlying the January 2025 Warrants are not registered under the Securities Act, elect instead to receive
upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth
in the January 2025 Warrants. Under the terms of the January 2025 Warrants, a holder (together with its affiliates) may not exercise
any portion of its January 2025 Warrant to the extent that the holder would beneficially own more than 4.99% or 9.99%, depending on the
individual investor, of the outstanding common stock immediately after exercise, or the Beneficial Ownership Limitation, except that
upon at least 61 days&#8217; prior notice from the holder to us, the holder may increase the Beneficial Ownership Limitation, provided
that the Beneficial Ownership Limitation in no event exceeds 19.99%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paulson
Investment Company, LLC, or Paulson, served as the exclusive placement agent for the issuance and sale of the securities. As compensation
for such placement agent services, we paid Paulson an aggregate cash fee equal to 7.0% of the gross proceeds received by us from the
offering, and a non-accountable expense of $25,000. As additional compensation to Paulson, we issued to the Paulson (or its designees)
a warrant, or the January 2025 Placement Agent Warrants, to purchase an aggregate of 147,656 shares at an exercise price per share equal
to $1.175 per share. The January 2025 Placement Agent Warrants are exercisable six months from the date of issuance and expire on the
fifth anniversary of the issue date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>November
2024 Financing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 22, 2024, we entered into securities purchase agreements, or the November 2024 Purchase Agreements, with certain institutional
and accredited investors, or the November 2024 Purchasers. The November 2024 Purchase Agreements provide for the sale and issuance by
us of an aggregate of: (i) 1,817,017 shares of our common stock in a registered direct offering and (ii) warrants to purchase 1,817,017
shares of common stock in a private placement, or the November 2024 Warrants. The shares and November 2024 Warrants were sold on a combined
basis for consideration of $1.175 for one share and a November 2024 Warrant. The exercise price of the November 2024 Warrants is $1.05
per share. One of the November 2024 Purchasers was our Chief Executive Officer, who purchased 42,553 shares and November 2024 Warrants
to purchase 42,553 shares, or the Affiliate Securities, at the same price and upon the same terms as the other November 2024 Purchasers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
November 2024 Warrants were immediately exercisable upon issuance and will expire five years following the date of issuance. The November
2024 Warrants contain standard adjustments to the exercise price including for stock splits, stock dividends and reorganizations. In
lieu of making the cash payment otherwise contemplated to be made upon exercise in payment of the aggregate exercise price, the holder
may, in the event the shares underlying the November 2024 Warrants are not registered under the Securities Act, elect instead to receive
upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth
in the November 2024 Warrants. Under the terms of the November 2024 Warrants, a holder (together with its affiliates) may not exercise
any portion of its November 2024 Warrant to the extent that the holder would beneficially own more than the Beneficial Ownership Limitation,
except that upon at least 61 days&#8217; prior notice from the holder to us, the holder may increase the Beneficial Ownership Limitation,
provided that the Beneficial Ownership Limitation in no event exceeds 19.99%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paulson
served as the exclusive placement agent for the issuance and sale of the securities. As compensation for such placement agent services,
we paid Paulson an aggregate cash fee equal to 7.0% of the gross proceeds received by us from the offering (excluding the Affiliate Securities),
and a non-accountable expense of $25,000. As additional compensation to Paulson, we issued to the Paulson (or its designees) a warrant,
or the November 2024 Placement Agent Warrants, to purchase an aggregate of 124,212 shares at an exercise price per share equal to $1.3125
per share. The November 2024 Placement Agent Warrants are exercisable six months from the date of issuance and expire on the fifth anniversary
of the issue date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supply
Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 17, 2024, we entered into a clinical supply agreement, or the Supply Agreement, with BeiGene Switzerland GmbH, or BeiGene, to
advance clinical evaluation of Decoy20, our novel product candidate designed to induce a broad immune response to fight cancer, in combination
with BeiGene&#8217;s anti-PD-1 antibody, tislelizumab, or the BeiGene Product, for the treatment of patients with advanced solid tumors,
or the Combination Study. We intend to seek approval from the FDA to initiate the Combination Study, which is anticipated to begin in
2025. Under the terms of the Supply Agreement, we will pay for all costs associated with the Combination Study (other than the cost of
the BeiGene Product), BeiGene will supply the BeiGene Product to us for the purposes of the study, and we will supply Decoy20 for the
purposes of the Combination Study. The Supply Agreement will terminate upon the earlier of (i) the one-year anniversary of the date that
we provide BeiGene with the Combination Study&#8217;s final clinical study report or (ii) the date of termination of the Combination
Study, subject to early termination in certain circumstances</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>August
2024 Financing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 8, 2024, we completed a registered direct offering, pursuant to which we sold and issued to certain investors, including one of
our officers, 1,643,837 shares of common stock. In addition, in a concurrent private placement, we issued to the investors unregistered
warrants to purchase 1,643,837 shares of common stock, or the August 2024 Private Placement. The warrants were immediately exercisable
at an exercise price of $1.70 per share and expire five years from the date of issuance. The combined purchase price for one share of
common stock and one warrant was $1.825, resulting in gross proceeds of approximately $3.0 million, before deducting placement agent
and other offering expenses in the amount of approximately $0.5 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Background</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approved
immunotherapies, such as Interluekin-2, Interferon-alpha and the more recently approved &#8220;checkpoint&#8221; and CAR-T therapies
produce durable responses in a few percent to about fifty percent of patients across about a dozen out of over one hundred different
types of cancer. Although checkpoint therapies are able to effectively cure many previously incurable patients, only about 15% of patients
receiving this type of therapy respond. The main limitation of existing immunotherapies is that they each activate only one or a small
number of key steps in either the innate or adaptive immune system, but there is general agreement that highly efficient cancer immunotherapy
will require activation of both innate and adaptive immunity. The human body&#8217;s innate and adaptive immune systems are each capable
of cell-mediated destruction of tumors if the tumor cells are recognized as foreign or damaged. Activation of innate and adaptive responses
is also dependent on immune cells sensing the presence of &#8220;danger.&#8221; The most potent immune cell activating danger signals
are released by bacteria and viruses in the setting of infection, and include agonists of immune cell receptors, such as Toll-Like (TLR),
NOD and STING. Bacterial danger signals, including TLR agonists are called pathogen-associated molecular patterns (PAMPs) and can activate
both innate and adaptive immune cells, including antigen-presenting cells, promoting innate (NK, macrophage) and adaptive (T cell-mediated)
destruction of tumors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
oldest form of cancer immunotherapy involves the provision of decoy danger signals from bacteria. It was based on the long-standing observation
of tumor regression in the setting of bacterial infection. Treatment of cancer patients with heat-killed bacteria (&#8220;Coley&#8217;s
toxins&#8221;) was established in 1891 and used for 70 years with significant success. For example, &#8805;5-year survival was reported
for 45% of 432 inoperable sarcoma, lymphoma, melanoma, and carcinoma patients. Despite this success, several limitations led to the abandonment
of this approach by the pharmaceutical industry. Although there was an indication that Coley&#8217;s toxins worked best when administered
intravenously (i.v.), it was too toxic when given by this route, limiting the approach to local administration, which produced highly
variable results. Another limitation was lack of knowledge about the mechanism of action, preventing optimization and standardization
of manufacturing, leading to another source of variability in clinical response. Due to this high variability, Coley&#8217;s toxins was
not grandfathered-in as an approved drug by the FDA in 1963 and was supplanted by radiation and chemotherapy, despite the fact that these
more modern approaches rarely produce durable responses in advanced cancer patients. Scientists now understand the mechanism of action
of Coley&#8217;s toxins. Gram-negative bacteria contain multiple immune-stimulating danger signals, including TLR agonists such as lipopolysaccharide
(LPS). Bacteria and purified or mono-specific TLR agonists, including LPS derivatives, have been validated and approved for prevention
and treatment of early stage cancer. However, a safe and effective TLR agonist-based approach for advanced cancer has been elusive, possibly
due to limitations in the ability of intratumorally administered, mono-specific TLR agonists to induce potent, systemic anti-tumor immune
responses. In addition, the intratumoral approach is not feasible with all tumor types or patients. Our hypothesis is that an effective
TLR agonist-based immunotherapy for advanced cancer will require invention of a packaged, multi-TLR agonist or multi-danger signal product
that is modified or attenuated to allow safe i.v. administration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Approach</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
patented approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor
immune responses can be achieved by using intact bacteria, containing multiple PAMPs, which have been attenuated so that they can be
administered safely intravenously. Because LPS appears to be the most important contributor to both toxicity and efficacy, our patented
product candidates are single strains of killed, non-pathogenic Gram-negative bacteria that have been treated in an effort to kill the
bacteria and significantly reduce, but not completely eliminate, the cell surface LPS-endotoxin activity. Our product candidates are
designed to have enhanced sufficient residual LPS to synergize with other PAMPs in the bacteria to efficiently prime innate and adaptive
immune pathways. This approach has led to broad anti-tumor and anti-viral activity in preclinical models, including durable anti-tumor
response synergy observed with each of four different classes of existing agents, including NSAIDs, checkpoint therapy, targeted antibody
therapy and low-dose chemotherapy. Tumor eradication by our technology is designed to produce both innate and adaptive immunological
memory and, importantly, not require provision of an exogenous tumor antigen, potentially due to the ability of LPS and other PAMPS to
activate dendritic cells that have already captured a tumor antigen.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
immune cells can participate in killing of tumors and viruses. As illustrated below, current therapies activate only one or a small subset
of both pathways and cure only a small percentage of patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_0001.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
technology, however, is designed to synergize with existing therapies to activate both innate and adaptive immune cells, inducing efficient
anti- tumor immune responses with a wide safety margin. Induction of adaptive anti-tumor immune responses and immunological memory by
our technology does not require an exogenous tumor antigen.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_0002.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Innate
and adaptive immune responses require identification of a tumor as foreign or not self. However, most steps required for migration and
activation of immune cells are unrelated to the tumor or are tumor non-specific. All innate and adaptive non-specific steps are induced
or promoted by immune system &#8220;danger signal&#8221; molecules, such as those found in our bacteria. Bacteria-derived danger signals
are also able to enhance the processing and recognition of tumor antigens, which are frequently present, but not &#8220;seen&#8221; by
the immune system.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-k_0003.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Results</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preclinical
Trials</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preclinical models, Indaptus treated bacteria induced less systemic toxicity than untreated bacteria but were still able to activate
innate and adaptive immune responses. Despite exhibiting reduced in vivo pyrogenicity and a higher maximally tolerated dose, our bacteria
were able to induce secretion of most cytokines and chemokines from mouse and human immune cells in vitro at levels comparable to those
seen with untreated bacteria. Our bacteria were also able to synergize with human immune cells to kill human tumor cells in vitro.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have observed significant single agent anti-tumor activity and/or combination therapy-mediated regression with durable responses in established
non-Hodgkin&#8217;s lymphoma, as well as colorectal, hepatocellular and pancreatic carcinoma in preclinical syngeneic and human tumor
xenograft models. Our bacteria synergized with each of four different classes of approved agents in preclinical models, including NSAIDs,
checkpoint therapy, targeted antibody therapy and low-dose chemotherapy to induce tumor regression, providing significant flexibility
for targeting of diverse types of cancer. Our technology is designed to eradicate tumors via activation of both innate (NK cell) and
adaptive (CD4+ and CD8+ T cell) mechanisms, with the goal of producing both innate and adaptive immunological memory. In our preclinical
studies, tumor eradication occurred at non-toxic doses of our bacteria, with a very wide (10 to &#8805;33-fold) therapeutic index. Notable
mechanism of action information has also been obtained, via gene expression analysis with treated tumors and plasma cytokine analysis,
demonstrating that our combination technology has the potential to turn &#8220;cold&#8221; tumors into &#8220;hot&#8221; tumors and induce,
activate or recruit innate and adaptive genes, cells and pathways. Immune cell pre-depletion studies have demonstrated that both innate
(NK) and adaptive (CD4 T and CD8 T) immune cells are involved in tumor eradication. We have also demonstrated significant single agent
activity against chronic Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infection in standard preclinical models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have carried out successful cGMP manufacturing and stability studies with our lead product candidate, Decoy20. In addition, IND-enabling
multi-dose toxicology studies have been completed and did not produce sustained induction of factors that are associated with cytokine
release syndrome.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_0004.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
chart above demonstrates that our bacteria synergize with Anti-PD-1 Checkpoint therapy to regress established mouse hepatocellular carcinoma
(HCC) Tumors. All mice (all groups) received a low-dose, non-steroidal anti-inflammatory drug (NSAID/Indomethacin), which increases the
number of regressions in the combination setting. Most regressions were durable, with 5/6 combination regressions stable through termination
at Day 91 and in a repeat experiment through termination at Day 143 (see next Figure below) (CR = complete response or complete regression).
The repeat experiment also produced 5/6 or 6/6 durable regressions per group over a 33-fold Indaptus concentration range and an absence
of safety concerns, demonstrating a very wide therapeutic index. Similar tumor eradication results have been obtained by combining our
bacteria with low-dose chemotherapy in a mouse non-Hodgkin&#8217;s lymphoma model. Eradication of established non-Hodgkin&#8217;s lymphoma
tumors by our technology has also been observed with human tumor xenografts, via activation of the innate immune system. Development
and preclinical efficacy characterization of a systemically administered multiple Toll-like receptor (TLR) agonist for antitumor immunotherapy
[abstract]. In: Proceedings of the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into
Survival&#894; Sept 30-Oct 3, 2018&#894; New York, NY. Philadelphia (PA): AACR&#894; Cancer Immunol Res 2019&#894;7(2 Suppl):Abstract
nr B178.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_0005.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
chart above illustrates that the synergistic tumor eradication by our technology and Anti-PD-1 produces immunological memory. Established
tumors were regressed in 11 mice by combination treatment as in the Figure above and then the mice were re-challenged with fresh HCC
tumor cells, without further treatment. All of the new tumors were rejected. Similar results have been obtained by combining our bacteria
with low-dose chemotherapy in a non-Hodgkin&#8217;s lymphoma model.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Clinical
Trial</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2022, the FDA allowed us to proceed under our IND application for a Phase 1 clinical trial in patients with advanced solid tumors
where currently approved therapies have failed, and in December 2022, we initiated this Phase 1 clinical trial which is an open label,
multi-center, dose escalation and expansion, single arm (monotherapy) study conducted in 2 parts. The Phase 1 study has begun with a
single dose escalation, which is planned to be followed by an expansion part with continuous weekly administration of Decoy20. The study
is enrolling patients with advanced/metastatic solid tumors, who have exhausted approved treatment options. The study&#8217;s objectives
are to assess the safety and tolerability of Decoy20, to determine the maximum tolerated dose and recommended Phase 2 dose, as well as
to assess Decoy20 pharmacokinetics PK, pharmacodynamics and clinical activity. The primary endpoint of the study is incidence, relatedness
and severity of adverse events and treatment-emergent adverse events and determining the number of subjects per cohort with dose limiting
toxicity-based adverse events. Secondary endpoints include the incidence of anti-drug antibodies and neutralizing antibodies pre- and
post-treatment, change in Decoy20 PK parameters over time, objective response rate in subjects with measurable disease and duration of
response.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2023, we completed the first cohort of patients who received a single dose in Part 1 of the Phase 1 clinical trial. Four patients
were enrolled and evaluable in the first cohort. Overall, patients experienced symptoms or adverse events (AEs) that were short-lived
and consistent with the mechanism of action of Decoy20. In September 2023, we advanced into the second cohort of the Phase 1 clinical
trial after receiving authorization from the Safety Review Committee. In early March 2024, we completed the second cohort of patients
who received a single dose in Part 1 of the Phase 1 clinical trial and, following authorization from the Safety Review Committee, advanced
into the multi-dosing cohort of the Phase 1 clinical trial. The second cohort dose was a reduction from the dosing in the first cohort
based on the significant pharmacodynamic effect seen with the first cohort and anticipated optimal Decoy20 safety profile for both multi-dosing
and combination approaches. <span style="color: #212529">In May 2024, we successfully dosed the first patient in the multi-dose portion
of the Phase I clinical trial with Decoy20. The primary goal of this stage of the trial was to evaluate the safety of Decoy20 when administered
multiple times to the same patient. We intend to progress Decoy20 into combination studies with a checkpoint inhibitor. In August 2024,
the Safety Review Committee convened to review the safety data at the higher Decoy20 dose with single dose administration and the safety
data at the lower Decoy20 dose with weekly administration. The data led to the decision to continue dosing additional patients at the
lower Decoy20 dose on a weekly schedule and initiate dosing patients at the higher Decoy20 dose on a weekly schedule. In October 2024,
the Safety Review Committee examined weekly administration data at the lower Decoy20 dose and cleared unrestricted enrollment of patients
at this dose. As of March 12, 2025, we have enrolled more than 20 patients in the weekly dosing among the two Decoy20 dose levels
and we have observed early signs of potential benefits emerging with some patients with stable disease. We are working to increase the
number of trial sites to accelerate patient enrollment and data collection.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2025, we announced that we received clinical trial authorization from Health Canada to initiate a clinical trial for Decoy20
which allows us to expand our ongoing U.S. clinical trial to Canadian sites. The trial will enroll patients in Canada under the current
protocol, which involves weekly dosing of Decoy20. We also plan to submit an amendment to Health Canada to initiate the Combination Study
in Canada.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business
Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
mission is to enhance and expand curative cancer immunotherapy for patients with unresectable or metastatic solid tumors and lymphomas,
which are responsible for approximately 90% of all cancer deaths.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business strategy includes:</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adding operational, financial
    and management information systems and personnel, including personnel to support our planned product development and commercialization
    efforts, as well as to support our reporting and other compliance obligations as a public reporting company&#894;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advancing to the expansion
    portion of the Phase 1 clinical trial for Decoy20&#894;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expanding our bacterial
    product platform to target additional types of cancer, as well as additional infectious diseases&#894;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining, expanding
    and protecting our intellectual property portfolio&#894; and</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seeking regulatory approvals
    for any product candidates that successfully complete clinical trials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competitive
Advantages</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
bacteria contain multiple constituents, capable of priming or activating many of the cellular components of both innate and adaptive
immunity, but have been attenuated by a patented process to reduce the potential for over-stimulation of the immune system and consequential
induction of undesirable autoimmune reactions. Our bacteria are also likely to be cleared very quickly by the liver and spleen, which
may further reduce the risk of non-specific autoimmune side effects, relative to other types of immunotherapy that are designed for continuous
exposure. We believe a short exposure of our products is sufficient to act alone and as a &#8220;primer&#8221; to enhance other products.
Additionally, our products can be manufactured by a highly cost-efficient process, potentially providing accelerated patient access in
both developed and developing geographical regions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Governmental
Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Among
others, the FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and
burdensome requirements upon companies involved in the clinical development, manufacture, marketing and distribution of drugs such as
those we are developing. These agencies and other federal, state and local entities regulate, among other things, the research and development,
testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion,
distribution, post-approval monitoring and reporting, sampling and export and import of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>U.S.
Regulation of Drugs and Biologics</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (FDCA) and its implementing regulations, and
biologics under the FDCA and the Public Health Service Act (PHSA) and its implementing regulations. FDA approval is required before any
new unapproved drug or dosage form, including a new use of a previously approved drug, can be marketed in the United States. Drugs and
biologics are also subject to other federal, state, and local statutes and regulations. The process required by the FDA before product
candidates may be marketed in the United States generally involves the following:</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion of extensive
    preclinical laboratory tests, animal studies and formulation studies, performed in accordance with the Good Laboratory Practices
    (GLP) regulations and other applicable regulations;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission to the FDA an
    IND, which must become effective before human clinical studies may begin and must be updated annually;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval by an independent
    institutional review board (IRB) or ethics committee representing each clinical site before each clinical study may be initiated;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance of adequate
    and well-controlled human clinical studies in accordance with Good Clinical Practice (GCP), requirements to establish the safety
    and efficacy, or with respect to biologics, the safety, purity and potency of the product candidate for each proposed indication;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparation of and submission
    to the FDA of a new drug application (NDA) or biologics license application, (BLA), after completion of all pivotal clinical studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a determination by the
    FDA within 60 days of its receipt of an NDA or BLA to file the application for review;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential review of the
    product application by an FDA advisory committee, where appropriate and if applicable;</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory completion
    of an FDA pre-approval inspection of the manufacturing facilities where the proposed product drug is produced to assess compliance
    with cGMP, to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality
    and purity, and of potential inspection of selected clinical investigation sites to assess compliance with GCPs; and</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA review and approval
    of an NDA or BLA prior to any commercial marketing or sale of the drug in the United States.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
a product candidate is identified for development, it enters the preclinical testing stage. Preclinical tests include laboratory evaluations
of product chemistry, toxicity and formulation, as well as animal studies. An IND sponsor must submit the results of the preclinical
tests, together with manufacturing information and analytical data, to the FDA as part of an IND. An IND is a request for authorization
from the FDA to administer an investigational drug product to humans. An IND will also include a protocol detailing, among other things,
the objectives of the clinical trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated,
if the trial includes an efficacy evaluation. Some preclinical testing may continue even after the IND is submitted. The IND automatically
becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, places the clinical trial on a clinical
hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Clinical
holds also may be imposed by the FDA at any time before or during clinical trials due to safety concerns about on-going or proposed clinical
trials or non-compliance with specific FDA requirements, and the trials may not begin or continue until the FDA notifies the sponsor
that the hold has been lifted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with GCPs, which include
the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical
trials must be conducted under protocols detailing the objectives of the trial, dosing procedures, subject selection and exclusion criteria
and the safety and effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND, and a separate
submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent
protocol amendments. While the IND is active, progress reports summarizing the results of the clinical trials and nonclinical studies
performed since the last progress report, among other information, must be submitted at least annually to the FDA, and written IND safety
reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies
suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant
risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the
protocol or investigator brochure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
an independent IRB at each institution participating in the clinical trial must review and approve each protocol before a clinical trial
commences at that institution and must also approve the information regarding the trial and the consent form that must be provided to
each trial subject or his or her legal representative, monitor the study until completed and otherwise comply with IRB regulations. The
FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients
are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution
if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with
unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized
by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial
may move forward at designated check points based on access to certain data from the trial. There are also requirements governing the
reporting of ongoing clinical studies and clinical study results to public registries, including clinicaltrials.gov.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical investigation of a drug is generally divided into three phases. Although the phases are usually conducted sequentially, they
may overlap or be combined.</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 1. The product candidate
    is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed
    to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side
    effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 2. The product candidate
    is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal
    dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may
    be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 3. The product candidate
    is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical
    efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials
    are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product
    approval.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-approval
trials, sometimes referred to as Phase 4 studies, may be conducted after initial marketing approval. These trials are used to gain additional
experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance
of Phase 4 clinical trials as a condition of approval of an NDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the development of a product candidate, sponsors are given opportunities to meet with the FDA at certain points. These points may be
prior to submission of an IND, at the end of Phase 2, and before an NDA or BLA is submitted. Meetings at other times may be requested.
These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide
advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Concurrent with clinical trials, companies
usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics
of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMPs. The manufacturing
process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer
must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must
be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable
deterioration over its shelf life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>NDA
and BLA Review Process</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development,
nonclinical studies and clinical trials are submitted to the FDA as part of an NDA or BLA requesting approval to market the product for
one or more indications. The NDA or BLA must include all relevant data available from pertinent preclinical studies and clinical trials,
including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s
chemistry, manufacturing and controls and proposed labeling, among other things. Data can come from company-sponsored clinical studies
intended to test the safety and effectiveness of the product, or from a number of alternative sources, including studies initiated and
sponsored by investigators. The submission of an NDA or BLA requires payment of a substantial application user fee to the FDA, unless
a waiver or exemption applies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the Pediatric Research Equity Act, or PREA, an NDA or BLA or supplement to an NDA or BLA must contain data to assess
the safety and effectiveness of the biological product candidate for the claimed indications in all relevant pediatric subpopulations
and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The Food and Drug
Administration Safety and Innovation Act requires that a sponsor who is planning to submit a marketing application for a drug or biological
product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit
an initial pediatric study plan within sixty days after an end-of-Phase 2 meeting or as may be agreed between the sponsor and FDA. Unless
otherwise required by regulation, PREA does not apply to any drug or biological product for an indication for which orphan designation
has been granted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Within
60 days following submission of the application, the FDA reviews the submitted BLA or NDA to determine if the application is substantially
complete before the agency accepts it for filing. The FDA may refuse to file any NDA or BLA that it deems incomplete or not properly
reviewable at the time of submission and may request additional information. In this event, the NDA or BLA must be resubmitted with the
additional information. Once an NDA or BLA has been accepted for filing, the FDA&#8217;s goal is to review standard applications within
ten months after the filing date, or, if the application qualifies for priority review, six months after the FDA accepts the application
for filing. In both standard and priority reviews, the review process may also be extended by FDA requests for additional information
or clarification. The FDA reviews an NDA to determine, among other things, whether a product candidate is safe and effective for its
intended use and whether its manufacturing is sufficient to assure and preserve the product&#8217;s identity, strength, quality and purity.
The FDA reviews a BLA to determine, among other things, whether a product candidate is safe, pure and potent and the facility in which
it is manufactured, processed, packed or held meets standards designed to assure the product&#8217;s continued safety, purity and potency.
When reviewing an NDA or BLA, the FDA may convene an advisory committee to provide clinical insight on application review questions.
The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
approving an NDA or BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not
approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements
and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA or
BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the FDA evaluates the NDA or BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug
substance will be produced, the FDA may issue an approval letter or a Complete Response Letter, or CRL. An approval letter authorizes
commercial marketing of the product with specific prescribing information for specific indications. A CRL indicates that the review cycle
of the application is complete, and the application will not be approved in its present form. A CRL usually describes the specific deficiencies
in the NDA or BLA identified by the FDA and may require additional clinical data, including additional clinical trials, or other significant
and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. If a CRL is issued, the sponsor must
resubmit the NDA or BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data
and information are submitted, the FDA may decide that the NDA or BLA does not satisfy the criteria for approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the
indicated uses for which such product may be marketed. For example, the FDA may approve the NDA or BLA with a Risk Evaluation and Mitigation
Strategy, or REMS, to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential
serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use,
and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods,
patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed
labeling or the development of adequate controls and specifications. The FDA may also require one or more Phase 4 post-market studies
and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further
marketing of the product based on the results of these post-marketing studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Expedited
Development and Review Programs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA offers a number of expedited development and review programs for qualifying product candidates. For example, the fast track program
is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, product candidates
are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate
the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product
candidate and the specific indication for which it is being studied. The sponsor of a fast track product candidate has opportunities
for more frequent interactions with the review team during product development and, once an NDA or BLA is submitted, the application
may be eligible for priority review. A fast track product candidate may also be eligible for rolling review, where the FDA may consider
for review sections of the NDA or BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule
for the submission of the sections of the NDA or BLA, the FDA agrees to accept sections of the NDA or BLA and determines that the schedule
is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA or BLA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy
designation to expedite its development and review. A product candidate can receive breakthrough therapy designation if preliminary clinical
evidence indicates that the product candidate, alone or in combination with one or more other drugs or biologics, may demonstrate substantial
improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early
in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and
guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate,
including involvement of senior managers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
marketing application for a drug or biologic submitted to the FDA for approval, including a product candidate with a fast track designation
and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval
process, such as priority review. A product candidate is eligible for priority review if it has the potential to provide a significant
improvement in the treatment, diagnosis or prevention of a serious disease or condition. For new-molecular-entity NDAs and original BLAs,
priority review designation means the FDA&#8217;s goal is to take action on the marketing application within six months of the 60-day
filing date (as compared to ten months under standard review).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
depending on the design of the applicable clinical trials, product candidates studied for their safety and effectiveness in treating
serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product candidate has
an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured
earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality
or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative
treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled
confirmatory clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical
benefit, and may require that such confirmatory studies be underway before granting any accelerated approval. Products receiving accelerated
approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required confirmatory studies in a timely
manner or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated
approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fast
track designation, breakthrough therapy designation, priority review, and accelerated approval do not change the standards for approval
but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later
decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will
not be shortened. We may explore some of these opportunities for our product candidates as appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Orphan
drug designation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which
is a disease or condition that affects fewer than 200,000 individuals in the United States or, if it affects more than 200,000 individuals
in the United States, there is no reasonable expectation that the cost of developing and making a drug product available in the United
States for this type of disease or condition will be recovered from sales of the product. Orphan designation must be requested before
submitting an NDA or BLA. After the FDA grants orphan designation, the identity of the therapeutic agent and its potential orphan use
are disclosed publicly by the FDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review
and approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such
designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to
market the same drug or biologic for the same disease or condition for seven years, except in limited circumstances, such as a showing
of clinical superiority to the product with orphan exclusivity or inability to manufacture the product in sufficient quantities. The
designation of such drug or biologic also entitles a party to financial incentives such as opportunities for grant funding towards clinical
trial costs, tax advantages and user-fee waivers. However, competitors, may receive approval of different products for the disease or
condition for which the orphan product has exclusivity or obtain approval for the same product but for a different disease or condition
for which the orphan product has exclusivity. Orphan exclusivity also could block the approval of a competing product for seven years
if a competitor obtains approval of the &#8220;same drug,&#8221; as defined by the FDA, or if the active ingredient of the product candidate
is determined to be contained within the competitor&#8217;s product for the same disease or condition. In addition, if an orphan designated
product receives marketing approval for a disease or condition broader than what is designated, it may not be entitled to orphan exclusivity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Post-Approval
Requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including,
among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and
distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new
indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements,
under which the FDA assesses an annual program fee for each product identified in an approved NDA or BLA. Drug and biologic manufacturers
and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic
unannounced inspections by the FDA and certain state agencies for compliance with cGMPs, which impose certain procedural and documentation
requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on
the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and
correction of any deviations from cGMPs and impose reporting requirements upon us and any third-party manufacturers that we may decide
to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain
compliance with cGMPs and other aspects of regulatory compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product
reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity
or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved
labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition
of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on the marketing
    or manufacturing of a product, complete withdrawal of the product from the market or product recalls;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines, warning letters
    or holds on post-approval clinical studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal of the FDA to approve
    pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product seizure or detention,
    or refusal of the FDA to permit the import or export of products;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consent decrees, corporate
    integrity agreements, debarment or exclusion from federal healthcare programs;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">mandated modification of
    promotional materials and labeling and the issuance of corrective information;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the issuance of safety
    alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information
    about the product; or</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions or the imposition
    of civil or criminal penalties.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA closely regulates the marketing, labeling, advertising and promotion of drug products and biologics. A company can make only those
claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the
approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure
to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential
civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s
labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties.
Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate
the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the
subject of off-label use of their products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Drug
Product Marketing Exclusivity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
exclusivity provisions authorized under the FDCA can delay the submission or the approval of certain marketing applications. For example,
the FDCA provides a five-year period of non-patent data exclusivity within the United States to the first applicant to obtain approval
of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing
the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period,
the FDA may not approve or even accept for review an abbreviated new drug application, or ANDA, or an NDA submitted under Section 505(b)(2),
or 505(b)(2) NDA, submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended
for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right
of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification
of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDCA alternatively provides three years of non-patent exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations,
other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval
of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the
modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from
approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and
three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be
required to conduct or obtain a right of reference to any preclinical studies and adequate and well-controlled clinical trials necessary
to demonstrate safety and effectiveness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pediatric
exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an additional
six months of marketing exclusivity attached to another period of existing exclusivity, including patent terms, if a sponsor conducts
clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor
to undertake the described clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Biosimilars
and Reference Product Exclusivity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated approval pathway for biological products that
are highly similar, or &#8220;biosimilar,&#8221; to or interchangeable with an FDA-approved reference biological product. The FDA has
issued several guidance documents outlining an approach to review and approval of biosimilars. Biosimilarity, which requires that there
be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency,
is generally shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product
is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results
as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and
the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks
of diminished efficacy relative to exclusive use of the reference biologic. A product shown to be biosimilar or interchangeable with
an FDA-approved reference biological product may rely in part on the FDA&#8217;s previous determination of safety and effectiveness for
the reference product for approval, which can potentially reduce the cost and time required to obtain approval to market the product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference
product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12
years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may
still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s
own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its
product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it
is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which
are governed by state pharmacy law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months
to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of existing exclusivity protection
or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written
Request&#8221; for such a study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Healthcare Laws</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical
companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states
and foreign jurisdictions in which they conduct their business and may constrain the financial arrangements and relationships through
which we research as well as sell, market and distribute any products for which we obtain marketing approval. Such laws include, without
limitation, federal and state anti-kickback, fraud and abuse, false claims, data privacy and security and physician and other healthcare
provider transparency laws and regulations. If our operations are found to be in violation of any of such laws or any other governmental
regulations that apply, they may be subject to penalties, including, without limitation, administrative, civil and criminal penalties,
damages, fines, disgorgement, the curtailment or restructuring of operations, integrity oversight and reporting obligations, exclusion
from participation in federal and state healthcare programs and imprisonment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Coverage
and Reimbursement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of any product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and
foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for
such product by third-party payors. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on
a plan-by-plan basis. The coverage determination process is often a time-consuming and costly process that will require us to provide
scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement
will be obtained. These third-party payors are increasingly reducing reimbursements for medical products, drugs and services. In addition,
the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price
controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Adoption of price controls
and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could
further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to
cover a product could reduce physician usage and patient demand for the product and also have a material adverse effect on sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Healthcare
Reform</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, each as amended,
collectively known as the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private
insurers, and significantly affected the pharmaceutical industry. The ACA contains a number of provisions, including those governing
enrollment in federal healthcare programs, reimbursement adjustments and changes to fraud and abuse laws. By way of example, the ACA:</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased the minimum level
    of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1% of the average manufacturer price;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">required collection of
    rebates for drugs paid by Medicaid managed care organizations;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">required manufacturers
    to participate in a coverage gap discount program, under which they must agree to offer 70 percent point-of-sale discounts off negotiated
    prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturers&#8217;
    outpatient drugs to be covered under Medicare Part D; and</span></td></tr>
  </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposed a non-deductible
    annual fee on pharmaceutical manufacturers or importers who sell &#8220;branded prescription drugs&#8221; to specified federal government
    programs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
legislative changes have been proposed and adopted in the United States since the ACA was enacted. On March 11, 2021, the American Rescue
Plan Act of 2021 was signed into law, which eliminated the statutory Medicaid drug rebate cap, beginning January 1, 2024. The rebate
was previously capped at 100% of a drug&#8217;s average manufacturer price, or AMP. Most recently, on August 16, 2022, the Inflation
Reduction Act of 2022, or IRA, was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in
price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare
Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap
discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and Human
Services (HHS) to implement many of these provisions through guidance, as opposed to regulation, for the initial years. On August 29,
2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the drug price negotiation programs
is currently subject to legal challenges. For that and other reasons, it is currently unclear how the IRA will be effectuated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products,
which has resulted in several Congressional inquiries, proposed and enacted legislation and executive orders issued by the President
designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer
patient programs, and reform government program reimbursement methodologies for drug products. Individual states in the United States
have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price
or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency
measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Data
Privacy and Security Laws</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Numerous
state, federal and foreign laws, regulations and standards govern the collection, use, access to, confidentiality and security of health-related
and other personal information, and could apply now or in the future to our operations or the operations of our partners. In the United
States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security
laws and consumer protection laws and regulations govern the collection, use, disclosure, and protection of health-related and other
personal information. In addition, certain foreign laws govern the privacy and security of personal data, including health-related data.
Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance
efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions
on data processing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition, government regulation
and a strong emphasis on proprietary products. While we believe that our technology, knowledge and scientific resources provide us with
certain competitive advantages, we face competition from many sources, including foreign and domestic pharmaceutical and biotechnology
companies, academic institutions, governmental agencies and public and private research institutions. Many of these competitors may have
access to greater capital and resources than us. These competitors also compete with us in recruiting and retaining qualified scientific
and management personnel. Any product candidates that we successfully develop and commercialize will compete with new immunotherapies
that may become available in the future. Our competitors include larger and better funded biopharmaceutical, biotechnology and therapeutics
companies, specifically companies focused on cancer immunotherapies, such as Amgen, Inc., AstraZeneca plc, BMS, Genentech, Inc., GlaxoSmithKline
PLC, Merck &amp; Co., Inc., Novartis AG, Pfizer Inc., Roche Holding Ltd and Sanofi S.A. On the other hand, many of these companies are
developing immunotherapeutics which may have potential to be used in concert with Decoy20 and in this regard, we view them as potentially
complimentary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to our lead candidate, Decoy20, there are a number of companies that are developing possible treatments for cancer, however,
we believe we are the only company using systemic administration of killed, non-pathogenic Gram-negative bacteria with reduced lipopolysaccharide-endotoxin
to stimulate innate and adaptive immune system pathways.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will be based in part upon our ability to successfully commercialize Decoy20 and to identify, develop and manage a portfolio
of therapeutics that are safer and more effective than competing products in our target indications. Our market opportunity has the potential
to be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer side effects,
are more convenient or are less expensive than any therapeutics we may develop. Our competitive position will also be dependent upon
our ability to attract and retain qualified personnel, to obtain patent protection or otherwise develop proprietary products or processes,
and protect our intellectual property, to differentiate our product from other therapeutics and to secure sufficient capital resources
for the period between technological conception and commercial sales. The availability of reimbursement from government and other third-party
payors will also significantly affect the pricing and competitiveness of our products. Our competitors may also obtain FDA or other regulatory
approval for their products more rapidly or with broader applications than we may obtain approval for ours, which could result in our
competitors establishing a strong market position before we are able to enter the market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends, at least in part, on our ability to protect our proprietary technology and intellectual property, and to operate without
infringing or violating the proprietary rights of others. We rely on a combination of patent, trademark, trade secret and copyright laws,
know-how, intellectual property licenses and other contractual rights (including confidentiality and invention assignment agreements)
to protect our proprietary technology and intellectual property, including related intellectual property rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patents</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 12, 2025, we own 58 granted patents and 11 pending patent applications to use within our field of business. Our patents and
patent applications generally relate to compositions and methods for treating cancer and infectious diseases, and our patents and any
patents that issue from our pending patent applications are expected to expire at various dates between 2033 and 2043.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to submit patent applications for each new product and technology that we develop. The patent outlook for companies like ours
is generally uncertain and may involve complex legal and factual questions. Our ability to maintain and consolidate our proprietary position
for our technology will depend on our success in obtaining effective claims and enforcing those claims once granted. We do not know whether
any of our patent applications or any patent applications that we may license will result in the issuance of any patents. Our issued
patents and those that may be issued in the future, or patents that we may exclusively license, may be challenged, narrowed, circumvented
or found to be invalid or unenforceable, which could limit our ability to stop competitors from marketing related products or the length
of term of patent protection that we may have for our products. We cannot be certain that we were the first to invent the inventions
claimed in our owned patents or patent applications. In addition, our competitors may independently develop similar technologies or duplicate
any technology developed by us, and the rights granted under any issued patents may not provide us with any meaningful competitive advantages
against these competitors. Furthermore, because of the extensive time required for development, testing and regulatory review of a potential
product, it is possible that, before any of our products can be commercialized, any related patent may expire or remain in force for
only a short period following commercialization, thereby reducing any advantage of the patent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Trade
Secrets and Confidential Information</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to patents, we rely on trade secrets and know-how to develop and maintain our competitive position. Trade secrets and know-how
can be difficult to protect. We rely on, among other things, confidentiality and invention assignment agreements to protect our proprietary
know-how and other intellectual property that may not be patentable, or that we believe is best protected by means that do not require
public disclosure. For example, we require our employees to execute confidentiality agreements in connection with their employment relationships
with us, and to disclose and assign to us inventions conceived in connection with their services to us. However, there can be no assurance
that these agreements will be enforceable or that they will provide us with adequate protection. We also seek to preserve the integrity
and confidentiality of our data, trade secrets and know-how by maintaining physical security of our premises and physical and electronic
security of our information technology systems.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be unable to obtain, maintain and protect the intellectual property rights necessary to conduct our business, and may be subject
to claims that we infringe or otherwise violate the intellectual property rights of others, which could materially harm our business.
For a more comprehensive summary of the risks related to our intellectual property, see Item 1A. &#8220;Risk Factors - Risks Related
to Our Intellectual Property.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Environmental
Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to various environmental, health and safety laws and regulations, including those governing laboratory procedures, the handling,
use, storage, treatment and disposal of hazardous materials and wastes and the cleanup of contaminated sites. Our operations involve
the use of potentially hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous
waste products. Although we generally contract with third parties for the operations that involve the disposal of hazardous materials
and wastes, we cannot eliminate the risk of contamination or injury from these materials. Based on information currently available to
us, we do not expect environmental costs and contingencies to have a material adverse effect on us. However, we could incur substantial
costs as a result of violations of or liabilities under environmental requirements in connection with our operations or property, including
fines, penalties and other sanctions, investigation and cleanup costs and third-party claims. In the event of contamination or injury
resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our
resources. See Part I. Item 1A. &#8220;Risk Factors &#8211; Risks Related to Healthcare Laws and Other Legal Compliance Matters - <i>Violations
of or liabilities under environmental, health and safety laws and regulations could subject us to fines, penalties or other costs that
could have a material adverse effect on the success of our business.</i>&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our business, operations and facilities are being operated in compliance in all material respects with applicable environmental
and health and safety laws and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Human
Capital Management</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, we had seven full-time employees. None of our employees are represented by labor unions or covered by collective
bargaining agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our future success will depend, in part, on our continued ability to attract, hire and retain qualified personnel. In particular,
we depend on the skills, experience and performance of our senior management and research personnel. We compete for qualified personnel
with other biotechnology, medical device, pharmaceutical and healthcare companies, as well as universities and non-profit research institutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
provide competitive compensation and benefits programs to help meet the needs of our employees. In addition to salaries, these programs
include incentive compensation plan, pension, healthcare and insurance benefits, paid time off, and family leave, among others. We also
use targeted equity-based grants with vesting conditions to facilitate retention of personnel, particularly for our key employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
success of our business is fundamentally connected to the well-being of our people. Accordingly, we are committed to the health and safety
of our employees and we consider our relations with our employees to be good.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Available
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain a corporate website at http://www.indaptusrx.com. The information contained on, or that can be accessed through, our website
is neither a part of nor incorporated into this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Copies
of our reports on Forms 10-K, Forms 10-Q and Forms 8-K, may be obtained, free of charge, electronically through our corporate website
at http://www.indaptusrx.com as soon as reasonably practicable after we file such material electronically with, or furnish to, the SEC.
Additionally, the SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding
issuers that file electronically with the SEC at www.sec.gov.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="v_001"></span>Item
1A. Risk Factors.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>You
should carefully consider the factors described below, together with all of the other information contained in this Annual Report, including
the audited consolidated financial statements and the related notes included in this Annual Report beginning on page F-1, before deciding
whether to invest in our common stock. If any of the risks discussed below actually occur, our business, financial condition, operating
results and cash flows could be materially adversely affected. This could cause the trading price of our common stock to decline, and
you may lose all or part of your investment.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Financial Position and Capital Requirements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are a clinical-stage company with a limited operating history. We are not currently profitable, do not expect to become profitable in
the near future and may never become profitable.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biotechnology company focused primarily on developing a novel and patented systemically-administered anti-cancer
and anti-viral immunotherapy. All of our product candidates are in the preclinical or early clinical development stage, and none of our
product candidates have been approved for marketing or are being marketed or commercialized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result, we have no meaningful historical operations upon which to evaluate our business and prospects and have not yet demonstrated
an ability to obtain marketing approval for any of our product candidates or successfully overcome the risks and uncertainties frequently
encountered by companies in the biopharmaceutical industry. As a result, we have not been profitable and have incurred significant operating
losses in every reporting period since our inception. For the year ended December 31, 2024, we reported a net loss of approximately $15.0
million and as of December 31, 2024, we had an accumulated deficit of approximately $60.4 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the foreseeable future, we expect to continue to incur losses, which will increase significantly from historical levels as we expand
our development activities, seek regulatory approvals for our product candidates, and begin to commercialize them if they are approved
by the FDA, the European Medicines Agency, or the EMA, or comparable foreign authorities. Further, the net losses we incur may fluctuate
significantly from quarter-to-quarter and year-to-year, such that a period-to-period comparison of our results of operations may not
be a good indication of our future performance. Even if we succeed in developing and commercializing one or more product candidates,
we may never become profitable, or even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent
periods. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#8217;
equity and working capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have identified conditions and events that raise substantial doubt regarding our ability to continue as a going concern.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred net losses and utilized cash in operations since inception as described above. In addition, as of December 31, 2024, we
had approximately $5.8 million and during the twelve months ended December 31, 2024, we used $12.3 million of cash in operations and
expect to continue to incur significant cash outflows and incur future additional losses to execute our operating plan. We believe that
the cash and cash equivalents as of December 31, 2024 together with proceeds from our January 2025 financing, will enable us to fund
our operating expenses and capital expenditure requirements into the second quarter of 2025. <span style="background-color: white">We
will need to increase our capital resources through equity and/or debt financings. We may also seek to finance our cash needs through
collaborations, strategic alliances, or license agreements with third parties and/or debt or equity financings. If sources of financing
are available, they may result in substantial dilution to our stockholders. We cannot provide any assurance that new financing will be
available to us on commercially acceptable terms or in the amounts required, if at all. Due to the uncertainty in securing additional
funding, and as existing cash resources are not sufficient to fund planned operations for at least 12 months from the date of this Annual
Report, we have concluded that substantial doubt exists about our ability to continue as a going concern. If we are unsuccessful in securing
sufficient financing, we may need to delay, reduce, or eliminate our research and development programs, which could adversely affect
our business prospects, or cease operations.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audited consolidated financial statements included in this Annual Report have been prepared on a going concern basis under which an entity
is able to realize its assets and satisfy its liabilities in the ordinary course of business. The audited consolidated financial statements
do not give effect to any adjustments relating to the carrying values and classification of assets and liabilities that would be necessary
should we be unable to continue as a going concern within one year after the date that the financial statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future operations are dependent upon the successful entry into collaborations, strategic alliances, or license agreements with third
parties and/or on the identification and successful completion of equity or debt financing and the achievement of profitable operations
at an indeterminate time in the future. There can be no assurances that we will be successful in completing these collaborations or alliances,
equity or debt financing or in achieving profitability. As such, there can be no assurance that we will be able to continue as a going
concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantial
doubt about our ability to continue as a going concern may materially and adversely affect the price per share of our common stock, and
it may be more difficult for us to obtain financing. If potential collaborators decline to do business with us or potential investors
decline to participate in any future financing due to such concerns, our ability to increase our cash position may be limited. The perception
that we may not be able to continue as a going concern may cause others to choose not to deal with us due to concerns about our ability
to meet our contractual obligations. If we are unable to continue as a going concern, you could lose all or part of your investment in
our Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Given
our lack of current cash flow, we will need to raise additional capital. If we are unable to raise a sufficient amount of capital when
needed in required amounts and on acceptable terms or at all, we may be forced to delay, limit or eliminate some or all of our research
programs, product development activities and commercialization efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
we will be unable to generate sufficient, if any, cash flow to fund our operations for the foreseeable future, we will need to seek additional
equity or debt financing to provide the capital required to maintain or expand our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that we will be able to raise sufficient additional capital on acceptable terms or at all. If such additional financing
is not available on satisfactory terms, or is not available in sufficient amounts, we may be required to delay, limit or eliminate some
or all of our research programs, product development activities and commercialization efforts, and our ability to achieve our business
objectives, our competitiveness, and our business, financial condition and results of operations may be materially adversely affected.
In addition, we may be required to grant rights to develop and market product candidates that we would otherwise prefer to develop and
market ourselves. Our inability to fund our business could lead to the loss of your investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements will depend on many factors, including, but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, progress, results and costs of preclinical studies and clinical trials&#894;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, prioritization and number of our clinical trials and other research and development programs&#894;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    amount of revenues we receive under future licensing, collaboration, development and commercialization arrangements with respect
    to our product candidates&#894; </span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of any pandemic, epidemic or other future health crisis on our business and operations&#894;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of the development and expansion of our operational infrastructure&#894; </span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs, timing and outcome of regulatory review of our product candidates&#894;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability of us, or our collaborators, to achieve development milestones, marketing approval and other events or developments under
    our potential future licensing agreements&#894; </span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights&#894; </span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of securing manufacturing arrangements for clinical or commercial production&#894;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of contracting with third parties to provide sales and marketing capabilities for us or establishing such capabilities ourselves&#894;
    </span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of acquiring or undertaking development and commercialization efforts for any future products, product candidates or technology&#894;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs associated with being a public company; and</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    cost that we may incur under future in- and out-licensing arrangements relating to one or more of our product candidates.</span></td>
    </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we believe we have sufficient funds for our current or future operating plans, we may continue to seek additional capital if market
conditions are favorable or in light of specific strategic considerations. Adequate additional financing may not be available to us on
acceptable terms, or at all. If we are unable to obtain sufficient funding on a timely basis, in required amounts or on favorable terms,
we may be required to significantly delay, reduce or eliminate one or more of our research or product development programs and/or commercialization
efforts. We may also be unable to expand our operations or otherwise capitalize on business opportunities as desired. Any of these events
could materially adversely affect our financial condition and business prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Raising
additional capital would cause dilution to our shareholders and may restrict our operations or require us to relinquish rights to our
technologies or product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity
and/or debt financings and collaborations, licensing agreements or other strategic arrangements. We may seek additional capital through
a combination of private and public equity offerings, &#8220;at-the-market&#8221; issuances, equity-linked and structured transactions,
debt (straight, convertible, or otherwise) financings, collaborations and licensing arrangements. To the extent that we raise additional
capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include
liquidation or other preferences that adversely affect your rights as a shareholder. For example, in June 2022, we entered into an at
the market offering agreement, which was amended on September 1, 2022, with a sales agent pursuant to which we may offer and sell from
time to time shares of our common stock for aggregate gross proceeds of up to $3.7 million, and in 2024, we sold 152,000 shares of our
common stock for aggregate gross proceeds of approximately $0.4 million. On August 6, 2024, we filed a prospectus supplement to reduce
the amount of shares registered under the prospectus for the ATM to $0.00 and to suspend the ATM program, but the ATM Agreement remains
in full force and effect. In August 2024, November 2024 and January 2025, we raised an aggregate of approximately $6.4 million, net of
placement agent and other offering expenses. In addition, in February 2025, we entered into a <span style="background-color: white">Standby
Equity Purchase Agreement pursuant to which we have the right, but not the obligation, to sell up to $20.0 million of our common stock
during a 36 month period, subject to the restrictions and satisfaction of the conditions in the Standby Equity Purchase Agreement. </span>We
may also issue in the future equity securities that provide for rights, preferences and privileges senior to those of our common stock.
Given our need for cash and that equity issuances are the most common type of fundraising for similarly situated companies, the risk
of dilution is particularly significant for our stockholders. Depending upon market liquidity at the time, additional sales of shares
registered at any given time could cause the trading price of our common stock to decline. Debt financing, if available, would result
in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take
specific actions such as incurring debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations,
strategic alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future
revenue streams or product candidates, or grant licenses on terms that are not favorable to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to the Discovery and Development of Our Product Candidates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are dependent on the success of one or more of our current product candidates, and we cannot be certain that any of them will receive
regulatory approval or be commercialized.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have spent significant time, money and effort on the development of our lead product candidate, Decoy20. As a result, our business is
largely dependent on the commencement of and success of clinical trials evaluating Decoy20 and our ability to complete the development
of, obtain regulatory approval for, and successfully commercialize Decoy20 in a timely manner. The process to develop, obtain regulatory
approval and commercialize Decoy20 is long, complex, costly and uncertain as to the outcome.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, no clinical trials designed to provide substantial evidence of safety, purity, potency or efficacy have been completed with any
of our product candidates. All of our product candidates will require additional development, including clinical trials as well as further
preclinical studies to evaluate their toxicology and optimize their formulation and regulatory approvals before they can be commercialized.
Positive results obtained during early development do not necessarily mean later development will succeed or that regulatory approvals
will be obtained. Our development efforts may not lead to commercial products, either because our product candidates fail to be safe
and effective, or in the case of our product candidates regulated as biologics, safe, pure and potent, or because we have inadequate
financial or other resources to advance our product candidates through the clinical development and approval processes. If any of our
product candidates fail to demonstrate safety, purity, potency or efficacy at any time or during any phase of development, we would experience
potentially significant delays in, or be required to abandon, development of the product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not anticipate that any of our current product candidates will be eligible to receive regulatory approval from the FDA, the EMA or
comparable foreign authorities and begin commercialization for a number of years, if ever. Even if we ultimately receive regulatory approval
for any of these product candidates, we or our potential future partners, if any, may be unable to commercialize them successfully for
a variety of reasons. These include, for example, the availability of alternative treatments, lack of cost-effectiveness, the cost of
manufacturing the product on a commercial scale and competition with other products. The success of our product candidates may also be
limited by the prevalence and severity of any adverse side effects. If we fail to commercialize one or more of our current product candidates,
we may be unable to generate sufficient revenues to attain or maintain profitability, and our financial condition may decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
and preclinical development involves a lengthy and expensive process with an uncertain outcome. Any difficulties or delays in the commencement
or completion, or the termination or suspension, of our current or planned clinical trials could result in increased costs to us, delay
or limit our ability to generate revenue or adversely affect our commercial prospects.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
obtaining approval from regulatory authorities for the commercialization of any of our product candidates, we must conduct extensive
clinical trials to demonstrate the safety, purity, and potency, or efficacy of the product candidate in humans. Preclinical and clinical
drug development is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any
time during the preclinical study or clinical trial process. Despite promising preclinical or clinical results, any product candidate
can unexpectedly fail at any stage of preclinical or clinical development. The historical failure rate for product candidates in our
industry is high.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results from preclinical studies or early clinical trials of a product candidate may not predict the results of later clinical trials
of the product candidate, and interim results of a clinical trial are not necessarily indicative of final results. Product candidates
in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed through
preclinical studies and initial clinical trials. It is not uncommon to observe results in clinical trials that are unexpected based on
preclinical studies and early clinical trials, and many product candidates fail in clinical trials despite very promising early results.
Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses. A number of companies in the pharmaceutical
and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier
studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
we can initiate clinical trials for any product candidates, we must submit the results of preclinical studies to the FDA, the EMA or
comparable foreign regulatory authorities along with other information, including information about product candidate chemistry, manufacturing
and controls and our proposed clinical trial protocol, as part of an IND or similar regulatory submission. The FDA, the EMA or comparable
foreign regulatory authorities may require us to conduct additional preclinical studies for any product candidate before it allows us
to initiate clinical trials under any IND or similar regulatory submission, which may lead to delays and increase the costs of our preclinical
development programs. Moreover, even if we commence clinical trials, issues may arise that could cause regulatory authorities to suspend
or terminate such clinical trials. Any such delays in the commencement or completion of our ongoing and planned clinical trials for our
product candidates could significantly affect our product development timelines and product development costs and harm our financial
position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not know whether our planned clinical trials will begin on time or be completed on schedule, if at all. The commencement, data readouts
and completion of clinical trials can be delayed for a number of reasons, including delays related to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    to generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the initiation or continuation of clinical
    trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    in obtaining allowance or approval from regulatory authorities to commence a trial or reaching a consensus with regulatory authorities
    on trial design;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA, the EMA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    failure or delay in reaching an agreement with CROs and clinical trial sites, the terms of which can be subject to extensive negotiation
    and may vary significantly among different CROs and trial sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in identifying, recruiting and training suitable clinical investigators;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    in obtaining approval from one or more institutional review boards (IRBs) or ethics committees at clinical trial sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IRBs
    refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional subjects,
    or withdrawing their approval of the trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    or amendments to the clinical trial protocol;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    sites deviating from the trial protocol or dropping out of a trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    by our CROs to perform in accordance with Good Clinical Practice (GCP) requirements or applicable regulatory rules and guidelines
    in other countries;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    in manufacturing sufficient quantities of our product candidates, or obtaining sufficient quantities of combination therapies, for
    use in clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subjects
    failing to enroll or remain in our trials at the rate we expect, or failing to return for post-treatment follow-up, including subjects
    failing to remain in our trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
    choosing an alternative product for the indications for which we are developing our product candidates, or participating in competing
    clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack
    of adequate funding to continue a clinical trial, or costs being greater than we anticipate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subjects
    experiencing severe or serious unexpected drug-related adverse effects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">occurrence
    of serious adverse events in trials of the same class of agents conducted by other companies that could be considered similar to
    our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">selection
    of clinical endpoints that require prolonged periods of clinical observation or extended analysis of the resulting data;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">transfer
    of manufacturing processes to larger-scale facilities operated by a contract manufacturing organization (CMO), delays or failure
    by our CMOs or us to make any necessary changes to such manufacturing process, or failure of our CMOs to produce clinical trial materials
    in accordance with current Good Manufacturing Practice (cGMP), regulations or other applicable requirements; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third
    parties being unwilling or unable to satisfy their contractual obligations to us in a timely manner.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials must be conducted in accordance with the FDA and other applicable regulatory authorities&#8217; legal requirements, regulations
and guidelines, and remain subject to oversight by these governmental agencies and ethics committees or IRBs at the medical institutions
where such clinical trials are conducted. We could also encounter delays if a clinical trial is suspended or terminated by us, by the
IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA, the
EMA or comparable foreign regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors,
including failure to conduct the clinical trial in accordance with regulatory requirements or applicable clinical trial protocols, adverse
findings from inspections of clinical trial sites by the FDA, the EMA or comparable foreign regulatory authorities, unforeseen safety
issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations
or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements
and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to
resubmit our clinical trial protocols to regulators or to IRBs for reexamination, which may impact the costs, timing or successful completion
of a clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation
in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA, the
EMA or comparable foreign regulatory authorities. The FDA, the EMA or comparable foreign regulatory authority may conclude that a financial
relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study.
The FDA, the EMA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable
clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection,
of our marketing applications by the FDA, the EMA or comparable foreign regulatory authority, as the case may be, and may ultimately
lead to the denial of marketing approval of one or more of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the FDA&#8217;s, the EMA&#8217;s and other regulatory authorities&#8217; policies with respect to clinical trials may change
and additional government regulations may be enacted. For instance, the regulatory landscape related to clinical trials in the EU recently
evolved. The EU Clinical Trials Regulation (CTR) which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became
applicable on January 31, 2022. While the Clinical Trials Directive required a separate clinical trial application (CTA) to be submitted
in each member state, to both the competent national health authority and an independent ethics committee, the CTR introduces a centralized
process and only requires the submission of a single application to all member states concerned. The CTR allows sponsors to make a single
submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state.
The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate
assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member
state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development
may proceed. The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by
the CTR varies. Clinical trials for which an application was submitted (i) prior to January 31, 2022 under the Clinical Trials Directive,
or (ii) between January 31, 2022 and January 31, 2023 and for which the sponsor has opted for the application of the Clinical Trials
Directive remain governed by said Directive until January 31, 2025. After this date, all clinical trials (including those which are ongoing)
will become subject to the provisions of the CTR. Compliance with the CTR requirements by us and our third-party service providers, such
as CROs, may impact our developments plans. If we are slow or unable to adapt to changes in existing requirements or the adoption of
new requirements or policies governing clinical trials, our development plans may be impacted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, many of the factors that cause, or lead to, the termination or suspension of, or a delay in the commencement or completion
of, clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Any resulting delays to our
clinical trials could shorten any period during which we may have the exclusive right to commercialize our product candidates. In such
cases, our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could
be significantly reduced. Any of these occurrences may harm our business, financial condition and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
expect to continue to incur significant research and development expenses and other operating expenses, which may make it difficult for
us to attain profitability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to expend substantial funds in research and development, including preclinical studies and clinical trials of our product candidates,
and to manufacture and market any product candidates in the event they are approved for commercial sale. We also may need additional
funding to develop or acquire complementary companies, technologies and assets, as well as for working capital requirements and other
operating and general corporate purposes. Moreover, our planned increases in staffing will dramatically increase our costs in the near
and long-term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the successful development of our product candidates is uncertain, we are unable to precisely estimate the actual funds we will require
to develop and potentially commercialize them. In addition, we may not be able to generate sufficient revenue, even if we are able to
commercialize any of our product candidates, to become profitable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may expend our limited resources to pursue a limited number of research programs, product candidates and specific indications and fail
to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to our limited financial and managerial resources, we must focus on a limited number of research programs and product candidates and
on specific indications. As such, we are currently focused on the development of Decoy20. As a result, we may forego or delay pursuit
of opportunities with other product candidates or for other indications for anti-cancer and anti-viral immunotherapy that later prove
to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products
or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific
indications may not yield any commercially viable products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
product candidates may cause undesirable side effects that could delay or prevent their regulatory approval or commercialization, cause
us to suspend or discontinue clinical trials, abandon a product candidate, limit the commercial profile of an approved product, or result
in other significant adverse implications on our business, financial condition and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with our product
candidates&#8217; use. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or
unexpected characteristics. For example, because the mechanism of action of our product candidates depends on stimulation of the immune
system, there is the potential for over-stimulation or undesirable immune reactions. Undesirable side effects caused by our product candidates,
whether used alone or in combination with other therapies, could cause us or regulatory authorities to interrupt, delay or halt clinical
trials or the delay or denial of regulatory approval by the FDA, the EMA or comparable foreign regulatory authorities, or, if such product
candidates are approved, result in a more restrictive label and other post-approval requirements. Any treatment-related side effects
could also affect patient recruitment or the ability of enrolled patients to complete the trial or could result in potential product
liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our product candidates are associated with undesirable side effects or have unexpected characteristics in preclinical studies or clinical
trial, when used alone or in combination with other approved products or product candidates, we may need to interrupt, delay or abandon
their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics
are less prevalent, less severe or more acceptable from a risk-benefit perspective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
in our ongoing and planned clinical trials may, in the future, suffer significant adverse events or other side effects not observed in
our preclinical studies or previous clinical trials. Patients treated with our product candidates may also be undergoing surgical, radiation
or chemotherapy treatments, which can cause side effects or adverse events that are unrelated to our product candidate, but may still
impact the success of our clinical trials. The inclusion of critically ill patients in our clinical trials may result in deaths or other
adverse medical events due to other therapies or medications that such patients may be using or due to the gravity of such patients&#8217;
illnesses. If such significant adverse events or other side effects are observed in any of our current or future clinical trials, we
may have difficulty recruiting patients to the clinical trials, or we may be required to abandon the trials or our development efforts
of that product candidate altogether. We, the FDA, other comparable regulatory authorities or an IRB may suspend clinical trials of a
product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable
health risks or adverse side effects. Even if the side effects do not preclude the product candidate from obtaining or maintaining regulatory
approval, undesirable side effects may inhibit market acceptance due to tolerability concerns as compared to other available therapies.
Any of these developments could materially harm our business, financial condition and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if any of our product candidates receives regulatory approval, and we or others later identify undesirable side effects caused by such
product, a number of potentially significant negative consequences could result. For example, the FDA could require us to adopt a Risk
Evaluation and Mitigation Strategy (REMS), to ensure that the benefits of treatment with such product candidate outweigh the risks for
each potential patient, which may include, among other things, a communication plan to health care practitioners, patient education,
extensive patient monitoring or distribution systems and processes that are highly controlled, restrictive and more costly than what
is typical for the industry. We or our collaborators may also be required to adopt a REMS or engage in similar actions, such as patient
education, certification of health care professionals or specific monitoring, if we or others later identify undesirable side effects
caused by any product that we develop alone or with collaborators. Other potentially significant negative consequences associated with
adverse events include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to suspend marketing of a product, or we may decide to remove such product from the marketplace;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may withdraw or change their approvals of a product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may require additional warnings on the label or limit access of a product to selective specialized centers with additional
    safety reporting and with requirements that patients be geographically close to these centers for all or part of their treatment;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to create a medication guide outlining the risks of a product for patients, or to conduct post-marketing studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to change the way a product is administered;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    could be subject to fines, injunctions, or the imposition of criminal or civil penalties, or be sued and held liable for harm caused
    to subjects or patients; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    product may become less competitive, and our reputation may suffer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these events could diminish the usage or otherwise limit the commercial success of our product candidates and prevent us from achieving
or maintaining market acceptance of our product candidates, if approved by the FDA or other regulatory authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may find it difficult to enroll patients in our clinical trials. If we encounter difficulties enrolling patients in our clinical trials,
our clinical development activities could be delayed or otherwise adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patient
enrollment is a significant factor in the timing of clinical trials, and the timing of our clinical trials depends, in part, on the speed
at which we can recruit patients to participate in our trials, as well as completion of required follow-up periods. We may not be able
to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible
patients to participate in these trials to such trial&#8217;s conclusion as required by the FDA or other comparable regulatory authorities.
The conditions for which we currently plan to evaluate our product candidates are diseases with limited patient pools from which to draw
for clinical trials. The eligibility criteria of our clinical trials, once established, may further limit the pool of available trial
participants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patient
enrollment for any of our clinical trials may be affected by other factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">size
    and nature of the targeted patient population;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">severity
    of the disease or condition under investigation;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability
    and efficacy of approved therapies for the disease or condition under investigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient
    eligibility criteria for the trial in question as defined in the protocol;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">perceived
    risks and benefits of the product candidate under study;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinicians&#8217;
    and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available
    therapies, including any products that may be approved for, or any product candidates under investigation for, the indications we
    are investigating;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">efforts
    to facilitate timely enrollment in clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient
    referral practices of physicians;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to monitor patients adequately during and after treatment;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">proximity
    and availability of clinical trial sites for prospective patients;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continued
    enrollment of prospective patients by clinical trial sites; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk that patients enrolled in clinical trials will drop out of such trials before completion.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
other pharmaceutical companies targeting these same diseases are recruiting clinical trial patients from these patient populations, which
may make it more difficult to fully enroll our clinical trials. We also rely on, and will continue to rely on, CROs and clinical trial
sites to ensure proper and timely conduct of our clinical trials and preclinical studies. Though we have entered into agreements governing
their services, we will have limited influence over their actual performance. Our inability to enroll a sufficient number of patients
for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment
delays in our clinical trials may result in increased development costs for our product candidates and jeopardize our ability to obtain
regulatory approval for the sale of our product candidates. Furthermore, even if we are able to enroll a sufficient number of patients
for our clinical trials, we may have difficulty maintaining enrollment of such patients in our clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interim,
&#8220;topline&#8221; and preliminary data from our clinical trials and preclinical studies that we announce or publish from time to
time may change as more patient data become available and are subject to audit and verification procedures that could result in material
changes in the final data.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may publicly disclose interim, topline, or preliminary data from our clinical trials and preclinical studies, which
is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change
following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations
and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate
all data. As a result, the interim, topline, or preliminary results that we report may differ from future results of the same studies
or trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated.
Topline and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially
different from the topline or preliminary data we previously published. As a result, topline and preliminary data should be viewed with
caution until the final data is available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim
data from clinical trials that we may complete are further subject to the risk that one or more of the clinical outcomes may materially
change as patient enrollment continues and more patient data becomes available. Adverse differences between interim, topline, or preliminary
data and final data could significantly harm our business prospects. Further, disclosure of such data by us or by our competitors could
result in volatility in the price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses
or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability
or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose
to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others
may not agree with what we determine is material or otherwise appropriate information to include in our disclosure, and any information
we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or
otherwise regarding a particular product candidate or our business. If the interim, topline, or preliminary data that we report differ
from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval
for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial
condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
efforts to discover product candidates beyond our current product candidates may not succeed, and any product candidates we recommend
for clinical development may not actually begin clinical trials.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to expand our existing pipeline of core assets. However, the process of researching and developing new product candidates is expensive,
time-consuming and unpredictable. Data from our current preclinical programs may not support the clinical development of our product
candidates, and we may not identify any additional products suitable for recommendation for clinical development. Moreover, any product
candidate we recommend for clinical development may not demonstrate, through preclinical studies, indications of safety and potential
efficacy that would support advancement into clinical trials. Such findings would potentially impede our ability to maintain or expand
our clinical development pipeline. Our ability to develop new product candidates and advance them into clinical development also depends
upon our ability to fund our research and development operations, and we cannot be certain that additional funding will be available
on acceptable terms, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
regulatory approval processes of the FDA, the EMA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable,
and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical development, manufacturing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution
of our product candidates are subject to extensive regulation by the FDA in the U.S. and by comparable foreign regulatory authorities
in foreign markets, such as the EMA in Europe. In the U.S., we are not permitted to market our product candidates in the U.S. until we
receive regulatory approval of a Biologics License Application (BLA) or New Drug Application (NDA) from the FDA. The process of obtaining
such regulatory approval is expensive, often takes many years following the commencement of clinical trials and can vary substantially
based upon the type, complexity and novelty of the product candidates involved, as well as the target indications and patient population.
Approval policies or regulations may change, and the FDA, EMA and comparable regulatory authorities have substantial discretion in the
approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and
expense invested in clinical development of product candidates, regulatory approval of a product candidate is never guaranteed. Of the
large number of drugs in development, only a small percentage successfully complete the FDA, EMA or comparable regulatory approval processes
and are commercialized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to obtaining approval to commercialize a product candidate in the U.S. or abroad, we must demonstrate with substantial evidence from
adequate and well-controlled clinical trials, and to the satisfaction of the FDA, EMA or comparable foreign regulatory authorities, that
such product candidates are safe and effective for their intended uses, and in the case of biological products, that such product candidates
are safe, pure and potent. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe
available nonclinical or clinical data support the safety purity, potency or efficacy of our product candidates, such data may not be
sufficient to obtain approval from the FDA and comparable foreign regulatory authorities. The FDA, EMA or comparable foreign regulatory
authorities, as the case may be, may also require us to conduct additional preclinical studies or clinical trials for our product candidates
either prior to or post-approval, or may object to elements of our clinical development program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA, EMA or comparable foreign regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
    authorities may disagree with the design or execution of our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative
    or ambiguous results from our clinical trials or results may not meet the level of statistical significance required by the FDA,
    EMA or comparable foreign regulatory agencies for approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">serious
    and unexpected drug-related side effects may be experienced by participants in our clinical trials or by individuals using drugs
    similar to our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    population studied in the clinical trial may not be sufficiently broad or representative to assure safety in the full population
    for which we seek approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
    authorities may not accept clinical data from trials that are conducted at clinical facilities or in countries where the standard
    of care is potentially different from that of their own country;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
    authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
    authorities may not agree that the data collected from clinical trials of our product candidates are acceptable or sufficient to
    support the submission of a BLA, NDA or other submission or to obtain regulatory approval in the U.S. or elsewhere, and such authorities
    may impose requirements for additional preclinical studies or clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
    authorities may disagree with us regarding the formulation, labeling and/or the product specifications of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
    may be granted only for indications that are significantly more limited than those sought by us, and/or may include significant restrictions
    on distribution and use;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
    authorities may find deficiencies in the manufacturing processes or facilities of the third-party manufacturers with which we contract
    for clinical and commercial supplies; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
    authorities may not accept a submission due to, among other reasons, the content or formatting of the submission.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to foreign markets, approval procedures vary among countries and, in addition to the foregoing risks, may involve additional
product testing, administrative review periods and agreements with pricing authorities. Even if we eventually complete clinical trials
and receive approval of a BLA, NDA or comparable foreign marketing application for our product candidates, the FDA or comparable foreign
regulatory authority may grant approval contingent on the performance of costly additional clinical trials and/or the implementation
of a REMS, which may be required because the FDA believes it is necessary to ensure safe use of the product after approval. Any delay
in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of that product candidate
and would materially adversely impact our business and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we obtain FDA approval for any of our product candidates in the United States, we may never obtain approval for or commercialize such
candidates in any other jurisdiction, which would limit our ability to realize their full market potential.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements
on a country-by-country basis regarding safety and efficacy. Approval by the FDA in the United States does not ensure approval by regulatory
authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our
ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities
in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval
processes vary among countries and can involve additional product testing and validation, as well as additional administrative review
periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical
studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country
and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale
in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international
markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or
if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market
potential of any product we develop will be unrealized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disruptions
at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain
or deploy key leadership and other personnel, prevent new or modified products from being developed, reviewed, approved or commercialized
in a timely manner or at all, which could negatively impact our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of the FDA and foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including
government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s or foreign regulatory authorities&#8217;
ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s
or foreign regulatory authorities&#8217; ability to perform routine functions. Average review times at the FDA and foreign regulatory
authorities have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research
and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disruptions
at the FDA and other agencies, such as the EMA following its relocation to Amsterdam and resulting staff changes, may also slow the time
necessary for new drugs, and biologics or modifications to approved drugs and biologics to be reviewed and/or approved by necessary government
agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several
times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separately,
in response to the global COVID-19 pandemic, the FDA postponed most inspections of domestic and foreign manufacturing facilities at various
points. Even though the FDA has since resumed standard inspection operations, any resurgence of the virus or emergence of new variants
may lead to further inspectional or administrative delays. If a prolonged government shutdown occurs, or if global health concerns continue
to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities,
it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions,
which could have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if we receive regulatory approval for
any product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant
additional expenses. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
regulatory approvals that we may receive for our product candidates will require the submission of reports to regulatory authorities
and surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions
for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management
requirements. For example, the FDA may require a REMS in order to approve our product candidates, which could entail requirements for
a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution
methods, patient registries and other risk minimization tools. In addition, if the FDA or foreign regulatory authorities approve our
product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion,
import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements
include submissions of safety and other post-marketing information and reports, registration, as well as on-going compliance with cGMPs
and GCP for any clinical trials that we may conduct. In addition, manufacturers of drug products and their facilities are subject to
continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP regulations
and standards. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated
severity or frequency, or problems with the facilities where the product is manufactured, a regulatory agency may impose restrictions
on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension
of manufacturing. In addition, failure to comply with FDA and other comparable foreign regulatory requirements may subject our company
to administrative or judicially imposed sanctions, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on product distribution or use, or requirements to conduct post-marketing studies or clinical trials;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
    restitutions, disgorgement of profits or revenues, warning letters, untitled letters or holds on clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    by the FDA to approve pending applications or supplements to approved applications submitted by us or suspension or revocation of
    approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    seizure or detention, or refusal to permit the import or export of our products; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
    or the imposition of civil or criminal penalties.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue
and could require us to expend significant time and resources in response and could generate negative publicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be promulgated that
could prevent, limit or delay marketing authorization of any product candidates we develop. We also cannot predict the likelihood, nature
or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad.
If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not
able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA strictly regulates marketing, labeling, advertising and promotion of prescription drugs. These regulations include standards and
restrictions for direct-to-consumer advertising, industry-sponsored scientific and educational activities, promotional activities involving
the internet and off-label promotion. Any regulatory approval that the FDA grants is limited to those specific diseases and indications
for which a product is deemed to be safe and effective by FDA. While physicians in the United States may choose, and are generally permitted,
to prescribe drugs for uses that are not described in the product&#8217;s labeling and for uses that differ from those tested in clinical
trials and approved by the regulatory authorities, our ability to promote any products will be narrowly limited to those indications
that are specifically approved by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are found to have promoted such off-label uses, we may become subject to significant liability. The U.S. federal government has levied
large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from
engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under
which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of any product candidates,
if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Dependence on Third Parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
commercial success of our product candidates depends upon their market acceptance among physicians, patients, healthcare payors and the
medical community.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if our product candidates obtain regulatory approval, our products, if any, may not gain market acceptance among physicians, patients,
healthcare payors and the medical community. The degree of market acceptance of any of our approved product candidates will depend on
a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effectiveness of our approved product candidates as compared to currently available products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient
    willingness to adopt our approved product candidates in place of current therapies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to provide acceptable evidence of safety and efficacy;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">relative
    convenience and ease of administration;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    prevalence and severity of any adverse side effects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on use in combination with other products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability
    of alternative treatments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pricing
    and cost-effectiveness assuming either competitive or potential premium pricing requirements, based on the profile of our product
    candidates and target markets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">effectiveness
    of our or our partners&#8217; sales and marketing strategy;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain sufficient third-party coverage or reimbursement; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    product liability claims.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the potential market opportunity for our product candidates is difficult to precisely estimate. Our estimates of the potential
market opportunity for our product candidates include several key assumptions based on our industry knowledge, industry publications,
third-party research reports and other surveys. Independent sources have not verified all of our assumptions. If any of these assumptions
prove to be inaccurate, then the actual market for our product candidates could be smaller than our estimates of our potential market
opportunity. If the actual market for our product candidates is smaller than we expect, our product revenues may be limited, it may be
harder than expected to raise funds, and it may be more difficult for us to achieve or maintain profitability. If we fail to achieve
market acceptance of our product candidates in the U.S. and abroad, our revenue will be limited and it will be more difficult to achieve
profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
rely on third parties to conduct our preclinical studies and clinical trials and perform other tasks. If these third parties do not successfully
carry out their contractual duties, meet expected deadlines, or comply with regulatory requirements, we may not be able to obtain regulatory
approval for or commercialize our product candidates and our business, financial condition and results of operations could be substantially
harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely upon third-party CROs, medical institutions, clinical investigators and contract laboratories to monitor and manage data for our
ongoing preclinical and clinical programs. These CROs, investigators and other third parties play a significant role in the conduct and
timing of these trials and subsequent collection and analysis of data. Though we expect to carefully manage our relationships with such
CROs, investigators and other third parties, there can be no assurance that we will not encounter challenges or delays in the future,
or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. Further,
while we have and will have agreements governing the activities of our third-party contractors, we have limited influence over their
actual performance. Nevertheless, we maintain responsibility for ensuring that each of our clinical trials and preclinical studies is
conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards and our reliance on these third parties
does not relieve us of our regulatory responsibilities. We and our CROs and other vendors are required to comply with requirements for
cGMP, or similar foreign requirements, GCP, and good laboratory practice (GLP), which are a collection of laws and regulations enforced
by the FDA, the EMA and comparable foreign authorities for all of our product candidates in clinical development. Regulatory authorities
enforce these regulations through periodic inspections of preclinical study and clinical trial sponsors, principal investigators, preclinical
study and clinical trial sites, and other contractors. If we or any of our CROs or vendors fail to comply with applicable regulations,
the data generated in our preclinical studies and clinical trials may be deemed unreliable, and the FDA, the EMA or comparable foreign
authorities may require us to perform additional preclinical studies and clinical trials before approving our marketing applications.
We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical
trials comply with GCP regulations. In addition, our clinical trials must be conducted with products produced consistent with cGMP regulations,
or similar foreign requirements. Our failure to comply with these regulations may require it to repeat clinical trials, which would delay
the development and regulatory approval processes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to enter into arrangements with CROs on commercially reasonable terms, or at all. In addition, our CROs will not be our
employees, and except for remedies available to us under our agreements with such CROs, we will not be able to control whether or not
they devote sufficient time and resources to our ongoing preclinical and clinical programs. If CROs do not successfully carry out their
contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the data they
obtain is compromised due to the failure to adhere to our protocols, regulatory requirements, or for other reasons, our clinical trials
may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product
candidates. CROs may also generate higher costs than anticipated. As a result, our business, financial condition and results of operations
and the commercial prospects for our product candidates could be materially and adversely affected, our costs could increase, and our
ability to generate revenue could be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, principal investigators for our clinical trials may be asked to serve as scientific advisors or consultants to us from time
to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation
result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation
of the study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical
trial itself may be jeopardized, which could result in the delay or rejection by the FDA of any BLA or NDA we submit. Any such delay
or rejection could prevent us from commercializing our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our CROs have the right to terminate their agreements with us in the event of an uncured material breach and under other specified
circumstances. If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative
third parties on commercially reasonable terms or at all. Switching or adding additional CROs, medical institutions, clinical investigators
or contract laboratories involves additional cost and requires management time and focus. In addition, there is a natural transition
period when a new CRO commences work replacing a previous CRO. As a result, delays occur, which can materially impact our ability to
meet our desired clinical development timelines. There can be no assurance that we will not encounter similar challenges or delays in
the future or that these delays or challenges will not have a material adverse effect on our business, financial condition or results
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
currently rely on third parties for the manufacture of our product candidates during clinical development, and expect to continue to
rely on third parties for the foreseeable future. This reliance on third parties increases the risk that we will not have sufficient
quantities of our product candidates, or such quantities at an acceptable cost, which could delay, prevent or impair our development
or potential commercialization efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not own or operate manufacturing facilities and have no current plans to develop our own clinical or commercial-scale manufacturing
capabilities. We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates, and related raw
materials for clinical development, as well as for commercial manufacture if any of our product candidates receives regulatory approval.
The facilities used by our third-party manufacturers must be approved for the manufacture of our product candidates by the FDA, EMA,
or any comparable foreign regulatory authority, pursuant to inspections that will be conducted after we submit an NDA or BLA to the FDA,
or submit a comparable marketing application to a foreign regulatory authority. We do not control the manufacturing process of, and are
completely dependent on, third-party manufacturers for compliance with cGMP requirements for manufacture of our product candidates. If
these third-party manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory
requirements of the FDA or any comparable foreign regulatory authority, they will not be able to secure and/or maintain regulatory approval
for the use of their manufacturing facilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we have no control over the ability of third-party manufacturers to maintain adequate quality control, quality assurance and
qualified personnel. If the FDA, EMA or any comparable foreign regulatory authority does not approve these facilities for the manufacture
our product candidates, or if such authorities withdraw any such approval in the future, we may be required to find alternative manufacturing
facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates,
if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions
being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures
or recalls, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect our financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
or a third party&#8217;s failure to execute on our manufacturing requirements on commercially reasonable terms and in compliance with
cGMP or other regulatory requirements could adversely affect our business in a number of ways, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    inability to initiate or complete clinical trials of our product candidates in a timely manner;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    in submitting regulatory applications, or receiving regulatory approvals, for our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subjecting
    third-party manufacturing facilities to additional inspections by regulatory authorities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements
    to cease development or to recall batches of our product candidates; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the event of approval to market and commercialize any product candidate, an inability to meet commercial demands.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we do not have any long-term commitments or supply agreements with any third-party manufacturers. We may be unable to establish
any long-term supply agreements with third-party manufacturers or to do so on acceptable terms, which increases the risk of failing to
timely obtain sufficient quantities of our product candidates or such quantities at an acceptable cost. Even if we are able to establish
agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of third-party manufacturers to comply with regulatory requirements and maintain quality assurance;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">breach
    of the manufacturing agreement by the third party;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to manufacture our product candidates according to our specifications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to manufacture our product according to our schedule or at all;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">misappropriation
    of our proprietary information, including our trade secrets and know-how; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">termination
    or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval, and any
related remedial measures may be costly or time consuming to implement. We do not currently have arrangements in place for redundant
supply or a second source for all required raw materials used in the manufacture of our product candidates. If our existing or future
third-party manufacturers cannot perform as agreed, we may be required to replace such manufacturers and we may be unable to replace
them on a timely basis or at all, which would have a material adverse impact on our financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
clinical supply or collaboration arrangement that we may enter into in the future may not be successful, which could adversely affect
our ability to develop and commercialize our current and potential future product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek clinical supply or collaboration arrangements with biopharmaceutical companies for the development or commercialization of our
current and potential future product candidates. For example, in October 2024, we entered into a clinical supply agreement with BeiGene
to advance the clinical trial evaluation of Decoy20 in combination with BeiGene&#8217;s anti-PD-1 antibody, tislelizumab (the &#8220;BeiGene
Product&#8221;) for the treatment of patients with advanced solid tumors (the &#8220;Combination Study&#8221;). Under our agreement with
BeiGene, we will rely on BeiGene for the supply of the Beigene Product. If BeiGene cannot perform as agreed, we may be unable to initiate
or complete the Combination Study in a timely manner or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that we decide to enter into collaboration agreements, we will face significant competition in seeking appropriate collaborators.
Moreover, collaboration arrangements are complex and time consuming to negotiate, execute and implement. We may not be successful in
our efforts to establish and implement collaborations or other alternative arrangements should we choose to enter into such arrangements,
and the terms of the arrangements may not be favorable to us. If and when we collaborate with a third party for development and commercialization
of a product candidate, we can expect to relinquish some or all of the control over the future success of that product candidate to the
third party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
success of our clinical supply and collaboration arrangements will depend heavily on the efforts and activities of our collaborators.
Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disagreements
between parties to a clinical supply or collaboration arrangement can lead to delays in developing or commercializing the applicable
product candidate and can be difficult to resolve in a mutually beneficial manner. In some cases, collaborations with biopharmaceutical
companies and other third parties are terminated or allowed to expire by the other party. Any such termination or expiration would adversely
affect our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to develop our own commercial organization or enter into agreements with third parties to sell and market our product candidates,
we may be unable to generate significant revenues.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have a sales and marketing organization, and we have no experience as a company in the sales, marketing and distribution of pharmaceutical
products. If any of our product candidates are ever approved for commercialization, we may be required to develop our sales, marketing
and distribution capabilities, or make arrangements with a third party to perform sales and marketing services. Developing a sales force
for any product resulting from any of our product candidates is expensive and time consuming and could delay any product launch. We may
be unable to establish and manage an effective sales force in a timely or cost-effective manner, if at all, and any sales force we do
establish may not be capable of generating sufficient demand for our product candidates. To the extent that we enter into arrangements
with collaborators or other third parties to perform sales and marketing services, our product revenues are likely to be lower than if
we marketed and sold our product candidates independently. If we are unable to establish adequate sales and marketing capabilities, independently
or with others, we may not be able to generate significant revenues and may not become profitable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Commercialization</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
successful commercialization of Decoy20 or any future product candidates, if approved, will depend in part on the extent to which governmental
authorities and health insurers establish coverage, adequate reimbursement levels and favorable pricing policies. Failure to obtain or
maintain coverage and adequate reimbursement for our products could limit our ability to market those products and decrease our ability
to generate revenue.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
availability of coverage and the adequacy of reimbursement by governmental healthcare programs such as Medicare and Medicaid, private
health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as Decoy20
and any future product candidates, if approved. Our ability to achieve coverage and acceptable levels of reimbursement for our products
by third-party payors will have an effect on our ability to successfully commercialize those products. Accordingly, we will need to successfully
implement a coverage and reimbursement strategy for any approved product candidate. Even if we obtain coverage for a given product by
a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably
high.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we participate in the Medicaid Drug Rebate Program or other governmental pricing programs, in certain circumstances, our products would
be subject to ceiling prices set by such programs, which could reduce the revenue we may generate from any such products. Participation
in such programs would also expose us to the risk of significant civil monetary penalties, sanctions and fines should we be found to
be in violation of any applicable obligations thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult
because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment
or procedure in which the product is used may not be available, which may impact physician utilization. We cannot be sure that coverage
and reimbursement in the United States, the European Union or elsewhere will be available, or at an acceptable level, for any product
that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
payors increasingly are challenging prices charged for biopharmaceutical products and services, and many third-party payors may refuse
to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available.
It is possible that a third-party payor may consider our products as substitutable and only offer to reimburse patients for the less
expensive product. Even if we are successful in demonstrating improved efficacy or improved convenience of administration with our products,
pricing of existing drugs may limit the amount we will be able to charge for our products. These payors may deny or revoke the reimbursement
status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize
an appropriate return on our investment in product development. If reimbursement is not available or is available only at limited levels,
we may not be able to successfully commercialize our products and may not be able to obtain a satisfactory financial return on products
that we may develop.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States,
third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in
determining the extent to which new drugs will be covered. Some third-party payors may require pre-approval of coverage for new or innovative
devices or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this
time what third-party payors will decide with respect to the coverage and reimbursement for Decoy20 and any future product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
and maintaining reimbursement status is time-consuming, costly and uncertain. The Medicare and Medicaid programs increasingly are used
as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs. However,
no uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage
and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often
a time consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each
payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.
Furthermore, rules and regulations regarding reimbursement change frequently and, in some cases, at short notice, and we believe that
changes in these rules and regulations are likely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outside
the United States, international operations are generally subject to extensive governmental price controls and other market regulations,
and we believe the increasing emphasis on cost-containment initiatives in Europe and other countries has and will continue to put pressure
on the pricing and usage of our products candidates, if approved in these jurisdictions. In many countries, the prices of medical products
are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own
prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation
could restrict the amount that we are able to charge for our products. Accordingly, in markets outside the United States, if any, the
reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable
revenue and profits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause
such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover
or provide adequate payment for our products. We expect to experience pricing pressures in connection with the sale of any of our products
due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes.
The downward pressure on healthcare costs in general, and prescription drugs, surgical procedures and other treatments in particular,
has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recently
enacted legislation, future legislation and healthcare reform measures may increase the difficulty and cost for us to obtain marketing
approval for and commercialize Decoy20 and any future product candidates and may affect the prices we may set.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and
regulatory changes to the healthcare system, including cost-containment measures that may reduce or limit coverage and reimbursement
for newly approved drugs and affect our ability to profitably sell any product candidates for which we obtain marketing approval. In
particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare
costs and improve the quality of healthcare.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
way of example, in March 2010, the ACA was enacted in the United States. The ACA established an annual, nondeductible fee on any entity
that manufactures or imports specified branded prescription drugs and biologic agents; extended manufacturers&#8217; Medicaid rebate
liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; expanded eligibility criteria
for Medicaid programs; expanded the entities eligible for discounts under the 340B drug pricing program; increased the statutory minimum
rebates a manufacturer must pay under the Medicaid Drug Rebate Program; established a new Patient-Centered Outcomes Research Institute
to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research; and
establishes a Center for Medicare &amp; Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare
and Medicaid spending.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
its enactment, there have been executive, judicial and Congressional challenges to certain aspects of the ACA, and on June 17, 2021,
the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling
on the constitutionality of the ACA. Prior to the Supreme Court&#8217;s decision, President Biden had issued an executive order to initiate
a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through
the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies
and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that
include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid
or the ACA. It is unclear how the healthcare reform measures will impact our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, other legislative changes have been proposed and adopted since the ACA was enacted. On March 11, 2021, the American Rescue
Plan Act of 2021 was signed into law, which eliminate the statutory cap on the Medicaid drug rebate, beginning January 1, 2024 at 100%
of a drug&#8217;s AMP. Further, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices
in light of the rising cost of prescription drugs. Such scrutiny has resulted in several recent congressional inquiries and proposed
and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship
between pricing and manufacturer patient assistance programs, and reform government program reimbursement methodologies for products.
Most recently, the Inflation Reduction Act of 2022, or IRA, included a number of significant drug pricing reforms, which include the
establishment of a drug price negotiation program within the U.S. Department of Health and Human Services, or HHS (beginning in 2026)
that requires manufacturers to charge a negotiated &#8220;maximum fair price&#8221; for certain selected drugs or pay an excise tax for
noncompliance, the establishment of rebate payment requirements on manufacturers under Medicare Parts B and D to penalize price increases
that outpace inflation (first due in 2023), and a redesign of the Part D benefit, as part of which manufacturers are required to provide
discounts on Part D drugs (beginning in 2025). The IRA permits the HHS Secretary to implement many of these provisions through guidance,
as opposed to regulation, for the initial years. On August 29, 2023, HHS announced the list of the first ten drug that will be subject
to price negotiations, although the drug price negotiation program is currently subject to legal challenges. For that and other reasons,
it is currently unclear how the IRA will be effectuated. Additional drug pricing proposals could appear in future legislation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and
biological product pricing, including price or reimbursement constraints, discounts, restrictions on certain product access and marketing
cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.
Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations,
financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding
procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare
programs. This could reduce the ultimate demand for Decoy20 and any future product candidates, if approved, or put pressure on our product
pricing, which could negatively affect our business, results of operations, financial condition and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that these new laws and other healthcare reform measures that may be adopted in the future may result in additional reductions
in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure
on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may
result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms
may prevent us from being able to generate revenue, attain profitability or commercialize Decoy20 and any future product candidates,
if approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Product
liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidates
that we may develop.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and
will face an even greater risk if we commercially sell any product candidates that we may develop. If we cannot successfully defend ourselves
against claims that our product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome,
liability claims may result in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased
    demand for any product candidates that we may develop;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injury
    to our reputation and significant negative media attention;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    investigations that could require costly recalls or product modifications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
    of clinical trial participants;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    costs to defend the related litigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
    monetary awards to trial participants or patients;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
    of potential revenue;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    diversion of management&#8217;s attention away from managing our business; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability to commercialize any product candidates that we may develop.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we maintain product liability insurance coverage, it may not be adequate to cover all liabilities that we may incur and is subject to
deductibles and coverage limitations. We anticipate that we will need to increase our insurance coverage when and if we successfully
commercialize any product candidate. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage
at a reasonable cost or in an amount adequate to satisfy any liability that may arise. If we are unable to obtain insurance at acceptable
cost or otherwise protect against potential product liability claims, we will be exposed to significant liabilities, which may materially
and adversely affect our business and financial position. These liabilities could prevent or interfere with our commercialization efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to a multitude of manufacturing risks, any of which could substantially increase our costs and limit the supply of our product
candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process of manufacturing our product candidates is complex, highly regulated, and subject to several risks. For example, the process
of manufacturing our product candidates is extremely susceptible to product loss due to contamination, equipment failure or improper
installation or operation of equipment, or vendor or operator error. Even minor deviations from normal manufacturing processes for any
of our product candidates could result in reduced production yields, product defects, and other supply disruptions. If microbial, viral,
or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are
made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination.
In addition, the manufacturing facilities in which our product candidates are made could be adversely affected by equipment failures,
labor shortages, natural disasters, power failures and numerous other factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, any adverse developments affecting manufacturing operations for our product candidates may result in shipment delays, inventory
shortages, lot failures, withdrawals or recalls, or other interruptions in the supply of our product candidates. We also may need to
take inventory write-offs and incur other charges and expenses for product candidates that fail to meet specifications, undertake costly
remediation efforts, or seek costlier manufacturing alternatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Competition, Retaining Key Employees and Managing Growth</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our competitors have product candidates that are approved faster, marketed more effectively, are better tolerated, have a more favorable
safety profile or are demonstrated to be more effective than our product candidates, our commercial opportunity may be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
industry in which we operate is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary
products. While we believe that our technology, knowledge, experience and scientific resources provide it with competitive advantages,
we face potential competition from many different sources, including commercial biotechnology enterprises, academic institutions, government
agencies and private and public research institutions. Any product candidates that we successfully develop and commercialize will compete
with existing immunotherapies and new immunotherapies that may become available in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical
studies, clinical trials, regulatory approvals and marketing approved products than we do. Smaller or early-stage companies may also
prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Our competitors
may succeed in developing technologies and therapies that are more effective, better tolerated or less costly than any which we are developing,
or that would render our product candidates obsolete and noncompetitive. Even if we obtain regulatory approval for any of our product
candidates, our competitors may succeed in obtaining regulatory approvals for their products earlier than we do. We will also face competition
from these third parties in recruiting and retaining qualified scientific and management personnel, in establishing clinical trial sites
and patient registration for clinical trials, and in acquiring and in-licensing technologies and products complementary to our programs
or advantageous to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key competitive factors affecting the success of each of our product candidates, if approved, are likely to be its efficacy, safety,
tolerability, frequency and route of administration, convenience and price, the level of branded and generic competition, market acceptance
by physicians and patients, and the availability of coverage and reimbursement from government and other third-party payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Patient Protection and Affordable Care Act, signed into law on March 23, 2010, includes a subtitle called the Biologics Price Competition
and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or
interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be
submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval
of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed.
During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves
a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical
trials to demonstrate the safety, purity and potency of its product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that any of our future product candidates approved as a biological product under a BLA should qualify for the 12-year period
of exclusivity. However, there is a risk that this exclusivity could be shortened due to Congressional action or otherwise, or that the
FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for
generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, could be substituted for any
one of our reference products in a way that is similar to traditional generic substitution for non-biological products will depend on
a number of marketplace and regulatory factors that are still developing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are highly dependent on our current senior management. If we fail to retain current members of our senior management and scientific personnel,
or to attract and keep additional key personnel, we may be unable to successfully develop or commercialize our product candidates. We
are highly dependent on our chief executive officer, Jeffrey A. Meckler, and our chief scientific officer, Michael J. Newman, Ph.D. Our
success depends on our continued ability to attract, retain and motivate highly qualified management and scientific personnel. However,
competition for qualified personnel is intense. We may not be successful in attracting qualified personnel to fulfill our current or
future needs on a full-time employment basis, or at all. In the event we are unable to fill critical open employment positions, we may
need to delay our operational activities and goals, including the development of the company&#8217;s product candidates, and may have
difficulty in meeting our obligations as a public company. We do not currently maintain &#8220;key person&#8221; insurance on any of
our employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, competitors and others are likely in the future to attempt to recruit our employees. The loss of the services of any of our
key personnel, the inability to attract or retain highly qualified personnel in the future or delays in hiring such personnel, particularly
senior management and other technical personnel, could materially and adversely affect our business, financial condition and results
of operations. In addition, the replacement of key personnel likely would involve significant time and costs and may significantly delay
or prevent the achievement of our business objectives. From time to time, our management seeks the advice and guidance of certain scientific
advisors and consultants regarding clinical and regulatory development programs and other customary matters. These scientific advisors
and consultants are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may
limit their availability to us. In addition, our scientific advisors may have arrangements with other companies to assist those companies
in developing products or technologies that may compete with us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need to increase the size of our organization and may not successfully manage our growth.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an early clinical-stage biotechnology company with a small number of employees, and our management systems currently in place are
not likely to be adequate to support our future growth plans. Our ability to grow and to manage our growth effectively will require us
to hire, train, retain, manage and motivate additional employees and to implement and improve our operational, financial and management
systems. These demands also may require the hiring of additional senior management personnel or the development of additional expertise
by our senior management personnel. Hiring a significant number of additional employees, particularly those at the management level,
would increase our expenses significantly. Moreover, if we fail to expand and enhance our operational, financial and management systems
in conjunction with our potential future growth, it could have a material adverse effect on our business, financial condition and results
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to adequately protect our proprietary or licensed technology in the marketplace.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
depend on our ability to protect our proprietary technology and products, or those that we may license. We intend to rely on trade secret,
patent, copyright and trademark laws, confidentiality, license, and other agreements with employees and third parties to protect our
intellectual property. Our success depends in large part on our ability and any licensor&#8217;s or licensee&#8217;s ability to obtain
and maintain patent protection in the U.S. and other countries with respect to our proprietary or licensed technology and products. We
cannot be certain that patent enforcement activities by future licensors will be conducted in compliance with applicable laws and regulations
or will result in valid and enforceable patents or other intellectual property rights. We also cannot be certain that future licensors
will allocate sufficient resources or prioritize their or our enforcement of such patents. Even if we are not a party to these legal
actions, an adverse outcome could prevent us from licensing intellectual property that we may need to operate our business, which would
have a material adverse effect on our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe we will be able to obtain, through prosecution of patent applications covering our owned technology, adequate patent protection
for our proprietary technology. If we are compelled to spend significant time and money protecting or enforcing our patents and future
patents that we may own, designing around patents held by others or licensing or acquiring, potentially for large fees, patents or other
proprietary rights held by others, our business, financial condition and results of operations may be materially and adversely affected.
If we are unable to effectively protect the intellectual property that we own or in-license, other companies may be able to offer the
same or similar products for sale, which could materially adversely affect our business, financial condition and results of operations.
The patents of others from whom we may license technology, and any future patents we may own, may be challenged, narrowed, invalidated
or circumvented, which could limit our ability to stop competitors from marketing the same or similar products or limit the length of
term of patent protection that we may have for our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be unable to acquire or in-license any compositions, methods of use, processes or other intellectual property rights from third parties
that we identify as necessary for our current or future product candidates. We may face competition with regard to acquiring and in-licensing
third-party intellectual property rights, including from a number of more established companies. These established companies may have
a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.
In addition, companies that perceive us to be a competitor may be unwilling to assign or license intellectual property rights to us.
We also may be unable to acquire or in- license third-party intellectual property rights on terms that would allow us to make an appropriate
return on our investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may enter into collaboration agreements with U.S. and foreign academic institutions to accelerate development of our current or future
preclinical product candidates. Typically, these agreements include an option for the company to negotiate a license to the institution&#8217;s
intellectual property rights resulting from the collaboration. Even with such an option, we may be unable to negotiate a license within
the specified timeframe or under terms that are acceptable to us. If we are unable to license rights from a collaborating institution,
the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our desired program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to successfully obtain required third-party intellectual property rights or maintain our existing intellectual property
rights, we may need to abandon development of the related program and our business, financial condition and results of operations could
be materially and adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Obtaining
and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection for licensed patents, pending patent applications and potential future
patent applications and patents could be reduced or eliminated for non-compliance with these requirements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodic
maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or patent applications will be due to
be paid to the United States Patent and Trademark Office &#8220;USPTO&#8221; and various governmental patent agencies outside of the
U.S. in several stages over the lifetime of the applicable patent and/or patent application. The USPTO and various non-U.S. governmental
patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent
application process. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the
applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application,
resulting in partial or complete loss of patent rights in the relevant jurisdiction. If this occurs with respect to our in-licensed patents
or patent applications we may file in the future, our competitors might be able to use our technologies, which would have a material
adverse effect on our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent positions of products are often complex and uncertain. The breadth of claims allowed in patents in the U.S. and many jurisdictions
outside of the U.S. may not be consistent. Changes in either the patent laws or interpretations of patent laws in the U.S. and other
countries may diminish the value of our licensed or owned intellectual property or create uncertainty. In addition, publication of information
related to our current product candidates and potential products may prevent us from obtaining or enforcing patents relating to these
product candidates and potential products, including without limitation composition-of-matter patents, which are generally believed to
offer the strongest patent protection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
that we may own now or may own or license in the future do not necessarily ensure the protection of our licensed or owned intellectual
property for a number of reasons, including, without limitation, the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    patents may not be broad or strong enough to prevent competition from other products that are identical or similar to our product
    candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    can be no assurance that the term of a patent can be extended under the provisions of patent term extensions afforded by U.S. law
    or similar provisions in foreign countries, where available;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    issued patents and patents that we may own now or may obtain or license in the future may not prevent generic or biosimilar entry
    into the market for our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we,
    or third parties from whom we in-license or may license patents, may be required to disclaim part of the term of one or more patents;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    may be prior art of which we are aware, which we do not believe affects the validity or enforceability of a patent claim, but which,
    nonetheless, ultimately may be found to affect the validity or enforceability of a patent claim;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    may be other patents issued to others that will affect our freedom to operate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the patents are challenged, a court could determine that they are invalid or unenforceable;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    might be a significant change in the law that governs patentability, validity and infringement of our licensed patents or any future
    patents we may own that adversely affects the scope of our patent rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    court could determine that a competitor&#8217;s technology or product does not infringe our patents or any future patents we may
    own; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    patents could irretrievably lapse due to failure to pay fees or otherwise comply with regulations or could be subject to compulsory
    licensing. If we encounter delays in our development or clinical trials, the period of time during which we could market our potential
    products under patent protection would be reduced.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 49; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
competitors may be able to circumvent patents or future patents that we may own by developing similar or alternative technologies or
products in a non-infringing manner. Our competitors may seek to market generic or biosimilar versions of any approved products by submitting
abbreviated new applications or biosimilar biological product applications to the FDA in which our competitors claim that our licensed
patents or any future patents we may own are invalid, unenforceable or not infringed. Alternatively, our competitors may seek approval
to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend or
assert our patents or any future patents we may own, including by filing lawsuits alleging patent infringement. In any of these types
of proceedings, a court or other agency with jurisdiction may find our licensed patents or any future patents we may own invalid or unenforceable.
We may also fail to identify patentable aspects of our research and development before it is too late to obtain patent protection. Even
if we own or in-license valid and enforceable patents, these patents still may not provide protection against competing products or processes
sufficient to achieve our business objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of a patent is not conclusive as to its inventorship, scope, ownership, priority, validity or enforceability. In this regard,
third parties may challenge our patents or any future patents we may own in the courts or patent offices in the U.S. and abroad. Such
challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable,
in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products,
or limit the duration of the patent protection of our technology and potential products. In addition, given the amount of time required
for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire
before or shortly after such product candidates are commercialized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
have a limited lifespan, and the protection patents afford is limited. In the United States, if all maintenance fees are timely paid,
the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Even if patents covering
our product candidates are obtained, once the patent life has expired for patents covering a product or product candidate, we may be
open to competition from competitive products and services. As a result, our patent portfolio may not provide us with sufficient rights
to exclude others from commercializing products similar or identical to ours. We may infringe the intellectual property rights of others,
which may prevent or delay our product development efforts and prevent us from commercializing, or increase the costs of commercializing,
our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends significantly on our ability to operate without infringing the patents and other intellectual property rights
of third parties. For example, there could be issued patents of which we are not aware that our current or potential future product candidates
infringe. There also could be patents that we believe we do not infringe upon, but that we may ultimately be found to infringe upon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
patent applications are in some cases maintained in secrecy until patents are issued. The publication of discoveries in the scientific
or patent literature frequently occurs substantially later than the date on which the underlying discoveries were made and patent applications
were filed. Because patents can take many years to issue, there may be currently pending applications of which we are unaware that may
later result in issued patents that our product candidates or potential products infringe. For example, pending applications may exist
that claim or can be amended to claim subject matter that our product candidates or potential products infringe. Competitors may file
continuing patent applications claiming priority to already issued patents in the form of continuation, divisional, or continuation-in-part
applications, in order to maintain the pendency of a patent family and attempt to cover our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 50; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
parties may assert that we are employing their proprietary technology without authorization and may sue us for patent or other intellectual
property infringement. These lawsuits are costly and could adversely affect our business, financial condition and results of operations
and divert the attention of managerial and scientific personnel. If we are sued for patent infringement, we would need to demonstrate
that our product candidates, potential products or methods either do not infringe the claims of the relevant patent or that the patent
claims are invalid, and we may not be able to do this. Proving invalidity is difficult. For example, in the U.S., proving invalidity
requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are
successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel
could be diverted in pursuing these proceedings, which could have a material adverse effect on us. In addition, we may not have sufficient
resources to bring these actions to a successful conclusion. If a court holds that any third-party patents are valid, enforceable and
cover our products or their use, the holders of any of these patents may be able to block our ability to commercialize our products unless
it acquires or obtains a license under the applicable patents or until the patents expire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to enter into licensing arrangements or make other arrangements at a reasonable cost or on reasonable terms. Any inability
to secure licenses or alternative technology could result in delays in the introduction of our products or lead to prohibition of the
manufacture or sale of products by us. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors
access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing
technology or product. In addition, in any such proceeding or litigation, we could be found liable for monetary damages, including treble
damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent. A finding of infringement could prevent us from
commercializing our product candidates or force us to cease some of our business operations, which could materially and adversely affect
our business, financial condition and results of operations. Any claims by third parties that we have misappropriated their confidential
information or trade secrets could have a similar material and adverse effect on our business, financial condition and results of operations.
In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect
on our ability to raise the funds necessary to continue our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
claims or lawsuits relating to infringement of intellectual property rights brought by or against us will be costly and time consuming
and may adversely affect our business, financial condition and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be required to initiate litigation to enforce or defend our licensed and owned intellectual property. Lawsuits to protect our intellectual
property rights can be very time consuming and costly. There is a substantial amount of litigation involving patent and other intellectual
property rights in the biopharmaceutical industry generally. Such litigation or proceedings could substantially increase our operating
expenses and reduce the resources available for development activities or any future sales, marketing or distribution activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
any infringement litigation, any award of monetary damages we receive may not be commercially valuable. Furthermore, because of the substantial
amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information
could be compromised by disclosure during litigation. Moreover, there can be no assurance that we will have sufficient financial or other
resources to file and pursue such infringement claims, which typically last for years before they are resolved. Further, any claims we
assert against a perceived infringer could provoke these parties to assert counterclaims against us alleging that we have infringed their
patents. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because
of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings
could have a material adverse effect on our ability to compete in the marketplace.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our patents and patent applications, and patents and patent applications that we may apply for, own or license in the future,
could face other challenges, such as interference proceedings, opposition proceedings, re-examination proceedings and other forms of
post-grant review. Any of these challenges, if successful, could result in the invalidation of, or in a narrowing of the scope of, any
of our patents and patent applications and patents and patent applications that we may apply for, own or license in the future subject
to challenge. Any of these challenges, regardless of their success, would likely be time consuming and expensive to defend and resolve
and would divert our management and scientific personnel&#8217;s time and attention.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is the case with other biotechnology companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining
and enforcing patents in the biotechnology industry involves both technological and legal complexity and is costly, time-consuming and
inherently uncertain. For example, the U.S. previously enacted and is currently implementing wide-ranging patent reform legislation.
Specifically, on September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law and included a
number of significant changes to U.S. patent law, and many of the provisions became effective in March 2013. However, it may take the
courts years to interpret the provisions of the Leahy-Smith Act, and the implementation of the statute could increase the uncertainties
and costs surrounding the prosecution of our licensed and future patent applications and the enforcement or defense of our licensed and
future patents, all of which could have a material adverse effect on our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available
in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard
to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents,
once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents
could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we might obtain in
the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to protect our intellectual property rights throughout the world.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing,
prosecuting and defending patents on product candidates throughout the world could be prohibitively expensive. Competitors may use our
licensed and owned technologies in jurisdictions where we have not licensed or obtained patent protection to develop their own products
and, further, may export otherwise infringing products to territories where we may obtain or license patent protection, but where patent
enforcement is not as strong as that in the U.S. These products may compete with our products in jurisdictions where we do not have any
issued or licensed patents and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent
them from competing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual
property protection, which could make it difficult for us to stop the infringement of our licensed patents and future patents we may
own, or marketing of competing products in violation of our proprietary rights generally. Further, the laws of some foreign countries
do not protect proprietary rights to the same extent or in the same manner as the laws of the U.S. As a result, we may encounter significant
problems in protecting and defending our licensed and owned intellectual property both in the U.S. and abroad. Proceedings to enforce
our future patent rights, if any, in foreign jurisdictions could result in substantial cost and divert our efforts and attention from
other aspects of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be unable to adequately prevent disclosure of trade secrets and other proprietary information.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to protect our proprietary technology and processes, we rely in part on confidentiality agreements with our corporate partners,
employees, consultants, manufacturers, outside scientific collaborators and sponsored researchers and other advisors. These agreements
may not effectively prevent disclosure of our confidential information and may not provide an adequate remedy in the event of unauthorized
disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information.
Failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to claims challenging the inventorship of our patents, any future patents we may own, and other intellectual property.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we are not currently experiencing any claims challenging the inventorship of our patents or our owned intellectual property, we may in
the future be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other
owned intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations
of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and
other claims challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable
intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could
have a material adverse effect on our business, financial condition and results of operations. Even if we are successful in defending
against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Healthcare Laws and Other Legal Compliance Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to various U.S. federal, state and foreign healthcare laws and regulations, which could increase compliance costs, and our
failure to comply with these laws and regulations could harm our results of operations and financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors,
patient organizations and customers expose us to broadly applicable foreign, federal and state fraud and abuse and other healthcare laws
and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations,
including how we research, market, sell and distribute any products for which we obtain marketing approval. Such laws include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting,
    offering, receiving or providing any remuneration (including any kickback, bribe or certain rebates), directly or indirectly, overtly
    or covertly, in cash or in kind, in return for, either the referral of an individual or the purchase, lease, or order, or arranging
    for or recommending the purchase, lease, or order of any good, facility, item or service, for which payment may be made, in whole
    or in part, under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge
    of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibit, among other things,
    individuals or entities from knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval
    that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false
    or fraudulent claim, or from knowingly making or causing to be made a false statement to avoid, decrease or conceal an obligation
    to pay money to the federal government. In addition, the government may assert that a claim including items or services resulting
    from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims
    Act;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which imposes criminal and civil liability for, among
    other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or
    knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection
    with the delivery of, or payment for, healthcare benefits, items or services. Similar to the federal Anti- Kickback Statute, a person
    or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for
    which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to
    report annually to the Centers for Medicare &amp; Medicaid Services (CMS), information related to payments and other &#8220;transfers
    of value&#8221; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician
    practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiology
    assistants and certified nurse-midwives), and teaching hospitals and other healthcare providers, as well as ownership and investment
    interests held by such healthcare professionals and their immediate family members; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous
    state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing
    arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private
    insurers; some state laws require biotechnology companies to comply with the biotechnology industry&#8217;s voluntary compliance
    guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report
    information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures;
    some state laws that require biotechnology companies to report information on the pricing of certain drug products; and some state
    and local laws that require the registration or pharmaceutical sales representatives.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efforts
to ensure that our current and future business arrangements with third parties will comply with applicable healthcare and privacy laws
and regulations will involve ongoing substantial costs. It is possible that governmental authorities will conclude that our business
practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare
laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that
may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines,
disgorgement, imprisonment, exclusion from participation in government-funded healthcare programs, such as Medicare and Medicaid, integrity
oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment
or restructuring of our operations. Defending against any such actions can be costly and time-consuming and may require significant financial
and personnel resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Therefore,
even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further,
if any of the physicians or other healthcare providers or entities with whom we expect to do business are found not to be in compliance
with applicable laws or regulations, they may be subject to significant criminal, civil or administrative sanctions, including exclusions
from government-funded healthcare programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Actual
or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements
could adversely affect our business, results of operations, and financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements
and regulations governing the collection, use, disclosure, retention, and security of personal information. Implementation standards
and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws,
regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business,
affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate
the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. Each of these laws
is subject to varying interpretations by courts and government agencies, creating complex compliance issues. If we fail to comply with
applicable laws and regulations, we may face government investigations and/or enforcement actions, fines, civil or criminal penalties,
private litigation or adverse publicity that could adversely affect our business, financial condition and results of operation. For example,
we may be subject to criminal penalties if we knowingly obtain or disclose individually identifiable health information from a covered
entity in a manner that is not authorized or permitted by the Health Insurance Portability and Accountability Act, as amended by the
Health Information Technology for Economic and Clinical Health Act of 2009, and regulations implemented thereunder or applicable state
laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Violations
of or liabilities under environmental, health and safety laws and regulations could subject us to fines, penalties or other costs that
could have a material adverse effect on the success of our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures, the handling,
use, storage, treatment and disposal of hazardous materials and wastes and the cleanup of contaminated sites. Our operations involve
the use of potentially hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous
waste products. We could incur substantial costs as a result of violations of or liabilities under environmental requirements in connection
with our operations or property, including fines, penalties and other sanctions, investigation and cleanup costs and third-party claims.
Although we generally contract with third parties for the disposal of hazardous materials and wastes from our operations, we cannot eliminate
the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous
materials, we could be held liable for any resulting damages, and any liability could exceed our resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact
of changes to applicable laws and regulations and cannot be certain of our future compliance. In addition, we may incur substantial costs
in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations
may impair our research, development or production efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting
from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain
insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal
of biological, hazardous or radioactive materials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Risks Related to Our Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business and operations may suffer in the event of information technology system failures, cyberattacks or deficiencies in our cybersecurity.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
collect and maintain information in digital form that is necessary to conduct our business, and we are increasingly dependent on information
technology systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store and transmit
large amounts of confidential information, including intellectual property, proprietary business information and personal information
of customers and our employees and contractors. It is critical that we do so in a secure manner to maintain the confidentiality and integrity
of such confidential information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
information technology systems and those of our third-party service providers, strategic partners and other contractors or consultants
are vulnerable to attack and damage or interruption from computer viruses and malware (e.g. ransomware), malicious code, natural disasters,
terrorism, war, telecommunication and electrical failures, hacking, cyberattacks, phishing attacks and other social engineering schemes,
employee theft or misuse, human error, fraud, denial or degradation of service attacks, sophisticated nation-state and nation-state-supported
actors or unauthorized access or use by persons inside our organization, or persons with access to systems inside our organization. We
have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may or could
have access to our confidential information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and
are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. As a result of
the changes brought about by the COVID-19 pandemic, we may also face increased cybersecurity risks due to our reliance on internet technology
and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities.
Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not
recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures.
We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately
investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent
controls, to avoid detection, and to remove or obfuscate forensic evidence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and certain of our service providers are from time to time subject to cyberattacks and security incidents. While we do not believe that
we have experienced any significant system failure, accident or security breach to date, if such an event were to occur and cause interruptions
in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a
loss, corruption or unauthorized disclosure of our trade secrets, personal information or other proprietary or sensitive information
or other similar disruptions. If a security breach or other incident were to result in the unauthorized access to or unauthorized use,
disclosure, release or other processing of personal information, it may be necessary to notify individuals, governmental authorities,
supervisory bodies, the media and other parties pursuant to privacy and security laws. We could also incur liability, including litigation
exposure, penalties and fines, and we could become the subject of regulatory action or investigation. Our competitive position could
be harmed and the further development and commercialization of our products and services could be delayed. We maintain cyber liability
insurance; however, this insurance may not be sufficient to cover the financial, legal, business or reputational losses that may result
from an interruption or breach of our systems. While we have implemented a cybersecurity risk management program, there can be no assurance
that our cybersecurity risk management program and processes, including our policies, controls or procedures, will be fully implemented,
complied with or effective in protecting our systems and information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our
management.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may consider strategic transactions, such as acquisitions of companies, asset purchases and out-licensing or in-licensing
of products, product candidates or technologies. Additional potential transactions that we may consider include a variety of different
business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations
and investments. Any such transaction may require us to incur non-recurring or other charges, may increase our near- and long-term expenditures
and may pose significant integration challenges or disrupt our management or business, which could adversely affect our business, financial
condition and results of operations. For example, these transactions may entail numerous operational and financial risks, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exposure
    to unknown liabilities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruption
    of our business and diversion of our management&#8217;s time and attention in order to develop acquired products, product candidates
    or technologies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incurrence
    of substantial debt or dilutive issuances of equity securities to pay for any of these transactions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">higher-than-expected
    transaction and integration costs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">write-downs
    of assets or goodwill or impairment charges;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
    amortization expenses;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    and cost in combining the operations and personnel of any acquired businesses or product lines with our operations and personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairment
    of relationships with key suppliers or customers of any acquired businesses or product lines due to changes in management and ownership;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    to retain key employees of any acquired businesses.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any
transactions that we do complete may be subject to the foregoing or other risks and could have a material adverse effect on our business,
financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 56; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with the continued listing requirements of the Nasdaq Capital Market, our common stock may be delisted and the price
of our common stock and our ability to access the capital markets could be negatively impacted.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
has established certain standards for the continued listing of a security on the Nasdaq Capital Market. The standards for continued listing
include, among other things, that the minimum bid price for the listed securities not fall below $1.00 per share for a period of 30 consecutive
trading days and that we maintain a minimum of $2,500,000 in stockholders&#8217; equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 31, 2025, we were notified, or the Notification Letter, by the Nasdaq Listing Qualifications that we are not in compliance with
the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2), or the Rule, for continued listing on The Nasdaq Capital
Market. The Notification Letter provides that the Company has 180 calendar days, or until July 30, 2025, to regain compliance with the
Rule. To regain compliance, the bid price of our common stock must have a closing bid price of at least $1.00 per share for a minimum
of 10 consecutive business days. In the event we do not regain compliance by July 30, 2025, we may then be eligible for an additional
180 days if we meet the continued listing requirement for market value of publicly held shares and all other initial listing standards
for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of our intention
to cure the deficiency during the second compliance period. If we do not qualify for the second compliance period or fail to regain compliance
during the second compliance period, then Nasdaq will notify us of its determination to delist our common stock, at which point we will
have an opportunity to appeal the delisting determination to a Hearings Panel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
assurance can be given that we will be able to regain compliance with the Rule. Failure to meet applicable Nasdaq continued listing standards
could result in a delisting of our common stock. A delisting of our common stock from Nasdaq could materially reduce the liquidity of
our common stock and result in a corresponding material reduction in the price of our common stock. In addition, delisting could harm
our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result in the potential
loss of confidence by investors, employees and fewer business development opportunities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
market price of our common stock is volatile and you may sustain a complete loss of your investment.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock currently trades on the Nasdaq Capital Market. The market price of our common stock has been, and is likely to continue
to be, volatile. The market price of our common stock may fluctuate significantly in response to numerous factors, some of which are
beyond our control, such as:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    to obtain the approvals necessary to commence clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">results
    of clinical and preclinical studies;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    of regulatory approval or the failure to obtain it, or specific label indications or patient populations for its use, or changes
    or delays in the regulatory review process;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    of technological innovations, new products or product enhancements by us or others;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    actions taken by regulatory agencies with respect to our clinical trials, manufacturing supply chain or sales and marketing activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    or developments in laws, regulations or decisions applicable to our product candidates or patents;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    adverse changes to our relationship with manufacturers, suppliers or partners;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    concerning our competitors or the pharmaceutical or biotechnology industries in general;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">achievement
    of expected product sales and profitability or our failure to meet expectations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    commencement of or results of, or involvement in, litigation, including, but not limited to, any product liability actions or intellectual
    property infringement actions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    major changes in our board of directors, management or other key personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">legislation
    in the United States, Europe and other foreign countries relating to the sale or pricing of pharmaceuticals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    by us of significant strategic partnerships, out-licensing, in-licensing, joint ventures, acquisitions or capital commitments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expiration
    or terminations of licenses, research contracts or other collaboration agreements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">public
    concern as to the safety of therapeutics we, any licensees or others develop;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">success
    of research and development projects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    concerning intellectual property rights or regulatory approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">variations
    in us and our competitors&#8217; results of operations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in earnings estimates or recommendations by securities analysts, if our common stock is covered by analysts;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">future
    issuances of common stock or other securities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    market conditions, including the volatility of market prices for shares of biotechnology companies generally, and other factors,
    including factors unrelated to our operating performance;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">political
    and economic instability, war or acts of terrorism (such as Russia&#8217;s invasion of Ukraine and the conflict in the Middle East)
    or natural disasters, emergence of a pandemic, or other widespread health emergencies (or concerns over the possibility of such an
    emergency, similar to the unprecedented COVID-19 pandemic); and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    other factors described in this &#8220;Risk Factors&#8221; section.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
factors and any corresponding price fluctuations may materially and adversely affect the market price of our common stock, which would
result in substantial losses by our investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the stock market in general, the Nasdaq Capital Market and the market for biotechnology companies in particular, have experienced extreme
price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of companies like theirs.
See also &#8220;General Risk Factors - &#8220;<i>Unfavorable global economic conditions could adversely affect our business, financial
condition or results of operations</i>.&#8221; Broad market and industry factors may negatively affect the market price of our common
stock regardless of our actual operating performance. In addition, a systemic decline in the financial markets and related factors beyond
our control may cause our share price to decline rapidly and unexpectedly. Price volatility of our common stock might be worse if the
trading volume of our common stock is low. In the past, following periods of market volatility, stockholders have often instituted securities
class action litigation. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock
price volatility in recent years. If we face such securities litigation, it could result in substantial costs and a diversion of management&#8217;s
resources and attention, which could harm our business. Future sales of our common stock could also reduce the market price of our stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
the liquidity of our common stock will be limited, not only in terms of the number of shares of common stock that can be bought and sold
at a given price, but by potential delays in the timing of executing transactions in our common stock and a reduction in security analyst
and media&#8217;s coverage of us, if any. These factors may result in lower prices for our common stock than might otherwise be obtained
and could also result in a larger spread between the bid and ask prices for our common stock. In addition, without a large float, our
common stock will be less liquid than the stock of companies with broader public ownership and, as a result, the trading prices of our
common stock may be more volatile. In the absence of an active public trading market, an investor may be unable to liquidate their investment
in our common stock. Trading of a relatively small volume of our common stock may have a greater impact on the trading price of our common
stock than would be the case if our public float were larger. We cannot predict the prices at which our common stock will trade in the
future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>An
active trading market for our common stock may not be sustained.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
active public trading market for our common stock may not be sustained. The lack of an active market may impair your ability to sell
your shares at the time you wish to sell them or at a price that you consider reasonable. The lack of an active market may also reduce
the fair value of your shares. An inactive market may also impair our ability to raise capital to continue to fund operations by selling
shares and may impair our ability to acquire other companies or technologies by using our shares as consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities or industry analysts do not publish or cease publishing research or reports, or publish unfavorable reports about us, our
business or our market, our share price and trading volume could be negatively impacted.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common stock could be influenced by the research and reports that industry or securities analysts may publish
about us, our business, our market or our competitors. We do not have any control over these analysts and cannot provide any assurance
that analysts will cover us or provide favorable coverage. If any of the analysts who may cover us adversely change their recommendation
regarding our common stock, or provide more favorable relative recommendations about our competitors, our share price would likely decline.
If any analyst who may cover us were to cease coverage of us or fail to regularly publish reports on us, we could lose visibility in
the financial markets, which in turn could negatively impact our share price or trading volume.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sales
of a substantial number of our shares in the public market by our existing shareholders could cause our share price to decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of a substantial number of our shares in the public market or the perception that these sales might occur, could depress the market price
of our securities and could impair our ability to raise capital through the sale of additional equity securities. We are not able to
predict the effect that sales may have on the prevailing market price of our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are a &#8220;smaller reporting company&#8221; and the reduced disclosure requirements applicable to smaller reporting companies may make
our common stock less attractive to investors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are considered a &#8220;smaller reporting company.&#8221; We are therefore entitled to rely on certain reduced disclosure requirements,
such as an exemption from providing selected financial data and executive compensation information. These exemptions and reduced disclosures
in our SEC filings due to our status as a smaller reporting company may make it harder for investors to analyze our results of operations
and financial prospects. We cannot predict whether investors will find our common stock less attractive because we may rely on these
exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common
stock and our stock prices may be more volatile.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Maintaining
and improving our financial controls and the requirements of being a public company may strain our resources, divert management&#8217;s
attention and affect our ability to attract and retain qualified board members.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, we are subject to the reporting requirements of the Securities Exchange Act of 1934, or the Exchange Act, the Sarbanes-Oxley
Act and The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) rules. The requirements of these rules and regulations increase our legal
and financial compliance costs, make some activities more difficult, time-consuming or costly and place strain on our personnel, systems
and resources. The Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our
business and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 59; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sarbanes-Oxley Act requires, among other things, that we disclose whether we maintain effective disclosure controls and procedures and
internal control over financial reporting. Ensuring that we have adequate internal financial and accounting controls and procedures in
place is a costly and time-consuming effort that needs to be re-evaluated frequently.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may need to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge.
Implementing any appropriate changes to our internal controls may require specific compliance training for our directors, officers and
employees, entail substantial costs, and take a significant period of time to complete. Such changes may not, however, be effective in
maintaining the adequacy of our internal controls, and any failure to maintain that adequacy, or consequent inability to produce accurate
financial statements on a timely basis, could increase our operating costs and could materially impair our ability to operate our business.
Moreover, effective internal controls are necessary for us to produce reliable financial reports and are important to help prevent fraud.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Nasdaq rules, we will be required to maintain a majority independent board of directors. The various rules and regulations
applicable to public companies make it more difficult and more expensive for us to maintain directors&#8217; and officers&#8217; liability
insurance, and we may be required to accept reduced coverage or incur substantially higher costs to maintain coverage. If we are unable
to maintain adequate directors&#8217; and officers&#8217; insurance, our ability to recruit and retain qualified officers and directors
will be significantly curtailed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is expected that the rules and regulations applicable to public companies will result in us incurring substantial legal and financial
compliance costs. These costs will decrease our net income or increase our net loss and may require us to reduce costs in other areas
of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could
have a material adverse effect on our share price.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company in the U.S., we incur significant accounting, legal and other expenses in order to comply with requirements of the SEC,
and the Nasdaq Capital Market, including requirements under Section 404 and other provisions of the Sarbanes-Oxley Act. Pursuant to Section
404, we are required to furnish a report by our management on our internal control over financial reporting. However, so long as we remain
a smaller reporting company, we will not be required to include an attestation report on internal control over financial reporting issued
by our independent registered public accounting firm. The process to document and evaluate our internal control over financial reporting
to achieve compliance with Section 404 within the prescribed period is both costly and challenging. If we fail to maintain the adequacy
of our internal control over financial reporting as such standards are modified, supplemented or amended from time to time, we may not
be able to ensure that we can conclude on an ongoing basis that we have effective internal control over financial reporting in accordance
with Section 404 of the Sarbanes-Oxley Act of 2002 and the related rules and regulations of the SEC. If we cannot in the future favorably
assess the effectiveness of our internal control over financial reporting, investor confidence in the reliability of our financial reports
may be adversely affected, which could have a material adverse effect on our share price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
the Domestication Merger (defined below), taken together with the Merger (defined below), fails to qualify as a Section 351(a) Exchange,
former U.S. holders of Intec Pharma (&#8220;Intec Israel&#8221;) ordinary shares may recognize taxable gain as a result of the Domestication
Merger.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 27, 2021, Intec Israel, Indaptus Therapeutics, Inc. and Domestication Merger Sub Ltd., an Israeli company and a wholly owned subsidiary
of Indaptus, completed a domestication merger (the &#8220;Domestication Merger&#8221;), pursuant to the terms and conditions of an Agreement
and Plan of Merger and Reorganization, dated April 27, 2021, whereby Domestication Merger Sub Ltd. merged with and into Intec Israel,
with Intec Israel being the surviving entity and a wholly-owned subsidiary of Indaptus Therapeutics, Inc. On August 3, 2021, Indaptus
Therapeutics, Inc. completed its merger with Decoy, pursuant to an Agreement and Plan of Merger and Reorganization (the &#8220;Merger
Agreement&#8221;), dated March 15, 2021, following which Decoy became the surviving entity and a wholly-owned subsidiary of Indaptus
Therapeutics, Inc. and the business conducted by Decoy became the business conducted by the combined company. Intec Israel intended for
the Merger to qualify as a Section 351(a) Exchange. The position of Intec Israel is not binding on the IRS or the courts, and Intec Israel
does not intend to request a ruling from the IRS with respect to the Merger. Accordingly, there can be no assurance that the IRS will
not challenge the qualification of the Domestication Merger and the Merger as a Section 351(a) Exchange or that a court will not sustain
such a challenge. If the IRS were to be successful in any such contention, or if for any other reason the Domestication Merger was not
treated as part of a Section 351(a) Exchange, the Domestication Merger could be a taxable event to the former U.S. holders of ordinary
shares of Intec Israel. Former holders of Intec Israel&#8217;s ordinary shares are urged to consult with their own tax advisors with
respect to the tax consequences of the Domestication Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Notwithstanding
that the Domestication Merger and the Merger together are intended to qualify as a Section 351(a) Exchange, the Domestication Merger
could be a taxable event for certain former U.S. Holders of Intec Israel ordinary shares.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the limitations and qualifications described in &#8220;<i>The Merger - Material U.S. Federal Income Tax Consequences of the Domestication
Merger and the Merger</i>,&#8221; described in the registration statement on Form S-4, as amended (File No. 333-255389), filed by us
with the SEC, or the Form S-4, including the application of the passive foreign investment company, or PFIC rules, the Domestication
Merger is intended to qualify, taken together with the Merger, as a Section 351(a) Exchange. Nonetheless, certain former U.S. Holders
of Intec Israel&#8217;s ordinary shares are likely to be taxed under the PFIC rules of the Code because of the likelihood that Intec
Israel is classified as a PFIC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Unfavorable
global economic or geopolitical conditions could adversely affect our business, financial condition or results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. For
example, the U.S. and global markets have been experiencing and are continuing to experience extreme volatility and disruptions in the
capital and credit markets and commodity prices due to rising inflation and interest rates, geopolitical tensions such as the conflict
between Russia and Ukraine and the armed conflict in Israel and Gaza, and other macroeconomic factors. A severe or prolonged economic
downturn, such as the current macroeconomic environment, could result in a variety of risks to our business, including, our ability to
raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers of raw
materials used to manufacture our product candidates for our clinical trials, possibly resulting in supply disruption. Furthermore, our
stock price may decline due in part to the volatility of the stock market and any general economic downturn.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in tax law and regulations could adversely affect our business, financial condition and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could affect the
tax treatment of any of our future earnings. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted,
changed, modified or applied adversely to us. Generally, future changes in applicable tax laws and regulations, or their interpretation
and application, potentially with retroactive effect, could have an adverse effect on our business, financial condition and results of
operations. We are unable to predict whether such changes will occur and, if so, the ultimate impact on our business. We urge investors
to consult with their legal and tax advisers regarding the implications of potential changes in tax laws on an investment in our common
stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_001"></span>Item
1B. Unresolved Staff Comments.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any unresolved comments issued by the SEC staff.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_002"></span>Item
1C. Cybersecurity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_985_ecyd--CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_iB_c20240101__20241231_gBFCRMPFAIAMT-B_zGViVzNcBlId" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="ConU000054-01" escape="true" id="Fact000054" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cybersecurity
Risk Management and Strategy</b></span></ix:nonNumeric></p>

<div id="xdx_C0B_gBFCRMPFAIAMT-B_zF5xZOsiKxL8"><ix:continuation continuedAt="ConU000054-02" id="ConU000054-01"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240101__20241231_zLEfoXgEJ78j" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000055" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock">We,
through our third party service provider that manages our information technology systems and networks, have developed and implemented
a cybersecurity risk management program intended to protect the confidentiality, <span id="xdx_904_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_ztltpBYvAQz5" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000056" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag">integrity</ix:nonNumeric></span>, and availability of our critical systems
and information.</ix:nonNumeric></span> Our cybersecurity risk management program includes a cybersecurity incident response plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
design and assess our program based on the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF). This does
not imply that we meet any particular technical standards, specifications, or requirements, only that we use the NIST CSF as a guide
to help us identify, assess, and manage cybersecurity risks relevant to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cybersecurity risk management program includes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecyd--CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_c20240101__20241231_zc0EMY0WcsEi" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000057" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">risk
    assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and
    our broader enterprise IT environment;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20240101__20241231_zcncos9boFdc" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000058" name="cyd:CybersecurityRiskRoleOfManagementTextBlock">designated
    team members are responsible for managing (1) our cybersecurity risk assessment processes, (2) our security controls, and (3) our
    response to cybersecurity incidents;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls;
    and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C03_gBFCRMPFAIAMT-B_zTpxFfX1z13h"><ix:continuation id="ConU000054-02">We
have not identified risks from known cybersecurity threats, that have <span id="xdx_906_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbT_c20240101__20241231_zcoKyztoAs1d" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000059" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">materially</ix:nonNumeric></span> affected or are reasonably likely to materially affect
us, including our operations, business strategy, results of operations, or financial condition. See Item 1A. &#8220;Risk Factors &#8211;
Our Risks Related to Our Business - <i>Our business and operations may suffer in the event of information technology system failures,
cyberattacks or deficiencies in our cybersecurity.</i>&#8221;</ix:continuation></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cybersecurity
Governance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_zK32IXvMjjJb" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000060" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">Our
Board considers cybersecurity risk as part of its risk oversight function and oversees our cybersecurity and other information technology
risks and management&#8217;s implementation of our cybersecurity risk management program.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board receives periodic reports from management on our cybersecurity risks. In addition, management updates the Board and the Audit Committee,
as necessary, regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecyd--CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_zpbdQB5TYPQb" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000061" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">Our
management team, including our Chief Operating Officer, is responsible for assessing and managing our material risks from cybersecurity
threats. Our Chief Operating Officer has primary responsibility for our overall cybersecurity risk management program and supervises
our retained provider of IT services and external cybersecurity consultants. Our Chief Operating Officer has experience supervising and
managing company security and privacy departments.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management team supervises efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means,
which may include briefings from external security personnel; threat intelligence and other information obtained from governmental, public
or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in the IT
environment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_003"></span>Item
2. Properties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive offices are located at 3 Columbus Circle, 15th Floor, New York, NY. In addition, we lease approximately 2,000 square
feet of office space in San Diego, California under a lease agreement that was amended on April 19, 2023 and will expire on October 31,
2025. <span style="background-color: white">We believe that our facilities are sufficient to meet our current needs and that suitable
additional space will be available as and when needed.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 62; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_004"></span>Item
3. Legal Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation
is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 12, 2025, there are no pending material legal proceedings, and we are currently not aware of any legal proceedings or claims
against us or our property that we believe will have any significant effect on our business, financial position or operating results.
None of our officers or directors is a party against us in any legal proceeding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_005"></span>Item
4. Mine Safety Disclosures.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="ar_006"></span>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_007"></span>Item
5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on the Nasdaq Capital Market under the name &#8220;Indaptus Therapeutics, Inc.&#8221; and ticker symbol &#8220;INDP&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Holders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 12, 2025, we had 22 record holders of our common stock. This number does not include the number of persons whose shares are
in nominee or in &#8220;street name&#8221; accounts through brokers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividend
Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid cash dividends to our shareholders, and we do not intend to pay cash dividends in the foreseeable future.
We intend to reinvest any earnings in developing and expanding our business. Any future determination relating to our dividend policy
will be at the discretion of our board of directors and will depend on a number of factors, including our financial condition, operating
results, contractual restrictions, capital requirements, business prospects, our strategic goals and plans to expand our business, applicable
law and other factors that our board of directors may deem relevant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
Authorized for Issuance under Equity Compensation Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
about our equity compensation plan under which the Company&#8217;s equity securities are authorized for issuance is set forth in &#8220;Part
III - Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221; of this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Sales of Unregistered Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Purchases
of Equity Securities by the Issuer and Affiliated Purchasers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
did not repurchase any of our equity securities during the quarter ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_008"></span>Item
6. [Reserved]</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 63; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_009"></span>Item
7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>You
should read the following discussion and analysis of our financial condition and results of operations along with our consolidated financial
statements and the related notes and other financial information included elsewhere in this Annual Report. The following discussion contains
forward-looking statements that are subject to risks, uncertainties and assumptions. You should review the sections titled &#8220;Summary
Risk Factors&#8221; and Part I, Item 1A. &#8220;Risk Factors&#8221; in this Annual Report for a discussion of important factors that
could cause actual results to differ materially from the results described below.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical biotechnology company developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy.
We have evolved from more than a century of immunotherapy advances. Our approach is based on the hypothesis that efficient activation
of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package
of immune system activating signals that can be administered safely intravenously. Our patented technology is composed of single strains
of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability
to prime or activate many of the cellular components of innate and adaptive immunity. This approach has led to broad anti-tumor and anti-viral
activity in preclinical models, including durable anti-tumor response synergy observed with each of four different classes of existing
agents, including NSAIDs, checkpoint therapy, targeted antibody therapy and low-dose chemotherapy. Tumor eradication by our technology
has demonstrated activation of both innate and adaptive immunological memory and, importantly, did not require provision of or targeting
a tumor antigen in preclinical models. In 2023, we initiated a <span style="background-color: white">Phase 1 clinical trial with our
lead clinical candidate, Decoy20, in patients with advanced solid tumors where currently approved therapies have failed</span>. For further
information regarding our business and operations, see &#8220;Part I. Item 1. Business.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Impact
of Macroeconomic Conditions on our Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Economic
developments such as inflation and interest rates have negatively affected the global financial markets and may reduce our ability to
access capital, which could negatively impact our short-term and long-term liquidity. The ultimate impact of current economic conditions
is highly uncertain and subject to change. While it is unknown how long these conditions will last and what the complete financial effect
will be to us, capital raise efforts and additional development of our technologies may be negatively affected. In addition, our business
operations expose us to risks associated with public health crises and epidemics/pandemics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Components
of Operating Results</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses account for a significant portion of our operating expenses. Research and development expenses consist primarily
of fees paid to contract research organizations, or CROs, and contract manufacturing organizations, or CMOs, as well as compensation
expenses for certain employees involved in the planning, managing, and analyzing the work of the CROs and CMOs and materials used for
research and development activities. We expense research and development costs as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
accrue expenses for manufacturing, preclinical studies and clinical trial activities performed by third parties based on estimates of
services received and efforts expended pursuant to agreements with CROs, CMOs, and other outside service providers. We determine these
estimates based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel
and external service providers as to the progress or stage of completion of the services. In the event advance payments are made to a
CRO, CMO, or outside service provider, we record the payments as a prepaid asset, which will be amortized or expensed as the contracted
services are performed. However, actual costs and timing of these activities are highly uncertain, subject to risks and may change depending
upon a number of factors, including our clinical development plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 64; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our research and development expenses to increase substantially for the foreseeable future as we continue to ramp up our clinical
development activities and incur expenses associated with hiring additional personnel to support our research and development efforts.
Our expenditures on future nonclinical and clinical development programs are subject to numerous uncertainties in timing and cost to
completion. The duration, costs and timing of preclinical studies and clinical trials and development of product candidates will depend
on a variety of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and receipt of regulatory approvals&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, rate of progress and expenses of preclinical studies and clinical trials and other research and development activities&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    safety monitoring and other studies requested by regulatory agencies&#894; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    and changing government regulation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process of conducting the necessary clinical research to obtain FDA and other regulatory approval is costly and time consuming and the
successful development of product candidates is highly uncertain. These risks and uncertainties associated with our research and development
projects are discussed more fully in Part I. Item 1A. &#8220;Risk Factors - <i>We expect to continue to incur significant research and
development expenses and other operating expenses, which may make it difficult for us to attain profitability</i>.&#8221; As a result
of these risks and uncertainties, we are unable to determine with any degree of certainty the duration and completion costs of our research
and development projects, or if, when, or to what extent we will generate revenues from the commercialization and sale of any of our
product candidates that obtain regulatory approval. We may never succeed in achieving regulatory approval for any of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
and Administrative Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses include compensation, employee benefits, and stock-based compensation, finance administration and human resources,
facility costs (including rent), professional service fees, and other general overhead costs to support our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our general and administrative expenses to increase for the foreseeable future as we continue to increase our headcount to support
our research and development activities and operations generally, the growth of our business and, if any of our product candidates receive
marketing approval, commercialization activities. We also expect to continue to incur additional expenses as a result of operating as
a public company, including expenses related to compliance with the rules and regulations of the SEC, additional director and officer
insurance expenses, investor relations activities, and other administrative and professional services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Income, Net</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income, net includes interest earned on deposits and investments and other items of income, expense, gain and loss that are incidental
to the core operations of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Year
Ended December 31, 2024 compared to Year Ended December 31, 2023</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables set forth our results of operations for the years ended December 31, 2024 and 2023 and the relative dollar and percentage
change between the two years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Change</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2024 to 2023)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">7,251,097</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">7,621,707</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(370,610</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">(4.9</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,114,654</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,756,767</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(642,113</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(7.3</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">15,365,751</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">16,378,474</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,012,723</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(6.2</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(15,365,751</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,378,474</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,012,723</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6.2</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other income, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">343,724</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">955,003</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(611,279</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(64.0</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(15,022,027</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(15,423,471</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">401,444</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2.6</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss attributable to common stockholders per share, basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.61</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.83</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.22</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(12.0</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted average number of shares used in calculating net loss per share, basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,355,710</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,401,047</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 65; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development expenses for the year ended December 31, 2024 amounted to approximately $7.2 million, a decrease of approximately
$0.4 million, or approximately 4.9%, compared with approximately $7.6 million for the year ended December 31, 2023. This decrease was
attributable primarily to a decrease of approximately $1.3 million for the development of our manufacturing processes of Decoy20 that
were mainly conducted in 2023 and was offset by an increase of approximately $0.9 million in costs associated with our Phase 1 clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
and Administrative Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
general and administrative expenses for the year ended December 31, 2024 amounted to approximately $8.1 million, a decrease of approximately
$0.7 million, or approximately 7.3%, compared with approximately $8.8 million for the year ended December 31, 2023. This decrease was
attributable primarily to a decrease of approximately $1.3 million in legal fees, recruitment costs, payroll and related expenses, franchise
tax, and directors&#8217; and officers&#8217; insurance expenses, and was offset by an increase of approximately $0.6 million in investor
relations and business development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Income</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, our other income, net was approximately $0.3 million, which represented a decrease of approximately
$0.6 million, or approximately 64.0%, as compared to the year ended December 31, 2023. The other income generated in the period consists
primarily of income earned on the Company&#8217;s cash and cash equivalent accounts, the balances of which were lower during the year
ended December 31, 2024 compared to the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently have any approved products and have never generated any revenue from product sales. Since our inception, we have funded
our operations primarily through public and private offerings of our equity securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2025, we completed a private placement for the sale and issuance by us of an aggregate of: (i) 2,109,383 shares of our common
stock and (ii) warrants to purchase 2,109,383 shares of common stock. The shares and warrants were sold on a combined basis for consideration
of $1.065 for one share and a warrant for aggregate gross proceeds of approximately $2.25 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, we completed a registered direct offering, pursuant to which we sold and issued to certain investors 1,817,017 shares
of our common stock in a registered direct offering. In addition, in a concurrent private placement, we issued to the investors unregistered
warrants to purchase 1,817,017 shares of common. The combined purchase price for one share of common stock and one warrant was $1.175,
resulting in gross proceeds of approximately $2.135 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 66; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2024, we completed a registered direct offering, pursuant to which we sold and issued to certain investors, 1,643,837 shares of
common stock. In addition, in a concurrent private placement, we issued to the investors unregistered warrants to purchase 1,643,837
shares of common stock. The combined purchase price for one share of common stock and one warrant was $1.825, resulting in gross proceeds
of approximately $3.0 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2022, we entered into an At The Market Offering Agreement (the &#8220;ATM Agreement&#8221;) which was amended on September 1, 2022
with H.C. Wainwright &amp; Co., LLC, as sales agent (&#8220;Wainwright&#8221;), pursuant to which we may offer and sell, from time to
time through Wainwright, shares of our common stock, par value $0.01 per share, for aggregate gross proceeds of up to $3.7 million. The
issuance and sale of common stock by us under the ATM Agreement is being made pursuant to our effective &#8220;shelf&#8221; registration
statement on Form S-3 filed with the SEC on September 1, 2022 and declared effective on September 9, 2022. In 2024, we sold 152,000 shares
of our common stock for aggregate gross proceeds of approximately $0.4 million. On August 6, 2024, we filed a prospectus supplement to
reduce the amount of shares registered under the prospectus for the ATM to $0.00 and to suspend the ATM program, but the ATM Agreement
remains in full force and effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2025, we entered into a <span style="background-color: white">SEPA with Yorkville pursuant to which we have the right, but not
the obligation, to sell up to $20.0 million of our common stock during a 36 month period, subject to the restrictions and satisfaction
of the conditions in the SEPA. Upon execution of the SEPA, we issued to Yorkville </span>305,960 commitment shares. No shares of common
stock have been sold under the SEPA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the cash and cash equivalents of approximately $5.8 million that we had as of December 31, 2024 <span style="background-color: white">together
with net proceeds of $2.0 million from our January 2025 financing,</span> will enable us to fund our operating expenses and capital expenditure
requirements into the second quarter of 2025. We will need to increase our capital resources through equity or debt financings, and
we may need to do so sooner than we expect. We may also seek to finance our cash needs through collaborations, strategic alliances, or
license agreements with third parties. If sources of financing are available, they may result in substantial dilution to our stockholders.
We cannot provide any assurance that new financing will be available to us on commercially acceptable terms or in the amounts required,
if at all. If we are unable to consummate a financing or other transaction, we may need to delay, reduce, or eliminate our research and
development programs, which could adversely affect our business prospects, or cease operations. These conditions raise substantial doubt
regarding our ability to continue as a going concern within one year after the date of this prospectus. For additional information, see
Note 1 to our consolidated financial statements included elsewhere in this Annual Report. We have based this estimate on assumptions
that may prove to be wrong, and we could use our capital resources sooner than we currently expect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no ongoing material financing commitments, such as lines of credit or guarantees, that are expected to affect our liquidity over
the next five years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was approximately $12.3 million for the year ended December 31, 2024, compared with net cash used in
operating activities of approximately $13.4 million for the year ended December 31, 2023. The approximately $1.1 million decrease in
net cash used was primarily attributable to changes in operating assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investing
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was no net cash provided by or used in investing activities for the year ended December 31, 2024. Net cash provided by investing activities
was approximately $17.1 million for the year ended December 31, 2023, which was related to the maturity of $24.0 million in marketable
securities, offset by net investment of approximately $6.9 million in marketable securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 67; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financing
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities for the year ended December 31, 2024 was approximately $4.8 million, which was provided by issuance
and sale of our common stock under the ATM Agreement and issuance and sale of our common stock and warrants in the August 2024 Offering
and in the November 2024 Offering. There was no net cash provided by or used in financing activities for the year ended December 31,
2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 35.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Funding
Requirements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating expenses increased in 2024 and are expected to continue to increase in the future in connection with our ongoing activities,
particularly as we expect to continue to ramp up our clinical development activities and incur expenses associated with hiring additional
personnel to support our research and development efforts. In addition, if we obtain marketing approval for any of our product candidates,
we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Furthermore,
we expect to continue to incur significant costs associated with operating as a public company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our existing cash and cash equivalents and marketable securities as of December 31, 2024 are adequate to fund our ongoing
activities into the second quarter of 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements will depend on many factors, including, but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, progress, results and costs of preclinical studies and clinical trials&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, prioritization and number of our clinical trials and other research and development programs&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    amount of revenues we receive under future licensing, collaboration, development and commercialization arrangements with respect
    to our product candidates&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of any pandemic, epidemic or other future health crisis on our business and operations&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of the development and expansion of our operational infrastructure&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs, timing and outcome of regulatory review of our product candidates&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability of us, or our collaborators, to achieve development milestones, marketing approval and other events or developments under
    our potential future licensing agreements&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of securing manufacturing arrangements for clinical or commercial production&#894;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of contracting with third parties to provide sales and marketing capabilities for us or establishing such capabilities ourselves&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of acquiring or undertaking development and commercialization efforts for any future products, product candidates or technology&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    magnitude of our general and administrative expenses&#894; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    cost that we may incur under future in- and out-licensing arrangements relating to one or more of our product candidates.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 68; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifying
potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process
that takes many years to complete, and we may never generate the necessary data or results required to obtain marketing approval and
achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues,
if any, will be derived from sales of product candidates that we do not expect to be commercially available for the next couple of years,
if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional
financing may not be available to us on acceptable terms, or at all. For example, the trading prices for our and other biopharmaceutical
companies&#8217; stock have been highly volatile as a result of current macroeconomic conditions and market volatility. As a result,
we may face difficulties raising capital through sales of our common stock on acceptable terms, if at all. If we are unsuccessful in
securing sufficient financing, we may need to delay, reduce, or eliminate our research and development programs, which could adversely
affect our business prospects, or cease operations. For additional information, see Note 1 to our consolidated financial statements included
elsewhere in this Annual Report and &#8220;Risk Factors&#8221; in Item 1A. of this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Contractual
Obligations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease liabilities represent our commitment for future rent made under a non-cancelable lease for our offices in San Diego, CA. The total
future payments for our operating lease obligation on December 31, 2024 were approximately $0.1 million and are due in the next twelve
months. For additional details regarding our lease, see Note 7 to our consolidated financial statements included in this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under the SEC
rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which
have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates
that affect the reported amounts of our assets, liabilities and expenses. Significant accounting policies employed by us, including the
use of estimates, are presented in the notes to our annual financial statements included in this Annual Report. We periodically evaluate
our estimates, which are based on historical experience and on various other assumptions that we believe to be reasonable under the circumstances.
Critical accounting policies are those that are most important to the portrayal of our financial condition and results of operations
and require our subjective or complex judgments, resulting in the need to make estimates about the effect of matters that are inherently
uncertain. If actual performance should differ from historical experience or if the underlying assumptions were to change, our financial
condition and results of operations may be materially impacted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our
consolidated financial statements:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounting
for Research and Development Costs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
record the costs associated with services provided by CROs and CMOs as they are incurred. Though the scope and timing of work are generally
based on signed agreements, some judgement is involved in determining periodic expenses because payment flows do not always match the
periods over which services and materials are provided to us. As a result, our management is required to make estimates of services received
and efforts expended pursuant to agreements established with these third-parties at each period-end date. During the year ended December
31, 2024, we incurred approximately $7.2 million of research and development expenses, of which approximately $4.0 million were for services
provided by our CROs and CMOs. As of December 31, 2024, we recorded an accrued liability of approximately $0.8 million for expenses incurred,
but not yet invoiced, and prepaid expenses and non-current other assets of approximately $0.8 million for payments made that relate to
future periods. Overestimating or underestimating the services received or efforts expended could cause us to overstate or understate
research and development expenses incurred within a reporting period, and related accrued and prepaid expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 69; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-Based
Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
expense related to stock options granted is measured at the grant date based on the estimated fair value of the award and is recognized
over the requisite service period of the individual grant, generally equal to the vesting period, on a straight-line basis. We determine
the estimated fair value of each stock option on the date of grant using the Black-Scholes valuation model which uses assumptions regarding
a number of complex and subjective variables. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent
with the expected term of the option in effect at the time of the grant. Expected volatility is based on an analysis of the historical
volatility of a peer group of companies. The expected term represents the period that we expect our stock options to be outstanding.
The expected term assumption is estimated using the simplified method set forth in the U.S. Securities and Exchange Commission&#8217;s
Staff Accounting Bulletin Topic 14, which is the mid-point between the option vesting date and the expiration date. We have never declared
or paid dividends on our common stock and have no plans to do so in the foreseeable future. Changes in these assumptions may lead to
variability with respect to the amount of stock compensation expense we recognize related to stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Issued Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
recently issued accounting pronouncements are discussed in Note 2, Significant Accounting Policies, to the consolidated financial statements
included in Item 8. &#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_010"></span>Item
7A. Quantitative and Qualitative Disclosures About Market Risk.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise
required under this Item 7A.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 70; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_011"></span>Item
8. Financial Statements and Supplementary Data.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDAPTUS
THERAPEUTICS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#au_001">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB name: <span id="xdx_905_edei--AuditorName_c20240101__20241231_zpjX4vXfbkGg"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000062" name="dei:AuditorName">HASKELL &amp; WHITE LLP</ix:nonNumeric></span> and</a> PCAOB ID: <span id="xdx_90E_edei--AuditorFirmId_c20240101__20241231_z51BgXeaPt97"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000063" name="dei:AuditorFirmId">200</ix:nonNumeric></span>)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
    FINANCIAL STATEMENTS</b>:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top; text-align: justify"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Balance Sheets as of December 31, 2024 and 2023</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top; text-align: justify"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2024 and 2023</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top; text-align: justify"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Stockholders&#8217; Equity for the years ended December 31, 2024 and 2023</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top; text-align: justify"><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top; text-align: justify"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 71; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="fin_001.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="au_001"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Stockholders and Board of Directors</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indaptus
Therapeutics, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Opinion
on the Consolidated Financial Statements </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Indaptus Therapeutics, Inc. (the &#8220;Company&#8221;) as of December&#160;31,
2024 and 2023, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for
each of the years then ended, and the related notes (collectively, the &#8220;consolidated financial statements&#8221;). In our opinion,
the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as
of December&#160;31, 2024 and 2023, and the consolidated results of its operations and its cash flows for each of the years then ended,
in conformity with U.S. generally accepted accounting principles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed
in Note 1 to the consolidated financial statements, the Company has experienced recurring losses, negative cash flows from operations,
and has limited capital resources. These matters raise substantial doubt about the Company&#8217;s ability to continue as a going concern.
Management&#8217;s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include
any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis
for Opinion</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion
on the consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting
Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with
the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part
of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing
an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether
due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that our audits provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Critical
Audit Matters</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Critical
audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required
to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the consolidated financial
statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit
matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Haskell &amp; White LLP</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HASKELL
    &amp; WHITE LLP</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--AuditorLocation_c20240101__20241231_z4mhzFmMQYB8"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000064" name="dei:AuditorLocation">Irvine,
California</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March&#160;13,
2025</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_003"></span>INDAPTUS
THERAPEUTICS, INC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Balance Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_111_zsUI5Qgh3zMb" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20241231_zOrSG7TfH9J9" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_zDnbFtnh5zUb" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsAbstract_iB_zUzm7tOPndG4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsCurrentAbstract_i01B_zEAcKgFGNxt8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACz6We_zl2EabbqDbVk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000072" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,786,753</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000073" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,362,053</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maACz6We_zxVoDHAcSNm9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000075" format="ixt:numdotdecimal" decimals="0" unitRef="USD">831,577</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000076" format="ixt:numdotdecimal" decimals="0" unitRef="USD">633,156</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AssetsCurrent_i02TI_mtACz6We_maAzj1y_zcY2F1hsELef" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000078" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,618,330</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000079" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,995,209</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsNoncurrentAbstract_i01B_zlUQumg6g4K7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_i02I_maANzKYo_zzEY5dCmtawa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0084">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000085" format="ixt:numdotdecimal" decimals="0" unitRef="USD">735</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_maANzKYo_z6WZfQgLqYV1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact000087" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,175</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact000088" format="ixt:numdotdecimal" decimals="0" unitRef="USD">173,206</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherAssetsNoncurrent_i02I_maANzKYo_zNoXeneUCHKk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other assets - deposits to third parties</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2024-12-31" id="Fact000090" format="ixt:numdotdecimal" decimals="0" unitRef="USD">638,251</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2023-12-31" id="Fact000091" format="ixt:numdotdecimal" decimals="0" unitRef="USD">754,728</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsNoncurrent_i02TI_mtANzKYo_maAzj1y_zMb7UMfKISn" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total non-current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2024-12-31" id="Fact000093" format="ixt:numdotdecimal" decimals="0" unitRef="USD">720,426</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2023-12-31" id="Fact000094" format="ixt:numdotdecimal" decimals="0" unitRef="USD">928,669</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Assets_i01TI_mtAzj1y_zH8I300YVefh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact000096" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,338,756</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000097" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,923,878</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zE05Tehl2wl1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Liabilities and stockholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesCurrentAbstract_i01B_zwh3H2jCPTW1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_i02I_maLCz7ML_zIIVkME0SHNh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts payable and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000105" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,309,717</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000106" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,672,327</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCz7ML_z4Y5vjqT4QB1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Operating lease liability, current portion</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000108" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,164</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact000109" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,705</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesCurrent_i02TI_mtLCz7ML_maLz0Bk_ze66EqLAzH6c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total current liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000111" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,393,881</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000112" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,774,032</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_zLIZE9JkrUrd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maLNzMWx_zkqpkocwa6h3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Operating lease liability, net of current portion</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0117">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="Fact000118" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,348</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesNoncurrent_i02TI_mtLNzMWx_maLz0Bk_ziCMdUDSXzOc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total non-current liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0120">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2023-12-31" id="Fact000121" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,348</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--Liabilities_i01TI_mtLz0Bk_maLASEz3yy_zCWMqPj5ljzd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-12-31" id="Fact000123" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,393,881</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" id="Fact000124" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,847,380</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CommitmentsAndContingencies_i01I_maLASEz3yy_zeD9wUrvsT2f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Commitments and contingencies (Note 7)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0126">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0127">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stockholders&#8217; equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CommonStockValue_i02I_maSEzXbL_zAEzhhyolcWc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><p style="margin-top: 0; margin-bottom: 0">Common stock: $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20241231_zmMAlpc1MpF1" title="Common stock, par value"><span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231_z5iT5urtSj6c" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000135" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000137" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span>
</span>par value, <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20241231_z89CCfZhzAPa" title="Common stock, shares authorized"><span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_zhv3KgC9zikc" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000139" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000141" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized
as of December 31, 2024 and December 31, 2023; <span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_c20241231_z7TpFNIkFf6f" title="Common stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_zBHZrvgE7Jwj" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000143" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000145" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,013,901</ix:nonFraction></ix:nonFraction></span>
</span>shares issued and outstanding as of December 31, 2024 and <span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_c20231231_zvOs2jy9O1s2" title="Common stock, shares issued"><span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_z7kWicW184q" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000147" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000149" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,401,047</ix:nonFraction></ix:nonFraction></span>
</span>shares issued and outstanding as of December 31, 2023</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="Fact000132" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,139</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000133" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,011</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PreferredStockValue_i02I_maSEzXbL_zS1Qd5ZcDKE5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><p style="margin-top: 0; margin-bottom: 0">Preferred stock: $<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20241231_zg7V9TgLzbLe" title="Preferred stock, par value"><span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20231231_z7VWRqXQfdxd" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000154" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000156" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span>
                                    par value, <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231_zOsbkeeHKNQk" title="Preferred stock, shares authorized"><span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_zRnVnv5E864j" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000158" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000160" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></ix:nonFraction></span></span>
                                    shares authorized as of December 31, 2024 and December 31, 2023; <span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_do_c20241231_z0J0W2OMYmne" title="Preferred stock, shares issued"><span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_do_c20231231_zObc31hrJbQ" title="Preferred stock, shares issued"><span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20241231_zxfwaChe25ab" title="Preferred stock, shares outstanding"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20231231_zETMvDGqpZIf" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000162" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000164" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000166" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000168" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span>
                                    shares issued or outstanding</p>
                                    <p style="margin-top: 0; margin-bottom: 0"></p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0151">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0152">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AdditionalPaidInCapital_i02I_maSEzXbL_zPhSi8kGsLKl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Additional paid in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" id="Fact000170" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,263,919</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" id="Fact000171" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,409,643</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzXbL_zkwKRMsVMbw" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000173" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">60,439,183</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000174" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">45,417,156</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockholdersEquity_i02TI_pp0p0_mtSEzXbL_maLASEz3yy_z0Zam85otQ73" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total stockholders&#8217; equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000176" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,944,875</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000177" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,076,498</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pp0p0_mtLASEz3yy_zv3JVm7F3948" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total liabilities and stockholders&#8217; equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000179" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,338,756</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000180" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,923,878</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the consolidated financial statements and report of independent registered public accounting firm</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_004"></span>INDAPTUS
THERAPEUTICS, INC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statements of Operations and Comprehensive Loss</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_113_zNFI6C362yhg" summary="xdx: Statement - Consolidated Statements of Operations and Comprehensive Loss" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231_zVsF7boabsgk" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230101__20231231_zeWwJ4mXb3fh" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingExpensesAbstract_iB_zhujfqRuFnjg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEzrVm_zrJ3VDmBjo02" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000185" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,251,097</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31" id="Fact000186" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,621,707</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--GeneralAndAdministrativeExpense_i01_maOEzrVm_z4hQ5aXtmc6b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000188" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,114,654</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31" id="Fact000189" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,756,767</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingExpenses_i01T_mtOEzrVm_msOILzQMX_zhO5usgOYXsa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-01to2024-12-31" id="Fact000191" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,365,751</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-012023-12-31" id="Fact000192" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,378,474</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingIncomeLoss_iT_mtOILzQMX_maNILzZuM_zEsxAocLEit3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Loss from operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000194" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,365,751</ix:nonFraction></span>)</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000195" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,378,474</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NonoperatingIncomeExpense_maNILzZuM_zMjmT0mEZeAa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other income, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000197" format="ixt:numdotdecimal" decimals="0" unitRef="USD">343,724</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-012023-12-31" id="Fact000198" format="ixt:numdotdecimal" decimals="0" unitRef="USD">955,003</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_iT_mtNILzZuM_zUrg6lyUtVhd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000200" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,022,027</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000201" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,423,471</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss available to common stockholders per share of common stock, basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareBasic_c20240101__20241231_zGdV889SEXX" title="Net loss available to common stockholders per share of common stock, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_909_eus-gaap--EarningsPerShareDiluted_c20240101__20241231_z6Rp8EYX0Qug" title="Net loss available to common stockholders per share of common stock, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000203" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-12-31" id="Fact000205" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.61</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zk9eC0M1QS6j" title="Net loss available to common stockholders per share of common stock, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_900_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_zZedQKzmCS1f" title="Net loss available to common stockholders per share of common stock, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31" id="Fact000207" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31" id="Fact000209" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.83</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted average number of shares used in calculating net loss per share, basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_zKrgVWKcFA88" title="Weighted average number of shares used in calculating net loss per share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_zlNjXDoLWYCg" title="Weighted average number of shares used in calculating net loss per share, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000211" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-12-31" id="Fact000213" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,355,710</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_zHL7zEao5Pn1" title="Weighted average number of shares used in calculating net loss per share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zA24ofaiVRd3" title="Weighted average number of shares used in calculating net loss per share, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31" id="Fact000215" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31" id="Fact000217" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,401,047</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_iT_maCINOTznTU_zy3Xqt89k3wc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000219" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,022,027</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000220" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,423,471</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_iB_zDSeu6CPWwAk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other comprehensive income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_iN_di_msCINOTznTU_zVXQEXMS6Jbb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Reclassification adjustment for interest earned on marketable securities included in net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0225">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="From2023-01-012023-12-31" id="Fact000226" format="ixt:numdotdecimal" decimals="0" unitRef="USD">430,993</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_maCINOTznTU_znQekALl2Vzl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Change in unrealized gain on marketable securities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0228">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2023-01-012023-12-31" id="Fact000229" format="ixt:numdotdecimal" decimals="0" unitRef="USD">334,559</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ComprehensiveIncomeNetOfTax_iT_mtCINOTznTU_zgp5qftl7xj2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Comprehensive loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-01-01to2024-12-31" id="Fact000231" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,022,027</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-01-012023-12-31" id="Fact000232" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,519,905</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the consolidated financial statements and report of independent registered public accounting firm</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_005"></span>INDAPTUS
THERAPEUTICS, INC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statements of Stockholders&#8217; Equity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 20pt; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_114_zhosjJZwWjIi" summary="xdx: Statement - Consolidated Statements of Stockholders' Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_ztpQ50NqV3Nc" style="border-bottom: Black 1pt solid; text-align: center">Amount</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_z4AixFMeNxWg" style="border-bottom: Black 1pt solid; text-align: center">Capital</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zBXDLsYMKlLd" style="border-bottom: Black 1pt solid; text-align: center">deficit</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zGC5w8OtP60b" style="border-bottom: Black 1pt solid; text-align: center">Income</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B3_z85M2JrlghE" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Common stock</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">Additional paid in</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">Accumulated</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">Accumulated <br/>Other Comprehensive</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Amount</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Capital</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">deficit</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Income</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_432_c20230101__20231231_eus-gaap--StockholdersEquity_iS_z0nMAvqqbL1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Balance, January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0s4zyZhd8xe" title="Balance, shares" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000240" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,401,047</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000234" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,011</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000235" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,443,705</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000236" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">29,993,685</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000237" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,434</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000238" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,630,465</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zZsQ2lGtNyU" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0242">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000243" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,965,938</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0244">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0245">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31" id="Fact000246" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,965,938</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_iN_di_zHHzxbQAF8Ol" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Reclassification adjustment for interest earned on marketable securities included in net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0248">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0249">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0250">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000251" format="ixt:numdotdecimal" decimals="0" unitRef="USD">430,993</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="From2023-01-012023-12-31" id="Fact000252" format="ixt:numdotdecimal" decimals="0" unitRef="USD">430,993</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_zJ3G27NY8t3g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in unrealized gain on marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0254">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0255">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0256">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000257" format="ixt:numdotdecimal" decimals="0" unitRef="USD">334,559</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2023-01-012023-12-31" id="Fact000258" format="ixt:numdotdecimal" decimals="0" unitRef="USD">334,559</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_zhUfmp8nijod" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0260">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0261">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact000262" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,423,471</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0263">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000264" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,423,471</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43F_c20240101__20241231_eus-gaap--StockholdersEquity_iS_zA3XoOCvuPcc" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Balance, December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjIPETWkluMb" title="Balance, shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000272" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,401,047</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000266" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,011</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000267" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,409,643</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000268" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">45,417,156</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0269">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000270" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,076,498</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43F_c20240101__20241231_eus-gaap--StockholdersEquity_iS_zzYCbY9V1xYl" style="display: none; vertical-align: bottom; background-color: White">
    <td>Balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4tXtV2XtZId" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000280" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,401,047</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000274" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,011</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000275" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,409,643</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000276" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">45,417,156</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0277">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000278" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,076,498</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_z4or6bUJFDsl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0282">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000283" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,305,849</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0284">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0285">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-01to2024-12-31" id="Fact000286" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,305,849</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zH682BtGWCd4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of shares of common stock, net of issuance costs (Note 6b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzIInVqJqQN" title="Issuance of shares of common stock, net of issuance costs (Note 6b), shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000294" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">152,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000288" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,520</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000289" format="ixt:numdotdecimal" decimals="0" unitRef="USD">352,591</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0290">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0291">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-01to2024-12-31" id="Fact000292" format="ixt:numdotdecimal" decimals="0" unitRef="USD">354,111</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--StockIssuedDuringPeriodValueNewIssuesOne_z0ta7q2mvpI6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of shares of common stock and warrants, net of issuance costs (Note 6c)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--StockIssuedDuringPeriodSharesNewIssuesOne_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH4T1a4ArpK7" title="Issuance of shares of common stock and warrants, net of issuance costs (Note 6c), shares" style="text-align: right"><ix:nonFraction name="INDP:StockIssuedDuringPeriodSharesNewIssuesOne" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000302" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,643,837</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="INDP:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000296" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,438</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="INDP:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000297" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,445,532</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0298">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0299">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="INDP:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2024-01-01to2024-12-31" id="Fact000300" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,461,970</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--StockIssuedDuringPeriodValueNewIssuesTwo_zXoa0npGjwhe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of shares of common stock and warrants, net of issuance costs (Note 6d)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--StockIssuedDuringPeriodSharesNewIssuesTwo_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrN6uIWract5" title="Issuance of shares of common stock and warrants, net of issuance costs (Note 6d), shares" style="text-align: right"><ix:nonFraction name="INDP:StockIssuedDuringPeriodSharesNewIssuesTwo" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000310" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,817,017</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="INDP:StockIssuedDuringPeriodValueNewIssuesTwo" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000304" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,170</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="INDP:StockIssuedDuringPeriodValueNewIssuesTwo" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000305" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,750,304</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0306">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0307">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="INDP:StockIssuedDuringPeriodValueNewIssuesTwo" contextRef="From2024-01-01to2024-12-31" id="Fact000308" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,768,474</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_zhdOE6O2lXZ8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0312">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0313">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="Fact000314" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,022,027</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0315">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000316" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,022,027</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43C_c20240101__20241231_eus-gaap--StockholdersEquity_iE_zJXLWlb35ewd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCb2QwIZnUPa" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000324" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,013,901</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000318" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,139</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000319" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,263,919</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000320" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">60,439,183</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0321">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000322" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,944,875</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_437_c20240101__20241231_eus-gaap--StockholdersEquity_iE_zKMelHs9curh" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWAqDtv1w5X3" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000332" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,013,901</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000326" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,139</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000327" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,263,919</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000328" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">60,439,183</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0329">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000330" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,944,875</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the consolidated financial statements and report of independent registered public accounting firm</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_006"></span>INDAPTUS
THERAPEUTICS, INC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statements of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_112_zuA6wwR1kFyi" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_496_20240101__20241231_z9C3Opqs3wd" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td id="xdx_49D_20230101__20231231_z5kAYgIHy0Qk" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December 31,</span></td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zPFiOhG8t3d7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_i01_maNCPBUzyDP_zUCrHysw3t2i" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000337" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,022,027</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000338" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,423,471</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zjsEkQww8gY3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--Depreciation_i02_maNCPBUzyDP_zQqYhztkFLBa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-01to2024-12-31" id="Fact000343" format="ixt:numdotdecimal" decimals="0" unitRef="USD">735</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-12-31" id="Fact000344" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,284</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_i02_maNCPBUzyDP_z2cGTqwJBLIj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-01to2024-12-31" id="Fact000346" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,305,849</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact000347" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,965,938</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--InterestEarnedOnMarketableSecurities_i02N_di_msNCPBUzyDP_zI7242zHtBj1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Interest earned on marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0349">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="INDP:InterestEarnedOnMarketableSecurities" contextRef="From2023-01-012023-12-31" id="Fact000350" format="ixt:numdotdecimal" decimals="0" unitRef="USD">430,993</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zcwR4iCpLE2f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msNCPBUzyDP_z1dGRPdEhhM7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Prepaid expenses and other current and non-current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-01-01to2024-12-31" id="Fact000355" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,944</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-012023-12-31" id="Fact000356" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">161,800</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInOtherOperatingAssets_i03N_di_msNCPBUzyDP_zShiSi98kbN2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Accounts payable and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2024-01-01to2024-12-31" id="Fact000358" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">474,057</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2023-01-012023-12-31" id="Fact000359" format="ixt:numdotdecimal" decimals="0" unitRef="USD">680,520</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_ecustom--IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet_i03_maNCPBUzyDP_zrtTO8pMLah1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Operating lease right-of-use asset and liability, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="INDP:IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet" contextRef="From2024-01-01to2024-12-31" id="Fact000361" format="ixt:numdotdecimal" decimals="0" unitRef="USD">142</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="INDP:IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet" contextRef="From2023-01-012023-12-31" id="Fact000362" format="ixt:numdotdecimal" decimals="0" unitRef="USD">647</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUzyDP_maCCERCzxHE_zRra8vRJJeji" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net cash used in operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000364" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,323,188</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-12-31" id="Fact000365" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,405,315</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zfL7inE4oD9e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PaymentsToAcquireMarketableSecurities_i01N_di_msNCPBUzjAS_zBnwOxouCqc9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Purchase of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0370">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="From2023-01-012023-12-31" id="Fact000371" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,859,432</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_i01_maNCPBUzjAS_zbiiEEKqpkz7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Maturity of marketable securities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0373">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" contextRef="From2023-01-012023-12-31" id="Fact000374" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,000,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUzjAS_maCCERCzxHE_zjpgG1EvRpJ9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net cash provided by investing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0376">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-12-31" id="Fact000377" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,140,568</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zzGKVTo2mxui" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maNCPBUzjQF_zWVNwb5oNIx4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of shares of common stock and warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-01to2024-12-31" id="Fact000382" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,510,591</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0383">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PaymentOfFinancingAndStockIssuanceCosts_i01N_di_msNCPBUzjQF_zfG3cucGMoDk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Issuance costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" contextRef="From2024-01-01to2024-12-31" id="Fact000385" format="ixt:numdotdecimal" decimals="0" unitRef="USD">762,703</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0386">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzjQF_maCCERCzxHE_zBXxrPgjrxk9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000388" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,747,888</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCCERCzxHE_zZQTGNafLLW" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net (decrease) increase in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2024-01-01to2024-12-31" id="Fact000391" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,575,300</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2023-01-012023-12-31" id="Fact000392" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,735,253</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zcMjYURv73p8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Cash and cash equivalents at beginning of year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000394" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,362,053</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000395" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,626,800</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zMZPwALvr2fk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents at end of year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-12-31" id="Fact000397" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,786,753</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000398" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,362,053</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_z0ydz0I30xNl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Noncash investing and financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--LeaseRenewalOptionExercise_i01_zLfXXPJVgkbg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">ASC 842 lease renewal option exercise</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0403">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="INDP:LeaseRenewalOptionExercise" contextRef="From2023-01-012023-12-31" id="Fact000404" format="ixt:numdotdecimal" decimals="0" unitRef="USD">236,506</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--TransactionCostsInAccountsPayableAndOtherCurrentLiabilities_i01_zV4klitjwKo3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Transaction costs in accounts payable and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="INDP:TransactionCostsInAccountsPayableAndOtherCurrentLiabilities" contextRef="From2024-01-01to2024-12-31" id="Fact000406" format="ixt:numdotdecimal" decimals="0" unitRef="USD">163,333</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0407">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ChangeInAccumulatedOtherComprehensiveIncomeLoss_i01_zZPTfSqb28O8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in accumulated other comprehensive income</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0409">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="INDP:ChangeInAccumulatedOtherComprehensiveIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000410" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">96,434</ix:nonFraction></td><td style="text-align: left">)</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--SupplementalCashFlowInformationAbstract_iB_z0nJkwrO7lP9" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; font-weight: bold; text-align: left">Supplemental cash flow disclosures</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxesPaidNet_zbgOEJY9FWoe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Cash paid for income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2024-01-01to2024-12-31" id="Fact000415" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2023-01-012023-12-31" id="Fact000416" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,600</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the consolidated financial statements and report of independent registered public accounting firm</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_007"></span>INDAPTUS
THERAPEUTICS, INC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Consolidated Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000418" name="us-gaap:NatureOfOperations"><p id="xdx_800_eus-gaap--NatureOfOperations_zqUCxD209197" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1: <span id="xdx_82E_zumxOemtx2qi">GENERAL</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indaptus
Therapeutics, Inc. and its wholly-owned subsidiaries, Decoy Biosystems, Inc. and Intec Pharma Ltd., collectively (the &#8220;Company&#8221;),
is a biotechnology company dedicated to enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic
solid tumors and lymphomas, which are responsible for more than 90% of all cancer deaths. The Company is developing a novel, multi-targeted
product that activates both innate and adaptive anti-tumor and anti-viral immune responses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks
and uncertainties</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to a number of risks similar to those of other companies of similar size in its industry, including, but not limited
to, the need for successful development of products, the need for additional capital (or financing) to fund operations (see below), competition
from substitute products and services from larger companies, protection of proprietary technology, patent litigation, and dependence
on key individuals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Going
concern and management&#8217;s plans</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has incurred net losses and utilized cash in operations since inception. For the year ended December 31, 2024, the Company incurred
a net loss of approximately $<span id="xdx_906_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20240101__20241231_zmnsGoAomsIg" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000420" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">15.0</ix:nonFraction></span> million, and as of December 31, 2024, the Company had an accumulated deficit of approximately $<span id="xdx_903_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20241231_zYo5hzF55qY" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000422" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">60.4</ix:nonFraction></span>
million. In addition, during the year ended December 31, 2024, the Company used approximately $<span id="xdx_90A_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20240101__20241231_zgXEi320GJt1" title="Net cash used in operating activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000424" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">12.3</ix:nonFraction></span> million of cash in operations and
expects to continue to incur significant cash outflows and incur future additional losses as clinical trials and commercialization of
the Company&#8217;s product candidates will require significant additional financing. The Company believes that, as of the date of the
issuance of these consolidated financial statements, it has adequate cash to fund its ongoing activities into the second quarter of
2025 based on its current operating plan. The Company plans to execute its operating plan by obtaining additional capital, principally
through entering into collaborations, strategic alliances, or license agreements with third parties and/or additional public or private
debt and equity financing, such as through the registered direct offerings and concurrent private placements that the Company completed
in August 2024 (the &#8220;August 2024 Offering&#8221;) and in November 2024 (the &#8220;November 2024 Offering&#8221;), and through
the private placement in January 2025 (the &#8220;January 2025 Offering&#8221;). Following these offerings, the Company raised a total
of approximately $<span id="xdx_905_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20240101__20241231_zm23B49uwDyl" title="Net of placement agent cost"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2024-01-01to2024-12-31" id="Fact000426" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.3</ix:nonFraction></span> million, net of placement agent and other offering expenses in the amount of approximately $<span id="xdx_90D_eus-gaap--NoninterestExpenseOfferingCost_pn5n6_c20250101__20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrRevrktynr6" title="Other offering cost"><ix:nonFraction name="us-gaap:NoninterestExpenseOfferingCost" contextRef="From2025-01-012025-01-31_us-gaap_SubsequentEventMember" id="Fact000428" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million. For more
details, see Note 6(c), 6(d) and 6(e). In addition, in February 2025, the Company entered into a <span style="background-color: white">Standby
Equity Purchase Agreement pursuant to which the Company has the right, but not the obligation, to sell up to $<span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20250201__20250228__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zMM325oknZff" title="Purchase ordinary shares"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2025-02-012025-02-28_custom_EquityPurchaseAgreementsMember_us-gaap_SubsequentEventMember" id="Fact000430" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">20.0</ix:nonFraction></span> million o<span style="color: #212529">f
the Company&#8217;s common stock </span>during a 36-month period, subject to the restrictions and satisfaction of the conditions in the
Standby Equity Purchase Agreement. For more details, see Note 6(f). </span>However, there is no assurance that additional capital and/or
financing will be available to the Company, and even if available, whether it will be on terms acceptable to the Company or in the amounts
required. If the Company is unsuccessful in securing sufficient financing, it may need to delay, reduce, or eliminate its research and
development programs, which could adversely affect its business prospects, or cease operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of these uncertainties, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The consolidated
financial statements do not include any adjustments to the carrying amounts and classifications of assets and liabilities that would
result if the Company was unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000432" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_80F_eus-gaap--SignificantAccountingPoliciesTextBlock_zzT8l1FpiXzc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2: <span id="xdx_82B_zidKcg8Oftzd">SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000434" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zHvtafAti2d2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basis
of presentation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#8220;US GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000436" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_zRVAz49Q8aMi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Principles
of consolidation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of Indaptus and its subsidiaries. Intercompany balances and transactions have
been eliminated upon consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000438" name="us-gaap:UseOfEstimates"><p id="xdx_84A_eus-gaap--UseOfEstimates_z7lX2mqACVBi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Use
of estimates</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in accordance with US GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements, and the
reported amounts of expenses during the reporting periods. The most significant estimates relate to the determination of the fair value
of stock-based compensation and the determination of period-end obligations to certain contract research organizations. Management evaluates
its estimates and assumptions on an ongoing basis using historical experience and other factors and makes adjustments when facts and
circumstances dictate. These estimates are based on information available as of the date of the consolidated financial statements; therefore,
actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000440" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zITshnNOMlMc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Loss
per share</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
per share, basic and diluted, is computed on the basis of the net loss for the period divided by the weighted average number of shares
of common stock outstanding during the period. Diluted loss per share is based upon the weighted average number of shares of common stock
and of common stock equivalents outstanding when dilutive. Common stock equivalents include outstanding stock options and warrants which
are included under the treasury stock method when dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000442" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zTVxb6GxtKPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following number of stock options and warrants were excluded from the calculation of diluted loss per share because their effect would
have been anti-dilutive for the periods presented (share data):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B7_z7noe3Or3OFi" style="display: none">SCHEDULE
OF ANTI-DILUTIVE SECURITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Weighted average</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Outstanding stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zzzBDQa1x78h" title="Anti-dilutive securities" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000444" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,519,419</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z8roWgWnW3W9" title="Anti-dilutive securities" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000446" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,979,196</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_znlKC6M6KURe" title="Anti-dilutive securities" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" id="Fact000448" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,935,282</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_za29FhSrik0l" title="Anti-dilutive securities" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact000450" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,090,787</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_z0zZABOUdWg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000452" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_846_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6fmJp0ekRI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
and cash equivalents</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. As of
December 31, 2024, and 2023, cash and cash equivalents consist primarily of checking and money market deposits. The Company&#8217;s cash
balances exceed those that are federally insured; however, the Company believes it is not exposed to significant credit risk due to the
financial strength of the depository institutions in which the cash and cash equivalents are held. To date, the Company has not recognized
any losses caused by uninsured balances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000454" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zAleiunrGJg3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Property
and equipment</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment assets are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over
the estimated useful lives of the assets. The Company uses an estimated useful life of <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersAndOtherOfficeEquipmentMember_zdj4BE7ssyu8" title="Estimated useful life"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_PropertyPlantAndEquipmentMember_custom_ComputersAndOtherOfficeEquipmentMember" format="ixt-sec:durwordsen" id="Fact000456" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">three years</ix:nonNumeric></span> for employee-related computers and
other office equipment and <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureMember_zt1TZj9uzmx5" title="Estimated useful life"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_PropertyPlantAndEquipmentMember_custom_FurnitureMember" format="ixt-sec:durwordsen" id="Fact000458" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">five years</ix:nonNumeric></span> for furniture. Leasehold improvements are amortized over the shorter of the lease-term or the estimated
useful life of the related asset.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000460" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_84A_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zrMB8XORfTug" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patents</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expenses patent costs, including related legal costs, as incurred and records such costs within general and administrative expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000462" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zF7nDBVoI5zc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and development expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses include costs directly attributable to the conduct of research and development programs, including the cost
of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research
and development activities, including clinical trials and professional services. All costs associated with research and development are
expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accrues for expenses resulting from obligations under agreements with contract research organizations (&#8220;CROs&#8221;), contract
manufacturing organizations (&#8220;CMOs&#8221;), and other outside service providers for which payment flows do not match the periods
over which services or materials are provided to the Company. Accruals are recorded based on estimates of services received and efforts
expended pursuant to agreements with CROs, CMOs, and other outside service providers. These estimates are typically based on contracted
amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers
as to the progress or stage of completion of the services. In the event advance payments are made to a CRO, CMO, or outside service provider,
the payments will be recorded as a prepaid expense, which will be amortized or expensed as the contracted services are performed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000464" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock"><p id="xdx_84D_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_z8xuuJUtuue8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and administrative expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses include compensation, employee benefits, and stock-based compensation for executive management, finance,
administration and human resources, facility costs (including rent), professional service fees, and other general overhead costs to support
the Company&#8217;s operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000466" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zdqqlKEERcNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income
taxes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences
attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective
tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred
tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation
allowance is recorded for deferred tax assets if it is more likely than not that some portion or all of the deferred tax assets will
not be realized in the foreseeable future. As of December 31, 2024, and 2023, the Company has recorded a full valuation allowance against
its deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized
income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or
measurement are reflected in the period in which the change in judgment occurs. The Company records interest related to unrecognized
tax benefits in interest expense and penalties in general and administrative expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000468" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_84C_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zF62OiizdLR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-based
compensation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures and records the expense related to stock-based payment awards based on the fair value of those awards as determined
using the Black-Scholes-Merton (&#8220;Black-Scholes&#8221;) model as of the date of grant. The Company recognizes stock-based compensation
expense over the requisite service period of the individual grant, generally equal to the vesting period, on a straight-line basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Black-Scholes model requires the use of highly subjective and complex assumptions, which determine the fair value of stock-based payment
awards, including the option&#8217;s expected term and the price volatility of the underlying stock. The Company estimates the fair value
of options granted by using the Black-Scholes model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
Volatility</i>&#8212;The Company estimates volatility for option grants by evaluating the historical volatility of a peer group of companies
for the period immediately preceding the option grant for a term that is approximately equal to the options&#8217; expected term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 79; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
Term</i>&#8212;The expected term of the Company&#8217;s options represents the period that the stock-based payment awards are expected
to be outstanding. The expected term is estimated using the simplified method for employee stock options since the Company does not have
adequate historical exercise data to estimate the expected term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk-Free
Interest Rate</i>&#8212;The risk-free interest rate is based on the implied yield currently available on U.S. Treasury zero-coupon issues
with a term that is equal to the options&#8217; expected term at the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividend
Yield</i>&#8212;The Company has not declared or paid dividends to date and does not anticipate declaring dividends. As such, the dividend
yield has been estimated to be zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has elected to recognize forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000470" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z7gde9Bxbz2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
value measurements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability
in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the
measurement date. The Company follows the established framework for measuring fair value and providing disclosures about fair value measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted prices in active
    markets for identical assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs other than Level
    1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable inputs which
    are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or
    similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
820, <i>Fair Value Measurement</i>, requires all entities to disclose the fair value of financial instruments, both assets and liabilities,
for which it is practicable to estimate fair value, and defines the fair value of a financial instrument as the amount at which the instrument
could be exchanged in a current transaction between willing parties. As of December 31, 2024, and 2023, the recorded values of cash and
cash equivalents, prepaid expenses, and accounts payable and other current liabilities approximate their fair values due to the short-term
nature of these items.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000472" name="INDP:NewAdoptedAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84E_ecustom--NewAdoptedAccountingPronouncementsPolicyPolicyTextBlock_zAcWFfnPQO1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Recently
adopted accounting pronouncements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
November 2023, the FASB issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures. The FASB amended the guidance in ASC
280, Segment Reporting (&#8220;ASC 280&#8221;), to require a public entity to disclose significant segment expenses and other segment
items on an annual and interim basis and to provide in interim periods all disclosures about a reportable segment&#8217;s profit or loss
and assets that are currently required annually. Public entities with a single reportable segment are required to provide the new disclosures
and all the disclosures required under ASC 280. The guidance is applied retrospectively to all periods presented in financial statements
unless it is impracticable. This new guidance is effective for public business entities for annual periods beginning after December 15,
2023, and for interim periods beginning after December 15, 2024. The Company adopted this new standard effective December 31, 2024. See
Note 9, Segment Information, for disclosures related to the adoption of ASU 2023-07.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000474" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_znDn13vSn9X1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span id="xdx_86B_zps4ItJ4JNDf">Recently
issued accounting pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense <span style="background-color: white">Disaggregation </span> Disclosures.
This ASU will require entities to provide enhanced disclosures, in a tabular format, related to certain expense categories included in
the statement of operations. The ASU aims to increase transparency and provide investors with more detailed information about the nature
of expenses reported on the face of the income statement. The new ASU is effective for annual reporting periods beginning after December
15, 2026 and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating
the impact of the adoption of this standard on the related disclosures</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures. This ASU does not change accounting for income
taxes but requires new disclosures focusing on two areas, the effective rate reconciliation and taxes paid. This new standard is effective
for public business entities for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently
evaluating the impact of the adoption of this standard on the related disclosures.</span></p>
</ix:nonNumeric><p id="xdx_85A_zrHdvVzL6ima" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000476" name="INDP:PrepaidExpenseAndOtherCurrentAssetsDisclosureTextBlock"><p id="xdx_808_ecustom--PrepaidExpenseAndOtherCurrentAssetsDisclosureTextBlock_zTYE2Mf9JAXa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3: <span id="xdx_821_zlYPptFFlEOg">PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000478" name="INDP:ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock"><p id="xdx_892_ecustom--ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock_z8ENLd2sfC94" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets are comprised of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zHZ1PU09hW0d" style="display: none">SCHEDULE
OF PREPAID EXPENSE AND OTHER CURRENT ASSETS</span></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20241231_zz8S2HWxhMPc" style="border-bottom: Black 1pt solid; display: none; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_zrwsaLIdXohl" style="border-bottom: Black 1pt solid; display: none; text-align: center">2023</td><td style="display: none; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PrepaidInsurance_iI_pp0p0_maPEAOAz50c_z689fbTuzGWc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Prepaid insurance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2024-12-31" id="Fact000480" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">506,489</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2023-12-31" id="Fact000481" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">554,097</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--PrepaidResearchAndDevelopment_iI_pp0p0_maPEAOAz50c_zsmHvMGxPZNl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="INDP:PrepaidResearchAndDevelopment" contextRef="AsOf2024-12-31" id="Fact000483" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">150,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="INDP:PrepaidResearchAndDevelopment" contextRef="AsOf2023-12-31" id="Fact000484" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,309</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPEAOAz50c_z103lWxDYz5e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other prepaid expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2024-12-31" id="Fact000486" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">175,088</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2023-12-31" id="Fact000487" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">61,750</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPEAOAz50c_zv7GQh85FQw2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000489" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">831,577</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000490" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">633,156</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPEAOAz50c_ztbE9QjeH7J5" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; text-align: left; padding-bottom: 2.5pt">Prepaid expenses and other current assets</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000492" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">831,577</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000493" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">633,156</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AE_zhng3EtopIif" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000495" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p id="xdx_806_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zMaNMhjaQ4g9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4: <span id="xdx_821_zwCUHTUaTl7i">ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000497" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z7Ghfw9tcRD3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
payable and other current liabilities are comprised of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zrXQEarVuofe" style="display: none">SCHEDULE
OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES</span></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: right">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20241231_zJNuo2kqCPZ5" style="border-bottom: Black 1pt solid; display: none; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20231231_zgmpYP5DlDhi" style="border-bottom: Black 1pt solid; display: none; text-align: center">2023</td><td style="display: none; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AccountsPayableCurrent_iI_pp0p0_maAPAOAzxRP_ztpjmkFOSvNd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Accounts payable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000499" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">870,229</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000500" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">806,004</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pp0p0_maAPAOAzxRP_znSBd8T5lr0c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued employee costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000502" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,371,498</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000503" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,213,054</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maAPAOAzxRP_zlKXwDdYWWy9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2024-12-31" id="Fact000505" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">72,054</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2023-12-31" id="Fact000506" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">39,165</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--AccruedResearchAndDevelopmentCurrent_iI_pp0p0_maAPAOAzxRP_z8rk0yw8NkD8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="INDP:AccruedResearchAndDevelopmentCurrent" contextRef="AsOf2024-12-31" id="Fact000508" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">860,958</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="INDP:AccruedResearchAndDevelopmentCurrent" contextRef="AsOf2023-12-31" id="Fact000509" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">439,024</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--AccruedBoardFeesCurrent_iI_pp0p0_maAPAOAzxRP_zfAV4Uc2wuli" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued board fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="INDP:AccruedBoardFeesCurrent" contextRef="AsOf2024-12-31" id="Fact000511" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">117,750</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="INDP:AccruedBoardFeesCurrent" contextRef="AsOf2023-12-31" id="Fact000512" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">117,750</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DelawareFranchiseTaxesPayableCurrent_iI_pp0p0_maAPAOAzxRP_zJiRSqpQT0ah" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Delaware franchise taxes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0514">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="INDP:DelawareFranchiseTaxesPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000515" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">40,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maAPAOAzxRP_z0rTZzcNdzia" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other accrued expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000517" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,228</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000518" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,330</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_pp0p0_mtAPAOAzxRP_zMpVQCMEKC6c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total accounts payable and other current liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000520" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,309,717</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000521" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,672,327</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zYgsqK7PcsUj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000523" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_807_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zib1MN8LgiC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5: <span id="xdx_82E_zXq2nXHnYhh9">STOCK-BASED COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has an equity incentive plan for grants to employees, officers, consultants, directors, and other service providers that was
approved in 2021 (the &#8220;2021 Plan&#8221;). The 2021 Plan provides for the grant of non-qualified stock options, incentive stock
options, restricted stock awards, restricted stock units, unrestricted stock awards, stock appreciation rights and other forms of stock-based
compensation. The 2021 Plan permits the Company&#8217;s board to change the type, terms, and conditions of awards as circumstances may
change. This flexibility to adjust the type of compensation to be granted is particularly important given current economic and world
events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 81; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000525" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zXAmXgmZyVk1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the stock option activity during the year ended December 31, 2024, is presented in the table below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zeyGQStcEPA6" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Weighted average</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of <br/> options</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercise <br/> price</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Remaining <br/> contractual <br/> life <br/> (in years)</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Intrinsic value</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Outstanding as of January 1, 2024</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zwDRGNlhFQP6" title="Number of options, outstanding balance" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31" id="Fact000527" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,050,197</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zqPGJvNypWcd" title="Weighted average exercise price, outstanding, balance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31" id="Fact000529" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.90</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zQuVqRd6KOq" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2023-01-012023-12-31" format="ixt-sec:duryear" id="Fact000531" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.9</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20241231_z9qeWdsE2tSj" title="Intrinsic value, outstanding balance" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-12-31" id="Fact000533" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">36,363</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_z5dyblhUVj47" title="Number of options, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-01to2024-12-31" id="Fact000535" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">838,250</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zNpvhPhY6vHb" title="Weighted average exercise price, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-12-31" id="Fact000537" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.54</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_pp0p0_c20240101__20241231_zpqtrVNV8h6c" title="Intrinsic value, granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0539">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left; padding-left: 10pt">Forfeited and cancelled</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231_zJcVASGjDmMe" title="Number of options, forfeited and cancelled" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2024-01-01to2024-12-31" id="Fact000541" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">625</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20241231_zzfIWwR9soo6" title="Weighted average exercise price, forfeited and cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0543">-</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_z9SBzHGDYs37" title="Number of options, outstanding balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31" id="Fact000545" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,887,822</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_zx4o6cMRJQme" title="Weighted average exercise price, balance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="Fact000547" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.06</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zmUbwefKtb3k" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:duryear" id="Fact000549" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.6</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240101__20241231_zH1kDjUIjIS4" title="Intrinsic value, Outstanding, balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0551">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_zfYJzxb1YpKb" title="Number of options, exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31" id="Fact000553" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,854,764</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zyCcs0JmxGdb" title="Weighted average exercise price, exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="Fact000555" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.54</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_z1y98MsH2l68" title="Weighted average remaining contractual life, Exercisable"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:duryear" id="Fact000557" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">6.8</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20240101__20241231_zv137HlKlX57" title="Intrinsic value, outstanding balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0559">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Vested and expected to vest as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20240101__20241231_zYfkN4Z22mm" title="Number of options, vested and expected to vest" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2024-12-31" id="Fact000561" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,887,822</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_zRkr1D4wLpql" title="Weighted average exercise price, vested and expected to vest"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="Fact000563" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.06</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zFuPTSGFqAoh" title="Weighted average remaining contractual life (in years), vested and expected to vest"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:duryear" id="Fact000565" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">7.6</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240101__20241231_zRHIFEfKL8g2" title="Intrinsic value, vested and expected to vest balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0567">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zzi5cqrNmD9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000569" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zSATXzgUajvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the total stock-based compensation expense included in the consolidated statements of operations for the periods
presented:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zDPSQrTLhZff">SCHEDULE
OF STOCK BASED COMPENSATION EXPENSES</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240101__20241231_zEowYqIwHx3e" style="border-bottom: Black 1pt solid; display: none; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20230101__20231231_zersO87Crwo2" style="border-bottom: Black 1pt solid; display: none; text-align: center">2023</td><td style="display: none; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zwS6iSu3ZWL8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000571" format="ixt:numdotdecimal" decimals="0" unitRef="USD">624,480</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000572" format="ixt:numdotdecimal" decimals="0" unitRef="USD">792,273</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zTQbkhyUTQQj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000574" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,681,369</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000575" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,173,665</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ShareBasedCompensation_zohOI9W2FCq3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-01to2024-12-31" id="Fact000577" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,305,849</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact000578" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,965,938</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zvl7kNmXeEZa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, total compensation cost not yet recognized related to unvested stock options was approximately $<span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20241231_zex7hvOGfFih" title="Share-based compensation, not yet recognized"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2024-12-31" id="Fact000580" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million, which
is expected to be recognized over a weighted-average period of approximately <span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231_zBQmLdCRC5Mc" title="Share-based compensation, not yet recognized, term"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:duryear" id="Fact000582" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.5</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates the fair value of stock options on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes
option-pricing model requires estimates of highly subjective assumptions, which affect the fair value of each stock option. The weighted
average inputs used to measure the value of the options granted during the years ended December 31, 2024 and 2023 are presented in the
table below. The weighted average fair value of stock options issued during the years ended December 31, 2024 and 2023 was $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231_zZZVhQl1go7a" title="Weighted average fair value of stock options issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-01to2024-12-31" id="Fact000584" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.31</ix:nonFraction></span> and
$<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zuV1qMdADOFc" title="Weighted average fair value of stock options issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31" id="Fact000586" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.43</ix:nonFraction></span> per share, respectively.</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000588" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zrcCTPEa0VWk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_z5EeR8Fixg7a" style="display: none">SCHEDULE
OF WEIGHTED AVERAGE INPUTS USED TO MEASURE VALUE OF OPTIONS GRANTED</span></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Exercise price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20241231_zlukEmmEsRN4" title="Exercise price" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2024-12-31" id="Fact000590" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.54</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20231231_zlWom0vDGvO2" title="Exercise price" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2023-12-31" id="Fact000592" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.70</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231_zNSCGk9H5jf5" title="Expected term (in years)"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:duryear" id="Fact000594" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.8</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zDz1s1bSj666" title="Expected term (in years)"><ix:nonNumeric contextRef="From2023-01-012023-12-31" format="ixt-sec:duryear" id="Fact000596" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.8</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231_zEMj6Ynoddpg" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-01to2024-12-31" id="Fact000598" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">114.78</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231_zY9sburtLfT7" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-012023-12-31" id="Fact000600" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">110.9</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231_zUc1dIbbB9o" title="Risk free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-01to2024-12-31" id="Fact000602" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.0</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231_zEAYfPdAp7dl" title="Risk free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-012023-12-31" id="Fact000604" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.7</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231_zYYuY7UHS391" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-01-01to2024-12-31" id="Fact000606" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_zporOTsZbj21" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-01-012023-12-31" id="Fact000608" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zdWOOj9D8ms" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000610" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zISc1R7Vjvle" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the exercise price of outstanding stock options as of December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zRHySXYFx62c" style="display: none">SCHEDULE
OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS</span></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt"><span style="text-decoration: underline">Exercise price</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Options <br/> outstanding</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>$0.01 - $8.00</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zAb9sL5u7fgi" title="Options outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceRangeOneMember" id="Fact000612" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,861,499</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">$<span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zKEYUUqRU9C7" title="Exercise price range lower range limit" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVYRVJDSVNFIFBSSUNFIE9GIE9VVFNUQU5ESU5HIFNUT0NLIE9QVElPTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2024-01-012024-12-31_custom_ExercisePriceRangeOneMember" id="Fact000614" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> - $<span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zFPPL2xF8cse" title="Exercise price range upper range limit" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVYRVJDSVNFIFBSSUNFIE9GIE9VVFNUQU5ESU5HIFNUT0NLIE9QVElPTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-01-012024-12-31_custom_ExercisePriceRangeOneMember" id="Fact000616" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.00</ix:nonFraction></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zFlofZCEAqhd" title="Options outstanding" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceRangeOneMember" id="Fact000618" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,861,499</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>$<span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zvcnbSm68Xx2" title="Exercise price range lower range limit" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVYRVJDSVNFIFBSSUNFIE9GIE9VVFNUQU5ESU5HIFNUT0NLIE9QVElPTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2024-01-012024-12-31_custom_ExercisePriceRangeTwoMember" id="Fact000620" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.01</ix:nonFraction></span> - $<span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zS0Jv3U0bKp5" title="Exercise price range upper range limit" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVYRVJDSVNFIFBSSUNFIE9GIE9VVFNUQU5ESU5HIFNUT0NLIE9QVElPTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-01-012024-12-31_custom_ExercisePriceRangeTwoMember" id="Fact000622" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.00</ix:nonFraction></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zAqwWC07acxk" title="Options outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceRangeTwoMember" id="Fact000624" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">992,250</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">$<span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zIKCOXNfzFOa" title="Exercise price range lower range limit" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVYRVJDSVNFIFBSSUNFIE9GIE9VVFNUQU5ESU5HIFNUT0NLIE9QVElPTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2024-01-012024-12-31_custom_ExercisePriceRangeThreeMember" id="Fact000626" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.01</ix:nonFraction></span> or higher</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zJ3TqrSUYHf7" title="Options outstanding" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2024-12-31_custom_ExercisePriceRangeThreeMember" id="Fact000628" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">34,073</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231_zD6QVuk5SHfl" title="Options outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2024-12-31" id="Fact000630" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,887,822</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zZlu8LxJak8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000632" name="INDP:CapitalizationTextBlock"><p id="xdx_802_ecustom--CapitalizationTextBlock_zQDr6vbLxSPf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6: <span id="xdx_827_zd4DzPIxkPF5">CAPITALIZATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2024 and December 31, 2023, the Company had <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zlGPvMVUFSt5" title="Common stock, shares authorized"><span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_zCn6Ojz7eTGa" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000634" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000636" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000,000</ix:nonFraction></ix:nonFraction></span></span>
    shares of common stock authorized and <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231_zpa5gZcgoJQ" title="Common stock, shares issued"><span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zwuk79Q4j3ub" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000638" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000640" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,013,901</ix:nonFraction></ix:nonFraction></span></span>
    and <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_zybpOiObkan4" title="Common stock, shares issued"><span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_zhIxN9rFWqb8" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000642" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000644" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,401,047</ix:nonFraction></ix:nonFraction></span></span>
    shares issued and outstanding, respectively. As of December 31, 2024 and December 31, 2023, the Company had <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_zH1QrIk6Atsg" title="Preferred stock, shares authorized"><span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231_zRihT3jroly4" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000646" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000648" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></ix:nonFraction></span></span>
    shares of preferred stock authorized. There were <span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20241231_zwai1cDwmOH8" title="Preferred stock, shares issued"><span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20231231_zPaXnSHWCqm2" title="Preferred stock, shares issued"><span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20241231_ztTEv39Awwha" title="Preferred stock, shares outstanding"><span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20231231_zfqiuOXVW4j4" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000650" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000652" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000654" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000656" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares of preferred stock issued or outstanding as of December 31, 2024 and
    2023. As of December 31, 2024 and December 31, 2023, there were warrants outstanding to purchase an aggregate of <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231_zGbw15QBQfX5" title="Warrants outstanding to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31" id="Fact000658" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,675,853</ix:nonFraction></span>
    and <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231_zWKGIVW8YPFd" title="Warrants outstanding to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-12-31" id="Fact000660" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,090,787</ix:nonFraction></span>
    shares of common stock, respectively. As of December 31, 2024, these warrants are exercisable at a weighted average price of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmfnXT32AZt" title="Weighted average exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact000662" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.52</ix:nonFraction></span>
    and their weighted average remaining contractual term is <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z99qsiitKYna" title="Weighted average, remaining contractual life"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember9626531" format="ixt-sec:duryear" id="Fact000664" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">3.5</ix:nonNumeric></span>
    years.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 82; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 1, 2022, the Company
    entered into an At The Market Offering Agreement (the &#8220;ATM Agreement&#8221;) which was amended on September 1, 2022 with a
    sales agent, pursuant to which the Company may offer and sell, from time to time through the sales agent, shares of the Company&#8217;s
    common stock, par value $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20220901__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zD8OFNxMCYm3" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-09-01_custom_AtTheMarketOfferingAgreementMember_custom_HCWainwrightAndCoLLCMember" id="Fact000666" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per share. The issuance and sale of common stock by the Company under the <span style="background-color: white">ATM
    Agreement</span> is being made pursuant to the Company&#8217;s effective &#8220;shelf&#8221; registration statement on Form S-3 filed
    with the SEC on September 1, 2022 and declared effective on September 9, 2022. <span style="background-color: white">In 2024, the
    Company sold <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zxCOyrv5Rnp8" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_custom_AtTheMarketOfferingAgreementMember_custom_HCWainwrightAndCoLLCMember" id="Fact000668" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">152,000</ix:nonFraction></span> shares of the Company&#8217;s common stock for aggregate gross proceeds of approximately $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zWBOeAH44Ir1" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-012024-12-31_custom_AtTheMarketOfferingAgreementMember_custom_HCWainwrightAndCoLLCMember" id="Fact000670" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span> million. </span>The
    Company&#8217;s ability to issue shares under the shelf registration statement on Form S-3 is limited by General Instruction I.B.6
    to Form S-3. On August 6<span style="background-color: white">, 2024, the Company filed a prospectus supplement to reduce the amount
    of shares registered under the prospectus for the ATM to $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240806__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zvuNyxGQ4UD7" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-08-06_custom_AtTheMarketOfferingAgreementMember_custom_HCWainwrightAndCoLLCMember" id="Fact000672" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00</ix:nonFraction></span> and to suspend the ATM program, but the ATM Agreement remains in full
    force and effect</span>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    August 8, 2024, the Company completed a registered direct offering, pursuant to which the Company sold and issued to certain investors,
    including an officer of the Company, <span id="xdx_902_eus-gaap--SharesIssued_iI_pid_c20240808__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zelDhdzt93F4" title="Shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2024-08-08_us-gaap_InvestorMember" id="Fact000674" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,643,837</ix:nonFraction></span> shares of the Company&#8217;s common stock at a purchase price per share of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240808_zXFr5mqby50l" title="Shares issued, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-08-08" id="Fact000676" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.825</ix:nonFraction></span>.
    In addition, in a concurrent private placement, the Company also issued to the purchasers in the August 2024 Offering unregistered
    warrants to purchase <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240808__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_ztIxvFUnmOY" title="Class of warrant or right, number of securities called by warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-08-08_us-gaap_WarrantMember_us-gaap_PrivatePlacementMember" id="Fact000678" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,643,837</ix:nonFraction></span> shares of the Company&#8217;s common stock (the &#8220;August 2024 Warrants&#8221;). The August 2024
    Warrants are immediately exercisable at an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240808__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTLaIQ9mVkAa" title="Class of warrant or right, exercise price of warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-08-08_us-gaap_WarrantMember" id="Fact000680" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.70</ix:nonFraction></span> per share and expire <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20240808__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyCK8qXJziT2" title="Warrants and rights outstanding, term"><ix:nonNumeric contextRef="AsOf2024-08-08_us-gaap_WarrantMember" format="ixt-sec:durwordsen" id="Fact000682" name="us-gaap:WarrantsAndRightsOutstandingTerm">five years</ix:nonNumeric></span> from the date of issuance. The
    total net proceeds were approximately $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240808__20240808_z74O81jkPrEc" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-08-082024-08-08" id="Fact000684" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.5</ix:nonFraction></span> million, after deducting placement agent and other offering expenses in the amount of
    approximately $<span id="xdx_906_eus-gaap--NoninterestExpenseOfferingCost_pn5n6_c20240808__20240808_zisvYsmJA2P" title="Noninterest expense offering cost"><ix:nonFraction name="us-gaap:NoninterestExpenseOfferingCost" contextRef="From2024-08-082024-08-08" id="Fact000686" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million. In September 2024, the Company filed a registration statement to register the resale by the investors
    of the shares of common stock issuable upon exercise of the August 2024 Warrants. The registration statement was declared effective
    on September 20, 2024.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 22, 2024, the
    Company completed a registered direct offering, pursuant to which the Company sold and issued to certain investors, including an
    officer of the Company, <span id="xdx_901_eus-gaap--SharesIssued_iI_pid_c20241122__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zpPaub8IlHyg" title="Shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2024-11-22_us-gaap_InvestorMember" id="Fact000688" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,817,017</ix:nonFraction></span> shares of the Company&#8217;s common stock at a purchase price per share of $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241122_zLZnRgBSmDP8" title="Shares issued, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-11-22" id="Fact000690" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.175</ix:nonFraction></span>. In addition,
    in a concurrent private placement, the Company also issued to the purchasers in the November 2024 Offering unregistered warrants
    to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241122__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3tH7DlmCpUc" title="Class of warrant or right, number of securities called by warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-11-22_us-gaap_WarrantMember" id="Fact000692" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,817,017</ix:nonFraction></span> shares of the Company&#8217;s common stock (the &#8220;November 2024 Warrants&#8221;). The November 2024 Warrants
    are immediately exercisable at an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241122__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTlEiDZ8Zn1" title="Class of warrant or right, exercise price of warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-11-22_us-gaap_WarrantMember" id="Fact000694" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.05</ix:nonFraction></span> per share and expire <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20241122__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaWIxo0Xyihl" title="Warrants and rights outstanding, term"><ix:nonNumeric contextRef="AsOf2024-11-22_us-gaap_WarrantMember" format="ixt-sec:durwordsen" id="Fact000696" name="us-gaap:WarrantsAndRightsOutstandingTerm">five years</ix:nonNumeric></span> from the date of issuance. The total net
    proceeds were approximately $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20241122__20241122_zssE98fAhfS4" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-11-222024-11-22" id="Fact000698" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.8</ix:nonFraction></span> million, after deducting placement agent and other offering expenses in the amount of approximately
    $<span id="xdx_903_eus-gaap--NoninterestExpenseOfferingCost_pn4n6_c20241122__20241122_z1Od3HuxhA4a" title="Noninterest expense offering cost"><ix:nonFraction name="us-gaap:NoninterestExpenseOfferingCost" contextRef="From2024-11-222024-11-22" id="Fact000700" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.35</ix:nonFraction></span> million. In December 2024, the Company filed a registration statement to register the resale by the investors of the shares
    of common stock issuable upon exercise of the November 2024 Warrants. The registration statement was declared effective on December
    31, 2024. In addition, in connection with the November 2024 Offering, the Company issued to the placement agent and its designees
    warrants to purchase an aggregate of <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zMvS2HFrdTZ5" title="Warrants to purchase aggregate shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_us-gaap_InvestorMember" id="Fact000702" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">124,212</ix:nonFraction></span> shares of common stock at an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231_z86TXieDX3xa" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31" id="Fact000704" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.3125</ix:nonFraction></span>. The placement agent warrants
    are exercisable six months from the date of issuance and expire on the fifth anniversary of the issue date. The fair value of a warrant
    to purchase <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_dc_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_ze9SNHpHHqIf" title="Fair value of a warrant to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_PrivatePlacementMember" id="Fact000706" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">one</ix:nonFraction></span> share of common stock that was issued to the placement agent was $<span id="xdx_903_eus-gaap--SharePrice_iI_pid_c20241231_z3LMabN6EdTe" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-12-31" id="Fact000708" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.93</ix:nonFraction></span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 16, 2025, the
    Company completed a private placement offering pursuant to which the Company sold and issued to certain investors an aggregate of
    <span id="xdx_90C_eus-gaap--SharesIssued_iI_pid_c20250116__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z6qmcF7ObzLi" title="Shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2025-01-16_us-gaap_InvestorMember_us-gaap_SubsequentEventMember" id="Fact000710" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,109,383</ix:nonFraction></span> shares of common stock and warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250116__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zbtOnOmhtoXf" title="Warrants purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-01-16_us-gaap_InvestorMember_us-gaap_SubsequentEventMember" id="Fact000712" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,109,383</ix:nonFraction></span> shares of common stock (the &#8220;January 2025 Warrants&#8221;).
    The shares and January 2025 Warrants were sold on a combined basis for consideration of $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250116__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z89ZL6bXm0Bi" title="Shares issued, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2025-01-16_us-gaap_SubsequentEventMember" id="Fact000714" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.065</ix:nonFraction></span> for one share and one January 2025
    Warrant. The January 2025 Warrants are immediately exercisable at an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250116__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0l8YbSRAU1c" title="Class of warrant or right, exercise price of warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-01-16_us-gaap_WarrantMember_us-gaap_SubsequentEventMember" id="Fact000716" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.94</ix:nonFraction></span> per share and expire <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250116__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLPiR2Q0oVo2" title="Warrants and rights outstanding, term"><ix:nonNumeric contextRef="AsOf2025-01-16_us-gaap_WarrantMember_us-gaap_SubsequentEventMember" format="ixt-sec:durwordsen" id="Fact000718" name="us-gaap:WarrantsAndRightsOutstandingTerm">five years</ix:nonNumeric></span> from
    the date of issuance. The total net proceeds were approximately $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250116__20250116__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zh1argJvdXa" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-01-162025-01-16_us-gaap_SubsequentEventMember" id="Fact000720" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.0</ix:nonFraction></span> million, after deducting placement agent and other offering
    expenses in the amount of approximately $<span id="xdx_90C_eus-gaap--NoninterestExpenseOfferingCost_pn4n6_c20250116__20250116__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1trsDX6pLYb" title="Noninterest expense offering cost"><ix:nonFraction name="us-gaap:NoninterestExpenseOfferingCost" contextRef="From2025-01-162025-01-16_us-gaap_SubsequentEventMember" id="Fact000722" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.25</ix:nonFraction></span> million. In February 2025, the Company filed a registration statement to register the
    resale by the investors of the shares of common stock and shares of common stock issuable upon exercise of the January 2025 Warrants.
    The registration statement was declared effective on February 11, 2025. In addition, in connection with the January 2025 Offering,
    the Company issued to the placement agent and its designees warrants to purchase an aggregate of <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250211__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zrmgqXaeK144" title="Warrants to purchase aggregate shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-02-11_us-gaap_InvestorMember" id="Fact000724" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">147,656</ix:nonFraction></span> shares of common stock at
    an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250211_zps1i9rlWV2i" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-02-11" id="Fact000726" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.175</ix:nonFraction></span>. The placement agent warrants are exercisable six months from the date of issuance and expire on the
    fifth anniversary of the issue date. The fair value of a warrant to purchase <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_dc_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zeztbEJsflDl" title="Fair value of a warrant to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_PrivatePlacementMember" id="Fact000728" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">one</ix:nonFraction></span> share of common stock that was issued to the placement
    agent was $<span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zC5XhSrpBj1h" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-12-31_us-gaap_PrivatePlacementMember" id="Fact000730" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.74</ix:nonFraction></span>.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 83; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 12, 2025, the
    Company <span style="background-color: white">entered into a Standby Equity Purchase </span>Agreement (the &#8220;SEPA&#8221;) with
    YA II PN, LTD., a Cayman Islands exempt limited company (&#8220;Yorkville&#8221;), which provides that, upon the terms and subject
    to the restrictions and satisfaction of the conditions in the SEPA, Yorkville is committed to purchase up to an aggregate of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20250212__20250212__dei--LegalEntityAxis__custom--YorkvilleMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpKf5biUcyj4" title="Purchase ordinary shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-02-122025-02-12_custom_YorkvilleMember_custom_StandbyEquityPurchaseAgreementsMember_us-gaap_SubsequentEventMember" id="Fact000732" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">20.0</ix:nonFraction></span>
    million of the Company&#8217;s shares of common stock over a 36-month period. At the Company&#8217;s option, the shares of common
    stock would be purchased by Yorkville from time to time at a price equal to 97% of the lowest of the three daily VWAPs during a three
    consecutive trading day period commencing on the date that the Company, subject to certain limitations, delivers a notice to Yorkville
    that the Company is committing Yorkville to purchase such shares of common stock. The Company may also specify a certain minimum
    acceptable price per share in each advance. The Company will control the timing and amount of sales of the Company&#8217;s shares
    to Yorkville. As consideration for Yorkville&#8217;s irrevocable commitment to purchase shares of the Company&#8217;s common stock
    upon the terms of and subject to restrictions and satisfaction of the conditions set forth in the SEPA, upon execution of the SEPA,
    the Company issued to Yorkville <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250212__20250212__dei--LegalEntityAxis__custom--YorkvilleMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zI7PfwYmxaTc" title="Commitment shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-02-122025-02-12_custom_YorkvilleMember_custom_StandbyEquityPurchaseAgreementsMember_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" id="Fact000734" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">305,960</ix:nonFraction></span> shares of common stock, as commitment shares. <span style="background-color: white">Under
    the applicable Nasdaq Rules and pursuant to the SEPA, in no event may the Company issue or sell to Yorkville more than <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250212__20250212__us-gaap--TypeOfArrangementAxis__custom--ExchangeCapMember__dei--LegalEntityAxis__custom--YorkvilleMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zSWuwsbgPitk" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-02-122025-02-12_custom_ExchangeCapMember_custom_YorkvilleMember_us-gaap_SubsequentEventMember" id="Fact000736" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,823,244</ix:nonFraction></span>
    shares of common stock (the &#8220;Exchange Cap&#8221;), which is 19.99% of the shares of common stock outstanding immediately prior
    to the execution of the SEPA, unless (i) the Company obtains stockholder approval to issue shares of common stock in excess of the
    Exchange Cap, or (ii) the average price of all applicable sales of common stock under the SEPA equals or exceeds $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250212__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementsMember__dei--LegalEntityAxis__custom--YorkvilleMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zMNAUoxt3hL" title="Shares issued, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2025-02-12_custom_StandbyEquityPurchaseAgreementsMember_custom_YorkvilleMember_us-gaap_SubsequentEventMember" id="Fact000738" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.81722</ix:nonFraction></span> per share
    (which represents the lower of (i) the Nasdaq Official Closing Price (as reflected on Nasdaq.com) on the trading day immediately
    preceding the effective date or (ii) the average Nasdaq Official Closing Price of the common stock (as reflected on Nasdaq.com) for
    the five trading days immediately preceding the effective date). </span>On February 12, 2025, the Company filed a Form S-1 covering
    the resale of up to <span id="xdx_901_ecustom--NumberOfResaleCommonStockComprised_pid_c20250212__20250212__dei--LegalEntityAxis__custom--YorkvilleMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNjHk7M2Kdah" title="Number of resale common stock comprised"><ix:nonFraction name="INDP:NumberOfResaleCommonStockComprised" contextRef="From2025-02-122025-02-12_custom_YorkvilleMember_custom_StandbyEquityPurchaseAgreementsMember_us-gaap_SubsequentEventMember" id="Fact000740" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></span> shares of common stock comprised of (i) <span id="xdx_904_ecustom--NumberOfCommitmentShares_pid_c20250212__20250212__dei--LegalEntityAxis__custom--YorkvilleMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zvYCCsv9gbf2" title="Commitment shares issued"><ix:nonFraction name="INDP:NumberOfCommitmentShares" contextRef="From2025-02-122025-02-12_custom_YorkvilleMember_custom_StandbyEquityPurchaseAgreementsMember_us-gaap_SubsequentEventMember" id="Fact000742" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">305,960</ix:nonFraction></span> commitment shares, and (ii) up to <span id="xdx_90D_ecustom--NumberOfCommitmentSharesToBeIssuedUponCertainConditions_pid_c20250212__20250212__dei--LegalEntityAxis__custom--YorkvilleMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementsMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4ocMnv8ECwj" title="Commitment shares to be issued upon certain conditions"><ix:nonFraction name="INDP:NumberOfCommitmentSharesToBeIssuedUponCertainConditions" contextRef="From2025-02-122025-02-12_custom_YorkvilleMember_custom_StandbyEquityPurchaseAgreementsMember_srt_MaximumMember_us-gaap_SubsequentEventMember" id="Fact000744" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,694,040</ix:nonFraction></span> shares
    of common stock reserved for issuance and sale to Yorkville under the SEPA. The Form S-1 was declared effective on February 13, 2025.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000746" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80C_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z0miqQVsBwpc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7: <span id="xdx_82F_zX8L3OIVyEa">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Litigation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business.
These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. Periodically,
the Company reviews the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential
loss from any claim or legal claim is considered probable and the amount of such potential loss can be estimated, the Company accrues
liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because
of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available,
the Company reassesses the potential liability related to pending claims and litigation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Leases</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2021, the Company entered into a noncancelable two-year operating lease agreement for approximately <span id="xdx_907_eus-gaap--AreaOfLand_iI_usqft_c20211001__srt--StatementGeographicalAxis__stpr--CA__us-gaap--TypeOfArrangementAxis__custom--TwoYearLeaseAgreementMember_z2gOvU5k7aw6" title="Area of land"><ix:nonFraction name="us-gaap:AreaOfLand" contextRef="AsOf2021-10-01_stpr_CA_custom_TwoYearLeaseAgreementMember" id="Fact000748" format="ixt:numdotdecimal" decimals="INF" unitRef="sqft">2,000</ix:nonFraction></span> square feet of office
space in San Diego, California. The base rent was $<span id="xdx_900_eus-gaap--LeaseAndRentalExpense_c20211001__20211001__srt--StatementGeographicalAxis__stpr--CA__us-gaap--TypeOfArrangementAxis__custom--TwoYearLeaseAgreementMember_z4k8zWNsWg6l" title="Base rent"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2021-10-012021-10-01_stpr_CA_custom_TwoYearLeaseAgreementMember" id="Fact000750" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,999</ix:nonFraction></span> per month with an increase of <span id="xdx_90C_ecustom--RateOfIncreaseInLeaseRent_pid_dp_uPure_c20211001__20211001__srt--StatementGeographicalAxis__stpr--CA__us-gaap--TypeOfArrangementAxis__custom--TwoYearLeaseAgreementMember_zeHwO7qa6F03" title="Rate of increase in lease rent"><ix:nonFraction name="INDP:RateOfIncreaseInLeaseRent" contextRef="From2021-10-012021-10-01_stpr_CA_custom_TwoYearLeaseAgreementMember" id="Fact000752" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction></span>% after the first anniversary of the lease term
commencement, which was November 1, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 19, 2023, the Company executed an amendment to <span id="xdx_901_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20230419__20230419_zSuzqnVwWydf" title="Operating lease, extend description"><ix:nonNumeric contextRef="From2023-04-192023-04-19" id="Fact000754" name="us-gaap:LesseeOperatingLeaseOptionToExtend">the lease agreement to extend the lease through October 31, 2025.</ix:nonNumeric></span> Accordingly, the
Company remeasured its operating lease liability under the agreement and recognized an incremental lease liability and right-of-use asset
of $<span id="xdx_901_eus-gaap--OperatingLeaseLiability_iI_c20230419_zhf2HlUv8eG7" title="Operating lease liability"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-04-19" id="Fact000756" format="ixt:numdotdecimal" decimals="0" unitRef="USD">236,506</ix:nonFraction></span>. The remeasurement was based on a <span id="xdx_902_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_c20230419_zlpHQycvTJ6c" title="Incremental borrowing rate"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="AsOf2023-04-19" id="Fact000758" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9</ix:nonFraction></span>% incremental borrowing rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 84; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000760" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z3RisQPkGIXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum annual lease payments and a reconciliation to the Company&#8217;s operating lease liability under the Company&#8217;s noncancelable
operating lease as of December 31, 2024 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zyf7vEqKPT65" style="display: none">SUMMARY OF MINIMUM LEASE PAYMENTS</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_492_20241231_z2PZRMxwOvqh" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_mtLOLLPzSwn_zQCoRnEkG5E" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Total minimum lease payments in 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2024-12-31" id="Fact000762" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86,862</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zEnBsCwROf7f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: amount representing interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2024-12-31" id="Fact000764" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,698</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zAXm3aw0rwBj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Present value of operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-12-31" id="Fact000766" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,164</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zAEZ8rsZSrOa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: current portion</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000768" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,164</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_z7fwp61UXO37" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liability, net of current portion</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0770">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zDUqlJEt6m32" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized rent expense of $<span id="xdx_907_eus-gaap--PaymentsForRent_c20240101__20241231_znp3ac0wfoOd" title="Rental expense"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2024-01-01to2024-12-31" id="Fact000772" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,847</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--PaymentsForRent_c20230101__20231231_z0EOnlGOGHVa" title="Rental expense"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2023-01-012023-12-31" id="Fact000774" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,742</ix:nonFraction></span> during the years ended December 31, 2024 and 2023, respectively. Total cash
payments for the operating lease totaled $<span id="xdx_907_eus-gaap--OperatingLeasePayments_c20240101__20241231_zUetMXs1F68c" title="Operating lease payments"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2024-01-01to2024-12-31" id="Fact000776" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,705</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--OperatingLeasePayments_c20230101__20231231_zIuNVfWHen93" title="Operating lease payments"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2023-01-012023-12-31" id="Fact000778" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99,254</ix:nonFraction></span> during the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000780" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80A_eus-gaap--IncomeTaxDisclosureTextBlock_zrZN08W838b4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8: <span id="xdx_82E_zrtFde83fKSb">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company had net operating loss carry forwards that may be available to reduce future years&#8217; taxable income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000782" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zTUhivYeNtv9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s provision for income taxes consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_z242BAKEQzPd" style="display: none">SCHEDULE
OF PROVISION FOR INCOME TAXES</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231_zLCL4eNfPQE6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231_znfb9i2Tirvk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzSdz_zT9WXNRuxvpd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Computed &#8220;expected&#8221; tax benefit</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-01to2024-12-31" id="Fact000784" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,154,290</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-012023-12-31" id="Fact000785" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,238,593</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzSdz_zHBWzLXsEXdj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-01-01to2024-12-31" id="Fact000787" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,768</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-012023-12-31" id="Fact000788" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,304</ix:nonFraction></td><td style="text-align: left"/></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_maITEBzSdz_z8QXT9poXWoe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-deductible items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000790" format="ixt:numdotdecimal" decimals="0" unitRef="USD">230,890</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="From2023-01-012023-12-31" id="Fact000791" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,842</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzSdz_zkmuv7KMfY3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in deferred tax asset valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-01to2024-12-31" id="Fact000793" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,454,200</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-012023-12-31" id="Fact000794" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,509,496</ix:nonFraction></td><td style="text-align: left"/></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_maITEBzSdz_zd2Vst94TdV5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" contextRef="From2024-01-01to2024-12-31" id="Fact000796" format="ixt:numdotdecimal" decimals="0" unitRef="USD">482,045</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" contextRef="From2023-01-012023-12-31" id="Fact000797" format="ixt:numdotdecimal" decimals="0" unitRef="USD">613,167</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmountReturnToProvisionAdjustments_maITEBzSdz_zyynnugD7Cgi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Return-to-provision adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="INDP:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmountReturnToProvisionAdjustments" contextRef="From2024-01-01to2024-12-31" id="Fact000799" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="INDP:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmountReturnToProvisionAdjustments" contextRef="From2023-01-012023-12-31" id="Fact000800" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,316</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzSdz_zIGJRcb3CRIg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2024-01-01to2024-12-31" id="Fact000802" format="ixt:numdotdecimal" decimals="0" unitRef="USD">621</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2023-01-012023-12-31" id="Fact000803" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,918</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzSdz_zFKUFZFpa7C7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Income tax expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="Fact000805" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,700</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact000806" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,450</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zvB6mdalE6E8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000808" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zTZ3FR6D4M28" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s net deferred tax assets were comprised of the following as of December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zgbOpEyrc719" style="display: none">SCHEDULE
OF NET DEFERRED TAX ASSETS</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20241231_zSXUmyXbCTaa" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20231231_zPRpDyGVFAnc" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_zWysNROiBnZc" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Net operating losses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-12-31" id="Fact000810" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,447,116</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31" id="Fact000811" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,846,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_z8ThOyPpXaTg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Capitalized research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2024-12-31" id="Fact000813" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,959,591</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2023-12-31" id="Fact000814" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,162,872</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_zF0phi160nWh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2024-12-31" id="Fact000816" format="ixt:numdotdecimal" decimals="0" unitRef="USD">288,756</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2023-12-31" id="Fact000817" format="ixt:numdotdecimal" decimals="0" unitRef="USD">261,052</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_iI_znJ534kLTMp9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="AsOf2024-12-31" id="Fact000819" format="ixt:numdotdecimal" decimals="0" unitRef="USD">249,495</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="AsOf2023-12-31" id="Fact000820" format="ixt:numdotdecimal" decimals="0" unitRef="USD">220,923</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsFrequentFlierLiability_iI_zCqjP36GDjka" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsFrequentFlierLiability" contextRef="AsOf2024-12-31" id="Fact000822" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,760</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsFrequentFlierLiability" contextRef="AsOf2023-12-31" id="Fact000823" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,761</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOther_iI_zQs0zjhFqFxi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2024-12-31" id="Fact000825" format="ixt:numdotdecimal" decimals="0" unitRef="USD">616</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2023-12-31" id="Fact000826" format="ixt:numdotdecimal" decimals="0" unitRef="USD">559</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzCTx_maDTALNzH2X_zZEfUKkg0W1c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total gross deferred tax assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-12-31" id="Fact000828" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,963,334</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-12-31" id="Fact000829" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,528,167</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_iNI_di_maDITLzRZ0_zFirxZXVNsc9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Right-of-use asset</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="INDP:DeferredTaxLiabilitiesRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact000831" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,340</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="INDP:DeferredTaxLiabilitiesRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact000832" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,373</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzRZ0_msDTALNzH2X_zpMKSOQ73S11" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Gross deferred tax liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2024-12-31" id="Fact000834" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,340</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2023-12-31" id="Fact000835" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,373</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzH2X_zkcee1TRsfmf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: Deferred tax asset valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact000837" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,945,994</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact000838" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,491,794</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzH2X_zl5cYOCzlixj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0840">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0841">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zpBQcQhW3nEf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income tax assets and liabilities are recorded for differences between the financial statement and tax basis of the assets and liabilities
that will result in taxable or deductible amounts in the future based on enacted laws and rates applicable to the periods in which the
differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets
to the amount expected to be realized</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 85; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to
the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits is
dependent on the Company&#8217;s ability to generate sufficient taxable income within the carryforward period. Because of the Company&#8217;s
recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned
future tax benefits is currently not likely to be realized and, accordingly, has provided a full valuation allowance for the years ended
December 31, 2024 and 2023. The net change in total valuation allowance for the years ended December 31, 2024 and 2023 was an increase
of $<span id="xdx_900_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20240101__20241231_z0XcFPhK3gI5" title="Valuation allowance change amount"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2024-01-01to2024-12-31" id="Fact000843" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.5</ix:nonFraction></span> million and increase of $<span id="xdx_90B_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20230101__20231231_zI4DoyCjUOC5" title="Valuation allowance change amount"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2023-01-012023-12-31" id="Fact000845" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.5</ix:nonFraction></span> million respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024, the Company has United States federal and state net operating loss (NOL) carryforwards of $<span id="xdx_909_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_z8HnJvHrsef7" title="Net operating loss (NOL) carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31_custom_FederalMember" id="Fact000847" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">35.3</ix:nonFraction></span> million and $<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__custom--StateMember_zea56iQfLLvb" title="Net operating loss (NOL) carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31_custom_StateMember" id="Fact000849" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.6</ix:nonFraction></span> million,
respectively. The federal NOL carryforwards generated in pre-2018 tax years of $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--TaxPeriodAxis__custom--ExpireInTwoThousandThirtySixMember__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_z3SVfRchMs0c" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31_custom_ExpireInTwoThousandThirtySixMember_custom_FederalMember" id="Fact000851" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million will begin to expire in 2036 while federal
NOLs generated after 2017 of $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--TaxPeriodAxis__custom--IndefinitePeriodMember__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_zBShpWSjvE9i" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31_custom_IndefinitePeriodMember_custom_FederalMember" id="Fact000853" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">34.4</ix:nonFraction></span> million will carry forward indefinitely. The state NOL carryforwards of $<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--TaxPeriodAxis__custom--ExpireInTwoThousandThirtyFiveMember__us-gaap--IncomeTaxAuthorityAxis__custom--StateMember_zer61JGsbbm" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31_custom_ExpireInTwoThousandThirtyFiveMember_custom_StateMember" id="Fact000855" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.6</ix:nonFraction></span> million will begin to
expire in 2035 unless previously utilized. At December 31, 2024, the Company also had Israel NOL carryforwards of $<span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__srt--StatementGeographicalAxis__country--IL_zFColA0xLhZ4" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31_country_IL" id="Fact000857" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">197.9</ix:nonFraction></span> million. The
Israel NOLs carry forward indefinitely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to utilize its net operating losses may be limited under Section 382 and 383 of the Internal Revenue Code. The
limitations apply if an ownership change, as defined by Section 382, occurs. Generally, an ownership change occurs when certain shareholders
increase their aggregate ownership by more than 50 percentage points over their lowest ownership percentage in a testing period (typically
three years). Although the Company has not undergone a Section 382 analysis, it is possible that the utilization of the net operating
losses, could be substantially limited. Additionally, U.S. tax laws limit the time during which these carryforwards may be utilized against
future taxes. As a result, the Company may not be able to take full advantage of these carryforwards for federal and state tax purposes.
Future changes in stock ownership may also trigger an ownership change and, consequently, a Section 382 limitation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the benefit of tax positions taken or expected to be taken in its tax returns in the consolidated financial statements
when it is more likely than not that the position will be sustained upon examination by authorities. Recognized tax positions are measured
at the largest amount of benefit that is <span id="xdx_90B_eus-gaap--IncomeTaxExaminationDescription_c20240101__20241231_zucLEhOVSrEa" title="Income tax examination description"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000859" name="us-gaap:IncomeTaxExaminationDescription">greater than 50% likely of being realized upon settlement</ix:nonNumeric></span>. As of December 31, 2024 and 2023
the Company has not recorded any unrecognized tax benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records interest related to unrecognized tax benefits in interest expense and penalties in general and administrative expenses.
As of December 31, 2024 and 2023, the Company recorded <span id="xdx_90F_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_iI_do_c20241231_zGXutwkTqx21" title="Unrecognized tax benefits, income tax penalties and interest accrued"><span id="xdx_906_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_iI_do_c20231231_zAtdHnNOJXb" title="Unrecognized tax benefits, income tax penalties and interest accrued"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="AsOf2024-12-31" id="Fact000861" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="AsOf2023-12-31" id="Fact000863" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> accrued interest and penalties related to unrecognized tax benefits. The Company
does not expect any significant changes in its tax positions that would warrant recognition of a liability for unrecognized income tax
benefits during the next 12 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company files U.S. federal and various state income tax returns and is subject to the examination for tax years back to 2021 and 2020
for federal and state purposes, respectively, and its NOL&#8217;s dating back to inception are subject to adjustment by the taxing authorities
if claimed on future tax filings for which the statute remain open to examination. The Company also files Israeli tax returns and is
subject to examination for tax years back to 2020. The Company is not currently under audit by the Internal Revenue Service or other
similar national, state and local authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000865" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_808_eus-gaap--SegmentReportingDisclosureTextBlock_zNfDbhvssg4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9: <span id="xdx_822_zeZIHDYvK10g">SEGMENT INFORMATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating
decision maker in deciding how to allocate resources in assessing performance. The Company operates as a <span id="xdx_901_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20240101__20241231_zOBWekpOhlp9" title="Number of reportable segments::XDX::1"><span style="-sec-ix-hidden: xdx2ixbrl0867">single</span></span> reporting segment, focusing
on the development of a novel and patented systemically administered anti-cancer and anti-viral immunotherapy. The Company&#8217;s chief
operating decision maker (&#8220;CODM&#8221;) is the chief executive officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM assesses
performance for the segment based on operating expenses as reported in the accompanying consolidated statement of operations. The Company
expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances the development of its
product candidates through pre-clinical and clinical trials. In addition, the measure of segment assets is reported on the accompanying
consolidated balance sheet as total assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 86; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
such, the CODM uses cash forecast models in deciding how to invest into the segment. Such cash forecast models are reviewed to assess
the entity-wide operating results and performance. Net loss is used to monitor budget versus actual results. Monitoring budgeted versus
actual results is used in assessing performance of the segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000869" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z0dognWGcGM3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents reportable segment loss, including significant expenses regularly provided to the CODM, attributable to the
Company&#8217;s reportable segment for the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zl3YUgJxanE2">SCHEDULE
OF REPORTABLE SEGMENT LOSS</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zsOxoeSs6ydl" style="border-bottom: Black 1pt solid; display: none; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zEZZk0RK9w59" style="border-bottom: Black 1pt solid; display: none; text-align: center">2023</td><td style="display: none; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ResearchAndDevelopmentExpense_hus-gaap--IncomeStatementLocationAxis__custom--ExternalResearchAndDevelopmentMember_zepfhC2OeXt" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">External research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_custom_ExternalResearchAndDevelopmentMember" id="Fact000871" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,355,449</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_ExternalResearchAndDevelopmentMember" id="Fact000872" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,683,828</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ResearchAndDevelopmentExpense_hus-gaap--IncomeStatementLocationAxis__custom--InternalPersonnelCostsMember_zVnbDcks6oOk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Internal personnel costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_custom_InternalPersonnelCostsMember" id="Fact000874" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,895,648</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_InternalPersonnelCostsMember" id="Fact000875" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,937,879</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_msNILz3BM_z0uL5JaqY5t9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000877" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,251,097</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31" id="Fact000878" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,621,707</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_msNILz3BM_zffPC4pkaJCc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000880" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,114,654</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31" id="Fact000881" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,756,767</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherOperatingIncomeExpenseNet_iN_di_maNILz3BM_zyLSWk6AqGU1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other income, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="From2024-01-01to2024-12-31" id="Fact000883" format="ixt:numdotdecimal" decimals="0" unitRef="USD">343,724</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="From2023-01-012023-12-31" id="Fact000884" format="ixt:numdotdecimal" decimals="0" unitRef="USD">955,003</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_iN_di_mtNILz3BM_zbZuKzFYFBB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000886" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,022,027</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000887" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,423,471</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zUpo773nd4Bk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000889" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_803_eus-gaap--SubsequentEventsTextBlock_zOMMw51kkpg4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10: <span id="xdx_82F_zzd3KEJcCJ7a">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluated subsequent events from December 31, 2024, the date of these consolidated financial statements, through March 13, 2024,
which represents the date the consolidated financial statements were issued, for events requiring recognition or disclosure in the consolidated
financial statements for the year ended December 31, 2024. The Company concluded that no events have occurred that would require recognition
or disclosure in the consolidated financial statements, except for the January 2025 Offering that was completed on January 16, 2025,
as described in Note 6(e) and for the SEPA that was entered with Yorkville on February 12, 2025, as described in Note 6(f).</span></p>

</ix:nonNumeric><p id="xdx_818_zFkeMF6I3qLf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_012"></span>Item
9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_013"></span>Item
9A. Controls and Procedures. Disclosure Controls and Procedures.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Limitations
on Effectiveness of Controls and Procedures</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how
well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design
of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply
judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Evaluation
of Disclosure Controls and Procedures</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management, with the participation of our principal executive officer and principal financial officer, evaluated, as of December 31,
2024, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act).
Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and
procedures were effective at the reasonable assurance level as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Management&#8217;s
Annual Report on Internal Control over Financial Reporting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over our financial reporting, as such term is defined
in Rule 13a-15(f) under the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria set forth
in &#8220;Internal Control- Integrated Framework (2013)&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission.
Based on our assessment, our management concluded that as of December 31, 2024, our internal control over financial reporting was effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 88; Options: NewSection; Value: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Attestation
Report of the Independent Registered Public Accounting Firm</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report does not include an attestation report of our registered public accounting firm regarding internal control over financial
reporting due to an exemption provided to issuers that are not &#8220;large accelerated filers&#8221; nor &#8220;accelerated filers&#8221;
under applicable SEC rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in Internal Control over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act)
during the quarter ended December 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal
control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_014"></span>Item
9B. Other Information.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">During
the three months ended December 31, 2024, no director or &#8220;officer&#8221; (as defined in Rule 16a-1(f) under the Exchange Act) of
the Company <span id="xdx_90F_eecd--Rule10b51ArrAdoptedFlag_dbF_c20241001__20241231_zIcfFXcNXLhc" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_909_eecd--NonRule10b51ArrAdoptedFlag_dbF_c20241001__20241231_zzwiIS6rPCba" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2024-10-012024-12-31" format="ixt:booleanfalse" id="Fact000890" name="ecd:Rule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2024-10-012024-12-31" format="ixt:booleanfalse" id="Fact000891" name="ecd:NonRule10b51ArrAdoptedFlag">adopted</ix:nonNumeric></ix:nonNumeric></span></span> or <span id="xdx_907_eecd--Rule10b51ArrTrmntdFlag_dbF_c20241001__20241231_zeCDk1zmPPR7" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_904_eecd--NonRule10b51ArrTrmntdFlag_dbF_c20241001__20241231_z3UoGQ8ZyjC2" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2024-10-012024-12-31" format="ixt:booleanfalse" id="Fact000892" name="ecd:Rule10b51ArrTrmntdFlag"><ix:nonNumeric contextRef="From2024-10-012024-12-31" format="ixt:booleanfalse" id="Fact000893" name="ecd:NonRule10b51ArrTrmntdFlag">terminated</ix:nonNumeric></ix:nonNumeric></span></span> a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221;
as each term is defined in Item 408(a) of Regulation S-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_015"></span>Item
9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="ar_016"></span>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_017"></span>Item
10. Directors and Executive Officers.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information relating to our executive officers and directors as of March 12, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 41%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive
    Officers</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey
    A. Meckler</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    J. Newman, Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Scientific Officer and Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nir
    Sassi</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Walt
    A. Linscott, Esq.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Operating Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Roger
    J. Waltzman</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Medical Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-Executive
    Directors</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Roger J. Pomerantz</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board of Directors</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hila
    Karah</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anthony
    J. Maddaluna</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">William
    B. Hayes</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
    J. Gilbert, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    E. Martell, M.D., Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biographical
information with respect to our executive officers and directors is provided below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Information
about Our Executive Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Jeffrey
A. Meckler </i></b>has served as our Chief Executive Officer since July 2021 and member of our board of directors since inception in
February 2021. Previously, Mr. Meckler served as our sole officer from inception to July 2021, Intec Israel&#8217;s Vice Chairman of
the board of directors from April 2017, as Intec Israel&#8217;s Chief Executive Officer from July 2017 and as President and Secretary
and director of Intec Parent, Inc. from March 2021 until the Merger. Mr. Meckler has served on numerous public and private corporate
boards and since October 2014 has served as a director of Travere Therapeutics (Nasdaq: TVTX). Mr. Meckler served as Chief Executive
Officer and a director of CoCrystal Pharma, Inc., a pharmaceutical company, from April 2015 to July 2016. He has also served as a director
of QLT, Inc. (Nasdaq: QLTI), a biotechnology company, from June 2012 to November 2016, as well as the Managing Director of The Andra
Group, a life sciences consulting firm since 2009. Mr. Meckler also served as Chief Executive Officer of Trieber Therapeutics from January
2017 to July 2017. Earlier in his career, Mr. Meckler held a series of positions at Pfizer Inc. in manufacturing systems, market research,
business development, strategic planning and corporate finance, which included playing a significant role in acquisitions and divestitures.
Mr. Meckler is the past President and continues to serve on the board of directors of Children of Bellevue, a non-profit organization
focused on advocating and developing pediatric programs at Bellevue Hospital Center. Mr. Meckler holds a B.S. in Industrial Management
and M.S. in Industrial Administration from Carnegie Mellon University. In addition, Mr. Meckler received his J.D. from Fordham University
School of Law. We believe that Mr. Meckler is qualified to serve on our board of directors because of his extensive executive leadership
experience in the biopharmaceutical industry, including his service at Pfizer, and his experience serving on public company boards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 89; Value: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Michael
J. Newman, Ph.D. </i></b>has served as our Chief Scientific Officer and a member of our board of directors since August 2021. Dr. Newman
is a pharmaceutical/biotechnology executive with over 40 years of experience carrying out and managing oncology research and development,
in addition to undergraduate and graduate research and training in microbiology. He was the Founder, President, Chief Executive Officer
and a member of the board of directors of Decoy (from August 2013 to August 2021). His previous positions also include faculty appointments
in Biochemistry at Brandeis University (from 1984 to 1987) and the Roche Institute of Molecular Biology (from 1987 to 1992), Senior Associate
Director of Oncology at Sandoz Pharmaceuticals (world-wide head of Cancer Biology), and Executive Director of Oncology at Novartis Pharmaceuticals
(Head of Cancer Biology in the U.S.) (from 1992 to 1997), and senior management at several Biotechnology companies (from 1998 to 2012).
Dr. Newman received a bachelor&#8217;s degree in Biology from the University of California at San Diego, a Ph.D. in Cell and Developmental
Biology from Harvard Medical School (National Science Foundation Pre-Doctoral Fellow), and carried out post-doctoral research at Cornell
University. We believe that Dr. Newman is qualified to serve on our board of directors because of his extensive scientific and research
background, as well as his experience as founder and CEO of Decoy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nir
Sassi </i></b>has served as our Chief Financial Officer since July 2021 and served as Intec Israel&#8217;s Chief Financial Officer from
March 2010 until the Merger (other than from January 2015 to August 2016, during which period Mr. Sassi served as Intec Israel&#8217;s
VP Finance), and its President from March 2021 until the Merger. Prior to his service with Intec Israel, Mr. Sassi served as a Senior
Manager at PricewaterhouseCoopers Israel, an accounting firm, from 2002 until 2010, including two years relocation to the PricewaterhouseCoopers
New York office. Mr. Sassi is a certified public accountant in Israel and has a bachelor&#8217;s degree in economics and accounting from
Ben Gurion University in Be&#8217;er Sheva, Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Walt
A. Linscott, Esq. </i></b>has served as our Chief Operating Officer since March 2023. Prior to that, he served as our Chief Business
Officer from July 2021 until March 2023. Mr. Linscott joined Intec Israel in October 2017 and served as its Chief Business Officer from
July 2018 until the Merger. Previously, from October 2017 to July 2018, Mr. Linscott served as Intec Israel&#8217;s Chief Administrative
Officer. Prior to his service with Intec Israel, Mr. Linscott co-founded a global consulting enterprise in October 2014 providing strategic
advice to developing companies and most recently served as the President and Chief Operating Officer of Treiber Therapeutics, Inc. from
March 2017 to October 2017. Mr. Linscott also has held senior level executive positions at public and private medical device and pharmaceutical
companies including Cocrystal Pharma, Inc., from July 2015 to March 2017, Carestream Health, Inc., from January 2011 to January 2015
and Solvay Pharmaceuticals, Inc., from 2001 to 2005. In addition to this experience, he was an associate and partner at Thompson Hine
LLP from 1990 to 2001, and again as a partner from 2005 to 2010 where he founded the firm&#8217;s Atlanta, Georgia office, served as
Partner in Charge and Chair of the firm&#8217;s Life Science Practice Group. Mr. Linscott holds a Master of Science in Experimental and
Translational Therapeutics from the University of Oxford, a Postgraduate Diploma in Global Business from the University of Oxford and
a Postgraduate Diploma in Entrepreneurship from Cambridge University. He earned a bachelor&#8217;s degree from Syracuse University and
a Juris Doctor from the University of Dayton School of Law. Mr. Linscott served on active duty as an Officer in the United States Marine
Corps prior to attending law school.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Roger
Waltzman M.D., M.B.A. </i></b>has served as our Chief Medical Officer since August 2023. Prior to that, he served as Chief Medical Officer
of Molecular Templates from 2019 to 2023 and in multiple senior drug development roles at Novartis Oncology from 2007 to 2013, where
he played a leading role in the development of imatinib, nilotinib, and ruxolitinib. From 2013 to 2016, Dr. Waltzman was the Full Development
Head of Malaria Drug Development at Novartis. More recently, Dr. Waltzman was CMO at Rgenix (now Inspirna), where he supervised the development
of immuno-oncology and metabolic inhibitor assets through Phase 1 a/b. Previously, he served as CSO at Jaguar Health and Napo Pharmaceuticals,
where he led scientific aspects of development and commercialization of Mytesi&#174; (crofelemer). Before joining the industry, Dr. Waltzman
held assistant professorships in medical oncology and palliative care at Saint Vincent&#8217;s Hospital and Mount Sinai School of Medicine
in New York. He completed his fellowship in hematology/oncology at Memorial Sloan Kettering Cancer Center. Dr. Waltzman earned a Master
of Business Administration at Columbia Business School and a Doctor of Medicine and Bachelor of Arts from Brown University.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 90; Value: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-Employee
Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Roger J. Pomerantz </i></b>has served as our Chairman since July 2021 and previously served on Intec Israel&#8217;s board of
directors from March 2018 until the Merger. Dr. Pomerantz served as Chairman and Chief Executive Officer of Contrafect Corporation
(Nasdaq: CFRX) from April 2019 to November 2023. Prior to that, he served as Vice Chairman of Contrafect from May 2014 to April
2019. Previously, Dr. Pomerantz was a Venture Partner at Flagship Pioneering from 2014 through 2019. In addition, from November 2013
to December 2019, Dr. Pomerantz served as Chairman of the board of directors of Seres Therapeutics, Inc. (Nasdaq: MCRB), a
biotechnology company, and as its President and Chief Executive Officer from June 2014 to January 2019. Prior to joining Seres, Dr.
Pomerantz was Worldwide Head of Licensing &amp; Acquisitions, Senior Vice President at Merck &amp; Co., Inc., where he oversaw all
licensing and acquisitions at Merck Research Laboratories, including external research, out-licensing regional deals, and academic
alliances. Previously, he served as Senior Vice President and Global Franchise Head of Infectious Diseases at Merck. Prior to
joining Merck, Dr. Pomerantz was Global Head of Infectious Diseases for J&amp;J. Dr. Pomerantz has. Since February 2020, he served
as Chairman of Collplant Biotechnologies (Nasdaq: CLPT), since May 2022 he served as Vice Chairman of Enlivex Therapeutics Ltd.
(Nasdaq: ENLV), and was previously a member of the board of directors of Viracta (Nasdaq: VIRX) from June 2020 until December 2024,
Rubius Therapeutics (Nasdaq: RUBY) from 2014 to 2019 and Evelo Therapeutics (Nasdaq: EVLO) from 2015 to 2016. Dr. Pomerantz earned his B.A. in biochemistry at the Johns Hopkins University and his M.D. at
the Johns Hopkins School of Medicine. He completed his internal medicine internship and residency training, and his subspecialty
clinical and research training in infectious diseases and virology at the Massachusetts General Hospital of Harvard Medical School.
His post-doctoral research training in molecular retrovirology was obtained at both Harvard Medical School and the Whitehead
Institute of the Massachusetts Institute of Technology (MIT). Dr. Pomerantz also served as the Chief Resident at the Massachusetts
General Hospital. Following his medical-scientist training, he was an Endowed, Tenured Professor of Medicine and Molecular
Pharmacology and Chairman of the Infectious Diseases Department of Thomas Jefferson University in Philadelphia. Dr. Pomerantz is an
internationally recognized expert in HIV molecular pathogenesis and latency. He has developed ten approved infectious disease drugs
in important diseases including HIV, HCV, tuberculosis, and Clostridium difficile infection. We believe Dr. Pomerantz is qualified
to serve on our board of directors because of his significant scientific, executive and board leadership experience in drug
development and in the pharmaceutical industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Hila
Karah </i></b>has served on our board since July 2021 and previously served as a member of Intec Israel&#8217;s board of directors since
December 2009 until the Merger. Ms. Karah is a managing Partner of Pitango HealthTech VC and an experienced board director. Prior to
Pitango she served as an independent business consultant to private and public companies on strategy, operations, financing, regulatory
and corporate governance. From 2006 until 2013, Ms. Karah was the chief investment officer of Eurotrust Ltd., a family office, where
she focused primarily on investments in life science, internet and high-tech companies. Prior to joining Eurotrust, Ms. Karah served
as a senior analyst at Perceptive Life Sciences Ltd., a New York-based life healthcare focused hedge fund. Prior to her position at Perceptive,
Ms. Karah was a research analyst at Oracle Partners Ltd., a healthcare-focused hedge fund based in Connecticut. Ms. Karah has served
on the board of Cyren Ltd., a cyber security company (Nasdaq, TASE: CYRN), since 2008 and the board of Dario Health Corp. (Nasdaq: DRIO)
since 2014. She also serves on the board of several private companies. Ms. Karah has a BA in molecular and cell biology from the University
of California, Berkeley, and has studied at the UCSB &#8211; UCSF Joint Medical Program. We believe Ms. Karah is qualified to serve on
our board of directors because of her longstanding service with Intec Israel, her investment career in life science companies, her scientific
background and experience serving on public company boards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 91; Value: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Anthony
J. Maddaluna </i></b>has served on our board since July 2021 and previously served on Intec Israel&#8217;s board of directors since December
2017 until the Merger. Mr. Maddaluna has more than 40 years of experience in the pharmaceutical manufacturing industry, including leadership
positions in plants, regions and globally. From January 2011 to December 2016, Mr. Maddaluna held a series of positions at Pfizer Inc.,
most recently serving as the Executive Vice President and President of Pfizer Global Supply. Prior to that Mr. Maddaluna served as Senior
Vice President of Pfizer Global Manufacturing Strategy and Supply Network Transformation from 2008 until 2011, and as Vice President
of Pfizer Global Manufacturing Europe Area from 1998 until 2008. Mr. Maddaluna served as a director of Albany Molecular Research Inc.
from February 2016 until its acquisition by The Carlyle Group and GTCR in August 2017 and currently serves on the board of managers for
the private company. Mr. Maddaluna holds a B.S. in Chemical Engineering from Northeastern University and an M.B.A. from Southern Illinois
University. We believe Mr. Maddaluna is qualified to serve on our board of directors because of his extensive experience in the pharmaceutical
manufacturing industry, including his service at Pfizer, and his experience serving on company boards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>William
B. Hayes </i></b>has served on our board since July 2021 and previously served on Intec Israel&#8217;s board of directors since June
2018 until the Merger. Most recently, Mr. Hayes was Executive Vice President, Chief Financial Officer and Treasurer of Laboratory Corporation
of America Holdings (LabCorp) (NYSE: LH), a diagnostics laboratory company. Mr. Hayes joined LabCorp in 1996, where he was responsible
for day-to-day operations of the revenue cycle function. He rose through a series of promotions and in 2005 was named Executive Vice
President, Chief Financial Officer and Treasurer of LabCorp, a role he held until his retirement in 2014. Prior to LabCorp, Mr. Hayes
was at KPMG for nine years in their audit department. Since October 2019, Mr. Hayes has served on the board of Builders FirstSource,
a supplier and manufacturer of building materials (Nasdaq: BLDR), and currently chairs its audit committee. Previously, Mr. Hayes served
as a director from March 2016 for Patheon N.V. (NYSE: PTHN), a pharmaceutical manufacturing company, until its acquisition by Thermo
Fisher in late 2017. Mr. Hayes holds a Bachelor of Science in accounting from the University of North Carolina at Greensboro. We believe
Mr. Hayes is qualified to serve on our board of directors because of his accounting background and experience serving on public company
boards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Mark
J. Gilbert </i></b>has served on our board of directors since November 2021. Dr. Gilbert brings more than 30 years of experience in global
medical and clinical research and development, and management of medical affairs. From March 2019 to March 2022, Dr. Gilbert served as
Executive Vice President of Research and Development at Acepodia, Inc., a clinical-stage biotechnology company addressing gaps in cancer
care and since June 2021, Dr. Gilbert has served as a Clinical Development Advisor to Decoy Biosystems, Inc., the Company&#8217;s wholly
owned-subsidiary. In addition, from October 2020 to January 2024, Dr. Gilbert served as the Chairman of the Scientific Advisory Board
at Inceptor Bio, LLC, a biotechnology company developing multiple next- generation cell and gene therapy platforms for underserved and
difficult-to-treat cancers, after January 2024 he remains an SAB member, and from October 2020, he serves as a Strategic Advisor at Kineticos
Ventures, a firm providing advisory services and capital to emerging life sciences firms. Prior to these positions, between November
2013 and January 2020, Dr. Gilbert was the Chief Medical Officer of Juno Therapeutics Inc., a biopharmaceutical company, where he led
the clinical development of some of the first CAR-T cell therapies. Before that, Dr. Gilbert held leadership positions at Bayer Schering
Pharma AG, where he served as Vice President and Head of Global Clinical Development, Therapeutic Area Oncology&#894; Berlex Pharmaceuticals,
Inc., where he served as Vice President of Medical Affairs, Oncology, and Vice President and Head of Global Medical Development Group,
Oncology&#894; and Immunex Corporation, where he served as Senior Medical Director, Clinical Research and Development. Between May 2019
and May 2021, Dr. Gilbert served as an Independent Director of Silicon Therapeutics, Inc., a fully integrated drug design and development
company. Dr. Gilbert earned a Bachelor of Science degree in Biochemistry from the University of Iowa and a Medical Doctor degree from
the University of Iowa College of Medicine. He trained in internal medicine, infectious disease and medical oncology at the University
of California, San Francisco, and the University of Washington, respectively. We believe Dr. Gilbert is qualified to serve on our board
of directors because of his significant scientific and executive in drug development and in the pharmaceutical industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 92; Value: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Robert
E. Martell, M.D., Ph.D. </i></b>has served on our board of directors since February 2023. Dr. Martell brings more than 20 years of experience
in the pharmaceutical industry. Dr. Martell is Chief Scientific Officer at Curis, having previously served as Head of Research &amp;
Development. From September 2011 to May 2018, Dr. Martell served on Curis&#8217; Board of Directors. He is also co-founder of Epi-Cure
Pharmaceuticals, a privately held early-stage biotechnology company, and served as its president and member of board of directors from
2016 to 2018. Dr. Martell served as Chief Medical Officer of Tesaro, Inc., a biopharmaceutical company developing Zejula and Varubi from
2012 to 2015; as Chief Medical Officer at MethylGene, a publicly traded biopharmaceutical focused on cancer therapeutics from 2005 to
2009; as Director of Oncology Global Clinical Research at Bristol-Myers Squibb, a biopharmaceutical company developing Sprycel, Erbitux
and Ixempra from 2002 to 2005; and as Associate/Deputy Director at Bayer Corporation Pharmaceutical Division developing Nexavar from
2000 to 2002. In addition, Dr. Martell is a part-time treating physician at Champlain Valley Hematology Oncology and he has held a number
of academic positions, including at Tufts Medical Center since 2009, where he has served in various roles including Associate Chief in
the Division of Hematology/Oncology, Director of the Neely Center for Clinical Cancer Research, Leader of the Cancer Center&#8217;s Program
in Experimental Therapeutics and Attending Physician; at Yale University School of Medicine as Assistant Clinical Professor of Oncology
from 2001 to 2005; and as Assistant Professor at Duke Medical Center from 1998 to 2000. Dr. Martell received a B.A. in chemistry from
Kalamazoo College, a Ph.D. in Pharmacology from University of Michigan and an M.D. from Wayne State University. He completed his Internal
Medicine internship and residency at Duke University Medical Center, and his Fellowship in Medical Oncology also at Duke.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Leadership Structure</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board is committed to promoting effective, independent governance of the Company. Our Board believes it is in the best interests of the
stockholders and the Company for the Board to have the flexibility to select the best director to serve as Chairman at any given time,
regardless of whether that director is an independent director or the Chief Executive Officer. Consequently, we do not have a policy
governing whether the roles of Chairman of the Board and Chief Executive Officer should be separate or combined. This decision is made
by our Board, based on the best interests of the Company considering the circumstances at the time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
the offices of the Chairman of the Board and the Chief Executive Officer are held by two different people. Dr. Pomerantz is our independent,
non-executive Chairman of the Board and Mr. Meckler is our Chief Executive Officer. The Chief Executive Officer is responsible for the
day to day leadership and performance of the Company, while the Chairman of the Board provides guidance to the Chief Executive Officer
and sets the agenda for Board meetings and presides over meetings of the Board. We believe that separation of the positions reinforces
the independence of the Board in its oversight of the business and affairs of the Company, and creates an environment that is more conducive
to objective evaluation and oversight of management&#8217;s performance, increasing management accountability and improving the ability
of the Board to monitor whether management&#8217;s actions are in the best interests of the Company and its stockholders. Furthermore,
we believe that Dr. Pomerantz is especially suited to serve as our Chairman of the Board, in light of his significant strategic management
experience in the U.S. healthcare industry, which provides him with a unique perspective on the best methods of growth for a life sciences
company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
our Board of Directors will continue to periodically review our leadership structure and may make such changes in the future as it deems
appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Role
of the Board in Risk Oversight</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
of the key functions of our Board is informed oversight of our risk management process. Our Board does not have a standing risk management
committee, but rather administers this oversight function directly through our Board as a whole, as well as through various standing
committees of our Board that address risks inherent in their respective areas of oversight. In particular, our Board is responsible for
monitoring and assessing strategic risk exposure. Our Board considers cybersecurity risk as part of its risk oversight function and oversees
our cybersecurity and other information technology risks and management&#8217;s implementation of our cybersecurity risk management program.
Our Audit Committee has the responsibility to consider and discuss our major financial risk exposures and the steps management will take
to monitor and control such exposures, including guidelines and policies to govern the process by which risk assessment and management
is undertaken. The Audit Committee also monitors compliance with legal and regulatory requirements and considers and approves or disapproves
any related person transactions. Our Compensation Committee assesses and monitors whether our compensation plans, policies and programs
comply with applicable legal and regulatory requirements. The Board does not believe that its role in the oversight of our risks affects
the Board&#8217;s leadership structure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 93; Value: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clawback
Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has adopted a Policy for Recovery of Erroneously Awarded Compensation (the &#8220;Clawback Policy&#8221;), in accordance
with the Nasdaq listing standards and Exchange Act Rule 10D-1, which applies to our current and former executive officers. Under the
Clawback Policy, we are required to recoup the amount of any Erroneously Awarded Compensation (as defined in the Clawback Policy) on
a pre-tax basis within a specified lookback period in the event of any Financial Restatement (as defined in the Clawback Policy), subject
to limited impracticability exception.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Policies
and Practices Related to the Grant of Certain Equity Awards</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we award stock options to our employees, including the named executive officers. Historically, the Company we awarded new-hire
option grants on or soon after a new hire&#8217;s employment start date and periodic annual refresh employee option grants, which refresh
grants are typically approved at a meeting of the compensation committee or board. Non-employee directors receive automatic initial and
annual stock option grants, at the time of a director&#8217;s appointment or election to the board and at the time of each annual meeting
of our stockholders, respectively. For additional information on our non-employee director compensation policy see below under the heading,
&#8220;Director Compensation.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not otherwise maintain any written policies on the timing of awards of stock options, stock appreciation rights, or similar instruments
with option-like features. It is the Company&#8217;s practice to not grant any awards to its named executive officers when in possession
of any material nonpublic information, and to wait until such material nonpublic information has been fully disclosed, widely disseminated
to the public and at least two full business days has passed after such material nonpublic information has been disclosed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
of Business Conduct and Ethics</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a Code of Business Conduct and Ethics that applies to our directors, officers and employees, including our principal executive officer,
principal financial officer, principal accounting officer or controller, or persons performing similar functions. The Code of Business
Conduct and Ethics is publicly available on our website at http://www.indaptusrx.com. We intend to satisfy the disclosure requirement
under Item 5.05 of Form 8-K regarding amendment to, or waiver from, a provision of our Code of Business Conduct and Ethics, as well as
Nasdaq&#8217;s requirement to disclose waivers with respect to directors and executive officers, by posting such information on our website
at texhe address and location specified above. The information contained on our website is not incorporated by reference into this Annual
Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Insider
Trading Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted an insider trading policy that governs the purchase, sale, and/or other transactions of our securities by our directors,
officers and certain other covered persons, and which is reasonably designed to promote compliance with applicable insider trading laws,
rules and regulations, and any listing standards applicable to us. A copy of our insider trading policy is filed as Exhibit 19.1 to this
Annual Report on Form 10-K. In addition, with regard to any trading in our own securities, it is our policy to comply with the federal
securities laws and the applicable exchange listing requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Committees
of the Board</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board has established four standing committees&#8212;Audit, Compensation, Nominating, and Science and Technology. Each of Audit, Compensation
and Nominating Committee operates under a written charter that has been approved by our Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
members of each of the Board committees and committee Chairpersons are set forth in the following chart.</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nominating</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Science and
    Technology</b></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark J. Gilbert, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">William B. Hayes</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairperson</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hila Karah</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairperson</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anthony J. Maddaluna</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairperson</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert E. Martell, M.D., Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael J. Newman, Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairperson</span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 94; Value: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Audit
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Audit Committee&#8217;s responsibilities include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointing,
    approving the compensation of, and assessing the independence of our independent registered public accounting firm&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitoring the rotation
    of the partners of our independent registered public accounting firm on our audit engagement team and considering periodically the
    rotation of auditing firms;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing the work of
    our independent registered public accounting firm&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and discussing
    with management and the independent registered public accounting firm the results of the annual audit, including our annual financial
    statements and related disclosures, and the results of the review by the independent registered public accounting firm of our quarterly
    financial statements and related disclosures&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discussing with management
    and the independent registered public accounting firm the adequacy of our internal control over financial reporting, disclosure controls
    and procedures, compliance with legal and regulatory requirements, and code of business conduct and ethics&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discussing with management
    and the independent registered public accounting firm our risk management policies&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing policies regarding
    hiring employees from the independent registered public accounting firm and procedures for the receipt and retention of accounting
    related complaints and concerns&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">meeting independently with
    our independent registered public accounting firm and management&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and providing
    oversight of any related person transactions, including establishing such policies and procedures as appropriate to facilitate such
    review&#894; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparing the audit committee
    report required by the SEC rules (which is included on page 11 of this proxy statement).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee charter is available on the Investors page of our website at <i>www.indaptusrx.com</i>. The members of the Audit Committee
are Mr. Hayes, Ms. Karah, and Dr. Martell. Mr. Hayes serves as the Chairperson of the committee. Our Board has affirmatively determined
that each of Mr. Hayes, Ms. Karah, and Dr. Martell is independent for purposes of serving on an audit committee under Rule 10A-3 promulgated
under the Exchange Act and the Nasdaq Rules, including those related to Audit Committee membership.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
members of our Audit Committee meet the requirements for financial literacy under the applicable Nasdaq rules. In addition, our Board
of Directors has determined that Mr. Hayes qualifies as an &#8220;audit committee financial expert,&#8221; as such term is defined in
Item 407(d)(5) of Regulation S-K, and under the similar Nasdaq Rules requirement that the Audit Committee have a financially sophisticated
member.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 95; Value: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensation
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Compensation Committee is responsible for assisting the Board in the discharge of its oversight responsibilities relating to the evaluation
of our executive officers (including the Chief Executive Officer), determining the compensation of our executive officers, and overseeing
the management of risks associated therewith. In fulfilling its purpose, our Compensation Committee has the following principal duties:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and
    approving, or recommending for approval by the Board, our overall compensation strategy and policies, including evaluating risks
    associated with our compensation policies and practices;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving,
    or recommending for approval by the Board, the compensation of our CEO and our other executive officers&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing and administering
    our cash and equity incentive plans&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and making recommendations
    to the Board of Directors with respect to non-employee director compensation&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and discussing
    annually with management our &#8220;Compensation Discussion and Analysis,&#8221; to the extent required&#894; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparing the annual compensation
    committee report, to the extent required by SEC rules.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee generally considers the Chief Executive Officer&#8217;s recommendations when making decisions regarding the compensation
of executive officers (other than the Chief Executive Officer). Pursuant to the Compensation Committee&#8217;s charter, which is available
on the Investors page of our website at <i>www.indaptusrx.com</i>, the Compensation Committee has the authority to retain or obtain the
advice of compensation consultants, legal counsel and other advisors to assist in carrying out its responsibilities. The Compensation
Committee did not engage the services of a compensation consultant in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee may delegate its authority under its charter to one or more subcommittees as it deems appropriate from time to
time. The Compensation Committee may also delegate to an officer the authority to grant equity awards to certain employees, as further
described in its charter and subject to the terms of our equity plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
members of our Compensation Committee are Mr. Maddaluna and Mr. Hayes. Mr. Maddaluna serves as the Chairperson of the Compensation Committee.
Each member of the Compensation Committee qualifies as an independent director under Nasdaq&#8217;s heightened independence standards
for members of a compensation committee and as a &#8220;non-employee director&#8221; as defined in Rule 16b-3 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nominating
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Nominating Committee&#8217;s responsibilities include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying
    individuals qualified to become Board members&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending to the Board
    the persons to be nominated for election as directors and to each Board committee&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing with the Chief
    Executive Officer and making recommendations to the Board with respect to our succession plans for the Chief Executive Officer and
    other executive officers&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and making recommendations
    to the Board the composition and chairperson of each Board committee&#894; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing the evaluation
    of the Board and its committees.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Nominating Committee charter is available on the Investors page of our website at <i>www.indaptusrx.com</i>. The members of our Nominating
Committee are Ms. Karah and Mr. Maddaluna. Ms. Karah serves as the Chairperson of the Nominating Committee. The Nominating Committee
has the authority to consult with outside advisors or retain search firms to assist in the search for qualified candidates or consider
director candidates recommended by our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 96; Value: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Science
and Technology Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Science and Technology Committee&#8217;s responsibilities include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and
    advising on our drug development strategy, including the selection of therapeutic targets, the design and execution of clinical trials,
    and the regulatory pathway for approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assessing our research
    pipeline and recommending changes or improvements to ensure a sustainable and diverse portfolio of drug candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluating our intellectual
    property strategy and overseeing the implementation of appropriate measures to protect our discoveries and inventions; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing our manufacturing
    strategy and overseeing the quality controls put in place to meet regulatory requirements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
members of our Science and Technology Committee are Dr. Gilbert, Mr. Maddaluna, Dr. Martell, and Mr. Newman. Mr. Newman serves as the
Chairperson of the Science and Technology Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aj_001"></span>Item
11. Executive Compensation.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
named executive officers for 2024, which consist of our principal executive officer and the next two most-highly compensated executive
officers who were serving as executive officers as of December 31, 2024 are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey A.
    Meckler, Chief Executive Officer and Director&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Walt. A. Linscott, Esq.,
    Chief Operating Officer; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Roger J. Waltzman, M.D.,
    Chief Medical Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 97; Value: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth all of the compensation awarded to, earned by or paid to our named executive officers during 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Name and<br/> Principal Position</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Salary<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Bonus<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock<br/> Awards<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option Awards<sup>(1)</sup></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-equity Incentive<br/> Plan<br/> Compensation</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All Other<br/> Compensation<sup>(2)<br/> </sup>($)</b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: left">Jeffrey A. Meckler,</td><td style="width: 2%">&#160;</td>
    <td style="width: 8%; text-align: center">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">575,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">219,421</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">287,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">75,296</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">1,157,217</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Chief Executive Office</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">565,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">134,221</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">223,175</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78,853</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,001,249</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Walt A. Linscott, Esq.,</td><td>&#160;</td>
    <td style="text-align: center">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">475,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">182,156</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">237,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,744</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">970,400</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">Chief Operating Officer</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">425,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53,688</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">212,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78,851</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">770,039</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Roger Waltzman, M.D.</td><td>&#160;</td>
    <td style="text-align: center">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">182,156</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,723</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">928,879</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Chief Medical Officer</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">196,742</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left"><sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140,811</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">196,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,612</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">586,165</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The amounts reported do not reflect the amounts actually received by our named executive officers. Instead, in accordance with SEC rules,
these amounts reflect the grant date fair value of stock options granted to our named executive officers during the fiscal years ended
December 31, 2024 and 2023, as computed in accordance with Financial Accounting Standard Board Accounting Standards Codification Topic
718 for stock-based compensation transaction. As required by SEC rules, the amounts shown exclude the impact of estimated forfeitures
related to service-based vesting conditions. Assumptions used in the calculation of these amounts are included in Note 5 to our consolidated
financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on
March 13, 2025. Our named executive officers will only realize compensation with regard to these options to the extent the trading price
of our common stock is greater than the exercise price of such options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
For 2024 and 2023, referenced amount is for the Company paid portion of medical and life insurance premiums, and Company 401(k) contributions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Amount represents a sign on bonus paid to Dr. Waltzman in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Narrative
Description to Summary Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Base
Salaries</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, base salaries for our named executive officers are initially established through arm&#8217;s length negotiation at the time
the executive is hired, taking into account such executive&#8217;s qualifications, experience and prior salary. Base salaries of our
named executive officers are approved and reviewed annually by our Compensation Committee or Board of Directors and adjustments to base
salaries are based on the scope of an executive&#8217;s responsibilities, individual contribution, prior experience and sustained performance.
Decisions regarding salary increases may take into account an executive officer&#8217;s current salary, equity ownership, and the amounts
paid to an executive officer&#8217;s peers inside our company by conducting an internal analysis, which compares the pay of an executive
officer to other members of the management team. Base salaries are also reviewed in the case of promotions or other significant changes
in responsibility. Base salaries are not automatically increased if the Board of Directors and Compensation Committee believe that other
elements of the named executive officer&#8217;s compensation are more appropriate in light of our stated objectives. This strategy is
consistent with our intent of offering compensation that is both cost-effective, competitive and contingent on the achievement of performance
objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
actual base salaries paid to all of our named executive officers for 2024 are set forth in the &#8220;Summary Compensation Table&#8221;
above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2024, our Compensation Committee approved base salary increases for 2024 for Mr. Meckler, Dr. Waltzman and Mr. Linscott to $575,000,
$500,000 and $475,000, respectively. These base salary increases represented adjustments of approximately 1.8%, 2.0% and 11.8%, respectively.
In January 2025, our Compensation Committee approved base salary increases for 2025 for Mr. Meckler, Dr. Waltzman and Mr. Linscott to
$595,000, $518,000 and $491,000, respectively. <span style="background-color: white">These base salary increases represented adjustments
of approximately 3.5%, 3.6% and 3.4%, respectively.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 98; Value: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Annual
Cash Performance Bonuses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
named executive officer is also eligible for a performance bonus based upon the achievement of certain corporate performance goals and
objectives approved by our Compensation Committee and Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bonuses
are set based on a percentage of the executive&#8217;s base salary as of the end of the bonus year and are expected to be paid out in
the first quarter of the following year. The target levels for 2024 executive bonuses were as follows: 50% for Mr. Meckler, 50% for Mr.
Linscott and 40% for Dr. Waltzman. All final bonus payments to our named executive officers are determined by our Compensation Committee
or our Board of Directors. The actual bonuses awarded in any year, if any, may be more or less than the target, depending on individual
performance and the achievement of corporate objectives and may also vary based on other factors at the discretion of the Compensation
Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
2024, the corporate performance objectives for our named executive officers were related to clinical milestones, research and development
goals, business development opportunities, financing objectives and human capital management objectives. These performance objectives
and areas of emphasis were used as a guide by the Compensation Committee and Board of Directors in determining overall corporate performance
for these executives as they represented those areas in which they were expected to focus their efforts during the year. Both qualitative
and quantitative guidelines were established for purposes of evaluating performance relating to these corporate objectives during 2024.
Based on its review of our overall performance relative to our corporate objectives, the Compensation Committee determined that every
goal was achieved or exceeded for annual bonus plan purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
overall achievement level was then used to determine each named executive officer&#8217;s bonus. The bonuses paid to our named executive
officers for 2024 are set forth in the &#8220;Summary Compensation Table&#8221; above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equity
Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
goals of our long-term, equity-based incentive awards are to align the interests of our named executive officers and other employees,
non-employee directors and consultants with the interests of our stockholders. Because vesting is based on continued employment, our
equity-based incentives also encourage the retention of our named executive officers through the vesting period of the awards. In determining
the size of the long-term equity incentives to be awarded to our named executive officers, we take into account a number of internal
factors, such as the relative job scope, the value of existing long-term incentive awards, individual performance history, prior contributions
to us and the size of prior grants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
reward and retain our named executive officers in a manner that best aligns employees&#8217; interests with stockholders&#8217; interests,
we use stock options as the primary incentive vehicles for long-term compensation. We believe that stock options are an effective tool
for meeting our compensation goal of increasing long-term stockholder value by tying the value of the stock options to our future performance.
Because employees are able to profit from stock options only if our stock price increases relative to the stock option&#8217;s exercise
price, we believe stock options provide meaningful incentives to employees to achieve increases in the value of our stock over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price of each stock option grant is the fair market value of our common stock on the grant date, as determined by our Board
of Directors from time to time. Stock option awards granted to our named executive officers generally vest as to one-third of the total
shares on the first anniversary of the grant date and thereafter the remaining shares vest in equal quarterly installments over the following
24 months. From time to time, our Compensation Committee may, however, determine that a different vesting schedule is appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2024, Mr. Meckler, Mr. Linscott and Dr. Waltzman and were granted stock options to purchase 100,000 shares, 75,000 shares and
75,000 shares of our common stock, respectively. The stock options vest as to one-third of the total shares on January 22, 2025 and thereafter
the remaining shares vest in equal quarterly installments over the following 24 months. In October 2024, Mr. Meckler, Mr. Linscott and
Dr. Waltzman were granted stock options to purchase 75,000 shares of our common stock, each. The stock options are fully vest following
18 months from grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 99; Value: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have had no program, plan or practice pertaining to the timing of stock option grants to named executive officers coinciding with the
release of material non-public information. Stock options granted to our named executive officers may be subject to accelerated vesting
in certain circumstance. For additional discussion, please see &#8220;Employment Agreements and Potential Payments on Employment Termination&#8221;
below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Elements of Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Retirement
Plans</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
January 1, 2023, we maintain a 401(k) retirement savings plan that allows eligible employees to contribute a portion of their compensation,
within limits prescribed by the Internal Revenue Code, on a pre-tax basis through contributions to the plan. Our named executive officers
are eligible to participate in the 401(k) plan. We believe that providing a vehicle for tax-deferred retirement savings through our 401(k)
plan adds to the overall desirability of our executive compensation package and further incentivizes our named executive officers in
accordance with our compensation policies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Employee
Benefits and Perquisites</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
named executive officers are eligible to participate in our health and welfare plans. We pay for the health and welfare benefits of our
named executive officers. We do not provide our named executive officers with any other significant perquisites or other personal benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>No
Tax Gross-Ups</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not make gross-up payments to cover our named executive officers&#8217; personal income taxes that may pertain to any of the compensation
paid or provided by our company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 100; Value: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards at Fiscal Year-End</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information concerning outstanding option awards as of December 31, 2024, for each named executive officer:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option
Awards</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Grant
    Date</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of Securities Underlying Unexercised<br/>
    Options Exercisable<br/>
    (#)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of Securities Underlying Unexercised<br/>
    Options<br/>
    Unexercisable<br/>
    (#)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity<br/>
    incentive<br/>
    plan awards: Number of<br/>
    securities<br/>
    underlying<br/>
    unexercised<br/>
    unearned<br/>
    options exercise price<br/>
    (#)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option<br/>
    Exercise Price<br/>
    ($)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option
    Expiration</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date<sup>(1)</sup></b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey
    A. Meckler, Chief Executive Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/10/17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,500</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">425.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/10/27</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/01/17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">813</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">425.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/01/27</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/11/17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,750</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">536.0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/11/27</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/28/18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,250</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">355.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/28/25</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/04/19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,562</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">611.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/04/26</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/15/20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,750</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/15/27</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/04/21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">375,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.87</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/4/2031</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/26/22</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(3)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">183,333</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,667</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.90</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/26/32</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/18/23</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(4)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58,333</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41,667</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.61</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/18/33</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/22/24</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(5)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.74</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/22/34</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/09/24</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(6)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.105</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/09/34</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Walt
    A. Linscott, Esq., Chief Operating Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/23/17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">750</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">684.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/23/27</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/11/17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,750</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">684.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/11/27</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/22/19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,125</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">610.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/22/26</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/13/19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,500</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72.0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/13/26</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/17/20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,125</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/17/27</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/16/20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,250</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/16/27</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/04/21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">210,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.87</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/4/2031</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/26/22</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(3)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,029</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,821</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.90</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/26/32</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/18/23</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(4)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,333</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,667</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.61</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/18/33</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/22/24</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(5)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.74</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/22/34</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/09/24</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(6)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.105</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/09/34</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Roger
    J. Waltzman, Chief Medical Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/07/23</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(7)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,500</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52,500</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.85</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/07/33</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/22/24</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(5)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.74</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/22/34</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/09/24</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(6)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.105</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/09/34</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The options have a seven-year term or ten-year term as noted in the table subject to earlier expiration upon termination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
The options vest over a period of three years from August 4, 2021, 33.3% on the first anniversary of such date and 8.33% every three
months thereafter, ending August 4, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
The options vest over a period of three years from January 26, 2022, 33.3% on the first anniversary of such date and 8.33% every three
months thereafter, ending January 26, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
The options vest over a period of three years from January 18, 2023, 33.3% on the first anniversary of such date and 8.33% every three
months thereafter, ending January 18, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
The options vest over a period of three years from January 22, 2024, 33.3% on the first anniversary of such date and 8.33% every three
months thereafter, ending January 18, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
The options vest over a period of three years from October 9, 2024, 33.3% on the first anniversary of such date and 8.33% every three
months thereafter, ending October 9, 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)
The options vest over a period of three years from August 7, 2023, 33.3% on the first anniversary of such date and 8.33% every three
months thereafter, ending August 7, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 101; Value: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
Agreements and Potential Payments on Employment Termination</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below is a description of the employment agreements with our named executive officers and a summary of the benefits that would
be payable upon termination of employment or in connection with a change in control to our named executive officers under their employment
agreements with us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Jeffrey
A. Meckler</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into an employment agreement with Jeffrey A. Meckler (the &#8220;Meckler Employment Agreement&#8221;), which superseded
and replaced his employment agreement dated December 11, 2017 with Intec Pharma, Inc., a subsidiary of Intec Israel, to serve as our
Chief Executive Officer. The Meckler Employment Agreement provides for an annual base salary, subject to review for an upward adjustment
on at least an annual basis. Mr. Meckler is eligible to participate in an annual executive bonus plan, pursuant to which he may earn
an annual target bonus of up to 50% of his base salary, based on the achievement of certain individual and company-wide objectives, which
shall be established by our Board of Directors on an annual basis. The Board may, in its discretion, grant Mr. Meckler a bonus in excess
of the target bonus if the performance criteria are exceeded or for such additional contributions that the Board may choose to recognize.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
termination of Mr. Meckler&#8217;s employment by us without cause or Mr. Meckler&#8217;s resignation for good reason, Mr. Meckler will
be entitled to a severance benefit equal to (i) twelve months of his base salary as in effect prior to the termination date, payable
in bi-monthly installments and (ii) an amount equal to Mr. Meckler&#8217;s cost of continued health insurance coverage for twelve months.
In addition, if Mr. Meckler is entitled to receive a bonus for the year of termination based on the achievement of pre-determined performance
goals (and ignoring any continuation of employment requirements), Mr. Meckler (or his representatives) shall be entitled to receive such
bonus on the same basis as the other participants in the bonus plan, except that the bonus amount shall be prorated based on the percentage
of days Mr. Meckler was employed relative to the total number of days in the bonus earning period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Mr. Meckler&#8217;s employment is terminated by us without cause or by Mr. Meckler for good reason during the one year period immediately
following a change in control or six months before a change in control, then Mr. Meckler will be entitled to receive, (i) eighteen months
of his base salary as in effect prior to the termination date, payable in bi-monthly installments, (ii) an amount equal to Mr. Meckler&#8217;s
cost of continued health insurance coverage for eighteen months, (iii) his target annual bonus for the year of termination, which shall
be paid within 30 days of termination, and (iv) full accelerated vesting of all of outstanding equity incentive awards upon the later
of the change in control or Mr. Meckler&#8217;s termination of employment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that Mr. Meckler&#8217;s employment terminates by reason of his death or disability, and Mr. Meckler is entitled to receive
a bonus for the year of termination based on the achievement of pre-determined performance goals (and ignoring any continuation of employment
requirements), Mr. Meckler (or his representatives) shall be entitled to receive such bonus on the same basis as the other participants
in the bonus plan, except that the bonus amount shall be prorated based on the percentage of days Mr. Meckler was employed relative to
the total number of days in the bonus earning period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Walt
A. Linscott, Esq.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into an employment agreement with Walt A. Linscott, Esq. (the &#8220;Linscott Employment Agreement&#8221;), which supersedes
and replaces his employment agreement dated October 23, 2017 with Intec Pharma, Inc., a subsidiary of Intec Israel. The Linscott Employment
Agreement provides for an annual base salary, subject to review for an upward adjustment on at least an annual basis. Mr. Linscott is
eligible to participate in an annual executive bonus plan, pursuant to which he may earn an annual target bonus of up to 50% of his base
salary, based on the achievement of certain individual and company-wide objectives, which shall be established by the Company&#8217;s
Board of Directors on an annual basis. The Board may, in its discretion, grant Mr. Linscott a bonus in excess of the target bonus if
the performance criteria are exceeded or for such additional contributions that the Board may choose to recognize.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 102; Value: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
termination of Mr. Linscott&#8217;s employment by us without cause or Mr. Linscott&#8217;s resignation for good reason, Mr. Linscott
will be entitled to a severance benefit equal to (i) twelve months of his base salary as in effect prior to the termination date, payable
in bi-monthly installments and (ii) an amount equal to Mr. Linscott&#8217;s cost of continued health insurance coverage for twelve months.
In addition, if Mr. Linscott is entitled to receive a bonus for the year of termination based on the achievement of pre-determined performance
goals (and ignoring any continuation of employment requirements), Mr. Linscott (or his representatives) shall be entitled to receive
such bonus on the same basis as the other participants in the bonus plan, except that the bonus amount shall be prorated based on the
percentage of days Mr. Linscott was employed relative to the total number of days in the bonus earning period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Mr. Linscott&#8217;s employment is terminated by us without cause or by Mr. Linscott for good reason during the one year period immediately
following a change in control or six months before a change in control, then Mr. Linscott will be entitled to receive, (i) eighteen months
of his base salary as in effect prior to the termination date, payable in bi-monthly installments, (ii) an amount equal to Mr. Linscott&#8217;s
cost of continued health insurance coverage for eighteen months, (iii) his target annual bonus for the year of termination, which shall
be paid within 30 days of termination, and (iv) full accelerated vesting of all of outstanding equity incentive awards upon the later
of the change in control or Mr. Linscott&#8217;s termination of employment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that Mr. Linscott&#8217;s employment terminates by reason of his death or disability, and Mr. Linscott is entitled to receive
a bonus for the year of termination based on the achievement of pre-determined performance goals (and ignoring any continuation of employment
requirements), Mr. Linscott (or his representatives) shall be entitled to receive such bonus on the same basis as the other participants
in the bonus plan, except that the bonus amount shall be prorated based on the percentage of days Mr. Linscott was employed relative
to the total number of days in the bonus earning period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Roger
J. Waltzman</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into an employment agreement with Roger J. Waltzman (the &#8220;Waltzman Employment Agreement&#8221;). The Waltzman Employment
Agreement provides for an annual base salary, subject to review for an upward adjustment on at least an annual basis. Dr. Waltzman is
eligible to participate in an annual executive bonus plan, pursuant to which he may earn an annual target bonus of up to 40% of his base
salary, based on the achievement of certain individual and company-wide objectives, which shall be established by the Company&#8217;s
Board of Directors on an annual basis. The Board may, in its discretion, grant Dr. Waltzman a bonus in excess of the target bonus if
the performance criteria are exceeded or for such additional contributions that the Board may choose to recognize.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
termination of Dr. Waltzman&#8217;s employment by us without cause or Dr. Waltzman&#8217;s resignation for good reason, Dr. Waltzman
will be entitled to a severance benefit equal to (i) twelve months of his base salary as in effect prior to the termination date, payable
in bi-monthly installments and (ii) an amount equal to Dr. Waltzman&#8217;s cost of continued health insurance coverage for twelve months.
In addition, if Dr. Waltzman is entitled to receive a bonus for the year of termination based on the achievement of pre-determined performance
goals (and ignoring any continuation of employment requirements), Dr. Waltzman (or his representatives) shall be entitled to receive
such bonus on the same basis as the other participants in the bonus plan, except that the bonus amount shall be prorated based on the
percentage of days Dr. Waltzman was employed relative to the total number of days in the bonus earning period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Dr. Waltzman&#8217;s employment is terminated by us without cause or by Dr. Waltzman for good reason during the one year period immediately
following a change in control or six months before a change in control, then Dr. Waltzman will be entitled to receive, (i) twelve months
of his base salary as in effect prior to the termination date, payable in bi-monthly installments, (ii) an amount equal to Dr. Waltzman&#8217;s
cost of continued health insurance coverage for eighteen months, (iii) his target annual bonus for the year of termination, which shall
be paid within 30 days of termination, and (iv) full accelerated vesting of all of outstanding equity incentive awards upon the later
of the change in control or Dr. Waltzman&#8217;s termination of employment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that Dr. Waltzman&#8217;s employment terminates by reason of his death or disability, and Dr. Waltzman is entitled to receive
a bonus for the year of termination based on the achievement of pre-determined performance goals (and ignoring any continuation of employment
requirements), Dr. Waltzman (or his representatives) shall be entitled to receive such bonus on the same basis as the other participants
in the bonus plan, except that the bonus amount shall be prorated based on the percentage of days Dr. Waltzman was employed relative
to the total number of days in the bonus earning period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 103; Value: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
Authorized for Issuance under Equity Compensation Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table gives information as of December 31, 2024 about shares of our common stock that may be issued upon the exercise of options
under the Indaptus Therapeutics, Inc. 2021 Stock Incentive Plan (the &#8220;2021 Plan&#8221;):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Plan Category</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of securities to be issued upon exercise of outstanding options, warrants and rights<sup>(1)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-average exercise price of outstanding options, warrants and rights</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in first column)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity compensation plan approved by security holders<sup>(2)</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">2,887,822</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">8.06</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">103,608</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Equity compensation plans not approved by security holders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
Represents stock options outstanding under the 2021 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Our 2021 Plan has an evergreen provision that allows for an annual increase on each January 1 from January 1, 2025 and ending on and
including January 1, 2029, equal to the lesser of (A) 5% of the aggregate number of shares of our shares of common stock outstanding
on the final day of the immediately preceding calendar year or (B) such smaller number of shares as is determined by our Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pay
Versus Performance Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information concerning the compensation of our named executive officers, or NEOs, the compensation actually
paid to our NEOs, as determined under SEC rules (and described below), our total shareholder return and our net loss, in each case for
each of the fiscal years ended December 31, 2022, 2023 and 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">(a)</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(b)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(c)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(d)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(e)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(f)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(h)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Summary<br/> Compensation<br/> Table Total for<br/> PEO ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation<br/> Actually Paid to<br/> PEO ($)<sup>(1)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Average<br/> Summary<br/> Compensation<br/> Table Total<br/> for non-PEO<br/> NEOs ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average<br/> Compensation<br/> Actually Paid to<br/> Non-PEO<br/> NEOs ($)<sup>(1)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Value of Initial<br/> Fixed $100<br/> Investment<br/> Based on:<br/> Total<br/> Shareholder<br/> Return ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net<br/> Loss ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 16%; text-align: center">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,157,217</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,029,281</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">949,640</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">845,621</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(15,022,027</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,001,249</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,122,094</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">744,039</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">799,786</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">121</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(15,423,471</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,680,532</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(38,385</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,062,955</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">500,074</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">41</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(14,322,798</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 97%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts represent
    compensation actually paid to our PEO and the average compensation actually paid to our remaining NEOs for the relevant fiscal year,
    as determined under SEC rules, which includes the individuals indicated in the table below for each fiscal year:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 104; Value: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PEO</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-PEO NEOs</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey A. Meckler</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Walt A. Linscott, Esq. and Roger Waltzman M.D.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey A. Meckler</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Walt A. Linscott, Esq. and Michael J. Newman, Ph.D.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey A. Meckler</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Walt A. Linscott, Esq. and Boyan Litchev, M.D.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amounts reported in the &#8220;Compensation Actually Paid to PEO&#8221; and &#8220;Average Compensation Actually Paid to Non-PEO NEOs&#8221;
columns do not reflect the actual compensation paid to or realized by our PEO or our non-PEO NEOs during each applicable year. The calculation
of compensation actually paid for purposes of this table includes point-in-time fair values of stock awards and these values will fluctuate
based on our stock price and various accounting valuation assumptions. See the Summary Compensation Table for certain other compensation
of our PEO and our non-PEO NEOs for each applicable fiscal year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
actually paid to our NEOs represents the &#8220;Total&#8221; compensation reported in the Summary Compensation Table for the applicable
fiscal year, as adjusted as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Adjustments</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">PEO</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Average non-PEO NEOs</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-weight: bold; text-align: left">Deduction for Amounts Reported under the &#8220;Stock Awards&#8221; and &#8220;Option Awards&#8221; Columns in the Summary Compensation Table for Applicable FY</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(219,421</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(182,156</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Remain Unvested as of Applicable FY End, determined as of Applicable FY End</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123,369</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">106,209</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Decrease for Awards Granted during Prior FY that were Outstanding and Unvested as of Applicable FY End, determined based on change in ASC 718 Fair Value from Prior FY End to Applicable FY End</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(46,684</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(29,455</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Increase for Awards Granted during Prior FY that Vested During Applicable FY, determined based on change in ASC 718 Fair Value from Prior FY End to Vesting Date</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,383</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">TOTAL ADJUSTMENTS</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(127,936</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(104,019</td><td style="font-weight: bold; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value or change in fair value, as applicable, of equity awards in the &#8220;Compensation Actually Paid&#8221; columns was determined
by reference to a Black Scholes value as of the applicable year-end or vesting date(s), determined based on the same methodology as used
to determine grant date fair value but using the closing stock price on the applicable revaluation date as the current market price and
with an estimated expected life using the simplified method, and in all cases based on volatility and risk free rates determined as of
the revaluation date based on the expected life period and based on an expected dividend rate of 0%. For additional information on the
assumptions used to calculate the valuation of the awards, see Note 5 to our consolidated financial statements included in our Annual
Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on March 13, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 105; Value: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Narrative
Disclosure to Pay Versus Performance Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Relationship
Between Financial Performance Measures</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
graph below compares the compensation actually paid to our PEO and the average of the compensation actually paid to our remaining NEOs,
with our cumulative TSR for the fiscal years ended December 31, 2022, 2023 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TSR
amounts reported in the graph assume an initial fixed investment of $100. We do not pay dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-k_007.jpg" alt="" style="width: 680px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
graph below compares the compensation actually paid to our PEO and the average of the compensation actually paid to our remaining NEOs,
with our net loss for the fiscal years ended December 31, 2022, 2023 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-k_006.jpg" alt="" style="width: 480px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides certain information concerning the compensation for services rendered in all capacities by each non-employee
director serving on our Board during the year ended December 31, 2024, other than Mr. Meckler, our Chief Executive Officer who did not
receive additional compensation for their service as a director and whose compensation is set forth in the Summary Compensation Table
under the section entitled Executive Compensation above. Dr. Newman, our Chief Scientific Officer, is also an employee and executive
officer, who did not receive additional compensation for his service as a director. Dr. Newman is not one of our named executive officers
for 2024 and so he does not appear in the Summary Compensation Table. Because Dr. Newman is an employee and an executive officer, he
is not required to be included in the table below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 106; Value: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Name</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fees earned<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock awards<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option awards<br/> ($)<sup>(1)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">All other compensation<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: left">Roger J. Pomerantz</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">150,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">66,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">216,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Hila Karah</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Anthony J. Maddaluna</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">96,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">William B. Hayes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Robert E. Martell</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Mark Gilbert</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81,500</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The amounts reported do not reflect the amounts actually received by our non-employee directors. Instead, in accordance with SEC rules,
these amounts reflect the grant date fair value of stock options granted to our non-employee directors during the fiscal year ended December
31, 2024, as computed in accordance with Financial Accounting Standard Board Accounting Standards Codification Topic 718 for stock-based
compensation transaction. As required by SEC rules, the amounts shown exclude the impact of estimated forfeitures related to service-based
vesting conditions. Assumptions used in the calculation of these amounts are included in Note 5 to our consolidated financial statements
included in our Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on March 13, 2025. Our
non-employee directors who have received options will only realize compensation with regard to these options to the extent the trading
price of our common stock is greater than the exercise price of such options. As of December 31, 2024, our non-employee directors held
the following numbers of stock options: Dr. Pomerantz, 182,000 stock options; Ms. Karah 53,781 stock options, Mr. Maddaluna 53,500 stock
options, Mr. Hayes 53,500 stock options, Mr. Martell 32,500 stock options, and Dr. Gilbert 58,750 stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to our director compensation policy, the annual retainer for non-employee directors is $50,000 and the annual retainer for the chair
of the Board of Directors is $150,000. Annual retainers for committee membership are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Audit committee chairperson</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">15,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Audit committee member</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Compensation committee chairperson</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Compensation committee member</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Nominating committee chairperson</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Nominating committee member</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Scientific and technology committee chairperson</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Scientific and technology committee member</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
fees are payable in advance in four equal quarterly installments during the first week of each quarter, provided that the amount of such
payment will be prorated for any portion of such quarter that a director is not serving on our Board of Directors, on such committee
or in such position. Non-employee directors are also reimbursed for reasonable out-of-pocket business expenses incurred in connection
with attending meetings of the Board of Directors and any committee of the Board of Directors on which they serve and in connection with
other business related to the Board of Directors. Directors may also be reimbursed for reasonable out-of-pocket business expenses authorized
by the Board of Directors or a committee that are incurred in connection with attending conferences or meetings with management in accordance
with a travel policy, as may be in effect from time to time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2023, the Board amended our director compensation policy to provide that, on the date an individual is first elected or appointed
as a non-employee director, such individual will receive a grant of 25,000 stock options, and that, on the date of each annual meeting
of stockholders, commencing with the annual meeting of stockholders for 2023, each non-employee director (other than the board chair)
will receive a grant of 12,500 stock options and the board chair will receive 30,000 stock options. The initial stock options vest in
over three years from the grant date in equal quarterly installments, subject to continued service on the Board and the options shall
also vest in full immediately upon a director&#8217;s death, disability or a change of control. The annual stock options vest in full
on the first anniversary of the grant date, subject to continued service on the Board and the options shall also vest in full immediately
upon a director&#8217;s death, disability or a change of control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 107; Value: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aj_002"></span>Item
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information with respect to holdings of our common stock by (i) stockholders who beneficially owned
more than 5% of the outstanding shares of our common stock, and (ii) each of our directors (which includes all nominees), each of our
named executive officers and all directors and executive officers as a group as of March 12, 2025, unless otherwise indicated. The number
of shares beneficially owned by each stockholder is determined under rules issued by the SEC. Under these rules, beneficial ownership
includes any shares as to which a person has sole or shared voting power or investment power. Applicable percentage ownership is based
on 14,429,244 shares of common stock outstanding as of March 12, 2025. In computing the number of shares beneficially owned by a person
and the percentage ownership of that person, shares of common stock subject to options, or other rights held by such person that are
currently exercisable or will become exercisable within 60 days of March 12, 2025 are considered outstanding, although these shares are
not considered outstanding for purposes of computing the percentage ownership of any other person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, the address of each beneficial owner listed below is 3 Columbus Circle, 15<sup>th</sup> Floor, New York, NY 10019.
We believe, based on information provided to us, that each of the stockholders listed below has sole voting and investment power with
respect to the shares beneficially owned by the stockholder unless noted otherwise, subject to community property laws where applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Name of Beneficial Owner</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares Beneficially Owned</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percentage of Shares Beneficially Owned</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: justify">Persons or entities holding 5% or more our outstanding common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Glen R. Anderson</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">1,190,400</td><td style="width: 1%; text-align: left"><sup>(1)</sup></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">8.2</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Matthew Joseph Nachtrab Revocable Trust dtd 12/15/2014</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,142,462</td><td style="text-align: left"><sup>(2)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Yehuda Shimoni</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,644,300</td><td style="text-align: left"><sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Thomas Mollick</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,438,598</td><td style="text-align: left"><sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15.7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: justify">Named executive officers and directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Michael J. Newman, Ph.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,752,164</td><td style="text-align: left"><sup>(5)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Jeffrey A. Meckler</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,035,636</td><td style="text-align: left"><sup>(6)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Roger Waltzman, M.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,750</td><td style="text-align: left"><sup>(7)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Walt A. Linscott, Esq.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">325,750</td><td style="text-align: left"><sup>(8)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Hila Karah</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,281</td><td style="text-align: left"><sup>(9)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Anthony J. Maddaluna</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,670</td><td style="text-align: left"><sup>(10)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">William B. Hayes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,000</td><td style="text-align: left"><sup>(11)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Dr. Roger J. Pomerantz</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">153,000</td><td style="text-align: left"><sup>(12)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Mark Gilbert, M.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,250</td><td style="text-align: left"><sup>(13)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Robert E. Martell, M.D., Ph.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left"><sup>(14)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: justify">All executive officers and directors as a group (11 persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,690,334</td><td style="text-align: left"><sup>(15)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22.3</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less than one
    percent.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 108; Value: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
solely upon a Schedule 13G/A filed with the SEC on August 17, 2023. 1,076,482 shares are held by the Anderson Family Trust U/A/D January
7, 2017 in which Glen R. Anderson is a trustee of the Anderson Family Trust and shares voting and dispositive control with his spouse,
and 113,918 shares are held by Mr. Anderson over which he has sole voting and dispositive power. The business address of Mr. Anderson
is 101 South 200 East, Suite 700, Salt Lake City, UT 84111.</span></p></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of (i) 1,071,231 shares of common stock, and (ii) 1,071,231 shares of common stock issuable upon exercise of warrants which are subject
    to either a 4.99% or 9.99% beneficial ownership limitation. The amounts and percentages in the table do not give effect to such beneficial
    ownership limitation.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of (i) 865,158 shares of common stock, and (ii) 779,142 shares of common stock issuable upon exercise of warrants which are subject
    to either a 4.99% or 9.99% beneficial ownership limitation. The amounts and percentages in the table do not give effect to such beneficial
    ownership limitation.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of (i) 1,212,837 shares of common stock, and (ii) 1,135,761 shares of common stock issuable upon exercise of warrants which are subject
    to either a 4.99% or 9.99% beneficial ownership limitation. The amounts and percentages in the table do not give effect to such beneficial
    ownership limitation.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of (i) 1,341,524 shares of common stock held by the Michael J. Newman Trust, dated January 21, 2008, Michael J. Newman, Trustee&#894;
    (ii) 26,832 shares of common stock held by Janet Lee Harris, Trustee of the Janet Harris Living Trust, executed on March 25, 2009.
    Ms. Harris is the spouse of Dr. Newman, and as such, Dr. Newman is deemed to beneficially own such shares; and (iii) 383,808 shares
    of common stock issuable upon exercise of outstanding options, of which 7,208 will vest within 60 days of days of March 12, 2025.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of (i) 202,859 shares of common stock, (ii) 127,485 shares of common stock issuable upon exercise of warrants, and (ii) 705,292 shares
    of common stock issuable upon exercise of outstanding options, of which 16,667 will vest within 60 days of days of March 12, 2025.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of 83,750 shares of common stock issuable upon exercise of outstanding options, of which 13,750 will vest within 60 days of March
    12, 2025.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of (i) 150 shares of common stock and (ii) 325,750 shares of common stock issuable upon exercise of outstanding options, of which
    9,583 will vest within 60 days of March 12, 2025.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of 41,281 shares of common stock issuable upon exercise of outstanding options.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of
    (i) 670 shares of common stock and (ii) 41,000 shares of common stock issuable upon exercise of outstanding options.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of
    41,000 shares of common stock issuable upon exercise of outstanding options.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of
    154,000 shares of common stock issuable upon exercise of outstanding options.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of
    46,250 shares of common stock issuable upon exercise of outstanding options.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of
    20,000 shares of common stock issuable upon exercise of outstanding options.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of
    (i) 1,572,035 shares of common stock, (ii) 127,485 shares of common stock issuable upon exercise of warrants, and (ii) 1,957,242
    shares of common stock issuable upon exercise of outstanding options, of which 53,875 will vest within 60 days of days of March 12,
    2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 109; Value: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aj_003"></span>Item
13. Certain Relationships and Related Transactions, and Director Independence.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Policies
and Procedures for Related Person Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with our audit committee charter, the Audit Committee is required to approve related party transactions. In general, the Audit
Committee will review any proposed transaction that has been identified as a related person transaction under Item 404 of Regulation
S-K, which means a transaction, arrangement or relationship in which we and any related person (as defined below) are participants in
which the amount involved exceeds the lesser of $120,000 or one percent of the average of the Company&#8217;s total assets at fiscal
year-end for the last two completed fiscal years, and in which any related person had, has or will have a direct or indirect material
interest. A &#8220;related person&#8221; includes (i) a director, director nominee or executive officer of the Company, (ii) any immediate
family member of the foregoing, or (iii) a security holder known to be a beneficial owner of more than 5% of any class of our voting
securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than the compensation agreements and other arrangements described under &#8220;Executive Compensation&#8221; and the transactions described
below, since January 1, 2022, there has not been and there is not currently proposed, any transaction or series of similar transactions
to which we were, or will be, a participant in which the amount involved exceeded, or will exceed, $120,000 (or, if less, 1% of the average
of our total assets at December 31, 2023 and 2022, as applicable) and in which any related person, had, or will have, a direct or indirect
material interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Participation
in 2024 Financings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>August
2024 Financing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 8, 2024, we completed a registered direct offering, pursuant to which we sold and issued to certain investors 1,643,837 shares
of our common stock. In addition, in a concurrent private placement, we issued to the investors unregistered warrants to purchase 1,643,837
shares of our common stock. The warrants are immediately exercisable at an exercise price of $1.70 per share and expire five years from
the date of issuance. The combined purchase price for one share of common stock and one warrant was $1.825, resulting in gross proceeds
of approximately $3.0 million, before deducting placement agent and other offering expenses in the amount of approximately $0.5 million.
One of the purchasers was Jeffrey Meckler, our Chief Executive Officer and director, who purchased 84,932 shares of common stock and
warrants to purchase 84,932 shares of common stock (at the same price and upon the same terms as the other purchasers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>November
2024 Financing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 25, 2024, we completed a registered direct offering, pursuant to which we sold and issued to certain investors 1,817,017 shares
of our common stock. In addition, in a concurrent private placement, we issued to the investors unregistered warrants to purchase 1,817,017
shares of our common stock. The warrants are immediately exercisable at an exercise price of $1.05 per share and expire five years from
the date of issuance. The combined purchase price for one share of common stock and one warrant was $1.175, resulting in gross proceeds
of approximately $2.13 million, before deducting placement agent and other offering expenses in the amount of approximately $0.345 million.
One of the purchasers was Jeffrey Meckler, our Chief Executive Officer and director, who purchased 42,553 shares of common stock and
warrants to purchase 42,553 shares of common stock (at the same price and upon the same terms as the other purchasers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
and Officer Indemnification and Insurance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into indemnification agreements with each of our directors and executive officers. These agreements, among other things,
require us or will require us to indemnify each director and executive officer to the fullest extent permitted by Delaware law, including
indemnification of expenses such as attorneys&#8217; fees, judgments, fines and settlement amounts incurred by the director or executive
officer in any action or proceeding, including any action or proceeding by or in right of us, arising out of the person&#8217;s services
as a director or executive officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also maintain an insurance policy that insures our directors and executive officers against certain liabilities, including liabilities
arising under applicable securities laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 110; Value: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aj_004"></span>Item
14. Principal Accountant Fees and Services.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the fees of Haskell &amp; White LLP, our independent registered public accounting firm, billed to us for their
professional services for each of the last two fiscal years:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fee Category</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Audit Fees</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">221,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">210,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Audit Related Fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax Fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">All Other Fees</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total Fees</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">221,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">210,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
Fees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
fees for the fiscal years ended December 31, 2024 and 2023 include fees for professional services rendered for the audit and quarterly
review of our financial statements included in our annual report on Form 10-K and quarterly reports on Form 10-Q filed with the SEC,
and services provided in connection with SEC filings, including consents and comfort letters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
Committee Pre-Approval Policy and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
a periodic basis, the Audit Committee reviews and generally pre-approves the services (and related fee levels or budgeted amounts) that
may be provided by Haskell &amp; White LLP without first obtaining specific pre-approval from the Audit Committee. The Audit Committee
may revise the list of general pre-approved services from time to time, based on subsequent determinations. Our Audit Committee pre-approves
all audit, review, and attest services proposed to be performed by our independent auditor that have not been generally pre-approved,
including the scope of services to be performed and the compensation to be paid to the auditor, prior to commencement of such engagements
of the independent auditor. Our Audit Committee has authorized all auditing and non-auditing services provided by Haskell &amp; White
LLP during the fiscal year ended December 31, 2024 and the fees paid for such services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="aj_005"></span>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aj_006"></span>Item
15. Exhibits and Financial Statement Schedules.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)(1)
Financial Statements.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 35.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements required by this item are listed in Item 8. &#8220;Financial Statements and Supplementary Data&#8221; in this Annual
Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 35.45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)(2)
Financial Statement Schedules.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statement schedules are omitted because they are either not applicable or the information required is presented in the financial
statements and notes thereto under Item 8. &#8220;Financial Statements and Supplementary Data&#8221; in this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)(3)
Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a list of exhibits filed as part of this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 111; Value: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
Index</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1++</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1638381/000121390021015265/ea137630ex2-1_intecpharma.htm" style="-sec-extract: exhibit">Agreement and Plan of Merger and Reorganization, dated as of March 15, 2021, by and among Intec Pharma Ltd., Intec Parent, Inc., Dillon Merger Sub Inc., Domestication Merger Sub Ltd., and Decoy Biosystems, Inc. (incorporated herein by reference to Exhibit 2.1 to Intec Israel&#8217;s Report on Form 8-K filed with the SEC on March 15, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1638381/000149315221010207/ex2-1.htm" style="-sec-extract: exhibit">Agreement and Plan of Merger, dated as of April 27, 2021, by and among Intec Pharma Ltd., Intec Parent, Inc. and Domestication Merger Sub Ltd. (incorporated herein by reference to Exhibit 2.1 to Intec Israel&#8217;s Report on Form 8-K filed with the SEC on April 30, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1857044/000149315221017640/ex3-1.htm" style="-sec-extract: exhibit">Amended and Restated Certificate of Incorporation of Indaptus Therapeutics, Inc., dated as of July 23, 2021 (incorporated herein by reference to Exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K filed with the SEC on July 23, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1857044/000149315224003441/ex3-1.htm" style="-sec-extract: exhibit">Amended and Restated Bylaws of Indaptus Therapeutics, Inc., dated as of January 22, 2024 (incorporated herein by reference to Exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K filed with the SEC on January 23, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1857044/000149315221018935/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Indaptus Therapeutics, Inc. dated August 3, 2021 (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on August 6, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1857044/000149315222007319/ex4-1.htm" style="-sec-extract: exhibit">Description of Securities Registered under Section 12 (incorporated herein by reference to Exhibit 4.1 of the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 21, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1638381/000121390020011132/ea121430ex10-2_intecpharma.htm" style="-sec-extract: exhibit">Form of Ordinary Share Purchase Warrant of Intec Parent, Inc. (incorporated herein by reference to Exhibit 10.2 to Intec Israel&#8217;s Current Report on Form 8-K filed with the SEC on May 6, 2020)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1857044/000149315221018114/ex10-3.htm" style="-sec-extract: exhibit">Form of Series A Common Stock Purchase Warrant of Intec Parent, Inc. (incorporated herein by reference to Exhibit 10.3 to Indaptus&#8217; Current Report on Form 8-K filed with the SEC on July 29, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1857044/000149315224023119/ex10-1.htm" style="-sec-extract: exhibit">Indaptus Therapeutics, Inc. Amended and Restated 2021 Stock Incentive Plan (incorporated herein by reference to Exhibit 10.1 to Indaptus&#8217; Current Report on Form 8-K filed with the SEC on June 7, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1857044/000149315223008010/ex10-2.htm" style="-sec-extract: exhibit">Form of Option Award Agreement (incorporated herein by reference to Exhibit 10.2 of the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 13, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1857044/000149315221018937/ex10-5.htm" style="-sec-extract: exhibit">Form of Indemnification Agreement (incorporated herein by reference to Exhibit 10.5 of the Company&#8217;s Current Report on Form 8-K filed with the SEC on August 6, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1857044/000149315221018937/ex10-1.htm" style="-sec-extract: exhibit">Employment Agreement between Jeffrey Meckler and Indaptus Therapeutics, Inc., effective as of August 4, 2021 (incorporated herein by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed with the SEC on August 6, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1857044/000149315221018937/ex10-2.htm" style="-sec-extract: exhibit">Employment Agreement between Michael J. Newman, Ph.D. and Indaptus Therapeutics, Inc., effective as of August 4, 2021 (incorporated herein by reference to Exhibit 10.2 of the Company&#8217;s Current Report on Form 8-K filed with the SEC on August 6, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1857044/000149315221018937/ex10-3.htm" style="-sec-extract: exhibit">Employment Agreement between Walt Linscott and Indaptus Therapeutics, Inc., effective as of August 4, 2021 (incorporated herein by reference to Exhibit 10.3 of the Company&#8217;s Current Report on Form 8-K filed with the SEC on August 6, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1857044/000149315222007319/ex10-6.htm" style="-sec-extract: exhibit">Employment Agreement between Nir Sassi and Indaptus Therapeutics, Inc., effective as of January 1, 2022 (incorporated herein by reference to Exhibit 10.6 of the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 21, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1857044/000149315224009769/ex10-8.htm" style="-sec-extract: exhibit">Employment Agreement between Roger J. Waltzman and Indaptus Therapeutics, Inc., effective as of August 7, 2023 (incorporated herein by reference to Exhibit 10.8 of the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 13, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1857044/000149315223016268/ex10-1.htm" style="-sec-extract: exhibit">Indaptus Therapeutics, Inc. Non-Employee Director Compensation Program (Effective April 2, 2023) (incorporated herein by reference to Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on May 11, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1857044/000149315224009769/form10-k.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement, dated July 23, 2021, between Intec Parent, Inc. and each purchaser identified on the signature pages hereto (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on July 29, 2021)</a></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1857044/000149315221018114/ex10-4.htm" style="-sec-extract: exhibit">Form of Registration Rights Agreement, dated July 23, 2021, between Intec Parent, Inc. and each purchaser identified on the signature pages hereto (incorporated herein by reference to Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on July 29, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1857044/000149315222024871/ex1-2.htm" style="-sec-extract: exhibit">At the Market Offering Agreement, dated June 1, 2022, by and between Indaptus Therapeutics, Inc. and H.C. Wainwright &amp; Co., LLC (incorporated by reference to Exhibit 1.2 of the Company&#8217;s Registration Statement on Form S-3 filed on September 1, 2022)</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 112; Value: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1857044/000149315224030671/ex1-1.htm" style="-sec-extract: exhibit">Placement Agent Agreement, dated as of July 23, 2024, by and between Indaptus Therapeutics, Inc. and Paulson Investment Company, LLC (incorporated by reference to Exhibit 1.1 to the Company&#8217;s Current Report on Form 8-K filed on August 8, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1857044/000149315224030671/ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on August 8, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1857044/000149315224030671/ex10-2.htm" style="-sec-extract: exhibit">Form of Warrant (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on August 8, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1857044/000149315224047422/ex1-1.htm" style="-sec-extract: exhibit">Placement Agent Agreement, dated as of October 29, 2024, by and between Indaptus Therapeutics, Inc. and Paulson Investment Company, LLC, and Amendment No. 1 to Placement Agent Agreement, dated as of November 20 2024 (incorporated by reference to Exhibit 1.1 to the Company&#8217;s Current Report on Form 8-K filed on November 22, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1857044/000149315224047422/ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on November 22, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1857044/000149315224047422/ex10-2.htm" style="-sec-extract: exhibit">Form of Warrant (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on November 22, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1857044/000149315224047422/ex10-3.htm" style="-sec-extract: exhibit">Form of Placement Agent Warrant (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed on November 22, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1857044/000149315225002145/ex10-4.htm" style="-sec-extract: exhibit">Placement Agent Agreement, dated as of January 12, 2025, by and between Indaptus Therapeutics, Inc. and Paulson Investment Company, LLC as amended by the First Amendment to the Placement Agent Agreement, dated as of December 30, 2024 (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K filed on January 14, 2025)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1857044/000149315225002145/ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on January 14, 2025)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1857044/000149315225002145/ex10-2.htm" style="-sec-extract: exhibit">Form of Warrant (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on January 14, 2025)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1857044/000149315225002145/ex10-3.htm" style="-sec-extract: exhibit">Form of Placement Agent Warrant (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed January 14, 2025)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1857044/000149315225006052/ex10-1.htm" style="-sec-extract: exhibit">Form of Standby Equity Purchase Agreement dated as of February 12, 2025 by and between the Company and YA II PN Ltd. (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed February 12, 2025)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex19-1.htm">Insider Trading Policy</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1857044/000149315222007319/ex21-1.htm" style="-sec-extract: exhibit">List of Subsidiaries (incorporated herein by reference to Exhibit 21.1 to the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 21, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex23-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Haskell &amp; White LLP, independent registered public accounting firm</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a)under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-2.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1857044/000149315224009769/ex97-1.htm" style="-sec-extract: exhibit">Indaptus Therapeutics, Inc. Policy for Recovery of Erroneously Awarded Compensation (incorporated herein by reference to Exhibit 97.1 of the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 13, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document
    (the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension
    Schema Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension
    Calculation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension
    Definition Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension
    Labels Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension
    Presentation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive
    Data File (formatted as Inline XBRL and contained in Exhibits 101)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished herewith</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates management contract or compensatory plan.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">++ </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The schedules to the agreement
    have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule will be furnished to the SEC upon
    request.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aj_007"></span>Item
16. Form 10-K Summary</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 113; Value: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report
to be signed on its behalf by the undersigned, thereunto duly authorized<b>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indaptus Therapeutics, Inc.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March
    13, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Jeffrey A. Meckler</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey A. Meckler</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>POWER
OF ATTORNEY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KNOW
ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Jeffrey Meckler and Nir
Sassi, and each of them acting individually, as his attorney-in-fact, each with full power of substitution, for him in any and all capacities,
to sign any and all amendments to this Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection
therewith, with the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said
attorney to any and all amendments to said Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on
behalf of the Registrant in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Jeffrey A. Meckler</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer
    and Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    13, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey
    A. Meckler</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Nir Sassi</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    13, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nir
    Sassi</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and
    Accounting Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Michal J. Newman, Ph.D.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Scientific Officer and Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    13, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    J. Newman, Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Roger J. Pomerantz, M.D.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board of Directors</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    13, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Roger J. Pomerantz, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Hila Karah</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    13, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hila
    Karah</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Anthony J. Maddaluna</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    13, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anthony
    J. Maddaluna</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Mark J. Gilbert</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    13, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
    J. Gilbert</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    William B. Hayes</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    13, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">William
    B. Hayes</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Robert E. Martell, M.D., Ph.D.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    13, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    E. Martell, M.D., Ph.D.</span></td>
    <td colspan="4" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 114; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
















</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>2
<FILENAME>ex19-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
19.1</B></FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INDAPTUS
THERAPEUTICS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INSIDER
TRADING POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Insider Trading Policy (the &ldquo;<B>Policy</B>&rdquo;) sets forth the policy for directors, officers, employees, consultants and contractors
of Indaptus Therapeutics, Inc. and its subsidiaries (the &ldquo;<B>Company</B>&rdquo;) with respect to transactions in the Company&rsquo;s
securities or securities of certain other publicly traded companies while in possession of confidential information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Applicability
of Policy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy applies to all transactions in the Company&rsquo;s Securities, including the purchase, sale or other disposition of ordinary shares,
preferred shares, restricted shares or units, options and warrants for ordinary shares, bonds and any other securities the Company may
issue from time to time, such as convertible debentures and other derivative securities relating to the Company&rsquo;s shares, whether
or not issued by the Company, such as exchange-traded options (the &ldquo;<B>Company&rsquo;s Securities</B>&rdquo;). It applies to all
directors, officers, employees, consultants and contractors of the Company as well as members of their immediate families, members of
their households and corporations, trusts or other entities under their control (collectively, &ldquo;<B>Insiders</B>&rdquo;). Directors,
officers, employees, consultants and contractors of the Company are responsible for ensuring that members of their immediate families
and members of their households comply with this Policy. This Policy also applies to any person who receives Material Non-Public Information
(as defined below) from any Insider.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General
Policy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is against Company policy for any Insider to make an unauthorized disclosure of any nonpublic information acquired in the work-place
or as a result of their position with the Company. It is also against Company policy for any Insider to misuse Material Nonpublic Information
in securities trading. The Company has established procedures for releasing material information in a manner that is designed to achieve
broad public dissemination of the information to the public immediately upon its release. As a director, officer, employee, consultant
or contractor of the Company, you may not, therefore, disclose Material Nonpublic information to anyone outside the Company, including
family members and friends. You also may not discuss the Company or its business in an internet &ldquo;chat room&rdquo; or similar internet-based
forum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Specific
Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Trading
                                            on Material Nonpublic Information</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Insider shall engage in any transaction involving a purchase or sale of the Company&rsquo;s Securities, including any offer to purchase
or offer to sell, during any period commencing with the date that he or she possesses Material Nonpublic Information concerning the Company,
and ending at the commencement of trading on the next Trading day following two full Trading days following the date of public disclosure
of that information, or at such time as such nonpublic information is no longer material. As used herein, the term &ldquo;<B>Trading
Day</B>&rdquo; shall mean a day on which the Nasdaq stock market is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
that may be necessary or justifiable for independent reasons (such as the need to raise money for an emergency expenditure) are not excepted
from the Policy. The securities laws do not recognize such mitigating circumstances, and, in any event, even the appearance of an improper
transaction must be avoided to preserve the Company&rsquo;s reputation for adhering to the highest standards of conduct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Short
                                            Sales</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Insider shall engage in a short sale of the Company&rsquo;s Securities. A short sale is in general a sale of securities not owned by
the seller. Transactions in certain put and call options for the Company&rsquo;s Securities may in some instances constitute a short
sale. Short sales may evidence an expectation on the part of the seller that the securities will decline in value, and therefore have
the potential to signal to the market that the seller lacks confidence in the Company&rsquo;s prospects. In addition, short sales may
reduce a seller&rsquo;s incentive to seek to improve the Company&rsquo;s performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Publicly
                                            Traded Options</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
transaction in publicly-traded options to purchase or sell the Company&rsquo;s Securities is, in effect, a bet on the short-term movement
of the Company&rsquo;s Securities and therefore may create the appearance that the director, officer, employee, consultant or contractor
of the Company is trading based on inside information. Transactions in options also may focus the Insider&rsquo;s attention on short-term
performance at the expense of the Company&rsquo;s long-term objectives. Accordingly, transactions in puts, calls or other derivative
securities, on an exchange or in any other organized market, by any Insider are prohibited by this Policy. Option positions arising from
certain types of hedging transactions are governed by the section below captioned &ldquo;Hedging Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Standing
                                            Orders</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Standing
orders should be used only for a very brief period of time and must be pre-cleared by the Chief Financial Officer. A standing order placed
with a broker to sell or purchase securities at a specified price leaves you with no control over the timing of the transaction. A standing
order transaction executed by the broker when you are aware of Material Nonpublic Information may result in unlawful insider trading.
Transactions pursuant to a plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange
Act</B>&rdquo;), discussed below, may be permitted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Hedging
                                            Transactions</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
forms of hedging or monetization transactions, such as zero-cost collars and forward sale contracts, allow an employee to lock in much
of the value of his or her share holdings, often in exchange for all or part of the potential for upside appreciation in the shares.
These transactions allow the Insider to continue to own the securities, but without the full risks and rewards of ownership. When that
occurs, Insider may no longer have the same objectives as the Company&rsquo;s other shareholders. For these reasons, hedging transactions
are prohibited under this Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Margin
                                            Accounts and Pledges</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
held in a margin account may be sold by the broker without the customer&rsquo;s consent if the customer fails to meet a margin call.
Similarly, securities pledged (or hypothecated) as collateral for a loan may be sold in foreclosure if the borrower defaults on the loan.
A margin or foreclosure sale that occurs when the pledgor is aware of Material Nonpublic Information may, under some circumstances, result
in unlawful insider trading. Because of this danger, Insiders are prohibited from pledging the Company&rsquo;s Securities or holding
Company&rsquo;s Securities in a margin account.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Short-Term
                                            Trading</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term
trading of the Company&rsquo;s Securities may be distracting to the person and may unduly focus the person on the Company&rsquo;s short-term
stock market performance instead of the Company&rsquo;s long-term business objectives. For these reasons, if you purchase or sell Company
Securities, you may not conduct an opposite way transaction in any Company Securities of the same class for at least six (6) months after
the purchase or sale, unless you first pre-clear the proposed transaction with the Chief Financial Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Tipping</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Insider shall disclose (commonly known as a &ldquo;tip&rdquo;) Material Nonpublic Information to any other person (including family members)
where such information may be used, or there is a reasonable basis to believe that such information may be used, by such person to his
or her profit by trading (buying or selling) in the securities of companies to which such information relates, nor shall such person
or related person make recommendations or express opinions on the basis of Material Nonpublic Information as to trading in the Company&rsquo;s
Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Advice
                                            Concerning Trading</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Insider may give trading advice of any kind about the Company or the Company&rsquo;s Securities to anyone while possessing Material Nonpublic
information about the Company. An Insider should always advise others, preferably in writing or electronically, not to trade in the Company&rsquo;s
Securities if doing so might violate the law or this policy. The Company strongly discourages any Insider from giving trading advice
concerning the Company&rsquo;s Securities or the Company to third parties even when such persons do not possess Material Nonpublic information
about the Company or the Company&rsquo;s Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Confidentiality
                                            of Nonpublic Information</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nonpublic
information relating to the Company is the property of the Company and the unauthorized disclosure of such information is forbidden.
In the event any Insider receives any inquiry for information from outside the Company, such as from a journalist, stock analyst or investor,
the inquiry should be referred to the Company&rsquo;s Chief Executive Officer or any designee of the Chief Executive Officer who is responsible
for coordinating and overseeing the release of such information to the investing public, analysts and others in compliance with applicable
laws and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Post-Termination
                                            Transactions</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you are in possession of Material Nonpublic Information when your employment or other service to the Company terminates or ceases, you
may not trade in the Company&rsquo;s Securities until that information has become public or is no longer material.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Potential
Criminal and Civil Liability and/or Disciplinary Action</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Liability
                                            for Insider Trading</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to federal and state securities laws, any person violating U.S. insider trading laws may be subject to penalties of up to $5,000,000
($25,000,000 for an entity) and up to 20 years in jail for engaging in transactions in the Company&rsquo;s Securities at a time when
they have knowledge of Material Nonpublic Information regarding the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Liability
                                            for Tipping</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insiders
may also be liable for improper transactions by any person (commonly referred to as a &ldquo;tippee&rdquo;) to whom they have disclosed
Material Nonpublic Information regarding the Company or to whom they have made recommendations or expressed opinions on the basis of
such information as to trading in the Company&rsquo;s Securities. The Securities and Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;)
has imposed large penalties even when the disclosing person did not profit from the trading. The SEC, the stock exchanges and the Financial
Industry Regulatory Authority use sophisticated electronic surveillance techniques to uncover insider trading. In recent years, criminal
prosecution of insiders has become much more common, particularly when such persons were aware of their obligations under the securities
laws and elected to ignore those obligations in acting on, or in tipping others concerning, Material Nonpublic Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Liability
                                            of Control Persons</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company or its supervisory personnel fail to take appropriate steps to prevent illegal insider trading, they may be subject to the
following penalties:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
A civil penalty of up to the greater of $2,140,973 (subject to adjustment for inflation) or three times the amount of profit gained
or loss avoided by the employee violator; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
A criminal penalty of up to $5,000,000 and up to 20 years in jail for individual violators and/or a fine of $25,000,000 for the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Possible
                                            Disciplinary Actions</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insiders
who violate this Policy may also be subject to disciplinary action by the Company, which may include ineligibility for future participation
in the Company&rsquo;s equity incentive plans or termination of employment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading
Guidelines and Requirements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Black-Out
                                            Periods and Trading Window</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Financial
                                            Black-Out Period</I>. The period beginning at the close of market on the 14th day of the
                                            last month of a fiscal quarter and ending at the commencement of trading on the next Trading
                                            Day following two full Trading Days after the date of public disclosure of the financial
                                            results for that fiscal quarter is a particularly sensitive period of time for transactions
                                            in the Company&rsquo;s Securities from the perspective of compliance with applicable securities
                                            laws. This sensitivity arises because directors, officers and certain employees involved
                                            in the preparation of the financial results will often possess Material Nonpublic Information
                                            about the expected financial results for the quarter during that period. This period of time
                                            is referred to as a &ldquo;financial black-out&rdquo; period. Accordingly, all officers,
                                            directors and employees are prohibited from trading during a financial black-out period except
                                            for transactions specifically permitted pursuant to the &ldquo;Certain Exceptions&rdquo;
                                            section below.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Special
                                            Black-Out Periods</I>. In addition, from time to time Material Nonpublic Information regarding
                                            the Company may be pending or there may be material developments known to the Company and
                                            not yet disclosed to the public. The Company may impose a special &ldquo;black-out&rdquo;
                                            period on all directors and officers (and those other Insiders identified by the Company
                                            from time to time and who have been notified that they have been so identified) prohibiting
                                            them from trading in the Company&rsquo;s Securities during a special black-out period and
                                            such persons should not disclose to others the fact of such suspension of trading.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Mandatory
                                            Trading Window Related to Financial Information</I>. To ensure compliance with this Policy
                                            and applicable federal and state securities laws, the Company requires that all Insiders
                                            refrain from conducting transactions involving the purchase or sale of the Company&rsquo;s
                                            Securities other than during the period (the &ldquo;<B>Trading Window</B>&rdquo;) commencing
                                            at the open of market on the third Trading Day following the date of public disclosure of
                                            the financial results for a particular fiscal quarter or year and continuing until the close
                                            of market on the 14th day prior to the end of the third calendar month of the next fiscal
                                            quarter. During the Trading Window, if the Company is in a special black-out period, the
                                            Company requires that all directors and officers and those certain identified Insiders refrain
                                            from conducting transactions involving the purchase or sale of the Company&rsquo;s Securities
                                            even though the Trading Window may otherwise be open. The prohibition against trading during
                                            the financial black-out period and special black-out period encompasses the fulfillment of
                                            &ldquo;limit orders&rdquo; by any broker for an Insider and the brokers with whom any such
                                            limit order is placed must be so instructed at the time it is placed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>It
should be noted, however, that even during a Trading Window, any person possessing Material Nonpublic Information concerning the Company,
whether or not subject to the financial or special black-out periods, should not engage in any transactions in the Company&rsquo;s Securities
(except for transactions specifically described in the &ldquo;Certain Exceptions&rdquo; section below) until such information has been
known publicly for at least two full Trading Days, whether or not the Company has recommended a suspension of trading to that person.
Trading in the Company&rsquo;s Securities during the Trading Window is <U>not</U> a &ldquo;safe harbor,&rdquo; and all Insiders should
use good judgment at all times and pre-clear all trades in accordance with the following paragraph.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Pre-Clearance
                                            of Trades</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
Insiders must refrain from purchasing, selling or otherwise disposing of (including by gift) or transacting in the Company&rsquo;s Securities
without first complying with the Company&rsquo;s &ldquo;pre-clearance&rdquo; process, even if the trade would take place in a Trading
Window. Each Insider must contact the Chief Financial Officer prior to commencing any trade in the Company&rsquo;s Securities with information
regarding the proposed transaction. The Chief Financial Officer will consult as necessary with senior management of the Company before
clearing any proposed trade. All trades that are pre-cleared must be effected within five business days of receipt of the pre-clearance.
A pre-cleared trade (or any portion of a pre-cleared trade) that has not been effected during the five business day period must be submitted
for pre-clearance determination again prior to execution. Notwithstanding receipt of preclearance, if the Insider becomes aware of Material
Nonpublic Information, or becomes subject to a blackout period before the transaction is effected, the transaction may not be completed.
Transactions under a previously established Rule 10b5-1 Trading Plan that has been preapproved in accordance with this Policy are not
subject to further pre-clearance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Individual
                                            Responsibility</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Every
Insider has the individual responsibility to comply with this Policy. He or she may, from time to time, have to forego a proposed transaction
in the Company&rsquo;s Securities even if he or she planned to make the transaction before learning of the Material Nonpublic Information
and even though he or she believes he or she may suffer an economic loss or forego anticipated profit by waiting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of your individual responsibility, you should take every practicable step to preserve the confidentiality of information. For example:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) Don&rsquo;t
discuss material information in elevators, hallways, restaurants, airplanes, taxicabs or any place where you can be overheard;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) Don&rsquo;t
gossip about confidential information;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) Don&rsquo;t
read confidential documents in public places or discard them where they can be retrieved by others;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) Don&rsquo;t
carry confidential documents in elevators, hallways, etc. in an exposed manner;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) Beware
of the carrying quality of conversations conducted on speaker telephones in offices, and the potential for eavesdropping on conversations
conducted on car or airplane telephones, on marine radios etc.;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) Don&rsquo;t
leave confidential documents in unattended conference rooms; don&rsquo;t leave confidential documents behind when the conference is over;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g) Cover
confidential documents on your desk before you leave your room; don&rsquo;t leave confidential papers lying where visitors can see them;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h) Be
careful when giving out the whereabouts of personnel not in the office or revealing the presence of specific visitors to the office.
The mere fact of a meeting or the destination of a trip may reveal something confidential; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) Under
no circumstances are employees to provide confidential Company documents or other information to third parties, without express consent
of the supervisor. This includes, but is not limited to, any confidential Company documents or information relating to customers, competitors
or suppliers of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j) Obviously,
a list such as this can only be suggestive. It is the responsibility of each employee to take whatever practicable steps are appropriate
to preserve the confidentiality of information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Applicability
of Policy to Inside Information Regarding Other Companies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy also applies to Material Nonpublic Information relating to other companies with which the Company conducts business, including
proposed business combinations (&ldquo;<B>Business Partners</B>&rdquo;), when that information is obtained in the course of employment
with, or other services performed on behalf of, the Company. Civil and criminal penalties, and termination of employment, may result
from trading on inside information regarding the Company&rsquo;s Business Partners. All Insiders should treat Material Nonpublic Information
about the Company&rsquo;s Business Partners with the same care required with respect to information related directly to the Company.
Similarly, you must not discuss Material Nonpublic Information relating to the Company&rsquo;s Business Partners in an internet &ldquo;chat
room&rdquo; or similar internet-based forum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Definition
of &ldquo;Material Nonpublic Information&rdquo;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is not possible to define all categories of Material Nonpublic Information. However, information should be regarded as material if there
is a reasonable likelihood that it would be considered important (within the total mix of information) to an investor in making an investment
decision regarding the purchase or sale of the Company&rsquo;s Securities. Either positive or negative information may be material.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
it may be difficult under this standard to determine whether particular information is material, there are various categories of information
that are particularly sensitive and, as a general rule, should always be considered material. Examples of such information may include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial results;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">news of major clinical or development milestones;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">early indications of clinical trial results;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">known but unannounced clinical trial results;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">known but unannounced analyses of clinical trial results;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
                                            communications to or from regulatory agencies, or other significant regulatory developments;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant developments related to intellectual property;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant developments related to collaboration relationships;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">proposals,
                                            plans or agreements, even if preliminary in nature, involving mergers, acquisitions, divestitures,
                                            recapitalizations, strategic alliances, licensing arrangements, or purchases or sales of
                                            substantial assets;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impending bankruptcy or financial liquidity problems;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cybersecurity or data security incidents;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">share splits;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">new equity or debt offerings;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">positive or negative developments in outstanding litigation;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant litigation exposure due to actual or threatened
litigation; and</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in senior management, the Company&rsquo;s auditors
or the board of directors.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nonpublic
information is information that has not been previously disclosed to the general public and is otherwise not available to the general
public. To be &ldquo;public&rdquo; the information must have been disseminated in a manner designed to reach investors generally, and
the investors must be given the opportunity to absorb the information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certain
Exceptions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following transactions are not subject to the prohibitions of the Policy under &ldquo;Trading Guidelines and Requirements&rdquo; above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Share
                                            Option Exercises</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s Policy does not apply to the exercise of an Insider share option if the shares acquired upon exercise are held rather
than sold, or if the shares are surrendered to the Company in payment of the exercise price or in satisfaction of any tax withholding
requirements in a manner permitted by the applicable equity award agreement, that in case do not involve a market sale of the Company&rsquo;s
Securities. The Policy does apply, however, to any sale of shares as part of a broker-assisted cashless exercise of an option, or any
other sale for the purpose of generating the cash needed to pay the exercise price of an option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Restricted
                                            Share Awards and RSUs</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy does not apply to the vesting of restricted shares or restricted stock units, or the withholding or forfeiture of shares to pay
for tax withholding obligations incident to such vesting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Rule
                                            10b5-1 Trading Plans and Non-Rule 10b5-1 Pre-Arranged Trading Programs</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rule
10b5-1 of the Exchange Act provides an affirmative defense against insider trading liability for transactions pursuant to a previously
established written plan, contract or instruction to trade in the Company&rsquo;s stock, entered into in good faith and in accordance
with the terms of Rule 10b5-1 at a time when the Insider was not aware of Material Nonpublic Information, even though the transaction
in question may occur at a time when such person is aware of Material Nonpublic Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading restrictions set forth in this Policy, other than those specified transactions specifically prohibited under the &ldquo;Specific
Policies&rdquo; section above, do not apply to transactions under a previously established contract, plan or instruction to trade in
the Company&rsquo;s Securities that complies with all applicable requirements of Rule 10b5-1 (a &ldquo;<B>Trading Plan</B>&rdquo;) or
transactions under a &ldquo;non-Rule 10b5-1 trading arrangement&rdquo; as defined by Item 408 of Regulation S-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
Insider may enter into a Trading Plan or a non-Rule 10b5-1 trading arrangement only when he or she is not in possession of Material Nonpublic
Information and only during a Trading Window.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
such Trading Plan or non-Rule 10b5-1 trading arrangement must be submitted to and pre-approved by the Chief Financial Officer, who may
impose such conditions on the implementation and operation of the Trading Plan as the Chief Financial Officer deems necessary or advisable.
Insiders may not adopt more than one Trading Plan at a time except under the limited circumstances permitted by Rule 10b5-1 and subject
to pre-approval by the Chief Financial Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
individual may only modify a Trading Plan during a Trading Window and, in any event, when the individual does not possess Material Nonpublic
Information. Modifications to and terminations of a Trading Plan or non-Rule 10b5-1 trading arrangement are subject to pre-approval by
the Chief Financial Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reserves the right to bar any transactions in the Company&rsquo;s Securities, including transactions pursuant to a Trading Plan
and any non-Rule 10b5-1 trading arrangements previously approved, if the Chief Financial Officer or the Board of Directors determines
that such a bar is in the best interests of the Company. In addition, the Company does not permit any trades in such a Trading Plan or
any non-Rule 10b5-1 trading arrangements to consist of any hedging transactions or other transactions prohibited by this Policy under
the &ldquo;Specific Policies&rdquo; section above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reserves the right to publicly disclose, announce, or respond to inquiries from the media regarding the adoption, modification,
or termination of a Trading Plan and non-Rule 10b5-1 trading arrangements, or the execution of transactions made under a Trading Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional
Guidance and Information &ndash; Directors and Officers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
and officers of the Company and certain other persons identified by the Company from time to time must also comply with the reporting
obligations and limitations on short-swing transactions set forth in Section 16 of the Exchange Act. The Company does not permit short-swing
and short sale transactions by executive officers or directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Priority
of Statutory or Regulatory Trading Restrictions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading prohibitions and restrictions set forth in this Policy will be superseded by any greater prohibitions or restrictions prescribed
by federal or state securities laws and regulations, e.g., contractual restrictions on the sale of securities (e.g. under lock-up agreements),
short-swing trading by Section 16 parties or restrictions on the sale of securities subject to Rule 144 under the Securities Act. Any
person who is uncertain whether other prohibitions or restrictions apply should ask the Chief Financial Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Inquiries</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
person who has a question about this Policy or its application to any proposed transaction may obtain additional guidance from the Chief
Financial Officer. Ultimately, however, the responsibility for adhering to this Policy and avoiding unlawful transactions rests with
the individual Insider.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certifications</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
directors, officers, employees, consultants and contractors must certify their understanding of, and intent to comply with, this Policy.
Please sign the certification attached hereto as Attachment 1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Last
Updated: June 14, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>ATTACHMENT
1</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. I
have read and understand the Company&rsquo;s Insider Trading Policy (the &ldquo;Policy&rdquo;). I understand that the Chief Financial
Officer is available to answer any questions I have regarding the Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. Since
the date this Policy became effective, or such shorter period of time that I have been a director, officer or other employee of the Company,
I have complied with the Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. I
will continue to comply with the Policy for as long as I am subject to the Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print
    Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 166.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex23-1_001.jpg" ALT=""></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the incorporation by reference in the Registration Statements on Form S-1 (Nos. 333-269000, 333-259771, 333-282069 and 333-284026),
the Registration Statements on Form S-3 (Nos. Nos. 333-267236, 333-230016 and 333-284707), and the Registration Statements on Form S-8
(333-259127, 333-270828 and 333-281466) of Indaptus Therapeutics, Inc. (the &ldquo;Company&rdquo;) of our report dated March 13, 2025,
relating to our audits of the Company&rsquo;s consolidated financial statements as of December 31, 2024 and 2023, and for each of the
years then ended, included in the Company&rsquo;s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the
U.S. Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
report dated March 13, 2025 contains an explanatory paragraph that states the Company has experienced recurring losses, negative cash
flows from operations, and has limited capital resources. These conditions raise substantial doubt about the Company&rsquo;s ability
to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome
of this uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 50%"><I>/s/ Haskell&amp; White LLP</I></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HASKELL
&amp; WHITE LLP</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Irvine,
California</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
13, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex23-1_002.jpg" ALT=""></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Jeffrey A. Meckler, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
                                            have reviewed this Annual Report on Form 10-K for the year ended December 31, 2024 of Indaptus
                                            Therapeutics, Inc. (the &ldquo;registrant&rdquo;);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on my knowledge, this report does not contain any untrue statement of a material fact or
                                            omit to state a material fact necessary to make the statements made, in light of the circumstances
                                            under which such statements were made, not misleading with respect to the period covered
                                            by this report;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on my knowledge, the financial statements, and other financial information included in this
                                            report, fairly present in all material respects the financial condition, results of operations
                                            and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining
                                            disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
                                            and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)and
                                            15d-15(f)) for the registrant and have:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            such disclosure controls and procedures, or caused such disclosure controls and procedures
                                            to be designed under our supervision, to ensure that material information relating to the
                                            registrant, including its consolidated subsidiaries, is made known to us by others within
                                            those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            such internal control over financial reporting, or caused such internal control over financial
                                            reporting to be designed under our supervision, to provide reasonable assurance regarding
                                            the reliability of financial reporting and the preparation of financial statements for external
                                            purposes in accordance with generally accepted accounting principles;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
                                            the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented
                                            in this report our conclusions about the effectiveness of the disclosure controls and procedures,
                                            as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
                                            in this report any change in the registrant&rsquo;s internal control over financial reporting
                                            that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
                                            fourth fiscal quarter in the case of an annual report) that has materially affected, or is
                                            reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
                                            reporting; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent
                                            evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
                                            and the audit committee of the registrant&rsquo;s board of directors (or persons performing
                                            the equivalent functions):</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            significant deficiencies and material weaknesses in the design or operation of internal control
                                            over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
                                            ability to record, process, summarize and report financial information; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            fraud, whether or not material, that involves management or other employees who have a significant
                                            role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
March 13, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
  Jeffrey A. Meckler</I></FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey A. Meckler</FONT></TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and Director</FONT></TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal executive officer)</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Nir Sassi, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
                                            have reviewed this Annual Report on Form 10-K for the year ended December 31, 2024 of Indaptus
                                            Therapeutics, Inc. (the &ldquo;registrant&rdquo;);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on my knowledge, this report does not contain any untrue statement of a material fact or
                                            omit to state a material fact necessary to make the statements made, in light of the circumstances
                                            under which such statements were made, not misleading with respect to the period covered
                                            by this report;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on my knowledge, the financial statements, and other financial information included in this
                                            report, fairly present in all material respects the financial condition, results of operations
                                            and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining
                                            disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
                                            and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)and
                                            15d-15(f)) for the registrant and have:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            such disclosure controls and procedures, or caused such disclosure controls and procedures
                                            to be designed under our supervision, to ensure that material information relating to the
                                            registrant, including its consolidated subsidiaries, is made known to us by others within
                                            those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            such internal control over financial reporting, or caused such internal control over financial
                                            reporting to be designed under our supervision, to provide reasonable assurance regarding
                                            the reliability of financial reporting and the preparation of financial statements for external
                                            purposes in accordance with generally accepted accounting principles;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
                                            the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented
                                            in this report our conclusions about the effectiveness of the disclosure controls and procedures,
                                            as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
                                            in this report any change in the registrant&rsquo;s internal control over financial reporting
                                            that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
                                            fourth fiscal quarter in the case of an annual report) that has materially affected, or is
                                            reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
                                            reporting; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent
                                            evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
                                            and the audit committee of the registrant&rsquo;s board of directors (or persons performing
                                            the equivalent functions):</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            significant deficiencies and material weaknesses in the design or operation of internal control
                                            over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
                                            ability to record, process, summarize and report financial information; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            fraud, whether or not material, that involves management or other employees who have a significant
                                            role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
March 13, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
  Nir Sassi</I></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 50%">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nir Sassi</FONT></TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal financial officer)</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indaptus
Therapeutics, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certification
Pursuant to</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. Section 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>as
Adopted Pursuant to</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
906 of the Sarbanes-Oxley Act of 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report of Indaptus Therapeutics, Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ended December
31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Jeffrey A. Meckler, Chief
Executive Officer and Director of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange
                                            Act of 1934; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            information contained in the Report fairly presents, in all material respects, the financial
                                            condition and results of operations of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
  Jeffrey A. Meckler</I></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 50%">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey A. Meckler</FONT></TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and Director</FONT></TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal executive officer)</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
March 13, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indaptus
Therapeutics, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certification
Pursuant to</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. Section 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>as
Adopted Pursuant to</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
906 of the Sarbanes-Oxley Act of 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report of Indaptus Therapeutics, Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ended December
31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Nir Sassi, Chief Financial
Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange
                                            Act of 1934; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            information contained in the Report fairly presents, in all material respects, the financial
                                            condition and results of operations of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
  Nir Sassi</I></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 50%">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nir Sassi</FONT></TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal financial officer)</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
March 13, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>form10-k_0001.jpg
<TEXT>
begin 644 form10-k_0001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $! <(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4**** "B
MBB@ HHHH **,T4 %%%% !1110 449HS0 449HH **** "BBD?[IH 7-,W G&
M<GTKG/%'C*V\-&*'8UU?3#,5K&<'']YCV6O-M7\0:OK+,;W4I+>/_GTT\^6@
M]BWWC_*BUQ7/9I]1M+4XGNH83_TTD5:CBUG3[APD=];2,?X4F4G^=>#?8[#:
M UI'(>I:4-(P^I)YIHM]-:48MK-3G  4#/Y<U+BUU"Z/H;(."#SU[4H8$X[U
MXQH7B.[\*R,\#S7FE(?W]C(Q=X@?XX6)R,=U/7J.E>N:;?6^HVL%S;2">"6,
M.DB]"*@9<HHHH *0T$XIDD@4<_D*6P#NII20.IKC_&?Q1\.^"$QJ%ZGV@#(M
MHOFD;\!TKRK5_P!IJ[F=QI>B)&G\,MY+R1_NCI7FXC,<-AG:<E<ER2W/H3>.
MN:,@]Z^9)/VD/$H7BUTW/LKUM>&_VF66YCBUW3DBMSUN[0Y"GUVFN"GGN"JS
MY;B]I%]3Z!'OUIPK/TG6K/6K"*\LIDN+:5<I(A!!J^IR*^@C*,TI1V9:\A:*
M**H HHHH **** "BBB@ HHHH **** "BBFR2>6N2.* '454N=0M[4IY\J0!V
MVJ97"AF[#/>K$3AT#>OJ,4 /HHHH **** "BBB@ HHHK4 HSQ136+= ,^] #
M&DVYP,@=3Z5R_B'XH^%?"6MV&CZQKUAIVJWV/L]I<3!9'R<#@],G@9ZUXO\
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M9CL(83::>C=77C?+]"1P:9H/PZN-2D6?60([08*Z<'W%S_>E?]=HXKTJV@6
MJ$0(@ 4!1@ #I6#M)[EQ)4&%'IBE)ITGW::O>ERE@W0_2ODC]M+PC-97.D>+
M[96\AA]ANSCA.Z$^W:OK?O\ TK(\2>'M/\6:-=Z3JEI'>V%TACFMY!D,I_K7
M%B\*L52=-DR7,K'YC0W\-['=V5W($@NU""8=(Y 04;\^/QKA?$6FW C>WN$,
M5Q$W[R)A]T^WJ.^?>OJ#XK?L3^)/#]Q+?>!+M=9T_DKIEV^VXB7^ZK]' 'K7
MA>J:!XKT!C8^(O!.KRK%\H<VC&6$>B2J#D#WK\_J8"M1FTXG%*#3L>4?V"7N
M0[#)ZY%=-H.G21NJ@%F/ 1>6<Y& HKIK#PO+J<R&S\/^+)9"=JPQZ:6))_VR
M,"O:OA?^RUXX\721O<Z<O@+1I>);FX83:E(OHHZ)GU]ZE82O5:BHM H-LP?A
M/X"O?'?BW1_"]HA:.Q(N=6G4?);@L"4)Z;B!C%?HI8VT=M#''&,1QJ%4>@ P
M!^E<K\.?ACH7PPT&/2-!LA;P!MTLS_-+._=W;J2:[)!M%?<Y=@?J<+/=G7"'
M**/IBLGQ#X>M/$5G]FO%<QAPX,3E&5AT(8=*ULT'FO7:-CPGQCIWCSX6>)I_
M&.AW5SXST"5$34_#TP N(HT&!+;,.K =5/6O0OA[\4?#OQ*T.'5-#U**>"0$
M/#(VV6%QPR.AY!!X-=;(G!(/(Y&*^(?VNO@V? FL?\)UX=$MAI>I2A-3BM)&
MC6"<\"3@_=;H??GO6$Y<BN=F$HPQ5149RY6^I]8>-?BAX7\":=)>:SKUE9HG
M1#*"Y/H%'/7'Y5\6:/\ M$6FC?M&:EXVM+>XA\+:@1;SVHZ[-H#3!.FXL ?H
M*^>]=UG["5:=I)I<Y#3,7/M@DGKU_&LZP\4+<S+&X.2?NL,$_0UY57&RE9P6
MQ^D8/ABA1A)5I<S>Q^NOA3QUH/C73H[O1=7M=1A8<M#(,@^XZ@UPGQD^-6F>
M$(D\/V-_Y_B/4/W*QVD1G-E&W#32A,[0HSC/>OSHMKNZTP/<V%S-9S%?OV\A
MCW?4*:^UO@AXIT#P]X'L+#X>Z!<^-]>G17U+482! D[#+"XN7_NG^$9-=U'$
MJOL?'YKDW]ER4W*ZD>I_!WQ/X?NK/_A'/#<&H36^F0CS;RZM'A220G+'+ ;F
M8Y.:])LKZ"]C9X)XYTR5W1,&&1U&1WKYTUZ;Q#J?C.TT+X@ZI?:;IEQ:FZD@
M\.,+?3HTW8VS3$^8YS@8& <UZ'X;\?\ PS\$I%X:TK6].TU(/NVJ,P R,DEB
M,9/KGGZUUO<^;EN>HY_/THR/6N4\/?$7P[XOGDCT;58+^6*%+B14!'E(Q(#/
MG!7[IX/-<G9?M'>"+G0?[5GU4:=&\US!%%.N9I3 ,LRJN<A@4*YZAU]:"3U;
M</44N:\]3XV^# 8#<Z]9V32P/=)'.Y!\I5#,6./E8 _<//%;7ASXE>&O%FJ7
M&FZ1K-K?WT$*7$L,+$E48 ANF#U'TR* .DDC!.<9_G7S+^T7\!?$7C'Q3+K_
M (1TG2;9DL574'B8PZAK,8<%[)9>D2LO5Q\QZ9Q7T^AR@]:9(N]L&@#X/T7Q
M=XK^$^M^*%\)^&M*\(WUY]DFOM#FG!TSPMIZC#3W#CY6NI!R(UZC%?9/@/Q4
MWB[26OOL\D,)DV12R."+A<#$J@<J&ZA3R*\W^-OP3L]8@U+Q-I.D2:MK-NC7
MJ:#'(L5OJM^J[8)+C/#&/J >..:\#^%WQ\U;X WD/A+Q3I"-;:=:/=ZS;Z=,
M+FXMI78/-//<.0CN V?(BR57GM0!]VT54TO4(-4LK:\MI%FM;B)989%Z,C#(
M/Y&K= !1110 4445J QEW;33Z** "BBC- !11D&C(]: "@T9H- ADK!5SWKY
M(\;Z9KVG^-]=TW0/#VDZYJ,>M17PEU@A/LEI.F))HB1R5(Z=Z^MW7<"*\)_:
M:^#A^(.CK>PV=[J""/[-JEAI=PUO=W=IG=B&08_>(PW ?Q=*PJQNM#NP==4:
MEV?+7A'PW;V+Z+(- _X2^_\ #GB>ZAN=5N@OA^*PB;+/*L/ N% /WN<UK6R1
M:5J^HZ*ES'=V\+M=6,\#AXY[21MT;HPX8#.WBH/B)HGAC5/!>K>)/'EQX7UG
MP]H;?V?X0&H7%S#+;.\>S[/J&"&\PD<D\CDUMZ#X.U#5M+\)>"O^$)B\,MIF
MD^?%XIT#45N+/2[@]+;8QWNC#DJQP<_C7FU*7.C]&R['K#5%5>J8Q7./FZX_
M2L[Q#81:AX>U"TE;Y9+>0KSC#!2RM]00#^%6]3M-<\)W'V7Q!H-X'Q\E_I-N
M]S:3X[J%RR'OM8<=C3K7PMXD\=P26&FZ/?:1I]TIBGUK58?L_E1,"':&(DL[
M[<@$@ $Y[5YRI34MC[VOF.%E1DU-:H]6EU:77OA]X#UAAC4Y=0T:[C<C!$SE
M5(]LJSY]C7U#&<LV#P"1^M?/.G:3;ZQX^\(>$M.1C8>&Q'JVI;!\D"1QE+2)
M_21RP<*>0J9Q@BOH.$Y0$XW'DXKZ*BK1/P+,9QG7]TGS4-Q<QVT,DLKK'%&I
M9W8X"@=2?:I1RHK-\2Z?+JOA[5+.W9%GN;66&,R#*AF4@9]N:W>QYA7T[Q7H
M^LLB6.IV5\TD*W*+!.LA,1. _!Z$\9J[;WD%X9%AD67RW,;A7#;7'53CH?8U
M\E:A^RKXWTKPY+I>@WNAQV[:9;6<:22R(UNZEFDVL5;]WO(9>"1SBK _9W^(
M^DZ9>V&GWVC0OJ88WM[_ &K<1EY=X<SX"_,Y'RG/;KG/&8'U#J%SI6F6S7E^
M]I;VJE0;F<HJ*68*N6/')( ]<U#J/B30_#PNTOM1LM,%K;_:KA995C,4).T.
M<]B>,^I KYLO?V;/'MWXHN9(K[28M$6S@LX8A=2_O A@8%E*G<08Y,9/\0Q@
M$UW/Q8^#'B+QQ\1H?%>AWEFO]FZ9;1V6FW[$V=]<QW32,EY&H)DC"$[#D%)!
MN .*!61Z]:>*=(NKU;.'4+9KTPBX^R^8!*(R =VP\A<$'..]:\4X+A>Y&X>X
MKY%\2?LQ_$/5[:VNHM:TQ]02QC@N/.NY99+Q5DWM;N[(08R.,G'*C'%>Q_ C
MX6:E\.UUJXUJ\;4]2OS;HMU+=/<3"*.)5".[ #(;>?E !X-:+8>QZXYRM(O>
M@_<]:%[TP&R,%4FN<?X@>'HO$Z>'7UFS777&Y=/>4"5N,X ]<<[>M=#)D#('
M0Y/6OG76_@WX[CUR_BT.XT@6-QK,NMQ:M=OB;,D;+Y$T03+$$@+(CJ56DP/H
M,3)(H/WAG .1@G_/IZ4,P."5W C(R1S_ )S7R'H?[*'C^YL)$UK6-.;9)NM(
M(]2N%CM%:YCDE"JB@*&19$P,\.1GFIYOV4?&=YY\DFM6,UR9+KR)$U&X_=0>
M3MLTVYP/+=58=<5/+'J@/K&:>*QCDDD:.&-%+N[854 &22<X&!S6-X5^(/AO
MQM'/)H&N66K)"!YK6TH. >A.?X3V;H:\-\'?!'XD6%S\0&U?6=(MT\1P1Q#[
M.TDT<TBI*DKE"!Y;.)%;>"S_ "D$8 K$\0?L[_$'Q#X4T_RY-)T#4M-T>PT-
MK*TNC(NJ102!I?-E*C"G VJ0>>I%4DEL@/J*UU_3;NXN;>WOK::XMF*3PQS*
M7A8=G7.1U'7UK15MW&#GWKXYU']EGQW:0:Y)I;Z$^IZO:06LNIWEY(UXJQX.
M&?9ACG@-Q@ 8Z5]1?#?2]2T+P1H>FZQ<+=ZM:V44%W<+(T@DD5<$[F +?4BA
M*P'3TAZ_A0.E(S@'FF S:=OH,&N4^)V@6OB/X>^(=-OX8Y[2>RE#HXR.$)!_
M @'\JZ8SB-7=L(JC=N8X&/4GL*^;/C!^U#%J-OJ?ACX;:7=^-=8*O;7.H:;;
MO-96AY#+O7(D<<\#@=ZSFU&-F=&'A*56/+O<_.[Q/!<-:P3ON!!!=F.2 1C/
M'7IR>U8./+RZMM(Q\V>!]#[UZ-/90QM]ED0H^"@CE78V<_,"N?7/3BLZ'PO:
MK<B;8BR@Y!P3CZ"OE912DS]ZI0YJ<+.[+^D2/)I^7!#D=NO2OJ/X"ZWX5UOP
M[IMMJ=QJ7P_\2VY^QVGBBPS;6E_@\*[']TSC."KCGUKYH*B"!]H# *6"MWQZ
MFOT%^ W@31_$O[-7A_1-4LTO=.U"S9IX90#EF).1[@UZ. 7O,^2XL<8X>'-O
M<YWQ=8ZU+<7-MXIL(/B39FU-J^I>&+G[/J4$&_>7:V!V%@1UC(/M7<>'O@WX
M$\4^%+::VTFZET^[MPOEWWF138R"=ZOR&R.>^:[3X?\ A%_!>@1:4]Q%=K =
MD4Z0")VC'W0X7 ) XSWKJ(^!UQ^%>PS\JT.#T#X.>'?#6A:QIEC;W BU>#R+
MZ>2X8SW VE26?.<D'&:S#^SAX!6>9XM!CM(Y((8##:R,B#RS\K  C#851G_9
M'7%>I 9&<Y_"E"T@/#M8_97\/:OK]G/)<2KH<<#BYTQLNUW<&/RUFDD)^9E7
M&..W!KO?"7PI\.^"]16]TJQ-M<B)XBV_.0^S?]<F-#_+K7:$#I_2@+@T *AX
MZ8HZT44 -9>&QP:\0\:?LI>%?'OC.YUC4I;F32-0E2[U3PX0K6=[=)@1W!S\
MR.  #M(##K7N)Y%(% H @M;1;.)8HU5(HU"(BC 4#@ 58HHH **** "BBBM@
M"BB@G% !3&.%XH8@JPR/3%><_$;QM?:;=VOA_0I$BUJ[B:>2\G3S(K" $#S6
M08W,3PJ]R/:A)R=D3*2BKL[75=>L-$@2>_O[6PBD<1K+<S+&K-V +$ GVJ[!
M,'C!#APW*E><_2OGR/PCIQN?MNI-=>([E<QM<^(+@7,;$\G9$V$CW#LHR.F:
MT/"7C'4OAWI=UX8M_#FHZV+:=WTB6(JEN+1OF2*25S^[\LED^8'A5ZYK:5"2
MV,8U4W9GNWF#_)IV[@&O!V\7>/[:[76)[VSNI(VW2^&;* >2T.<%%N6(<S 9
M<' 4D;>XKH&^/5K:H+N[\,>([#1T ,FH7%EM$8S@ETSOV@]\8'6H=*:5S3VD
M=CUDX(P:BEB# $#D=.:BL[F*\@AN()5F@F021R(<AE/((/N*M=1^%0:=#RWX
MC_ 7PUX_NSJ<UK'8ZWE6^WQ0(_F%3E?.C<%)0#TW D=C7EVA?!G6OA3XA\0:
MOIW@?3M9N-;D$NHZEH%\UO-<,O0FVE;8I]D85]0[@2 1]*0A0"!C-92IQEJ=
M5/%UJ*LGH?/:>,+V)-LW@OQA:2=!&-,WY_%'(_'-2PVOCCQDYM](T.Y\)VQX
M?6]>53/ #U:"V4MND'8N2N>W:O?F;:"3C]*8$7< <9ZCGFI5-+<Z)YC5E&R1
MRW@'X?Z5\/\ 1_L6G1R2232M<W5Y=2>;<7<[<O+*_=C^0' P.*Z\(,9Z4Q H
M/8'TJ0,,=16J26QYS;D[L  .E##(Q1O7U%!< \D50B/R57HO/J37E7Q_^','
MC_P_HZ?V(NLW5OJMJS*6(,=OY@\W)!!*[>HKUD'/(I&4'L/QI60'S7X^\-ZA
M>^*8[GQ-X(U?6]*_L^*WT+3- O-W]FW22L"QD5D\MV38PD)P K+R>*XCQ'IG
MQI\6V>JV>JVVJ7%[;:M')]ELBT*J/,8)+!.-JF,1;=T>6RV6XYK[(,:YX!].
M!1Y2 @X.1QG'.*- !8@%&,],X]S2QQ;21SSSS3QVXI33 &&%IJ]*7/XT4 +]
M>E,,:E>G3I3Z* *E]9PW5H]O/$LMO*ICDC(R&5N""/3!.:^:[?X8>(_"GPI\
M3:5X6\-OH=[?7EW<S2VE\5N7MX[P,EO'SDF2WWJK*1C(&>:^GB,TA16.<8^E
M 'R)XDT[QK:6T-A\+M$\0_#KPK?7<L*S20M-<QWC+&(Y4MF,GEVP_>DH=JNX
MW$J.OJ7[,'A3Q!X3\)ZO9>);?4HKK[<K1R:G/YLDRB) 7') !8,<#N<= *]F
M,8#9^;CG('Z8IZHH P.@Q0 QHMQR5R*?''M/3 ]*6C_/6@!<;3BLO78;RXT^
M>/3[U=.NW&([IXA($/KM/!K3SP:8^T'J.>XH ^?-*\%7_P ;M<U,^*M?U35?
M VG3"S@TY818VVKS+_K99!'\TD0;Y0I.#@UZIKENW@#X?WJ^%/#4=S-8VVW3
M]$L8TA223I&O& JY.6/IFNIC10%&5QDX &!4K!9%*D\8YQ2LGN-R=SPKP7^R
MMX/MO!,ECXITBWUWQ'JA>\UC4Y3^\DNI3OD$;YRB*3M4+Q@#WKRWQC^P=*LC
M/X0\2K#:D_)9:RA<(/0.ISCZBOL;RUY I!M& 37-.C";U1Z.'S/%X5\U.;/S
MMU7]D7XIZ6[[=$L]20 X-G>* WT#8KZK_95&K:+\-;?PSXATV?1]8TF5XFM+
M@#YHB<HZ$<,O7D5[-C/3GTK)\1>'H]?TZ2$3SV5SC]S>6S;986]0>_T/!IT\
M/"F[Q1T8W-L3CZ485[.QLIMY.,&I  ?_ *U>8_#;7_%<^L7NB^(;W2KNYTS*
M3M;QO%-*IYCE"?=PPZ^_2O34^[70TCQ;6% Q2XHI,TK(!<48I-P/3FEHL@#%
M&***+( Q1BBBBR ,48HHHL@#%%%%%D 44450!0>E%!Z4 <[XX\4)X+\*:KK<
MT+W*641<0IPTA) 4?F1SVKQ_3[6[\Z]U+59%N=:U(I)<2PCY$51^[AC!_A&>
MOKD]Z]QU;3+?6K"YL+N(3VMS&T4L;=&4C!%>">#]\>F75I+/]M@T^[GL;:\S
M_KHHVVJQ]P/E_P" ^]=V$BI2U./$)M(X/XA_V:/$E\?$\<+0*8SI"WS2"U%H
M$&=@''G>9NW9Y/%;7@^W\9SZ--)::AI,&C/=S?V2NL6\TEW]CS^Z,I!&3G."
M>=N >17H );;&X4J3N =0P^HR.,>HHDG8)+-Y3W#K$\HA1@6E<*2(Q[L0H'O
M7;[!QDYBEB/:TU24;-=3G]*UC4TUN#0]>CL_M5U;2W%G>Z>S-#,(BHF0JW*,
MH96ZX.:VIK=+J":%I"L=Q \+,V2-KJ1S[9YQ7C_VK4-0T^Q\?2:W<KJEOH\U
MY"ZLO]G6ZN%9K/R^N"51#GYBRUZ]82R7=K;2>0ULT\44WD2GYHRZ E6/J.E*
ME4C535B<3AZN'Y9-K4W_ (*^+6&G:?X/U6TFT_6M+LU1?-(:.[B0[/.B<?>'
M3(X(KU;&>E>-_#+2V\1^.KO7FS'9Z'YFEVJ]&DF8*9F([ <*!WZU[(*\BJK3
M:1U4FY1NS$\8SS6WAC6KBW9TN8K"=XFC&6#B-BI [G.*^16^-_Q$\!Z?$+^Z
MDU;4K30[-@U_:,MO?2/OD,F5'RNR@)CL1[U]I2)O!XSQWJ"2PCD&&ABD'!PR
M C(Z8]*@U/E1/VDO%^AZ7K<ETEMJ&H7$C2Z9:O9RAD)DY@  ^?8A5L]>:=XK
M^.GCB7Q%)X<B$, C2U\Z_L+=Q(DXFM6E50<YC=9F&?1#Z5]3FR4RB7RX_,!R
M'*#=DC&<^N/Z4L=FB.6$4>\C&_8,\=!GN!0!X%\=?&GBW0/B1-:::;Z+PDNC
M6LVK7UB@:>P5KPH\L"D?.VT*&[JN6%>=W'QR^(-AKLM];QRO9FW%O'!/"SV5
MLF\*MT[$ L,*IZ_QU]B2VP?DJ#V(QP5[@_6F-:J\1C,410KM*E!@CT(]*8'A
MGAWXE>//$_@'QQJ?]FVL.J:;;Q#3;:!&<O*8M[R;CPX.<J!]*XBZ^,FJ^#M,
MM?\ A#]8U#Q?]LDA6^OM>BQ:Z?,4RT?F8!#.WR[?X*^KHH%C VHJ   !0!C'
M';VXJ%M-B\MHC#$8F;<8_+&TG.<D=,^](#QO]GCQ1XG\1^(/%Q\17%T\<,L9
MMX)TPD.X994.!D#IFO<LYJM%$0QX"CJ<<<U848% "T444 %%%% !1110 444
M4 %%%% !1110 4R0#(R/I3Z:Z[L>@YH ^:/C=XKU/3/B;JUM#XHU/1YK;1H)
M]'L+09BNKLRX92NT[\CC&>!67;_'SXD:K/J%I%I>F:9.EV;<1W44DDEF$1V;
MS$7KOV<'H-U?4<MA%-(CR11R.@^5G0%E/L>HI!8HLKR+''&[_?95&YO<GO\
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ML [XXIX;/7B@:,E?#M@NNMK"VBC4Y(1;O<CAFC'(4UJQC"^]#/M[4@E7..]
M-H<2!UII89Z\^E07%RL(=W(1%&2SD  =SD]A7RA\6_\ @H3X1\&:M>:1X5TR
M;QA>VK&.6ZBD$=HK@X*AS][&.U1*<8?$S>CAZN(?+2C<^M0X'H,<4Y6'3/2O
MS_T;_@IAKD=V#J_@.VDM03N6QO<RA?;<,$^U?67P5_:"\'_'319+[PY>LUU
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M2#7_ !,NH:9;@(UK:VPB-RJGY!(W7IC..N*]JMK98((XHD6.*,!511@*HX
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M3> ZC(^7OWKT^N;^(&L67A_PAKNJZE:?;].L+":ZN+7:&\V-$9F0 \9(!ZT
M6O!6JR:YX.T+496#37EA!<.0, L\:L3CMR36U7*_#+QC8_$+X?\ AOQ-IEN]
MIIVKZ?#>V]O( &BC= 54@<# -=4.M !1110 4A%+0.: (W3)SZGN*9)!Q@8
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M+GO@=A5KX,_%NP^-_P /M/\ &.D:7JNEZ3J&YK1-8A$,TT8.!(%#'Y3V.>:
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M>-/%(4Y!M+5P+6!AZ2W.PX](Z^EE^Z6P03R: 'YP.:BEE4 =3[ TDDJE&!)
MP<MG@#UST%?,GC#XK>*OV@_%%]\/_A'?G2]"LY&M_$OQ"C4-'9]FM;$GB6XQ
MP7Z)GUH VOBA\==<\5>,KOX6_!U;;4/&T:XUCQ%<KYFF^&HS_%+CB6X_NPCO
M@M@5V_P4^!&A?!30;RWTZ2YU;6]4E-UK?B/4R)+[5KGO+,Y[#D*@^50>!Z[G
MPJ^$GACX.>$;?PYX6TY++3HV,DCN3)/=2GEYIG/+R,>2Q_2NS /<T 1.5@C:
M9V"(BDLS'  QDD_3%5-+\0:;K4;2V&I6M_$N-SVLZRJN?4J3CI5J\M4N[:6"
M:..>WE0QR12KN5U(P5(/!!!QBODW0?V+-7_9[O-:\0_ 7Q:-#U#4;V2\N_#'
MB&!9M'O8RQ9+?* 20;,L%D4G /*T ?7 D#' ]QTIRX.<5\]>#/VK],M/$-KX
M1^*.@WGPG\93XAM[;5I%DTV_8?\ /K>K^[?/.%)5O49KW^&Y1ER"&4]&'0_0
M]Z .$^/7P^C^*7PA\6>&) &>_P!/E6'J-LP&Z-ACN&45E?LQ>/9/B3\#?".L
MW39U-+065\K<M'<PGRI WOE<_C7J;L&(/ISQ7SC^SP#\.OC9\7/AM(WEV;7J
M>*M*C)P!!=<2A1W D7_QZ@#Z0I330X/KC^=(S@8Z_AVH ?4;3(I(W#=C.W(S
M7/\ C;X@>'?AWH5QK?B;6[+0-)@'SW=_,(D'L,_>)[ 9S7@TGQV^)/QQ=K;X
M+^%1I'A^4X?Q_P"-()(+;;_>M+(XDG..A?8I]: /<?B%\3?"GPK\/3Z[XQ\0
MZ?X<TB+@W6H3",.<=$'5SZ*H)/I7A2_&'XM?M!(8OA+X:_X0#PE+Q_PG_CBS
M*SRISE[+3CAG[%7F*+[&ND\ _LD^%O#WB&/Q;XRU'4/BKX^ R-?\4$2I;$]1
M:6W^IM@.P52PQUYKV36=>TSP[92W^KZC;Z9:P@L]Q>S+"BCN<MC''- 'DGP\
M_9*\%>$-6D\1^(/MGQ(\;7$9CNO$WC!Q>SE6ZI#&?W4"=@L:# X)->SZ?86^
MFVD-M;01VUM"@CBAA4*D:@8"J.P]A7@&J?MI^#]2U&?2?AWH^O?%;68_E\KP
MO9,]LI_V[I]L2CWR>*XOQSX4_:I^,UWH-W8ZQHOP5TR*[!N;'3KS[??O;G[Q
ME8IY60.BC//>@#Z^#@],^E.JCI%G+8:79VLUU+?301+&]U, 'F( R[8 &3UX
MXJ]0 'BHY' '7MGIFG.^SDCWXKS?X]_&+3_@?\-]2\37=J^I7@9++2]*AYFU
M"_E8);VR#J2SD9QT4,>U 'F'[1VJWGQH\=:?\ ?#EU);+JMLNH^-]3MR<Z?H
MP;BV# _++=,#&.X3>V,8KZ%T71;+0-+LM-TRSCL=-LH([:UMH%VI#$@VHBCL
M  !^%>6?LU_!Z^^&7@Z[U'Q)<1ZG\1?%%R=9\5ZDARLEZRX%O&>T,"XB0#@!
M<XRQKV3<(URQP .6/2@!_7&!BFLX7.>U,>[BB5I)'5$0$L[$ */4GM7@_C']
ML#PI!K<WASP%I^H?%3Q<AV'3/#*"2"!O^F]T?W46.^6S[4 >];\L,9S]*\=^
M*G[4W@#X7ZPNA7&H77B3Q=-Q#X5\,6QU#4Y3VS%'G8/>0J.:XK_A47QC^-R,
M_P 2_&@^'WAN7_F4O DV+F1?[MQJ##<?<1 #_:KUSX7?!;P7\&=*;3_!OANQ
MT*.3_73PINN+@_WI9FR\A[Y8F@#PCQIX!^.G[5'AB_TC7);'X&>#+V/*65J_
M]H>()V!#1F65"L5N,A<K&6;&Y<C->W_ ?X/6GP,^'.E>%+74;_6YH!YM[JNI
MW#SW%Y<,!OD8N3@$@ *#@  >]>B '@Y^OO2[0.F?SH %&!S5>]+"-PA*N4(!
M'7..*LU#+N\Y=O'&": /&?V1=8\1:S\$-.E\6S:A<:]#?WUO--J<9CG95N9!
M&2"!QLVX/IBO:^0.:\O^!7Q>D^,FA^);^73AIK:1XBOM!$:R^9Y@MW"B0^F[
M/3VKTUI JG/ZT $D@1<DD=N*\4^._P <K_PEJ5AX%\!V,/B/XIZVA-CI\C'R
M-.AZ->WA'W(5Z[3RY  I?CO\=[GP;?6'@KP58Q^)/BCK:'^SM+)/DV471KR[
M(^Y$G7!Y8C K4^!'P&L_A%I=_>7E_)XD\;ZY)]JU_P 2W0_?7LW94_N0IT2,
M< 4 ,^!GP(L?@WHM]//J$WB7QIK4PO/$/B>\&;C4KG&/^ 1)T2,?*H XSS7K
M<8P@SUQ21KM7! ]Z?0 4444 0R@[NG'/-?,OP(\$^'-%_:M^.=YINA6-A?YT
M\&Z@A"R'S$9I.?\ :8 FOIV3[I&:^?/@WQ^U'\=/KI7_ **:@#Z%3A12T@X%
M+0 4444 %%%% !10>*1FQG\J #-&>OM7E7Q4_:9^'?P3U6TT[QGXC31KRZC\
MV)'MY'#+TZJ",D\8ZUVNA>.-%\0Z;'?66JVLT$D"W.#*JLD;#*LZDY7CUQ0!
MT!/!%>2_M1_#BX^)_P $O$VE:>VS6[6%=4TF4<-'>6[>;$1[EEV_1J[Y/&&C
M2&W"ZSI["X_U.+J/][SCY>>>>.*K:AX[\/6,MG#=:[I\4UY=&RMU-PN9K@<F
M)>?O =J ,CX(?$,?%3X5>%O%2PRV[ZG812S0S1E'BFQB12IY'S UV6H7<5A:
MS7,\@AMXD:665NBHHRQ_  UFV^MZ1':RS6U_9):6TACED29!'$V>58YPIR>A
MKDM6^._@.Q^&-WX]OO$5G!X*MY6MY=4E_P!4&$_D,F.^7^7WH \W_8^L+OQM
M:^,OC-K%O)!J?Q"U(SZ?#.N)+71K?,-C'@\KN56E([F2OHB\NHK.TDEE<1Q1
M(7>1C@*H&23["LU-;TJT%I:B]LK<S1J+: 2HC2*0=@1<C.1T XXKCM:^/7P]
ML;&^>\\26$]G;K.MY+$WFQQ>4ZQR*^.F&< @T >07OB'Q'^V3J=QHWA6\O/#
M'P9@D:'4?$L),5YK[+PT%F>J0\$-+WY KZ+\'>"M%\ >'+#0?#VG0:3HUA$(
M;>SMEPB+_4GJ6/))Y--L-2T#3-$MI[6[TVTT90([=XI4CMQGA40@[1]!5+Q7
M\3_#/@N6TAU?6;>SNKMBL$&X-(YVEONCG& 3F@#K5&.^13LUA:/XNTK6H+66
MVU&W87-L+N-&D57,)&1(5)R%]ZNZ;K5GK-JMSI]Y!>V[$@2V\@D0D=1D'M0!
MH<_2FNK,F-V#V([4J]!GGZ4X\4 <]XQ\#Z!X]\.W.B>(]'L]=T>X4+)9:A")
M8R!W /0CG##!%>!GX)?$7X"-]J^#WB,^(/#4?S-X"\67+2(B_P!VSNSEX_97
MW#C&17TGJ5]%IUE-=7$@AMX(VED<_P *J,L?R%<EX+^*WA3XC74EMX>U:+4I
MTL;;461 5*P7 )A?IT8*: .4^$O[1^B?$S7;CPQ?Z9JGA#QQ:QF2Z\/:W"4F
M51U>-Q\LB?[2GI7(?'A'\ _'SX2_$2*%EM+BXE\+:L\:$XAG&8F;'82 <]LU
MZ+XT^,?@#P)XTT71_$.K65AX@U$!+/S8LO&A./F?'[M2QP,D FNQO+O2S?I8
MW-Q9M=L/,6TG=&?CG(0\\=<T 3:YKUCX9T2]U75;F*QTVRB::XN9VPD4:\EB
M?3%?/<W[0/CCXTR/9_!3PKC2F;RW\<>*(FM]/4=S;Q??G([' 'O7O,VJ:'K=
MA>Q/?:=J%BJD72/+')$H[B3G 'UKDX_C=\/X=/6>#7[(:?;ZDVAJ8!^Z6Z1"
MQB&!@853TXXH XKPA^R9X?M=<A\5?$;5KSXI>,80)$O]?P;.S8<G[/:#]W&!
MV)!/O4.N_MF>"TU)]'\$:;K?Q.UR$F(V?A>R::*-U.,/,0(T&>.O:MOP]^UK
M\*O%.GW=[9>*XVL+>6WMGNY[>2*'?/)Y4(#,,-N?C(KN/A_K?A.^L=5M?"/V
M&*TT;4IM+O8;"%88X+N+'FQL  ,C<"30!X]Y?[1WQ4D5L^'_ (-Z/)S_ -!7
M52I]AB)#[9.,5H:)^Q/X%FOH]3\=7>K_ !3UI#N^T^++QIX5;_8MEQ$H]MIK
MV_3-8T[6#OL;^VO@!DFUF60 $\'()XR"/P-:@7:: *&DZ#8Z#81V.F6EMIEE
M$ $MK*%8HU'H% Q5P6R^IJ6D8X^M ""G UX_X_\ VK/AE\,?%Y\+^)/$RZ;K
MGR;;0VTCEMW0*0N"?ITKTO\ MZS2-I'O8$1(UE<R2*I1&^Z2">,]LT :,[%
MI&.O.>@'K7R_\-+>7]I3XWS?$Z]21?A[X*GN-,\'6<P(%[?#,=WJ;(>N/FBB
M)Z ,1R:^D%UBPFDN4%_:N;,XN0LRGR>,_/S\O'/-<;X@^,/@+P+;E=0\0Z9I
MEI!IK:L&1@(5M?-$?F KP=TC;0!RS' H [B6:+3K9Y96\NWB0LTC=%7DDGV
M&37S]J/[6DOCR^ETGX->#[_XB7Z,8VUB3-GHUNV2"6N7'SXP>$!SBNHMOVJ/
MA7JOA?2]8'BVRDTK5=5308GE1E(O) <6\B,,J2O.&[&NH\&?$#P;K6M^)/"/
MAZ^LEO\ PH\4.I:=:H(X[%G7<HXP!P">.G.: /*(?V:/%'Q:*W7QH\=W.N63
M\_\ "(^&"^GZ4@S]V1@1+/Z') ->Z^$/ ^@> =#AT;PWHUCH6DQ *EI80+#'
MZ<A1R?<Y)K@=+_:G^%>KS>($LO&6GS'0(VGOVRPVQJ<%D)&) #Q\N>:KWO[6
M_P *[#P?I_B>7Q7"^CW]P]K;O##(\CS*,LAC"[@0/44 >R(@0 #H.E+L!K*\
M)^*-.\:>'K'6M)G-SIUY&)8)2A0LI[X(!'XUKT %)GD#UI&)&:X7XG?&CPE\
M&])M=4\8:U%HUG<R>5!O4N\K8R=J*"Q"@$DXP!0!W8.::S$,!7$Z!\9?!?B?
M6XM(TSQ+87FH3Z=!JL$4<PQ-;3LXBDC/\6XHPP.?EKIUUJPEDND6^MG>T_X^
M4$JYAXS\_/R\>M '$_"23P3&OBJR\%VZVJVNM3_VM&L;(#?MAI&^;KG(.1Q7
M._'7XZ77@2ZTWP=X-T[_ (2/XEZ^C#2M+'$5N@X:ZN&Z+$G7W/ KM5^(GA.'
MQ-'H4>LV*ZG>VC:FJ1,NR2!6"-+O'!&X@9)K5M[K09]:EFBN--FU6& QRS(\
M;3QQ Y(8@Y"YZ]J .!^!'P+MOA+8ZA?ZE?2>(_'>NL+G7O$=T,RW<G:-/[D*
M=%0<8KUM$V _7O7+GX@^'HM8M=/.JVS7%S;/>1.D@,30HVUF\S.T8)Q4[^/O
M#Z:CIFG_ -NZ>;W5 YL(5N%)N0GWBF#SCOB@#HQTI:9"Q:,$\FGT %%-;H:X
MOXG?%[PI\'=#BU7Q=K4.D6LTGE0AP6DF?&=J(H); Y..@% '9R9QC'4U\_?!
MV)T_:>^.+R1R)&YTPJ[(0K8B;H>_X5Z))\;O!&SP>X\36,B>+I3!H;Q2;EOW
M R0A^E8NG?M)?#74/B-/X*M?$5M_PE(N&LY(&A9 TRC)C\S&TMCMG- 'K*@[
M12D$5Y%\2?VJ/AK\'_$4>@>+/$8TK59$1T@-M(^X-]T J""?:O3]*U6'5["V
MO;9_-M;F-98I,$;E(R#@]* +U% HH ****  TC#/MSFD,@ SV'7VIBW"GOCU
M'I0!X[^TM\+-4^*GAWPU::/;V<EU8>(;#4IFNPHS;PRAW )'4@<#O7SGK_[)
MOQ1U_P")GC'5Y$TR.PU>VU&T\RVNVCCN8YG4PJ8QRNT*03Z]*^[6*]2<<$_2
MC(7G.1UP!0!^=7[0OPBNM'\?Q>$M T)[N]U*VTFWT::VMY0-$\HXF:%E^0@G
M+DD]N:W/#'[%GCS2#I%U>I!J.H:7J&#)>7^]90UO)%]MC&/D=6=6_O-CVK[U
MPH88"GOGT%*%4@%LC_&@#X3\(?LA?$#P_P"#+:UOH8M8NK/6M.O;S2[K4R;7
M7(K99%=C@81F9U?YL[B@S6TO[)?Q$\0? ?X9?#*6]TKPMIVGZKJ6K:Z\*B\1
M \L[VD$:/Q(O[_+$]"BD=*^TT(4=1UP".?Y4]64]Q[$<YH ^(C^R9\0=8\+:
M4^NIINH>*] \*:?X?TK5$NG4^=::FTB7 S]QFMMNX]=Q(K+U;]CKQ^VE>.M.
ML-+T58=1DUV6W87)1+W[;=0S1+(,?+M6-E)]Z^\."1R"#R*5B$X)Z?G0!\,R
M_LH>/&L4O)=#TF[TQM6N+Q/ $FH.+.V$EJL*S++W9'!DV^_K5.W_ &//B18:
MU9QW::;XDN8KC[6?%MU>,+H1_9&B%IL/\"L1@^G-?>#%>.00>GO0LBGC/ H
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M4S)DLK ':<=173?"SX[>)_B7\;-/LKBQAT;PC?Z'<:AI\,5XES)=A)_+$D@
M!B;@_+R.V>*])T']G/X<>&+"2RTGPEI]E:RQ^7)&BGYUWB3DYR27 8DYY%6_
M!_P+\"^ /%.I^)?#GA>QTG7=29FNKZW4[Y-QRP&3A03R0,#/.* /%O$W[:T7
MA;Q_KF@2>'K;4;>VBF%E=6&I!C)/&RKY<Q*A(\EQG#-M[US5Q^V+XI\!6/BJ
M[\2Z+87>HV>M2Q#1H=3#-!:QQH66!D0F4_-G<P51W(KWN+]F/X8IXCU?7AX+
MTXZIJRRI>S.&991(,2?(3M7=WV@9ZFLRX_8_^#\VBV.E/X!TLV%G,\\</SC<
MSC#[FW9<' R&)' XHT \G\:?MGZ]9^&O$.I:7X3L[&R:/4+/0M1NM329YK^V
M@\\>=;@92(KNRV<@@9 !!K9T3]J.]TJZNM.U?29KS6KNZ@MK)'ND$,U\R6WG
M6T6%!"(D_FY.20&KO/!'[)_@#PGK'B75Y=%M=6U77&N8I[F[B&5M9L!K8 '&
MT* N?O$#!-=;I'P2\%:&^D-:>';.W.CWC:AI[!2S6]PT(@,BDGJ8@%_+T%.X
M'GW[/W[3K_'CQ%K5C'X5O=+TN.+[;INJ2(_DW5L9FB <LH D.TMA2PQWS6#-
M^UO>Z;J6L-JGA:RT[2$N=3L-+OY=93_2;BR.'\Y=N84?/'4@C!'(KV+P3\&O
M!GPUU/6M2\+Z%!HMWJ\OG7CV[-ASDG"J3A%R2=J #)Z5Q_AO]E/X>:1-XLN=
M2T6WU[4/$\]Y)J-[>1_O)(KB3>T(P<*!A1N7#':"23S2N!X;XG_;#\8Z_P"&
M&NM"L-/\/O;VVJ17SM/YC"XMA$8VAWJIVMOP=P!&>E=DW[9%UX<TQDU_PD(]
M7A5H3;VFH"3SITV&4*2HX$;[^/0_6O4[3]E_X7Z;I%GID7@ZR^P6CR21Q2/(
M^6D0)(7+,2^Y57.XGH*W9?@QX)NI8YIO#FG2R1W$EU&TD>XI*\?E,PSZI\OT
MIW \/U_]MJ#2O[$OK70+>YT2_N53>=0)N7@>411SHBH0$+'J[#..,U:\0?M>
M7MCH.MW6F>"9]1O]'*PZE;FY+)93-(R[9-JEMH10YP#PPXKTO5/V9/A;K$NB
MM>^"].F71H%M[%!N5(HU;>B[00&"MR,@X/2LS3_V9?"UYH7BC2_%6_Q<?$FI
MG5-0N+I/L[LX&V)4\HJ5")A0<Y/.>M%P/0? /BVW\<>#M(\06<D$T&HVR3JU
MM,)H@2.0K]P#WKIA65X?\,:;X4TBSTG2+2'3M-LXEA@M;9 D<:#HH [5J]*3
M ****0!3).U%% #&Z"I(ON'ZT44 .I#T-%% #7IT?0444 (WWA]:A?[Z_0T4
M4 6'Z+]:*** $/2D/W*** (_XJ7UHHH !]]/\]J=;_=;ZT44 ++UI!THHH *
M<G4_2BB@!C?='U%,;_4'_>/\Z** )9ON+3(NIHHH >_2E'0444 (_2HW_P!6
M:** !_N+]*>GWQ]!110 DWWF^G]#44'W9?\ @/\ *BB@!Z?>6IUZFBB@!3VH
M/0T44 ,?[IJ%NU%% "4].E%% #3]XU*G0_6BB@!P^\*;)]]:** (5^\_^]3Y
M.E%% #A]]:CMO]6?K_6BB@"9_NK4+_>-%% #F_U?X4U?];'_ +M%% #D_P!8
,*E'2BB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>form10-k_0002.jpg
<TEXT>
begin 644 form10-k_0002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #K <(# 2(  A$! Q$!_\0
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MF5*W*C]%RO+8UZB@]$>K7G[0EI;)C7_"]W:V3_><;)U]\BNF\*7-O>VJZ_\
M#C6/L18Y?3WRUI/G^%HSRA/JO2O)R6D0[OF]0>15&%;KPUJ":QX=;[)J$/SR
M6D9Q#=KU*.O3)'1NU<\,5J?08_AJFZ3E3U:/L3X9?$R+XA:=<[K:2PU:PG-K
M?64A!,,H]#W4]0:[V,Y4'L>>*^8;'Q:B6VG?$SP^IP8E75K0#'GP9PP8#_EI
M&>_7'%?2FGWD.H65O<V\@>"9%D1E/!!&17L4ZG/&Y^/XO#RP]3EDK%X=*CE
MR,U(O2D=01S6K.,\>U_3_P"S?$]]98*K='[7;MV.>'7],_C7/WML6^8?E7L?
MB/PW:^(8%24&*>++0SQ\/&?8^GJ*\YUCPYJVEL?M%F;R$' N;1-WXLO4?AFM
M*<N7<35SCI[5A<)<1.(KF)<!\97&?ND=P:=+JGV4J;ZTE@)Z/$0Z'Z=Q5^22
MV1]C3-&PZJ\9']*D@:-^+=9KC'\$43,?RQ5<RZ,7*5[*::]0FU0VD+?+]JF
M+G_=7L?>NP^&WAU+W4!=JI^PZ<S)$S-EII_XW)[@=,U'HG@C4=9F$E\K:;9G
M!*_\MY![XX05Z;ING6VFV\=M:Q"&",;511@ 5FW<:+L)!4X'0X^M24U!A>*=
M2&1G.TD8_&OF#]M3PHS>']/\56Z[C8-Y%RH'/EN>#^!KZA(!!%9FNZ%8>(-)
MN=.O[>.[L[A"DD4@R&4]:XL7AUB:3ILEJZL?EW9ZE#,)+6YRMM<CRW<'./[K
M?GBN2\3:-+:SR6\YQ/&V/4'W!]#7U3\5OV+-8TZ:6^\#7:7UF22-+O&PT8_N
MHW<>QKP?5O"/C;00UIKW@K5;A(SL$@MV++[+(N<CZU^?5,OK49643CE#EZ'D
M7]A;I7+ 9KI-"TXJ42-296P HY/MQ76VG@/4;UE,/A'Q/(['&Q+'()_WJ]A^
M&G[+?CCQ-=127=@G@K22/WD]P1->NO<*.B_6IAA*]5\JB"A*3*'P/^'-S\0?
M'&GZ* JZ=HQ6ZU*4'C?D'RE]>0/UK]!X(EA145=JJ  !V KD/AO\,M"^%V@)
MI6AVHBB)WR3N=TDS=V9CU-=JJ@ 5]QE^"6$I\KW9UP7+H!P,UEZWHMCKL"0W
MMNEP@.5W#E6[$'J#[BM0#.<TTJ#T 'O7KHKS/GWQIX8\2_!/5M1\:>%+F?6M
M%G/VC5]"O)2S8 YDA8]" /NGK7H_P^^+7ASXC^%K;6M,OE6VF3)CG(5T;NK#
MVKL;FWCG5DE57C8$,K#((/!%?GS^TQ\([CX1^,6OM',UOX<UF1I(T@E9(X)_
MXD(' !ZBL:M1THN:6QZV PT,?45&3Y7W/IOXM?M.^$OAW#):K*^K:Q(K)%:V
MX!7..[>E?,7[/O[0:?"GQ1K4NJ6[-H>M3FYG2 <VTI/4#N.?TKY\U;Q EE(1
MAS*>>/F8_B:=I/B2*\<@KACP4;J:\>>-G)W/TC#\.X6C1E1EKS;L_5WPC\3-
M \;Z=]MTC4HIX3W/RG/T/2O)/B+\:=/\;^(#X2TNRO\ 4]'M)=VLW=D@VX7!
M$*DD9W'J1V&.]?#ME<RVSHEM?7&GPS.JRO#*RA4) 8X!],U]T_#OQ;9Q>'K;
M0OA/X8CU6S@4"36;IA%:;OXF+\M(V<YP/QKTL/B?;*S/B,VRA95-*]TSU#P#
MXV'B'0;C49](E\/Z= QCM_M;J"\:C[V!P![5VMA<)=6L4T4OG1.NY7]17S5&
MT.O>,]4TCXG:M>/'8%=L$<@M]-F++N"JBG>^!G[QKT:T^.O@/3(S8VFL(L=H
M!$L$43X '&U>.>/3L*[$[GS35F>L45Y[J?QC\/Z?X(U'Q7'>->Z39LR%X%P9
M'!QM3.,G/'I63+^T1X.\ZV@BU-KBXN-NV.)"PC+*7P[#@8 Y.:8CU<U3U"#[
M3"\/F-%O0C<O5?<5Y[_POWP.C;6\0PK)O,>"#U"Y)''(P.HXKK_"/BO3/&VD
M1ZGI5R+NT=F57P000<$$'H: /A7Q7\.M0\"^,;OP1:1ZA%XD>4ZAH/BAKDI9
MZ;:D[I[B0 C=,6+9!!SP.!7T9\"/BQX?;4?^%=_VMJ5_XFLXC<R7.J@%KP$Y
M,JL"1M.<@=J[OXQ?#:S^*/@R^T.YG:S\S;(LZC@%&#!7'="0,KW%?!O@.:?2
MOBA<2V?B"PT[Q-8VLIC\2WFY-%M+=6.Z&SB<[I3C(R3@9;'04 ?IC&<GJ3]:
MDKQ7X5?M":5XYTKPY;:G.NF>*=2LWO6TOG(@4E?//]R-\94G^]7L4$ID*D-N
M4C.0>/K0!8HHHH **** "BBB@#+UR"YN]+NK>RN39W4D;)'<!=QC8@X;'?!P
M:^)/%^L>*O&'Q!T?PK\1-2OH3I -E<1Z&[P2?:)&Q;:JNW[\?12O1&Z\5]UN
MA/0#WS61=^&=.N=8AU5[&WDU.&,PQW;H/,6-CDJ&ZXX'% 'CWPD^!VI>'DU&
MY\0W<,\FJJ8]6TV%5:RU!ERHN=A'R2.NTL!P2*]SL;:*TLX8HHTBBC0*B*,!
M0!@ "I(X1&N .E2 8&* # ]*6BB@ HHHH 83R?I7BGQ\LS;:CX<U58()E\R;
M3Y%N5W1'S4(3>/[I8*#]:]K/)-<OXY\)0>-?#%_I,[F'SU(CF7K$XY5A[@X-
M1--K0VHS5.HI/8^'-=T*^?4+L^*+:RU.^O\ 0)K6>RL42'1H)(V^5'N00R$_
M+Q[TV;5-.@31;V&?3(5%E#INIVFF70GBT^=03$K/U(()&3Z5U,GPR@\+Z@?#
M.LQVVA:/<R3W>OV%S$TT&O'&1+#*3\C9&2G7TKB_!6KP/HFHCPGX?\,:E9>)
MM1$5AHDH-C<2VD7RR.P;EV7'45Y=:FFN5GZ%@,8X25:+O8Z- O48/T.01ZY[
MT?Q @CCH*VM4^$NM>%;:.?0+87]@ZAY-':7][:N1\RQ.?OKUX-9%EHWB?6)?
M*T_PM>QR$@&742L,2?4Y)./:O+>'E%Z'Z)1S?#5:3FY6.P^"!!L/%^FR+FPB
MN2WE]1AX\N/SYKW_ .!$DLGPK\.F;+$0;5W=0H8A?TQ7A5AX;G^'_A.71(;@
M7WBSQ%*T8\@8R[C:64=D1>]?3OA70E\.>'M-TR(_N[2!(@?7 QFO<P\7&"N?
MC>>UZ=;$.4#= Q4<@R1DGZ5(.E13*6Q@9Q[UWGRYRMK\3/"UY>/:0Z[9/=)=
M261B$HW"=%W.A'J!S6O:^(M+OKR6T@U"VEN8D61X4E!95/0X!Z'%>!^(OV7=
M5NM5OM1TG6[6QNKR[O+J8-!N61I@ A]F49&>X-<G:_LVZ[\/M%$EQXNTBU<+
MY+7E]N7Y"'&PMN&=H;(]Q0!]0ZAK^C:?:SW5S>6B00(SRR,ZG:H^\3]*CNO$
M^CZ2EA)<7EM;17W%LY('FG;NX_ $U\N:_P#LW7$MAX?GB\<:7::):P-#]H9R
MJSNY;>2=WS[LCJ>U>P?%;X,P?$[P?X9T>YU4V&GZ5+'-+<P2>6TBK&5^5P>!
MD@^]*R [6#XG>&)C8@:Q; WTA2URV/.(_N^M=%;:G:7$D?E7,4GF E-K@[P#
M@X^E?-]]^S'KWBF(33>+H!-]V*ZLXL;46,(I7G"DXR<>IKKO@O\  C4/AQK
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M&#Y+'46QP=I^1B?0@&OD1E B?"#:1TS7Z9Z9X#TSQ;\*=$T>ZMT:U%G \+*
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M(V++SUSS0!)28S2T4 1R+N4KTR.M?,_[1F@WGP?\3Z?\9_"L$GF6ICM/%%G
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M;R:];^,/B/JTGC[Q@O[R)[Q<6-@>NVW@^ZN./F.3Q7N\4(5=N%  P !QCZ4
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M;I&/KP* /$SX\^/'Q+'_ !37@K3_ (>Z6YXU#Q/<>?=%2,[EMX^ ?9FIUO\
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MW?*Y"A0,Y([8KYZ^*7[:%H?"'AN\\!ACJ>J^(%T:YBU"T??9$ M('0#(;;C
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M@^+;_7+5M.O?$/B.]U<63L"T$;L%0$CU50?QKVT'(S0 M%%% !3EZ4VG+TH
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MO>EI%[TM !V_QIH0#L.:=10 WRP<<=*/+4'.*=10 P1J 1C@TOEJ3D@9IU%
M##&#G^=(R#:![XJ2FGM]: $6%1]?6@Q@@CL1BGT4 ,\I<8P/RI1&!G Y/>G4
M4 ,$*C/')ZFE6,*H '2G44 &<]Z/Q-%% !3=BGG IU% #2@^N?6D,8/:GT4
M,\I1V[8H\E?0?E3Z* &^6">@SZXH,:GL/RIU% #3&,8[4UH$;JHYZC%244 ,
M\M3@D XZ9I?+4=J=10 PPJ3D@4JH%' Q3J* &^6*#&#^%.HH :(U ' XXS0(
MU]!Q[4ZB@!H0>E C IU% #?+7=NVC/KBA8P.@%.HH 9Y2]<#-'E*>U/HH 8(
LE'84HC"C  'X4ZB@!JH%IV .U%% !1110 4444 %.7I3:<O2@!:*** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form10-k_0003.jpg
<TEXT>
begin 644 form10-k_0003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %< ?0# 2(  A$! Q$!_\0
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M3^%OD?\ [XK-_9D_:K\<_%[Q?;Z5=^-?"6IW%_8N\NCRV4NGWVEW6W*HJ/\
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M/F6O9/VE/VEO'_PIN;J/P]XL\)Z#IFB:+!=6VDS6[W^H7[>4K;)47_4)_MT
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M@Z:NH:EJUE8V#?=NKNX2*)O]UJLV^L:=>:8NHVU];3:>Z^;]KAE5HMO]_?\
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MO]K;0!XM_P %$&!_8R^)^[_H')_Z-2OAKXC?#/Q%\/?!/P9UWXG>,?$7C[X
M:K;Z=-J>GK+Y2:9.R)Y6[^_%\WZ5^L>M:-9:]I\MAJ%C!J%E/Q+;W,2RQ/\
M[RM5:_\ "VD:EHIT:[TJTN-(*+'_ &?-;JT&S^[L^[0!^4OQC%CXO^//QT_X
M3/7_  EI5K%9P?\ ".7WBF6??;Z<T2^5<:;Y7RLWW/N?-74?&/1WU73O@0VJ
M^/\ PWXA\1P>%ITBL?'5M+;Z/K*;ODE\UOE2?;M^_P#W*_1C6/A'X.\0?V2=
M2\*:+J#:6BI8M=V"2_9D7[BIN^[5[Q3X \.^.=.BL?$7A_3=;LH_G6WU"U25
M%_W5;[M 'Y2?$'Q]H_BS]A738XO#,W@_2M)\<Q6ET;*^ENK2X^?][+:L_P W
ME?["5W^D3>#]+_:9B3]G:]DN4N/ E_+K$6FRRO%]J\K_ $=Y?^FM?9'[17[,
M<'QL^'WAWPKH][:^$[/1M8M]22.WLU:)UB;.P*OW:]4\,^ = \'/<3Z+H>FZ
M5<77SW,UE:I;M.W]YMJT ?D,)_AY;?LQ>!=8\"W]S<?M/R^(;<L%GE_MA[WS
M?WJ2I_SSV_WZ]SA^$WA[XJ?M+_M52>,[%-2;2- L+A+1I&\J*Z?3]SR[4?[R
M,E?H#9_"_P *6'B.7Q#:^&M)MM?E&'U2*RB6Y;_@>VM"#PGI,%W?W46E645Y
MJ*A+V9($#77R_P#+5MOS4 ?DQ9V:>*O@9^SG=7WC'1O[6CL;^*UT3QS%*VB:
MDJRML267[JR_W-]6]:^(-]KW[#&NV/ACPPWA+3-+\:066N-IE[+=:?/ W^M>
M)OX8/[VSY:_4J_\ A9X2UGPW'X>O_#&DWFAQ?-%I\]C$]NG^ZG:M&P\(:+IV
M@)H=GI%A;:*B>7_9T5JHM]G]W9]V@#\X?@YH^BV'B/XJKX>\?^'=-T*?P:ZW
MVG_#V"ZN(;5MGR72,WR^;_LI7&_LR:IH_P /OC9\(+'^RO"7C/\ M=OLFF>*
M?"%Y+;ZFO]^6_@_B_P!KS:_47PO\._#G@:TFMO#F@:7H-O,S-+#I]FD*2?[V
MVJ_AWX4^$?"6M76L:)X6T;1M5N_]?>V6GQ132_[S+0!Y?^VSXQTCP#^S/XSU
M37M%O_$.E-$EK+I^G3O;O*LKJOS2K\R)_>:OA[]G>?2M#_;1\.0Z'<^$K32K
MWP;<M+8^#997MT_<,R+<2O\ ZV>OU0U#2;?5K">SO+:*YM9T:.2"9-R,O3:R
M_P 2US^A_"KPAX;CLETKPQH^F"SW?9OLEC%%Y.[[^WY?XJ /S>^ _P )9-+_
M &*OB!\4?"-G=W?Q3_XFEK9W<4KO+;V_F_.L2_[N^JW[*^E:?_PLOX)7WA?Q
MGX0L-;EMG;4;'1'NI=0U2+;^]2__ (5E1O[]?J'HWAS3M!LS::7I]MIMIN9_
ML]I$L4>YOO?*M9FA?#/PIX4U>^U31?#.E:1J=_\ \?-W8V:12R_[S*M 'S'_
M ,%(H+6\\ _#FWU"WBN;"X\9Z?#<0R_<E1LJRU\N>(?"'B']GW]JGX,_!F_B
MDN?!5IX^BU_PIJKM_JK6=]KVO_ 'K]4=7\,Z9X@C@CU33[74D@E6XB2YA5_+
M=?XO]ZFZCX5TG6KNRO+[3K6[NK%O-M+BX@61X'_O(W:@#\F;Q_AIJ?@K]H/4
M/BSJ4\'QPA\1WBZ2EU/(E_%M;_1$LE_N[J]#\->!I/BS^U'\#]%^)]K<WEU+
M\.EN-3T^[D9/M$J[]GFK7Z(ZS\,O"FO:_;Z[J?AK2;_6K7B#4+JSB>:+_<=E
MK6;PQIDNMKJ\FGVKZJD?E+>F!?.5/[NZ@#\^OV7Y/BEX:^$OQ#T?X)V.CZE=
M:7XZO+5+'Q#._E06?]Q*@_:,N_#>O^,O &D_']M0^%/Q&_L=Y8OB)X;NO*T^
M%MS_ .B[_P"*OT-TGPYIFA"Y.GZ;:V/VF7SI_L\2IO?^\WJU5O%'@O0_&^G_
M &'Q!HUAK=D?^7?4+594_P"^6H _*NZ^)GB#Q%^SG^TWX6/C-OB;X.T*RLVT
MSQG+#LENI7E3=$\O_+7:E7]!F^'5GXR_98N_@Y?2W/Q+NKB*+Q(MG+(UU+:^
M4OVC[8K?[>_[W^U7W[\;OV=-*^)/P#\2?#'PZNG^#+75H$ACEM+%?*BVNC?Z
MI-N[[M;_ ,./A+H'PWTG2/LVEZ8_B"TTRVTVYUN*S2*XN4B39\S_ 'J".;D/
MRFT:S?7M/U[4-=\8^%_"WQ/_ .$RD_XF.J-=2^(XI5G_ '421)_RP9?^ U[1
M\1;OX?ZA^U%X^LOVD]01-/B\-V[:$UPSQ6[_ "_O6M_^FNZOT!G\#>"[GQ,G
MB*YT#19O$,0VKJSVD37"_P# _O5-XK\%>$?&[6[>(=#TG6VMVW0MJ-K%-Y7^
M[NJ>8CVM+^<_/RYOO#DWQO\ V-?^$.N==N?##?;ULYO$#-]JEBVM]_=3_AU\
M*?!FA?%7]LF^T_18;:Z\/V$\6G2KN_T=9;25Y=O_  *OT*?0M!GO+"ZETW3I
MKO3AMLY7@3=;?[G]W_@-.30- AGU*==/L5EU-=M[*L2?Z3_#^]_O4<P>UI?S
MGY@ZQ?0I^QK^RA'XEN+B#X93ZMM\42PL_E&+SFV>?M_AW5]9?L?3_!.W\=_$
M:Q^#=_JEQ812Q/>)$S-H\;_].K?=_P!ZOH>;PUX:E\-?\(^^DZ8V@[/*_LUK
M=/L^STV?=I?"WA_P]X,TQ=.T'3=.T6RW;_L^G1+;IN_W5HY@]O2_F.I5@:"?
M:J(U. =9E_%JGAN5F;Y?_0JH(U83^&18WT;Z9_'0OWEH-B:BBB@ HHHH ***
M* "BBB@ ICT^F/0!E:U>#3M)O;KM!&\GY+7Y/_$/XL>)?%OB6^U#4M2N;AIY
M69$\]D2)/X$14>OU5\:D)X5U;_KTE_\ 0*_'?7O^/Q?]VOI<@PU+&XOV50_+
MN,*]6G[.,9%P>,-3/_+>?_P*E_\ BZ=_PF.II_RWF_\  J7_ .+K!_BKH_!G
MA6#Q:^H*VI_8'LK5[MD>+=O5:_2ZF19;2CS2B?F].IB*LN6,R+_A,M2_Y^)O
M^_\ +_\ %T?\)EJ7_/Q-_P!_Y?\ XNK%M\-_$=_=7$5G8L_V=MC.\JI_G[U/
MB^%WBEYW@&F*[[5^;S5VLWS?(O\ M?+]VN;^S<F_E-O98S^\4QXQU,_\O$W_
M (%2_P#Q=(?&NIC_ );S?^!$O_Q54]8T2^T2+3'OH%A^WP+=1)O^?8WW-R?P
MUG[/]FNZ&19;./-&F<LJE6$O>D>A_#[XN>*/"OBK3[O2M5N;;;*K2Q>>SPRK
M_<96K]8=&NFO=,MIF'SR1JU?C9X?RFLV_P#UU3_T*OV-\,'_ (D.G_\ 7!/_
M $&OS7B'"4L)B/9TC].X1KU:O/S2-I/FI]0PU-7RA^GA1110 4444 %%%% !
M1110 4444 %%%% #-FZE5=HQ3J* "BBB@ HHHH **** "BBB@ HHHH ****
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MD7\'_?=>A#&SA[D:9R5<&I^_*1Y1H7_(8M_]]?\ T.OV-\,C_BG]/_ZX1_\
MH-?CIH_EOXE_<;?L_G_NMGW/OU^QGA?_ ) .G_\ 7O'_ .@U^<\2RY\3S'V7
M!\>254V(?NU)4</W:DKXP_5 HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "D[4M% $+U\S_'[_DN_P ,
M_P#KG<?^RU],;Z^9_C__ ,EY^&G^[<?^RUG4^$\;,OX)]*P?ZM*IZKK%EH]O
MY^H7EM96Z_>EN95B3_QZK4/^K2O#?VF?"]SX@M]#GBL=0N8;-Y?WME MTB.R
M?+YMN_\ K4_]!K0]6E\!H^*OV=M+\72ZK?6VN7]A=ZCJ?]JK=V^UO*9K?R&5
M/^ 5FP_LJ^'K:P^S+J>I/^ZGB?YDWMYMO% __CL2_P#?5>+^'KSXL3:IK>F>
M'(M6L/$NG1?9TT__ )@EK%]E^XN[_EKYNRM_PQ8?$](-"75=1\7W.B_VA+Y#
M6*K%>K/^Z_X^-_WH-_FT&AZ!;_LY^%M,O[19O$D\B12H^E6[RIO@VS>;,J?W
MMTO_ 'S7OZ/\VYODKXYO?AW\1AXQ7Q&NFWLVL(CP13;T:&)/M[LBJO\ !^ZV
MU[5^S_'X@3P_>_\ "0MKCWWFKY_]L,K?O_\ EKY'_3+=0!Z\W4U\O^"O^3R_
M&7_8,BKZ=W_+7S%X(_Y/+\7_ /8,BKGE]D\+,?CI?XCZ@2I5Z5$G05*.E:GM
M1V%HHHJRPHHHH **** "BBB@ I.U+2-TH P/&$33^&M4C5&=VMI55%_B^2OQ
MTUZ$/?[=OW?D^9?XO[E?M%.@>(C;UKP7QC^QUX$\5ZW=ZHR7NEW-TV^=-/GV
M([?WMM>KEN/_ +/K>UC$^*XAR>OF7+[ _,1X?X=N_P#X#1L9/X6_[YK])?\
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M**** *SU^;G[=O\ R627_KSB_P#9Z_2,5^;O[=O_ "5^7_KSB_\ 9Z]C*/\
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MUZ]_PF'P_2%5=+;[!$K)/9?87\V>?]UY4JR_PJFUOEKC/'?B#3?$5UI]Y9K
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M16-]\EP^W[_R5DZ3_P G:P_]B]_[-65<\O%_Q:9](I]RI:B3[E2UB>^%%%%
M%:3_ -EK\W?VZ^?B]+G_ )]8/_9J_2)_XZ^6/VIOV7M4^+&MV^MZ#/!]M6)8
M);>X;;O5?NMNKT<OKQP^)C5D?)<1X2KB\)RTC\]-[[:;O]J^DO\ AA3XB_\
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MQ&_YXV/_ (%5^LX3B7"4J$83^R?A<\DS#G_AGS?3/FW5])?\,)_$C_GCI_\
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M';?_ +%!)*_W*B=*EWTQY?N_+06*GW*393=[?W:EH 9LHV?W:'?;1O;^):"
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M6UI<Z@NL6Z2_:UB?_1_X]^[^&K%S\$=8F?18M/GBFN[S2HKVYBN/D\B=F?\
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M;NZWW%POE2I^_P#[WWZTI8G&\WOTR)4<)_,>:QGE6K]-?V+?^2(:?_UWG_\
M0Z_,2!_WB_P?-7Z=?L6G_BR6F[O^>\__ *'7Q?%WQ4SZ+A/W<;(Z^_\ C1;(
M]Q FFW.Y&:+=N_BK3^'?CY/$5M]ANI?^)E%][?\ \M%KRW4O"NM?;[UFTR?8
MT\K[]O\ #70?"_PA/JM^FJRLT-K:O^Z?[CRM7Q,J=/V9^O\ -+F/,/\ @H2_
M_%'^'O\ KZE_] KX4\/Z1>>)-9M]*L?+^VS[MGFML3Y5WON?_=6ONG_@H5\G
M@[P]_P!?4O\ Z!7Q!X*\01^$O%5EJ\\#7,-NLJM$C;7^9'7_ -FK]!X5E.-"
MIR'XOQ#R_P!I2YRQ%X#UA]C0?8IK)[9KW^TXKK_0DB5]CL\O^]5*;PWJ$/B.
M+0_*CFU"65(HO)E66)]WW&W_ -VMVV\<Z59^&E\)P:9>OX:>S>*5WE7[6\K2
M^;YO]W^';LJOHGC*T\,>*)=:TK1?):*S:+3K>67?Y4K+M^T/_>;[WR5];3K8
MOE]X\FI3PWV9&9>>%=7TW5]0TV73+F:XTYMMU]G3S43_ &]R_P /^W3]5\)Z
MOH,OEWUC.DN[9L2)W^;^Y777_P 78-8\/16-YIES#?*D7FW>F77V=)VB3:F]
M/[NVKO\ POC[-:O!!I$\R*KRJEQ=+^ZN/^64J?[GS5/UC&_R![#"2^T<+9^#
M=>U7[1Y6D7:)!;/>R>= \7[I7VO_ -\[JJ3:%JJ?=T^[F1IWM8I88'=)95_@
M7Y/O5Z>_Q^MGTM+/^R-0?>TKMOG3Y-WE?(G_ 'Z_\?J+_A?<']LW&JQZ/=I+
M.JV[6_VE?L\42RO*CJG\,OS??J(XK&\WO4B_J^$_F/+;FVGT^[>"YMI+:X3[
MR7",KU]-?L#<_%2Y_P"O%_\ T*OGKQ?XG_X2J\T^Y\AH7M=/BLF\UM[RLO\
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M[YE_^(H_X;G^ W_12M(_[YE_^(KU-/AUX3?_ )EC2?\ P!B_^(IW_"M_"O\
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M^&P_@+_T4/0O_'O_ (BFM^V!\!'_ .:A:$?^^_\ XBO3O^%;^#O^A5T;_P
M(O\ XFC_ (5IX._Z%?1O_ &+_P"(J></94NQYO#^V9\"X4VI\2-$1?\ 9W__
M !%2_P##:7P-_P"BDZ-_WT__ ,37H?\ PK3PC_T*NC?^ ,7_ ,33_P#A6GA'
M_H5=&_\  &+_ .)JBX*VQYU_PV?\#?\ HI6C?]]-_P#$TS_AL_X&_P#12-&_
M[Z?_ .(KTC_A6/A'_H5M&_\  &+_ .(H_P"%:>$?^A5T;_P!B_\ B:"SS%_V
MQO@1+][XBZ(?]_=_\31_PV'\!O\ HH6A_P#CW_Q%>E_\*W\(_P#0L:-_X 1?
M_$T?\*W\(_\ 0L:-_P" $7_Q-!AR4G]D\S_X;#^ O_10]!_\>_\ B*/^&O\
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MV-+^0XC_ (:H^"'_ $4#P]_W]JS9_M)_!N_3=!XZ\/;5_O72+75_\*D\$?\
M0G:#_P" $7_Q%,F^#/@.Y;=+X,T*1_\ KPBHYP]C2_D.>3]HGX01OO7QSX<5
MO[WVI*G3]I;X3?\ 0_Z!_P"!B5J_\*3^'G_0DZ)_X Q4_P#X4C\/O^A*T+_P
M BJ=S2$(0^ S%_:9^%*?\U!\/_\ @<E-_P"&F?A-_P!%"\/_ /@<E:G_  H[
MX>_]"/H?_@!%2_\ "D/A]_T)6@_^ ,7_ ,34%F._[2?PF^[_ ,)_H'_@<E0/
M^T/\(#_S/7AP?]O25N?\*0^'W_0E:%_X 14?\*1^'W_0E:%_X 159$H0G\9@
M_P##1/P=_P"AY\.?^!24?\-%?![_ *'OPY_X%)6]_P *.^'G_0E:%_X Q4[_
M (4C\/O^A+T+_P  8J"/8TOY#!_X:'^$&Y?^*Z\.?^!25R7[(_C!OB+X;\8:
ME<ZB-;MU\0W45G<#YT\C=\FS_9KTO_A2/P^_Z$K0O_ "*NBT+PUI7A;3_L6D
M:=;:7:[MWD6<7E+N_P" U/,'L:7\A?\ [,MO^?>/_OBC^S+;_GWC_P"^*GW#
MUI-_^U57%[&'\A7&EVO_ #[I_P!\5.ELL*[5546C>?[U/Z=Z C""^&(]$VT4
M)15&X4444 1.^Q:\J^*_QOB\ :KI^AZ9HUYXF\2WX=K?2;$JK[5_C=OX5KU-
M@#CBOGS24,_[86M;_G5?#L6W_9_>U/,>;C:LH1C&'VAO_"\/BWN^7X.77_@Q
MBH_X7=\7/^B.7/\ X,8J^A-B[*?LJ.4Q^J5O^?\ (^=O^%W_ !@_Z(Y<_P#@
MQBKB_BY>>-?CKX)O?"/C'X(7=_HMTT3.D6J1(RNC[E=6KT*#]J[PY;>+O&VF
MZE ;72="BEEM=0MY/-:^\J5(K@(G]Y)75:=_PU5H$WB&WTXV-[I5H\'FRZA?
M0;$BE67RGB_WJ.4?U*M_S_D96G?%[XJ:7:0VEI\%[FWM;=%BBB748OD15^5:
MM?\ "[/BY_T1ZY_\&,5;,W[4WA&W@=I8-32Z5UVVCVNR5X=F[[0O_3+9\U=)
MX7^.'AOQ=XO/A[3I)GG=7>"X:+9#<;55W5&_V5=:OE%]4K?\_P"1P7_"ZOB]
M_P!$@G_\&<5,F^.GQ4LXFGN?@]?/ B[F6WOXG=O]VOHC "\U!=Q!XL'!%'*1
M+"UHQYO:R./^%GQ0TKXJ^%H=<TCS5A+/%+;RIME@E7[\3K_>KNU^Y7S]^RX-
MNK_%E?X?^$SO?E_X!%7OR'Y*#LP5256CS2%=>!7->//&VG?#[PQ>Z[JLGDV5
MFF]WV_-72,_%?//[:[M_PIQ]K-\UU%NK6$?:3Y"<PQ$L+AIU8_9/--1_X*$P
MPW<J6_AAC&OW3<7B[O\ QU:J#_@H>P_YE:'_ ,#?_L*^)'?]^ZT;]_RU^GT.
M$J-:E&<I'XO/B3,.?W9'VU_P\2_ZE6#_ ,#/_L*3_AXI_P!2G#_X&?\ V%?$
MS[47=\M(DR[/X?\ ?K;_ %0PW_/PC_6/,O\ GX?;?_#Q4_\ 0IP_^!G_ -A2
M_P##Q5O^A5A_\#/_ +"OB9)MZ[EVO3?,5]^W;5?ZHX;_ )^!_K'FG_/P^VO^
M'B7_ %*L'_@9_P#84G_#Q-F9?^*5A_\  S_["OB;>O\ #1]VG_J?0_F#_6/,
MO^?A^HWP*_:;T7XT3W%C#:2Z7JL2[_LDS;]Z?WE:O;TK\U_V)'9/C#8(ORCR
MI?\ T"OTGWX9*_,L=AHX7$RH?RGZKP]CZN/PGM*I/Z55N)O*_P"^:L9.:R?$
M?&AW[?Q>0_\ Z#7"ES:'T%6?)2E(^8?B)^W5I/AC7[K3-&TE]56UE\IKN658
MHF9?O;:Y4?\ !0[_ *EBW_\  W_["OC'6G9]4FW-_$U4@N#\U?I&!X6IXNA&
MK*1^)U^(\>JLN21]N?\ #P__ *EBW_\  S_["C_AXA_U+%O_ .!G_P!A7Q&Z
MJG\-,WQNVWY?^^J]#_4_#?\ /TYO]8\R_P"?A]O_ /#Q#_J6+?\ \#/_ +"C
M_AXA_P!2Q;_^!G_V%?$&8]^WY:-Z_P"S1_J?AO\ GZ5_K'F7_/P^W_\ AXA_
MU+%O_P"!G_V%'_#Q!OX?#$/_ (&?_85\1[5_NTZC_4[#?\_2?]8\R_Y^'Z$_
M#3]N?1O%_B2UTC5M)ETE[M_*BNDG\V'?_=;^[7U/;3+-$K5^-'A$@^*-/Q_S
MWB_]#6OV+T;_ )!UK_US2O@LVR^.7U_91D?H7#6:5\PC+VYH[\_=H^:BF2=*
M\0^WYCPOX\?M0Z-\&KR'3VLI=4U65?-^SPML6)/[[M7C;?\ !1-]G_(IP_\
M@9_]A7D/[94S?\+GU?YF9D$7_H%> N#\^ZON\GX>CF&&]K*1^.9EQ#C:6)E"
ME+E/MG_AXL__ $*T/_@9_P#84O\ P\5/_0K0_P#@9_\ 85\1/0^U/XEKW?\
M4^A_,>7_ *QYE_S]/MS_ (>+O_T*T/\ X&?_ &%+_P /%C_T*T/_ (&?_85\
M2?*G^Q0_WOFVT?ZH8;_GX'^L>9?\_#[:?_@HK_U+$/\ X&__ &%,3_@HFS_\
MRQ#_ .!O_P!A7Q7_  ?_ &-,1Z?^I]'^8C_63,/YC[HTK_@H5!->)]L\*O\
M9_XGM[I7=:^KO!'C&P\<Z!9ZWI<WVG3[R/S8G]J_&]';>GS?Q5^FW[%QS\$-
M-'?SY_\ T.OCL\RF.6RC&,C[/AS.,3CJWLJ\CW[M36^]1373>U?)'Z0<1\4O
MBCIOPL\-/JVI++-NE6""UMUWRSRM]Q%6O+Q\>?B?<?O+;X07BV[?=^TZC$K_
M /?-3?M)HC^._A#&WSH_B+[K_P#7)J[[_EJ_^_6L:?,?/U*E>MB)0A+EY3SS
M_A>/Q7?_ )I'=?\ @QBH_P"%W?%G_HD%U_X,8J]&V;_EIGS?=56_[YK;ZM_>
M*^KU_P#G[(\\_P"%W?%G_HD%S_X,8J/^%X_%G_HD5Q_X,XJ]&_S\],_]#H^K
M?W@]C7_Y^2/._P#A>/Q9_P"B077_ (,8J;_PN[XK_P 7P@N?_!C%7HSO\^W;
M_P!\4]_D;[NQZ/JW]X/J]?\ Y^R/-O\ A>7Q5_Z(_<_^#&*NS^$WQN@^(]]J
M6D7VD7GAOQ'IVW[3I5]]\+_?1E^\M:S[=GSUY;H_R_M;V^WC?X<^;_:^>L94
M^0SYJ^'JP_><Q]*0T^F0_<:GT'T@4444 ,;^*OGG1-W_  V/KO\ V+T7_H=?
M0CU\]Z&__&8^O?\ 8O0?^AU/VCQL=\5+_$>\:MJUGH>G3WU]<QVEE!'YLLTK
M;41:Y[PS\2/#?CR*]30]<MKMX%VR^2VUHMWW6IOQ=\,7GC;X9>)=!T_R_MM_
M8O;Q>;]S<U>.']F*[LI?"5S!J$]S?1-%_:LMQ/L_U5OLBV*OWE5_FV51[)TE
M_P#LO_#J\\/:/IWV5[9-)E?;>Q3[;B5I?]:L[_Q[V^]4NL?LV^#-7O[B\?[7
M]K=Y;B2&6Z_=;I6W_,G]W=7AMA^S)\3;;PO>P7-\U_K'VJ"6+???Z/+*J.KW
M$J?Q;]R_]\5TEG^SO\19O$&NRZGK37,-W.DLES#.ZI<1/+$[1;?O?*B.E!9I
M>%OV9=!N9=1@\6^*UU+Q!%Y4MO\ V?=8:PM=OE*B[OX63Y:]1\)?#KP1H7C+
M[=HURTVKV4\_FPI/O2)Y4175E_A^5$KPK4_V8?'&GRZJ^E0V,WVR55:X>Z;S
M?LZRRO%%_P  W+5S0_V;/'VG6NK117]M;7=Y:LUU=V]X_P#I]PUNB[G_ .^6
M7=0(^N5O(BB-YL>Q_N'=]ZGS/NB:OD>V_9N\<WD3SL\6FHNV6PT]-3E=+-_-
M1O\ T'=7UFJ,EO\ ,WS[:#*I\!X1^RY_R&?BS_V.=Y_Z!%7H-_\ %_1[&]N[
M.6"[\V!VB?\ =5YY^RW_ ,AKXL_]CC>_^@15G>)+.Z?Q1K&VVG='NG^=(JVP
MU.,_C/&P<I1P_NGJG@'Q_P#\)#<2V-VVRY5V:#_IJE>:_MN_\D=D_P"OF*CP
M/X;N_$.O(T#-;) V^65/X:3]MKY/@T__ %\Q5LXPAB(<IAFDI3R^KS'YH-_K
M7_WJ;FGLV7_X%37#R.B01M-*S*B1)]YW9MJU_0N%G&&'A*9^ QASSY46M-O&
ML-2MYU6"9]R+LN$W)_P*O2K_ $?0]2^*KV,L^EVVGV\_E1:9"OE>;\FY/G^[
M\[5E>)_@OK/A[6[>QBG@O(GM7N)[N7_1XK=HGV2HV[^XSI5>3X4:J^C)?6S0
M7DOV7[1+%#+]SY]O_ J\NOB:%7WHU#V:="M"/PG1:)X&_P"$JEEE\1Z?;>'K
MBUB^2TL6\J6Z1I=N]T_V/_'J?\8_"N@^&_"7A5M'@@\V65HI[M/ORJJ??9:Q
M--^"?BC4M1MVG:*S278DMP\^_P"SHR?QU0N?A1K]G]V!7BV?N$>?Y[AMGS^4
MG^[7GT:L8SYO:F]2G*<>7V9QU*_W?FK:\3^#-5\'RPKJ:P;96>)7AEW_ +V+
M[Z?[WW:QB,FOJHU8U8<T3P:D)4M)'T/^Q%_R673O^N4O_H%?H)XJ^(6G^$KR
MWMKR.=WE3<ODINK\_?V)/^2QV'^Y+_Z!7V5\7[:>YUO3_+@E=/*;[BU^$YI"
M,\PJ<Y^P\+2Y< :5A\7+6;Q*D?S)I4ZJN^5?FB?_ .)KNO$3J^@7[*W_ "P?
M_P! KYTATVYO+J*SBMI/M$OR+"ZU[I#I$^@>!);&>X:YF@M71I7_ -RO+JTX
MPDN4^JG*4J,^8_(/6_\ D*R_Y_CJD:NZQ_R%9?\ @54C7[KE'^XQ/YXQ'\9B
M5Z!XA2SO_AOX:9O[)TJ[NHIWGN_(^=O*?Y$^6H]$^$%]KUAX4NTU!(;?6_-=
MMZ_\>OE?W_\ >JF_PKUQ%E:")7B2)I8GFEV>:B_?V)_%66(Q-'$2Y8RY3NH4
M*D?LG87G@^SUO6X=#L;/3;/P:T5AY7B>5MCIN^^Z/_$SOO39_#6G>?#KPUH/
M@OQ;.L'G7J6OVB"*[;?+ WSI\C_Q;]F__@=>>)\)?$<WVVSC6VN4LOGEMTNO
MDB;9N?Y/[R)\U:&M_"+6K:_EB6>*\B2=[?\ M":YVQ2NKHB)_O?.GR5Y[Y85
M/XYZ7++E_AGG\/\ JDW?W:-_SUT?B'P!KGAO2O[0U"VCAM_DW?O?GBW?<WI_
MM[:YS9L:OI:%2%6/NGSM6G*$O>-CPE_R,^F?]=XO_0TK]>KW7X/#/A>+4+E6
M>!556\K[_P U?D-X23_BI=,_Z^8O_0UK]7OB#"]S\-BL2,[?N/D3_?6OR+B>
M'^WGZ1P?+W:AE:W\9()+>W;2X)EF65'E2X3[T7\:UZ'HFL6VO:7%?6DN^*7_
M ,=_V:^;7MI[9':6"2%%_C=:]?\ A-X9OM'L+B[N9&A2Z^=;1_X/]JOEZU.$
M(^Z?I5.4I'P1^V9_R6G6_P#ME_Z!7@P7DBO=_P!L[_DMFM_]LO\ T"O%]!TI
M]>\0:;IBR^2]Y<I;[]N[;NK]=X<J1I9?S'\_9E'FQU6/]XS'.*[CP/?Q6WA#
MQ>TMIILTUG:07%M<7<&]TE:X16_WOEJ76/A9<VUJT]C?;T1I5GBU!?L[Q+$^
MS?\ \#_AHL/@YKTWVWS]J/:JFZ&W??NEWIOM_P#9;Y]U>Q7QM"K3^(5#"5H2
MYN4MZ#HGV/PTESH>GZ7XMU!M6:UOI77Y(K78C1;-_P!U7^?Y_P#9KM?!/PK\
M*IK.E7-S+;7_ -H7<\7F[[>7=_ G^Y7!7_PBUJVM[2?3I?[2\VQ@N)WMWVIO
ME3S4MT_O?)\U48?A+XAN9WMHEC=X%25H4NO]5N3?_P"@5X_-&?O1KGH\LOM4
MS%\86T5AXPUBV@B5+2*\9(D3[BK63\U=WJ7PBU>VNGBMI;::)6V?:WEV1;V^
MXG^]6+K'@'7O#VE?VAJ%M%;1+L\V+S?WL6[[N]/^ M7T%#&T.6,.8\:KAJGQ
M<I@IO\U/]ZOTX_8M_P"2):;_ -=I_P#T.OS'3_6I_O5^G/[&/_)$--_Z[2_^
MAU^=\8?Q*9]9PC_OIV]_\8M*MI;JV6"[\V)FBW[/XZTO 'CE?%5FT4[*FH1?
M>3^\O]^O&-2L+G^U-0_T:?9]JE?_ %7^W71?#'PW>:EKT6H*S6UI;M\TJ?\
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MFLU_L[Q5+?ZCKR:5OG>6^B:UN)6V7"_W=J;5_P" 5-V3]4H?R'U</AMX5?\
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MPOIT>J+!<ROL>*6QB=]TOS?=9E^[478OJ=#^0^FO^%<^%_N_\(_I?T^Q)_\
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M]G+::)K&K76KVDLUI<;;BS2SNO*1]O\ #N_BI!]4H?RGUD?A[X;9>-!TT_\
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MVMQ;:OX:TV_MY_*\U)HOO^4NU/\ OFJ3_L_?#EY-*D;P=I/_ !*%\JQ_<?\
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M(K5%>)E7_:^[\E 'TG8_ KX>65AJNFV?AC2X;2_E5KR%$^^R_,G^[4TGP,\
MS^(;[7&\+Z>^J7T#V]U<^5_K59=K[E^[\R_Q5X3KEQ=P:G\$_&,6N3^'Y_%F
MM17>L0#Y[>5FM?\ 5?[*UN_M(?&CQ!X"\:Q:-9^)+3P1IB^'Y]5M=2U"R\]-
M1O5?:MFO9?E7.W[WS4 >WQ_##PK#.TRZ%9([M:NS+%_S[+MM_P#OC^&NGN[6
M*]MY8)T6:*5=KHR_>6OD?3OVE/%VJ>-X?M6J6.A7J6M@\7@BYLV>XU'S[)9W
M='^\FV5]G^SM^>L;3/VI/$__  B2ZU_PENGZHXNK5]8M$TYD_L17EVS12M_L
MK0!]&I^SM\-XM'O=*3P;I<>GWCI+/"L7WW3[C_[RU9TSX.^ ]%26QL?#.DVR
M2P2Q-;I%LW12_P"M_P" MMKP?X6_&WQW\6/BMI^E6'B*U@\->??W330V&[[5
M!'+MB17;[GRUT/[0GCO7O"7CMT\-26UGJLNCV<4%]-!YOE-+J"1/_P".T ;S
M?LMZ-_PMO3?&LM]NM]+E\^QTR*S1/*?RO*VM+]YHE7^"NVTCX&_#_3!JUO9>
M%M-ACU&2.6]A1/O,K[T^7^'YOFKS*/Q3XL\1?L]_&*TU/5"_B/1&U;2X-5T^
MV\IY5BAW(RI_>^>O)/A/XV\:^'$'B+3?$JZKI3-X5L[RWN+;S?M_GVZ)*Z2_
M\LOO_P#?24 ?:WB3PKI7C#1KC2M9L8M2T^==DMO,OR-7#W_P%\'?\(G+H>C:
M59:#MMY8+6XMK=7>#?\ ?^]]_P#X%7A_[-7[1/Q ^*_Q9O=-UF'3TTA'O//L
MO,1+BP\J5EB^7[W\'\?]ZF^//BCJ_P ,?VCO%MY=^*OLVB.FDK+8W<7[JW@9
MW665?_BZ /7O@U^SGH/PHMIFW1ZKJLETUZ]V\"0HKLGE-L5?N_*M;6I_L^_#
MS5;FRNKOPEILD]G MK SQ?<1?N+_ +6W^&OFGQ=^TO\ $"ZTK5=8\.:Y9)IV
MEZ=<:K$[6.Y;Q5OU@5?]W:]:6M?M ^,]!UR7PWX@\8V7AVSBU.\AE\5SV*;/
MW=K%+%!L^XK,TO\ XY0!]<:+X=T[PW9_9=,M8K.U,C2^5$OR[V^\U9FN?#CP
MUXGN[NXU31;2_GNX%MIVF3=YL2MO16_X%\U>&?L[_%7Q]\7?%XNM9NH](TJS
MT.SNY-)6SV/=3R[_ -[N;YD1MJMM_P!JOII* .#\2_!+P)XO5TUKPQI^HJUP
MUU^^B_Y:_P 34GB'X*>"?%6FR6.J>&=/O+)W67R6BV@.J;4V[?N_+7H&U:-J
MT <%>_!3P-?WNA7<_A?39KK0T2+3G:+_ (]53[NS_=JI<_ +X?76MZCK$OA'
M2SJ>HLS75V8?GE9OO?\ Q5>D;5HVK0!P2_!;P3!X@O=<3PQ8)J=Y%Y$]QY7W
MU;[WRUE)^SGX!M-'BTS3= AT>U6^BU)Q8LR/++%]S<_WJ]2V4;* &(FRGT[;
M1MH ;13MM% "T444 %%%% !1110 4C?=-+10!E7FD6E_,DL]I%<R(NQ6DC5]
MJ_Q)4'_".:8\3Q-I]ML:+[/L\I?]5_<_W:V6XI4.: .?O/!^C:G&L5SI%E<0
MI/\ :EBF@1U\W_GK_O5;_L:S=MS6,.[S//\ NK_K?[]:]% &!JOA72M;GM9]
M2TJSOY;9M\3W4"R^5_N;ONU*?#VF_8[BV_L^V^S3KMEM_*7;+_O5M44 8UAX
M>TW3=)33+/3;:VT_;L^R0Q*D6W_=J.X\+Z5>VEU;3Z9:36]U%Y$\3P*R2Q?W
M'_O5NT4 8:>&-,A2PVZ9:+]@_P"/39;JOD?[G]VDOO#>G:C<>==Z=;7$KQ>0
MTLL2LWE?W?\ =K=HH P(?"ND6T0BBTBRBB\KRMBP)]S^[_NTS4?!^BZK:W%M
M?:197-O.RM)%<0*Z.R_==JWTI] &9#IMM;3M-':1QRM&L32HJK\B_P /^[5&
M]\)Z/J&KQ:K/I5M+J<4;117SP+Y\2-][:_WA70TQ_N4 <5X'^%_ASX>>&TT/
M1M*@ALMC1-YJ*SRJSL_SM_%]]JT4\!>'DT7^QUT+3DTK=N^Q?94\G=_N5TI^
M\*=0!BOH-@\BR?8H-Z;&7]TO\/W/^^:A?PGI$[V32Z7:,]E*TULS0+^X=OXD
M_NM704S^.@"G)I\%Q-%-+!'))#\T;LOSJU4=5\-Z7K[6_P#:>EVU_P"0WFQ?
M:XEEV-_LUM4)0!D+X>TZ%=JZ? B[E?8L:_>7[M,T[PYI6FW-Q<VFFV]K<3MN
MEEBB57EW?WMM;M% &,^@6+S^9]BMQ+YS7&_;_P M67:S_P"]MK/F\&Z%/=VU
MS+HFGM-:Q?9X)'MUWQ1?>VHW\(_V:ZFF?QT <WJWA/3M1TN:R6'[&)8I4\ZT
M_=2Q;_OLC_PTSP'X'TKX=>%[#P_HL#6^G6*%(UD?<[;CN9F;^]UKJJ* .?A\
M):-:ZA>WT&CV4-[>ILNKA+=-TJ_W7_O5&O@S0H+K3[F/1-/2XTY=EK+]F3?
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G(JJSJO\ "O\ #5]/N4^B@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>form10-k_0004.jpg
<TEXT>
begin 644 form10-k_0004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #" 5X# 2(  A$! Q$!_\0
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MT7[DA?EC54Q$_P @/F+\W)Y ->D^(_'6B^&?"][XBN[M7TJSMFNY9+;]ZQC
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M*Q>;S<[=L:D?\M&##"G'UK(T?]J?PQJVMW]D]O=Z7!;Q[HIM2C,1NI"H(2,
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M3ENRY$9N$SN3<1QC!R3Q[TK 20?!OP5:K;B#PQID)M[QM0A9+=08[ANLJ^_
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MHV0O!##D<U6\11);?![5$4$(F@2@%V+'BV;J3R3[FKOQ1;_BW/B7G_EPE_\
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MLM)-UXDO5U6U8Q:+%YPC*2!MKR?<7=C Y[T)-B<DCW":\6..1GPB*I9F8@
M#DD]A7S_ .%_B9>>,?&?C?2_ <274L]\KRZY>1M]CM4$:H67H96)#8 ('&2<
M5VD/@36OB'(+OQY<[-+/SQ>%=/<BVQU'VJ3AIV!Q\O" CHU:?P_LX;/Q+XV@
MMX8X88=0A2.*--JHHMTPH Z >G3VJ](D-.6QR?PK^%&A>'/B=XMOGA_M3Q!&
M+:635[X!YVEE1FD91TCR0.%Q@<"NS\-Q@_%'QN3SB#31R/\ 8EY_6G>&++4;
M7X@^+KJXT^:VL+H6@MKMW1EGV(P;"CD=>^*FT+2M4M/B%XJO[FTB32[^&S6U
MN$G#.[1JX?<F/E&6'.:AMLM12+OQ%LKS4_ FNV>GVGVV^N+22*& .$WL1C&X
M\"M70%ECT6PBGB\F>.WC1X]P;8P4 C(Z\U="AU(;G/4&E"B/I@"@H7RR"3NQ
M]*:%V#).3G-#S"-2S.%4<EF. />F).MS$K!E>-AD%2""/K2N!B:GXQBL/%VD
M^'VL;J27489IX[M /)3RMNX,<Y!^8=JP?$AA_P"%M^#=YB$QL-1"!R-^<19*
M]^F>G:HO&FHV^D?$CPG?7DP@LHK'40\K,< GR,#'<G!P.O!KF/$MZ_BSXC>$
M;JPTJ73[E;>]2UUB[@4R1QE4\QXXVYSP@!;CYNAK&56,5W%>QO\ Q&UZWTSQ
MGX*?)N+F&:X(LK<!IGW0E5VK[GN>*TX_#^L^+PK:[<G3=./72;"3YG7^[-,.
M2#W5< ^M<UJWA-="^('@'[ 87CFNKM[VXO\ =-=7#" X;?G&0?48'8"O46E2
MRA,DTBQ0Q@N[LWRJHY)YZ ?I4J$I.\PO?8\[^ +:?+X$NWL8RD0UC4(W!1D
M*7+H  >P55&1UQ7GW[0'B?Q-K7Q \*>&?!=Y;1?9;Q)-2N6C5OL5PYQ!\S<>
M9L\XA.O0D=*M^#?'U_JOAP^%?!4\-WKUU?ZA--JA >WTJV:[DQ,Y'#.P^XG?
MJ>!72>(?ASHGA'1O FF6EJ;A8O%%K<R7-V?,GGG*2EIY'/+.3W_#IQ6G)I9&
MT'[.5Y([WP3X(T[P'HD>F:;&_EAFEFGE;=-<S-R\LK'EG8]2?IP*Q_B],L'A
M_2V>5(1_;-B-TC[?^6P[FN\11D_UJKJN@Z?KD"0ZC96]]"CK*D=Q$'57!RK
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M0%93"(U8L"W.>_:LCPI\?M);XH>.+U/!NNIYZ6T<=U]F\MIEBW(&;S=FQ6#
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M?B+XNTK5;1+;2K6UL;O30MLZ2(LR/O25CPT@*#(7[N0/<@'HPHIN<#T^IHW
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M,V@>']*TN2X-ZUC:QVWVDJ%+[%"[L=NE>4W/BOXSIX3\N+PAHDFOFQ$K7?\
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MT?XP^"O$&D:=J5CXJTEK+4+=KNW:XN! \D2DAF\N3# *00<@8(.:U1XT\/\
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$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>form10-k_0005.jpg
<TEXT>
begin 644 form10-k_0005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #9 <(# 2(  A$! Q$!_\0
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MYD)&PLP&V39C QM/6@#Z6-W#%LWR+&'(5,L!N)Z >M/\P,>C'G .VO%_B_\
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M=;:0-WL:X/4/@;\2K"_\0:YH-R+34=224/ =6D=9(_L\:*I.,&0,K8? R>M
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MH8VDMS/M!8@# 8 !\@G-?26F:/::1816-C;16MI"NR.")0J*OH!^)-7!'M7
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M=\ >'=-N-!BMXFN;^.WN=3O;:6ZAL(B"3*T49#/R O!'WO:O4ZC>(.>1GV-
M'QU\0/C;\5-4N/$NF:=8_P!C6MHB_9[O3+:0WQ VD3(C YCEW'@@%<#D\UZA
M\"_B9XI\4^(==T?Q(B7 TVQ@F@GMK-T&3D%996.?//!*;%QR1D$5[F(0K%@
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M.QD1@OWE\L8Z9YY%4;'X\?$!=6O84T6!S!'<W5II,]C<O<:H0A94AF+;8]A
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M &8V@V4DL4SV-HTT*A8Y6A4M&!T"DC@#TIS:-;N7+6MN[/G<3&#NR,'.>N0
M#ZX%:-% &6VAVC212O96S20L9(I#$NZ-CU93C(/N*DL]*M[.6:2"U@@><YE>
M&,(9#ZL1U/UJ^1GZT"@! N 12@8%'2EH **** "BBB@ HHHH **** "BBB@
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MX>X61=G!$C@,_'<@&H-7^#^DZCXGNM?6YNTOYT,15IBT:1L,2A5[;UX(K/\
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M=S $+Z<T >KIU;ZT^HT.6/&.M24 %%%% !1110 4444 %%%% !1110 4444
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M<#M^ZN>/3?@?\8=3^)5QKJZI!81K;1P7ULVFEF\J&8,1;S9)_?IMPP&.3T%
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MH\VJZ#(+3(U"U9;NS<<D2IR/^^AE?^!5\H>'/%]EXR\0Z!/XRL([>?Q)9?\
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MUC4;@$_Z"$,<3_P(Y)R"V#V.!6 GQ>B\=_;K.SUBQ\+:?;/Y5SJ%W=1B<@Y
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MCABMM(W)&P(W%(9)&$70#AF)Z\=*]7BT[XM3R^5%XN\.!WVM!MM QDB\KYG
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MO?E#<_\ //G_ 'JKZCI_Q<L"YC\6^'IY29#:6TMIY9N&#KL0G=W3?NQR#MH
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M?45Z,!@4M 'GFN? 'P!XFLI;/5?"FFWMM+J,FK/')%]ZZ< 22$@YRP50PZ$
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E%% !1110 4444 %%%% !1110 AZ5)49Z5)0 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>fin_001.jpg
<TEXT>
begin 644 fin_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !I 7P# 2(  A$! Q$!_\0
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M(.>/X>#@XR#[C'OUK^53]I/_ (*D_MS?#9/#FO\ A/Q5\,%\,ZJ;K1]1:_\
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MZ<URGB_QAX9\"^'-?\8^,M>TGPKX6\,Z1>:]XA\1^(=4MM*T30]$TJU:[O\
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MC>#2%XCW XQCC<,>WIQ]!W%?2%C^R_\ &Z]M;+4K#PWI\MGJ.G6M_8S0>,?
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MET?D,ZSFA5P?AQF?AUD6'Q&)H9WQR\MX:Q/_  @M<0X7AO/I9ME..PF)5?\
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M1 TG[$'A36]4\/>-OVC/'=H8O&W[1'B&?Q=!!.SL^E> [7_0_!FD6?VIM_\
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M_P 6?^Y$_P#5E>#J^E_A_P#\B%X(_P"Q0\+_ /IGLZ^9_P!OP^7^R1\67]O
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MLZC\>_%&EP>%L6EU]FTO4]5O@/&%Y?\ V.SN_L.G^%M-.I>.]4)Y&AD:\?E
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M'L+MU)!'<X'0 'S_ /L=?\FL?!__ +$Y/_2R]KS?_@G)_P FG> _^PCXH_\
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MY^SU\*?&&D^._ GP]M="\4Z-_:?]F:I;ZC?7)MEU6QNM)O %O;M\A].NY$(
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M\5?"'Q U3X9-J.J>&]5TH:-XVU=F:-G.O:[H/B'00#ZYU/\ ;>TO0?%OQO\
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M>6.F:?XDU3X.:9X+_MZ6+0V\11F5=^KXD_:H\!>%OV9?C1^UCJ6@^-9_A_\
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M_:VN_CY>?!GQ/I_PK^,'P+N-;N_C+C_A-/%U[\(?A!\8-?\  E__ ,(MX?\
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MBLSPF&2PN,Q;Q>*PJY7_ &GB7A$EA;V^IXU:.V.CL<99?'CX3ZKJ/B72]/\
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MP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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?="O%_#^/]:L445T&H4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>form10-k_007.jpg
<TEXT>
begin 644 form10-k_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 9'"BT# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]:,CUH **,CUHR/6@ HHR/6C(]: "BC(]:,CUH **,CUHR/6@ HHR/6C(]:
M"BC(]:,CUH **,CUHR/6@ HHR/6C(]: "BC(]:,CUH **,CUHR/6@ HHR/6C
M(]: "BC(]:,CUH **,CUHR/6@ HHR/6C(]: "BC(]:,CUH **,CUHR/6@ HH
MR/6C(]: "BC(]:,CUH **,CUHR/6@ HHR/6C(]: "BC(]:,CUH **,CUHR/6
M@ HHR/6C(]: "BC(]:,CUH **,CUHR/6@ HHR/6C(]: "BC(]:,CUH **,CU
MHR/6@ HHR/6C(]: "BC(]:,CUH **,CUHR/6@ HHR/6C(]: "BC(]:,CUH *
M*,CUHR/6@ HHR/6C(]: "BC(]:,CUH **,CUHR/6@ HHR/6C(]: "BC(]:,C
MUH **,CUHR/6@ HHR/6C(]: "BC(]:,CUH **,CUHR/6@ HHR/6C(]: "BC(
M]:,CUH **,CUHR/6@ HHR/6C(]: "BC(]:,CUH **,CUHR/6@ HHR/6C(]:
M"BC(]:,CUH **,CUHR/6@ HHR/6C(]: "BC(]:,CUH **,CUHR/6@ HHR/6C
M(]: "BC(]:,CUH **,CUHR/6@ HHR/6C(]: "BC(]:,CUH **,CUHR/6@ HH
MR/6C(]: "BC(]:,CUH **,CUHR/6@ HHR/6C(]: "BC(]:,CUH **,CUHR/6
M@ HHR/6C(]: "BC(]:,CUH **,CUHR/6@ HHR/6C(]: "BC(]:,CUH **,CU
MHR/6@ HHR/6C(]: "BC(]:,CUH **,CUHR/6@ HHR/6C(]: "BC(]:,CUH *
M*,CUHR/6@ HHR/6C(]: "BC(]:,CUH **,CUHR/6@ HHR/6C(]: "BC(]:,C
MUH **,CUHR/6@ HHR/6C(]: "BC(]:,CUH **,CUHR/6@ HHR/6C(]: "BC(
M]:,CUH **,CUHR/6@ HHR/6C(]: "BC(]:,CUH **,CUHR/6@ HHR/6C(]:
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MW'_/2M"B@#/^QW'_ #TH^QW'_/2M"B@#/^QW'_/2C['<?\]*T** ,_['<?\
M/2C['<?\]*T** ,_['<?\]*/L=Q_STK0HH S_L=Q_P ]*/L=Q_STK0HH S_L
M=Q_STH^QW'_/2M"B@#/^QW'_ #TH^QW'_/2M"B@#/^QW'_/2C['<?\]*T**
M,_['<?\ /2C['<?\]*T** ,_['<?\]*/L=Q_STK0HH S_L=Q_P ]*/L=Q_ST
MK0HH S_L=Q_STH^QW'_/2M"B@#/^QW'_ #TH^QW'_/2M"B@#/^QW'_/2C['<
M?\]*T** ,_['<?\ /2C['<?\]*T** ,_['<?\]*/L=Q_STK0HH S_L=Q_P ]
M*/L=Q_STK0HH S_L=Q_STH^QW'_/2M"B@#/^QW'_ #TH^QW'_/2M"B@#/^QW
M'_/2C['<?\]*T** ,_['<?\ /2C['<?\]*T** ,_['<?\]*/L=Q_STK0HH S
M_L=Q_P ]*/L=Q_STK0HH S_L=Q_STH^QW'_/2M"B@#/^QW'_ #TH^QW'_/2M
M"B@#/^QW'_/2C['<?\]*T** ,_['<?\ /2C['<?\]*T** ,_['<?\]*/L=Q_
MSTK0HH S_L=Q_P ]*/L=Q_STK0HH S_L=Q_STH^QW'_/2M"B@#/^QW'_ #TH
M^QW'_/2M"B@#/^QW'_/2C['<?\]*T** ,_['<?\ /2C['<?\]*T** ,_['<?
M\]*/L=Q_STK0HH S_L=Q_P ]*/L=Q_STK0HH S_L=Q_STH^QW'_/2M"B@#/^
MQW'_ #TH^QW'_/2M"B@#/^QW'_/2C['<?\]*T** ,_['<?\ /2C['<?\]*T*
M* ,_['<?\]*/L=Q_STK0HH S_L=Q_P ]*/L=Q_STK0HH S_L=Q_STH^QW'_/
M2M"B@#/^QW'_ #TH^QW'_/2M"B@#/^QW'_/2C['<?\]*T** ,_['<?\ /2C[
M'<?\]*T** ,_['<?\]*/L=Q_STK0HH S_L=Q_P ]*/L=Q_STK0HH S_L=Q_S
MTH^QW'_/2M"B@#/^QW'_ #TH^QW'_/2M"B@#/^QW'_/2C['<?\]*T** ,_['
M<?\ /2C['<?\]*T** ,_['<?\]*/L=Q_STK0HH S_L=Q_P ]*/L=Q_STK0HH
M S_L=Q_STH^QW'_/2M"B@#/^QW'_ #TH^QW'_/2M"B@#/^QW'_/2C['<?\]*
MT** ,_['<?\ /2C['<?\]*T** ,_['<?\]*/L=Q_STK0HH S_L=Q_P ]*/L=
MQ_STK0HH S_L=Q_STH^QW'_/2M"B@#/^QW'_ #TH^QW'_/2M"B@#/^QW'_/2
MC['<?\]*T** ,_['<?\ /2C['<?\]*T** ,_['<?\]*/L=Q_STK0HH S_L=Q
M_P ]*/L=Q_STK0HH S_L=Q_STH^QW'_/2M"B@#/^QW'_ #TH^QW'_/2M"B@#
M/^QW'_/2C['<?\]*T** ,_['<?\ /2C['<?\]*T** ,_['<?\]*/L=Q_STK0
MHH S_L=Q_P ]*/L=Q_STK0HH S_L=Q_STH^QW'_/2M"B@#/^QW'_ #TH^QW'
M_/2M"B@#/^QW'_/2C['<?\]*T** ,_['<?\ /2C['<?\]*T** ,_['<?\]*/
ML=Q_STK0HH S_L=Q_P ]*/L=Q_STK0HH S_L=Q_STH^QW'_/2M"B@#/^QW'_
M #TH^QW'_/2M"B@#/^QW'_/2C['<?\]*T** ,_['<?\ /2C['<?\]*T** ,_
M['<?\]*/L=Q_STK0HH S_L=Q_P ]*/L=Q_STK0HH S_L=Q_STH^QW'_/2M"B
M@#/^QW'_ #TH^QW'_/2M"B@#/^QW'_/2C['<?\]*T** ,_['<?\ /2C['<?\
M]*T** ,_['<?\]*/L=Q_STK0HH S_L=Q_P ]*/L=Q_STK0HH S_L=Q_STH^Q
MW'_/2M"B@#/^QW'_ #TH^QW'_/2M"B@#/^QW'_/2C['<?\]*T** ,_['<?\
M/2C['<?\]*T** ,_['<?\]*/L=Q_STK0HH S_L=Q_P ]*/L=Q_STK0HH S_L
M=Q_STH^QW'_/2M"B@#/^QW'_ #TH^QW'_/2M"B@#/^QW'_/2C['<?\]*T**
M,_['<?\ /2C['<?\]*T** ,_['<?\]*/L=Q_STK0HH S_L=Q_P ]*/L=Q_ST
MK0HH S_L=Q_STH^QW'_/2M"B@#/^QW'_ #TH^QW'_/2M"B@#/^QW'_/2C['<
M?\]*T** ,_['<?\ /2C['<?\]*T** ,_['<?\]*/L=Q_STK0HH S_L=Q_P ]
M*/L=Q_STK0HH S_L=Q_STH^QW'_/2M"B@#/^QW'_ #TH^QW'_/2M"B@#/^QW
M'_/2C['<?\]*T** ,_['<?\ /2C['<?\]*T** ,_['<?\]*/L=Q_STK0HH S
M_L=Q_P ]*/L=Q_STK0HH S_L=Q_STH^QW'_/2M"B@#/^QW'_ #TH^QW'_/2M
M"B@#/^QW'_/2C['<?\]*T** ,_['<?\ /2C['<?\]*T** ,_['<?\]*/L=Q_
MSTK0HH SQ:3_ //2C[)<?\]?UK0I.: *(M)_^>M6+>%X@=[;JGHH **** "B
MBB@ J.:2.*,M*P5>Y-254U&T%[920DD9!P10!C:M9:5KEA,ZA)&C'45YO9^&
MKF\NY39.8_+)/!JPDNH^%KRZCE#O!(3BH=,\7+:32B&-B\F1P* .H\'Z],EU
M)IMY)YDB' )KT J&Q7G'@G0+B349M3N@1YAW &O1^ 1^5 'EWCIB/%UG@<Y%
M>B6#^5IJR/V7-><>.EN#XTLGCC9D&,D"O2;3;<:>B$8!4 T >:^)=;AUG6EL
M)9A%"&YR:Z:ZO]&T_P )S6L%W&S"(X /)-27W@#2;^Y,LI82'G(K,U7X>Z=;
MZ5<31RREXT)4'O0!F?#74+4)<?:9@C%CM4GK4'B=UB\96CE<1LPPU1> _#T&
MH2O+-OC>-^!ZUTWCGP_)=VL,]LOS0#.1UH [2%PT$90Y4J.:\P\=3))XLLXX
M_G;(R!3]/^( TW3S9W,,AF4;0<5%X>TRYUWQ -5F5O+5L@-0!Z7IJE;"($8.
M.E6Z08QQTI: "BBB@ HHHH **** "BBB@ HHHH **** &LVVL+Q%H-GJ.GR
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $HHH
MI6 ***6BP!11118 HI**=A7%HI**+!<6BDHHL%Q:***!A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C=*6@C- &=JNFVU[9
MR+)"KL1@'%<IH7A*VM=1:6:V##/&17=$@<4?*.0!0 V...% D:A5]!3\<YHX
M/-+0!6FT^UN)1++"K..A-3"-5&%&!3Z* &E ?K2/&LD9C<94\$4^B@"M;6%K
M:9\B%4SUP*G>-9%VL,J>HIU% &9)X>TF63>]E$6]<5<@M(+5=L$:QKZ"IZ*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#@4@.32D9HQ@<4 (5YS3A3
M%5L\GBGT %%%% ",,C%,.$44\C(I-F5P: &E=Y!!IXQTHQA<"@# ]Z %HHHH
M **** "D)P,TM(1D4 -"[CNS2L.U!4XP*4CCWH 3@#FG4FW(YI: "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2BD9@HS0&!&:+BL+10310
M.P9HS110%@I*"<4;J+AS(**-U&ZBXN9!11NHW47#F0HI:;FE+8&:!BT4F0!D
MTH.>E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2
M'I2T4 )@ <T9%)@D\TNT=J $QS3J0 CK2T %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *#10: &M]QOI7S-XO_P"1MNO]XU],M]QOI7S-
MXO\ ^1MNO]XUTX?XCS\?\*,GO24O>DKUEL>.M@HHHI$QW"BBB@IA1110 444
M4 :WA+_D:[7_ 'A7TRO^K3Z5\S>$O^1KM?\ >%?3*_ZM/I7F8GXCV,#LQ1TI
M%ZTHZ4B]:X^IW2W%I:2EJBF+1112 **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *#10: &M]QOI7S-XO_P"1MNO]
MXU],M]QOI7S-XO\ ^1MNO]XUTX?XCS\?\*,GO24O>DKUEL>.M@HHHI$QW"BB
MB@IA1112N 4444P-;PG_ ,C7:_[PKZ84_NT^E?,_A/\ Y&JU_P!X5]+KQ$GT
MKS,3\1Z^ >X\=*1>M Z4#K7)8[Y;BTM!HH93%HI*6DF 4444P"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** #-%)10 M%%)0 M%)BDQS2N(=1FDHIC%S1FDHH#07-&:
M2B@!:*0\T4"%HIN:6AC%HI*#23 6BD%+3 **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBD) &2<4 +12!E;HP/T-+0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI:2EI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 44<4<4 %%'%'% !11Q1Q0 44<4<4 %%'%'% !11Q1Q0 44<4<4 %%'%'%
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MED=@%QUKSOP'$TNNWMP!F-\X- $>E(DOCMI3SAZ]1GRT4BD?+BO*H<:=X_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4!<"EHH 3%+110 A4$Y-&!2T4 (!B@J#UI:* $P*  *6B@ QS360,03VIU%
M!BC&*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@&MX2_Y&RU_WA7TRGW%^E?,WA+_D:[7_ 'A7TROW$^E>7B/B/9P7PCJ2C/%
M.:Y.IW]0%'>CI2U0I""EHQ2XI#84444 -+9XI%/8T!,-FEV\YH 0* 3[TPJP
M;Y>E2;>:7% "  _6LK4/#UAJ4OF7$0+?2M14VDG-.Q4V$T4+33[>QC\J% J^
MPK,\4W<]AH\C6P)8@]*W_+Z\TR:UCGB:.50RD8YJ>5F;BSY8N;N__M=KH/)Y
MF_IFOHCP9<7=SH$$MSG)'>J$GPZTZ34/M7&,YVXKK+2".TA6", *O %**:W)
MIQ<7J3,47YG(7W-(D\4G"2(Q]C7G7Q(UZZT]##"652.HKSGPGXOU&+7X8?/>
M57;!S5\R-'-(^CA2U#%*7AC;N5!IZL33N/F0^BF;J4M@9-%REJ.HJ,R<97D4
M>9E<KR:8[$E%-1MP]Z=0(**3-% KBT444#"BC-&: "BDS2T %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M "4&B@TF+H':HY/]1)_NFI.U1R?ZB3_=--#?PGS%XC_Y&B[_ -XU0[U?\1_\
MC1=_[QJAWKV*6Q\S/^(Q****V$PHHHH$%%%% !1110A(*W? W_(WV_U%85;O
M@;_D;[?ZBL:WPLUH_&?29Z#Z4@I3T'TI!7D,^E6PHZTZFBEI$H6BBB@8444E
M "T4W-&:!V'44E+0(**** "BDI: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYM(G8Z]\0-1U&Z86<A2,^]<K=WDUW+FXE9G/O5VP\-ZEJ.W['"Q!]J] \/\
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M(]C [,4=*1>M*.E(O6N/J=TMQ:6DI:HIBT444@"BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$TQ2XN'*CKM->EZ7X3TS3H5 MU+COBM[:,8 P/:@+@5O&"6IVPP\(ZC8T2-
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M8ZHP2V'#I1358-TIU6:BT4&D% "T444 %%%% !1110 4444 %%%% !0:*#0
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MHIG)&1Q2CCJ: '44UFP,]: P(STH =1FF$,3D'BG#D>] "TF:;N(.,4[CK0
MM%-.32+P.30 _-%,W\]*49H =1FF+P3DT%N>E #Z*:":09W<F@!^:*:6P>E
M)- #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML=*BN@PYI<9I:2J!1 #%-*<YS3J6@L:O3IBGBDI:0@-(*6B@04444#"BBB@
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M\JY--4YY[4%V)1135.>E*<T"%HIH)S3J "BBB@ HHHH **** "BBB@ HHHH
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MS #T)H [P4M06MS'=P++&<J:GH **,T4 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** $H-%!I,70.U1R?ZB3_=-2=JCD_U$G^Z::&_A/F+Q'_R-%W_ +QJAWJ_
MXC_Y&B[_ -XUGY&>M>Q2V/F9_P 1A1116PF%%%% @HHHH ****$)!6[X&_Y&
M^W^HK"K>\#?\C?;_ %%8UOA9K1^,^DCT'TI!2GH/I2"O(9](MBKJG_(,G_W:
M\;E_X^)/]XU[)JG_ "#)_P#=KQJ4C[1)_O&O!S7X$?09+\;%HHH->4]D?0]P
MHHHK/J'0****L HHHJ%N#%[4UNE.[4UNE.?P%1^,ZCP)_P A)J]*KS3P(?\
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M*MS+*0* +]-( Y->>S_$QUG*PZ>TD8/WP#71Z'XIMM:4  (_=: .@'(I:0#
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M;/\ \\S^5'VV?_GF?RH O\T<U0^VS_\ /,_E1]MG_P">9_*@"_S1S5#[;/\
M\\S^5'VV?_GF?RH O\T<U0^VS_\ /,_E1]MG_P">9_*@"_S1S5#[;/\ \\S^
M5'VV?_GF?RH O\T<U0^VS_\ /,_E1]MG_P">9_*@"_S1S5#[;/\ \\S^5'VV
M?_GF?RH O\T<U0^VS_\ /,_E1]MG_P">9_*@"_S1S5#[;/\ \\S^5'VV?_GF
M?RH O\T<U0^VS_\ /,_E1]MG_P">9_*@"_S1S5#[;/\ \\S^5'VV?_GF?RH
MO\T<U0^VS_\ /,_E1]MG_P">9_*@"_S1S5#[;/\ \\S^5'VV?_GF?RH O\T<
MU0^VS_\ /,_E1]MG_P">9_*@"_S1S5#[;/\ \\S^5'VV?_GF?RH O\T<U0^V
MS_\ /,_E1]MG_P">9_*@"_S1S5#[;/\ \\S^5'VV?_GF?RH O\T<U0^VS_\
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MVV?_ )YG\J/ML_\ SS/Y4 7^:.:H?;9_^>9_*C[;/_SS/Y4 7^:.:H?;9_\
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ML_\ SS/Y4?;9_P#GF?RH O\ -'-4/ML__/,_E1]MG_YYG\J +_-'-4/ML_\
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M48'H*6B@!,#T%&!Z"EHH 3 ]!1@>@I:* $P/048'H*6B@!,#T%&!Z"EHH 3
M]!1@>@I:* $P/048'H*6B@!A "-P.E?-/B\_\59=8'\1KZ7;[C?2OF;Q?_R-
MMU_O&NG#_$>?C_A1C@ONI3UI>])7JK8\=;!11103'<****"F%%%% !1110!K
M^$CCQ5:C_:%?2Z ;%X[5\S^$O^1KM?\ >%?3,?W%^E>;B]SUL%LQV!Z55U$#
M[!,<=%-6JJ:C_P >$W^[7GU':#/5AK)'C4WF3:A* Q #4!I$++N-.N.+R7''
MS4WKS7R\Z[4F?9TL.G!#5#GEG.*7C^\U.-)BLI3F]F="I0CNA./[S48']YJ7
M%&*GFJ=Q\E/L)@?WFHX_O-2XHQ1S5.X<E/L)@?WF_.D"@MPS?G3L4"G[6<5J
MQ>QA+9#-\B9PQKU'P>Q?2%+<UY<_0UZAX-/_ !)UKU<OJ.4CP\TIJ,=#H2!G
MH*7 ]!0:7M7NO8^;6XF!Z"EP/044M)%"8'H*,#T%+13 3 ]!1@>@I:* $P/0
M48'H*6B@!,#T%&!Z"EHH 3 ]!1@>@I:* $P/048'H*6B@!,#T%&!Z"EHH 3
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M'2GT@.12T %%%% !1110 4444 %%%% !1110 4444 %%%% !2&EIA+;\ <4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4 %%%% !1110 4444 %!HH- #6^XWTKYF\7_ /(VW7^\:^F6^XWTKYF\7_\
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M"O(9](MBKJG_ "#)_P#=KQN7_CXD_P!XU[)JG_(,G_W:\;E_X^)/]XUX.:_
MCZ#)?C84445Y3V1]#W"BBBL^H= HHHJP"BBBH6X,7M36Z4[M36Z4Y_ 5'XSJ
M/ G_ "$FKTJO-? G_(2:O2J^GP/\)'QF8_QV%%%%=QYX4444 %%%% !1110
M4444 %%%% !1110 4444 %(>E+2'..* &L@="K?=-00V5M#)OC4!JL#)'--1
M0#P: '8YYI&P.G6E).?:DP%.XT '(&!U--12I.XT\C)!%-9?,[X(H <, \4Z
MD XYHXZ4 (<'K2#"]!3CP.*!SU% "TTD'BEX%':@ ' I:!THH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@!" >M*!BBB@ Q1110 48HHH ****
M "BBB@ HHHH *,444 %%%% !1110 48HHH **** #%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% #6&1P::3@8)YI20&J&Z>.",SR'"J,T ]-24;@.1FLC7]"A
MUNR>&0#<1P:Y#4?B9#;:GY*D>6#@UVFBZW;:W:":V;/'-0]3)M3T."T?X4C3
M]2%S-('0-D"O3(HPD*QJ,!1@5(N>]&[)XIK38J,%'4%Z4^FJ!FG51=[ABDP*
M6BE8 HHHI@)BEHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?- *6D%+1'804444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 444F>: %HH-(,T >+?%/5[
MVWU0V\,C*GM6/\/M>OUU:.V:1V5SSFO8=>\*V&M O-&#+ZU1T+P5I^D2^<(Q
MO'3BLGN<_+:5SJU&V,9/:A<G.:3EP,=J>#@5HCHW0F.:=VI U+GBJ8K6 4M(
M#FEI#O<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *#10:
M&M]QOI7S-XO_ .1MNO\ >-?3+?<;Z5\S>+_^1MNO]XUTX?XCS\?\*,GO24O>
MDKUEL>.M@HHHI$QW"BBB@IA1110 4444 :WA+_D;+7_>%?3*?<7Z5\S>$O\
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M]16%6]X&&?%UN?<5C6^%FU'XSZ2/0?2D%*<8'/:@?45Y#/HUL5-4_P"09/\
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MVCK7IY=_$/#S3^"C2^R7'_/2D^R7'_/7]:T**^@>Q\R9XM+C_GK^M+]DN?\
MGK^M7Q2T1V S_LES_P ]?UH^R7/_ #U_6M"BF!G_ &2Y_P">OZT?9+G_ )Z_
MK6A10!G_ &2Y_P">OZT?9+G_ )Z_K6A10!G_ &2Y_P">OZT?9+G_ )Z_K6A1
M0!G_ &2Y_P">OZT?9+G_ )Z_K6A10!G_ &2Y_P">OZT?9+G_ )Z_K6A10!G_
M &2Y_P">OZT?9+G_ )Z_K6A10!G_ &2Y_P">OZT?9+G_ )Z_K6A10!G_ &2Y
M_P">OZT?9+G_ )Z_K6A10!G_ &2Y_P">OZT?9+G_ )Z_K6A10!G_ &2Y_P">
MOZT?9+G_ )Z_K6A10!G_ &2Y_P">OZT?9+G_ )Z_K6A10!G_ &2Y_P">OZT?
M9+G_ )Z_K6A10!G_ &2Y_P">OZT?9+G_ )Z_K6A10!G_ &2Y_P">OZT?9+G_
M )Z_K6A10!G_ &2Y_P">OZT?9+G_ )Z_K6A10!G_ &2Y_P">OZT?9+G_ )Z_
MK6A10!G_ &2Y_P">OZT?9+G_ )Z_K6A10!G_ &2Y_P">OZT?9+G_ )Z_K6A1
M0!G_ &2Y_P">OZT?9+G_ )Z_K6A10!G_ &2Y_P">OZT?9+G_ )Z_K6A10!G_
M &2Y_P">OZT?9+G_ )Z_K6A10!G_ &2Y_P">OZT?9+G_ )Z_K6A10!G_ &2Y
M_P">OZT?9+G_ )Z_K6A10!G_ &2Y_P">OZTGV.X'_+7]:T:;R30!G"SN=V3)
M^M++92RH5+]:T.*0KCG-3**8DNYY/XW^'S2PM>P#+CDXKR68213&)T*NAQ7U
M@Z+,C)( 5/'->5^/_!"*&O[*/GJ0!6$J=M3BQ%"^L3F?!OC&XT^YCM)Y2(V.
M.3TKVBW#W$*30S;E89X-?,$D4L,V9,I(#Q7H_@/QQ-92I97\A\L\ DU,9V9G
M1JM>ZSUUK2X?GS*7[)<XQYE307*742RP,&0^E6-W8=:Z5(]",B@+.Y'67]:7
M[)<?\]:T*2K+*/V2X_YZT?9+C_GK5^EQ4B,_[)<_\]?UH^R7/_/7]:T**8&?
M]DN?^>OZT?9+G_GK^M:%% &?]DN?^>OZT?9+G_GK^M:%)0!G_9+C_GI0;2X_
MYZ_K6A0:3%T,_P"R7'_/7]:4VTRPR[GS\IJ\>E1R9\B3_=-5$;^%GS#XACD7
MQ-=Y/\1K/#$-@BM7Q&3_ ,)-=_[QK,!&:]>EL?,R_B,.M%'>BMA,****!!11
M10 4444(2"MOP3&[^+K<JV.16)6_X%'_ !5UOSW%95OA-:/QGT(]K,S B3M3
M/L=S_P ]?UJ_CH?:E!KQWJ?2+X3'OK>>/3)][[OEKR<K()Y,_P!ZO9=5.--G
M/^S7CLDI^T2<?Q5X.:_"CZ')?B8T]>:4D'I2-\U)MP:\I[(^@[BT445GU#H%
M%%%6 4445"W!@S CB@[L<4FWO3B^T54_@*C\9T/@A)#J35Z UI<%B1)^M<)X
M&D+:DW%>DU]+@?X2/C<Q?[]HH?9+G_GK^M'V2Y_YZ_K6A17>><9_V2Y_YZ_K
M1]DN?^>OZUH44 9_V2Y_YZ_K1]DN?^>OZUH44 9_V2Y_YZ_K1]DN?^>OZUH4
M4 9_V2X_YZ_K2?8[C_GK^M:-% &>+2X'_+7]:LV\4D8.]LU/10 4444 %%%%
M !3)94A0LYPOK3ZJZC:F[LI(0<$CB@#$UK2])UBPGF0))(BYRM>::?X:N[VY
ME>RE*&,DX!JY%<ZGX4OKJ.YWO;RDXJ*R\70Z?-*;=&+RY&!0!TGA?Q--;/+8
MW;&1X^,UE7$MSXO\6-9%L6R'[M7O!?A^:XO9[^Y4A)LGFJ6J6M]X7\3MJ-M&
M3;D\X% '6W/@+29-/\F*$+*!PWO7,^%-6NM(UR?2)VW(I(45J7'Q)LVLMMO'
M)]J(QC'>J'@O1[N]UN75K]" Q)7(H H9$?Q&CDG^4EN,UZQY@WC XQUKSSQW
MHLPU&+5;=3F/'W:2/XAPII/V=HG^TA=O2@#,U@B?XC(8#N?=VKU>#/D)NZXY
MKS7P9I$]WKC:Q<*>3D;J].H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *:RD]Z=10!& 5]Z0Q!\A^5/8U+10!QGB?PM:7;)+%:@MWP*U
M= T.SLK-6%LJR?2M[ /6B@!HR3Z 53N]'L+]MUS;)(WJ15ZB@#-M]!TRTD#P
M6J(P[@5?52#R<BGT4 4KK2;&]/\ I%NC_45%;Z%IEHV^"TC1AW K2HH 9RR\
M<8JO=Z=:7Z;;J!9![BK=% &9!X?TNWYBLXU^@K051&A"C@=!3Z* /.=5T6;7
M/$*,]N52)LAL5Z!#'Y=K'&?X5 J7: <X%+0!G3Z'IMPQ>:U1SZD4^TTJPLSO
MMK9(V]0*O44 ,.>HJG=:/I]^=US;(Y]Q5^B@#.MM%TVR<-;VB(WJ!5\@D9'&
M*=10!3NM,L]0'^DVZ2'W%00:!I5HX>&SC5AW K3HH ;_  \#%*.E+10 @.:
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MC;=?[QKIP_Q'GX_X49 //2@]:7O25ZRV/'6P4444B8[A11104PHHHH ****
M-?PC_P C7:_[PKZ83[B_2OF;PE_R-EK_ +PKZ93[B_2O,Q>Y[.#^$6JVH_\
M'A-_NU:[U5U'_CPF_P!VN"I\#/0I_&CQNY(^V2\?Q4#&*+G_ (_)?]ZF]J^3
MJ?$S[NE\"%/6DH-%9(U"BBBF 4444 %"]>:*44#?PC9,;37I_@T_\29:\N?[
MIKU'P;_R!EKU,N_B'AYK_!1T1I*=25[[V/F@%% I:(["$HI:*8"44M% "44M
M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M
M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M
M% "44M% "4F:=12 9C-+S3J*H'J1,"<#.*)(4FB,<JAE/4&G.,XI6!V<5,E<
M1Y!\0? 3/NOK)< <X%>4NLJ/L8E94-?6,D27$+12J"",'->-^/\ P*T#/?V:
M';G. *Y:E*VJ//KTN1\\0\!>.GLBEC?-\IX!->P0RI-&L\+!E89XKY4C,L#_
M +_*N#\M>I>!/'!M=EG?/E#P"31"=MRZ-6ZU/8<Y&30.>E01RK<1+)&P*,,C
M%2J,# KJ3.Q2'!@:7-1LN!\O6E0$=>M58TMH/HHHI$!110*0PHHHI@%(:6@T
MF+H(>E1R#]Q)_NFI>U1R?ZB3_=--#?PGS'XC_P"1FN^?XC6<#STK0\1_\C1=
M_P"\:H=Z]BEL?,S_ (C$/6BBBMA,****!!1110 4444(2"M[P-_R-UO]16#6
M[X&_Y&^W^HK&M\+-:/QGTF>@^E(*4]!]*05Y#/I%L5=4_P"0;/\ [M>-RD?:
M9./XJ]DU3_D&3_[M>-R_\?$G^\:\'-?@1]!DGQL=QBD/6DHKRGLCZ'N%%%%9
M]0Z!1115@%%%%0MP8H'%(^,4O:FMTIS^ J/QG4>!,?VBW%>D]Z\V\"?\A)J]
M*KZ? _PD?&9C_'8E%+17<>>)12T4 )12T4 )12T4 %%%% !1110 4444 %%%
M% !0:** ,[4]*M=0M)%GA5V(X.*Y#0O"-M;ZJQN+4,F>,BO0*3 ]* (XHH[=
M D2!5'84RYL[>\CV3QAE]#5BB@#('AC1U;<+*,-ZXK2BACMT$<:!5%2T4 1S
M0Q31E)4#*>Q%9I\-Z07\S[%'N]<5K44 16\$-O'LAC"*.P%2T44 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7-./*>96@XO0W/ ?CH_+8W;<#A2:]8CE66(/&00>XKY1BGD@99(R5=.U>N>
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M5YKX$_Y"35Z57T^!_A(^,S'^.PHHHKN//"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M *#10: &M]QOI7S-XO\ ^1MNO]XU],M]QOI7S-XO_P"1MNO]XUTX?XCS\?\
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M-)WH[446)84&B@T,.@=JCD_U$G^Z:D[5')_J)/\ =--#?PGS%XC_ .1HN_\
M>-4.]7_$?_(T7?\ O&J'>O8I;'S,_P"(Q****V$PHHHH$%%%% !1110A(*W?
M W_(WV_U%85;O@;_ )&^W^HK&M\+-:/QGTF>@^E(*4]!]*05Y#/I%L5=4_Y!
MD_\ NUXW+_Q\2?[QKV35/^09/_NUXW+_ ,?$G^\:\'-?@1]!DOQL****\I[(
M^A[A1116?4.@44458!1114+<&+VIK=*=VIK=*<_@*C\9U'@3_D)-7I5>:^!/
M^0DU>E5]/@?X2/C,Q_CL****[CSPHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZGLFG:A%J4'F1GBKZ\"N4\$9.E5U:]*]JA.4H)L^?KTU"HTA:***W,0HHHH
M**** "BBB@ HHHH *0TM,:F@M<*,FA3D4N,&@AQLPQ7)>.I9O[%E2+=C'.*Z
MUUW# .*K75I#<P-#,H8,,5#%..FA\K6YODU2,Q-,1YG2OISP]YDFBVK2YW;!
MUK-M/ ^FVUZ;CRE;G.,5TJ(D:A$&U1T I)$4Z75DM%%%6;A1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOM_J*PJW? W_ "-]O]16-;X6:T?C/I,]!]*04IZ#Z4@KR&?2+8JZI_R#)_\
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M 9QFF*3NW&GYYXK1(ZVFMA]%%% PHHHH **** "BBB@ HHHH **** "BBB@
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M%% !113<G- #J*.U(&!.* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 4444 %%%% !1110 4444 %%%% !1110 C GO28/K2DJ.I _&D^AS0 #/>E
M&>*/8T!0#F@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]5=1_P"/";_=JUWJKJ/_ !X3?[M<%3X&>C3^-'C=S_Q^2_[U-[4ZY_X_)?\
M>IO:ODZGQ,^ZI? @-%!HK)&H4444P"BBB@ I124HH&_A(W^Z:]1\&_\ (&6O
M+G^Z:]1\&_\ (&6O4R[^(>'FO\%'1TE+25[[V/F@%+2"EHCL(****8!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% "8HHS2T )4:DN2&'%2,<"D.<<=
M:!,8?DX XKE/&'A&#7+-W5 )0,]*ZWH.:13NSFAJZLS*4.969\LZQI5QI%RU
MO*A50>IJSX=U^ZT2^26-SY>>1FO;_&?@^#6[-G1 )0.,"O!=7TNYT>Y:"5""
M#@5P58.F[Q."4'2>A]'>'?$5MKEBCJX\S'(K9D_U$F?[IKYK\*^(I]#O(V+G
M83R,U[YI&N6^LZ<TD3@G9R,UU4:BFK=3HIU^;1GSSXB9U\57F.FXU0EQ)C'6
MK_B679XINUQU8U1=?+ 8=Z^@H*R/,Q3UT$ P,44 Y&:*U9S(****@8444528
M!1110MQ(*W? W_(WV_U%85;O@;_D;[?ZBL*WPLUH_&?29Z#Z4@I3T'TI!7D,
M^D6Q5U3_ )!D_P#NUXW+_P ?$G^\:]DU3_D&3_[M>-R_\?$G^\:\'-?@1]!D
MOQL****\I[(^A[A1116?4.@44458!1114+<&+VIK=*=VIK=*<_@*C\9U'@3_
M )"35Z57FO@3_D)-7I5?3X'^$CXS,?X["BBBNX\\**** "BBB@ HHHH ****
M "BBB@ HHHH **** "@T44 -"G.<T9#< TU0P)W'BA3'D[6!/UH <%([TZF(
M&!.ZGT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%,?/44  ?YB",4UI0C'=PH[T$@D ]:YCQYJLFFZ.!"<.YQF
M@#.\8^(8H)XA;W0&/O8-;WAS5;:]LU9;D/(1R,UYC)X;D>RCO;R4N)AG&:6V
M6XT*2&6S61D9AG% 'M?6@G SVJM8RO/IT$K##,@)%4/$&KQ:5I[%F'F.,**
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MHHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH
M,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,TF:6D/2@!I(V-]*^9
M_%X_XJRZ_P!XU]+DC:_TKYI\7X_X2RZ_WC730^(\_'_"8X))HH&<T'K7K+8\
M=;!1112)CN%%%%!3"BBB@ HHHH U_"/_ "-=K_O"OIA/N+]*^:/"(!\5VO\
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M>:\U\"EO[2:O2J^FP/\ "1\9F/\ '8N:,T45W'GAFC-%% !FC-%% !FC-%%
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M*/X=0OI?VII'^TE=W6@#T6"YBN4#PN'3U%35YEX,U>XM-:;2+EB #@;J]-H
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M@_NT .^UP?WZ/M<']^F_88/[M'V&#^[0 [[7!_?H^UP?WZ;]A@_NT?88/[M
M#OM<']^C[7!_?IOV&#^[1]A@_NT .^UP?WZ/M<']^F_88/[M'V&#^[0 [[7!
M_?H^UP?WZ;]A@_NT?88/[M #OM<']^C[7!_?IOV&#^[1]A@_NT .^UP?WZ/M
M<']^F_88/[M'V&#^[0 [[7!_?H^UP?WZ;]A@_NT?88/[M #OM<']^C[7!_?I
MOV&#^[1]A@_NT .^UP?WZ/M<']^F_88/[M'V&#^[0 [[7!_?H^UP?WZ;]A@_
MNT?88/[M #OM<']^C[7!_?IOV&#^[1]A@_NT .^UP?WZ/M<']^F_88/[M'V&
M#^[0 [[7!_?H^UP?WZ;]A@_NT?88/[M #OM<']^C[7!_?IOV&#^[1]A@_NT
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M#^[0 [[7!_?H^UP?WZ;]A@_NT?88/[M #OM<']^C[7!_?IOV&#^[1]A@_NT
M.^UP?WZ/M<']^F_88/[M'V&#^[0 [[7!_?H^UP?WZ;]A@_NT?88/[M #OM<'
M]^C[7!_?IOV&#^[1]A@_NT .^UP?WZ/M<']^F_88/[M'V&#^[0 [[7!_?H^U
MP?WZ;]A@_NT?88/[M #OM<']^C[7!_?IOV&#^[1]A@_NT .^UP?WZ/M<']^F
M_88/[M'V&#^[0 [[7!_?H^UP?WZ;]A@_NT?88/[M #OM<']^C[7!_?IOV&#^
M[1]A@_NT .^UP?WZ/M<']^F_88/[M'V&#^[0 [[7!_?H^UP?WZ;]A@_NT?88
M/[M #OM<']^C[7!_?IOV&#^[1]A@_NT .^UP?WZ/M<']^F_88/[M'V&#^[0
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MQ$5W;J07MNQ^]S1]CCQC'%)_9\ /"TFKBEY#OM4#@@MD5P'CKPI:ZK;M/;H
MX&3@5WWV&+' I'M(1;R KD;34[Z,RE34EJ?+%S&;6<VK?PG!IN/+^[TK2\0Q
MHOB6\&.-QQ6:Q.W J)0G2]Z)X.(TE:([.>:*:#Q2[J]7#UXU%H968M% .:*[
M>9+1@%%%%:VTN 4445"!!6[X'9%\76^XX.16%6YX(C1_%UON'.165;X36C\9
M]&FYA4C+=J/MD _BI&LXF()':D^PP'M7COR/HU\)7U&ZB?39RAS\M>1O,K3R
M<?Q5ZWJ-I%%IL^P8^6O(G5%N)./XC7@YK\*/H<E^-@QW4;2.:#UXI237E/9'
MT'<2BBBL^H= HHHJP"CK114+<&(5(IV\ <T$DB@[<<TY_ 5'XSI?!$Z_VDW%
M>B?:X 2"W->=>!XT;4FKT,V4)).WFOIL#_"1\;F-O;L=]K@_OT?:X/[]-^PP
M?W:/L,']VN\\X=]K@_OT?:X/[]-^PP?W:/L,']V@!WVN#^_1]K@_OTW[#!_=
MH^PP?W: '?:X/[]'VN#^_3?L,']VC[#!_=H =]K@_O4GVR#^_2?88?[M)]@A
M]* '_:X?[]21RI+]TYJ$6,(_AJ6*%(ONC% $E%%% !1110 5',F^%U(SD8J2
MJM_>+8VCSLN0O:@#RK6=&U+0-0FN[-"8Y3DXJ+P[XDBMM0S>CJ?F4UW5GXEL
M?$-E=1* &C!X-<CH^AV%_J5T;@;=N<&@#O[233[JPEFTP(I(R=HQ7E]MJO\
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M_"RQ \\5ZN7  XXHW'J!Q0!2T;3(]*T]+=!C YK0H%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%% !1110 4444 %%%% !1110 4444 !I*4TE"!A3)?\ 42?[II],E_X]Y/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCI4HS6IU"[CG-*%PV:5?6EK0T2&MG-"]:=13+N+1112$%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4&B@T -;[C?2OF;Q?_P C;=?[QKZ9;[C?2OF;Q?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCTCPMI^D#%N@ ^E:&EWJZA8QW _B%6\$\4+<:BMP!'W12@;12*H2EQSFK+%
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MTE>^]CYH!2T@I:([""BBBF 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.M$4-.V@B\L:>HQ2'U%*IK3H7;J.HHHI %%%% !1110 4444 %%%% !1110
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M?)U/B9]U2^! :*#162-0HHHI@%%%% !2BDI10-_"1O\ =->H^#?^0,M>7/\
M=->H^#?^0,M>IEW\0\/-?X*.CI*6DKWWL?- *6D%+1'804444P"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:2O?>Q\T I:04M$=A!1113 **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>\/^T:S@PSS5[Q#*Q\37>4_B-4%;GE:]>EL?,R_B,6BCO16PF%%%% @HHHH
M****$%[A6]X&_P"1OM_J*P:V_!,K)XNMP%SR*QK;&M!VF?2N>!]*!5-[N16
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MP= PZ'FO)M=9?^%C(,<;J]6M\?9X\=,4 2T444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4ASFEI",B@!A +#-<9XTU?5M+DCDLL^5GG'I7;
M;>,55O=/AOK9H9E!R.M 'GNLZ_:ZQI]L'8"8 ;\FJ?B.]M&\.V]O;A6FR/N]
M:;XF\#-92B6VE.UST':M;PMX$6,)=W<ID&<A#0!L>&[U=.\.)->$JH7O7+WV
ML7/B[4OLMG<K';*<'FN[UG0HM6T\VB-Y28QQ7&P?"G[(^^WU%HSG)QF@#K]%
MTS3]'M519HO-(Y;<.M3ZY:QWVBW"Y#G8<$<URDWPZNI2I_M:0$>YKK='TIM-
MLA;RS&;C!)[T <!X$U,:?>365P?+7?\ Q<5L>/-?B_LUK.VD61Y!@[3FKFL^
M!;?4IC+!+Y#GN*IZ9\.8[2[6>YNC/M.<-0 [P;HL?_"*NLJ$22 ]?I7-^%KM
MO#?B.Y@G^2*1^IKUB*".%0D:A5 Q@5SOB+P=;:V=ZL(9/[PH A\5^(((=)=;
M>57:1<<&LSX<:>1:3W$JD,YR*6U^&XC=3/>M*%/0UVEC:PV-J(HU"JHH S+K
MQ386=\MF[8D)QUK,\>::VHZ*)8ADCYJY3Q1I[7/BJ":U)8A^<5ZG' LMA'%*
M,C8 1^% '&>!]?BCT\6=U($:/@;C65XZU7^U[B*QM3O4-SMK6U+X<QWEVT\%
MT8<GH*N:-X$M],N!-+-YS#UH CO=#C;P0(E7]X(P?QK(\ ZLNGQM8W+A &XW
M&O1S$AB\LJ-F,8KCM6\ 0ZA<&:&X,)/I0!G^/]:CN;/[#:N'9S_":OZ'HD?_
M  A1C9")60YINF_#V&SNUGGN3,5[&NT2)(XA&J@+C&* /+/!5^=%U&>TG.Q&
M?^*NA\:Z_;KI3VUO*KO(,<&K&M^!X-5F,L4ODN>XK/M/AND-PDL]X90IZ'-
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M ;A?[HHPO]T4[%&* &X7^Z*,+_=%.Q1B@!N%_NBC"_W13L48H ;A?[HHPO\
M=%.Q1B@!N%_NBC"_W13L48H ;A?[HHPO]T4[%&* &X7^Z*,+_=%.Q1B@!N%_
MNBC"_P!T4[%&* &X7^Z*,+_=%.Q1B@!N%_NBC"_W13L48H ;A?[HHPO]T4[%
M&* &X7^Z*,+_ '13L48H ;A?[HHPO]T4[%&* &X7^Z*,+_=%.Q1B@!N%_NBC
M"_W13L48H ;A?[HHPO\ =%.Q1B@!N%_NBC"_W13L48H ;A?[HHPO]T4[%&*
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M487^Z*=BC% #<+_=%&%_NBG8HQ0 W"_W11A?[HIV*,4 -PO]T487^Z*=BC%
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MPOI/]&_BIW@!=9DC6%&_T0'FO2]9TP:OI<MDS[1)U-5/#GAY/#]IY"2;QZT
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MQ6?+I$3R;MHKHINS/'S'#5:ZO"5B/1C(T +YK4VY--@A6",*!3PW-3.6IZ6
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF/T:JM[R!NYZ7X(_Y!&*Z@5RW@?_ )!5=37UF&_AH^'Q?\:04445T',%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4&B@T -;[C?2OF;Q?_ ,C;=?[QKZ9;[C?2OF;Q?_R-MU_O&NG#_$>?C_A1
MD]Z2E[TE>LMCQUL%%%%(F.X4444%,**** "BBB@#6\)?\C9:_P"\*^F4^XOT
MKYF\)?\ (V6O^\*^F4^XOTKS,7N>S@_A'=ZJZC_QX3?[M6N]5=1_X\)O]VN"
MI\#/1I_&CQNY_P"/R7_>IO:G7/\ Q^2_[U-[5\G4^)GW5+X$!HH-%9(U"BBB
MF 4444 %**2E% W\)&_W37J/@W_D#+7ES_=->H^#?^0,M>IEW\0\/-?X*.CI
M*6DKWWL?- *6D%+1'804444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% $%X,VDO^Z:\9N_^0C-_O5[1=?\ 'K+_ +IKQ>[/
M_$RG/^T:\;-OX9[>3R_>\HSO4<URML-['BGEL]*R]95VLR5KQZ>J1[6.G*C%
MR@KCX]3CFGX(YK3,J, ,9KSZT%P+I,!L9KN;-<A7?IBMYQ4=3@P.8U<1[E2)
M..1P*2G'[QV]*;7,I\S/<2BOA"BBBLW\0H[BCK3'Z-3QUIC]&K3[2$]STKP/
M_P @JNIKEO __(*KJ:^KPW\-'Q&+_C2"BBBN@Y@HHHH **** "BBB@ HHHH
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M@I:([""BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !0:*#0 UON-]*^9O%__(VW7^\:^F6^XWTKYF\7_P#(VW7^
M\:Z</\1Y^/\ A1D]Z2E[TE>LMCQUL%%%%(F.X4444%,**** "BBB@#6\)?\
M(V6O^\*^F4^XOTKYF\)?\C9:_P"\*^F4^XOTKS,7N>S@_A'=ZJZC_P >$W^[
M5KO574?^/";_ ':X*GP,]&G\:/&[G_C\E_WJ;VIUS_Q^2_[U-[5\G4^)GW5+
MX$!HH-%9(U"BBBF 4444 %**2E% W\)&_P!TUZCX-_Y RUY<_P!TUZCX-_Y
MRUZF7?Q#P\U_@HZ.DI:2O?>Q\T I:04M$=A!1113 **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH 2@T4&DQ= [5')_J)/\ =-2=
MJCD_U$G^Z::&_A/F+Q'_ ,C1=_[QJAWJ_P"(_P#D:+O_ 'C5#O7L4MCYF?\
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M<P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !0:*#0 UON-]*^9O%_\ R-MU_O&OIEON-]*^9O%__(VW7^\:Z</\
M1Y^/^%&3WI*7O25ZRV/'6P4444B8[A11104PHHHH **** -;PE_R-EK_ +PK
MZ93[B_2OF;PE_P C9:_[PKZ93[B_2O,Q>Y[.#^$=WJKJ/_'A-_NU:[U5U'_C
MPF_W:X*GP,]&G\:/&[G_ (_)?]ZF]J=<_P#'Y+_O4WM7R=3XF?=4O@0&B@T5
MDC4****8!1110 4HI*44#?PD;_=->H^#?^0,M>7/]TUZCX-_Y RUZF7?Q#P\
MU_@HZ.DI:2O?>Q\T I:04M$=A!1113 **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF;Q?_P C;=?[QKIP_P 1Y^/^%&3WI*7O25ZRV/'6P4444B8[A11104PHHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ*QK?"S6C\9])GH/I2"E/0?2D%>0SZ1;%75/^09/_NUXW+_Q\2?[QKV35/\
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MZ*;G.10.E #J*P_$.LR:-;>:JAO:I]%U!M8TQ+E@%)/04 :M%1A@QPIZ5)0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44E% A:*2B@+
MBT4E%)L8M%)13 6BDHH 6BDHH 0GFE!I",T 8I6)UN.IC*&!!&13LT=J;&T<
MSJG@;1M7E,MQ"-Q]!45A\/-"TZ82PP_,/45U5*:E)$J$>Q5N%2*PD2-0JA<8
M%>/7O_'_ #?[U>QW8_T27_=->-WW_(0F_P!ZO+S#561[V4R4)/0C[44#I17@
M\W+H?2\C?O)A1114+>XE)WU"BBBJYM2^H44442744_<=Q1UIC]&IXZTQNC4X
M>_(=O=YCTKP1_P @FNIKE_!'_((_&NG%?5X?X$CX7%.]:0M%%%=)SA1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%!H 2@T4&DQ(#TJ.7_42?
M[IJ2F2_ZF3_=-- ]CYA\1_\ (T7?^\:H5?\ $?\ R-%W_O&J%>W1C[I\]5CR
MS;$HHHJS'4****0:A1110&H4444T-KE5PK=\#?\ (WV_U%85;W@7_D;[?ZBL
M:_PLTP^LSZ2/0?2@4OI1VKQVSZ-;%/5/^09/_NUXW+_Q\2_[QKV/53_Q+9_]
MVO&Y?^/B3_>KP\Q7.N4]W*)<DFQ:*6DKQY2MH?3*.EPHHHJ>MS._0****=RV
MM HHHJ;V)3N["]J:U.IK5:]]<I<O<]XZCP)_R$FKTJO-/ W_ "$FKTH5]+@7
M^[L?%X]WK-BT445WG %%%% !1110 4444 %%%% !1110 4444 %%%% !112,
M0HR: %HJO<S&&U>8?PC-86C>)FU2_:W* 8.,T =+132N3G-( V\^E #Z*:%P
M>M)\VX@]* 'T4Q!C(SFGT %%,<9&,XIP&!0 M%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 =J0>AI:;UY% #0,,:I:OJ4>DZ>\\A XXJ^#7+^/+*6]T(B+.5.3B@
M#SW5[[6-=$LRN1 O058\/>)+[15C6[RMNS8R>E5K?7((=+-HZE9$X/'6NOT_
M2-.\6^'(H'*H\9SD=: .RM+J*>WCEB(82#.15RL_2M,32[)+96+A1@$U? P*
M %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@T44 )1FC%&/>F,
M,T9HQ[T8I &:***+"N%%+12L E%+10 E%+10 A.*;FG$9I,"DD[CNA*=29%+
MFJ>HKH2ES11BLTG<""\_X])?]TUXU??\A";_ 'J]DO/^/.7_ '37C5\W_$PF
MX/WO2O,QKU/8RS=C!TH-(&XZ&C=[&O$DM=CZF,UR[BT4F[V-)N]C32\C+F5]
MQU%)N]C2;O8TK:[&G,K[CJ*3=[&C=[&JEML16FGU%%-;H:4-[&F,W!X-%%6E
ML6I+V=KGIG@@_P#$IKJ17*>""?[*KJATKZ7#RNCXC%+][(6BBBNLY@HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4@QVI3TIA&%^6@ W<XQ4%S):HI6YD4*W&&-6 < 9ZUR7CG2+J
M_L ]H[!U.>* ,?QIH&FI9F:UC =^XKF[32]7\/:9'J4-R3&3DKGM3[CQ!+'I
M7V*]5O,C& 30VN-?:+%80*S2$X- 'H.F>)?/\.&^V&21%Y4=36)%\29I)-IT
MJ0<XZ&MWPIHW]FZ6HF&3(,E2*W#:6B\FWB'_   4 5-)U9M3B#F QY[&M,G%
M1H$ _=H /88IQ(/!H <*6D P*6@ HHHH ****  UGW!E:;8C5H$9K.SC4<4
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M,FA59![&+.4_X0'1_P#G@/RJ6V\$Z993BXMX@LJ]#BNFR:6B5274%1BMC/\
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M_6M"BF(S_LUU_P ]/UH^S77_ #T_6M"B@#/^S77_ #T_6C[-=?\ /3]:T**
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M% "44N*,4 )CFD(SWI<48H CF3S82E$$?E1!/2I H%+0 E%+BC% "44N*,4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=M '7<=<TAPW:N7TOQYIVI2B+:8V/9JZ@.K('0Y!]* #;@T^F*P>GT %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "''>DQN'!I,'=STJ
M*0NLH5.E $@& >Y%-5O,&#P:J:EJEOI$'FSL/I7,R_$BP1OEMW;'<4 =J!M
M&:&XZUBZ+XDL]>A8PL%<?PDUHSW*6-J9;A@ .YH G*EF!S@"E9,G@UQEW\1[
M"VD*+"\F.ZUKZ+XILM=&V$['_ND\T ;@PO6F^9\Q##CL:;)(D,;23,%5>YKD
M[[XAZ=:W#0K$TNWNO- '8J-HZTC GFN9T;QSI^L70MP#$YZ!JZ+)CW.S#RP,
MYH D^\,#BE P,&N4U7QY8Z;)L5#*0<86DL_'UA=.BM&8RW]Z@#J]QW8QQ0P&
MX<TQ)1<0K)$<@\T\#.,]: 'T444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% "%L4'D48!JK>W\5E$6D8 "@"<+AN33JXJ]^(]C92[#
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M4.3;QMU'2O3K"S^Q6,<*?P@9H MA<&GTB_=%+0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 1OR>3@4O0Y[>M#88X(Z49WC:* //?&FF
MZKJ6I01VZL;<M\U='8^$].M[$1R0(SE.21WQ6Z6VX4KFLS7=>MM(LV=F!<C
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MH5#@]:DJ)!DY;K4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BB@G% !11UI"<4 +1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !12 @TM !12 @TM !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2'GBEI,\XH
M:1V!H SQFD95!R6Q]32JJYR#F@!PI:0'-+0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZAE(*GH13JXKP%K%YJ$4MO<HRB'@;J[,G YH =13-X/%.Y[4 +1110 4444
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M<<E>*15(ZT #]!CK3AT%& : V: %HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *BN(5G@>-P"&&*EI"<"@#RK5O"^H:%<SWFF E9,E@*P
M--GUR[NVAAA(9N&(%>WSH98'CQ]X8K(TO0O[.NVGX.XT 9GA#PK_ &.6N9OF
MFDY.>U=A3<\]*=0 48%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "D;..*6B@!@;-+NSTI< 4  4 -W$GBGT@ %+0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 )F@TE**$*XF32T4AH8[CJ0TE+20
MK@*6DHIV"XM%)118+BT4E%%@N!H%% H&!-%%%%Q6"BBBAC#-+24M2@"BBBJ
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"
M,-ANE>!_%B9%\3 U[YCDYKG-6\$:5K=W]HNTW-6M.2B[G/5ISFK'S>9HSCGF
MG&5*]_/PS\/J<^53O^%:Z">?*KM6+21P/"3N?/OFQT>;'_D5]!_\*ST'_GE1
M_P *ST#_ )Y4/%H/JDWN?/GFQT>;'7T'_P *ST#_ )XFE_X5IH'_ #Q-3]9B
M+ZE,^>_-CH\V.OH3_A6F@?\ /$T?\*TT#_GB:/K,0^I3/GOS8Z/-CKZ$_P"%
M::!_SQ-'_"M- _YXFCZS$/J4SY[\Z,<DXK=\#3>9XQM]H)&1S7LK_#'P^PYB
M-6=-\!Z/I=VMQ;1X=>AQ4RQ":LC6&%Y'=G4=,5QGCS0'O[,W< S,G( KLE.6
MQ2LBOPP!![&N)GHQ/.?"WC3[+!'8ZBGE%.-QKH-2\::;:P%K:997(Z"K.H>#
M],U%RTB;2?[HJG;?#_2+=]WSM]:E%6.8\/V][K7B(:@P98P<T>*+273?$R:D
M$)7N:](LK&WL8]D"!13;[3[748S%.@.:87,>U\8Z6=,65[A1(%Y2N)C#^)?$
MWVA(R8U;.:Z__A7VD%RQW\]JV=-T.TTD8MDQ]: *^NA8O#[*QQM7'Z5R/PY*
MMJ%R5Z<UW]Y9Q7MN8I_N&J>E:%9:2SM:C!;K0!B_$A@OAEO]ZG^ 61M!BQR<
M5NZCIEOJMM]GNQE>M+IVF6VDP"*W&%% '"?$IXO]'BZ-O%-\5F1?"EE@9 05
MV6J^';+69$DG&64Y%<OX^_T6P@M8\")0!0!/X/\ $]A#HB174HB*>M87C'68
MO$%['9V(\Y<CD5LZ#X.TW4]#BDFW9;KMK?TOPCI6D2B2!,N/[U #M*L'@\)B
MT*X;RR,5YUI5M8Z/KDL.JVX"NV=Q%>P<YXZ5DZMX;T[5W#W*8;U% '/W][X/
MM+9I8HH)9 .%45I>&=0M[_3WEM[00I@XP,5!%\/=%C?<-YSZFNCL;"#3[;R(
M5 04 >6S%1XVCR<9>O5IS_H4G_7,_P JRY/#.GS7XO-O[U3FMAT#1E.Q&* /
M*/#3))XNF+'!#&M[4/$HM]?:VU"+_1N@8BN@M?#-A97;72K^\)S4NJ>'K#6$
M'VE/Q% '+:\_A>YTUVMWB\\CY=O6J7A!KF/2+X*#]T[6K?C^'FC(X8;SCWK?
MM=,M;&W^SPH AX- 'EOA2>P_M*<ZVPSO."];GB?5-'AT>>.P@1U9<%U'2MZ]
M\"Z5>R%W5E).3MJ:'P?I<5DUJ%+(PYS0!0^'14^&,IR"U<AXA9[+QM;W-SE8
M@P^8UZAIFF6VC68MK88CSFJFL>'++7-INEZ="* )HM6LM0LG^SSJ_P G05YS
MI,JGQKMQCYZ[W3/#5CHRD0EB&XYIR>&["&^^VHN),YH P_B)I,VH64,L*EC%
MR<4GA3Q391:<+>\F$3QC'-=FZK-$4(!5A@YKG+KP)I%S(9&5E).3B@#E/%^M
MKX@NH[&P_>*#C<*V;JQ>P\%_9Y#@[>:VM/\ "6G::P>V7+#N:U+JP2_MS#<#
MY/04 <7\-,+!<**M_$=BND1D=,\UT6G:+:Z2K"U7!:I-0TN#5;80W0RM &%X
M$>*32!MZXYKH=2#?V;<"/AMAQ4.GZ7;:7'Y=L,"K;JSC:3P>M 'D'A^>S&O3
M+K1&S<<;JZ'Q-J>DV>D3)IMNCAUY9!Q6_J/@G2M1<M(I5R<Y%2V_A'3K>R:V
MVEE88^:@#)^'!63PQ)M_B8\5R[^;X;\4/.T9$<C9+5Z;I&CV^C6Q@MAA2<TW
M4=$L]5&+E ?I0!G7'C+2H[#SEN5:3;G9WS3/#7BB37W<>041>C8J#_A7FC^9
MO^?Z5T&GZ7;:7;^5:H%% 'GGQ(BE@O;2<*?+5P6:NUT;7M.OK&"."Y5Y!& 5
M[YQ5O4M+M=7M3;W:@CUK+TCP;INBW!G@+%LYP: .'UI6T;Q,+RY^6-VR#78M
MXUTU=/!BE#R;.E:&K:!9ZW@7R_*/NXJA;^ ='@?>H8^QH X3P[=->^+FN74A
M2V15WQ/,S>*XQ=D_9/?I7?6OAO3K68/"@#"EU3PU8ZKCSU_&@#(BN?#,%HK6
MR123!>%'7-<OX.NA<>/+EPGEYS\M=G9>"=+L9Q-'N+#UJ]:>'+"SU%KZ%,3M
MU(H X[XB6[+?0W6W*KC)KHM"U.TU3PX8+>4-((R"OI6OJ.E0ZI"8K@ J:HZ1
MX:T_0&9K8-F3KF@#S[0-2@T7Q8\%X^Q&?[QKTO5(+?5='EV@2!T^4UGZAX*T
MC4I_.E0A\YR*U5^RZ+IVUY L,8XW&@#QF\U&;3!_908@L^,5ZGX4TTV>F12Y
MY=<D5YXUM;^)O&_G6R_NE;MTKUZ"'R+:.)>BC% $N<-DUYY\2255#C(XKT+A
MC@]17G_Q$?:T:G[IQ0!=\)>*-/CT2.*YF6(IZUS/BK5H_$>LQVMDOFH&'(KH
M='\&Z5J.BPRR;LL.=IK=TGPEI>DS"6WCRX[F@#C_ !G'>6?A^Q@A!"*!OQ5_
MP[/X9_LE!,8FG ^8-US79:CI\6HP^3*H*'K7/+\/M(BE\R(N&SGK0!Q6N:A#
M<>+K"*UM_+C5A@@=:[_Q>VWP^3C/R_TJPWA;3GEAE9!YD70XK2NK**]MS!.,
MIB@#C/AJX-K<<\YZ5@ZY$^B^*CJ4D9*.W7%>D:;HMII.[[*N-W6G:GH]IJ\(
MCN4!'TH S8/%^EOIPE$Z[]OW:\WLM3?4?&1=%(0O7H,?@'28WW*'^E7+7PGI
MEG.)88\..] &U&#Y"#O@5S/CJ&6;0I1&,@#FNG!((7L!4<UNES"\,H!1Q@T
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M0 T+@Y!I>33L8I",T (#3<MO]J>1E<"D (7% !CYNE1L#OR#4HSCFD"@'-
M>1QUI 3_ !"E(XXZTB*W.Z@ 8EA@4T1G^]4@7!XZ48YXH :"0=M#97I3L4F#
MF@!H( RW4TI//3BE90W6E(!&* &DKWI2<#IQ044T8.?:@ P"N0.:0':O-.QC
MI01GK0!$RE07!S[4V-6)\S]*GQQB@#'2@!N=WL:;)E0.,T\KGGO2@'O0 P
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% "8I,4M)3%RABC%%% <J%Q1BDI:5AV"BBDJ7<!:*2BE=A<6BD
MHHNPN+10*6JW"XF**6BBP7"BBBF 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 )D4<4A'O2]J3  P- (-,S@]*7/M0AC\TF:;GVHS[4W="'44F[VH
MW>U"8"T4F[VHW>U "T4F[VHW>U "TF::SD#I2@Y&<47$*""<4N:08ZTF/>AW
M#0=GC-('!I"I(XJ/+*,;>:E-]1DH<$G%.!S4*@'D=>]/'Y58#B<#- .1D4GM
MU% _(4@'44TM@<<TF=P]* 'TA(!IJ\=\T [\Y% #LC.*6F@#IGFF(C(22<T
M29I:;GC-(1NZ&@!^::&!.*%4CJ<TFX \C'O0 XD 4!@W2HO+8MNW9%*1N&%X
M- $N:"<4T#Y<9YH''6@!0<TM(,8XI.E #J,TG:C(]: %HJ)MRG<.13N7&>E
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M$ZIX]33+PVSQ_-G JG<>.M651+!IY>+J3M[4 >A,!CFD7;U%<[X>\5PZT C
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MBCKQ7GMQXYU8CS+;3R\7][;VK9\.^,(=7;RI0$F[K0!U( 44P8<FG8^;.:"
M <=: ,3Q1J%QIFEM-;?>%<+IFK^+==BDDMB<*:['QKSHC#/:LWX<*5TZ;GC-
M &&VM^+=*;=?AC&.M=18>*5U+0Y)HS^^4?K6AXI:S&C3BZ90=AVUYMX9#II5
MX4SLR<&@"W::]XMU:_EALB=B$UHO'X[; R<55\$ZU8:;>7/VN<1ELXS7;?\
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M6\O=/T=KB]4F11R!7DWAS6]1L/$,L\%H9)9"0RXZ5ZQ)J,DFBFXN[?'&2A%
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M;<2Q]>] &AC/- II/.!3Q0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT?Q'I^D)+';VAD<G[V*W/B%%<R: %ML[@W./2L#PMK>A6-FEO?HOVG')*YH
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M &%++9:J#%''G:V*U-7^(<$91-*7SV)P>* )/&EG;V'AM[>WC  '%6/AP/\
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M?U+3"M@J&X)X*K@UI?#N&XBL)/.SCMF@#M<#.12BFC"+S2K0 ZBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW-P)Y(@9!SFM*B@",((XP@'R@8Q6>N@:=]K-T(!YI.=U:E% ##\B_P J8F]
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MT *.  >33J8.#S3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ,4444 &**** #&:  ***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ Q1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%!.* &;B<TH)Q0!S[4U@^[CI0 ^EIJG/UIU
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4F 3G%
M+10 4444 &!1110 8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **:6P:.2>M #J*8S$$"EW4 .HI,YI.
M: '44T\<DX%-\V,G"N"?0&@-"2BF9- .:8#Z*2C-(!:*::.E*X#J*BEW-"X0
M_,1Q7FPU_5=-\8+:7DI^SLW )JBE&YZ=142R"2(2(>",BL#QAK$FD:$9XVVR
M'@46)9TE%<9X#OM3U"T>XOV+*W*YKL%)//:D).X^BFY9E/&#4%V[PV$SC[RJ
M2*!EFBO._#'B+4+W6Y;>X8E V!7H?.[VH 6BF,2K9[4*Q;I0 ^BF\AL]J&SC
M@4 .HIJ;L?-2]>E "T4T-DXI><T +14>YF)&TCWIV2JYZT .HKS[QAXEO8]1
MAT^P)21SC-;GAZRUFW(?49MX(SC- '2T4QCM^;/ %<=?>*+N+5Q;);OL)QNQ
M0!VE%10.SP(Q')&:?E@>F: '45&Y93N[5!=SO!923 9*C(% %NBN3\/^(;K4
M[]XI('5%/4BKUYXIM;35DT]E)E<X% &]144[E+=Y .57.*Y'3O$]W?ZNUK]G
M=$4XW$4 =G13.< =Z=@XH 6BF$MD#%<_XRU"YT[2?.MCA\]: .CHKE?!6IW6
MI6)DN7W-74;N<4 .HKG_ !;K3:+I+S)]X]#7*Z%_PDVH6_\ :C3G[.<L$SU%
M 'I5%<?HWB.\O]3^S20.JJ<%B*ZXY/2@!U%-W?A0"2.E #J*@,Q#[ I/O4GS
M 9_2@!]%1"0N.!BGJ210 ZBJE_*\6GW$BC#*I(KA_"7B'4+_ %B2"Y<E V!0
M!Z'2$9%!.#69KFJKI%@UPW3M0!#XAU9M)L_,7!J70K^74M-6X8#FO*-5O=7\
M0K),CE8 >!5K0/$E_HBPQ79(@+8&: /8  #[TZJMM=)<V<=R"-I7-<CX@\<I
M9I/!;H3* <$4 =Q17FG@37]5U:^<WDA\O/ )KT>201*SM]U10!)17FFN^)=1
MU'5C8Z2Y!!QD52EU#Q+X?99=0E9XSUYH ]8HK+T/5$U32DN@P.1S7(^*/%%T
M]\+#3'Q*>.* /0J*\GEG\5:,@NKN9FBZD9KNO"^MKK6G>;N&\<$4 ;U%-5LG
M'I7)^(O$=UIM^D$,#NI.,@4 ==15:RF>XLHI6&&89(J8EASC/M0 ^BF EN2,
M4HSG.>* '45&[,?E P:<,JG/)H =13$<OR1BC<P;&TX]: 'T4S<=^,4%B& '
M- #Z**9\RG)Z4 /HJE?WHTZU>YD&449-5M#UR'7;9KBW&$4XH UJ*09(STHY
MH 6BF%6YYI5R!@T .HIN[G%-WEFV@=* )**09QS36DVD B@!]%-Y)SGBE.2#
MB@!:*9DHO/-4=4U>+2K4SS#Y10!HT52TW4$U.Q6ZA'R-TJV"0,F@!U%87B35
MI],M@\$3.?:G^'-4FU.R,DT;(WH: -JBDYQ[TGS =,T .HIIR<&D+X.,4 /H
MJ+<RG!Y)J09"^] "T4W=\N<4TN3C H DHI"<"FY+=* 'T4WD"A6+=L4 .HI,
MXXQ2<^M #J*3\::68/@*2* 'T5&-RG+=*7Y@<]J 'T4T;B#VIJAU)+'(H DH
MIH)8>E*,]Z %HI#GM0<\4 +13<G/2EYQ0 M%-R57IDT#=UH =12<D4T!@.3S
M0 ^BD' Y/-)@YZ\4 .HIA<AL;33LYH 6BF*&&<\T*&W9/2@!]%-.3TI"2>G:
M@!]%1_/NSCBI* "BF'<&)[5A7?BNUM-5CT]U/F.<"@#H**0],T DCI0 M%,
M8$D]*:)"S=.* ):*:K;B>*,G=C'XT .HI.]>>>*?$E_::W':VS%4+8)H ]$H
MJM8R.]A [\LR@DU,0Q/M0 ^B@44 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:?(P%9!\7ZY?0"73+8R#OQ4'CN -!:9.%P,BNP\)6\$.APF&,+D<G'6@#G]
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MU3N?%_B:U(GDL_\ 1<_>V]JS_"]I9W?BNY$\6YE<X->A>)X4_L*6/: BH>*
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M#(.]7?B+"CZ;&^!N!ZT =;9W:7EK'-$<A@":E=EAC>5CPHR:YCP*SMI0W-D
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY9-\EG&6]<5+_8^F@!/LR8'3B@#FVTEM4\'1Q(OSA<X-8^A:Y:^'HWM=3M0
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M/ K2#N:MA%"!5&%':@#RG0]X^)3 JV,]<<5O?$4L+9=JDY'85UPTVRAN3=)
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
9HHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>form10-k_006.jpg
<TEXT>
begin 644 form10-k_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /]"10# 2(  A$! Q$!_\0
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MK6HH R?[(_VC1_9'^T:UJ* ,G^R/]HT?V1_M&M:B@#)_LC_:-']D?[1K6HH
MR?[(_P!HT?V1_M&M:B@#)_LC_:-']D?[1K6HH R?[(_VC1_9'^T:UJ* ,G^R
M/]HT?V1_M&M:B@#)_LC_ &C1_9'^T:UJ* ,G^R/]HT?V1_M&M:B@#)_LC_:-
M']D?[1K6HH R?[(_VC1_9'^T:UJ* ,G^R/\ :-']D?[1K6HH R?[(_VC1_9'
M^T:UJ* ,G^R/]HT?V1_M&M:B@#)_LC_:-']D?[1K6HH R?[(_P!HT?V1_M&M
M:B@#)_LC_:-']D?[1K6HH R?[(_VC1_9'^T:UJ* ,G^R/]HT?V1_M&M:B@#)
M_LC_ &C1_9'^T:UJ* ,G^R/]HT?V1_M&M:B@#)_LC_:-']D?[1K6HH R?[(_
MVC1_9'^T:UJ* ,G^R/\ :-']D?[1K6HH R?[(_VC1_9'^T:UJ* ,G^R/]HT?
MV1_M&M:B@#)_LC_:-']D?[1K6HH R?[(_P!HT?V1_M&M:B@#)_LC_:-']D?[
M1K6HH R?[(_VC1_9'^T:UJ* ,G^R/]HT?V1_M&M:B@#)_LC_ &C1_9'^T:UJ
M* ,G^R/]HT?V1_M&M:B@#)_LC_:-']D?[1K6HH R?[(_VC1_9'^T:UJ* ,G^
MR/\ :-']D?[1K6HH R?[(_VC1_9'^T:UJ* ,G^R/]HT?V1_M&M:B@#)_LC_:
M-']D?[1K6HH R?[(_P!HT?V1_M&M:B@#)_LC_:-']D?[1K6HH R?[(_VC1_9
M'^T:UJ* ,G^R/]HT?V1_M&M:B@#)_LC_ &C1_9'^T:UJ* ,G^R/]HT?V1_M&
MM:B@#)_LC_:-']D?[1K6HH R?[(_VC1_9'^T:UJ* ,G^R/\ :-']D?[1K6HH
M R?[(_VC1_9'^T:UJ* ,G^R/]HT?V1_M&M:B@#)_LC_:-']D?[1K6HH R?[(
M_P!HT?V1_M&M:B@#)_LC_:-']D?[1K6HH R?[(_VC1_9'^T:UJ* ,G^R/]HT
M?V1_M&M:B@#)_LC_ &C1_9'^T:UJ* ,G^R/]HT?V1_M&M:B@#)_LC_:-']D?
M[1K6HH R?[(_VC1_9'^T:UJ* ,G^R/\ :-']D?[1K6HH R?[(_VC1_9'^T:U
MJ* ,G^R/]HT?V1_M&M:B@#)_LC_:-']D?[1K6HH R?[(_P!HT?V1_M&M:B@#
M)_LC_:-']D?[1K6HH R?[(_VC1_9'^T:UJ* ,G^R/]HT?V1_M&M:B@#)_LC_
M &C1_9'^T:UJ* ,G^R/]HT?V1_M&M:B@#)_LC_:-']D?[1K6HH R?[(_VC1_
M9'^T:UJ* ,G^R/\ :-']D?[1K6HH R?[(_VC1_9'^T:UJ* ,G^R/]HT?V1_M
M&M:B@#)_LC_:-']D?[1K6HH R?[(_P!HT?V1_M&M:B@#)_LC_:-']D?[1K6H
MH R?[(_VC1_9'^T:UJ* ,G^R/]HT?V1_M&M:B@#)_LC_ &C1_9'^T:UJ* ,G
M^R/]HT?V1_M&M:B@#)_LC_:-']D?[1K6HH R?[(_VC1_9'^T:UJ* ,G^R/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\3K82:5'<?Q(PQ0!V]E<"[M(IUZ.N:L5A^$Y&D\/VI;^X*W* "BBB@ HHHH
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M+^^* )**C^T1?WQ1]HB_OB@"2BH_M$7]\4?:(O[XH DHJ/[1%_?%'VB+^^*
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M+^^* )**C^T1?WQ1]HB_OB@"2BH_M$7]\4?:(O[XH DHJ/[1%_?%'VB+^^*
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M+^^* )**C^T1?WQ1]HB_OB@"2BH_M$7]\4?:(O[XH DHJ/[1%_?%'VB+^^*
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M9_[QK8YHYH Q_P"S9_[QH_LV?^\:V.:.: ,?^S9_[QH_LV?^\:V.:.: ,?\
MLV?^\:/[-G_O&MCFCF@#'_LV?^\:/[-G_O&MCFCF@#'_ +-G_O&C^S9_[QK8
MYHYH Q_[-G_O&C^S9_[QK8YHYH Q_P"S9_[QH_LV?^\:V.:.: ,?^S9_[QH_
MLV?^\:V.:.: ,?\ LV?^\:/[-G_O&MCFCF@#'_LV?^\:/[-G_O&MCFCF@#'_
M +-G_O&C^S9_[QK8YHYH Q_[-G_O&C^S9_[QK8YHYH Q_P"S9_[QH_LV?^\:
MV.:.: ,?^S9_[QH_LV?^\:V.:.: ,?\ LV?^\:/[-G_O&MCFCF@#'_LV?^\:
M/[-G_O&MCFCF@#'_ +-G_O&C^S9_[QK8YHYH Q_[-G_O&C^S9_[QK8YHYH Q
M_P"S9_[QH_LV?^\:V.:.: ,?^S9_[QH_LV?^\:V.:.: ,?\ LV?^\:/[-G_O
M&MCFCF@#'_LV?^\:/[-G_O&MCFCF@#'_ +-G_O&C^S9_[QK8YHYH Q_[-G_O
M&C^S9_[QK8YHYH Q_P"S9_[QH_LV?^\:V.:.: ,?^S9_[QH_LV?^\:V.:.:
M,?\ LV?^\:/[-G_O&MCFCF@#'_LV?^\:/[-G_O&MCFCF@#'_ +-G_O&C^S9_
M[QK8YHYH Q_[-G_O&C^S9_[QK8YHYH Q_P"S9_[QH_LV?^\:V.:.: ,?^S9_
M[QH_LV?^\:V.:.: ,?\ LV?^\:/[-G_O&MCFCF@#'_LV?^\:/[-G_O&MCFCF
M@#'_ +-G_O&C^S9_[QK8YHYH Q_[-G_O&C^S9_[QK8YHYH Q_P"S9_[QH_LV
M?^\:V.:.: ,?^S9_[QH_LV?^\:V.:.: ,?\ LV?^\:/[-G_O&MCFCF@#'_LV
M?^\:/[-G_O&MCFCF@#'_ +-G_O&C^S9_[QK8YHYH Q_[-G_O&C^S9_[QK8YH
MYH Q_P"S9_[QH_LV?^\:V.:.: ,?^S9_[QH_LV?^\:V.:.: ,?\ LV?^\:/[
M-G_O&MCFCF@#'_LV?^\:/[-G_O&MCFCF@#'_ +-G_O&C^S9_[QK8YHYH Q_[
M-G_O&C^S9_[QK8YHYH Q_P"S9_[QH_LV?^\:V.:.: ,?^S9_[QH_LV?^\:V.
M:.: ,?\ LV?^\:/[-G_O&MCFCF@#'_LV?^\:/[-G_O&MCFCF@#'_ +-G_O&C
M^S9_[QK8YHYH Q_[-G_O&C^S9_[QK8YHYH Q_P"S9_[QH_LV?^\:V.:.: ,?
M^S9_[QH_LV?^\:V.:.: ,?\ LV?^\:/[-G_O&MCFCF@#'_LV?^\:/[-G_O&M
MCFCF@#'_ +-G_O&C^S9_[QK8YHYH Q_[-G_O&C^S9_[QK8YHYH Q_P"S9_[Q
MH_LV?^\:V.:.: ,?^S9_[QH_LV?^\:V.:.: ,?\ LV?^\:/[-G_O&MCFCF@#
M'_LV?^\:/[-G_O&MCFCF@#'_ +-G_O&C^S9_[QK8YHYH Q_[-G_O&C^S9_[Q
MK8YHYH Q_P"S9_[QH_LV?^\:V.:.: ,?^S9_[QH_LV?^\:V.:.: ,?\ LV?^
M\:/[-G_O&MCFCF@#'_LV?^\:/[-G_O&MCFCF@#'_ +-G_O&C^S9_[QK8YHYH
M Q_[-G_O&C^S9_[QK8YHYH Q_P"S9_[QH_LV?^\:V.:.: ,?^S9_[QH_LV?^
M\:V.:.: ,?\ LV?^\:/[-G_O&MCFCF@#'_LV?^\:/[-G_O&MCFCF@#'_ +-G
M_O&C^S9_[QK8YHYH Q_[-G_O&C^S9_[QK8YHYH Q_P"S9_[QH_LV?^\:V.:.
M: ,?^S9_[QH_LV?^\:V.:.: ,?\ LV?^\:/[-G_O&MCFCF@#'_LV?^\:/[-G
M_O&MCFCF@#'_ +-G_O&C^S9_[QK8YHYH Q_[-G_O&C^S9_[QK8YHYH Q_P"S
M9_[QH_LV?^\:V.:.: ,;^S9_[QH_LV?^\:V>:.: (;:+RHP#UJ;O1TH% !CF
MEHHH **** "J.I_\>QJ]5'4_^/8T )I7_'G^-7N]4=*_X\_QJ]WH 6BBB@!#
MVI>U(>U+VH PQ_R$S]:VQT%8@_Y"9^M;8Z"@ [TM)WI: "BBB@ HHHH ****
M "BBB@!,=ZIWUG%>VCQRQJQQQD5=I"<=J .4T+P_%!=R230+P>,BNK"JH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 &**** "BBB@ HHHH *HZG_P >QJ]5'4_^/8T
M)I7_ !Y_C5[O5'2O^//\:O=Z %HHHH 0]J7M2'M2]J ,,?\ (3/UK;'05B#_
M )"9^M;8Z"@ [TM)WI: "BBB@ HHHH **** "BBB@ I/K2T4 )BEHHH ****
M "BBB@!,4<YI:* "BBB@ HHHH **** "BBB@!*6BB@!/K1SVI:* "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MHZG_ ,>QJ]5'4_\ CV- ":5_QY_C5[O5'2O^//\ &KW>@!:*** $/:E[4A[4
MO:@##'_(3/UK;'05B#_D)GZUMCH* #O2TG>EH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ JCJ?_'L:O51U/\ X]C0 FE?\>?XU>[U1TK_ (\_QJ]WH 6BBB@!#VI>
MU(>U+VH PQ_R$S]:VQT%8@_Y"9^M;8Z"@ [TM)WI: "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBD)Q0 M%&>*0'- "T4A;!Q2Y!H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B@T@.:!7%HI,T9H&+11
M1F@ HHHH **** "BD)Q1NH%<6BDS2T#"BBB@ HI,T9H 6BDS1F@!:*3-&: %
MHHHH **,T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44F><4$X%*X"T4
M@/%+1< HHHI@%%%% !12%L4A;% [#J*;O%+F@0M%(3BDW4 .HHS1F@ HI,TA
M;% /0=13=X-*3B@2=Q:*,T9H&%%&:* "BBB@ HHHS0 449HH **** "BBB@
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MT;T_O#\Z\K_X6=I']R2C_A9VD?W)*KVL2OK$3U7S$_O#\Z3S8\XWC/UKRO\
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M 3_H\7_?-":0H4_N(ORKJ>*L<GU.+/G#^R]0_P"?:3\J/[+U#_GVD_*OH_\
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M:O=ZHZ5_QY_C5[O0 M%%% "'M2]J0]J7M0!AC_D)GZUMCH*Q!_R$S]:VQT%
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M:O=ZHZ5_QY_C5[O0 M%%% "'M2]J0]J7M0!AC_D)GZUMCH*Q!_R$S]:VQT%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "@T4&@"GJG_ "#+C_<-?+VK
M?\A^Y_WC7U#J?_(-N/\ <-?+^K_\A^Y_WC7+7/.QNQ6/4T4=S17&CS8[!111
M3)6X4444F5,Z/P!_R-,7^]7TB.@KYN\ ?\C3%_O5](CH*[Z.QZV#^$6BBBMS
MM"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !12$X%(S;4W=AUH
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M2Z'M7P>_Y )^M>F5YG\'O^0"?K7IE>A2^$]VA_#04M)2UH]S5!1113&%%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ [TM)WI: "BBB@ HHHH **** &'EL TORL<9YH;CD#)JO>7"VMJ\QP& [T
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MGI2%E!R7 _&G @C@YH 3/S8IU(,9QWI: "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!10**8!1110 4444 %%%% !1110 4444 %4=3_X]C5ZJ.I_\>QH 32O^//\
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MJVL-I^D G:<$BJ]RWB70"EW<,[QC[PK6^&]K"[3WK)F5R>37;:G;BYTV>.5
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M_!IE%G=\]ZVH?$=6%^(]7IU1^;'_ 'Q1YT?]\5WL]DD%%1^='_?%'G1_WQ3
MDHJ/SH_[XH\Z+^^* )**C\Z+^^*/.B_OB@!Y.*4'--4JPR.:7O0 M%(#S2T
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MSI_[QK9HH QO[.G_ +QH_LZ?^\:V:* ,;^SI_P"\:/[.G_O&MFB@#&_LZ?\
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MWPSLY&)%U+&I.<*:[[%)@9S0!S.D>"M/TIQ(I,K#N_-=!.L:V[%AA .@J8
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *#10: *>I_\ (-N/]PU\OZO_ ,A^Y_WC7U!J?_(,N/\
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MM.--/6@3/ ?BK_R-S?[M<57:_%7_ )&YO]VN*KSJWQ'B8CXPHHHK(P"BBB@
MIK_ZM_I3J:_^K?Z4T$NA[5\'O^0"?K7IE>9_![_D GZUZ97H4OA/=H?PT%+2
M4M:/<U04444QA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4&B@T 4]4_Y!EQ_N&OE[5O^0_<_P"\
M:^H=4_Y!EQ_N&OE[5O\ D/W/^\:Y:YYV-V*YZFB@]317&CS8[!1113)6X444
M4F5,Z/P!_P C3%_O5](CH*^;O '_ "-,7^]7TB.@KOH['K8/X1:***W.T***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:O=ZHZ5_QY_C5[O0 M%%% "'M2]J0]J7M0!AC_D)GZUMCH*Q!_R$S]:VQT%
M!WI:3O2T %%%% !110>G% "$XHR?2@=.:* %%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 !HH-%  ::>M.--/6@3/ ?BK_ ,C<
MW^[7%5VOQ5_Y&YO]VN*KSJWQ'B8CXPHHHK(P"BBB@ IK_P"K?Z4ZFO\ ZM_I
M302Z'M7P>_Y )^M>F5YG\'O^0"?K7IE>A2^$]VA_#04M)2UH]S5!1113&%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !0:*#0!3U3_D&7'^X:^7M6_P"0_<_[QKZAU3_D&7'^X:^7
MM6_Y#]S_ +QKEKGG8W8KGJ:*#U-%<:/-CL%%%%,E;A111294SH_ '_(TQ?[U
M?2(Z"OF[P!_R-,7^]7TB.@KOH['K8/X1:***W.T**** "BBB@ HHHH ****
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MV-.TL;KAN,CM0!WV[G'2C=SC%>4"'QK%;_:[BY+ #<0/2NE\'^*SJH>UNO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA^:W3/<"N)^)4HCT,1'&688H Z3PU<M=Z);2MU*#BM>L'P>I3P[; _W16]0
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M[A_*C[?=?W#^5 &S16-]ONO[A_*C[?=?W#^5 &S16-]ONO[A_*C[?=?W#^5
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M</Y4?;[K^X?RH V:*QOM]U_</Y4?;[K^X?RH V:*QOM]U_</Y4?;[K^X?RH
MV:*QOM]U_</Y4?;[K^X?RH V:*QOM]U_</Y4?;[K^X?RH V:*QOM]U_</Y4?
M;[K^X?RH V:*QOM]U_</Y4?;[K^X?RH V:*QOM]U_</Y4?;[K^X?RH V:*QO
MM]U_</Y4?;[K^X?RH V:*QOM]U_</Y4?;[K^X?RH V:*QOM]U_</Y4?;[K^X
M?RH V:*QOM]U_</Y4?;[K^X?RH V:*QOM]U_</Y4?;[K^X?RH V:*QOM]U_<
M/Y4?;[K^X?RH V:*QOM]U_</Y4?;[K^X?RH V:*QOM]U_</Y4?;[K^X?RH V
M:*QOM]U_</Y4?;[K^X?RH V:*QOM]U_</Y4?;[K^X?RH V:*QOM]U_</Y4?;
M[K^X?RH V:*QOM]U_</Y4?;[K^X?RH V:*QOM]U_</Y4?;[K^X?RH V:*QOM
M]U_</Y4?;[K^X?RH V:*QOM]U_</Y4?;[K^X?RH V:*QOM]U_</Y4?;[K^X?
MRH V:*QOM]U_</Y4?;[K^X?RH V:*QOM]U_</Y4?;[K^X?RH V#1WK&^WW7]
MP_E1]ON?[AH0I&P>M<C\2?\ D3[OZ5K&_N0,[#^5<Q\0;J>7PC<;EQFHJ;&>
M(TIGA$?_ ![K4A[5''Q$F:?G=S7FRW/""BBBD(**** $->N?!7_CROO]ZO)<
M94^M>G_"&XEAM;P*N>:VH;G5A?B/9/2EK%_M"Z)_U9Q2_;[K^X?RKO9[/0V:
M*Q?M]U_<-+]ONO[A_*F!LT5C?;[K^X?RH^WW7]P_E0!LT5C?VA<_W#2?VA<_
MW#0!M457MI6DCRW6IQG- "T444 %%%% !5'4_P#CV-7JHZG_ ,>QH 32O^//
M\:O=ZHZ5_P >?XU>[T +1110 A[4O:D/:E[4 88_Y"9^M;8Z"L0?\A,_6ML=
M!0 =Z6D[TM !33G=U^6G4A (YH C>,,C*2?F%>42W%QX;\9M+<F9K65O7BO6
MRO-9NK:);:M!LF0;^S8H Y"_UBSN]1BN+:=508+ FL_QAK\6M0VMA8(99 X#
M,.<53O\ P4RZGY44S!2>>:[7P]X/L]'196Q)(1G)H TM.TJ--&AMKA0P"#((
MI!X<TK.?LD7_ 'S6N ,<=*,'- $%M:0VB;84"KZ"I1G#$]*?2$9&* /'KR93
M\1U7'&ZO7UPJ#Z5S$G@Z*37AJ?F#.<XKJ<# 'I0!YS\0M-=/+U-5)\M@>*V_
M#WB[3M0TV(32K&Z* <FNDO+."^MV@G0,C=JXBZ^&T+W#-!<&.,G[H- &-XNU
M<Z_JD=A8YDCS@D5Z%HUJNE:)!"1@JO-4-!\(6>BG>0))?[QK>N AB;S#Q@T
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M29& DESPQ[4 :VDVOV+38(/[JBKM-4$=^*=0 4444 %%%% "$XI" PP:=BD
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MB8CXPHHHK(P"BBB@ IK_ .K?Z4ZFO_JW^E-!+H>U?![_ ) )^M>F5YG\'O\
MD GZUZ97H4OA/=H?PT%+24M:/<U04444QA1110 4444 %%%% !1110 4444
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MD(**** $->N?!7_CROO]ZO(S7KGP5_X\K[_>K:A\1U87XCUGTI:3TI:[V>R
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *#10: *>J?\@RX_W#7R]JW_(?N?\ >-?4.J?\@RX_W#7R]JW_ "'[G_>-
M<M<\[&[%<]310>IHKC1YL=@HHHIDK<****3*F='X _Y&F+_>KZ1'05\W> /^
M1IB_WJ^D1T%=]'8];!_"+1116YVA1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (:.]!H[T(3
M$/6N1^)/_(H7?TKKCUKD?B3_ ,BA=_2HJ;&=?^&SYWC_ ./=:D/:HX_^/=:D
M/:O-EN>$)1112$%%%% "&O7/@K_QY7W^]7D9KUSX*_\ 'E??[U;4/B.K"_$>
ML^E+2>E+7>SV0%% HI@%%%% !1110 4444 %%%% !1110 51U/\ X]C5ZJ.I
M_P#'L: $TK_CS_&KW>J.E?\ 'G^-7N] "T444 (>U+VI#VI>U &&/^0F?K6V
M.@K$'_(3/UK;'04 '>EI.]+0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 &B@T4 !IIZTXTT]:!,\!^*O
M_(W-_NUQ5=K\5?\ D;F_W:XJO.K?$>)B/C"BBBLC **** "FO_JW^E.IK_ZM
M_I302Z'M7P>_Y )^M>F5YG\'O^0"?K7IE>A2^$]VA_#04M)2UH]S5!1113&%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !0:*#0!3U3_D&7'^X:^7M6_Y#]S_ +QKZAU3_D&7'^X:
M^7M6_P"0_<_[QKEKGG8W8KGJ:*#U-%<:/-CL%%%%,E;A111294SH_ '_ "-,
M7^]7TB.@KYN\ ?\ (TQ?[U?2(Z"N^CL>M@_A%HHHK<[0HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** $-'>@T=Z$)B'K7(_$G_D4+OZ5UQZUR/Q)_Y%"[^E14V,Z_\-GSO'_Q
M[K4A[5''_P >ZU(>U>;+<\(2BBBD(**** $->N?!7_CROO\ >KR,UZY\%?\
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M>"?E1]DM_P#G@GY4>P#ZC$^8&\/ZV%Q]C;GVILOAO6UB(6T;D>E?4#6=N?\
ME@GY4"TM\8,"?E5*BD..%46<#\*K&[LM)*74/EGW%>B]J9'#'&,(@4>U25NE
M8[(1Y582EHHH+"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %!HH- %/4_\ D&7'^X:^7M6_
MY#]S_O&OJ'4^-,N,_P!PU\OZOC^W;DC^\:Y:YY^,*W<T4$$4E<:/-B+1124R
M5N+1100<9%)E3.D^'_\ R-,7^]7T@.@KYP^'V/\ A*(O7=7T>,\?2N^AL>MA
M/@%HHHK<[ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "DI:2@ [5Q_Q'_Y$^[^E=@>E<=\1
M_P#D3;L^U9U-C"M\+/GF/_CW6I#VID:DQ( >,<T_&>E><TTSPI)\PE%+M/K1
MM/K2'J)12[3ZT;3ZT!J-KUSX+?\ 'E??[U>2,-H!)KUSX*C_ $*^/^U6V'3Y
MCHPE^<]7I12'M2@5Z![G06BBB@04444 %%%% !110,T %%)WI: "BBB@ JCJ
M?_'L:O51U/\ X]C0 FE?\>?XU>[U1TK_ (\_QJ]WH 6BBB@!#VI>U(>U+VH
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M[?=_W#6OY:_W11Y:>@I,=C(^WW?]PT?;[O\ N&M?RU_NBCRU_NBD!D?;[O\
MN&C[?=_W#6OY:_W11Y:>@H0&1]ON_P"X:/M]W_<-:_EIZ"CRT]!3 R/M]W_<
M-'V^[_N&M?RT]!1Y:>@H R/M]W_<-'V^[_N&M?RT]!1Y:>@H R/M]W_<-'V^
M[_N&M?RT]!1Y:>@H R/M]W_<-'V^[_N&M?RT]!1Y:>@H R/M]W_<-'V^[_N&
MM?RT]!1Y:>@H R/M]W_<-'V^[_N&M?RT]!1Y:>@H R/M]W_<-'V^[_N&M?RT
M]!1Y:>@H R/M]W_<-'V^[_N&M?RT]!1Y:>@H R/M]W_<-'V^[_N&M?RT]!1Y
M:>@H R/M]W_<-'V^[_N&M?RT]!1Y:>@H R/M]W_<-'V^[_N&M?RT]!1Y:>@H
M R/M]W_<-'V^[_N&M?RT]!1Y:>@H R/M]W_<-'V^[_N&M?RT]!1Y:>@H R/M
M]W_<-'V^[_N&M?RT]!1Y:>@H R/M]W_<-'V^[_N&M?RT]!1Y:>@H R/M]W_<
M-'V^[_N&M?RT]!1Y:>@H R/M]W_<-'V^[_N&M?RT]!1Y:>@H R/M]W_<-'V^
M[_N&M?RT]!1Y:>@H R/M]W_<-'V^[_N&M?RT]!1Y:>@H R/M]W_<-'V^[_N&
MM?RT]!1Y:>@H R/M]W_<-'V^[_N&M?RT]!1Y:>@H R/M]W_<-'V^[_N&M?RT
M]!1Y:>@H R/M]W_<-'V^[_N&M?RT]!1Y:>@H R/M]W_<-'V^[_N&M?RT]!1Y
M:>@H R/M]W_<-'V^[_N&M?RT]!1Y:>@H R/M]W_<-'V^[_N&M?RT]!1Y:>@H
M R/M]W_<-'V^[_N&M?RT]!1Y:>@H R/M]W_<-'V^[_N&M?RT]!1Y:>@H R/M
M]W_<-'V^[_N&M?RT]!1Y:>@H R/M]W_<-'V^[_N&M?RT]!1Y:>@H R/M]W_<
M-'V^[_N&M?RT]!1Y:>@H R/M]W_<-'V^[_N&M?RT]!1Y:>@H R/M]W_<-'V^
M[_N&M?RT]!1Y:>@H R/M]W_<-'V^[_N&M?RT]!1Y:>@H R/M]W_<-'V^[_N&
MM?RT]!1Y:>@H R/M]W_<-'V^[_N&M?RT]!1Y:>@H R/M]W_<-'V^[_N&M?RT
M]!1Y:>@H R/M]W_<-!O[O'W#6OY:>@H\M?[HH PKN[N9-+N-Z$?*:^<=3!;6
M;DDX.XU]1W\)FT^:-5^9E(%>#W_PZUNXU2>58&V,3@US5DWL<.+BWL<:,C_:
MI<_[-=4/AKKR_=B:C_A6^O\ _/)JY5"78\^-.?8Y7/\ LT9_V:ZO_A6^O_\
M/)J3_A6VO_\ /)J.278E4IWV.5S_ +-!Y'7'M75?\*VU_P#YY-2'X::ZQR8F
MH<)=BI4I]BMX%8Q^)H=O/S5[W)?W2R[50XQ7E/A#P-JVF:_%<3P$1J<Y->V;
M%_NBNRBFEJ>GA8M1U,C[?=_W#1]ON_[AK7\I/04>6GH*W.LR/M]W_<-'V^[_
M +AK7\M/04>6GH* ,C[?=_W#1]ON_P"X:U_+3T%'EIZ"@#(^WW?]PT?;[O\
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M@#(^WW?]PT?;[O\ N&M?RT]!1Y:>@H R/M]W_<-'V^[_ +AK7\M/04>6GH*
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M!0!D?;[O^X:/M]W_ '#6OY:>@H\M/04 16KNZ OU-3]Z ,#@4"@!:*0=:6@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5'4_^/8U>
MJCJ?_'L: $TK_CS_ !J]WJCI7_'G^-7N] "T444 (>U+VI#VI>U &&/^0F?K
M6V.@K$'_ "$S]:VQT% !WI:3O2T %%%% !1110 44G.<]J.O2@!:*!10 444
ME "T44F: %HHI#P* %HI,GTHH 6BBB@ HHI* %HHI,>] "T4G- )]* %HHHH
M **0$]Q1@DT +1110 444E "T49HH **3FC)STH 6BBB@ HI,G/2CDT +12
M4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %4=3_X]C5ZJ.I_\>QH 32O
M^//\:O=ZHZ5_QY_C5[O0 M%%% "'M2]J0]J7M0!AC_D)GZUMCH*Q!_R$S]:V
MQT% !WI:3O2T %%%% !13=PQFLS6-?L]&@\RX;)/11UH NM>0I)Y989J<$8R
M*\>NO'(FU?S([>41@UW^@>*[#5XA&KB.4#[K&@#H@<BEI%((XI<T (>G% Z<
MTN<5S6M^,+'225SYKC^%>M '2'VHZ?6N!@^)MHS*);26)2<;F'%=GI^HV^HV
MZS0NK!O0T 6^:,5#<74-M"TDTBQJHSEC7$7'Q-LHYWC@MY)=AP67D4 =[S2U
MS&@^-++6VV >2_HU=-D$4 +1129YH #GM2UB:]XFL]"BW3,"W]T=:YF'XFVK
MON:SE5,_>(XH ] Z4"J.FZM:ZK:K/;2JV1D@'D5:DFCAA,DC!4'4F@"0Y[4H
M]ZX;4?B38VEXUM#$\[+U*<U<T7QW8:M<>0X\B3L'XH ZVBF"13C:=P/<5D:W
MXDL=#3-PXWXX7/- &SS1BN C^)]K))M-I*%S]['%=?I6L6VK6WFP.#ZJ#R*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **,T4 %%%% !1110 51U/_CV-7JHZG_Q[&@!-*_X\_QJ]WJC
MI7_'G^-7N] "T444 (>U+VI#VI>U &&/^0F?K6V.@K$'_(3/UK;'04 '>EI.
M]+0 4AXI:0^U #1]XUY3KC_:/&L<.H.4@W<9Z5ZN!W[US?B7PG;ZZGG$[)U&
M0PH Q+^PTT7\45HB.AQD@4W4_ LJZA;W^G2&/!!90:Y*XT_7-!U$!-TJ9XKI
MM$\;W%O?):ZDI4-P,B@#T6V#+;1A_O!0#4F:8DT4D0E#C8PSDFF?:[?./.CS
M_O4 5M9N9+72YI8E+/C@"O/?"?A^74M9EOM0B;;G(#5Z<?+E3&59?SI%B2-=
ML:A1[4 8FN^'-.OM,EC:!4"+D$#%<EX"ED34Y;-7/DQ$[036]XQ\21:=8-:0
MOON)1M '-5_ VAR6EN;ZX!5WYP: ,WXBZ@UULTV-BC,P&0:Z+P[X4T[3]+A5
MH5DD= 68C-<7XC;[3XYMPP_=AAUKU6WXMXPH^7:* /+_ !GI(T74HKRS/EH6
MR0.*]#T&[^VZ/!-G)*\FN>^(<,1T-G8_..E7O NX^&(-Q^E '2$'<#VIDL@B
MBDE)X5<T\<#!K/ULE-$N]O7RS0!YG:0'Q3XQG6Y8M;QM\H[5Z)-X:TYM.:V,
M"8V]<5Q7PT0237$CC+[SS7IK#<ISTH \G\,3'0_%TFFJS%';Y03VKH_'^HM!
MIOV2)BC2=:PM81$^)%I)"NW'6G>/6:;5[7>=JDCB@#9\$^%+&#2DNI$$DLO)
M+#-9WCS0+2TCCO[-?*E0Y;;Q7<:&BQZ3"JC"A16?XOBB?1)=R@Y% $?A+4C=
M^'!,3ED7DUPR6X\6>-'2=R8HSTSQ6UX+:2+PY? '@*<52^'**VJW<KC+ER,T
M =P_AK2_L?D>0@^7&[%>?: \GASQJ]EO)@E;Y1FO664,I4]*\M\1Q^7X]T_R
M!G!^:@#U)<$9'>ESSBF1G]TK=..:?P#GUH \Q\>7TEYK4&F1N?+8X< UUFB^
M%=/LK%%,*OE>217"W*M)\19!)RH;@5ZS$H$* < "@#RCQ3IT/AOQ+!>VI*(Y
M&0#QFN^N-6\KPW]K/WFCXKG?B;!$^FP_*/,\P'-&I3NO@2,*,L(P* ,7P=HR
M:_K=U?7V753E5/-=CX@\,Z=>:/,J0*CJ,A@*S?AO&O\ 9KR?QD\UVEPJFWD!
M&5*G- 'G?P[OI$NY=/=RP0X&33?B%?-=W\&E*Y 9L$"J_AL>5XXF\OA2>E0Z
ML/.^(P\WE0> : .TT+PIIUEIR*T*N2N22*XSQCI8T#6K;4;$E(]PW**]4AQY
M";1Q@5Q/Q*C1=")',A88H Z[2KP7NG03=V0&KM87A$L?#UKO&&V"MV@ HHHH
M ***0G% "YHI#UJ*X?9&2* )L48K&.H3@D!#BC^T9_[AH V<48K&_M&?^X:/
M[1G_ +AH V<48K&_M&?^X:/[1G_N&@#9Q1BL;^T9_P"X:/[1G_N&@#9Q1BL;
M^T9_[AH_M&?^X: -G%&*QO[1G_N&C^T9_P"X: -G%&*QO[1G_N&C^T9_[AH
MV<48K&_M&?\ N&C^T9_[AH V<48K&_M&?^X:/[1G_N&@#9Q1BL;^T9_[AH_M
M&?\ N&@#9Q1BL;^T9_[AH_M&?^X: -G%&*QO[1G_ +AH_M&?^X: -G%&*QO[
M1G_N&C^T9_[AH V<48K&_M&?^X:/[1G_ +AH V<48K&_M&?^X:/[1G_N&@#9
MQ1BL;^T9_P"X:/[1G_N&@#9Q1BL;^T9_[AH_M&?^X: -G%&*QO[1G_N&C^T9
M_P"X: -G%&*QO[1G_N&C^T9_[AH V<48K&_M&?\ N&C^T9_[AH V<48K&_M&
M?^X:/[1G_N&@#9Q1BL;^T9_[AH_M&?\ N&@#9Q1BL;^T9_[AH_M&?^X: -G%
M&*QO[1G_ +AH_M&?^X: -G%&*QO[1G_N&C^T9_[AH V<48K&_M&?^X:/[1G_
M +AH V<48K&_M&?^X:/[1G_N&@#9Q1BL;^T9_P"X:/[1G_N&@#9Q1BL;^T9_
M[AH_M&?^X: -G%&*QO[1G_N&C^T9_P"X: -G%&*QO[1G_N&C^T9_[AH V<48
MK&_M&?\ N&C^T9_[AH V<48K&_M&?^X:/[1G_N&@#9Q1BL;^T9_[AH_M&?\
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MX: -G%&*QO[1G_N&C^T9_P"X: -G%&*QO[1G_N&C^T9_[AH V<48K&_M&?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4=3_X]
MC5ZJ.I_\>QH 32O^//\ &KW>J.E?\>?XU>[T +1110 A[4O:D/:E[4 88_Y"
M9^M;8Z"L0?\ (3/UK;'04 '>EI.]+0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5'
M4_\ CV-7JHZG_P >QH 32O\ CS_&KW>J.E?\>?XU>[T +1110 A[4O:D/:E[
M4 88_P"0F?K6V.@K$'_(3/UK;'04 '>EI.]+0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !112&@!:*2B@!:*2ES0 449H
MH **3-&:!7%HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %4=3_P"/8U>JCJ?_ ![&@!-*_P"//\:O=ZHZ5_QY_C5[O0 M
M%%% "'M2]J0]J7M0!AC_ )"9^M;8Z"L0?\A,_6ML=!0 =Z6D[TM !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %!HI#0)AF
MBC%&*!:AFC-&**5QA1111<844M&:=Q6$-****!A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M1FB@ HH!!Z44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%&: "BBB@ HHHH **** "BBB@ HHHH ***"<=: "B
MC-&0* "BBB@ HHR,XHH **** "BBB@ HHHH **** "BBB@ HHS1F@ HHHS0
M449HH **** "BBB@ HHS10 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZR(&C8,I[BF ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW%99%#KW% #N2,=Z!Z$\T9^7/>HI)HH,-+(%)]30!*F><TZD5@ZAE.0>AI:
M"BBB@ HHHH *0]*6HKF=+:W>:0X51DT /VG=FD/ YYKAQ\2].#RIAF*-C@4Z
M/XD6+@GRW 'J* .W/'0=:087J:S-(U^SU>(/#(N3VS5C4[^'3+5KF<_*M %P
MD&@@GH:X,?$^P9R$C9@#C(%2GXE6"KDQO],4 =ODCMFE!)ZC%<WHGBV#7)?+
MB1E^HKH)94@B+RN%4=R: 'GGH:;AB?O]*Y+4?B!IUE.8DS(1_=YJLGQ*T\R*
M&C90QY)% ';EN,@9-*#D<\&J=AJ=IJ,(DM95;(Z U<&2.1@T .HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *HZG_ ,>QJ]5'4_\ CV- ":5_QY_C5[O5'2O^//\
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M(W<UZU87L>H6<=Q$<AA7'?$JWCFL(6? *G@UI^!?^0$HSG% '4T444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ=M&<T8&<T 1&*-^6B0GOQ3E1-N$4+]!BGA0#FEQ0 W(/&*0 +D[0/I3\4@
M Q0 F>*8RC;PH!/<5(0",48% #0HVX//UIAAB[1*3]*E(!I<4 ,4*O  'KBD
M.V3Y6'%/"@&C H A9(EQF)3^%/PNWH"/2G[1F@* 2?6@!!C:!C IK!6.UE!7
MWI^!00",4 1B,*<QHJ^XIVU=V2![&G!0HP*1D#8S0 =^:"%888 CWIV*0@'K
M0!$(E!XC4>X%+\N[;D\5(0"*,#&* $*JW# 'TS0001Z4N!2D9% #& 8$$ CW
MH12B[1@"G;1C%&* #/%,4AU.13P *"H- #!%$IR$4'Z4K!"1N4'\*<0",&@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *HZG_Q[&KU4=3_X]C0 FE?\>?XU>[U1TK_C
MS_&KW>@!:*** $/:E[4A[4O:@##'_(3/UK;'05B#_D)GZUMCH* #O2TG>EH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ JCJ?_ ![&KU4=3_X]C0 FE?\ 'G^-7N]4
M=*_X\_QJ]WH 6BBB@!#VI>U(>U+VH PQ_P A,_6ML=!6(/\ D)GZUMCH* #O
M2TG>EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKJ"IR#WI6&:  DCH,T<FDY XHZC!H 4DC&!FEI@RM/H **** "BBB@ HHHH
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M$D&48,/45DZYH^G:HBB^8+@\$FN8\%Z[.\[:=< G8<9-/^(\LT5G%)!(5(8
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M0370W]M:ZC8-%.X,+=3FO,?"/A*/4[9)S.RE3T!KN=;M_LOAR6WC<AD0X;-
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M<5\-O.&IW"S(0V3G-=[XDMGNM NH8^69>* .=^'>TZ5N_BYK:\5Y_P"$?N&
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MN]4=*_X\_P :O=Z %HHHH 0]J7M2'M2]J ,,?\A,_6ML=!6(/^0F?K6V.@H
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MXE;,VQ).=PP*W].TBSU;0;<7<(SM':M;4=%LM4*&ZBWE3D5<B@CAB6)%PJC
M% &58^&M-T^4201#</45JG!Y8<#M3BO<=:7:,8- &1?^'=/U282SQ G'85+9
MZ%86$92*(8/K6EC P*,4 9]OI%I;SF=(P&]A4E[IUMJ*!9U# '/-7 ,"DVC.
M: (X84@B6*( *HQ275K!>0M#.@96]:F"@9Q363<N">?6@#"3P?I"2!U@ (.:
MT)])LKN%8I8%VITXJ\%(0#//K2XXYH ;%&L,:H@PJC IQ%*** *UY96]_"89
MT#*?6LZT\,Z;92;H(]K=:V<4FWTZT 121),ABE4%,=#6--X.TBXDWM#^5;VW
M(YI0,# H HV&E6FGKMMXU ^E7<YSBC:.U*!B@!.W/6HY8HYHS',@92,'(J4@
M'K1B@#GY?!FCS2>8\/O6I8Z=:6$>RW10!5S&1BFA /NT *<,,GM5*_TZTU)
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M(KCSUAP^<UOXYR*0J&.30!2GTFRN0OF1*=O3BK,5O%#%Y2#"=,5)M&.*7:*
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MAXI2/FS2D>G% &?#H]E;W;7*1@2-U-6+NT@OHO*G3*U.4!(/>EQ0!3M;**P
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MDHI7"PM)1118!,TM %%*S'<****=A7"EI,T"F%A:*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *HZG_ ,>QJ]5'4_\ CV- ":5_
MQY_C5[O5'2O^//\ &KW>@!:*** $/:E[4A[4O:@##'_(3/UK;'05B#_D)GZU
MMCH* #O2TG>EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JCJ?_'L:O51U/\ X]C0
M FE?\>?XU>[U1TK_ (\_QJ]WH 6BBB@!#VI>U(>U+VH PQ_R$S]:VQT%8@_Y
M"9^M;8Z"@ [TM)WI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "D+8ZT'I2'D<4 *&!Z4 GO
M2$''&,T?>% "@Y-(&!.*4 @8I!U[4 .HHHH :6P<4M'>FLNXCF@!RDGK2TWC
M=3J "D# G%!.*3G/ H 4L <49.?:D)QUI<<YH 6BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1+93<(#M'4UJG5;'<%^TQY/O0!Y[\1)Y9K^#3V8B&9@#7<Z#I\.F:-;PVZC
M49/K7'?$:P;[/'?Q@N$((*UO^%O$%GJ&CV\1E"2JF&#&@"3QAI]O>:'-)*@W
MJI(-8GPUO)7L)('8E48@5=\9:_;0Z9):PR+)(XQ@&H?AUIK6FE&=P0TAS@T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %4=3_P"/8U>JCJ?_ ![&@!-*_P"//\:O=ZHZ5_QY_C5[O0 M%%%
M"'M2]J0]J7M0!AC_ )"9^M;8Z"L0?\A,_6ML=!0 =Z6D[TM !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %4=3_ ./8U>JCJ?\ Q[&@!-*_X\_QJ]WJCI7_ !Y_C5[O
M0 M%%% "'M2]J0]J7M0!AC_D)GZUMCH*Q!_R$S]:VQT% !WI:3O2T %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 51U/_CV-7JHZG_Q[&@!-*_X\_QJ]WJCI7_'G^-7
MN] "T444 (>U+2-Q2T 8?34SGUK;!^45B%L:@Q)QS6M]HB"CYA0!+WI:A^U1
M?WA2_:(O[XH EHJ+[1%_?%'VB+^^* ):*B^T1?WQ1]HB_OB@"6BHOM$7]\4?
M:(O[XH EHJ+[1%_?%'VB+^^* ):*B^T1?WQ1]HB_OB@"6BHOM$7]\4?:(O[X
MH EHJ+[1%_?%'VB+^^* ):*B^T1?WQ1]HB_OB@"6BHOM$7]\4?:(O[XH EHJ
M+[1%_?%'VB+^^* ):*B^T1?WQ1]HB_OB@"6BHOM$7]\4?:(O[XH EHJ+[1%_
M?%'VB+^^* ):*B^T1?WQ1]HB_OB@"6BHOM$7]\4?:(O[XH EHJ+[1%_?%'VB
M+^^* ):*B^T1?WQ1]HB_OB@"6BHOM$7]\4?:(O[XH EHJ+[1%_?%'VB+^^*
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M+^^* ):*B^T1?WQ1]HB_OB@"6BHOM$7]\4?:(O[XH EHJ+[1%_?%'VB+^^*
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M+^^* ):*B^T1?WQ1]HB_OB@"6BHOM$7]\4?:(O[XH EHJ+[1%_?%'VB+^^*
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M+^^* ):*B^T1?WQ1]HB_OB@"6BHOM$7]\4?:(O[XH EHJ+[1%_?%'VB+^^*
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M'_YZFC^R'_YZFM:B@#)_LA_^>IH_LA_^>IK6HH R?[(?_GJ:/[(?_GJ:UJ*
M,G^R'_YZFC^R'_YZFM:B@#)_LA_^>IH_LA_^>IK6HH R?[(?_GJ:/[(?_GJ:
MUJ* ,G^R'_YZFC^R'_YZFM:B@#)_LA_^>IH_LA_^>IK6HH R?[(?_GJ:/[(?
M_GJ:UJ* ,G^R'_YZFC^R'_YZFM:B@#)_LA_^>IH_LA_^>IK6HH R?[(?_GJ:
M/[(?_GJ:UJ* ,G^R'_YZFC^R'_YZFM:B@#)_LA_^>IH_LA_^>IK6HH R?[(?
M_GJ:/[(?_GJ:UJ* ,G^R'_YZFC^R'_YZFM:B@#)_LA_^>IH_LA_^>IK6HH R
M?[(?_GJ:/[(?_GJ:UJ* ,G^R'_YZFC^R'_YZFM:B@#)_LA_^>IH_LA_^>IK6
MHH R?[(?_GJ:/[(?_GJ:UJ* ,G^R'_YZFC^R'_YZFM:B@#)_LA_^>IH_LA_^
M>IK6HH R?[(?_GJ:/[(?_GJ:UJ* ,G^R'_YZFC^R'_YZFM:B@#)_LA_^>IH_
MLA_^>IK6HH R?[(?_GJ:/[(?_GJ:UJ* ,G^R'_YZFC^R'_YZFM:B@#)_LA_^
M>IH_LA_^>IK6HH R?[(?_GJ:/[(?_GJ:UJ* ,G^R'_YZFC^R'_YZFM:B@#)_
MLA_^>IH_LA_^>IK6HH R?[(?_GJ:/[(?_GJ:UJ* ,G^R'_YZFC^R'_YZFM:B
M@#)_LA_^>IH_LA_^>IK6HH R?[(?_GJ:/[(?_GJ:UJ* ,G^R'_YZFC^R'_YZ
MFM:B@#)_LA_^>IH_LA_^>IK6HH R?[(?_GJ:/[(?_GJ:UJ* ,G^R'_YZFC^R
M'_YZFM:B@#)_LA_^>IH_LA_^>IK6HH R?[(?_GJ:/[(?_GJ:UJ* ,G^R'_YZ
MFC^R'_YZFM:B@#)_LA_^>IH_LA_^>IK6HH R?[(?_GJ:/[(?_GJ:UJ* ,G^R
M'_YZFC^R'_YZFM:B@#)_LA_^>IH_LA_^>IK6HH R?[(?_GJ:/[(?_GJ:UJ*
M,G^R'_YZFC^R'_YZFM:B@#)_LA_^>IH_LA_^>IK6HH R?[(?_GJ:/[(?_GJ:
MUJ* ,G^R'_YZFC^R'_YZFM:B@#)_LA_^>IH_LA_^>IK6HH R?[(?_GJ:/[(?
M_GJ:UJ* ,G^R'_YZFC^R'_YZFM:B@#)_LA_^>IH_LA_^>IK6HH R?[(?_GJ:
M/[(?_GJ:UJ* ,G^R'_YZFC^R'_YZFM:B@#)_LA_^>IH_LA_^>IK6HH R?[(?
M_GJ:/[(?_GJ:UJ* ,G^R'_YZFC^R'_YZFM:B@#)_LA_^>IH_LA_^>IK6HH R
M?[(?_GJ:/[(?_GJ:UJ* ,G^R'_YZFC^R'_YZFM:B@#)_LA_^>IH_LA_^>IK6
MHH R?[(?_GJ:/[(?_GJ:UJ* ,G^R'_YZFC^R'_YZFM:B@#)_LA_^>IH_LA_^
M>IK6HH R?[(?_GJ:/[(?_GJ:UJ* ,G^R'_YZFC^R'_YZFM:B@#)_LA_^>IH_
MLA_^>IK6HH R?[(?_GJ:/[(?_GJ:UJ* ,G^R'_YZFC^R'_YZFM:B@#)_LA_^
M>IH_LA_^>IK6HH R?[(?_GJ:/[(?_GJ:UJ* ,G^R'_YZFC^R'_YZFM:B@#)_
MLA_^>IH_LA_^>IK6HH R?[(?_GJ:/[(?_GJ:UJ* ,G^R'_YZFC^R'_YZFM:B
M@#)_LA_^>IH_LA_^>IK6HH R?[(?_GJ:/[(?_GJ:UJ* ,G^R'_YZFC^R'_YZ
MFM:B@#)_LA_^>IH_LA_^>IK6HH R?[(?_GJ:/[(?_GJ:UJ* ,G^R'_YZFC^R
M'_YZFM:B@#)_LA_^>IH_LA_^>IK6HH R?[(?_GJ:/[(?_GJ:UJ* ,G^R'_YZ
MFC^R'_YZFM:B@#)_LA_^>IH_LA_^>IK6HH R?[(?_GJ:/[(?_GJ:UJ* ,G^R
M'_YZFC^R'_YZFM:B@#)_LA_^>IH_LA_^>IK6HH R?[(?_GJ:/[(?_GJ:UJ*
M,G^R'_YZFC^R'_YZFM:B@#)_LA_^>IH_LA_^>IK6HH R?[(?_GJ:/[(?_GJ:
MUJ* ,G^R'_YZFC^R'_YZFM:B@#)_LA_^>IH_LA_^>IK6HH R?[(?_GJ:/[(?
M_GJ:UJ* ,G^R'_YZFC^R'_YZFM:B@#)_LA_^>IH_LA_^>IK6HH R?[(?_GJ:
M/[(?_GJ:UJ* ,G^R'_YZFC^R'_YZFM:B@#)_LA_^>IH_LA_^>IK6HH R?[(?
M_GJ:/[(?_GJ:UJ* ,G^R'_YZFC^R'_YZFM:B@#)_LA_^>IH_LA_^>IK6HH R
M?[(?_GJ:/[(?_GJ:UJ* ,G^R'_YZFC^R'_YZFM:B@#)_LA_^>IH_LA_^>IK6
MHH R?[(?_GJ:/[(?_GJ:UJ* ,G^R'_YZFC^R'_YZFM:B@#)_LA_^>IH_LA_^
M>IK6HH R?[(?_GJ:/[(?_GJ:UJ* ,G^R'_YZFC^R'_YZFM:B@#)_LA_^>IH_
MLA_^>IK6HH R?[(?_GJ:/[(?_GJ:UJ* ,G^R'_YZFC^R'_YZFM:B@#)_LA_^
M>IH_LA_^>IK6HH R?[(?_GJ:/[(?_GJ:UJ* ,G^R'_YZFC^R'_YZFM:B@#)_
MLA_^>IH_LA_^>IK6HH R?[(?_GJ:/[(?_GJ:UJ* ,G^R'_YZFC^R'_YZFM:B
M@#)_LA_^>IH_LA_^>IK6HH R?[(?_GJ:/[(?_GJ:UJ* ,G^R'_YZFC^R'_YZ
MFM:B@#)_LA_^>IH_LA_^>IK6HH R?[(?_GJ:/[(?_GJ:UJ* ,G^R'_YZFC^R
M'_YZFM:B@#)_LA_^>IH_LA_^>IK6HH R?[(?_GJ:/[(?_GJ:UJ* ,G^R'_YZ
MFC^R'_YZFM:B@#)_LA_^>IH_LA_^>IK6HH R?[(?_GJ:/[(?_GJ:UJ* ,G^R
M'_YZFC^R'_YZFM:B@#)_LA_^>IH_LA_^>IK6HH R?[(?_GJ:3^R&Z%\BM>B@
M"O;0>0NW-3YYI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
2*** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ex23-1_001.jpg
<TEXT>
begin 644 ex23-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !J G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
E10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ex23-1_002.jpg
<TEXT>
begin 644 ex23-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  X G # 2(  A$! Q$!_\0
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M@XX[YKJ-*:<"Z@GN'N#!/L61P Q&U6YP .Y[4 :%%%% !1110 4444 %%%%
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@SD@<T45G.I*:LS2%*,'>)-11169J%%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>18
<FILENAME>indp-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaSLabP9z5Z8yekhvWB0bVmq7yMkcGb6FiNcjp42gesO -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:INDP="http://indaptusrx.com/20241231" elementFormDefault="qualified" targetNamespace="http://indaptusrx.com/20241231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://indaptusrx.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss" id="StatementsOfOperationsAndComprehensiveLoss">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
          <link:definition>00000005 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/General" id="General">
          <link:definition>999014 - Disclosure - GENERAL</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
          <link:definition>999015 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/PrepaidExpensesAndOtherCurrentAssets" id="PrepaidExpensesAndOtherCurrentAssets">
          <link:definition>999016 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/AccountsPayableAndOtherCurrentLiabilities" id="AccountsPayableAndOtherCurrentLiabilities">
          <link:definition>999017 - Disclosure - ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
          <link:definition>999018 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/Capitalization" id="Capitalization">
          <link:definition>999019 - Disclosure - CAPITALIZATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999020 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999021 - Disclosure - INCOME TAXES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/SegmentInformation" id="SegmentInformation">
          <link:definition>999022 - Disclosure - SEGMENT INFORMATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999023 - Disclosure - SUBSEQUENT EVENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
          <link:definition>999024 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/SignificantAccountingPoliciesTables" id="SignificantAccountingPoliciesTables">
          <link:definition>999025 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" id="PrepaidExpensesAndOtherCurrentAssetsTables">
          <link:definition>999026 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/AccountsPayableAndOtherCurrentLiabilitiesTables" id="AccountsPayableAndOtherCurrentLiabilitiesTables">
          <link:definition>999027 - Disclosure - ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
          <link:definition>999028 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
          <link:definition>999029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>999030 - Disclosure - INCOME TAXES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/SegmentInformationTables" id="SegmentInformationTables">
          <link:definition>999031 - Disclosure - SEGMENT INFORMATION (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/GeneralDetailsNarrative" id="GeneralDetailsNarrative">
          <link:definition>999032 - Disclosure - GENERAL (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" id="ScheduleOfAnti-dilutiveSecuritiesDetails">
          <link:definition>999033 - Disclosure - SCHEDULE OF ANTI-DILUTIVE SECURITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/SignificantAccountingPoliciesDetailsNarrative" id="SignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999034 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails" id="ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails">
          <link:definition>999035 - Disclosure - SCHEDULE OF PREPAID EXPENSE AND OTHER CURRENT ASSETS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails" id="ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails">
          <link:definition>999036 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/ScheduleOfStockOptionActivityDetails" id="ScheduleOfStockOptionActivityDetails">
          <link:definition>999037 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/ScheduleOfStockBasedCompensationExpensesDetails" id="ScheduleOfStockBasedCompensationExpensesDetails">
          <link:definition>999038 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION EXPENSES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/ScheduleOfWeightedAverageInputsUsedToMeasureValueOfOptionsGrantedDetails" id="ScheduleOfWeightedAverageInputsUsedToMeasureValueOfOptionsGrantedDetails">
          <link:definition>999039 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE INPUTS USED TO MEASURE VALUE OF OPTIONS GRANTED (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetails" id="ScheduleOfExercisePriceOfOutstandingStockOptionsDetails">
          <link:definition>999040 - Disclosure - SCHEDULE OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetailsParenthetical" id="ScheduleOfExercisePriceOfOutstandingStockOptionsDetailsParenthetical">
          <link:definition>999041 - Disclosure - SCHEDULE OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS (Details) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
          <link:definition>999042 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/CapitalizationDetailsNarrative" id="CapitalizationDetailsNarrative">
          <link:definition>999043 - Disclosure - CAPITALIZATION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/SummaryOfMinimumLeasePaymentsDetails" id="SummaryOfMinimumLeasePaymentsDetails">
          <link:definition>999044 - Disclosure - SUMMARY OF MINIMUM LEASE PAYMENTS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>999045 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/ScheduleOfProvisionForIncomeTaxesDetails" id="ScheduleOfProvisionForIncomeTaxesDetails">
          <link:definition>999046 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/ScheduleOfNetDeferredTaxAssetsDetails" id="ScheduleOfNetDeferredTaxAssetsDetails">
          <link:definition>999047 - Disclosure - SCHEDULE OF NET DEFERRED TAX ASSETS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999048 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/ScheduleOfReportableSegmentLossDetails" id="ScheduleOfReportableSegmentLossDetails">
          <link:definition>999049 - Disclosure - SCHEDULE OF REPORTABLE SEGMENT LOSS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://indaptusrx.com/role/SegmentInformationDetailsNarrative" id="SegmentInformationDetailsNarrative">
          <link:definition>999050 - Disclosure - SEGMENT INFORMATION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="indp-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="indp-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="indp-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="indp-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" />
    <element id="INDP_EquityPurchaseAgreementsMember" name="EquityPurchaseAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_ComputersAndOtherOfficeEquipmentMember" name="ComputersAndOtherOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_FurnitureMember" name="FurnitureMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_ExercisePriceRangeOneMember" name="ExercisePriceRangeOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_ExercisePriceRangeTwoMember" name="ExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_ExercisePriceRangeThreeMember" name="ExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_AtTheMarketOfferingAgreementMember" name="AtTheMarketOfferingAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_HCWainwrightAndCoLLCMember" name="HCWainwrightAndCoLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_YorkvilleMember" name="YorkvilleMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_StandbyEquityPurchaseAgreementsMember" name="StandbyEquityPurchaseAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_ExchangeCapMember" name="ExchangeCapMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_TwoYearLeaseAgreementMember" name="TwoYearLeaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_FederalMember" name="FederalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_StateMember" name="StateMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_ExpireInTwoThousandThirtySixMember" name="ExpireInTwoThousandThirtySixMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_IndefinitePeriodMember" name="IndefinitePeriodMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_ExpireInTwoThousandThirtyFiveMember" name="ExpireInTwoThousandThirtyFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_ExternalResearchAndDevelopmentMember" name="ExternalResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_InternalPersonnelCostsMember" name="InternalPersonnelCostsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_StockIssuedDuringPeriodValueNewIssuesOne" name="StockIssuedDuringPeriodValueNewIssuesOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_StockIssuedDuringPeriodSharesNewIssuesOne" name="StockIssuedDuringPeriodSharesNewIssuesOne" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_StockIssuedDuringPeriodValueNewIssuesTwo" name="StockIssuedDuringPeriodValueNewIssuesTwo" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_StockIssuedDuringPeriodSharesNewIssuesTwo" name="StockIssuedDuringPeriodSharesNewIssuesTwo" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_InterestEarnedOnMarketableSecurities" name="InterestEarnedOnMarketableSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_LeaseRenewalOptionExercise" name="LeaseRenewalOptionExercise" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_TransactionCostsInAccountsPayableAndOtherCurrentLiabilities" name="TransactionCostsInAccountsPayableAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_ChangeInAccumulatedOtherComprehensiveIncomeLoss" name="ChangeInAccumulatedOtherComprehensiveIncomeLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" name="DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_PrepaidExpenseAndOtherCurrentAssetsDisclosureTextBlock" name="PrepaidExpenseAndOtherCurrentAssetsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_DisclosureCapitalizationAbstract" name="DisclosureCapitalizationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_CapitalizationTextBlock" name="CapitalizationTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_NewAdoptedAccountingPronouncementsPolicyPolicyTextBlock" name="NewAdoptedAccountingPronouncementsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock" name="ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_PrepaidResearchAndDevelopment" name="PrepaidResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_AccruedResearchAndDevelopmentCurrent" name="AccruedResearchAndDevelopmentCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_AccruedBoardFeesCurrent" name="AccruedBoardFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_DelawareFranchiseTaxesPayableCurrent" name="DelawareFranchiseTaxesPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_NumberOfResaleCommonStockComprised" name="NumberOfResaleCommonStockComprised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_NumberOfCommitmentShares" name="NumberOfCommitmentShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_NumberOfCommitmentSharesToBeIssuedUponCertainConditions" name="NumberOfCommitmentSharesToBeIssuedUponCertainConditions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_RateOfIncreaseInLeaseRent" name="RateOfIncreaseInLeaseRent" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmountReturnToProvisionAdjustments" name="EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmountReturnToProvisionAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="INDP_DeferredTaxLiabilitiesRightOfUseAsset" name="DeferredTaxLiabilitiesRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>19
<FILENAME>indp-20241231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://indaptusrx.com/role/Cover" xlink:href="indp-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/BalanceSheets" xlink:href="indp-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/BalanceSheetsParenthetical" xlink:href="indp-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="indp-20241231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/StatementsOfStockholdersEquity" xlink:href="indp-20241231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/StatementsOfCashFlows" xlink:href="indp-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/General" xlink:href="indp-20241231.xsd#General" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/SignificantAccountingPolicies" xlink:href="indp-20241231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="indp-20241231.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/AccountsPayableAndOtherCurrentLiabilities" xlink:href="indp-20241231.xsd#AccountsPayableAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/Stock-basedCompensation" xlink:href="indp-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/Capitalization" xlink:href="indp-20241231.xsd#Capitalization" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/CommitmentsAndContingencies" xlink:href="indp-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/IncomeTaxes" xlink:href="indp-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/SegmentInformation" xlink:href="indp-20241231.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/SubsequentEvents" xlink:href="indp-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies" xlink:href="indp-20241231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/SignificantAccountingPoliciesTables" xlink:href="indp-20241231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="indp-20241231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/AccountsPayableAndOtherCurrentLiabilitiesTables" xlink:href="indp-20241231.xsd#AccountsPayableAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/Stock-basedCompensationTables" xlink:href="indp-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/CommitmentsAndContingenciesTables" xlink:href="indp-20241231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/IncomeTaxesTables" xlink:href="indp-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/SegmentInformationTables" xlink:href="indp-20241231.xsd#SegmentInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/GeneralDetailsNarrative" xlink:href="indp-20241231.xsd#GeneralDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:href="indp-20241231.xsd#ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="indp-20241231.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails" xlink:href="indp-20241231.xsd#ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails" xlink:href="indp-20241231.xsd#ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="indp-20241231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfStockBasedCompensationExpensesDetails" xlink:href="indp-20241231.xsd#ScheduleOfStockBasedCompensationExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfWeightedAverageInputsUsedToMeasureValueOfOptionsGrantedDetails" xlink:href="indp-20241231.xsd#ScheduleOfWeightedAverageInputsUsedToMeasureValueOfOptionsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetails" xlink:href="indp-20241231.xsd#ScheduleOfExercisePriceOfOutstandingStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetailsParenthetical" xlink:href="indp-20241231.xsd#ScheduleOfExercisePriceOfOutstandingStockOptionsDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="indp-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/CapitalizationDetailsNarrative" xlink:href="indp-20241231.xsd#CapitalizationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/SummaryOfMinimumLeasePaymentsDetails" xlink:href="indp-20241231.xsd#SummaryOfMinimumLeasePaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="indp-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="indp-20241231.xsd#ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfNetDeferredTaxAssetsDetails" xlink:href="indp-20241231.xsd#ScheduleOfNetDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/IncomeTaxesDetailsNarrative" xlink:href="indp-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfReportableSegmentLossDetails" xlink:href="indp-20241231.xsd#ScheduleOfReportableSegmentLossDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/SegmentInformationDetailsNarrative" xlink:href="indp-20241231.xsd#SegmentInformationDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_InterestEarnedOnMarketableSecurities" xlink:label="loc_INDPInterestEarnedOnMarketableSecurities" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_INDPInterestEarnedOnMarketableSecurities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet" xlink:label="loc_INDPIncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_INDPIncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="loc_us-gaapProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="loc_us-gaapPaymentOfFinancingAndStockIssuanceCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentOfFinancingAndStockIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/General" xlink:title="999014 - Disclosure - GENERAL" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/SignificantAccountingPolicies" xlink:title="999015 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="999016 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/AccountsPayableAndOtherCurrentLiabilities" xlink:title="999017 - Disclosure - ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/Stock-basedCompensation" xlink:title="999018 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/Capitalization" xlink:title="999019 - Disclosure - CAPITALIZATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/CommitmentsAndContingencies" xlink:title="999020 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/IncomeTaxes" xlink:title="999021 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/SegmentInformation" xlink:title="999022 - Disclosure - SEGMENT INFORMATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/SubsequentEvents" xlink:title="999023 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies" xlink:title="999024 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/SignificantAccountingPoliciesTables" xlink:title="999025 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="999026 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/AccountsPayableAndOtherCurrentLiabilitiesTables" xlink:title="999027 - Disclosure - ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/Stock-basedCompensationTables" xlink:title="999028 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/CommitmentsAndContingenciesTables" xlink:title="999029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/IncomeTaxesTables" xlink:title="999030 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/SegmentInformationTables" xlink:title="999031 - Disclosure - SEGMENT INFORMATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/GeneralDetailsNarrative" xlink:title="999032 - Disclosure - GENERAL (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:title="999033 - Disclosure - SCHEDULE OF ANTI-DILUTIVE SECURITIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="999034 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails" xlink:title="999035 - Disclosure - SCHEDULE OF PREPAID EXPENSE AND OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_PrepaidResearchAndDevelopment" xlink:label="loc_INDPPrepaidResearchAndDevelopment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_INDPPrepaidResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails" xlink:title="999036 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_AccruedResearchAndDevelopmentCurrent" xlink:label="loc_INDPAccruedResearchAndDevelopmentCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_INDPAccruedResearchAndDevelopmentCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_AccruedBoardFeesCurrent" xlink:label="loc_INDPAccruedBoardFeesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_INDPAccruedBoardFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_DelawareFranchiseTaxesPayableCurrent" xlink:label="loc_INDPDelawareFranchiseTaxesPayableCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_INDPDelawareFranchiseTaxesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999037 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfStockBasedCompensationExpensesDetails" xlink:title="999038 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION EXPENSES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfWeightedAverageInputsUsedToMeasureValueOfOptionsGrantedDetails" xlink:title="999039 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE INPUTS USED TO MEASURE VALUE OF OPTIONS GRANTED (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetails" xlink:title="999040 - Disclosure - SCHEDULE OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetailsParenthetical" xlink:title="999041 - Disclosure - SCHEDULE OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999042 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/CapitalizationDetailsNarrative" xlink:title="999043 - Disclosure - CAPITALIZATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/SummaryOfMinimumLeasePaymentsDetails" xlink:title="999044 - Disclosure - SUMMARY OF MINIMUM LEASE PAYMENTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999045 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="999046 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmountReturnToProvisionAdjustments" xlink:label="loc_INDPEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmountReturnToProvisionAdjustments" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_INDPEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmountReturnToProvisionAdjustments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfNetDeferredTaxAssetsDetails" xlink:title="999047 - Disclosure - SCHEDULE OF NET DEFERRED TAX ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="loc_INDPDeferredTaxLiabilitiesRightOfUseAsset" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_INDPDeferredTaxLiabilitiesRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/IncomeTaxesDetailsNarrative" xlink:title="999048 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfReportableSegmentLossDetails" xlink:title="999049 - Disclosure - SCHEDULE OF REPORTABLE SEGMENT LOSS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaapOtherOperatingIncomeExpenseNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherOperatingIncomeExpenseNet" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/SegmentInformationDetailsNarrative" xlink:title="999050 - Disclosure - SEGMENT INFORMATION (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>20
<FILENAME>indp-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://indaptusrx.com/role/Cover" xlink:href="indp-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/BalanceSheets" xlink:href="indp-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/BalanceSheetsParenthetical" xlink:href="indp-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="indp-20241231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/StatementsOfStockholdersEquity" xlink:href="indp-20241231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/StatementsOfCashFlows" xlink:href="indp-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/General" xlink:href="indp-20241231.xsd#General" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/SignificantAccountingPolicies" xlink:href="indp-20241231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="indp-20241231.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/AccountsPayableAndOtherCurrentLiabilities" xlink:href="indp-20241231.xsd#AccountsPayableAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/Stock-basedCompensation" xlink:href="indp-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/Capitalization" xlink:href="indp-20241231.xsd#Capitalization" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/CommitmentsAndContingencies" xlink:href="indp-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/IncomeTaxes" xlink:href="indp-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/SegmentInformation" xlink:href="indp-20241231.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/SubsequentEvents" xlink:href="indp-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies" xlink:href="indp-20241231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/SignificantAccountingPoliciesTables" xlink:href="indp-20241231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="indp-20241231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/AccountsPayableAndOtherCurrentLiabilitiesTables" xlink:href="indp-20241231.xsd#AccountsPayableAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/Stock-basedCompensationTables" xlink:href="indp-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/CommitmentsAndContingenciesTables" xlink:href="indp-20241231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/IncomeTaxesTables" xlink:href="indp-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/SegmentInformationTables" xlink:href="indp-20241231.xsd#SegmentInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/GeneralDetailsNarrative" xlink:href="indp-20241231.xsd#GeneralDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:href="indp-20241231.xsd#ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="indp-20241231.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails" xlink:href="indp-20241231.xsd#ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails" xlink:href="indp-20241231.xsd#ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="indp-20241231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfStockBasedCompensationExpensesDetails" xlink:href="indp-20241231.xsd#ScheduleOfStockBasedCompensationExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfWeightedAverageInputsUsedToMeasureValueOfOptionsGrantedDetails" xlink:href="indp-20241231.xsd#ScheduleOfWeightedAverageInputsUsedToMeasureValueOfOptionsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetails" xlink:href="indp-20241231.xsd#ScheduleOfExercisePriceOfOutstandingStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetailsParenthetical" xlink:href="indp-20241231.xsd#ScheduleOfExercisePriceOfOutstandingStockOptionsDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="indp-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/CapitalizationDetailsNarrative" xlink:href="indp-20241231.xsd#CapitalizationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/SummaryOfMinimumLeasePaymentsDetails" xlink:href="indp-20241231.xsd#SummaryOfMinimumLeasePaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="indp-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="indp-20241231.xsd#ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfNetDeferredTaxAssetsDetails" xlink:href="indp-20241231.xsd#ScheduleOfNetDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/IncomeTaxesDetailsNarrative" xlink:href="indp-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfReportableSegmentLossDetails" xlink:href="indp-20241231.xsd#ScheduleOfReportableSegmentLossDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/SegmentInformationDetailsNarrative" xlink:href="indp-20241231.xsd#SegmentInformationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/Defaults" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_StockIssuedDuringPeriodValueNewIssuesOne" xlink:label="loc_INDPStockIssuedDuringPeriodValueNewIssuesOne_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_INDPStockIssuedDuringPeriodValueNewIssuesOne_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:label="loc_INDPStockIssuedDuringPeriodSharesNewIssuesOne_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_INDPStockIssuedDuringPeriodSharesNewIssuesOne_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_StockIssuedDuringPeriodValueNewIssuesTwo" xlink:label="loc_INDPStockIssuedDuringPeriodValueNewIssuesTwo_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_INDPStockIssuedDuringPeriodValueNewIssuesTwo_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_StockIssuedDuringPeriodSharesNewIssuesTwo" xlink:label="loc_INDPStockIssuedDuringPeriodSharesNewIssuesTwo_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_INDPStockIssuedDuringPeriodSharesNewIssuesTwo_60" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/General" xlink:title="999014 - Disclosure - GENERAL" />
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/SignificantAccountingPolicies" xlink:title="999015 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="999016 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/AccountsPayableAndOtherCurrentLiabilities" xlink:title="999017 - Disclosure - ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/Stock-basedCompensation" xlink:title="999018 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/Capitalization" xlink:title="999019 - Disclosure - CAPITALIZATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/CommitmentsAndContingencies" xlink:title="999020 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/IncomeTaxes" xlink:title="999021 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/SegmentInformation" xlink:title="999022 - Disclosure - SEGMENT INFORMATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/SubsequentEvents" xlink:title="999023 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies" xlink:title="999024 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/SignificantAccountingPoliciesTables" xlink:title="999025 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="999026 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/AccountsPayableAndOtherCurrentLiabilitiesTables" xlink:title="999027 - Disclosure - ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/Stock-basedCompensationTables" xlink:title="999028 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/CommitmentsAndContingenciesTables" xlink:title="999029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/IncomeTaxesTables" xlink:title="999030 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/SegmentInformationTables" xlink:title="999031 - Disclosure - SEGMENT INFORMATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/GeneralDetailsNarrative" xlink:title="999032 - Disclosure - GENERAL (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_EquityPurchaseAgreementsMember" xlink:label="loc_INDPEquityPurchaseAgreementsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_INDPEquityPurchaseAgreementsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="loc_us-gaapNoninterestExpenseOfferingCost_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNoninterestExpenseOfferingCost_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_50" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:title="999033 - Disclosure - SCHEDULE OF ANTI-DILUTIVE SECURITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="999034 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaapFairValueByAssetClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapFairValueByAssetClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="loc_us-gaapPropertyPlantAndEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_us-gaapPropertyPlantAndEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ComputersAndOtherOfficeEquipmentMember" xlink:label="loc_INDPComputersAndOtherOfficeEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_INDPComputersAndOtherOfficeEquipmentMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_FurnitureMember" xlink:label="loc_INDPFurnitureMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_INDPFurnitureMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails" xlink:title="999035 - Disclosure - SCHEDULE OF PREPAID EXPENSE AND OTHER CURRENT ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails" xlink:title="999036 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999037 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfStockBasedCompensationExpensesDetails" xlink:title="999038 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapShareBasedCompensation_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfWeightedAverageInputsUsedToMeasureValueOfOptionsGrantedDetails" xlink:title="999039 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE INPUTS USED TO MEASURE VALUE OF OPTIONS GRANTED (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetails" xlink:title="999040 - Disclosure - SCHEDULE OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ExercisePriceRangeOneMember" xlink:label="loc_INDPExercisePriceRangeOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_INDPExercisePriceRangeOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ExercisePriceRangeTwoMember" xlink:label="loc_INDPExercisePriceRangeTwoMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_INDPExercisePriceRangeTwoMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ExercisePriceRangeThreeMember" xlink:label="loc_INDPExercisePriceRangeThreeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_INDPExercisePriceRangeThreeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetailsParenthetical" xlink:title="999041 - Disclosure - SCHEDULE OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ExercisePriceRangeOneMember" xlink:label="loc_INDPExercisePriceRangeOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_INDPExercisePriceRangeOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ExercisePriceRangeTwoMember" xlink:label="loc_INDPExercisePriceRangeTwoMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_INDPExercisePriceRangeTwoMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ExercisePriceRangeThreeMember" xlink:label="loc_INDPExercisePriceRangeThreeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_INDPExercisePriceRangeThreeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999042 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/CapitalizationDetailsNarrative" xlink:title="999043 - Disclosure - CAPITALIZATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_260" xlink:type="arc" order="264" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_AtTheMarketOfferingAgreementMember" xlink:label="loc_INDPAtTheMarketOfferingAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_INDPAtTheMarketOfferingAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_StandbyEquityPurchaseAgreementsMember" xlink:label="loc_INDPStandbyEquityPurchaseAgreementsMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_INDPStandbyEquityPurchaseAgreementsMember_250" xlink:type="arc" order="252" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ExchangeCapMember" xlink:label="loc_INDPExchangeCapMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_INDPExchangeCapMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_HCWainwrightAndCoLLCMember" xlink:label="loc_INDPHCWainwrightAndCoLLCMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_INDPHCWainwrightAndCoLLCMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_YorkvilleMember" xlink:label="loc_INDPYorkvilleMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_INDPYorkvilleMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_290" xlink:type="arc" order="293" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_310" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_310" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_310" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_310" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_310" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_310" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_310" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_310" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_310" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_310" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_310" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_310" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued_310" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_310" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_310" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_310" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="loc_us-gaapNoninterestExpenseOfferingCost_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNoninterestExpenseOfferingCost_310" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice_310" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_310" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_310" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_NumberOfResaleCommonStockComprised" xlink:label="loc_INDPNumberOfResaleCommonStockComprised_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_INDPNumberOfResaleCommonStockComprised_310" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_NumberOfCommitmentShares" xlink:label="loc_INDPNumberOfCommitmentShares_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_INDPNumberOfCommitmentShares_310" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_NumberOfCommitmentSharesToBeIssuedUponCertainConditions" xlink:label="loc_INDPNumberOfCommitmentSharesToBeIssuedUponCertainConditions_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_INDPNumberOfCommitmentSharesToBeIssuedUponCertainConditions_310" xlink:type="arc" order="22" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/SummaryOfMinimumLeasePaymentsDetails" xlink:title="999044 - Disclosure - SUMMARY OF MINIMUM LEASE PAYMENTS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999045 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="loc_us-gaapProductLiabilityContingencyLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="loc_us-gaapProductLiabilityContingencyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapProductLiabilityContingencyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_CA" xlink:label="loc_stprCA_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprCA_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_TwoYearLeaseAgreementMember" xlink:label="loc_INDPTwoYearLeaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_INDPTwoYearLeaseAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapAreaOfLand_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_RateOfIncreaseInLeaseRent" xlink:label="loc_INDPRateOfIncreaseInLeaseRent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_INDPRateOfIncreaseInLeaseRent_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaapLesseeOperatingLeaseOptionToExtend_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseOptionToExtend_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaapLesseeOperatingLeaseDiscountRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDiscountRate_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapPaymentsForRent_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapOperatingLeasePayments_70" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="999046 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfNetDeferredTaxAssetsDetails" xlink:title="999047 - Disclosure - SCHEDULE OF NET DEFERRED TAX ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/IncomeTaxesDetailsNarrative" xlink:title="999048 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_FederalMember" xlink:label="loc_INDPFederalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_INDPFederalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_StateMember" xlink:label="loc_INDPStateMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_INDPStateMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaapTaxPeriodAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapTaxPeriodAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ExpireInTwoThousandThirtySixMember" xlink:label="loc_INDPExpireInTwoThousandThirtySixMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_INDPExpireInTwoThousandThirtySixMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_IndefinitePeriodMember" xlink:label="loc_INDPIndefinitePeriodMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_INDPIndefinitePeriodMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ExpireInTwoThousandThirtyFiveMember" xlink:label="loc_INDPExpireInTwoThousandThirtyFiveMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_INDPExpireInTwoThousandThirtyFiveMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IL" xlink:label="loc_countryIL_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryIL_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaapIncomeTaxExaminationDescription_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationDescription_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaapUnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_110" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfReportableSegmentLossDetails" xlink:title="999049 - Disclosure - SCHEDULE OF REPORTABLE SEGMENT LOSS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ExternalResearchAndDevelopmentMember" xlink:label="loc_INDPExternalResearchAndDevelopmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_INDPExternalResearchAndDevelopmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_InternalPersonnelCostsMember" xlink:label="loc_INDPInternalPersonnelCostsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_INDPInternalPersonnelCostsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaapOtherOperatingIncomeExpenseNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherOperatingIncomeExpenseNet_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/SegmentInformationDetailsNarrative" xlink:title="999050 - Disclosure - SEGMENT INFORMATION (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>21
<FILENAME>indp-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_EquityPurchaseAgreementsMember" xlink:label="INDP_EquityPurchaseAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_EquityPurchaseAgreementsMember" xlink:to="INDP_EquityPurchaseAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_EquityPurchaseAgreementsMember_lbl" xml:lang="en-US">Equity Purchase Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Asset Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US">Property, Plant and Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ComputersAndOtherOfficeEquipmentMember" xlink:label="INDP_ComputersAndOtherOfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_ComputersAndOtherOfficeEquipmentMember" xlink:to="INDP_ComputersAndOtherOfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_ComputersAndOtherOfficeEquipmentMember_lbl" xml:lang="en-US">Computers and Other Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_FurnitureMember" xlink:label="INDP_FurnitureMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_FurnitureMember" xlink:to="INDP_FurnitureMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_FurnitureMember_lbl" xml:lang="en-US">Furniture [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ExercisePriceRangeOneMember" xlink:label="INDP_ExercisePriceRangeOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_ExercisePriceRangeOneMember" xlink:to="INDP_ExercisePriceRangeOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_ExercisePriceRangeOneMember_lbl" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ExercisePriceRangeTwoMember" xlink:label="INDP_ExercisePriceRangeTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_ExercisePriceRangeTwoMember" xlink:to="INDP_ExercisePriceRangeTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_ExercisePriceRangeTwoMember_lbl" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ExercisePriceRangeThreeMember" xlink:label="INDP_ExercisePriceRangeThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_ExercisePriceRangeThreeMember" xlink:to="INDP_ExercisePriceRangeThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_ExercisePriceRangeThreeMember_lbl" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_AtTheMarketOfferingAgreementMember" xlink:label="INDP_AtTheMarketOfferingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_AtTheMarketOfferingAgreementMember" xlink:to="INDP_AtTheMarketOfferingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_AtTheMarketOfferingAgreementMember_lbl" xml:lang="en-US">At The Market Offering Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_HCWainwrightAndCoLLCMember" xlink:label="INDP_HCWainwrightAndCoLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_HCWainwrightAndCoLLCMember" xlink:to="INDP_HCWainwrightAndCoLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_HCWainwrightAndCoLLCMember_lbl" xml:lang="en-US">HC Wainwright and Co LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_YorkvilleMember" xlink:label="INDP_YorkvilleMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_YorkvilleMember" xlink:to="INDP_YorkvilleMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_YorkvilleMember_lbl" xml:lang="en-US">Yorkville [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_StandbyEquityPurchaseAgreementsMember" xlink:label="INDP_StandbyEquityPurchaseAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_StandbyEquityPurchaseAgreementsMember" xlink:to="INDP_StandbyEquityPurchaseAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_StandbyEquityPurchaseAgreementsMember_lbl" xml:lang="en-US">Standby Equity Purchase Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ExchangeCapMember" xlink:label="INDP_ExchangeCapMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_ExchangeCapMember" xlink:to="INDP_ExchangeCapMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_ExchangeCapMember_lbl" xml:lang="en-US">Exchange Cap [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_CA" xlink:label="stpr_CA" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_CA_lbl" xml:lang="en-US">CALIFORNIA</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_TwoYearLeaseAgreementMember" xlink:label="INDP_TwoYearLeaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_TwoYearLeaseAgreementMember" xlink:to="INDP_TwoYearLeaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_TwoYearLeaseAgreementMember_lbl" xml:lang="en-US">Two Year Lease Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_FederalMember" xlink:label="INDP_FederalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_FederalMember" xlink:to="INDP_FederalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_FederalMember_lbl" xml:lang="en-US">Federal [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_StateMember" xlink:label="INDP_StateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_StateMember" xlink:to="INDP_StateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_StateMember_lbl" xml:lang="en-US">State [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodAxis_lbl" xml:lang="en-US">Tax Period [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ExpireInTwoThousandThirtySixMember" xlink:label="INDP_ExpireInTwoThousandThirtySixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_ExpireInTwoThousandThirtySixMember" xlink:to="INDP_ExpireInTwoThousandThirtySixMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_ExpireInTwoThousandThirtySixMember_lbl" xml:lang="en-US">Expire In 2036 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_IndefinitePeriodMember" xlink:label="INDP_IndefinitePeriodMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_IndefinitePeriodMember" xlink:to="INDP_IndefinitePeriodMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_IndefinitePeriodMember_lbl" xml:lang="en-US">Indefinite Period [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ExpireInTwoThousandThirtyFiveMember" xlink:label="INDP_ExpireInTwoThousandThirtyFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_ExpireInTwoThousandThirtyFiveMember" xlink:to="INDP_ExpireInTwoThousandThirtyFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_ExpireInTwoThousandThirtyFiveMember_lbl" xml:lang="en-US">Expire In 2035 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IL" xlink:label="country_IL" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IL" xlink:to="country_IL_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_IL_lbl" xml:lang="en-US">ISRAEL</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ExternalResearchAndDevelopmentMember" xlink:label="INDP_ExternalResearchAndDevelopmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_ExternalResearchAndDevelopmentMember" xlink:to="INDP_ExternalResearchAndDevelopmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_ExternalResearchAndDevelopmentMember_lbl" xml:lang="en-US">External Research and Development [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_InternalPersonnelCostsMember" xlink:label="INDP_InternalPersonnelCostsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_InternalPersonnelCostsMember" xlink:to="INDP_InternalPersonnelCostsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_InternalPersonnelCostsMember_lbl" xml:lang="en-US">Internal Personnel Costs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Non-current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets - deposits to third parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total non-current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability, current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total non-current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 7)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock: $0.01 par value, 200,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 12,013,901 shares issued and outstanding as of December 31, 2024 and 8,401,047 shares issued and outstanding as of December 31, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock: $0.01 par value, 5,000,000 shares authorized as of December 31, 2024 and December 31, 2023; no shares issued or outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss available to common stockholders per share of common stock, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss available to common stockholders per share of common stock, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of shares used in calculating net loss per share, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of shares used in calculating net loss per share, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US">Other comprehensive income:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_lbl" xml:lang="en-US">Reclassification adjustment for interest earned on marketable securities included in net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Change in unrealized gain on marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of shares of common stock, net of issuance costs (Note 6b)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of shares of common stock, net of issuance costs (Note 6b), shares</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_StockIssuedDuringPeriodValueNewIssuesOne" xlink:label="INDP_StockIssuedDuringPeriodValueNewIssuesOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_StockIssuedDuringPeriodValueNewIssuesOne" xlink:to="INDP_StockIssuedDuringPeriodValueNewIssuesOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_StockIssuedDuringPeriodValueNewIssuesOne_lbl" xml:lang="en-US">Issuance of shares of common stock and warrants, net of issuance costs (Note 6c)</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:label="INDP_StockIssuedDuringPeriodSharesNewIssuesOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:to="INDP_StockIssuedDuringPeriodSharesNewIssuesOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_StockIssuedDuringPeriodSharesNewIssuesOne_lbl" xml:lang="en-US">Issuance of shares of common stock and warrants, net of issuance costs (Note 6c), shares</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_StockIssuedDuringPeriodValueNewIssuesTwo" xlink:label="INDP_StockIssuedDuringPeriodValueNewIssuesTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_StockIssuedDuringPeriodValueNewIssuesTwo" xlink:to="INDP_StockIssuedDuringPeriodValueNewIssuesTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_StockIssuedDuringPeriodValueNewIssuesTwo_lbl" xml:lang="en-US">Issuance of shares of common stock and warrants, net of issuance costs (Note 6d)</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_StockIssuedDuringPeriodSharesNewIssuesTwo" xlink:label="INDP_StockIssuedDuringPeriodSharesNewIssuesTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_StockIssuedDuringPeriodSharesNewIssuesTwo" xlink:to="INDP_StockIssuedDuringPeriodSharesNewIssuesTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_StockIssuedDuringPeriodSharesNewIssuesTwo_lbl" xml:lang="en-US">Issuance of shares of common stock and warrants, net of issuance costs (Note 6d), shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_InterestEarnedOnMarketableSecurities" xlink:label="INDP_InterestEarnedOnMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_InterestEarnedOnMarketableSecurities" xlink:to="INDP_InterestEarnedOnMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="INDP_InterestEarnedOnMarketableSecurities_lbl" xml:lang="en-US">Interest earned on marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current and non-current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Accounts payable and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet" xlink:label="INDP_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet" xlink:to="INDP_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet_lbl" xml:lang="en-US">Operating lease right-of-use asset and liability, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US">Purchase of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xml:lang="en-US">Maturity of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of shares of common stock and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xml:lang="en-US">Issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Noncash investing and financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_LeaseRenewalOptionExercise" xlink:label="INDP_LeaseRenewalOptionExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_LeaseRenewalOptionExercise" xlink:to="INDP_LeaseRenewalOptionExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_LeaseRenewalOptionExercise_lbl" xml:lang="en-US">ASC 842 lease renewal option exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_TransactionCostsInAccountsPayableAndOtherCurrentLiabilities" xlink:label="INDP_TransactionCostsInAccountsPayableAndOtherCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_TransactionCostsInAccountsPayableAndOtherCurrentLiabilities" xlink:to="INDP_TransactionCostsInAccountsPayableAndOtherCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_TransactionCostsInAccountsPayableAndOtherCurrentLiabilities_lbl" xml:lang="en-US">Transaction costs in accounts payable and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ChangeInAccumulatedOtherComprehensiveIncomeLoss" xlink:label="INDP_ChangeInAccumulatedOtherComprehensiveIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_ChangeInAccumulatedOtherComprehensiveIncomeLoss" xlink:to="INDP_ChangeInAccumulatedOtherComprehensiveIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_ChangeInAccumulatedOtherComprehensiveIncomeLoss_lbl" xml:lang="en-US">Change in accumulated other comprehensive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental cash flow disclosures</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Cash paid for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="cyd_MaterialCybersecurityIncidentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentAbstract" xlink:to="cyd_MaterialCybersecurityIncidentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentAbstract_lbl" xml:lang="en-US">Material Cybersecurity Incident [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Nature [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Scope [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Timing [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">GENERAL</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="INDP_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="INDP_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Prepaid Expenses And Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_PrepaidExpenseAndOtherCurrentAssetsDisclosureTextBlock" xlink:label="INDP_PrepaidExpenseAndOtherCurrentAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_PrepaidExpenseAndOtherCurrentAssetsDisclosureTextBlock" xlink:to="INDP_PrepaidExpenseAndOtherCurrentAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_PrepaidExpenseAndOtherCurrentAssetsDisclosureTextBlock_lbl" xml:lang="en-US">PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_DisclosureCapitalizationAbstract" xlink:label="INDP_DisclosureCapitalizationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_DisclosureCapitalizationAbstract" xlink:to="INDP_DisclosureCapitalizationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_DisclosureCapitalizationAbstract_lbl" xml:lang="en-US">Capitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_CapitalizationTextBlock" xlink:label="INDP_CapitalizationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_CapitalizationTextBlock" xlink:to="INDP_CapitalizationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_CapitalizationTextBlock_lbl" xml:lang="en-US">CAPITALIZATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT INFORMATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Patents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair value measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_NewAdoptedAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="INDP_NewAdoptedAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_NewAdoptedAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="INDP_NewAdoptedAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_NewAdoptedAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently adopted accounting pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently issued accounting pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ANTI-DILUTIVE SECURITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock" xlink:label="INDP_ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock" xlink:to="INDP_ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PREPAID EXPENSE AND OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTION ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK BASED COMPENSATION EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WEIGHTED AVERAGE INPUTS USED TO MEASURE VALUE OF OPTIONS GRANTED</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">SCHEDULE OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">SUMMARY OF MINIMUM LEASE PAYMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROVISION FOR INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF NET DEFERRED TAX ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">SCHEDULE OF REPORTABLE SEGMENT LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Net of placement agent cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="us-gaap_NoninterestExpenseOfferingCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseOfferingCost" xlink:to="us-gaap_NoninterestExpenseOfferingCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoninterestExpenseOfferingCost_lbl" xml:lang="en-US">Other offering cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Purchase ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="INDP_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="INDP_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract_2_lbl" xml:lang="en-US">Schedule Of Prepaid Expense And Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_PrepaidResearchAndDevelopment" xlink:label="INDP_PrepaidResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_PrepaidResearchAndDevelopment" xlink:to="INDP_PrepaidResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_PrepaidResearchAndDevelopment_lbl" xml:lang="en-US">Prepaid research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other prepaid expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued employee costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_AccruedResearchAndDevelopmentCurrent" xlink:label="INDP_AccruedResearchAndDevelopmentCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_AccruedResearchAndDevelopmentCurrent" xlink:to="INDP_AccruedResearchAndDevelopmentCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_AccruedResearchAndDevelopmentCurrent_lbl" xml:lang="en-US">Accrued research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_AccruedBoardFeesCurrent" xlink:label="INDP_AccruedBoardFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_AccruedBoardFeesCurrent" xlink:to="INDP_AccruedBoardFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_AccruedBoardFeesCurrent_lbl" xml:lang="en-US">Accrued board fees</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_DelawareFranchiseTaxesPayableCurrent" xlink:label="INDP_DelawareFranchiseTaxesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_DelawareFranchiseTaxesPayableCurrent" xlink:to="INDP_DelawareFranchiseTaxesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_DelawareFranchiseTaxesPayableCurrent_lbl" xml:lang="en-US">Delaware franchise taxes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other accrued expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total accounts payable and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of options, outstanding balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, outstanding, balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Intrinsic value, outstanding balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of options, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xml:lang="en-US">Intrinsic value, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of options, forfeited and cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, forfeited and cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of options, outstanding balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Intrinsic value, Outstanding, balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of options, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual life, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Intrinsic value, outstanding balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of options, vested and expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, vested and expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years), vested and expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Intrinsic value, vested and expected to vest balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Total stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Exercise price range lower range limit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Exercise price range upper range limit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Share-based compensation, not yet recognized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Share-based compensation, not yet recognized, term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average fair value of stock options issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Fair value of a warrant to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average, remaining contractual life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares issued, price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrants exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants and rights outstanding, term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseOfferingCost" xlink:to="us-gaap_NoninterestExpenseOfferingCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NoninterestExpenseOfferingCost_2_lbl" xml:lang="en-US">Noninterest expense offering cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants purchase shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Purchase ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_NumberOfResaleCommonStockComprised" xlink:label="INDP_NumberOfResaleCommonStockComprised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_NumberOfResaleCommonStockComprised" xlink:to="INDP_NumberOfResaleCommonStockComprised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_NumberOfResaleCommonStockComprised_lbl" xml:lang="en-US">Number of resale common stock comprised</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_NumberOfCommitmentShares" xlink:label="INDP_NumberOfCommitmentShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_NumberOfCommitmentShares" xlink:to="INDP_NumberOfCommitmentShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_NumberOfCommitmentShares_lbl" xml:lang="en-US">Commitment shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_NumberOfCommitmentSharesToBeIssuedUponCertainConditions" xlink:label="INDP_NumberOfCommitmentSharesToBeIssuedUponCertainConditions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_NumberOfCommitmentSharesToBeIssuedUponCertainConditions" xlink:to="INDP_NumberOfCommitmentSharesToBeIssuedUponCertainConditions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_NumberOfCommitmentSharesToBeIssuedUponCertainConditions_lbl" xml:lang="en-US">Commitment shares to be issued upon certain conditions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments in 2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: amount representing interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of operating lease liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Less: current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="us-gaap_ProductLiabilityContingencyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductLiabilityContingencyTable" xlink:to="us-gaap_ProductLiabilityContingencyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductLiabilityContingencyTable_lbl" xml:lang="en-US">Product Liability Contingency [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="us-gaap_ProductLiabilityContingencyLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductLiabilityContingencyLineItems" xlink:to="us-gaap_ProductLiabilityContingencyLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductLiabilityContingencyLineItems_lbl" xml:lang="en-US">Product Liability Contingency [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of land</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Base rent</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_RateOfIncreaseInLeaseRent" xlink:label="INDP_RateOfIncreaseInLeaseRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_RateOfIncreaseInLeaseRent" xlink:to="INDP_RateOfIncreaseInLeaseRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_RateOfIncreaseInLeaseRent_lbl" xml:lang="en-US">Rate of increase in lease rent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xml:lang="en-US">Operating lease, extend description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US">Incremental borrowing rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Rental expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Computed &#8220;expected&#8221; tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State taxes, net of federal benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Non-deductible items</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in deferred tax asset valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmountReturnToProvisionAdjustments" xlink:label="INDP_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmountReturnToProvisionAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmountReturnToProvisionAdjustments" xlink:to="INDP_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmountReturnToProvisionAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmountReturnToProvisionAdjustments_lbl" xml:lang="en-US">Return-to-provision adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Capitalized research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xml:lang="en-US">Accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsFrequentFlierLiability" xlink:label="us-gaap_DeferredTaxAssetsFrequentFlierLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsFrequentFlierLiability" xlink:to="us-gaap_DeferredTaxAssetsFrequentFlierLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsFrequentFlierLiability_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total gross deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="INDP_DeferredTaxLiabilitiesRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="INDP_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="INDP_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Gross deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: Deferred tax asset valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Total net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation allowance change amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationDescription" xlink:to="us-gaap_IncomeTaxExaminationDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xml:lang="en-US">Income tax examination description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US">Unrecognized tax benefits, income tax penalties and interest accrued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Total research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xml:lang="en-US">Other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of reportable segments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_PrepaidExpenseAndOtherCurrentAssetsDisclosureTextBlock" xlink:to="INDP_PrepaidExpenseAndOtherCurrentAssetsDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_PrepaidExpenseAndOtherCurrentAssetsDisclosureTextBlock_doc" xml:lang="en-US">Prepaid Expense and Other Current Assets Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock" xlink:to="INDP_ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock_doc" xml:lang="en-US">Schedule Of Prepaid Expense And Other Assets [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_PrepaidResearchAndDevelopment" xlink:to="INDP_PrepaidResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_PrepaidResearchAndDevelopment_doc" xml:lang="en-US">Prepaid research and development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_AccruedResearchAndDevelopmentCurrent" xlink:to="INDP_AccruedResearchAndDevelopmentCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_AccruedResearchAndDevelopmentCurrent_doc" xml:lang="en-US">Accrued research and development current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_AccruedBoardFeesCurrent" xlink:to="INDP_AccruedBoardFeesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_AccruedBoardFeesCurrent_doc" xml:lang="en-US">Accrued board fees current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_DelawareFranchiseTaxesPayableCurrent" xlink:to="INDP_DelawareFranchiseTaxesPayableCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_DelawareFranchiseTaxesPayableCurrent_doc" xml:lang="en-US">Delaware franchise taxes payable current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_ExercisePriceRangeOneMember" xlink:to="INDP_ExercisePriceRangeOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_ExercisePriceRangeOneMember_doc" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_ExercisePriceRangeTwoMember" xlink:to="INDP_ExercisePriceRangeTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_ExercisePriceRangeTwoMember_doc" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_ExercisePriceRangeThreeMember" xlink:to="INDP_ExercisePriceRangeThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_ExercisePriceRangeThreeMember_doc" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_CapitalizationTextBlock" xlink:to="INDP_CapitalizationTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_CapitalizationTextBlock_doc" xml:lang="en-US">Capitalization {Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_AtTheMarketOfferingAgreementMember" xlink:to="INDP_AtTheMarketOfferingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_AtTheMarketOfferingAgreementMember_doc" xml:lang="en-US">At The Market Offering Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_HCWainwrightAndCoLLCMember" xlink:to="INDP_HCWainwrightAndCoLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_HCWainwrightAndCoLLCMember_doc" xml:lang="en-US">HC Wainwright and Co LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_StockIssuedDuringPeriodValueNewIssuesOne" xlink:to="INDP_StockIssuedDuringPeriodValueNewIssuesOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_StockIssuedDuringPeriodValueNewIssuesOne_doc" xml:lang="en-US">Stock issued during period value new issues one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_StockIssuedDuringPeriodValueNewIssuesTwo" xlink:to="INDP_StockIssuedDuringPeriodValueNewIssuesTwo_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_StockIssuedDuringPeriodValueNewIssuesTwo_doc" xml:lang="en-US">Stock issued during period value new issues two.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:to="INDP_StockIssuedDuringPeriodSharesNewIssuesOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_StockIssuedDuringPeriodSharesNewIssuesOne_doc" xml:lang="en-US">Stock issued during period shares new issues one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_StockIssuedDuringPeriodSharesNewIssuesTwo" xlink:to="INDP_StockIssuedDuringPeriodSharesNewIssuesTwo_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_StockIssuedDuringPeriodSharesNewIssuesTwo_doc" xml:lang="en-US">Stock issued during period shares new issues two.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_InterestEarnedOnMarketableSecurities" xlink:to="INDP_InterestEarnedOnMarketableSecurities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_InterestEarnedOnMarketableSecurities_doc" xml:lang="en-US">Interest earned on marketable securities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet" xlink:to="INDP_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet_doc" xml:lang="en-US">Operating lease right-of-use asset and liability, net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_LeaseRenewalOptionExercise" xlink:to="INDP_LeaseRenewalOptionExercise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_LeaseRenewalOptionExercise_doc" xml:lang="en-US">Lease renewal option exercise.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_TransactionCostsInAccountsPayableAndOtherCurrentLiabilities" xlink:to="INDP_TransactionCostsInAccountsPayableAndOtherCurrentLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_TransactionCostsInAccountsPayableAndOtherCurrentLiabilities_doc" xml:lang="en-US">Transaction costs in accounts payable and other current liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_ChangeInAccumulatedOtherComprehensiveIncomeLoss" xlink:to="INDP_ChangeInAccumulatedOtherComprehensiveIncomeLoss_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_ChangeInAccumulatedOtherComprehensiveIncomeLoss_doc" xml:lang="en-US">Change in unrealized gain/loss on marketable securities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_EquityPurchaseAgreementsMember" xlink:to="INDP_EquityPurchaseAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_EquityPurchaseAgreementsMember_doc" xml:lang="en-US">Equity Purchase Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_TwoYearLeaseAgreementMember" xlink:to="INDP_TwoYearLeaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_TwoYearLeaseAgreementMember_doc" xml:lang="en-US">Two Year Lease Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_RateOfIncreaseInLeaseRent" xlink:to="INDP_RateOfIncreaseInLeaseRent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_RateOfIncreaseInLeaseRent_doc" xml:lang="en-US">Rate of increase in lease rent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmountReturnToProvisionAdjustments" xlink:to="INDP_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmountReturnToProvisionAdjustments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmountReturnToProvisionAdjustments_doc" xml:lang="en-US">Effective income tax rate reconciliation share based compensation excess tax benefit amount return to provision adjustments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="INDP_DeferredTaxLiabilitiesRightOfUseAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_DeferredTaxLiabilitiesRightOfUseAsset_doc" xml:lang="en-US">Deferred tax liabilities right of use asset.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_FederalMember" xlink:to="INDP_FederalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_FederalMember_doc" xml:lang="en-US">Federal [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_StateMember" xlink:to="INDP_StateMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_StateMember_doc" xml:lang="en-US">State [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_ExpireInTwoThousandThirtySixMember" xlink:to="INDP_ExpireInTwoThousandThirtySixMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_ExpireInTwoThousandThirtySixMember_doc" xml:lang="en-US">Expire In Two Thousand Thirty Six [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_IndefinitePeriodMember" xlink:to="INDP_IndefinitePeriodMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_IndefinitePeriodMember_doc" xml:lang="en-US">Indefinite Period [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_ExpireInTwoThousandThirtyFiveMember" xlink:to="INDP_ExpireInTwoThousandThirtyFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_ExpireInTwoThousandThirtyFiveMember_doc" xml:lang="en-US">Expire In Two Thousand Thirty Five [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_ExternalResearchAndDevelopmentMember" xlink:to="INDP_ExternalResearchAndDevelopmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_ExternalResearchAndDevelopmentMember_doc" xml:lang="en-US">External Research and Development [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_InternalPersonnelCostsMember" xlink:to="INDP_InternalPersonnelCostsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_InternalPersonnelCostsMember_doc" xml:lang="en-US">Internal Personnel Costs [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_FurnitureMember" xlink:to="INDP_FurnitureMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_FurnitureMember_doc" xml:lang="en-US">Furniture [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_ComputersAndOtherOfficeEquipmentMember" xlink:to="INDP_ComputersAndOtherOfficeEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_ComputersAndOtherOfficeEquipmentMember_doc" xml:lang="en-US">Computers and Other Office Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_YorkvilleMember" xlink:to="INDP_YorkvilleMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_YorkvilleMember_doc" xml:lang="en-US">Yorkville [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_StandbyEquityPurchaseAgreementsMember" xlink:to="INDP_StandbyEquityPurchaseAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_StandbyEquityPurchaseAgreementsMember_doc" xml:lang="en-US">Standby Equity Purchase Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_NumberOfResaleCommonStockComprised" xlink:to="INDP_NumberOfResaleCommonStockComprised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_NumberOfResaleCommonStockComprised_doc" xml:lang="en-US">Number of resale common stock comprised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_NumberOfCommitmentSharesToBeIssuedUponCertainConditions" xlink:to="INDP_NumberOfCommitmentSharesToBeIssuedUponCertainConditions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_NumberOfCommitmentSharesToBeIssuedUponCertainConditions_doc" xml:lang="en-US">Number of commitment shares to be issued upon certain conditions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_ExchangeCapMember" xlink:to="INDP_ExchangeCapMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_ExchangeCapMember_doc" xml:lang="en-US">Exchange Cap [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_NewAdoptedAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="INDP_NewAdoptedAccountingPronouncementsPolicyPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_NewAdoptedAccountingPronouncementsPolicyPolicyTextBlock_doc" xml:lang="en-US">New Adopted Accounting Pronouncements Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_NumberOfCommitmentShares" xlink:to="INDP_NumberOfCommitmentShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="INDP_NumberOfCommitmentShares_doc" xml:lang="en-US">Commitment shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_2_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_InterestEarnedOnMarketableSecurities" xlink:to="INDP_InterestEarnedOnMarketableSecurities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_InterestEarnedOnMarketableSecurities_3_lbl" xml:lang="en-US">Interest earned on marketable securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_2_lbl" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_2_lbl" xml:lang="en-US">Payment of Financing and Stock Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_2_lbl" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="INDP_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="INDP_DeferredTaxLiabilitiesRightOfUseAsset_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="INDP_DeferredTaxLiabilitiesRightOfUseAsset_3_lbl" xml:lang="en-US">DeferredTaxLiabilitiesRightOfUseAsset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_2_lbl" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>22
<FILENAME>indp-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://indaptusrx.com/role/Cover" xlink:href="indp-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/BalanceSheets" xlink:href="indp-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/BalanceSheetsParenthetical" xlink:href="indp-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="indp-20241231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/StatementsOfStockholdersEquity" xlink:href="indp-20241231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/StatementsOfCashFlows" xlink:href="indp-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/General" xlink:href="indp-20241231.xsd#General" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/SignificantAccountingPolicies" xlink:href="indp-20241231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="indp-20241231.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/AccountsPayableAndOtherCurrentLiabilities" xlink:href="indp-20241231.xsd#AccountsPayableAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/Stock-basedCompensation" xlink:href="indp-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/Capitalization" xlink:href="indp-20241231.xsd#Capitalization" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/CommitmentsAndContingencies" xlink:href="indp-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/IncomeTaxes" xlink:href="indp-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/SegmentInformation" xlink:href="indp-20241231.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/SubsequentEvents" xlink:href="indp-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies" xlink:href="indp-20241231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/SignificantAccountingPoliciesTables" xlink:href="indp-20241231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="indp-20241231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/AccountsPayableAndOtherCurrentLiabilitiesTables" xlink:href="indp-20241231.xsd#AccountsPayableAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/Stock-basedCompensationTables" xlink:href="indp-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/CommitmentsAndContingenciesTables" xlink:href="indp-20241231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/IncomeTaxesTables" xlink:href="indp-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/SegmentInformationTables" xlink:href="indp-20241231.xsd#SegmentInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/GeneralDetailsNarrative" xlink:href="indp-20241231.xsd#GeneralDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:href="indp-20241231.xsd#ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="indp-20241231.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails" xlink:href="indp-20241231.xsd#ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails" xlink:href="indp-20241231.xsd#ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="indp-20241231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfStockBasedCompensationExpensesDetails" xlink:href="indp-20241231.xsd#ScheduleOfStockBasedCompensationExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfWeightedAverageInputsUsedToMeasureValueOfOptionsGrantedDetails" xlink:href="indp-20241231.xsd#ScheduleOfWeightedAverageInputsUsedToMeasureValueOfOptionsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetails" xlink:href="indp-20241231.xsd#ScheduleOfExercisePriceOfOutstandingStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetailsParenthetical" xlink:href="indp-20241231.xsd#ScheduleOfExercisePriceOfOutstandingStockOptionsDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="indp-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/CapitalizationDetailsNarrative" xlink:href="indp-20241231.xsd#CapitalizationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/SummaryOfMinimumLeasePaymentsDetails" xlink:href="indp-20241231.xsd#SummaryOfMinimumLeasePaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="indp-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="indp-20241231.xsd#ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfNetDeferredTaxAssetsDetails" xlink:href="indp-20241231.xsd#ScheduleOfNetDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/IncomeTaxesDetailsNarrative" xlink:href="indp-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/ScheduleOfReportableSegmentLossDetails" xlink:href="indp-20241231.xsd#ScheduleOfReportableSegmentLossDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://indaptusrx.com/role/SegmentInformationDetailsNarrative" xlink:href="indp-20241231.xsd#SegmentInformationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_StockIssuedDuringPeriodValueNewIssuesOne" xlink:label="loc_INDPStockIssuedDuringPeriodValueNewIssuesOne" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_INDPStockIssuedDuringPeriodValueNewIssuesOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:label="loc_INDPStockIssuedDuringPeriodSharesNewIssuesOne" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_INDPStockIssuedDuringPeriodSharesNewIssuesOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_StockIssuedDuringPeriodValueNewIssuesTwo" xlink:label="loc_INDPStockIssuedDuringPeriodValueNewIssuesTwo" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_INDPStockIssuedDuringPeriodValueNewIssuesTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_StockIssuedDuringPeriodSharesNewIssuesTwo" xlink:label="loc_INDPStockIssuedDuringPeriodSharesNewIssuesTwo" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_INDPStockIssuedDuringPeriodSharesNewIssuesTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_InterestEarnedOnMarketableSecurities" xlink:label="loc_INDPInterestEarnedOnMarketableSecurities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_INDPInterestEarnedOnMarketableSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet" xlink:label="loc_INDPIncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_INDPIncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="loc_us-gaapProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="loc_us-gaapPaymentOfFinancingAndStockIssuanceCosts" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentOfFinancingAndStockIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_LeaseRenewalOptionExercise" xlink:label="loc_INDPLeaseRenewalOptionExercise" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_INDPLeaseRenewalOptionExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_TransactionCostsInAccountsPayableAndOtherCurrentLiabilities" xlink:label="loc_INDPTransactionCostsInAccountsPayableAndOtherCurrentLiabilities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_INDPTransactionCostsInAccountsPayableAndOtherCurrentLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ChangeInAccumulatedOtherComprehensiveIncomeLoss" xlink:label="loc_INDPChangeInAccumulatedOtherComprehensiveIncomeLoss" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_INDPChangeInAccumulatedOtherComprehensiveIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="loc_cydCybersecurityRiskRoleOfManagementTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskRoleOfManagementTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="loc_cydMaterialCybersecurityIncidentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentNatureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentNatureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentScopeTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentScopeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentTimingTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentTimingTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/General" xlink:title="999014 - Disclosure - GENERAL">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/SignificantAccountingPolicies" xlink:title="999015 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="999016 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS">
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="loc_INDPDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_PrepaidExpenseAndOtherCurrentAssetsDisclosureTextBlock" xlink:label="loc_INDPPrepaidExpenseAndOtherCurrentAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_INDPDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_INDPPrepaidExpenseAndOtherCurrentAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/AccountsPayableAndOtherCurrentLiabilities" xlink:title="999017 - Disclosure - ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/Stock-basedCompensation" xlink:title="999018 - Disclosure - STOCK-BASED COMPENSATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/Capitalization" xlink:title="999019 - Disclosure - CAPITALIZATION">
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_DisclosureCapitalizationAbstract" xlink:label="loc_INDPDisclosureCapitalizationAbstract" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_CapitalizationTextBlock" xlink:label="loc_INDPCapitalizationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_INDPDisclosureCapitalizationAbstract" xlink:to="loc_INDPCapitalizationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/CommitmentsAndContingencies" xlink:title="999020 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/IncomeTaxes" xlink:title="999021 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/SegmentInformation" xlink:title="999022 - Disclosure - SEGMENT INFORMATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/SubsequentEvents" xlink:title="999023 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies" xlink:title="999024 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_NewAdoptedAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_INDPNewAdoptedAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_INDPNewAdoptedAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/SignificantAccountingPoliciesTables" xlink:title="999025 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="999026 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="loc_INDPDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock" xlink:label="loc_INDPScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_INDPDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_INDPScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/AccountsPayableAndOtherCurrentLiabilitiesTables" xlink:title="999027 - Disclosure - ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/Stock-basedCompensationTables" xlink:title="999028 - Disclosure - STOCK-BASED COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/CommitmentsAndContingenciesTables" xlink:title="999029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/IncomeTaxesTables" xlink:title="999030 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/SegmentInformationTables" xlink:title="999031 - Disclosure - SEGMENT INFORMATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/GeneralDetailsNarrative" xlink:title="999032 - Disclosure - GENERAL (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_EquityPurchaseAgreementsMember" xlink:label="loc_INDPEquityPurchaseAgreementsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_INDPEquityPurchaseAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="loc_us-gaapNoninterestExpenseOfferingCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNoninterestExpenseOfferingCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:title="999033 - Disclosure - SCHEDULE OF ANTI-DILUTIVE SECURITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="999034 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaapFairValueByAssetClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapFairValueByAssetClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="loc_us-gaapPropertyPlantAndEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_us-gaapPropertyPlantAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ComputersAndOtherOfficeEquipmentMember" xlink:label="loc_INDPComputersAndOtherOfficeEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_INDPComputersAndOtherOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_FurnitureMember" xlink:label="loc_INDPFurnitureMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_INDPFurnitureMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails" xlink:title="999035 - Disclosure - SCHEDULE OF PREPAID EXPENSE AND OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="loc_INDPDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_INDPDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_PrepaidResearchAndDevelopment" xlink:label="loc_INDPPrepaidResearchAndDevelopment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_INDPDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_INDPPrepaidResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_INDPDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_INDPDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails" xlink:title="999036 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_AccruedResearchAndDevelopmentCurrent" xlink:label="loc_INDPAccruedResearchAndDevelopmentCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_INDPAccruedResearchAndDevelopmentCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_AccruedBoardFeesCurrent" xlink:label="loc_INDPAccruedBoardFeesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_INDPAccruedBoardFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_DelawareFranchiseTaxesPayableCurrent" xlink:label="loc_INDPDelawareFranchiseTaxesPayableCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_INDPDelawareFranchiseTaxesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999037 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfStockBasedCompensationExpensesDetails" xlink:title="999038 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfWeightedAverageInputsUsedToMeasureValueOfOptionsGrantedDetails" xlink:title="999039 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE INPUTS USED TO MEASURE VALUE OF OPTIONS GRANTED (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetails" xlink:title="999040 - Disclosure - SCHEDULE OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ExercisePriceRangeOneMember" xlink:label="loc_INDPExercisePriceRangeOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_INDPExercisePriceRangeOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ExercisePriceRangeTwoMember" xlink:label="loc_INDPExercisePriceRangeTwoMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_INDPExercisePriceRangeTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ExercisePriceRangeThreeMember" xlink:label="loc_INDPExercisePriceRangeThreeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_INDPExercisePriceRangeThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetailsParenthetical" xlink:title="999041 - Disclosure - SCHEDULE OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ExercisePriceRangeOneMember" xlink:label="loc_INDPExercisePriceRangeOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_INDPExercisePriceRangeOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ExercisePriceRangeTwoMember" xlink:label="loc_INDPExercisePriceRangeTwoMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_INDPExercisePriceRangeTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ExercisePriceRangeThreeMember" xlink:label="loc_INDPExercisePriceRangeThreeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_INDPExercisePriceRangeThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999042 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/CapitalizationDetailsNarrative" xlink:title="999043 - Disclosure - CAPITALIZATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_DisclosureCapitalizationAbstract" xlink:label="loc_INDPDisclosureCapitalizationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_INDPDisclosureCapitalizationAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_AtTheMarketOfferingAgreementMember" xlink:label="loc_INDPAtTheMarketOfferingAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_INDPAtTheMarketOfferingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_StandbyEquityPurchaseAgreementsMember" xlink:label="loc_INDPStandbyEquityPurchaseAgreementsMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_INDPStandbyEquityPurchaseAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ExchangeCapMember" xlink:label="loc_INDPExchangeCapMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_INDPExchangeCapMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_HCWainwrightAndCoLLCMember" xlink:label="loc_INDPHCWainwrightAndCoLLCMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_INDPHCWainwrightAndCoLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_YorkvilleMember" xlink:label="loc_INDPYorkvilleMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_INDPYorkvilleMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="loc_us-gaapNoninterestExpenseOfferingCost" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNoninterestExpenseOfferingCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_NumberOfResaleCommonStockComprised" xlink:label="loc_INDPNumberOfResaleCommonStockComprised" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_INDPNumberOfResaleCommonStockComprised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_NumberOfCommitmentShares" xlink:label="loc_INDPNumberOfCommitmentShares" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_INDPNumberOfCommitmentShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_NumberOfCommitmentSharesToBeIssuedUponCertainConditions" xlink:label="loc_INDPNumberOfCommitmentSharesToBeIssuedUponCertainConditions" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_INDPNumberOfCommitmentSharesToBeIssuedUponCertainConditions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/SummaryOfMinimumLeasePaymentsDetails" xlink:title="999044 - Disclosure - SUMMARY OF MINIMUM LEASE PAYMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999045 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="loc_us-gaapProductLiabilityContingencyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapProductLiabilityContingencyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="loc_us-gaapProductLiabilityContingencyLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_us-gaapProductLiabilityContingencyLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_CA" xlink:label="loc_stprCA" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprCA" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_TwoYearLeaseAgreementMember" xlink:label="loc_INDPTwoYearLeaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_INDPTwoYearLeaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapAreaOfLand" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_RateOfIncreaseInLeaseRent" xlink:label="loc_INDPRateOfIncreaseInLeaseRent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_INDPRateOfIncreaseInLeaseRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaapLesseeOperatingLeaseOptionToExtend" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseOptionToExtend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaapLesseeOperatingLeaseDiscountRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDiscountRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="999046 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmountReturnToProvisionAdjustments" xlink:label="loc_INDPEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmountReturnToProvisionAdjustments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_INDPEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmountReturnToProvisionAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfNetDeferredTaxAssetsDetails" xlink:title="999047 - Disclosure - SCHEDULE OF NET DEFERRED TAX ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsFrequentFlierLiability" xlink:label="loc_us-gaapDeferredTaxAssetsFrequentFlierLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsFrequentFlierLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="loc_INDPDeferredTaxLiabilitiesRightOfUseAsset" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_INDPDeferredTaxLiabilitiesRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/IncomeTaxesDetailsNarrative" xlink:title="999048 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_FederalMember" xlink:label="loc_INDPFederalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_INDPFederalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_StateMember" xlink:label="loc_INDPStateMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_INDPStateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaapTaxPeriodAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapTaxPeriodAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ExpireInTwoThousandThirtySixMember" xlink:label="loc_INDPExpireInTwoThousandThirtySixMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_INDPExpireInTwoThousandThirtySixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_IndefinitePeriodMember" xlink:label="loc_INDPIndefinitePeriodMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_INDPIndefinitePeriodMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ExpireInTwoThousandThirtyFiveMember" xlink:label="loc_INDPExpireInTwoThousandThirtyFiveMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_INDPExpireInTwoThousandThirtyFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_srtStatementGeographicalAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IL" xlink:label="loc_countryIL" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryIL" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaapIncomeTaxExaminationDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaapUnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/ScheduleOfReportableSegmentLossDetails" xlink:title="999049 - Disclosure - SCHEDULE OF REPORTABLE SEGMENT LOSS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_ExternalResearchAndDevelopmentMember" xlink:label="loc_INDPExternalResearchAndDevelopmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_INDPExternalResearchAndDevelopmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="indp-20241231.xsd#INDP_InternalPersonnelCostsMember" xlink:label="loc_INDPInternalPersonnelCostsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_INDPInternalPersonnelCostsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaapOtherOperatingIncomeExpenseNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherOperatingIncomeExpenseNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://indaptusrx.com/role/SegmentInformationDetailsNarrative" xlink:title="999050 - Disclosure - SEGMENT INFORMATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapNumberOfReportableSegments" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437011259920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 12, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INDAPTUS
THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001857044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">86-3158720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3
Columbus Circle<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">15th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(646)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">427-2727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    stock, par value $0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INDP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,039,986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,429,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">None.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">HASKELL & WHITE LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Irvine,
California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437016275600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,786,753<span></span>
</td>
<td class="nump">$ 13,362,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">831,577<span></span>
</td>
<td class="nump">633,156<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">6,618,330<span></span>
</td>
<td class="nump">13,995,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">82,175<span></span>
</td>
<td class="nump">173,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets - deposits to third parties</a></td>
<td class="nump">638,251<span></span>
</td>
<td class="nump">754,728<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">720,426<span></span>
</td>
<td class="nump">928,669<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">7,338,756<span></span>
</td>
<td class="nump">14,923,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and other current liabilities</a></td>
<td class="nump">3,309,717<span></span>
</td>
<td class="nump">2,672,327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current portion</a></td>
<td class="nump">84,164<span></span>
</td>
<td class="nump">101,705<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,393,881<span></span>
</td>
<td class="nump">2,774,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">73,348<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">73,348<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">3,393,881<span></span>
</td>
<td class="nump">2,847,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock: $0.01 par value, 200,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 12,013,901 shares issued and outstanding as of December 31, 2024 and 8,401,047 shares issued and outstanding as of December 31, 2023</a></td>
<td class="nump">120,139<span></span>
</td>
<td class="nump">84,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock: $0.01 par value, 5,000,000 shares authorized as of December 31, 2024 and December 31, 2023; no shares issued or outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">64,263,919<span></span>
</td>
<td class="nump">57,409,643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(60,439,183)<span></span>
</td>
<td class="num">(45,417,156)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">3,944,875<span></span>
</td>
<td class="nump">12,076,498<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 7,338,756<span></span>
</td>
<td class="nump">$ 14,923,878<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437016361824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">12,013,901<span></span>
</td>
<td class="nump">8,401,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">12,013,901<span></span>
</td>
<td class="nump">8,401,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437010431552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 7,251,097<span></span>
</td>
<td class="nump">$ 7,621,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">8,114,654<span></span>
</td>
<td class="nump">8,756,767<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">15,365,751<span></span>
</td>
<td class="nump">16,378,474<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(15,365,751)<span></span>
</td>
<td class="num">(16,378,474)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">343,724<span></span>
</td>
<td class="nump">955,003<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (15,022,027)<span></span>
</td>
<td class="num">$ (15,423,471)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss available to common stockholders per share of common stock, basic</a></td>
<td class="num">$ (1.61)<span></span>
</td>
<td class="num">$ (1.83)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss available to common stockholders per share of common stock, diluted</a></td>
<td class="num">$ (1.61)<span></span>
</td>
<td class="num">$ (1.83)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares used in calculating net loss per share, basic</a></td>
<td class="nump">9,355,710<span></span>
</td>
<td class="nump">8,401,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares used in calculating net loss per share, diluted</a></td>
<td class="nump">9,355,710<span></span>
</td>
<td class="nump">8,401,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification adjustment for interest earned on marketable securities included in net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (430,993)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized gain on marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">334,559<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (15,022,027)<span></span>
</td>
<td class="num">$ (15,519,905)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-17A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437009435056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 84,011<span></span>
</td>
<td class="nump">$ 54,443,705<span></span>
</td>
<td class="num">$ (29,993,685)<span></span>
</td>
<td class="nump">$ 96,434<span></span>
</td>
<td class="nump">$ 24,630,465<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">8,401,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,965,938<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,965,938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification adjustment for interest earned on marketable securities included in net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(430,993)<span></span>
</td>
<td class="num">(430,993)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized gain on marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">334,559<span></span>
</td>
<td class="nump">334,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(15,423,471)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(15,423,471)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 84,011<span></span>
</td>
<td class="nump">57,409,643<span></span>
</td>
<td class="num">(45,417,156)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,076,498<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">8,401,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,305,849<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,305,849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification adjustment for interest earned on marketable securities included in net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized gain on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(15,022,027)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(15,022,027)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares of common stock, net of issuance costs (Note 6b)</a></td>
<td class="nump">$ 1,520<span></span>
</td>
<td class="nump">352,591<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">354,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares of common stock, net of issuance costs (Note 6b), shares</a></td>
<td class="nump">152,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_INDP_StockIssuedDuringPeriodValueNewIssuesOne', window );">Issuance of shares of common stock and warrants, net of issuance costs (Note 6c)</a></td>
<td class="nump">$ 16,438<span></span>
</td>
<td class="nump">2,445,532<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,461,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_INDP_StockIssuedDuringPeriodSharesNewIssuesOne', window );">Issuance of shares of common stock and warrants, net of issuance costs (Note 6c), shares</a></td>
<td class="nump">1,643,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_INDP_StockIssuedDuringPeriodValueNewIssuesTwo', window );">Issuance of shares of common stock and warrants, net of issuance costs (Note 6d)</a></td>
<td class="nump">$ 18,170<span></span>
</td>
<td class="nump">1,750,304<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,768,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_INDP_StockIssuedDuringPeriodSharesNewIssuesTwo', window );">Issuance of shares of common stock and warrants, net of issuance costs (Note 6d), shares</a></td>
<td class="nump">1,817,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 120,139<span></span>
</td>
<td class="nump">$ 64,263,919<span></span>
</td>
<td class="num">$ (60,439,183)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,944,875<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="nump">12,013,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_INDP_StockIssuedDuringPeriodSharesNewIssuesOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares new issues one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">INDP_StockIssuedDuringPeriodSharesNewIssuesOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>INDP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_INDP_StockIssuedDuringPeriodSharesNewIssuesTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares new issues two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">INDP_StockIssuedDuringPeriodSharesNewIssuesTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>INDP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_INDP_StockIssuedDuringPeriodValueNewIssuesOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value new issues one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">INDP_StockIssuedDuringPeriodValueNewIssuesOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>INDP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_INDP_StockIssuedDuringPeriodValueNewIssuesTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value new issues two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">INDP_StockIssuedDuringPeriodValueNewIssuesTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>INDP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-17A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437010423296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (15,022,027)<span></span>
</td>
<td class="num">$ (15,423,471)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">735<span></span>
</td>
<td class="nump">1,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,305,849<span></span>
</td>
<td class="nump">2,965,938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_INDP_InterestEarnedOnMarketableSecurities', window );">Interest earned on marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(430,993)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current and non-current assets</a></td>
<td class="num">(81,944)<span></span>
</td>
<td class="nump">161,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Accounts payable and other current liabilities</a></td>
<td class="nump">474,057<span></span>
</td>
<td class="num">(680,520)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_INDP_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet', window );">Operating lease right-of-use asset and liability, net</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">647<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(12,323,188)<span></span>
</td>
<td class="num">(13,405,315)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(6,859,432)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments', window );">Maturity of marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">24,000,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">17,140,568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of shares of common stock and warrants</a></td>
<td class="nump">5,510,591<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="num">(762,703)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">4,747,888<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(7,575,300)<span></span>
</td>
<td class="nump">3,735,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">13,362,053<span></span>
</td>
<td class="nump">9,626,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">5,786,753<span></span>
</td>
<td class="nump">13,362,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Noncash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_INDP_LeaseRenewalOptionExercise', window );">ASC 842 lease renewal option exercise</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">236,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_INDP_TransactionCostsInAccountsPayableAndOtherCurrentLiabilities', window );">Transaction costs in accounts payable and other current liabilities</a></td>
<td class="nump">163,333<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_INDP_ChangeInAccumulatedOtherComprehensiveIncomeLoss', window );">Change in accumulated other comprehensive income</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(96,434)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_INDP_ChangeInAccumulatedOtherComprehensiveIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in unrealized gain/loss on marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">INDP_ChangeInAccumulatedOtherComprehensiveIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>INDP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_INDP_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease right-of-use asset and liability, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">INDP_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>INDP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_INDP_InterestEarnedOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest earned on marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">INDP_InterestEarnedOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>INDP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_INDP_LeaseRenewalOptionExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease renewal option exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">INDP_LeaseRenewalOptionExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>INDP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_INDP_TransactionCostsInAccountsPayableAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs in accounts payable and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">INDP_TransactionCostsInAccountsPayableAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>INDP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437015381408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (15,022,027)<span></span>
</td>
<td class="num">$ (15,423,471)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437010034128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437010521344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cybersecurity
Risk Management and Strategy</b></span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90C_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240101__20241231_zLEfoXgEJ78j">We,
through our third party service provider that manages our information technology systems and networks, have developed and implemented
a cybersecurity risk management program intended to protect the confidentiality, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_ztltpBYvAQz5">integrity</span>, and availability of our critical systems
and information.</span> Our cybersecurity risk management program includes a cybersecurity incident response plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">61</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
design and assess our program based on the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF). This does
not imply that we meet any particular technical standards, specifications, or requirements, only that we use the NIST CSF as a guide
to help us identify, assess, and manage cybersecurity risks relevant to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cybersecurity risk management program includes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_c20240101__20241231_zc0EMY0WcsEi">risk
    assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and
    our broader enterprise IT environment;</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20240101__20241231_zcncos9boFdc">designated
    team members are responsible for managing (1) our cybersecurity risk assessment processes, (2) our security controls, and (3) our
    response to cybersecurity incidents;</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls;
    and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

We
have not identified risks from known cybersecurity threats, that have <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_906_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbT_c20240101__20241231_zcoKyztoAs1d">materially</span> affected or are reasonably likely to materially affect
us, including our operations, business strategy, results of operations, or financial condition. See Item 1A. &#8220;Risk Factors &#8211;
Our Risks Related to Our Business - <i>Our business and operations may suffer in the event of information technology system failures,
cyberattacks or deficiencies in our cybersecurity.</i>&#8221;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">We,
through our third party service provider that manages our information technology systems and networks, have developed and implemented
a cybersecurity risk management program intended to protect the confidentiality, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_ztltpBYvAQz5">integrity</span>, and availability of our critical systems
and information.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our
Board considers cybersecurity risk as part of its risk oversight function and oversees our cybersecurity and other information technology
risks and management&#8217;s implementation of our cybersecurity risk management program.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our
management team, including our Chief Operating Officer, is responsible for assessing and managing our material risks from cybersecurity
threats. Our Chief Operating Officer has primary responsibility for our overall cybersecurity risk management program and supervises
our retained provider of IT services and external cybersecurity consultants. Our Chief Operating Officer has experience supervising and
managing company security and privacy departments.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text">designated
    team members are responsible for managing (1) our cybersecurity risk assessment processes, (2) our security controls, and (3) our
    response to cybersecurity incidents;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">risk
    assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and
    our broader enterprise IT environment;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437018157200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">GENERAL</a></td>
<td class="text"><p id="xdx_800_eus-gaap--NatureOfOperations_zqUCxD209197" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1: <span id="xdx_82E_zumxOemtx2qi">GENERAL</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indaptus
Therapeutics, Inc. and its wholly-owned subsidiaries, Decoy Biosystems, Inc. and Intec Pharma Ltd., collectively (the &#8220;Company&#8221;),
is a biotechnology company dedicated to enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic
solid tumors and lymphomas, which are responsible for more than 90% of all cancer deaths. The Company is developing a novel, multi-targeted
product that activates both innate and adaptive anti-tumor and anti-viral immune responses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks
and uncertainties</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to a number of risks similar to those of other companies of similar size in its industry, including, but not limited
to, the need for successful development of products, the need for additional capital (or financing) to fund operations (see below), competition
from substitute products and services from larger companies, protection of proprietary technology, patent litigation, and dependence
on key individuals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Going
concern and management&#8217;s plans</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has incurred net losses and utilized cash in operations since inception. For the year ended December 31, 2024, the Company incurred
a net loss of approximately $<span id="xdx_906_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20240101__20241231_zmnsGoAomsIg" title="Net loss">15.0</span> million, and as of December 31, 2024, the Company had an accumulated deficit of approximately $<span id="xdx_903_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20241231_zYo5hzF55qY" title="Accumulated deficit">60.4</span>
million. In addition, during the year ended December 31, 2024, the Company used approximately $<span id="xdx_90A_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20240101__20241231_zgXEi320GJt1" title="Net cash used in operating activities">12.3</span> million of cash in operations and
expects to continue to incur significant cash outflows and incur future additional losses as clinical trials and commercialization of
the Company&#8217;s product candidates will require significant additional financing. The Company believes that, as of the date of the
issuance of these consolidated financial statements, it has adequate cash to fund its ongoing activities into the second quarter of
2025 based on its current operating plan. The Company plans to execute its operating plan by obtaining additional capital, principally
through entering into collaborations, strategic alliances, or license agreements with third parties and/or additional public or private
debt and equity financing, such as through the registered direct offerings and concurrent private placements that the Company completed
in August 2024 (the &#8220;August 2024 Offering&#8221;) and in November 2024 (the &#8220;November 2024 Offering&#8221;), and through
the private placement in January 2025 (the &#8220;January 2025 Offering&#8221;). Following these offerings, the Company raised a total
of approximately $<span id="xdx_905_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20240101__20241231_zm23B49uwDyl" title="Net of placement agent cost">6.3</span> million, net of placement agent and other offering expenses in the amount of approximately $<span id="xdx_90D_eus-gaap--NoninterestExpenseOfferingCost_pn5n6_c20250101__20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrRevrktynr6" title="Other offering cost">1.1</span> million. For more
details, see Note 6(c), 6(d) and 6(e). In addition, in February 2025, the Company entered into a <span style="background-color: white">Standby
Equity Purchase Agreement pursuant to which the Company has the right, but not the obligation, to sell up to $<span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20250201__20250228__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zMM325oknZff" title="Purchase ordinary shares">20.0</span> million o<span style="color: #212529">f
the Company&#8217;s common stock </span>during a 36-month period, subject to the restrictions and satisfaction of the conditions in the
Standby Equity Purchase Agreement. For more details, see Note 6(f). </span>However, there is no assurance that additional capital and/or
financing will be available to the Company, and even if available, whether it will be on terms acceptable to the Company or in the amounts
required. If the Company is unsuccessful in securing sufficient financing, it may need to delay, reduce, or eliminate its research and
development programs, which could adversely affect its business prospects, or cease operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of these uncertainties, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The consolidated
financial statements do not include any adjustments to the carrying amounts and classifications of assets and liabilities that would
result if the Company was unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437015227616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--SignificantAccountingPoliciesTextBlock_zzT8l1FpiXzc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2: <span id="xdx_82B_zidKcg8Oftzd">SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zHvtafAti2d2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basis
of presentation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#8220;US GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_zRVAz49Q8aMi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Principles
of consolidation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of Indaptus and its subsidiaries. Intercompany balances and transactions have
been eliminated upon consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_84A_eus-gaap--UseOfEstimates_z7lX2mqACVBi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Use
of estimates</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in accordance with US GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements, and the
reported amounts of expenses during the reporting periods. The most significant estimates relate to the determination of the fair value
of stock-based compensation and the determination of period-end obligations to certain contract research organizations. Management evaluates
its estimates and assumptions on an ongoing basis using historical experience and other factors and makes adjustments when facts and
circumstances dictate. These estimates are based on information available as of the date of the consolidated financial statements; therefore,
actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zITshnNOMlMc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Loss
per share</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
per share, basic and diluted, is computed on the basis of the net loss for the period divided by the weighted average number of shares
of common stock outstanding during the period. Diluted loss per share is based upon the weighted average number of shares of common stock
and of common stock equivalents outstanding when dilutive. Common stock equivalents include outstanding stock options and warrants which
are included under the treasury stock method when dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zTVxb6GxtKPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following number of stock options and warrants were excluded from the calculation of diluted loss per share because their effect would
have been anti-dilutive for the periods presented (share data):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B7_z7noe3Or3OFi" style="display: none">SCHEDULE
OF ANTI-DILUTIVE SECURITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Weighted average</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Outstanding stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zzzBDQa1x78h" style="width: 16%; text-align: right" title="Anti-dilutive securities">2,519,419</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z8roWgWnW3W9" style="width: 16%; text-align: right" title="Anti-dilutive securities">1,979,196</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_znlKC6M6KURe" style="text-align: right" title="Anti-dilutive securities">3,935,282</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_za29FhSrik0l" style="text-align: right" title="Anti-dilutive securities">3,090,787</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_z0zZABOUdWg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6fmJp0ekRI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
and cash equivalents</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. As of
December 31, 2024, and 2023, cash and cash equivalents consist primarily of checking and money market deposits. The Company&#8217;s cash
balances exceed those that are federally insured; however, the Company believes it is not exposed to significant credit risk due to the
financial strength of the depository institutions in which the cash and cash equivalents are held. To date, the Company has not recognized
any losses caused by uninsured balances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zAleiunrGJg3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Property
and equipment</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment assets are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over
the estimated useful lives of the assets. The Company uses an estimated useful life of <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersAndOtherOfficeEquipmentMember_zdj4BE7ssyu8" title="Estimated useful life">three years</span> for employee-related computers and
other office equipment and <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureMember_zt1TZj9uzmx5" title="Estimated useful life">five years</span> for furniture. Leasehold improvements are amortized over the shorter of the lease-term or the estimated
useful life of the related asset.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zrMB8XORfTug" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patents</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expenses patent costs, including related legal costs, as incurred and records such costs within general and administrative expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zF7nDBVoI5zc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and development expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses include costs directly attributable to the conduct of research and development programs, including the cost
of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research
and development activities, including clinical trials and professional services. All costs associated with research and development are
expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accrues for expenses resulting from obligations under agreements with contract research organizations (&#8220;CROs&#8221;), contract
manufacturing organizations (&#8220;CMOs&#8221;), and other outside service providers for which payment flows do not match the periods
over which services or materials are provided to the Company. Accruals are recorded based on estimates of services received and efforts
expended pursuant to agreements with CROs, CMOs, and other outside service providers. These estimates are typically based on contracted
amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers
as to the progress or stage of completion of the services. In the event advance payments are made to a CRO, CMO, or outside service provider,
the payments will be recorded as a prepaid expense, which will be amortized or expensed as the contracted services are performed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_z8xuuJUtuue8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and administrative expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses include compensation, employee benefits, and stock-based compensation for executive management, finance,
administration and human resources, facility costs (including rent), professional service fees, and other general overhead costs to support
the Company&#8217;s operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zdqqlKEERcNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income
taxes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences
attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective
tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred
tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation
allowance is recorded for deferred tax assets if it is more likely than not that some portion or all of the deferred tax assets will
not be realized in the foreseeable future. As of December 31, 2024, and 2023, the Company has recorded a full valuation allowance against
its deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized
income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or
measurement are reflected in the period in which the change in judgment occurs. The Company records interest related to unrecognized
tax benefits in interest expense and penalties in general and administrative expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zF62OiizdLR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-based
compensation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures and records the expense related to stock-based payment awards based on the fair value of those awards as determined
using the Black-Scholes-Merton (&#8220;Black-Scholes&#8221;) model as of the date of grant. The Company recognizes stock-based compensation
expense over the requisite service period of the individual grant, generally equal to the vesting period, on a straight-line basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Black-Scholes model requires the use of highly subjective and complex assumptions, which determine the fair value of stock-based payment
awards, including the option&#8217;s expected term and the price volatility of the underlying stock. The Company estimates the fair value
of options granted by using the Black-Scholes model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
Volatility</i>&#8212;The Company estimates volatility for option grants by evaluating the historical volatility of a peer group of companies
for the period immediately preceding the option grant for a term that is approximately equal to the options&#8217; expected term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
Term</i>&#8212;The expected term of the Company&#8217;s options represents the period that the stock-based payment awards are expected
to be outstanding. The expected term is estimated using the simplified method for employee stock options since the Company does not have
adequate historical exercise data to estimate the expected term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk-Free
Interest Rate</i>&#8212;The risk-free interest rate is based on the implied yield currently available on U.S. Treasury zero-coupon issues
with a term that is equal to the options&#8217; expected term at the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividend
Yield</i>&#8212;The Company has not declared or paid dividends to date and does not anticipate declaring dividends. As such, the dividend
yield has been estimated to be zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has elected to recognize forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z7gde9Bxbz2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
value measurements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability
in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the
measurement date. The Company follows the established framework for measuring fair value and providing disclosures about fair value measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted prices in active
    markets for identical assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs other than Level
    1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable inputs which
    are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or
    similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
820, <i>Fair Value Measurement</i>, requires all entities to disclose the fair value of financial instruments, both assets and liabilities,
for which it is practicable to estimate fair value, and defines the fair value of a financial instrument as the amount at which the instrument
could be exchanged in a current transaction between willing parties. As of December 31, 2024, and 2023, the recorded values of cash and
cash equivalents, prepaid expenses, and accounts payable and other current liabilities approximate their fair values due to the short-term
nature of these items.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_ecustom--NewAdoptedAccountingPronouncementsPolicyPolicyTextBlock_zAcWFfnPQO1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Recently
adopted accounting pronouncements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
November 2023, the FASB issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures. The FASB amended the guidance in ASC
280, Segment Reporting (&#8220;ASC 280&#8221;), to require a public entity to disclose significant segment expenses and other segment
items on an annual and interim basis and to provide in interim periods all disclosures about a reportable segment&#8217;s profit or loss
and assets that are currently required annually. Public entities with a single reportable segment are required to provide the new disclosures
and all the disclosures required under ASC 280. The guidance is applied retrospectively to all periods presented in financial statements
unless it is impracticable. This new guidance is effective for public business entities for annual periods beginning after December 15,
2023, and for interim periods beginning after December 15, 2024. The Company adopted this new standard effective December 31, 2024. See
Note 9, Segment Information, for disclosures related to the adoption of ASU 2023-07.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_znDn13vSn9X1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span id="xdx_86B_zps4ItJ4JNDf">Recently
issued accounting pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense <span style="background-color: white">Disaggregation </span> Disclosures.
This ASU will require entities to provide enhanced disclosures, in a tabular format, related to certain expense categories included in
the statement of operations. The ASU aims to increase transparency and provide investors with more detailed information about the nature
of expenses reported on the face of the income statement. The new ASU is effective for annual reporting periods beginning after December
15, 2026 and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating
the impact of the adoption of this standard on the related disclosures</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures. This ASU does not change accounting for income
taxes but requires new disclosures focusing on two areas, the effective rate reconciliation and taxes paid. This new standard is effective
for public business entities for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently
evaluating the impact of the adoption of this standard on the related disclosures.</span></p>
<p id="xdx_85A_zrHdvVzL6ima" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437018363104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_INDP_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Prepaid Expenses And Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_INDP_PrepaidExpenseAndOtherCurrentAssetsDisclosureTextBlock', window );">PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p id="xdx_808_ecustom--PrepaidExpenseAndOtherCurrentAssetsDisclosureTextBlock_zTYE2Mf9JAXa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3: <span id="xdx_821_zlYPptFFlEOg">PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_ecustom--ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock_z8ENLd2sfC94" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets are comprised of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zHZ1PU09hW0d" style="display: none">SCHEDULE
OF PREPAID EXPENSE AND OTHER CURRENT ASSETS</span></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20241231_zz8S2HWxhMPc" style="border-bottom: Black 1pt solid; display: none; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_zrwsaLIdXohl" style="border-bottom: Black 1pt solid; display: none; text-align: center">2023</td><td style="display: none; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PrepaidInsurance_iI_pp0p0_maPEAOAz50c_z689fbTuzGWc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Prepaid insurance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">506,489</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">554,097</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--PrepaidResearchAndDevelopment_iI_pp0p0_maPEAOAz50c_zsmHvMGxPZNl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,309</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPEAOAz50c_z103lWxDYz5e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other prepaid expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">175,088</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">61,750</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPEAOAz50c_zv7GQh85FQw2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">831,577</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">633,156</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPEAOAz50c_ztbE9QjeH7J5" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; text-align: left; padding-bottom: 2.5pt">Prepaid expenses and other current assets</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right">831,577</td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right">633,156</td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AE_zhng3EtopIif" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_INDP_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">INDP_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>INDP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_INDP_PrepaidExpenseAndOtherCurrentAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expense and Other Current Assets Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">INDP_PrepaidExpenseAndOtherCurrentAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>INDP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437114375168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p id="xdx_806_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zMaNMhjaQ4g9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4: <span id="xdx_821_zwCUHTUaTl7i">ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z7Ghfw9tcRD3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
payable and other current liabilities are comprised of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zrXQEarVuofe" style="display: none">SCHEDULE
OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES</span></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: right">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20241231_zJNuo2kqCPZ5" style="border-bottom: Black 1pt solid; display: none; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20231231_zgmpYP5DlDhi" style="border-bottom: Black 1pt solid; display: none; text-align: center">2023</td><td style="display: none; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AccountsPayableCurrent_iI_pp0p0_maAPAOAzxRP_ztpjmkFOSvNd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Accounts payable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">870,229</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">806,004</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pp0p0_maAPAOAzxRP_znSBd8T5lr0c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued employee costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,371,498</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,213,054</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maAPAOAzxRP_zlKXwDdYWWy9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72,054</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,165</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--AccruedResearchAndDevelopmentCurrent_iI_pp0p0_maAPAOAzxRP_z8rk0yw8NkD8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">860,958</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">439,024</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--AccruedBoardFeesCurrent_iI_pp0p0_maAPAOAzxRP_zfAV4Uc2wuli" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued board fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117,750</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DelawareFranchiseTaxesPayableCurrent_iI_pp0p0_maAPAOAzxRP_zJiRSqpQT0ah" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Delaware franchise taxes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0514">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maAPAOAzxRP_z0rTZzcNdzia" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other accrued expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">17,228</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">17,330</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_pp0p0_mtAPAOAzxRP_zMpVQCMEKC6c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total accounts payable and other current liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,309,717</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,672,327</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zYgsqK7PcsUj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437015395280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_807_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zib1MN8LgiC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5: <span id="xdx_82E_zXq2nXHnYhh9">STOCK-BASED COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has an equity incentive plan for grants to employees, officers, consultants, directors, and other service providers that was
approved in 2021 (the &#8220;2021 Plan&#8221;). The 2021 Plan provides for the grant of non-qualified stock options, incentive stock
options, restricted stock awards, restricted stock units, unrestricted stock awards, stock appreciation rights and other forms of stock-based
compensation. The 2021 Plan permits the Company&#8217;s board to change the type, terms, and conditions of awards as circumstances may
change. This flexibility to adjust the type of compensation to be granted is particularly important given current economic and world
events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zXAmXgmZyVk1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the stock option activity during the year ended December 31, 2024, is presented in the table below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zeyGQStcEPA6" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Weighted average</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of <br/> options</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercise <br/> price</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Remaining <br/> contractual <br/> life <br/> (in years)</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Intrinsic value</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Outstanding as of January 1, 2024</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zwDRGNlhFQP6" style="width: 10%; text-align: right" title="Number of options, outstanding balance">2,050,197</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zqPGJvNypWcd" title="Weighted average exercise price, outstanding, balance">10.90</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zQuVqRd6KOq" title="Weighted average remaining contractual life (in years)">7.9</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20241231_z9qeWdsE2tSj" style="width: 10%; text-align: right" title="Intrinsic value, outstanding balance">36,363</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_z5dyblhUVj47" style="text-align: right" title="Number of options, granted">838,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zNpvhPhY6vHb" title="Weighted average exercise price, granted">1.54</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_pp0p0_c20240101__20241231_zpqtrVNV8h6c" style="text-align: right" title="Intrinsic value, granted"><span style="-sec-ix-hidden: xdx2ixbrl0539">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left; padding-left: 10pt">Forfeited and cancelled</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231_zJcVASGjDmMe" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, forfeited and cancelled">(625</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20241231_zzfIWwR9soo6" title="Weighted average exercise price, forfeited and cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0543">-</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_z9SBzHGDYs37" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, outstanding balance">2,887,822</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_zx4o6cMRJQme" title="Weighted average exercise price, balance">8.06</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zmUbwefKtb3k" title="Weighted average remaining contractual life (in years)">7.6</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240101__20241231_zH1kDjUIjIS4" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, Outstanding, balance"><span style="-sec-ix-hidden: xdx2ixbrl0551">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_zfYJzxb1YpKb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, exercisable">1,854,764</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zyCcs0JmxGdb" title="Weighted average exercise price, exercisable">11.54</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_z1y98MsH2l68" title="Weighted average remaining contractual life, Exercisable">6.8</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20240101__20241231_zv137HlKlX57" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, outstanding balance"><span style="-sec-ix-hidden: xdx2ixbrl0559">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Vested and expected to vest as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20240101__20241231_zYfkN4Z22mm" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, vested and expected to vest">2,887,822</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_zRkr1D4wLpql" title="Weighted average exercise price, vested and expected to vest">8.06</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zFuPTSGFqAoh" title="Weighted average remaining contractual life (in years), vested and expected to vest">7.6</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240101__20241231_zRHIFEfKL8g2" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, vested and expected to vest balance"><span style="-sec-ix-hidden: xdx2ixbrl0567">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zzi5cqrNmD9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zSATXzgUajvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the total stock-based compensation expense included in the consolidated statements of operations for the periods
presented:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zDPSQrTLhZff">SCHEDULE
OF STOCK BASED COMPENSATION EXPENSES</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240101__20241231_zEowYqIwHx3e" style="border-bottom: Black 1pt solid; display: none; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20230101__20231231_zersO87Crwo2" style="border-bottom: Black 1pt solid; display: none; text-align: center">2023</td><td style="display: none; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zwS6iSu3ZWL8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">624,480</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">792,273</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zTQbkhyUTQQj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,681,369</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,173,665</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ShareBasedCompensation_zohOI9W2FCq3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,305,849</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,965,938</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zvl7kNmXeEZa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, total compensation cost not yet recognized related to unvested stock options was approximately $<span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20241231_zex7hvOGfFih" title="Share-based compensation, not yet recognized">1.0</span> million, which
is expected to be recognized over a weighted-average period of approximately <span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231_zBQmLdCRC5Mc" title="Share-based compensation, not yet recognized, term">1.5</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates the fair value of stock options on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes
option-pricing model requires estimates of highly subjective assumptions, which affect the fair value of each stock option. The weighted
average inputs used to measure the value of the options granted during the years ended December 31, 2024 and 2023 are presented in the
table below. The weighted average fair value of stock options issued during the years ended December 31, 2024 and 2023 was $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231_zZZVhQl1go7a" title="Weighted average fair value of stock options issued">1.31</span> and
$<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zuV1qMdADOFc" title="Weighted average fair value of stock options issued">1.43</span> per share, respectively.</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zrcCTPEa0VWk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_z5EeR8Fixg7a" style="display: none">SCHEDULE
OF WEIGHTED AVERAGE INPUTS USED TO MEASURE VALUE OF OPTIONS GRANTED</span></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Exercise price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20241231_zlukEmmEsRN4" style="width: 16%; text-align: right" title="Exercise price">1.54</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20231231_zlWom0vDGvO2" style="width: 16%; text-align: right" title="Exercise price">1.70</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231_zNSCGk9H5jf5" title="Expected term (in years)">5.8</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zDz1s1bSj666" title="Expected term (in years)">5.8</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231_zEMj6Ynoddpg" title="Volatility">114.78</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231_zY9sburtLfT7" title="Volatility">110.9</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231_zUc1dIbbB9o" title="Risk free rate">4.0</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231_zEAYfPdAp7dl" title="Risk free rate">3.7</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231_zYYuY7UHS391" title="Dividend yield">0.0</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_zporOTsZbj21" title="Dividend yield">0.0</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A0_zdWOOj9D8ms" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zISc1R7Vjvle" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the exercise price of outstanding stock options as of December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zRHySXYFx62c" style="display: none">SCHEDULE
OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS</span></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt"><span style="text-decoration: underline">Exercise price</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Options <br/> outstanding</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>$0.01 - $8.00</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zAb9sL5u7fgi" style="text-align: right" title="Options outstanding">1,861,499</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">$<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVYRVJDSVNFIFBSSUNFIE9GIE9VVFNUQU5ESU5HIFNUT0NLIE9QVElPTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zKEYUUqRU9C7" title="Exercise price range lower range limit">0.01</span> - $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVYRVJDSVNFIFBSSUNFIE9GIE9VVFNUQU5ESU5HIFNUT0NLIE9QVElPTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zFPPL2xF8cse" title="Exercise price range upper range limit">8.00</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zFlofZCEAqhd" style="width: 16%; text-align: right" title="Options outstanding">1,861,499</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>$<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVYRVJDSVNFIFBSSUNFIE9GIE9VVFNUQU5ESU5HIFNUT0NLIE9QVElPTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zvcnbSm68Xx2" title="Exercise price range lower range limit">8.01</span> - $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVYRVJDSVNFIFBSSUNFIE9GIE9VVFNUQU5ESU5HIFNUT0NLIE9QVElPTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zS0Jv3U0bKp5" title="Exercise price range upper range limit">16.00</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zAqwWC07acxk" style="text-align: right" title="Options outstanding">992,250</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">$<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVYRVJDSVNFIFBSSUNFIE9GIE9VVFNUQU5ESU5HIFNUT0NLIE9QVElPTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zIKCOXNfzFOa" title="Exercise price range lower range limit">16.01</span> or higher</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zJ3TqrSUYHf7" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding">34,073</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231_zD6QVuk5SHfl" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding">2,887,822</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zZlu8LxJak8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437014967776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITALIZATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_INDP_DisclosureCapitalizationAbstract', window );"><strong>Capitalization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_INDP_CapitalizationTextBlock', window );">CAPITALIZATION</a></td>
<td class="text"><p id="xdx_802_ecustom--CapitalizationTextBlock_zQDr6vbLxSPf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6: <span id="xdx_827_zd4DzPIxkPF5">CAPITALIZATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2024 and December 31, 2023, the Company had <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zlGPvMVUFSt5" title="Common stock, shares authorized"><span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_zCn6Ojz7eTGa" title="Common stock, shares authorized">200,000,000</span></span>
    shares of common stock authorized and <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231_zpa5gZcgoJQ" title="Common stock, shares issued"><span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zwuk79Q4j3ub" title="Common stock, shares outstanding">12,013,901</span></span>
    and <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_zybpOiObkan4" title="Common stock, shares issued"><span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_zhIxN9rFWqb8" title="Common stock, shares outstanding">8,401,047</span></span>
    shares issued and outstanding, respectively. As of December 31, 2024 and December 31, 2023, the Company had <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_zH1QrIk6Atsg" title="Preferred stock, shares authorized"><span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231_zRihT3jroly4" title="Preferred stock, shares authorized">5,000,000</span></span>
    shares of preferred stock authorized. There were <span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20241231_zwai1cDwmOH8" title="Preferred stock, shares issued"><span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20231231_zPaXnSHWCqm2" title="Preferred stock, shares issued"><span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20241231_ztTEv39Awwha" title="Preferred stock, shares outstanding"><span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20231231_zfqiuOXVW4j4" title="Preferred stock, shares outstanding">no</span></span></span></span> shares of preferred stock issued or outstanding as of December 31, 2024 and
    2023. As of December 31, 2024 and December 31, 2023, there were warrants outstanding to purchase an aggregate of <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231_zGbw15QBQfX5" title="Warrants outstanding to purchase">6,675,853</span>
    and <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231_zWKGIVW8YPFd" title="Warrants outstanding to purchase">3,090,787</span>
    shares of common stock, respectively. As of December 31, 2024, these warrants are exercisable at a weighted average price of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmfnXT32AZt" title="Weighted average exercise price">6.52</span>
    and their weighted average remaining contractual term is <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z99qsiitKYna" title="Weighted average, remaining contractual life">3.5</span>
    years.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 1, 2022, the Company
    entered into an At The Market Offering Agreement (the &#8220;ATM Agreement&#8221;) which was amended on September 1, 2022 with a
    sales agent, pursuant to which the Company may offer and sell, from time to time through the sales agent, shares of the Company&#8217;s
    common stock, par value $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20220901__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zD8OFNxMCYm3" title="Common stock, par value">0.01</span> per share. The issuance and sale of common stock by the Company under the <span style="background-color: white">ATM
    Agreement</span> is being made pursuant to the Company&#8217;s effective &#8220;shelf&#8221; registration statement on Form S-3 filed
    with the SEC on September 1, 2022 and declared effective on September 9, 2022. <span style="background-color: white">In 2024, the
    Company sold <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zxCOyrv5Rnp8" title="Shares issued">152,000</span> shares of the Company&#8217;s common stock for aggregate gross proceeds of approximately $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zWBOeAH44Ir1" title="Proceeds from issuance of common stock">0.4</span> million. </span>The
    Company&#8217;s ability to issue shares under the shelf registration statement on Form S-3 is limited by General Instruction I.B.6
    to Form S-3. On August 6<span style="background-color: white">, 2024, the Company filed a prospectus supplement to reduce the amount
    of shares registered under the prospectus for the ATM to $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240806__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zvuNyxGQ4UD7" title="Common stock, par value">0.00</span> and to suspend the ATM program, but the ATM Agreement remains in full
    force and effect</span>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    August 8, 2024, the Company completed a registered direct offering, pursuant to which the Company sold and issued to certain investors,
    including an officer of the Company, <span id="xdx_902_eus-gaap--SharesIssued_iI_pid_c20240808__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zelDhdzt93F4" title="Shares issued">1,643,837</span> shares of the Company&#8217;s common stock at a purchase price per share of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240808_zXFr5mqby50l" title="Shares issued, price per share">1.825</span>.
    In addition, in a concurrent private placement, the Company also issued to the purchasers in the August 2024 Offering unregistered
    warrants to purchase <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240808__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_ztIxvFUnmOY" title="Class of warrant or right, number of securities called by warrants or rights">1,643,837</span> shares of the Company&#8217;s common stock (the &#8220;August 2024 Warrants&#8221;). The August 2024
    Warrants are immediately exercisable at an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240808__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTLaIQ9mVkAa" title="Class of warrant or right, exercise price of warrants or rights">1.70</span> per share and expire <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20240808__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyCK8qXJziT2" title="Warrants and rights outstanding, term">five years</span> from the date of issuance. The
    total net proceeds were approximately $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240808__20240808_z74O81jkPrEc" title="Proceeds from issuance of common stock">2.5</span> million, after deducting placement agent and other offering expenses in the amount of
    approximately $<span id="xdx_906_eus-gaap--NoninterestExpenseOfferingCost_pn5n6_c20240808__20240808_zisvYsmJA2P" title="Noninterest expense offering cost">0.5</span> million. In September 2024, the Company filed a registration statement to register the resale by the investors
    of the shares of common stock issuable upon exercise of the August 2024 Warrants. The registration statement was declared effective
    on September 20, 2024.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 22, 2024, the
    Company completed a registered direct offering, pursuant to which the Company sold and issued to certain investors, including an
    officer of the Company, <span id="xdx_901_eus-gaap--SharesIssued_iI_pid_c20241122__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zpPaub8IlHyg" title="Shares issued">1,817,017</span> shares of the Company&#8217;s common stock at a purchase price per share of $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241122_zLZnRgBSmDP8" title="Shares issued, price per share">1.175</span>. In addition,
    in a concurrent private placement, the Company also issued to the purchasers in the November 2024 Offering unregistered warrants
    to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241122__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3tH7DlmCpUc" title="Class of warrant or right, number of securities called by warrants or rights">1,817,017</span> shares of the Company&#8217;s common stock (the &#8220;November 2024 Warrants&#8221;). The November 2024 Warrants
    are immediately exercisable at an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241122__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTlEiDZ8Zn1" title="Class of warrant or right, exercise price of warrants or rights">1.05</span> per share and expire <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20241122__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaWIxo0Xyihl" title="Warrants and rights outstanding, term">five years</span> from the date of issuance. The total net
    proceeds were approximately $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20241122__20241122_zssE98fAhfS4" title="Proceeds from issuance of common stock">1.8</span> million, after deducting placement agent and other offering expenses in the amount of approximately
    $<span id="xdx_903_eus-gaap--NoninterestExpenseOfferingCost_pn4n6_c20241122__20241122_z1Od3HuxhA4a" title="Noninterest expense offering cost">0.35</span> million. In December 2024, the Company filed a registration statement to register the resale by the investors of the shares
    of common stock issuable upon exercise of the November 2024 Warrants. The registration statement was declared effective on December
    31, 2024. In addition, in connection with the November 2024 Offering, the Company issued to the placement agent and its designees
    warrants to purchase an aggregate of <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zMvS2HFrdTZ5" title="Warrants to purchase aggregate shares">124,212</span> shares of common stock at an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231_z86TXieDX3xa" title="Warrants exercise price">1.3125</span>. The placement agent warrants
    are exercisable six months from the date of issuance and expire on the fifth anniversary of the issue date. The fair value of a warrant
    to purchase <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_dc_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_ze9SNHpHHqIf" title="Fair value of a warrant to purchase">one</span> share of common stock that was issued to the placement agent was $<span id="xdx_903_eus-gaap--SharePrice_iI_pid_c20241231_z3LMabN6EdTe" title="Share price">0.93</span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 16, 2025, the
    Company completed a private placement offering pursuant to which the Company sold and issued to certain investors an aggregate of
    <span id="xdx_90C_eus-gaap--SharesIssued_iI_pid_c20250116__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z6qmcF7ObzLi" title="Shares issued">2,109,383</span> shares of common stock and warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250116__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zbtOnOmhtoXf" title="Warrants purchase shares">2,109,383</span> shares of common stock (the &#8220;January 2025 Warrants&#8221;).
    The shares and January 2025 Warrants were sold on a combined basis for consideration of $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250116__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z89ZL6bXm0Bi" title="Shares issued, price per share">1.065</span> for one share and one January 2025
    Warrant. The January 2025 Warrants are immediately exercisable at an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250116__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0l8YbSRAU1c" title="Class of warrant or right, exercise price of warrants or rights">0.94</span> per share and expire <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250116__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLPiR2Q0oVo2" title="Warrants and rights outstanding, term">five years</span> from
    the date of issuance. The total net proceeds were approximately $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250116__20250116__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zh1argJvdXa" title="Proceeds from issuance of common stock">2.0</span> million, after deducting placement agent and other offering
    expenses in the amount of approximately $<span id="xdx_90C_eus-gaap--NoninterestExpenseOfferingCost_pn4n6_c20250116__20250116__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1trsDX6pLYb" title="Noninterest expense offering cost">0.25</span> million. In February 2025, the Company filed a registration statement to register the
    resale by the investors of the shares of common stock and shares of common stock issuable upon exercise of the January 2025 Warrants.
    The registration statement was declared effective on February 11, 2025. In addition, in connection with the January 2025 Offering,
    the Company issued to the placement agent and its designees warrants to purchase an aggregate of <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250211__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zrmgqXaeK144" title="Warrants to purchase aggregate shares">147,656</span> shares of common stock at
    an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250211_zps1i9rlWV2i" title="Warrants exercise price">1.175</span>. The placement agent warrants are exercisable six months from the date of issuance and expire on the
    fifth anniversary of the issue date. The fair value of a warrant to purchase <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_dc_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zeztbEJsflDl" title="Fair value of a warrant to purchase">one</span> share of common stock that was issued to the placement
    agent was $<span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zC5XhSrpBj1h" title="Share price">0.74</span>.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 12, 2025, the
    Company <span style="background-color: white">entered into a Standby Equity Purchase </span>Agreement (the &#8220;SEPA&#8221;) with
    YA II PN, LTD., a Cayman Islands exempt limited company (&#8220;Yorkville&#8221;), which provides that, upon the terms and subject
    to the restrictions and satisfaction of the conditions in the SEPA, Yorkville is committed to purchase up to an aggregate of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20250212__20250212__dei--LegalEntityAxis__custom--YorkvilleMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpKf5biUcyj4" title="Purchase ordinary shares">20.0</span>
    million of the Company&#8217;s shares of common stock over a 36-month period. At the Company&#8217;s option, the shares of common
    stock would be purchased by Yorkville from time to time at a price equal to 97% of the lowest of the three daily VWAPs during a three
    consecutive trading day period commencing on the date that the Company, subject to certain limitations, delivers a notice to Yorkville
    that the Company is committing Yorkville to purchase such shares of common stock. The Company may also specify a certain minimum
    acceptable price per share in each advance. The Company will control the timing and amount of sales of the Company&#8217;s shares
    to Yorkville. As consideration for Yorkville&#8217;s irrevocable commitment to purchase shares of the Company&#8217;s common stock
    upon the terms of and subject to restrictions and satisfaction of the conditions set forth in the SEPA, upon execution of the SEPA,
    the Company issued to Yorkville <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250212__20250212__dei--LegalEntityAxis__custom--YorkvilleMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zI7PfwYmxaTc" title="Commitment shares issued">305,960</span> shares of common stock, as commitment shares. <span style="background-color: white">Under
    the applicable Nasdaq Rules and pursuant to the SEPA, in no event may the Company issue or sell to Yorkville more than <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250212__20250212__us-gaap--TypeOfArrangementAxis__custom--ExchangeCapMember__dei--LegalEntityAxis__custom--YorkvilleMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zSWuwsbgPitk" title="Shares issued">2,823,244</span>
    shares of common stock (the &#8220;Exchange Cap&#8221;), which is 19.99% of the shares of common stock outstanding immediately prior
    to the execution of the SEPA, unless (i) the Company obtains stockholder approval to issue shares of common stock in excess of the
    Exchange Cap, or (ii) the average price of all applicable sales of common stock under the SEPA equals or exceeds $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250212__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementsMember__dei--LegalEntityAxis__custom--YorkvilleMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zMNAUoxt3hL" title="Shares issued, price per share">0.81722</span> per share
    (which represents the lower of (i) the Nasdaq Official Closing Price (as reflected on Nasdaq.com) on the trading day immediately
    preceding the effective date or (ii) the average Nasdaq Official Closing Price of the common stock (as reflected on Nasdaq.com) for
    the five trading days immediately preceding the effective date). </span>On February 12, 2025, the Company filed a Form S-1 covering
    the resale of up to <span id="xdx_901_ecustom--NumberOfResaleCommonStockComprised_pid_c20250212__20250212__dei--LegalEntityAxis__custom--YorkvilleMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNjHk7M2Kdah" title="Number of resale common stock comprised">10,000,000</span> shares of common stock comprised of (i) <span id="xdx_904_ecustom--NumberOfCommitmentShares_pid_c20250212__20250212__dei--LegalEntityAxis__custom--YorkvilleMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zvYCCsv9gbf2" title="Commitment shares issued">305,960</span> commitment shares, and (ii) up to <span id="xdx_90D_ecustom--NumberOfCommitmentSharesToBeIssuedUponCertainConditions_pid_c20250212__20250212__dei--LegalEntityAxis__custom--YorkvilleMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementsMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4ocMnv8ECwj" title="Commitment shares to be issued upon certain conditions">9,694,040</span> shares
    of common stock reserved for issuance and sale to Yorkville under the SEPA. The Form S-1 was declared effective on February 13, 2025.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_INDP_CapitalizationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalization {Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">INDP_CapitalizationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>INDP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_INDP_DisclosureCapitalizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">INDP_DisclosureCapitalizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>INDP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437015386000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z0miqQVsBwpc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7: <span id="xdx_82F_zX8L3OIVyEa">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Litigation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business.
These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. Periodically,
the Company reviews the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential
loss from any claim or legal claim is considered probable and the amount of such potential loss can be estimated, the Company accrues
liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because
of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available,
the Company reassesses the potential liability related to pending claims and litigation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Leases</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2021, the Company entered into a noncancelable two-year operating lease agreement for approximately <span id="xdx_907_eus-gaap--AreaOfLand_iI_usqft_c20211001__srt--StatementGeographicalAxis__stpr--CA__us-gaap--TypeOfArrangementAxis__custom--TwoYearLeaseAgreementMember_z2gOvU5k7aw6" title="Area of land">2,000</span> square feet of office
space in San Diego, California. The base rent was $<span id="xdx_900_eus-gaap--LeaseAndRentalExpense_c20211001__20211001__srt--StatementGeographicalAxis__stpr--CA__us-gaap--TypeOfArrangementAxis__custom--TwoYearLeaseAgreementMember_z4k8zWNsWg6l" title="Base rent">7,999</span> per month with an increase of <span id="xdx_90C_ecustom--RateOfIncreaseInLeaseRent_pid_dp_uPure_c20211001__20211001__srt--StatementGeographicalAxis__stpr--CA__us-gaap--TypeOfArrangementAxis__custom--TwoYearLeaseAgreementMember_zeHwO7qa6F03" title="Rate of increase in lease rent">3</span>% after the first anniversary of the lease term
commencement, which was November 1, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 19, 2023, the Company executed an amendment to <span id="xdx_901_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20230419__20230419_zSuzqnVwWydf" title="Operating lease, extend description">the lease agreement to extend the lease through October 31, 2025.</span> Accordingly, the
Company remeasured its operating lease liability under the agreement and recognized an incremental lease liability and right-of-use asset
of $<span id="xdx_901_eus-gaap--OperatingLeaseLiability_iI_c20230419_zhf2HlUv8eG7" title="Operating lease liability">236,506</span>. The remeasurement was based on a <span id="xdx_902_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_c20230419_zlpHQycvTJ6c" title="Incremental borrowing rate">9</span>% incremental borrowing rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z3RisQPkGIXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum annual lease payments and a reconciliation to the Company&#8217;s operating lease liability under the Company&#8217;s noncancelable
operating lease as of December 31, 2024 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zyf7vEqKPT65" style="display: none">SUMMARY OF MINIMUM LEASE PAYMENTS</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_492_20241231_z2PZRMxwOvqh" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_mtLOLLPzSwn_zQCoRnEkG5E" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Total minimum lease payments in 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">86,862</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zEnBsCwROf7f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: amount representing interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,698</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zAXm3aw0rwBj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Present value of operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84,164</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zAEZ8rsZSrOa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: current portion</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(84,164</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_z7fwp61UXO37" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liability, net of current portion</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0770">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zDUqlJEt6m32" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized rent expense of $<span id="xdx_907_eus-gaap--PaymentsForRent_c20240101__20241231_znp3ac0wfoOd" title="Rental expense">101,847</span> and $<span id="xdx_908_eus-gaap--PaymentsForRent_c20230101__20231231_z0EOnlGOGHVa" title="Rental expense">100,742</span> during the years ended December 31, 2024 and 2023, respectively. Total cash
payments for the operating lease totaled $<span id="xdx_907_eus-gaap--OperatingLeasePayments_c20240101__20241231_zUetMXs1F68c" title="Operating lease payments">101,705</span> and $<span id="xdx_90F_eus-gaap--OperatingLeasePayments_c20230101__20231231_zIuNVfWHen93" title="Operating lease payments">99,254</span> during the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437014379792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--IncomeTaxDisclosureTextBlock_zrZN08W838b4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8: <span id="xdx_82E_zrtFde83fKSb">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company had net operating loss carry forwards that may be available to reduce future years&#8217; taxable income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zTUhivYeNtv9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s provision for income taxes consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_z242BAKEQzPd" style="display: none">SCHEDULE
OF PROVISION FOR INCOME TAXES</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231_zLCL4eNfPQE6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231_znfb9i2Tirvk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzSdz_zT9WXNRuxvpd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Computed &#8220;expected&#8221; tax benefit</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(3,154,290</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(3,238,593</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzSdz_zHBWzLXsEXdj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11,768</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,304</td><td style="text-align: left"></td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_maITEBzSdz_z8QXT9poXWoe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-deductible items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">230,890</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61,842</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzSdz_zkmuv7KMfY3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in deferred tax asset valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,454,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,509,496</td><td style="text-align: left"></td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_maITEBzSdz_zd2Vst94TdV5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">482,045</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">613,167</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmountReturnToProvisionAdjustments_maITEBzSdz_zyynnugD7Cgi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Return-to-provision adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,316</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzSdz_zIGJRcb3CRIg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">621</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">13,918</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzSdz_zFKUFZFpa7C7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Income tax expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,700</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,450</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zvB6mdalE6E8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zTZ3FR6D4M28" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s net deferred tax assets were comprised of the following as of December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zgbOpEyrc719" style="display: none">SCHEDULE
OF NET DEFERRED TAX ASSETS</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20241231_zSXUmyXbCTaa" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20231231_zPRpDyGVFAnc" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_zWysNROiBnZc" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Net operating losses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">53,447,116</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">51,846,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_z8ThOyPpXaTg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Capitalized research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,959,591</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,162,872</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_zF0phi160nWh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">288,756</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">261,052</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_iI_znJ534kLTMp9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">249,495</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">220,923</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsFrequentFlierLiability_iI_zCqjP36GDjka" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,760</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,761</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOther_iI_zQs0zjhFqFxi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">616</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">559</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzCTx_maDTALNzH2X_zZEfUKkg0W1c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total gross deferred tax assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">56,963,334</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">54,528,167</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_iNI_di_maDITLzRZ0_zFirxZXVNsc9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Right-of-use asset</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(17,340</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(36,373</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzRZ0_msDTALNzH2X_zpMKSOQ73S11" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Gross deferred tax liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(17,340</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(36,373</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzH2X_zkcee1TRsfmf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: Deferred tax asset valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(56,945,994</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(54,491,794</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzH2X_zl5cYOCzlixj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0840">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0841">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zpBQcQhW3nEf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income tax assets and liabilities are recorded for differences between the financial statement and tax basis of the assets and liabilities
that will result in taxable or deductible amounts in the future based on enacted laws and rates applicable to the periods in which the
differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets
to the amount expected to be realized</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to
the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits is
dependent on the Company&#8217;s ability to generate sufficient taxable income within the carryforward period. Because of the Company&#8217;s
recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned
future tax benefits is currently not likely to be realized and, accordingly, has provided a full valuation allowance for the years ended
December 31, 2024 and 2023. The net change in total valuation allowance for the years ended December 31, 2024 and 2023 was an increase
of $<span id="xdx_900_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20240101__20241231_z0XcFPhK3gI5" title="Valuation allowance change amount">2.5</span> million and increase of $<span id="xdx_90B_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20230101__20231231_zI4DoyCjUOC5" title="Valuation allowance change amount">2.5</span> million respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024, the Company has United States federal and state net operating loss (NOL) carryforwards of $<span id="xdx_909_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_z8HnJvHrsef7" title="Net operating loss (NOL) carryforwards">35.3</span> million and $<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__custom--StateMember_zea56iQfLLvb" title="Net operating loss (NOL) carryforwards">7.6</span> million,
respectively. The federal NOL carryforwards generated in pre-2018 tax years of $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--TaxPeriodAxis__custom--ExpireInTwoThousandThirtySixMember__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_z3SVfRchMs0c" title="Operating loss carryforwards">0.8</span> million will begin to expire in 2036 while federal
NOLs generated after 2017 of $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--TaxPeriodAxis__custom--IndefinitePeriodMember__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_zBShpWSjvE9i" title="Operating loss carryforwards">34.4</span> million will carry forward indefinitely. The state NOL carryforwards of $<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--TaxPeriodAxis__custom--ExpireInTwoThousandThirtyFiveMember__us-gaap--IncomeTaxAuthorityAxis__custom--StateMember_zer61JGsbbm" title="Operating loss carryforwards">7.6</span> million will begin to
expire in 2035 unless previously utilized. At December 31, 2024, the Company also had Israel NOL carryforwards of $<span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__srt--StatementGeographicalAxis__country--IL_zFColA0xLhZ4" title="Operating loss carryforwards">197.9</span> million. The
Israel NOLs carry forward indefinitely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to utilize its net operating losses may be limited under Section 382 and 383 of the Internal Revenue Code. The
limitations apply if an ownership change, as defined by Section 382, occurs. Generally, an ownership change occurs when certain shareholders
increase their aggregate ownership by more than 50 percentage points over their lowest ownership percentage in a testing period (typically
three years). Although the Company has not undergone a Section 382 analysis, it is possible that the utilization of the net operating
losses, could be substantially limited. Additionally, U.S. tax laws limit the time during which these carryforwards may be utilized against
future taxes. As a result, the Company may not be able to take full advantage of these carryforwards for federal and state tax purposes.
Future changes in stock ownership may also trigger an ownership change and, consequently, a Section 382 limitation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the benefit of tax positions taken or expected to be taken in its tax returns in the consolidated financial statements
when it is more likely than not that the position will be sustained upon examination by authorities. Recognized tax positions are measured
at the largest amount of benefit that is <span id="xdx_90B_eus-gaap--IncomeTaxExaminationDescription_c20240101__20241231_zucLEhOVSrEa" title="Income tax examination description">greater than 50% likely of being realized upon settlement</span>. As of December 31, 2024 and 2023
the Company has not recorded any unrecognized tax benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records interest related to unrecognized tax benefits in interest expense and penalties in general and administrative expenses.
As of December 31, 2024 and 2023, the Company recorded <span id="xdx_90F_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_iI_do_c20241231_zGXutwkTqx21" title="Unrecognized tax benefits, income tax penalties and interest accrued"><span id="xdx_906_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_iI_do_c20231231_zAtdHnNOJXb" title="Unrecognized tax benefits, income tax penalties and interest accrued">no</span></span> accrued interest and penalties related to unrecognized tax benefits. The Company
does not expect any significant changes in its tax positions that would warrant recognition of a liability for unrecognized income tax
benefits during the next 12 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company files U.S. federal and various state income tax returns and is subject to the examination for tax years back to 2021 and 2020
for federal and state purposes, respectively, and its NOL&#8217;s dating back to inception are subject to adjustment by the taxing authorities
if claimed on future tax filings for which the statute remain open to examination. The Company also files Israeli tax returns and is
subject to examination for tax years back to 2020. The Company is not currently under audit by the Internal Revenue Service or other
similar national, state and local authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437114341824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text"><p id="xdx_808_eus-gaap--SegmentReportingDisclosureTextBlock_zNfDbhvssg4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9: <span id="xdx_822_zeZIHDYvK10g">SEGMENT INFORMATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating
decision maker in deciding how to allocate resources in assessing performance. The Company operates as a <span id="xdx_901_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20240101__20241231_zOBWekpOhlp9" title="Number of reportable segments::XDX::1"><span style="-sec-ix-hidden: xdx2ixbrl0867">single</span></span> reporting segment, focusing
on the development of a novel and patented systemically administered anti-cancer and anti-viral immunotherapy. The Company&#8217;s chief
operating decision maker (&#8220;CODM&#8221;) is the chief executive officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM assesses
performance for the segment based on operating expenses as reported in the accompanying consolidated statement of operations. The Company
expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances the development of its
product candidates through pre-clinical and clinical trials. In addition, the measure of segment assets is reported on the accompanying
consolidated balance sheet as total assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
such, the CODM uses cash forecast models in deciding how to invest into the segment. Such cash forecast models are reviewed to assess
the entity-wide operating results and performance. Net loss is used to monitor budget versus actual results. Monitoring budgeted versus
actual results is used in assessing performance of the segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z0dognWGcGM3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents reportable segment loss, including significant expenses regularly provided to the CODM, attributable to the
Company&#8217;s reportable segment for the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zl3YUgJxanE2">SCHEDULE
OF REPORTABLE SEGMENT LOSS</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zsOxoeSs6ydl" style="border-bottom: Black 1pt solid; display: none; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zEZZk0RK9w59" style="border-bottom: Black 1pt solid; display: none; text-align: center">2023</td><td style="display: none; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ResearchAndDevelopmentExpense_hus-gaap--IncomeStatementLocationAxis__custom--ExternalResearchAndDevelopmentMember_zepfhC2OeXt" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">External research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,355,449</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,683,828</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ResearchAndDevelopmentExpense_hus-gaap--IncomeStatementLocationAxis__custom--InternalPersonnelCostsMember_zVnbDcks6oOk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Internal personnel costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,895,648</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,937,879</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_msNILz3BM_z0uL5JaqY5t9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,251,097</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,621,707</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_msNILz3BM_zffPC4pkaJCc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,114,654</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,756,767</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherOperatingIncomeExpenseNet_iN_di_maNILz3BM_zyLSWk6AqGU1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other income, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(343,724</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(955,003</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_iN_di_mtNILz3BM_zbZuKzFYFBB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,022,027</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,423,471</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zUpo773nd4Bk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437014382736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_803_eus-gaap--SubsequentEventsTextBlock_zOMMw51kkpg4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10: <span id="xdx_82F_zzd3KEJcCJ7a">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluated subsequent events from December 31, 2024, the date of these consolidated financial statements, through March 13, 2024,
which represents the date the consolidated financial statements were issued, for events requiring recognition or disclosure in the consolidated
financial statements for the year ended December 31, 2024. The Company concluded that no events have occurred that would require recognition
or disclosure in the consolidated financial statements, except for the January 2025 Offering that was completed on January 16, 2025,
as described in Note 6(e) and for the SEPA that was entered with Yorkville on February 12, 2025, as described in Note 6(f).</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437010330992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zHvtafAti2d2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basis
of presentation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#8220;US GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_zRVAz49Q8aMi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Principles
of consolidation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of Indaptus and its subsidiaries. Intercompany balances and transactions have
been eliminated upon consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--UseOfEstimates_z7lX2mqACVBi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Use
of estimates</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in accordance with US GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements, and the
reported amounts of expenses during the reporting periods. The most significant estimates relate to the determination of the fair value
of stock-based compensation and the determination of period-end obligations to certain contract research organizations. Management evaluates
its estimates and assumptions on an ongoing basis using historical experience and other factors and makes adjustments when facts and
circumstances dictate. These estimates are based on information available as of the date of the consolidated financial statements; therefore,
actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per share</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zITshnNOMlMc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Loss
per share</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
per share, basic and diluted, is computed on the basis of the net loss for the period divided by the weighted average number of shares
of common stock outstanding during the period. Diluted loss per share is based upon the weighted average number of shares of common stock
and of common stock equivalents outstanding when dilutive. Common stock equivalents include outstanding stock options and warrants which
are included under the treasury stock method when dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zTVxb6GxtKPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following number of stock options and warrants were excluded from the calculation of diluted loss per share because their effect would
have been anti-dilutive for the periods presented (share data):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B7_z7noe3Or3OFi" style="display: none">SCHEDULE
OF ANTI-DILUTIVE SECURITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Weighted average</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Outstanding stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zzzBDQa1x78h" style="width: 16%; text-align: right" title="Anti-dilutive securities">2,519,419</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z8roWgWnW3W9" style="width: 16%; text-align: right" title="Anti-dilutive securities">1,979,196</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_znlKC6M6KURe" style="text-align: right" title="Anti-dilutive securities">3,935,282</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_za29FhSrik0l" style="text-align: right" title="Anti-dilutive securities">3,090,787</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_z0zZABOUdWg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><p id="xdx_846_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6fmJp0ekRI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
and cash equivalents</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. As of
December 31, 2024, and 2023, cash and cash equivalents consist primarily of checking and money market deposits. The Company&#8217;s cash
balances exceed those that are federally insured; however, the Company believes it is not exposed to significant credit risk due to the
financial strength of the depository institutions in which the cash and cash equivalents are held. To date, the Company has not recognized
any losses caused by uninsured balances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zAleiunrGJg3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Property
and equipment</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment assets are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over
the estimated useful lives of the assets. The Company uses an estimated useful life of <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersAndOtherOfficeEquipmentMember_zdj4BE7ssyu8" title="Estimated useful life">three years</span> for employee-related computers and
other office equipment and <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureMember_zt1TZj9uzmx5" title="Estimated useful life">five years</span> for furniture. Leasehold improvements are amortized over the shorter of the lease-term or the estimated
useful life of the related asset.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Patents</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zrMB8XORfTug" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patents</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expenses patent costs, including related legal costs, as incurred and records such costs within general and administrative expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zF7nDBVoI5zc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and development expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses include costs directly attributable to the conduct of research and development programs, including the cost
of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research
and development activities, including clinical trials and professional services. All costs associated with research and development are
expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accrues for expenses resulting from obligations under agreements with contract research organizations (&#8220;CROs&#8221;), contract
manufacturing organizations (&#8220;CMOs&#8221;), and other outside service providers for which payment flows do not match the periods
over which services or materials are provided to the Company. Accruals are recorded based on estimates of services received and efforts
expended pursuant to agreements with CROs, CMOs, and other outside service providers. These estimates are typically based on contracted
amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers
as to the progress or stage of completion of the services. In the event advance payments are made to a CRO, CMO, or outside service provider,
the payments will be recorded as a prepaid expense, which will be amortized or expensed as the contracted services are performed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and administrative expenses</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_z8xuuJUtuue8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and administrative expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses include compensation, employee benefits, and stock-based compensation for executive management, finance,
administration and human resources, facility costs (including rent), professional service fees, and other general overhead costs to support
the Company&#8217;s operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zdqqlKEERcNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income
taxes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences
attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective
tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred
tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation
allowance is recorded for deferred tax assets if it is more likely than not that some portion or all of the deferred tax assets will
not be realized in the foreseeable future. As of December 31, 2024, and 2023, the Company has recorded a full valuation allowance against
its deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized
income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or
measurement are reflected in the period in which the change in judgment occurs. The Company records interest related to unrecognized
tax benefits in interest expense and penalties in general and administrative expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zF62OiizdLR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-based
compensation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures and records the expense related to stock-based payment awards based on the fair value of those awards as determined
using the Black-Scholes-Merton (&#8220;Black-Scholes&#8221;) model as of the date of grant. The Company recognizes stock-based compensation
expense over the requisite service period of the individual grant, generally equal to the vesting period, on a straight-line basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Black-Scholes model requires the use of highly subjective and complex assumptions, which determine the fair value of stock-based payment
awards, including the option&#8217;s expected term and the price volatility of the underlying stock. The Company estimates the fair value
of options granted by using the Black-Scholes model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
Volatility</i>&#8212;The Company estimates volatility for option grants by evaluating the historical volatility of a peer group of companies
for the period immediately preceding the option grant for a term that is approximately equal to the options&#8217; expected term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
Term</i>&#8212;The expected term of the Company&#8217;s options represents the period that the stock-based payment awards are expected
to be outstanding. The expected term is estimated using the simplified method for employee stock options since the Company does not have
adequate historical exercise data to estimate the expected term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk-Free
Interest Rate</i>&#8212;The risk-free interest rate is based on the implied yield currently available on U.S. Treasury zero-coupon issues
with a term that is equal to the options&#8217; expected term at the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividend
Yield</i>&#8212;The Company has not declared or paid dividends to date and does not anticipate declaring dividends. As such, the dividend
yield has been estimated to be zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has elected to recognize forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value measurements</a></td>
<td class="text"><p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z7gde9Bxbz2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
value measurements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability
in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the
measurement date. The Company follows the established framework for measuring fair value and providing disclosures about fair value measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted prices in active
    markets for identical assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs other than Level
    1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable inputs which
    are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or
    similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
820, <i>Fair Value Measurement</i>, requires all entities to disclose the fair value of financial instruments, both assets and liabilities,
for which it is practicable to estimate fair value, and defines the fair value of a financial instrument as the amount at which the instrument
could be exchanged in a current transaction between willing parties. As of December 31, 2024, and 2023, the recorded values of cash and
cash equivalents, prepaid expenses, and accounts payable and other current liabilities approximate their fair values due to the short-term
nature of these items.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_INDP_NewAdoptedAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted accounting pronouncements</a></td>
<td class="text"><p id="xdx_84E_ecustom--NewAdoptedAccountingPronouncementsPolicyPolicyTextBlock_zAcWFfnPQO1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Recently
adopted accounting pronouncements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
November 2023, the FASB issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures. The FASB amended the guidance in ASC
280, Segment Reporting (&#8220;ASC 280&#8221;), to require a public entity to disclose significant segment expenses and other segment
items on an annual and interim basis and to provide in interim periods all disclosures about a reportable segment&#8217;s profit or loss
and assets that are currently required annually. Public entities with a single reportable segment are required to provide the new disclosures
and all the disclosures required under ASC 280. The guidance is applied retrospectively to all periods presented in financial statements
unless it is impracticable. This new guidance is effective for public business entities for annual periods beginning after December 15,
2023, and for interim periods beginning after December 15, 2024. The Company adopted this new standard effective December 31, 2024. See
Note 9, Segment Information, for disclosures related to the adoption of ASU 2023-07.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting pronouncements</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_znDn13vSn9X1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span id="xdx_86B_zps4ItJ4JNDf">Recently
issued accounting pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense <span style="background-color: white">Disaggregation </span> Disclosures.
This ASU will require entities to provide enhanced disclosures, in a tabular format, related to certain expense categories included in
the statement of operations. The ASU aims to increase transparency and provide investors with more detailed information about the nature
of expenses reported on the face of the income statement. The new ASU is effective for annual reporting periods beginning after December
15, 2026 and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating
the impact of the adoption of this standard on the related disclosures</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures. This ASU does not change accounting for income
taxes but requires new disclosures focusing on two areas, the effective rate reconciliation and taxes paid. This new standard is effective
for public business entities for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently
evaluating the impact of the adoption of this standard on the related disclosures.</span></p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_INDP_NewAdoptedAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>New Adopted Accounting Pronouncements Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">INDP_NewAdoptedAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>INDP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437015402096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">SCHEDULE OF ANTI-DILUTIVE SECURITIES</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zTVxb6GxtKPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following number of stock options and warrants were excluded from the calculation of diluted loss per share because their effect would
have been anti-dilutive for the periods presented (share data):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B7_z7noe3Or3OFi" style="display: none">SCHEDULE
OF ANTI-DILUTIVE SECURITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Weighted average</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Outstanding stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zzzBDQa1x78h" style="width: 16%; text-align: right" title="Anti-dilutive securities">2,519,419</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z8roWgWnW3W9" style="width: 16%; text-align: right" title="Anti-dilutive securities">1,979,196</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_znlKC6M6KURe" style="text-align: right" title="Anti-dilutive securities">3,935,282</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_za29FhSrik0l" style="text-align: right" title="Anti-dilutive securities">3,090,787</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437018337744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_INDP_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Prepaid Expenses And Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_INDP_ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock', window );">SCHEDULE OF PREPAID EXPENSE AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p id="xdx_892_ecustom--ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock_z8ENLd2sfC94" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets are comprised of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zHZ1PU09hW0d" style="display: none">SCHEDULE
OF PREPAID EXPENSE AND OTHER CURRENT ASSETS</span></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20241231_zz8S2HWxhMPc" style="border-bottom: Black 1pt solid; display: none; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_zrwsaLIdXohl" style="border-bottom: Black 1pt solid; display: none; text-align: center">2023</td><td style="display: none; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PrepaidInsurance_iI_pp0p0_maPEAOAz50c_z689fbTuzGWc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Prepaid insurance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">506,489</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">554,097</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--PrepaidResearchAndDevelopment_iI_pp0p0_maPEAOAz50c_zsmHvMGxPZNl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,309</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPEAOAz50c_z103lWxDYz5e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other prepaid expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">175,088</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">61,750</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPEAOAz50c_zv7GQh85FQw2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">831,577</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">633,156</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPEAOAz50c_ztbE9QjeH7J5" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; text-align: left; padding-bottom: 2.5pt">Prepaid expenses and other current assets</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right">831,577</td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right">633,156</td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_INDP_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">INDP_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>INDP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_INDP_ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Prepaid Expense And Other Assets [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">INDP_ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>INDP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437015484688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">SCHEDULE OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z7Ghfw9tcRD3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
payable and other current liabilities are comprised of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zrXQEarVuofe" style="display: none">SCHEDULE
OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES</span></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: right">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20241231_zJNuo2kqCPZ5" style="border-bottom: Black 1pt solid; display: none; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20231231_zgmpYP5DlDhi" style="border-bottom: Black 1pt solid; display: none; text-align: center">2023</td><td style="display: none; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AccountsPayableCurrent_iI_pp0p0_maAPAOAzxRP_ztpjmkFOSvNd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Accounts payable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">870,229</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">806,004</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pp0p0_maAPAOAzxRP_znSBd8T5lr0c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued employee costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,371,498</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,213,054</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maAPAOAzxRP_zlKXwDdYWWy9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72,054</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,165</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--AccruedResearchAndDevelopmentCurrent_iI_pp0p0_maAPAOAzxRP_z8rk0yw8NkD8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">860,958</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">439,024</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--AccruedBoardFeesCurrent_iI_pp0p0_maAPAOAzxRP_zfAV4Uc2wuli" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued board fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117,750</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DelawareFranchiseTaxesPayableCurrent_iI_pp0p0_maAPAOAzxRP_zJiRSqpQT0ah" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Delaware franchise taxes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0514">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maAPAOAzxRP_z0rTZzcNdzia" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other accrued expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">17,228</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">17,330</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_pp0p0_mtAPAOAzxRP_zMpVQCMEKC6c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total accounts payable and other current liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,309,717</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,672,327</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437016331136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">SCHEDULE OF STOCK OPTION ACTIVITY</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zXAmXgmZyVk1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the stock option activity during the year ended December 31, 2024, is presented in the table below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zeyGQStcEPA6" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Weighted average</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of <br/> options</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercise <br/> price</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Remaining <br/> contractual <br/> life <br/> (in years)</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Intrinsic value</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Outstanding as of January 1, 2024</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zwDRGNlhFQP6" style="width: 10%; text-align: right" title="Number of options, outstanding balance">2,050,197</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zqPGJvNypWcd" title="Weighted average exercise price, outstanding, balance">10.90</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zQuVqRd6KOq" title="Weighted average remaining contractual life (in years)">7.9</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20241231_z9qeWdsE2tSj" style="width: 10%; text-align: right" title="Intrinsic value, outstanding balance">36,363</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_z5dyblhUVj47" style="text-align: right" title="Number of options, granted">838,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zNpvhPhY6vHb" title="Weighted average exercise price, granted">1.54</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_pp0p0_c20240101__20241231_zpqtrVNV8h6c" style="text-align: right" title="Intrinsic value, granted"><span style="-sec-ix-hidden: xdx2ixbrl0539">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left; padding-left: 10pt">Forfeited and cancelled</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231_zJcVASGjDmMe" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, forfeited and cancelled">(625</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20241231_zzfIWwR9soo6" title="Weighted average exercise price, forfeited and cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0543">-</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_z9SBzHGDYs37" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, outstanding balance">2,887,822</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_zx4o6cMRJQme" title="Weighted average exercise price, balance">8.06</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zmUbwefKtb3k" title="Weighted average remaining contractual life (in years)">7.6</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240101__20241231_zH1kDjUIjIS4" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, Outstanding, balance"><span style="-sec-ix-hidden: xdx2ixbrl0551">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_zfYJzxb1YpKb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, exercisable">1,854,764</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zyCcs0JmxGdb" title="Weighted average exercise price, exercisable">11.54</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_z1y98MsH2l68" title="Weighted average remaining contractual life, Exercisable">6.8</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20240101__20241231_zv137HlKlX57" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, outstanding balance"><span style="-sec-ix-hidden: xdx2ixbrl0559">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Vested and expected to vest as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20240101__20241231_zYfkN4Z22mm" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, vested and expected to vest">2,887,822</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_zRkr1D4wLpql" title="Weighted average exercise price, vested and expected to vest">8.06</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zFuPTSGFqAoh" title="Weighted average remaining contractual life (in years), vested and expected to vest">7.6</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240101__20241231_zRHIFEfKL8g2" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, vested and expected to vest balance"><span style="-sec-ix-hidden: xdx2ixbrl0567">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">SCHEDULE OF STOCK BASED COMPENSATION EXPENSES</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zSATXzgUajvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the total stock-based compensation expense included in the consolidated statements of operations for the periods
presented:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zDPSQrTLhZff">SCHEDULE
OF STOCK BASED COMPENSATION EXPENSES</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240101__20241231_zEowYqIwHx3e" style="border-bottom: Black 1pt solid; display: none; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20230101__20231231_zersO87Crwo2" style="border-bottom: Black 1pt solid; display: none; text-align: center">2023</td><td style="display: none; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zwS6iSu3ZWL8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">624,480</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">792,273</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zTQbkhyUTQQj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,681,369</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,173,665</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ShareBasedCompensation_zohOI9W2FCq3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,305,849</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,965,938</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">SCHEDULE OF WEIGHTED AVERAGE INPUTS USED TO MEASURE VALUE OF OPTIONS GRANTED</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zrcCTPEa0VWk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_z5EeR8Fixg7a" style="display: none">SCHEDULE
OF WEIGHTED AVERAGE INPUTS USED TO MEASURE VALUE OF OPTIONS GRANTED</span></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Exercise price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20241231_zlukEmmEsRN4" style="width: 16%; text-align: right" title="Exercise price">1.54</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20231231_zlWom0vDGvO2" style="width: 16%; text-align: right" title="Exercise price">1.70</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231_zNSCGk9H5jf5" title="Expected term (in years)">5.8</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zDz1s1bSj666" title="Expected term (in years)">5.8</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231_zEMj6Ynoddpg" title="Volatility">114.78</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231_zY9sburtLfT7" title="Volatility">110.9</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231_zUc1dIbbB9o" title="Risk free rate">4.0</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231_zEAYfPdAp7dl" title="Risk free rate">3.7</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231_zYYuY7UHS391" title="Dividend yield">0.0</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_zporOTsZbj21" title="Dividend yield">0.0</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">SCHEDULE OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zISc1R7Vjvle" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the exercise price of outstanding stock options as of December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zRHySXYFx62c" style="display: none">SCHEDULE
OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS</span></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt"><span style="text-decoration: underline">Exercise price</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Options <br/> outstanding</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>$0.01 - $8.00</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zAb9sL5u7fgi" style="text-align: right" title="Options outstanding">1,861,499</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">$<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVYRVJDSVNFIFBSSUNFIE9GIE9VVFNUQU5ESU5HIFNUT0NLIE9QVElPTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zKEYUUqRU9C7" title="Exercise price range lower range limit">0.01</span> - $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVYRVJDSVNFIFBSSUNFIE9GIE9VVFNUQU5ESU5HIFNUT0NLIE9QVElPTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zFPPL2xF8cse" title="Exercise price range upper range limit">8.00</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zFlofZCEAqhd" style="width: 16%; text-align: right" title="Options outstanding">1,861,499</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>$<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVYRVJDSVNFIFBSSUNFIE9GIE9VVFNUQU5ESU5HIFNUT0NLIE9QVElPTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zvcnbSm68Xx2" title="Exercise price range lower range limit">8.01</span> - $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVYRVJDSVNFIFBSSUNFIE9GIE9VVFNUQU5ESU5HIFNUT0NLIE9QVElPTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zS0Jv3U0bKp5" title="Exercise price range upper range limit">16.00</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zAqwWC07acxk" style="text-align: right" title="Options outstanding">992,250</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">$<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVYRVJDSVNFIFBSSUNFIE9GIE9VVFNUQU5ESU5HIFNUT0NLIE9QVElPTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zIKCOXNfzFOa" title="Exercise price range lower range limit">16.01</span> or higher</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zJ3TqrSUYHf7" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding">34,073</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231_zD6QVuk5SHfl" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding">2,887,822</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437015122944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">SUMMARY OF MINIMUM LEASE PAYMENTS</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z3RisQPkGIXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum annual lease payments and a reconciliation to the Company&#8217;s operating lease liability under the Company&#8217;s noncancelable
operating lease as of December 31, 2024 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zyf7vEqKPT65" style="display: none">SUMMARY OF MINIMUM LEASE PAYMENTS</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_492_20241231_z2PZRMxwOvqh" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_mtLOLLPzSwn_zQCoRnEkG5E" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Total minimum lease payments in 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">86,862</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zEnBsCwROf7f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: amount representing interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,698</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zAXm3aw0rwBj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Present value of operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84,164</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zAEZ8rsZSrOa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: current portion</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(84,164</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_z7fwp61UXO37" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liability, net of current portion</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0770">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437117398016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">SCHEDULE OF PROVISION FOR INCOME TAXES</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zTUhivYeNtv9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s provision for income taxes consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_z242BAKEQzPd" style="display: none">SCHEDULE
OF PROVISION FOR INCOME TAXES</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231_zLCL4eNfPQE6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231_znfb9i2Tirvk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzSdz_zT9WXNRuxvpd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Computed &#8220;expected&#8221; tax benefit</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(3,154,290</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(3,238,593</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzSdz_zHBWzLXsEXdj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11,768</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,304</td><td style="text-align: left"></td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_maITEBzSdz_z8QXT9poXWoe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-deductible items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">230,890</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61,842</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzSdz_zkmuv7KMfY3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in deferred tax asset valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,454,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,509,496</td><td style="text-align: left"></td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_maITEBzSdz_zd2Vst94TdV5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">482,045</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">613,167</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmountReturnToProvisionAdjustments_maITEBzSdz_zyynnugD7Cgi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Return-to-provision adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,316</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzSdz_zIGJRcb3CRIg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">621</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">13,918</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzSdz_zFKUFZFpa7C7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Income tax expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,700</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,450</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">SCHEDULE OF NET DEFERRED TAX ASSETS</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zTZ3FR6D4M28" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s net deferred tax assets were comprised of the following as of December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zgbOpEyrc719" style="display: none">SCHEDULE
OF NET DEFERRED TAX ASSETS</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20241231_zSXUmyXbCTaa" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20231231_zPRpDyGVFAnc" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_zWysNROiBnZc" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Net operating losses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">53,447,116</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">51,846,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_z8ThOyPpXaTg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Capitalized research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,959,591</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,162,872</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_zF0phi160nWh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">288,756</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">261,052</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_iI_znJ534kLTMp9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">249,495</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">220,923</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsFrequentFlierLiability_iI_zCqjP36GDjka" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,760</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,761</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOther_iI_zQs0zjhFqFxi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">616</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">559</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzCTx_maDTALNzH2X_zZEfUKkg0W1c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total gross deferred tax assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">56,963,334</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">54,528,167</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_iNI_di_maDITLzRZ0_zFirxZXVNsc9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Right-of-use asset</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(17,340</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(36,373</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzRZ0_msDTALNzH2X_zpMKSOQ73S11" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Gross deferred tax liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(17,340</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(36,373</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzH2X_zkcee1TRsfmf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: Deferred tax asset valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(56,945,994</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(54,491,794</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzH2X_zl5cYOCzlixj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0840">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0841">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437117510160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">SCHEDULE OF REPORTABLE SEGMENT LOSS</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z0dognWGcGM3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents reportable segment loss, including significant expenses regularly provided to the CODM, attributable to the
Company&#8217;s reportable segment for the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zl3YUgJxanE2">SCHEDULE
OF REPORTABLE SEGMENT LOSS</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zsOxoeSs6ydl" style="border-bottom: Black 1pt solid; display: none; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zEZZk0RK9w59" style="border-bottom: Black 1pt solid; display: none; text-align: center">2023</td><td style="display: none; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ResearchAndDevelopmentExpense_hus-gaap--IncomeStatementLocationAxis__custom--ExternalResearchAndDevelopmentMember_zepfhC2OeXt" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">External research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,355,449</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,683,828</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ResearchAndDevelopmentExpense_hus-gaap--IncomeStatementLocationAxis__custom--InternalPersonnelCostsMember_zVnbDcks6oOk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Internal personnel costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,895,648</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,937,879</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_msNILz3BM_z0uL5JaqY5t9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,251,097</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,621,707</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_msNILz3BM_zffPC4pkaJCc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,114,654</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,756,767</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherOperatingIncomeExpenseNet_iN_di_maNILz3BM_zyLSWk6AqGU1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other income, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(343,724</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(955,003</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_iN_di_mtNILz3BM_zbZuKzFYFBB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,022,027</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,423,471</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437016287968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 16, 2025</div></th>
<th class="th"><div>Nov. 22, 2024</div></th>
<th class="th"><div>Aug. 08, 2024</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,022,027<span></span>
</td>
<td class="nump">$ 15,423,471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,439,183<span></span>
</td>
<td class="nump">45,417,156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,323,188<span></span>
</td>
<td class="nump">$ 13,405,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Net of placement agent cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseOfferingCost', window );">Other offering cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseOfferingCost', window );">Other offering cost</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Equity Purchase Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Purchase ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Includes offering costs of open-end investment companies, and closed-end funds with a continuous offering period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=INDP_EquityPurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=INDP_EquityPurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437009461152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF ANTI-DILUTIVE SECURITIES (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">2,519,419<span></span>
</td>
<td class="nump">1,979,196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">3,935,282<span></span>
</td>
<td class="nump">3,090,787<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437018148704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - Property, Plant and Equipment [Member]<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Computers and Other Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=INDP_ComputersAndOtherOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=INDP_ComputersAndOtherOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=INDP_FurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=INDP_FurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437010515440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PREPAID EXPENSE AND OTHER CURRENT ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_INDP_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Prepaid Expenses And Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 506,489<span></span>
</td>
<td class="nump">$ 554,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_INDP_PrepaidResearchAndDevelopment', window );">Prepaid research and development</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">17,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">175,088<span></span>
</td>
<td class="nump">61,750<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 831,577<span></span>
</td>
<td class="nump">$ 633,156<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_INDP_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">INDP_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>INDP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_INDP_PrepaidResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">INDP_PrepaidResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>INDP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437010527264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 870,229<span></span>
</td>
<td class="nump">$ 806,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued employee costs</a></td>
<td class="nump">1,371,498<span></span>
</td>
<td class="nump">1,213,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">72,054<span></span>
</td>
<td class="nump">39,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_INDP_AccruedResearchAndDevelopmentCurrent', window );">Accrued research and development</a></td>
<td class="nump">860,958<span></span>
</td>
<td class="nump">439,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_INDP_AccruedBoardFeesCurrent', window );">Accrued board fees</a></td>
<td class="nump">117,750<span></span>
</td>
<td class="nump">117,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_INDP_DelawareFranchiseTaxesPayableCurrent', window );">Delaware franchise taxes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">17,228<span></span>
</td>
<td class="nump">17,330<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Total accounts payable and other current liabilities</a></td>
<td class="nump">$ 3,309,717<span></span>
</td>
<td class="nump">$ 2,672,327<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_INDP_AccruedBoardFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued board fees current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">INDP_AccruedBoardFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>INDP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_INDP_AccruedResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">INDP_AccruedResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>INDP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_INDP_DelawareFranchiseTaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Delaware franchise taxes payable current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">INDP_DelawareFranchiseTaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>INDP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437016322528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTION ACTIVITY (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, outstanding balance</a></td>
<td class="nump">2,050,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding, balance</a></td>
<td class="nump">$ 10.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value, outstanding balance</a></td>
<td class="nump">$ 36,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, granted</a></td>
<td class="nump">838,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted</a></td>
<td class="nump">$ 1.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue', window );">Intrinsic value, granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, forfeited and cancelled</a></td>
<td class="num">(625)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, forfeited and cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, outstanding balance</a></td>
<td class="nump">2,887,822<span></span>
</td>
<td class="nump">2,050,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, balance</a></td>
<td class="nump">$ 8.06<span></span>
</td>
<td class="nump">$ 10.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value, Outstanding, balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 36,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, exercisable</a></td>
<td class="nump">1,854,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable</a></td>
<td class="nump">$ 11.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, Exercisable</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value, outstanding balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of options, vested and expected to vest</a></td>
<td class="nump">2,887,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, vested and expected to vest</a></td>
<td class="nump">$ 8.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life (in years), vested and expected to vest</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Intrinsic value, vested and expected to vest balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437016242768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK BASED COMPENSATION EXPENSES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,305,849<span></span>
</td>
<td class="nump">$ 2,965,938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">624,480<span></span>
</td>
<td class="nump">792,273<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 1,681,369<span></span>
</td>
<td class="nump">$ 2,173,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437114532496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF WEIGHTED AVERAGE INPUTS USED TO MEASURE VALUE OF OPTIONS GRANTED (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 1.54<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">114.78%<span></span>
</td>
<td class="nump">110.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437016339872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding</a></td>
<td class="nump">2,887,822<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=INDP_ExercisePriceRangeOneMember', window );">Exercise Price Range One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding</a></td>
<td class="nump">1,861,499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=INDP_ExercisePriceRangeTwoMember', window );">Exercise Price Range Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding</a></td>
<td class="nump">992,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=INDP_ExercisePriceRangeThreeMember', window );">Exercise Price Range Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding</a></td>
<td class="nump">34,073<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=INDP_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=INDP_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=INDP_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=INDP_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=INDP_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=INDP_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437008785536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS (Details) (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=INDP_ExercisePriceRangeOneMember', window );">Exercise Price Range One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price range lower range limit</a></td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price range upper range limit</a></td>
<td class="nump">8.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=INDP_ExercisePriceRangeTwoMember', window );">Exercise Price Range Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price range lower range limit</a></td>
<td class="nump">8.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price range upper range limit</a></td>
<td class="nump">16.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=INDP_ExercisePriceRangeThreeMember', window );">Exercise Price Range Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price range lower range limit</a></td>
<td class="nump">$ 16.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=INDP_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=INDP_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=INDP_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=INDP_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=INDP_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=INDP_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437018994704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based compensation, not yet recognized</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based compensation, not yet recognized, term</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of stock options issued</a></td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="nump">$ 1.43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437008133840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITALIZATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 12, 2025</div></th>
<th class="th"><div>Jan. 16, 2025</div></th>
<th class="th"><div>Nov. 22, 2024</div></th>
<th class="th"><div>Aug. 08, 2024</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 11, 2025</div></th>
<th class="th"><div>Aug. 06, 2024</div></th>
<th class="th"><div>Sep. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,013,901<span></span>
</td>
<td class="nump">8,401,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,013,901<span></span>
</td>
<td class="nump">8,401,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Fair value of a warrant to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,675,853<span></span>
</td>
<td class="nump">3,090,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,510,591<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.175<span></span>
</td>
<td class="nump">$ 1.825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseOfferingCost', window );">Noninterest expense offering cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Purchase ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 354,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseOfferingCost', window );">Noninterest expense offering cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Fair value of a warrant to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,817,017<span></span>
</td>
<td class="nump">1,643,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,109,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,109,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=INDP_AtTheMarketOfferingAgreementMember', window );">At The Market Offering Agreement [Member] | HC Wainwright and Co LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=INDP_StandbyEquityPurchaseAgreementsMember', window );">Standby Equity Purchase Agreements [Member] | Yorkville [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="nump">$ 0.81722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Purchase ordinary shares</a></td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_INDP_NumberOfResaleCommonStockComprised', window );">Number of resale common stock comprised</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_INDP_NumberOfCommitmentShares', window );">Commitment shares issued</a></td>
<td class="nump">305,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=INDP_StandbyEquityPurchaseAgreementsMember', window );">Standby Equity Purchase Agreements [Member] | Yorkville [Member] | Subsequent Event [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_INDP_NumberOfCommitmentSharesToBeIssuedUponCertainConditions', window );">Commitment shares to be issued upon certain conditions</a></td>
<td class="nump">9,694,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=INDP_ExchangeCapMember', window );">Exchange Cap [Member] | Yorkville [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">2,823,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Fair value of a warrant to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,817,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average, remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Fair value of a warrant to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,643,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Purchase ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Standby Equity Purchase Agreements [Member] | Yorkville [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">305,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_INDP_NumberOfCommitmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitment shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">INDP_NumberOfCommitmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>INDP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_INDP_NumberOfCommitmentSharesToBeIssuedUponCertainConditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of commitment shares to be issued upon certain conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">INDP_NumberOfCommitmentSharesToBeIssuedUponCertainConditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>INDP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_INDP_NumberOfResaleCommonStockComprised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of resale common stock comprised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">INDP_NumberOfResaleCommonStockComprised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>INDP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Includes offering costs of open-end investment companies, and closed-end funds with a continuous offering period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=INDP_AtTheMarketOfferingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=INDP_AtTheMarketOfferingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=INDP_HCWainwrightAndCoLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=INDP_HCWainwrightAndCoLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=INDP_StandbyEquityPurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=INDP_StandbyEquityPurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=INDP_YorkvilleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=INDP_YorkvilleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=INDP_ExchangeCapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=INDP_ExchangeCapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437008275824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF MINIMUM LEASE PAYMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Apr. 19, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments in 2025</a></td>
<td class="nump">$ 86,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: amount representing interest</a></td>
<td class="num">(2,698)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liability</a></td>
<td class="nump">84,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 236,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(84,164)<span></span>
</td>
<td class="num">$ (101,705)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 73,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437014541536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 19, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 01, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Operating lease, extend description</a></td>
<td class="text">the lease agreement to extend the lease through October 31, 2025.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 236,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Incremental borrowing rate</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rental expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,847<span></span>
</td>
<td class="nump">$ 100,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,705<span></span>
</td>
<td class="nump">$ 99,254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">CALIFORNIA | Two Year Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_INDP_RateOfIncreaseInLeaseRent', window );">Rate of increase in lease rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_INDP_RateOfIncreaseInLeaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of increase in lease rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">INDP_RateOfIncreaseInLeaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>INDP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductLiabilityContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductLiabilityContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=INDP_TwoYearLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=INDP_TwoYearLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437014563824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF PROVISION FOR INCOME TAXES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Computed &#8220;expected&#8221; tax benefit</a></td>
<td class="num">$ (3,154,290)<span></span>
</td>
<td class="num">$ (3,238,593)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="num">(11,768)<span></span>
</td>
<td class="nump">1,304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Non-deductible items</a></td>
<td class="nump">230,890<span></span>
</td>
<td class="nump">61,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in deferred tax asset valuation allowance</a></td>
<td class="nump">2,454,200<span></span>
</td>
<td class="nump">2,509,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Stock-based compensation</a></td>
<td class="nump">482,045<span></span>
</td>
<td class="nump">613,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_INDP_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmountReturnToProvisionAdjustments', window );">Return-to-provision adjustments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">41,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">621<span></span>
</td>
<td class="nump">13,918<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 2,450<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_INDP_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmountReturnToProvisionAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation share based compensation excess tax benefit amount return to provision adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">INDP_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmountReturnToProvisionAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>INDP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479176/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437008165072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF NET DEFERRED TAX ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 53,447,116<span></span>
</td>
<td class="nump">$ 51,846,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">2,959,591<span></span>
</td>
<td class="nump">2,162,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">288,756<span></span>
</td>
<td class="nump">261,052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals</a></td>
<td class="nump">249,495<span></span>
</td>
<td class="nump">220,923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsFrequentFlierLiability', window );">Operating lease liabilities</a></td>
<td class="nump">17,760<span></span>
</td>
<td class="nump">36,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">616<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">56,963,334<span></span>
</td>
<td class="nump">54,528,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_INDP_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="num">(17,340)<span></span>
</td>
<td class="num">(36,373)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(17,340)<span></span>
</td>
<td class="num">(36,373)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Deferred tax asset valuation allowance</a></td>
<td class="num">(56,945,994)<span></span>
</td>
<td class="num">(54,491,794)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_INDP_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">INDP_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>INDP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsFrequentFlierLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from frequent flier obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsFrequentFlierLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437007992144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance change amount</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationDescription', window );">Income tax examination description</a></td>
<td class="text">greater than 50% likely of being realized upon settlement<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits, income tax penalties and interest accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">ISRAEL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">197,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=INDP_FederalMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">35,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=INDP_FederalMember', window );">Federal [Member] | Expire In 2036 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=INDP_FederalMember', window );">Federal [Member] | Indefinite Period [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">34,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=INDP_StateMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">7,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=INDP_StateMember', window );">State [Member] | Expire In 2035 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 7,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=INDP_FederalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=INDP_FederalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=INDP_ExpireInTwoThousandThirtySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=INDP_ExpireInTwoThousandThirtySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=INDP_IndefinitePeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=INDP_IndefinitePeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=INDP_StateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=INDP_StateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=INDP_ExpireInTwoThousandThirtyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=INDP_ExpireInTwoThousandThirtyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437120729360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF REPORTABLE SEGMENT LOSS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development</a></td>
<td class="nump">$ 7,251,097<span></span>
</td>
<td class="nump">$ 7,621,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">8,114,654<span></span>
</td>
<td class="nump">8,756,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income, net</a></td>
<td class="num">(343,724)<span></span>
</td>
<td class="num">(955,003)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">15,022,027<span></span>
</td>
<td class="nump">15,423,471<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=INDP_ExternalResearchAndDevelopmentMember', window );">External Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development</a></td>
<td class="nump">4,355,449<span></span>
</td>
<td class="nump">4,683,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=INDP_InternalPersonnelCostsMember', window );">Internal Personnel Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development</a></td>
<td class="nump">$ 2,895,648<span></span>
</td>
<td class="nump">$ 2,937,879<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=INDP_ExternalResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=INDP_ExternalResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=INDP_InternalPersonnelCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=INDP_InternalPersonnelCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46437014362848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>Integer</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>70
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M#+K4RK2*S(!AHS_WA4RH;(E,_'[Q <VHFW#9SI3(8"6'A2&+WB'Y)Q;,?;I
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M,,T+\(F5K,XYN+7A%#@#WVZOP?NWOUS.M'F5=9CEV["?-F'Q2-AKGI\#@J8
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M66GKCAH:CY3<$&6C4<TVRKDIL]$-$_8USHS"IPSS3#R10DO.4FH@);>44Y$
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MJCI'5!TCBW(KGDN#&WO9S/#L!<H&X/.%E.:I8W?WYC07_P502P,$%     @
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M.Z.:=%234:H_4P%SPQNFI(!-Q;2Q<[6E+K(M5GI"8H)QG";Q!5F'79:D63I
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M+:&7I\H:P/>5E.;P8 ?H_AU8_ =02P,$%     @ TCMM6O1- TL'!@  )B8
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M 7:S@\]4:03/KP/FE/D:8%UB00+/?'J M>P"N^E%DW<KP3<YO**@^;,U>*T
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MY@5X/];H=NH!*VBN4T__!E!+ P04    " #2.VU:FEMS*(H%  "/"P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6R-5MMN&S<0?==7#)0T2 !%-SM.
MZAM@)TX:(!<C2=N'H@_4<J1ES"4W)-?RYNM[AKN2E<)Q^V!K>9GAF7-FACQ>
M^W 52^9$-Y5U\618IE0?3B:Q*+E2<>QK=EA9^E"IA&%836(=6.EL5-G)?#H]
MF%3*N.'I<9Z[#*?'ODG6.+X,%)NJ4J$]9^O7)\/9<#/QR:S*)!.3T^-:K?@S
MI]_KRX#19.M%FXI=--Y1X.7)\&QV>+XO^_.&/PROX\XW220+[Z]D\%:?#*<"
MB"T723PH_%SS2[96' '&M][G<'ND&.Y^;[R_SK$CEH6*_-+;/XU.Y<GPQ9 T
M+U5CTR>__HW[>)Z)O\+;F/_3NM\['5+1Q.2KWA@(*N.Z7W73\_!_#.:]P3SC
M[@[**%^II$Z/@U]3D-WP)A\YU&P-<,:)*)]3P*J!73I]<_'AXM/9N^-)@C.9
MFA2]X7EG./^)X6Q.[[U+9:0+IUG_Z& "%%LH\PV4\_F]'E]Q,::]V8CFT_G^
M/?[VMJ'M97][/_'W,:R4,]^5J#^BE]Y%;XU673(X39>!([O43?@EO39.N<(H
M2Y\QR<B\%.FOLT5, ;GS]UT4=0#V[P8@]708:U7PR;"6L\(U#T\?/9@=3(_N
M"6]_&][^?=[O4^Y>P[MA??CXY6(P.Z3>*[UU6M6IB8,O)0=5<Y-,$4>8AD9"
MG@$WZ]);VS[U:\<:5;V(1AL5#&,?M/0MG1L?VP@J=RW?NL0%798*-47ODAZ/
M"$F<J_2:;4N/4\GTZ,&+^7QZ]-)7M7)M'LV.GHP&)I*BA?%P43IO_:J%<=Z#
M4M2F@&Z:DB=VI6CI5OE(OL$.+:.B"4K.H0++',A45>-\RC&VA!Y'-=:S\FN3
M2FJ<,%0DM;!,6*TXJ2@I4PQR-E%J*A]B/L6V55UZM,P1F#%%22HP^E:LD7E&
M[,4]=C,E@*-?I[](UBEK-V T*]33F$ Y]9$3 M8,7GR=@R'G,1A1A:9CGB85
M5HR(!W7PNBF2.$Y=HP,1D1:(C(QS&&2$2C25Z)43:X'>S<OPV@2D?B9D"YN!
MYI.)5W$@VQI!F=#HP5 4E(,=E-#_*PL$+RB;:H& $%X0:XJF,E8%64RECRPK
MF?5>/?&'J<VV:+XS<.<D,TZC"X9VA*_"-J+BB!9- A.)+ PD_N1')&GC&/(+
MS;$I"HYQV=@-?5+.<D9/5?R7@=+:2"-0HD9M$GX?8WK9]02W>B+8EPU8P'T8
M<L^(]#@RTT(NMB>C' FG[&2P#+[*%8%Q _(WAV:VI>(,T%'>947#'1Y&LCGU
M=U:'MT9-0>J6;K-^)'DJ$5D<N.I;G#C7C.M:,Y0:P/Z*6R'07!O=* LQWWC$
M,BB\*-EUP4HY7+["CE39[/E1I-HJ]Z.^I1(A4#P!=#D\%:R/2([L )W!0B\-
MWJ)DVRY!$4:B9,&U3(P)-VGFO67(+$"UM K.V;)I_9TRV]3JCQVH[<&Y;&H0
M<V-P+4O/>$BS9^,I'4S'^S2;C_?H '^S\4PZN=.+=G#QK3&II<LF%(B%Z6P5
M. =-=1-B@P(0?;NRW3U= I=QD,O]-N]DRB_LEGG8XJ%AJ:GE\R'" )KE8,?3
MEEP(74$97.S%%9VAL*364,T2%/8#VP]EELE R^@J#*T'L\A-[9L%*GV!9Q;=
M=8I:0!0$##00.QG7H.BE=ZY\;H-= G2MIMC>C&!YN;T$X^TEJ'V.NBM Z1XM
MZN4KRK);SE4M+36$-G>IRC>N3_;"JAC-4CISS@B1#JG3KUK3 97ZS[UK[1NK
M!STC9OF#%FL$T+C<B?\KK+NNU\G.(ZEB%)T\!44/8.W>2]O9[6OSK'MDW6[O
MGJKO4;,&P5A>PG0Z?OYLV&7(9I!\G9]<:,!XP.7/$B]F#K(!ZTN/$N\'<L#V
M#7[Z#U!+ P04    " #2.VU:N\"H9-80   <+0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6RM6FUO&S<2_KZ_@G!Q10O(LBTG3>R\ ([CI +RXO-+
MB\/A/E"[E,1ZM5277#OJK[]G9LC=E2RYP>&^V)*6',[[/#/<UP^NOO-S8X+Z
MMB@K_V9O'L+R].# YW.ST'[HEJ;"DZFK%SK@:ST[\,O:Z((W+<J#T>'A+P<+
M;:N]MZ_YM\OZ[6O7A-)6YK)6OEDL=+UZ9TKW\&;O:"_]<&5G\T _'+Q]O=0S
M<VW"[?*RQK>#EDIA%Z;RUE6J-M,W>V='I^^>T7I>\)LU#[[W69$D$^?NZ,NX
M>+-W2 R9TN2!*&C\NS?GIBR)$-CX,]+<:X^DC?W/B?H'EAVR3+0WYZ[\W19A
M_F;OY9XJS%0W9;AR#[^:*,]SHI>[TO-?]2!KCT=[*F]\<(NX&1PL;"7_];>H
MA]Z&EX<[-HSBAA'S+0<QE^]UT&]?U^Y!U;0:U.@#B\J[P9RMR"C7H<93BWWA
M[?7XXY?QA_'YV9<;=79^_O7VR\WXRT=U^?73^'Q\<?WZ(. 06GJ01X+OA.!H
M!\&CD?KLJC#WZJ(J3+%.X #<M2R.$HOO1D]2?&_RH3H^&JC1X>C9$_2.6Y&/
MF=[Q#GIG>>Z:*MAJIBY=:7-KO/KWV<2'&B[RGVT2"[UGV^E1V)SZI<[-FSW$
MA3?UO=E[^^,/1[\<OGJ"VV<MM\^>HOZ_&.A)@MO9_?+UYB(;G:J_.4V]T][Z
MS$T5;ZV"YM"ZF9LL=Y6'-@L=3*&FMM)5;G6I/)88!''P"KO"W*ASMUCJ:J7F
M^MZHB3$5T5KJ&MLL16GNZ@*;#0(AS/E[--:RMJ"Y+&&NF:E,K<MR1<_-,LA>
M4,]N*TO?KNE8/O)L86J;:_73CS^\'(T.7]U>JX]G9Y?\[>C5ST-UV9(EN3HQ
MOE\P["^;PK!TD5\^>EP5>AD:KW0%_O";;R;>%E;7<+DA'@=3YU$;$UV2T+(6
MGEAYS6G+LYXRUI,I+3( \]$LP=T:KT-UZPU)8'RP"Y:>N!?=BC1XN(/_1VJ/
M6D+:_;.Q,#523H4<3>M5</AV9WH'$<_:(Z\OA>4PUT'IZ129EXT"'EQ-;.M%
MJQRL-T&VEE9/;&F#C:0*Z_/2^:8V2BQ"YJ>3UQ8R:45F29ZU3;B!*'0'$^8;
MBIL'M:*IR<6(BJQCAX/GN *6@B+5POF@O)U5=@IW C.=^+4IB0OHA3DR,"O;
M*>J<6=.V5O>Z;-A$R.KYW3X5DT*1 X '61UY?4Q#6-DW>.XFI9WIJ&BG<E,'
MU%Y6$R4P18&IZWRN4*EU9?^2I4/UN;.@(4Z(]8R\<K<=F2/\G3E2QX1B7S6>
M/L\M9*"X*EF'<&AR'=KOP'\->7,\%XKD+/A4_(%J)@[W,(<WTQ)>D.6VSIL%
M;,8!4-B<K,=:]VM>!G\0G8$O6PD@8:W=:UOJ20D&VBS3]XN_C>!7M QHP-5F
MD(&M!D^A1A1VC\U-22X);X98M5M@K>OS-52?G/<9E*#\G'A<_SI@O>71L<L&
M/ R4]6QW^D+"$).BW<AQ!32&"/ *+/$/8G\0N+<HJFJRXE\?&'.02]\C'<ZP
MKUE,<#"Y&)T=,]IB@3/8YQ1@&>FY(!OV?%[(#]5[85#.[B0"8Z)X3CO?=;+:
M.#ECW]C@AI(+7%&J0X\S]@]6%A#;D"K&]CTI\?;W1CFC!].I#[I&/F6WL_D\
M8X%D(P0"1A$-!T!:I)Q5)+ P,'.QR0EEU*DK@63IJ)[,3QP*QT*,Q/.B \$G
M=9DW91O?Q7;%3TRN&\^5!?G#2$9]((_,NO*)8^Q^XG'#8WPJU*#]D]!$&.B?
M4>G/?[UX?_OI(OOZ0:':C_??CS_=WHQ_NU#7%^>W5^,;E/OL]PTS9Q\B]152
MC#($\!3@F6$] *)E!-$(IQUG7W?:9#1X?G0R>'9THHX&)R].!D<GOV2_)W4=
M#TZ.GP]&+T?X='AR.'CQ\H4ZUW[._I/CPYH#D#T2GJ H1W!0TBE+)*C9'/"@
MM%A-X.#>M,F'806R4H#_AY6$7&THPS-LA83  C%)+1MD4G9]I-J)><3!4)V1
MJV=])3!.E;I#FAC(IJW\,\^H*X V:(ELR=R@[\KO2&V</%UE5F"VOD-**%":
MO VQ(D7!"<D<O7CEF7K6X@BXG"&V.5E)08;QIZ:(P,E65&"+5VKN'@RL.U@#
M9Q-@#?R*$ L4_94+E.==5$2_#.8@@D6U]7?(**D*9OTT6YMJ!IVGS"Q"N)IY
M"#8TXA:H81R@,3QVJ8RDF)L2R>K&<99?9QS&8FYKDSLP^9<I,OJ9XLJ0BAHO
MZ;.IH@):Y$5($+UN'5;L:W3FDJOECI\3@ $_7$D*@B0YH01V'R"J9D$1C@<0
M&?S8B-/>][YQ)8BI@-*13QF9NA&*O7V"[RD;.=@IHZ>I^- .,VU*^/F]::N'
M<+;F)+2.$M.VG5/3Q0#%-:H.)1+Y>(FUFY'6HJ8E/V2A ;0DJ9(  HB0S<P,
M#A ?:\[734TZ)TV2A>J"0#%LSFLX-.$&$=T+'"D @RQI@[-;/'JHKB+*8:,4
M<-72B5E:YOY^12H?<G@!G)L':BE"J.VD"8PH(JA#H!8-<B\4U>*K3;K+VLUJ
MO5C3A.SU@5$?'(V0_T"2^S;\EU@;0+6K&H5&!?TM C,!5F:Q+-W*4.JOS-22
M8M%5)/#702[@1P0?P36J.LAI]2YU\%R$,76?\1Q^Q_ N"!W:!0&G<&TP2F&-
MQM%RV)R5T<;D>(X<&T=REMVI*HB?15F+OF,,U_P,(50W1D!0:S3!9<0BU](^
M&I9BKF=PY%ZJ_QM@W#:&YU=??>H*!^VN#(U/0U!5P-*.K9_[6SMC$2Y!24JZ
M(@7>2XDBD23;P="LDBE !9S0<?:"_6(BC&4\H]"/.Y+FJ5)UAJ8\%.D7R6NC
M(F$BTF1:)8''F2^"Z0YCDYLF\EAG$',2K< >Z(J\6(TVHS+Z1DL[N*ER4N5
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M<VAE971S+W-H965T,38N>&ULE59I;^,V$/WN7S'P+A9;0.M#<1P[FP1PKM9
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ME ? +B\HZ+1<[9T.EWG/FB],SBF-:H.F,4NY+DL5$@\ E[C6I&SVTK06,I4
M95B+?G.=EA& 6E24QSP[)D);CO*;)<ASJ3)$8(*J=N2TU(PO%EHL*/%;53#M
M*,1Q![92I(9Z#ZW%UDJZW?%)Z%(!D 1:;D@W3L,V!RT:OSVZ/F<']F6-L8$
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MV/9.C#017A&X)_+4 15SKIY5J9]&E7IX*M9^>&O1]&[[[H'052ZK[LZ[!5J
M>9-D'-3D%OK&%H,LX:SGA)JNG+>%I>6%7FP35](.T4R"WS*J7#L>\ F_-9IC
M]6I):=!P^A^EL[=K1/I)L-VU_$CF!:W69>A[0W@J])-,W(5'T54V," <-!+S
MQGD6EJ5QMR>54+F:#=KV3O.X\;YYA:GDWJK36SETI7_U7'];O[B_].^KM\?]
M6_^O:&D0/Z[A<XCVNB?##M/^3;I_L&KMWE[/E+5JY3XN!4?<= !_GRMEJP<R
M4/]WQL7_ 5!+ P04    " #2.VU:IT(R8U,%  #&"P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6R-5MMNVS@0?==7$&Y1M(#JBRQ;=IH8R,5M S1Q
MX*2[6"SV@9;&%E&)5$G*3OY^9TA9=;9.L ^)27'FS)DSP\OI3ND?)@>P[+$L
MI#GKY-96)[V>27,HN>FJ"B2NK)4NN<6IWO1,I8%GSJDL>E&_/^Z57,C.[-1]
MN].S4U7;0DBXT\S49<GUTP44:G?6&73V'Y9BDUOZT)N=5GP#]V"_5W<:9[T6
M)1,E2".49!K69YWSP<E%3/;.X \!.W,P9I3)2JD?-+G.SCI](@0%I)80./YL
MX1**@H"0QL\&L].&),?#\1[]L\L=<UEQ Y>J^%-D-C_K3#HL@S6O"[M4NZ_0
MY#,BO%05QOUG.V\;33LLK8U59>.,#$HA_2]_;'0X<)CT7W"(&H?(\?:!',LK
M;OGL5*L=TV2-:#1PJ3IO)"<D%>7>:EP5Z&=G]_,O-_/;!W9]^WFQO#E_N%[<
MGO8L M-R+VU +CQ(] +((&(W2MK<L+G,('L.T$-&+:UH3^LB>A7Q"M(N&PY"
M%O6C^!6\89OFT.$-7TH3-MA)EBVA4MH*N6%_GZ^,U=@4_QS+UZ/%Q]%HHYR8
MBJ=PUL&=8$!OH3-[]V8P[G]ZA6O<<HU?0_^_)7D5Y#C%V\7#/)B>L",1V*("
MS4F9P'BM#.,:J,$1.6/<L%25E9)N1:T9EPR'PCXQOL+-SG:Y2'-FH.((@W["
MI!IP(*0_.6@+"L3<<E'P50$,/S/8\J+V:ZLG9G-@:2Y@S51+)H-4N .@Y#]
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MMA)'X_VM):X-AY+V]LEX^/K)^U:;G;#;CV;_PMT3(I\\):\ZWUM.BESYZAA
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M+W=O<FMS:&5E=',O<VAE970R,2YX;6Q]E6UOVC 0Q]_S*4Z9-+42:QZ@#W2
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MEBL:IL9,Z>^%0CO0^X1S==KH!,W_</034$L#!!0    ( -([;5H=)^S5&P4
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M"E^2E=<,C$@70#6"<D8$VSH!9L+>0@MJ/_8*_INRRE0[,K?U^LHD5Y[V$MY
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MO^2F]JCT(6^.3[%7E)!R*DJI, .^ +5"VE%0=>?5L@<[WM9)WA:5E+'\@4P
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MZ$IAABNZPZ'0&^C]@G.UFV@'^UMA_W]02P,$%     @ TCMM6M #1@MD P
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M0)54A*;X756Z1'W.,5V"'G]#=YDIW.=;2%^ _SPDX<D(^D)?B@R'T+/4C17
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M7!NH_05C<C/1 :I^+?@-4$L#!!0    ( -([;5H,4Z9P: (   X'   9
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M Z8"Y/LUI>*EH0X![:$O^@U02P,$%     @ TCMM6DL2])*L!   G!<  !D
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M [I"+T]WZ.+7#P-32-<*P/0R-[>I&WS$C8W19QJ+!4?WL0_^/H I8\X#Q]O
M;[$6\0Z\%FK;EPA;N%,1T/A\\[8FG':>QW:"USZ6QP5A<'4K"\I'C^1-%KI
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MC&2/"$QMD.]7E(J'B6I;JJ[3_0U02P,$%     @ TCMM6N?!(6,/ P  &0L
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M* &R:"'%1(O<5N&YT%33[7!%71>E,:#]A1!Z-S$'5'T\_ -02P,$%     @
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M37Y*:EV>,5279]A?BRWB\D%HU]&*/=6O[KCKA@_5+%2S4<U!-1?5/%3S42U
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M17EQ\>8RXTQ+UGE6SD07&Z-W6B[216M(T%MDH)IUY#V;+W^76[<V;VWIH._
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MZ3WM-LGS9+'Y\E%$=R(M%RA^?I\D^>N+LH/G8LNY&?;E?P%02P,$%     @
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M[H8535$Q$333;<*,"METZ.%*]I&(J07R_H)2\3I1G4?5F8;_ 5!+ P04
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M 0J!I)J7:P2Q*Z9L =<J4:5BZL$^C8(PC#$F W=_&HS%$/=#XGE>8_@"-&Q
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MDVF^5U_!Y#\=7!*YHEPA!DL#&1P-#$>9[\;G)UJDV8;V0F@MDNQP#<3X)ON
MN;\40C^>V '*WT0F_P)02P,$%     @ TCMM6DWKF51! P  % H  !D   !X
M;"]W;W)K<VAE971S+W-H965T-#4N>&ULK9;);MLP$(9?A5"+(@62:%^<V@;B
M)0L0)X:=M(>B!T8:6T(D4B5I.WW[DI(B+Y&%%LC%%JF9?[[AD.)T-Y2]\!A
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MDM##*M"@#&0="61::$*)B#D:DPBB?0%=4M?HUAOZP&I5'$%XCFSS%%F&Y30
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M[RC1;5NT$U2-+\6M0EO8?EC9/PEH%V#W=TKA>>(.Z/Y-V5]02P,$%     @
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M8$@45>_!G?=1N'I/A>O_=0Y_ U!+ P04    " #2.VU:EXJ[',     3 @
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M3P894+DV("\ R N[D E]04\2)4QT?]=OY)3+HFKD3C #\2. ^-$N(JDE+YE
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MX_/?276ZW1N>C[\O'R<[[_@=9P=_[!:_4$L#!!0    ( -([;5HF^H>GM0$
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M_Z9VC6M5-D=_UOW4FW\"4$L! A0#%     @ TCMM6@=!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #2
M.VU:$\_NQNX    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " #2.VU:F5R<(Q &  "<)P  $P
M@ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( -([;5H%54;1
MZP<  &,T   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " #2.VU:<7CGF:(%  #V&   &
M@($N$   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ TCMM
M6K/<&+[= @  V0D  !@              ("!!A8  'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    ( -([;5HWU)%I>@0  "D0   8
M      " @1D9  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M" #2.VU:]$T#2P<&   F)@  &               @(')'0  >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ TCMM6I8RA_A*!@  !1P  !@
M             ("!!B0  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    ( -([;5J, /BU2@(  *,%   8              " @88J  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #2.VU:X15B(4,"  "0
M!@  &               @($&+0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ TCMM6B@#34)_!@  6A4  !@              ("!?R\
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( -([;5J:6W,H
MB@4  (\+   9              " @30V  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ TCMM6KO J&36$   '"T  !D
M ("!]3L  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " #2
M.VU:@1*R9N,"  #"!@  &0              @($"30  >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( -([;5JC#P0+0@,  #T'   9
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M970Q-RYX;6Q02P$"% ,4    " #2.VU:IT(R8U,%  #&"P  &0
M    @('3;P  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M -([;5JHTHH1*P,  %('   9              " @5UU  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ TCMM6JF\;E[U$0  .S4  !D
M             ("!OW@  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    " #2.VU:460S:A #  !$!@  &0              @('KB@  >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( -([;5HCX[-OZ0(
M *0&   9              " @3*.  !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ TCMM6F35:@U% P  &P<  !D              ("!
M4I$  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " #2.VU:
M'2?LU1L%  #4#   &0              @('.E   >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    ( -([;5IG>@IC#@,  *T&   9
M      " @2":  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ TCMM6CL>U@R-!   (0H  !D              ("!99T  'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #2.VU:T -&"V0#   9!P
M&0              @($IH@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    ( -([;5H6>)L X@0  #LC   9              " @<2E  !X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ TCMM6LY#2 8!
M P  NPD  !D              ("!W:H  'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    " #2.VU:#%.F<&@"   .!P  &0
M@($5K@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( -([
M;5H@_WS3MP(  "T'   9              " @;2P  !X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL4$L! A0#%     @ TCMM6I'=]P9B P    H  !D
M         ("!HK,  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
M    " #2.VU:2Q+TDJP$  "<%P  &0              @($[MP  >&PO=V]R
M:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( -([;5IF-,R=30,  - +
M   9              " @1Z\  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL
M4$L! A0#%     @ TCMM6F= 8#<7 P  D @  !D              ("!HK\
M 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " #2.VU:@?V#
M1-L"  "!"@  &0              @('PP@  >&PO=V]R:W-H965T<R]S:&5E
M=#,V+GAM;%!+ 0(4 Q0    ( -([;5KGP2%C#P,  !D+   9
M  " @0+&  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @
MTCMM6CZEH._F @  TP<  !D              ("!2,D  'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6Q02P$"% ,4    " #2.VU:Z[4)C=D-  !1O   &0
M            @(%ES   >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4
M Q0    ( -([;5KXL?:#(@,  *4*   9              " @77:  !X;"]W
M;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ TCMM6IOV4TY7!
M'A4  !D              ("!SMT  'AL+W=O<FMS:&5E=',O<VAE970T,2YX
M;6Q02P$"% ,4    " #2.VU:M',A,J4#  !O"@  &0              @(%<
MX@  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( -([;5H<
M;PFCN0,   <,   9              " @3CF  !X;"]W;W)K<VAE971S+W-H
M965T-#,N>&UL4$L! A0#%     @ TCMM6I8740V2!   'QD  !D
M     ("!*.H  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4
M" #2.VU:3>N95$$#   4"@  &0              @('Q[@  >&PO=V]R:W-H
M965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( -([;5J9*COU,P(  *<$   9
M              " @6GR  !X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L!
M A0#%     @ TCMM6BTQYG=) P  ^!0   T              ( !T_0  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " #2.VU:EXJ[',     3 @  "P
M        @ %'^   7W)E;',O+G)E;'-02P$"% ,4    " #2.VU:+:\3CVL$
M  #T'@  #P              @ $P^0  >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ TCMM6OTLU:6N 0  P1L  !H              ( !R/T  'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ TCMM6B;ZAZ>U 0
MW!L  !,              ( !KO\  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     #8 -@"Q#@  E $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>88</ContextCount>
  <ElementCount>245</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>35</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>999014 - Disclosure - GENERAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/General</Role>
      <ShortName>GENERAL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999015 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/SignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999016 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/PrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999017 - Disclosure - ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/AccountsPayableAndOtherCurrentLiabilities</Role>
      <ShortName>ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999018 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/Stock-basedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999019 - Disclosure - CAPITALIZATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/Capitalization</Role>
      <ShortName>CAPITALIZATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999020 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999021 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999022 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/SegmentInformation</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999023 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999024 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999025 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://indaptusrx.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999026 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://indaptusrx.com/role/PrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999027 - Disclosure - ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/AccountsPayableAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://indaptusrx.com/role/AccountsPayableAndOtherCurrentLiabilities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999028 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/Stock-basedCompensationTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://indaptusrx.com/role/Stock-basedCompensation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://indaptusrx.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999030 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://indaptusrx.com/role/IncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999031 - Disclosure - SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/SegmentInformationTables</Role>
      <ShortName>SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://indaptusrx.com/role/SegmentInformation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999032 - Disclosure - GENERAL (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/GeneralDetailsNarrative</Role>
      <ShortName>GENERAL (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://indaptusrx.com/role/General</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999033 - Disclosure - SCHEDULE OF ANTI-DILUTIVE SECURITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails</Role>
      <ShortName>SCHEDULE OF ANTI-DILUTIVE SECURITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999034 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/SignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://indaptusrx.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999035 - Disclosure - SCHEDULE OF PREPAID EXPENSE AND OTHER CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails</Role>
      <ShortName>SCHEDULE OF PREPAID EXPENSE AND OTHER CURRENT ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999036 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999037 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/ScheduleOfStockOptionActivityDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTION ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999038 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/ScheduleOfStockBasedCompensationExpensesDetails</Role>
      <ShortName>SCHEDULE OF STOCK BASED COMPENSATION EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999039 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE INPUTS USED TO MEASURE VALUE OF OPTIONS GRANTED (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/ScheduleOfWeightedAverageInputsUsedToMeasureValueOfOptionsGrantedDetails</Role>
      <ShortName>SCHEDULE OF WEIGHTED AVERAGE INPUTS USED TO MEASURE VALUE OF OPTIONS GRANTED (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999040 - Disclosure - SCHEDULE OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetails</Role>
      <ShortName>SCHEDULE OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999041 - Disclosure - SCHEDULE OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetailsParenthetical</Role>
      <ShortName>SCHEDULE OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999042 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://indaptusrx.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999043 - Disclosure - CAPITALIZATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/CapitalizationDetailsNarrative</Role>
      <ShortName>CAPITALIZATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://indaptusrx.com/role/Capitalization</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999044 - Disclosure - SUMMARY OF MINIMUM LEASE PAYMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/SummaryOfMinimumLeasePaymentsDetails</Role>
      <ShortName>SUMMARY OF MINIMUM LEASE PAYMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999045 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://indaptusrx.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999046 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/ScheduleOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>SCHEDULE OF PROVISION FOR INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999047 - Disclosure - SCHEDULE OF NET DEFERRED TAX ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/ScheduleOfNetDeferredTaxAssetsDetails</Role>
      <ShortName>SCHEDULE OF NET DEFERRED TAX ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999048 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://indaptusrx.com/role/IncomeTaxesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999049 - Disclosure - SCHEDULE OF REPORTABLE SEGMENT LOSS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/ScheduleOfReportableSegmentLossDetails</Role>
      <ShortName>SCHEDULE OF REPORTABLE SEGMENT LOSS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999050 - Disclosure - SEGMENT INFORMATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://indaptusrx.com/role/SegmentInformationDetailsNarrative</Role>
      <ShortName>SEGMENT INFORMATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://indaptusrx.com/role/SegmentInformationTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="form10-k.htm">form10-k.htm</File>
    <File>indp-20241231.xsd</File>
    <File>indp-20241231_cal.xml</File>
    <File>indp-20241231_def.xml</File>
    <File>indp-20241231_lab.xml</File>
    <File>indp-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>fin_001.jpg</File>
    <File>form10-k_0001.jpg</File>
    <File>form10-k_0002.jpg</File>
    <File>form10-k_0003.jpg</File>
    <File>form10-k_0004.jpg</File>
    <File>form10-k_0005.jpg</File>
    <File>form10-k_006.jpg</File>
    <File>form10-k_007.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="421">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>77
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-k.htm": {
   "nsprefix": "INDP",
   "nsuri": "http://indaptusrx.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    },
    "schema": {
     "local": [
      "indp-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "indp-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "indp-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "indp-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "indp-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 222,
   "keyCustom": 23,
   "axisStandard": 15,
   "axisCustom": 0,
   "memberStandard": 15,
   "memberCustom": 19,
   "hidden": {
    "total": 64,
    "http://xbrl.sec.gov/dei/2024": 7,
    "http://fasb.org/us-gaap/2024": 48,
    "http://indaptusrx.com/20241231": 9
   },
   "contextCount": 88,
   "entityCount": 1,
   "segmentCount": 35,
   "elementCount": 474,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 421,
    "http://xbrl.sec.gov/dei/2024": 40,
    "http://xbrl.sec.gov/cyd/2024": 8,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://indaptusrx.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://indaptusrx.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://indaptusrx.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss",
     "longName": "00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://indaptusrx.com/role/StatementsOfStockholdersEquity",
     "longName": "00000005 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://indaptusrx.com/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-10-012024-12-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-012024-12-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://indaptusrx.com/role/General",
     "longName": "999014 - Disclosure - GENERAL",
     "shortName": "GENERAL",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://indaptusrx.com/role/SignificantAccountingPolicies",
     "longName": "999015 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://indaptusrx.com/role/PrepaidExpensesAndOtherCurrentAssets",
     "longName": "999016 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "INDP:PrepaidExpenseAndOtherCurrentAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "INDP:PrepaidExpenseAndOtherCurrentAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://indaptusrx.com/role/AccountsPayableAndOtherCurrentLiabilities",
     "longName": "999017 - Disclosure - ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES",
     "shortName": "ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://indaptusrx.com/role/Stock-basedCompensation",
     "longName": "999018 - Disclosure - STOCK-BASED COMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://indaptusrx.com/role/Capitalization",
     "longName": "999019 - Disclosure - CAPITALIZATION",
     "shortName": "CAPITALIZATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "INDP:CapitalizationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "INDP:CapitalizationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://indaptusrx.com/role/CommitmentsAndContingencies",
     "longName": "999020 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://indaptusrx.com/role/IncomeTaxes",
     "longName": "999021 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://indaptusrx.com/role/SegmentInformation",
     "longName": "999022 - Disclosure - SEGMENT INFORMATION",
     "shortName": "SEGMENT INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://indaptusrx.com/role/SubsequentEvents",
     "longName": "999023 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies",
     "longName": "999024 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://indaptusrx.com/role/SignificantAccountingPoliciesTables",
     "longName": "999025 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://indaptusrx.com/role/PrepaidExpensesAndOtherCurrentAssetsTables",
     "longName": "999026 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "INDP:ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "INDP:PrepaidExpenseAndOtherCurrentAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "INDP:ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "INDP:PrepaidExpenseAndOtherCurrentAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://indaptusrx.com/role/AccountsPayableAndOtherCurrentLiabilitiesTables",
     "longName": "999027 - Disclosure - ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES (Tables)",
     "shortName": "ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://indaptusrx.com/role/Stock-basedCompensationTables",
     "longName": "999028 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://indaptusrx.com/role/CommitmentsAndContingenciesTables",
     "longName": "999029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://indaptusrx.com/role/IncomeTaxesTables",
     "longName": "999030 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://indaptusrx.com/role/SegmentInformationTables",
     "longName": "999031 - Disclosure - SEGMENT INFORMATION (Tables)",
     "shortName": "SEGMENT INFORMATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://indaptusrx.com/role/GeneralDetailsNarrative",
     "longName": "999032 - Disclosure - GENERAL (Details Narrative)",
     "shortName": "GENERAL (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://indaptusrx.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails",
     "longName": "999033 - Disclosure - SCHEDULE OF ANTI-DILUTIVE SECURITIES (Details)",
     "shortName": "SCHEDULE OF ANTI-DILUTIVE SECURITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://indaptusrx.com/role/SignificantAccountingPoliciesDetailsNarrative",
     "longName": "999034 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_PropertyPlantAndEquipmentMember_custom_ComputersAndOtherOfficeEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_PropertyPlantAndEquipmentMember_custom_ComputersAndOtherOfficeEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://indaptusrx.com/role/ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails",
     "longName": "999035 - Disclosure - SCHEDULE OF PREPAID EXPENSE AND OTHER CURRENT ASSETS (Details)",
     "shortName": "SCHEDULE OF PREPAID EXPENSE AND OTHER CURRENT ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "INDP:ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock",
       "INDP:PrepaidExpenseAndOtherCurrentAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "INDP:ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock",
       "INDP:PrepaidExpenseAndOtherCurrentAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails",
     "longName": "999036 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES (Details)",
     "shortName": "SCHEDULE OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://indaptusrx.com/role/ScheduleOfStockOptionActivityDetails",
     "longName": "999037 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)",
     "shortName": "SCHEDULE OF STOCK OPTION ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://indaptusrx.com/role/ScheduleOfStockBasedCompensationExpensesDetails",
     "longName": "999038 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION EXPENSES (Details)",
     "shortName": "SCHEDULE OF STOCK BASED COMPENSATION EXPENSES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://indaptusrx.com/role/ScheduleOfWeightedAverageInputsUsedToMeasureValueOfOptionsGrantedDetails",
     "longName": "999039 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE INPUTS USED TO MEASURE VALUE OF OPTIONS GRANTED (Details)",
     "shortName": "SCHEDULE OF WEIGHTED AVERAGE INPUTS USED TO MEASURE VALUE OF OPTIONS GRANTED (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetails",
     "longName": "999040 - Disclosure - SCHEDULE OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS (Details)",
     "shortName": "SCHEDULE OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetailsParenthetical",
     "longName": "999041 - Disclosure - SCHEDULE OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS (Details) (Parenthetical)",
     "shortName": "SCHEDULE OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS (Details) (Parenthetical)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_ExercisePriceRangeOneMember",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_ExercisePriceRangeOneMember",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://indaptusrx.com/role/Stock-basedCompensationDetailsNarrative",
     "longName": "999042 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)",
     "shortName": "STOCK-BASED COMPENSATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://indaptusrx.com/role/CapitalizationDetailsNarrative",
     "longName": "999043 - Disclosure - CAPITALIZATION (Details Narrative)",
     "shortName": "CAPITALIZATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "INDP:CapitalizationTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://indaptusrx.com/role/SummaryOfMinimumLeasePaymentsDetails",
     "longName": "999044 - Disclosure - SUMMARY OF MINIMUM LEASE PAYMENTS (Details)",
     "shortName": "SUMMARY OF MINIMUM LEASE PAYMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "999045 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "From2023-04-192023-04-19",
      "name": "us-gaap:LesseeOperatingLeaseOptionToExtend",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-04-192023-04-19",
      "name": "us-gaap:LesseeOperatingLeaseOptionToExtend",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://indaptusrx.com/role/ScheduleOfProvisionForIncomeTaxesDetails",
     "longName": "999046 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES (Details)",
     "shortName": "SCHEDULE OF PROVISION FOR INCOME TAXES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://indaptusrx.com/role/ScheduleOfNetDeferredTaxAssetsDetails",
     "longName": "999047 - Disclosure - SCHEDULE OF NET DEFERRED TAX ASSETS (Details)",
     "shortName": "SCHEDULE OF NET DEFERRED TAX ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://indaptusrx.com/role/IncomeTaxesDetailsNarrative",
     "longName": "999048 - Disclosure - INCOME TAXES (Details Narrative)",
     "shortName": "INCOME TAXES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://indaptusrx.com/role/ScheduleOfReportableSegmentLossDetails",
     "longName": "999049 - Disclosure - SCHEDULE OF REPORTABLE SEGMENT LOSS (Details)",
     "shortName": "SCHEDULE OF REPORTABLE SEGMENT LOSS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OtherOperatingIncomeExpenseNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://indaptusrx.com/role/SegmentInformationDetailsNarrative",
     "longName": "999050 - Disclosure - SEGMENT INFORMATION (Details Narrative)",
     "shortName": "SEGMENT INFORMATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": null,
     "uniqueAnchor": null
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://indaptusrx.com/role/AccountsPayableAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r39",
      "r42",
      "r672"
     ]
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheets",
      "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and other current liabilities",
        "totalLabel": "Total accounts payable and other current liabilities",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r506"
     ]
    },
    "INDP_AccruedBoardFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "AccruedBoardFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued board fees",
        "documentation": "Accrued board fees current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "INDP_AccruedResearchAndDevelopmentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "AccruedResearchAndDevelopmentCurrent",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued research and development",
        "documentation": "Accrued research and development current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r9",
      "r14",
      "r283",
      "r286",
      "r316",
      "r383",
      "r384",
      "r644",
      "r645",
      "r646",
      "r648",
      "r649",
      "r650",
      "r651"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r506",
      "r729"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r648",
      "r649",
      "r650",
      "r651",
      "r681",
      "r730"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r194"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r556",
      "r567",
      "r581",
      "r607"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r559",
      "r570",
      "r584",
      "r610"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r595"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r602"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r560",
      "r571",
      "r585",
      "r602",
      "r611",
      "r615",
      "r623"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anti-dilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_AreaOfLand": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AreaOfLand",
     "presentation": [
      "http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of land",
        "documentation": "Area of land held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative",
      "http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://indaptusrx.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets [Default Label]",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r79",
      "r96",
      "r115",
      "r141",
      "r147",
      "r152",
      "r155",
      "r165",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r278",
      "r280",
      "r299",
      "r363",
      "r421",
      "r486",
      "r487",
      "r506",
      "r527",
      "r668",
      "r669",
      "r690"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r97",
      "r115",
      "r165",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r278",
      "r280",
      "r299",
      "r506",
      "r668",
      "r669",
      "r690"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r165",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r278",
      "r280",
      "r299",
      "r668",
      "r669",
      "r690"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "INDP_AtTheMarketOfferingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "AtTheMarketOfferingAgreementMember",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "At The Market Offering Agreement [Member]",
        "documentation": "At The Market Offering Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r539",
      "r541",
      "r563"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r539",
      "r541",
      "r563"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r539",
      "r541",
      "r563"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r614"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "stpr_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2024",
     "localname": "CA",
     "presentation": [
      "http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA"
       }
      }
     },
     "auth_ref": []
    },
    "INDP_CapitalizationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "CapitalizationTextBlock",
     "presentation": [
      "http://indaptusrx.com/role/Capitalization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CAPITALIZATION",
        "documentation": "Capitalization {Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r94",
      "r476"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of year",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r58",
      "r113"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (decrease) increase in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r58"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash investing and financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "INDP_ChangeInAccumulatedOtherComprehensiveIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "ChangeInAccumulatedOtherComprehensiveIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in accumulated other comprehensive income",
        "documentation": "Change in unrealized gain/loss on marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of a warrant to purchase",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants purchase shares",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://indaptusrx.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (Note 7)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r74",
      "r365",
      "r408"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://indaptusrx.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r172",
      "r173",
      "r462",
      "r662",
      "r664"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative",
      "http://indaptusrx.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r517",
      "r518",
      "r519",
      "r521",
      "r522",
      "r523",
      "r524",
      "r648",
      "r649",
      "r651",
      "r681",
      "r728",
      "r730"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheetsParenthetical",
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheetsParenthetical",
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r409"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheetsParenthetical",
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheetsParenthetical",
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r48",
      "r409",
      "r427",
      "r730",
      "r731"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock: $0.01 par value, 200,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 12,013,901 shares issued and outstanding as of December 31, 2024 and 8,401,047 shares issued and outstanding as of December 31, 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r367",
      "r506"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r597"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r102",
      "r104",
      "r109",
      "r360",
      "r375",
      "r376"
     ]
    },
    "INDP_ComputersAndOtherOfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "ComputersAndOtherOfficeEquipmentMember",
     "presentation": [
      "http://indaptusrx.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computers and Other Office Equipment [Member]",
        "documentation": "Computers and Other Office Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principles of consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r478"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r549",
      "r633"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r549",
      "r633"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r551",
      "r635"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r551",
      "r635"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r544",
      "r628"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r545",
      "r629"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r545",
      "r629"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r543",
      "r627"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r546",
      "r630"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r548",
      "r632"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r548",
      "r632"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r549",
      "r633"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r552",
      "r636"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r550",
      "r634"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r547",
      "r631"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Gross deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r73",
      "r254"
     ]
    },
    "us-gaap_DeferredTaxAssetsFrequentFlierLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsFrequentFlierLiability",
     "crdr": "debit",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from frequent flier obligations."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized research and development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating losses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accruals",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Deferred tax asset valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "INDP_DeferredTaxLiabilitiesRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right-of-use asset",
        "documentation": "Deferred tax liabilities right of use asset.",
        "label": "DeferredTaxLiabilitiesRightOfUseAsset"
       }
      }
     },
     "auth_ref": []
    },
    "INDP_DelawareFranchiseTaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "DelawareFranchiseTaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delaware franchise taxes payable",
        "documentation": "Delaware franchise taxes payable current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r29"
     ]
    },
    "INDP_DisclosureCapitalizationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "DisclosureCapitalizationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://indaptusrx.com/role/Stock-basedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK-BASED COMPENSATION",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r195",
      "r225",
      "r226",
      "r228",
      "r496"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "INDP_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses And Other Current Assets",
        "verboseLabel": "Schedule Of Prepaid Expense And Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r541",
      "r563"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r541",
      "r563",
      "r603"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss available to common stockholders per share of common stock, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r131",
      "r133",
      "r135",
      "r136",
      "r137",
      "r140",
      "r273",
      "r276",
      "r289",
      "r290",
      "r361",
      "r377",
      "r480"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss available to common stockholders per share of common stock, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r133",
      "r135",
      "r136",
      "r137",
      "r140",
      "r273",
      "r276",
      "r289",
      "r290",
      "r361",
      "r377",
      "r480"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss per share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r139"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://indaptusrx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r241",
      "r498"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r641",
      "r674",
      "r675"
     ]
    },
    "INDP_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmountReturnToProvisionAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmountReturnToProvisionAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return-to-provision adjustments",
        "documentation": "Effective income tax rate reconciliation share based compensation excess tax benefit amount return to provision adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://indaptusrx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r241",
      "r498"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued employee costs",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfStockBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://indaptusrx.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation, not yet recognized",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://indaptusrx.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation, not yet recognized, term",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r534"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative",
      "http://indaptusrx.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r90",
      "r106",
      "r107",
      "r108",
      "r117",
      "r118",
      "r119",
      "r121",
      "r126",
      "r128",
      "r130",
      "r142",
      "r166",
      "r167",
      "r168",
      "r189",
      "r263",
      "r264",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r307",
      "r308",
      "r316",
      "r374",
      "r383",
      "r384",
      "r385",
      "r394",
      "r447"
     ]
    },
    "INDP_EquityPurchaseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "EquityPurchaseAgreementsMember",
     "presentation": [
      "http://indaptusrx.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Purchase Agreements [Member]",
        "documentation": "Equity Purchase Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r556",
      "r567",
      "r581",
      "r607"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r553",
      "r564",
      "r578",
      "r604"
     ]
    },
    "INDP_ExchangeCapMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "ExchangeCapMember",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange Cap [Member]",
        "documentation": "Exchange Cap [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "INDP_ExercisePriceRangeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "ExercisePriceRangeOneMember",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetails",
      "http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range One [Member]",
        "documentation": "Exercise Price Range One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "INDP_ExercisePriceRangeThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "ExercisePriceRangeThreeMember",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetails",
      "http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range Three [Member]",
        "documentation": "Exercise Price Range Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "INDP_ExercisePriceRangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "ExercisePriceRangeTwoMember",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetails",
      "http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range Two [Member]",
        "documentation": "Exercise Price Range Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "INDP_ExpireInTwoThousandThirtyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "ExpireInTwoThousandThirtyFiveMember",
     "presentation": [
      "http://indaptusrx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expire In 2035 [Member]",
        "documentation": "Expire In Two Thousand Thirty Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "INDP_ExpireInTwoThousandThirtySixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "ExpireInTwoThousandThirtySixMember",
     "presentation": [
      "http://indaptusrx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expire In 2036 [Member]",
        "documentation": "Expire In Two Thousand Thirty Six [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "INDP_ExternalResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "ExternalResearchAndDevelopmentMember",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfReportableSegmentLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "External Research and Development [Member]",
        "documentation": "External Research and Development [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://indaptusrx.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r499"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://indaptusrx.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r499"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value measurements",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "INDP_FederalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "FederalMember",
     "presentation": [
      "http://indaptusrx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal [Member]",
        "documentation": "Federal [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r560",
      "r571",
      "r585",
      "r611"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r560",
      "r571",
      "r585",
      "r611"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r560",
      "r571",
      "r585",
      "r611"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r560",
      "r571",
      "r585",
      "r611"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r560",
      "r571",
      "r585",
      "r611"
     ]
    },
    "INDP_FurnitureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "FurnitureMember",
     "presentation": [
      "http://indaptusrx.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture [Member]",
        "documentation": "Furniture [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      },
      "http://indaptusrx.com/role/ScheduleOfReportableSegmentLossDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfReportableSegmentLossDetails",
      "http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r431"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfStockBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "INDP_HCWainwrightAndCoLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "HCWainwrightAndCoLLCMember",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "HC Wainwright and Co LLC [Member]",
        "documentation": "HC Wainwright and Co LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_IL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "IL",
     "presentation": [
      "http://indaptusrx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ISRAEL"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r539",
      "r541",
      "r563"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfReportableSegmentLossDetails",
      "http://indaptusrx.com/role/ScheduleOfStockBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r293",
      "r297",
      "r298",
      "r380",
      "r382",
      "r432",
      "r474",
      "r500",
      "r700"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfReportableSegmentLossDetails",
      "http://indaptusrx.com/role/ScheduleOfStockBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r293",
      "r297",
      "r298",
      "r380",
      "r382",
      "r432",
      "r474",
      "r500",
      "r700"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://indaptusrx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r240",
      "r241",
      "r250",
      "r260",
      "r498",
      "r678"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://indaptusrx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r240",
      "r241",
      "r250",
      "r260",
      "r498",
      "r678"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://indaptusrx.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r236",
      "r240",
      "r246",
      "r247",
      "r248",
      "r251",
      "r258",
      "r265",
      "r267",
      "r268",
      "r269",
      "r393",
      "r498"
     ]
    },
    "us-gaap_IncomeTaxExaminationDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationDescription",
     "presentation": [
      "http://indaptusrx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax examination description",
        "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r88",
      "r129",
      "r130",
      "r141",
      "r148",
      "r155",
      "r239",
      "r240",
      "r266",
      "r378",
      "r498"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r237",
      "r238",
      "r251",
      "r252",
      "r257",
      "r262",
      "r390"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in deferred tax asset valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r498",
      "r674"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computed \u201cexpected\u201d tax benefit",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r498"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-deductible items",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r245",
      "r674"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r674",
      "r675"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State taxes, net of federal benefit",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r498",
      "r674"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for income taxes",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r112",
      "r259",
      "r260"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "INDP_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use asset and liability, net",
        "documentation": "Operating lease right-of-use asset and liability, net."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts payable and other current liabilities",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current and non-current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "INDP_IndefinitePeriodMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "IndefinitePeriodMember",
     "presentation": [
      "http://indaptusrx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite Period [Member]",
        "documentation": "Indefinite Period [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r560",
      "r571",
      "r585",
      "r602",
      "r611",
      "r615",
      "r623"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r542",
      "r626"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r542",
      "r626"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r542",
      "r626"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r329",
      "r479",
      "r661"
     ]
    },
    "INDP_InterestEarnedOnMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "InterestEarnedOnMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest earned on marketable securities",
        "documentation": "Interest earned on marketable securities.",
        "label": "Interest earned on marketable securities"
       }
      }
     },
     "auth_ref": []
    },
    "INDP_InternalPersonnelCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "InternalPersonnelCostsMember",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfReportableSegmentLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Internal Personnel Costs [Member]",
        "documentation": "Internal Personnel Costs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestorMember",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r687",
      "r688"
     ]
    },
    "us-gaap_LeaseAndRentalExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseAndRentalExpense",
     "crdr": "debit",
     "presentation": [
      "http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Base rent",
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": []
    },
    "INDP_LeaseRenewalOptionExercise": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "LeaseRenewalOptionExercise",
     "crdr": "credit",
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASC 842 lease renewal option exercise",
        "documentation": "Lease renewal option exercise."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental borrowing rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://indaptusrx.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF MINIMUM LEASE PAYMENTS",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://indaptusrx.com/role/SummaryOfMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total minimum lease payments in 2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://indaptusrx.com/role/SummaryOfMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: amount representing interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease, extend description",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r46",
      "r115",
      "r165",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r279",
      "r280",
      "r281",
      "r299",
      "r407",
      "r481",
      "r527",
      "r668",
      "r690",
      "r691"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r75",
      "r369",
      "r506",
      "r647",
      "r659",
      "r685"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r93",
      "r115",
      "r165",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r279",
      "r280",
      "r281",
      "r299",
      "r506",
      "r668",
      "r690",
      "r691"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r41",
      "r42",
      "r43",
      "r46",
      "r115",
      "r165",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r279",
      "r280",
      "r281",
      "r299",
      "r668",
      "r690",
      "r691"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_MaterialCybersecurityIncidentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r574",
      "r575"
     ]
    },
    "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r574",
      "r576"
     ]
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r574",
      "r577"
     ]
    },
    "cyd_MaterialCybersecurityIncidentNatureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentNatureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Nature [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r574",
      "r577"
     ]
    },
    "cyd_MaterialCybersecurityIncidentScopeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentScopeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Scope [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r574",
      "r577"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTimingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentTimingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Timing [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r574",
      "r577"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r177",
      "r192",
      "r233",
      "r291",
      "r324",
      "r379",
      "r381",
      "r388",
      "r399",
      "r400",
      "r451",
      "r453",
      "r455",
      "r456",
      "r458",
      "r472",
      "r473",
      "r491",
      "r493",
      "r495",
      "r501",
      "r502",
      "r503",
      "r504",
      "r515",
      "r670",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://indaptusrx.com/role/General"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GENERAL",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r89"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://indaptusrx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/GeneralDetailsNarrative",
      "http://indaptusrx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "negatedLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r60"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://indaptusrx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://indaptusrx.com/role/ScheduleOfReportableSegmentLossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/GeneralDetailsNarrative",
      "http://indaptusrx.com/role/ScheduleOfReportableSegmentLossDetails",
      "http://indaptusrx.com/role/StatementsOfCashFlows",
      "http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://indaptusrx.com/role/StatementsOfStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net loss",
        "verboseLabel": "Net Income (Loss)",
        "negatedLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r60",
      "r77",
      "r91",
      "r101",
      "r103",
      "r108",
      "r115",
      "r120",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r129",
      "r130",
      "r134",
      "r165",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r273",
      "r276",
      "r290",
      "r299",
      "r373",
      "r429",
      "r445",
      "r446",
      "r525",
      "r668"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently issued accounting pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "INDP_NewAdoptedAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "NewAdoptedAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently adopted accounting pronouncements",
        "documentation": "New Adopted Accounting Pronouncements Policy [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "us-gaap_NoninterestExpenseOfferingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoninterestExpenseOfferingCost",
     "crdr": "debit",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative",
      "http://indaptusrx.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other offering cost",
        "verboseLabel": "Noninterest expense offering cost",
        "documentation": "Includes offering costs of open-end investment companies, and closed-end funds with a continuous offering period."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income, net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "INDP_NumberOfCommitmentShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "NumberOfCommitmentShares",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment shares issued",
        "documentation": "Commitment shares."
       }
      }
     },
     "auth_ref": []
    },
    "INDP_NumberOfCommitmentSharesToBeIssuedUponCertainConditions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "NumberOfCommitmentSharesToBeIssuedUponCertainConditions",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment shares to be issued upon certain conditions",
        "documentation": "Number of commitment shares to be issued upon certain conditions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://indaptusrx.com/role/SegmentInformationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of reportable segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r483",
      "r490",
      "r653"
     ]
    },
    "INDP_NumberOfResaleCommonStockComprised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "NumberOfResaleCommonStockComprised",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of resale common stock comprised",
        "documentation": "Number of resale common stock comprised."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r482",
      "r652",
      "r654",
      "r655",
      "r656",
      "r657"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://indaptusrx.com/role/SummaryOfMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Present value of operating lease liability",
        "verboseLabel": "Operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheets",
      "http://indaptusrx.com/role/SummaryOfMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability, current portion",
        "negatedLabel": "Less: current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheets",
      "http://indaptusrx.com/role/SummaryOfMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r313"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://indaptusrx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other accrued expenses",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets - deposits to third parties",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://indaptusrx.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reclassification adjustment for interest earned on marketable securities included in net loss",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r54",
      "r100",
      "r164"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://indaptusrx.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in unrealized gain on marketable securities",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99",
      "r164"
     ]
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherOperatingIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/ScheduleOfReportableSegmentLossDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfReportableSegmentLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other income, net",
        "label": "Other Operating Income (Expense), Net",
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r642",
      "r660"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r558",
      "r569",
      "r583",
      "r609"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r561",
      "r572",
      "r586",
      "r612"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r561",
      "r572",
      "r586",
      "r612"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r590"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentOfFinancingAndStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Issuance costs",
        "label": "Payment of Financing and Stock Issuance Costs",
        "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rental expense",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://indaptusrx.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net of placement agent cost",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r187"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheetsParenthetical",
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r409"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheetsParenthetical",
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r187"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheetsParenthetical",
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r409",
      "r427",
      "r730",
      "r731"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock: $0.01 par value, 5,000,000 shares authorized as of December 31, 2024 and December 31, 2023; no shares issued or outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r366",
      "r506"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://indaptusrx.com/role/ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheets",
      "http://indaptusrx.com/role/ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "INDP_PrepaidExpenseAndOtherCurrentAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "PrepaidExpenseAndOtherCurrentAssetsDisclosureTextBlock",
     "presentation": [
      "http://indaptusrx.com/role/PrepaidExpensesAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PREPAID EXPENSES AND OTHER CURRENT ASSETS",
        "documentation": "Prepaid Expense and Other Current Assets Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r492",
      "r660"
     ]
    },
    "INDP_PrepaidResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "PrepaidResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid research and development",
        "documentation": "Prepaid research and development."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative",
      "http://indaptusrx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of shares of common stock and warrants",
        "verboseLabel": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity of marketable securities",
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ProductLiabilityContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductLiabilityContingencyLineItems",
     "presentation": [
      "http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Liability Contingency [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r665",
      "r666",
      "r667"
     ]
    },
    "us-gaap_ProductLiabilityContingencyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductLiabilityContingencyTable",
     "presentation": [
      "http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Liability Contingency [Table]",
        "documentation": "Disclosure of information about product liability contingency arising from reasonably possible loss from liability related to individual product."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r665",
      "r666",
      "r667"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://indaptusrx.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r315"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://indaptusrx.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentMember",
     "presentation": [
      "http://indaptusrx.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Member]",
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r315",
      "r362",
      "r372",
      "r506"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r84",
      "r87",
      "r371"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://indaptusrx.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r315"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://indaptusrx.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r177",
      "r190",
      "r192",
      "r221",
      "r222",
      "r223",
      "r233",
      "r291",
      "r322",
      "r323",
      "r324",
      "r379",
      "r381",
      "r388",
      "r399",
      "r400",
      "r451",
      "r453",
      "r455",
      "r456",
      "r458",
      "r472",
      "r473",
      "r491",
      "r493",
      "r495",
      "r501",
      "r502",
      "r503",
      "r504",
      "r515",
      "r519",
      "r663",
      "r670",
      "r683",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r177",
      "r190",
      "r192",
      "r221",
      "r222",
      "r223",
      "r233",
      "r291",
      "r322",
      "r323",
      "r324",
      "r379",
      "r381",
      "r388",
      "r399",
      "r400",
      "r451",
      "r453",
      "r455",
      "r456",
      "r458",
      "r472",
      "r473",
      "r491",
      "r493",
      "r495",
      "r501",
      "r502",
      "r503",
      "r504",
      "r515",
      "r519",
      "r663",
      "r670",
      "r683",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697"
     ]
    },
    "INDP_RateOfIncreaseInLeaseRent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "RateOfIncreaseInLeaseRent",
     "presentation": [
      "http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rate of increase in lease rent",
        "documentation": "Rate of increase in lease rent."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r553",
      "r564",
      "r578",
      "r604"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r191",
      "r317",
      "r318",
      "r364",
      "r370",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r426",
      "r428",
      "r450"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r191",
      "r317",
      "r318",
      "r364",
      "r370",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r426",
      "r428",
      "r450",
      "r689"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://indaptusrx.com/role/ScheduleOfReportableSegmentLossDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfReportableSegmentLossDetails",
      "http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "verboseLabel": "Total research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r474",
      "r486",
      "r698"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfStockBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r554",
      "r565",
      "r579",
      "r605"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r555",
      "r566",
      "r580",
      "r606"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r562",
      "r573",
      "r587",
      "r613"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheets",
      "http://indaptusrx.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r65",
      "r368",
      "r386",
      "r387",
      "r392",
      "r410",
      "r506"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r117",
      "r118",
      "r119",
      "r121",
      "r126",
      "r128",
      "r130",
      "r166",
      "r167",
      "r168",
      "r263",
      "r264",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r282",
      "r284",
      "r285",
      "r287",
      "r288",
      "r307",
      "r308",
      "r383",
      "r385",
      "r394",
      "r730"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://indaptusrx.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase ordinary shares",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://indaptusrx.com/role/AccountsPayableAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://indaptusrx.com/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF ANTI-DILUTIVE SECURITIES",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://indaptusrx.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://indaptusrx.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF PROVISION FOR INCOME TAXES",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://indaptusrx.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF NET DEFERRED TAX ASSETS",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfStockBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "INDP_ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock",
     "presentation": [
      "http://indaptusrx.com/role/PrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF PREPAID EXPENSE AND OTHER CURRENT ASSETS",
        "documentation": "Schedule Of Prepaid Expense And Other Assets [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://indaptusrx.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r315"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://indaptusrx.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF REPORTABLE SEGMENT LOSS",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://indaptusrx.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STOCK BASED COMPENSATION EXPENSES",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r69"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetails",
      "http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement by range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://indaptusrx.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://indaptusrx.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STOCK OPTION ACTIVITY",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r66"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://indaptusrx.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF WEIGHTED AVERAGE INPUTS USED TO MEASURE VALUE OF OPTIONS GRANTED",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://indaptusrx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "auth_ref": [
      "r160",
      "r161",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r396",
      "r397",
      "r398",
      "r452",
      "r454",
      "r457",
      "r459",
      "r461",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r475",
      "r494",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r516",
      "r519",
      "r671",
      "r699",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://indaptusrx.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENT INFORMATION",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r141",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r149",
      "r150",
      "r151",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r162",
      "r483",
      "r484",
      "r485",
      "r486",
      "r488",
      "r489",
      "r490"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expenses",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://indaptusrx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfStockBasedCompensationExpensesDetails",
      "http://indaptusrx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Total stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r209"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average, remaining contractual life",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfWeightedAverageInputsUsedToMeasureValueOfOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfWeightedAverageInputsUsedToMeasureValueOfOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfWeightedAverageInputsUsedToMeasureValueOfOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfWeightedAverageInputsUsedToMeasureValueOfOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk free rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of options, exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted average exercise price, exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options, forfeited and cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intrinsic value, granted",
        "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options, granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://indaptusrx.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average fair value of stock options issued",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Intrinsic value, outstanding balance",
        "periodEndLabel": "Intrinsic value, Outstanding, balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of options, outstanding balance",
        "periodEndLabel": "Number of options, outstanding balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r201"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, outstanding, balance",
        "periodEndLabel": "Weighted average exercise price, balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r201"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Intrinsic value, vested and expected to vest balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of options, vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted average exercise price, vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, forfeited and cancelled",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r199",
      "r218",
      "r219",
      "r220",
      "r221",
      "r224",
      "r229",
      "r230",
      "r231",
      "r232"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetails",
      "http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetails",
      "http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetails",
      "http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price range lower range limit",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options outstanding",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price range upper range limit",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfWeightedAverageInputsUsedToMeasureValueOfOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Intrinsic value, outstanding balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life, Exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life (in years)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://indaptusrx.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life (in years), vested and expected to vest",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssued",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued, price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://indaptusrx.com/role/SignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r114"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "INDP_StandbyEquityPurchaseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "StandbyEquityPurchaseAgreementsMember",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Standby Equity Purchase Agreements [Member]",
        "documentation": "Standby Equity Purchase Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "INDP_StateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "StateMember",
     "presentation": [
      "http://indaptusrx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State [Member]",
        "documentation": "State [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative",
      "http://indaptusrx.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r48",
      "r51",
      "r52",
      "r90",
      "r106",
      "r107",
      "r108",
      "r117",
      "r118",
      "r119",
      "r121",
      "r126",
      "r128",
      "r130",
      "r142",
      "r166",
      "r167",
      "r168",
      "r189",
      "r263",
      "r264",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r307",
      "r308",
      "r316",
      "r374",
      "r383",
      "r384",
      "r385",
      "r394",
      "r447"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://indaptusrx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r396",
      "r397",
      "r398",
      "r452",
      "r454",
      "r457",
      "r459",
      "r461",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r475",
      "r494",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r516",
      "r519",
      "r671",
      "r699",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative",
      "http://indaptusrx.com/role/ScheduleOfReportableSegmentLossDetails",
      "http://indaptusrx.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r142",
      "r308",
      "r328",
      "r389",
      "r395",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r409",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r430",
      "r431",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r447",
      "r520"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative",
      "http://indaptusrx.com/role/ScheduleOfReportableSegmentLossDetails",
      "http://indaptusrx.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r142",
      "r163",
      "r308",
      "r328",
      "r389",
      "r395",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r409",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r430",
      "r431",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r447",
      "r520"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r557",
      "r568",
      "r582",
      "r608"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative",
      "http://indaptusrx.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of shares of common stock, net of issuance costs (Note 6b), shares",
        "verboseLabel": "Shares issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r47",
      "r48",
      "r65",
      "r391",
      "r447",
      "r460"
     ]
    },
    "INDP_StockIssuedDuringPeriodSharesNewIssuesOne": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesNewIssuesOne",
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of shares of common stock and warrants, net of issuance costs (Note 6c), shares",
        "documentation": "Stock issued during period shares new issues one."
       }
      }
     },
     "auth_ref": []
    },
    "INDP_StockIssuedDuringPeriodSharesNewIssuesTwo": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesNewIssuesTwo",
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of shares of common stock and warrants, net of issuance costs (Note 6d), shares",
        "documentation": "Stock issued during period shares new issues two."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative",
      "http://indaptusrx.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of shares of common stock, net of issuance costs (Note 6b)",
        "verboseLabel": "Purchase ordinary shares",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r47",
      "r48",
      "r65",
      "r394",
      "r447",
      "r460",
      "r526"
     ]
    },
    "INDP_StockIssuedDuringPeriodValueNewIssuesOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "StockIssuedDuringPeriodValueNewIssuesOne",
     "crdr": "credit",
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of shares of common stock and warrants, net of issuance costs (Note 6c)",
        "documentation": "Stock issued during period value new issues one."
       }
      }
     },
     "auth_ref": []
    },
    "INDP_StockIssuedDuringPeriodValueNewIssuesTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "StockIssuedDuringPeriodValueNewIssuesTwo",
     "crdr": "credit",
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of shares of common stock and warrants, net of issuance costs (Note 6d)",
        "documentation": "Stock issued during period value new issues two."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://indaptusrx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheets",
      "http://indaptusrx.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r51",
      "r52",
      "r62",
      "r411",
      "r427",
      "r448",
      "r449",
      "r506",
      "r527",
      "r647",
      "r659",
      "r685",
      "r730"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://indaptusrx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative",
      "http://indaptusrx.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r320"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative",
      "http://indaptusrx.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r320"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative",
      "http://indaptusrx.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r320"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://indaptusrx.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r321"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental cash flow disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://indaptusrx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://indaptusrx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "INDP_TransactionCostsInAccountsPayableAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "TransactionCostsInAccountsPayableAndOtherCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction costs in accounts payable and other current liabilities",
        "documentation": "Transaction costs in accounts payable and other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "INDP_TwoYearLeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "TwoYearLeaseAgreementMember",
     "presentation": [
      "http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Year Lease Agreement [Member]",
        "documentation": "Two Year Lease Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative",
      "http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://indaptusrx.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://indaptusrx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized tax benefits, income tax penalties and interest accrued",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r497"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r82",
      "r83",
      "r85",
      "r86"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://indaptusrx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation allowance change amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative",
      "http://indaptusrx.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r517",
      "r518",
      "r521",
      "r522",
      "r523",
      "r524"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and rights outstanding, term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r682",
      "r683",
      "r684"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares used in calculating net loss per share, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r137"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://indaptusrx.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares used in calculating net loss per share, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r137"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://indaptusrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "INDP_YorkvilleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://indaptusrx.com/20241231",
     "localname": "YorkvilleMember",
     "presentation": [
      "http://indaptusrx.com/role/CapitalizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Yorkville [Member]",
        "documentation": "Yorkville [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-17A"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "Instruction",
   "Paragraph": "2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "SubTopic": "740",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>78
<FILENAME>0001493152-25-010136-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-25-010136-xbrl.zip
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M[[B@\$U1L7X\2E+GX,#VI-I2W(,=;,IGZ44^JSF5U<<:=TR?(X8 I#6E1JZ
M %S)N$1-13W7-!#@U)%.:%L9&1)1-(,6R[0/UQ7'A8W!<$KT"DKL8SA&,7)5
MWRKFECYXTB =1K>HZ%NFC/=*QX,J'1M1,O4+E0ZXKN\T%[(ZX<O<ZQY/G@D<
M<Q?A;C-"6Y<8\+ H6Y@S%S*GA'<2P-1TLT2EQ%#_75O)TKJ&)A3\!QD#*L)2
MAO>(%8-E%PY\C.%QW] H2->7&[NQ#TL7=Z7W>R?W'?$,ZPFD%-?@8UHT;C>D
MI"G5L:6.G/_X;K3_PXO1S__\'KO\A,,6&4Z6XFL. \+X@V<,WS.2"N!)AJN(
M.95NP,Y6K$!A9U544>&WH&C9T$['%70(E8G8EZC-*]0+MNX<MI6\QDQ>/H:V
M1&&-8_<VWRW,$8@TJ^$MGA2LC[^)!'MR,XFV?</$B![:S_K$J*97^1Y2Y=N(
M6KHGP$D9H[:.QK<BC-WK?$]?-6G\30A2;+('0BFX)/9#18([B\_;%1OPE70]
M5I/3Z[BI"Z86(O1%PE*40T @DYW4V+O/>0)4*4*+\U7N'/EGC<\U;4VPIBQG
M&#2H+F3E#6QGVVSRC9E^W._SWS40&;;38<?,*9ZCH?X(?3/L7I1N+]:%PLZ[
M'^LUF[*=2"Q<SG?%M_G]#X@P??7WE:C];7K(VR2>_FTZ?A/%/=:Y3>$2NGOU
M^OGQ&XZTN 8!8PG'7,3=N:G4 J@1KBZ5"T;M_U#-N#WUA&W#=6:18[4GJO)$
M2:Q@=%J@B>3/&A0?;!_S5UJ$KZFIW]Q/_) 26+$.U<V]Q'W2R^3+3H5K0/JN
M@+#FSH90$8E6?,C* IOG7,IN8P?7!#RJ;[S.1&Z';X4P'7H_2ZXQYDM)K$ZI
M:<6CUID,QJZ0-F'U?KD$%38*^\^/74E,W__)A@90+"M\%R'O]T(GR*7.+]%%
M]@5;4AH)!Q!TZM9AA_.C9HE<O?N&5-WC.%5WG:DT:;W<SQ$+?2[-P7>6]+23
MU=P<&\F*:<7M:9MPUMP4>VTTO9G1F'@-3-FWMO?#MQI5"=HR/KC1>K,(1\\<
M(QSTJF*HGF.X[1#)BGGZ+>&6Z>LC2UHH!-?>A)+9FVX:K38@47#=E:O'(+SD
MEF)NT]:;1:L!UEZO'/7*T7WO^7@3E*,SO'M_536RK!NUFLTR*T$YB]<7_[PK
M(&B]N<21Q]"0Q[==<I6EW.<^RRG)Y"7<^I(<":X@5B<I"[CD>M- >,X"=+X
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MWM8?V<V$.K#/P VN7Q>7V%S.L>GZ(Z?4-L[TC;YQ6\(W\GPX"*;5*%A<H+&
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M'Y$$OFY8 FO5O_UX^#L5K?_U_+?W;_X_4$L#!!0    ( -([;5K\]I?N^00
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MW.*39R<8.I-"X+PA(U+T0X480'S$R]Z;\7S];E0XJW"VRZ"?_$5P!BP2"3*
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ML/7]S/Z7.,&-X&P1SIU9"[B-Q659QD)NK8(@U0B-0KJYQH18&0O'\=$WZ-C
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M8^N?S<M)KUS2/X_Z!OZ">NGFV)R,>KJ6_&*OEG;K@ZGQ%1;FU\GH8\7QN>Q
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M*Q?MC$=#CY,]8X.39&0B-_S;A2 _HJCK*N#DL7H(>8'*0IUQ"5:WV+=F6G_
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M-=\S8GZ+(0MKY:#6-SZ[A:=F;?F4A'.#^-> @RT3/E'8P__->K[S(7'7K[K
MZ *]^Q=*WMQ+2WB._. <?PJ4FE(%A(F2N(T52&2?9YA3573?KV$/TBB[G!?-
M9#N[)483>*&^(9Z^:Q%VFY4466=,DI]S"I-?\[8\2K&,.T[>?=E<_EOG#8,4
M_4[WK='-8REYSE+);>[:U[>JL,8''%S<%"?Y!)7H!\W,$]E_VP<S7%4I5M"5
M'-4J&1L%V<26T5NLS5B(9%(+XZ.CCC<8\C360#+)%9W<PMR?Z&]U*J_.]TQ/
M-CE\F<G/PILS6:2.5>#X%R@K"]]LNB.(,)G9S&.:]D7PW'LM:IF-_AS'K\?/
M*'<8K)L*0;MX"%%A=@+G;=@\:JE]Q+IS#\IZD.S.]?@%UVB@L 1YC_.61D8R
M"EJ)*DZNK@Z+QA?0]V"Y.N?\]D6]S:KI0]G3R_-LD_](.%6T_O WWAHYKKT$
MEHW!6A"G/\<9NFFE.Y_M-0D(^S9AM093^>F$4V?K.NV%E[GB[Y"-U3+'@A$K
MO&3GS(;E5;0VM-KWH.;3/R? FF\W5E^D7.+T8"Q7+-\@O$7&O?4C.DH(VJL_
M*;AC[4EP$8M 5H<OK2V+\@Y"\7F#?".B%2*G>H&P:0I59A;P<=%;@ENS5%4*
M[25B&U:*%<JH2:KL2\17'9[+HR-B!69LV9A&$IO:89_AU3.23L]VXXQT72LS
MB4"-*?AD6U[M4'E\_)(I>8<SG4M*%X(ZO'*$H(;; ;B=Q5TA*4V3J/5W]2;^
M#4XKN4CS00LV=-$QCN=?5,,?5)\4@E"ED^9RITR$H -Z"=\FBXO#D?D46HJ(
MIUJ_(+S?8WI?L/<R4R1Y>N!XIGI(EURC(*I,9% +B1K8LZQY#J8&L&3-)E,[
M*!.Y;4J4[7#E!:OZ%1,3S:/UY65LC3EJQ72[>T'R<6 AX+/??L_^28>4LS5^
M3)1@IV 90<L2@BINONENO00D9FW3)R8*0?*;YIIO1^=>"L90%>AV!' <^0QG
MC$4#HS2B.$^3GUJI1HE%B"UC;P4_#A""I.+:G LG&PYV3IO]6+Y7M&K@SB_P
M^>S[Q+OP2V_5^U^";<U>HT/V/]W+5<<+DC0/S"T=;?,&Y*08<CH,K)MC;(M'
MD!4DL<6GMDA+S@LI$5M9AG=C:$4Z5$E_NUUJNIEW=XHG!!DPKJ@@HAJ59XR"
ML7KG"4P<E Z'M'ICBMP@,J4.YC878MO9FO[K9#LM69\H^FR*P\6_6YS3XAH3
M9JB).,Y=%'!D.HXKCQNF2!I:9=M QZ.1/^ RN!_V9M:ESD1UWFEVS,KP?!+V
M<O@=64:>H)"!WP,LV6ZR<_4H3%W9=+63U!_46++5.\QHZP0D$:O[>6RI494-
M3\[S%ZB.5DY^J!L,69%TJ+3ZJ6U?VG!N9&-$-2<S5#/OMOW,G1<.>SXL\WH!
MT7E)@$15X\7S WR8^!CX*?Y'W%XWC"4#&FN$DEY*Z_>K*W=5"["^PJ]NF\(\
M9H?G8S/27GW:TQSR+S(=TX.QY\DC.4EQ[?A=/'^NSF*C83_6IUC0D[-OV! F
M#A2>&<97/:2H\S2^C%3Y(^4PA//D6SH3<ND?TP8K?RAK0"X,DRWH_%SN[H;'
M4^=3@]S"FHB3Y,NI\PZ!^VCDYO[N-9F^X]VL\AY,V+.*>W8&T@D.4Q<U8\R=
MO];&09*:ZH?2=&G!29('@KI^UP-69K1&"%OQ?HVTSY0%@9YCT=70Z)@V\R;?
M/D'0R9A6^GZ_]JJ;(HWESW\3=/'LTU;/QY1?(:ES>G8.P#A5F1=.QX\G"G8Q
MWV(]@%EC(HWRE/@?RX3#Z):1@N/^,R(R/\<>C29;AA4N3JN/5#5G:DAR'=&&
MY8A*(:CLWRSWLFA4==JH\41,D6VS.>2Z-?AWH.X\Q*[(H)Y0/HO\?A]Y/<IL
M5(R-IE%;A*"41KDAK#@[K!D.9:\^#3GVSX89-%Y7MOW=ERK$K_3J%-6)WYW7
MSDVF7AN\4H=M@W?._^E=%4@=^X3=%SJ*\$!/=#)#EU<^+7SY,F NC_\D8NAV
M !D4RB%6\5]NM-3UK'Q4TM+YL..0C%>\%E3;J48ZR$U!J^"--Y"CS) IT&J>
M03FVSV**^F+7DC3MV/K-S,.)WV?YG_YE:BI UG5N"/HZ:5FCG.A_;5_"Z]+$
M$X&#^GU+=QQEY?3HR]SX,A>K=1<]_]@NTT2M=N]":7YQC(-YCTZ%<4NX_TYV
MK7$9H./Q8"L*)0X7 &"N'L^,GT-V9M>T4\'>H]9]G=3X#:HBS\>S<-%C[6H5
M^^)GM%S^A,:[JHN#12$6-JLWASZ<*['Z%M7LJ4,5:549/H4'95$X(@&(J@:$
M((9D?"5A)Z#= E4G:Q0"B>U.#5^K!BJS3PXV&>?_V;AVR-W^X"K(YM(N*;\-
MZ%@JIQAH9ZY">=?YZ0B_U1T+FF!^/DYJ_%=&]:=/P,6E%?AV().&VKV2:LD>
MC4FX\3TO:L>M0R4T30NPB^IT-'JS^0.NLPZ_4LBD ,=)+0GD6X4 PFT0[XO?
MAB$V3?RL&I[GR+.-TUE#X[\X<)-^$S!PR1P^)9ZOWQ%_:?0A%"#^VD<HH?-*
MBG5\H+-D=*;'">">I2P+QDE['(<V%X*20A7;I_35E7PC4R""BQC+?RVEUK4_
MYD67!R'U/J5;SA@4S<6X0.-4B'&.2E#YA'?9[*XNC+^"$+13-T@.$KNVX#UN
M<UHJX99(+?7]C=,,EFI15<G66O>P!A*K3XXDLB&"7?-,?X0Z\'NTC2HK4N<L
MMUULV>I<&A'4"WL(5A ,F_V.?B(1%X^U"]#L%732T]Y\&B_)S?-]W9VT^[T0
MA :O4.1P4[^<-)/I/5K6+"$HSG!)0_IL_SU=PVS(I0&=@4GK0<,N?Q&ZE9>7
M5TG[NGMY1%S<IM=^:Y=Q1(3 2]!*K#8N(RVEX\LZ5P[3?B)HJRM>K.C+I8.2
MT46Z;P>Q4/;IYBW73RF='2AI>+-/P+OL;1;&_9<&#0?>/;QS\E>&N;=%\#^L
MC<6H8Z#9T%>_@FM*@CL'EP8:+=M4-U^I,V+/.XM9'OAZTI JZ^48>-RAN]Q!
MY^I]#N-PQL>/;#D31$N1WFF5MAJ\6UU7KDP]K$O)%?G;W*AEUK3H/65/?R?#
M8$H(.O6(@>T[V4(^XO^TI_1!29FY,2NT\6STUZ! C(ZFM?_M*3LX4H/0[>:.
MZ"2ID7B!7%K@;RQQ+(YQ@J?6H=NG&2=./?5+F[.W[$\O_%Q0W_37+4W)@J'Y
M)'L:>B6!9= *K23R%(FTOI8^R-*T"6LD.HR[#T-!$6\"P8S,/DG@_<3J&?8*
M8^+XTM;E%&"LE#R)+]BC6"ZWTY14(("*P.!(XP[L:?9J%'S_ E'D2GQ[K&ZP
M$$D/89"%"1R%7=_A5!T3^@GP=*@:T=&I*H;_WE@.G9!>M(O?*DGKJG&\04OK
M6%ROF(+)CM ;0<6OY[^D29YPTZ##"]/HIGCY-W1]%(O4CMR98\*UW<EZT5%;
M@N= UDVI/U^6IW^_C_-IKW4[S(9*_7N_5\WX.S3AR^>V.4R2$ 1^U;<]Q[:E
M4!'VR>-D-W(D9]?)-%VC)"OEX9HGN)+R_807_--KG< 3;XHRA9:(_W,1<9?(
M-2>D0+></]@OK^$_0Z_BSCSC.8GJ6AO_39G_ ;',%IC@%]P(;D>ND^+(>"'(
M4T3K^'5TFT\_&\G+6MU%679D: DJ-I$SN.%V'H*P3OHN! $Z0A OE\+LY(<!
M(E2QI<B.+J)>AU-0;%(7$M"A\G+KF1NB,0/1&%5V&.,K!&E)1E"6"^E"$-^1
M3OFZ@;TI!*5Z=@I!G(ML2<'G)>A;$3Z W[ &Z70+R4BR[HH0=,(?L=:I;N]9
M?'?+)[XRP/[,2,!M\H!1H73QP9L5KW=89>I>&2_6*[:0?*,F88'<E[1;OQ-[
M$,LS !X/0EG1&.><;$-_>$-#X8 _DXU8_4+@QS(IZ^X$>*&V$/3"VUD(\B!+
M"@K_K*T5<G1'0F QC2< $O< D+_X^+= !8A=;:." _5VS5]GP1+0:@Z3=[N.
M;A<O<@"28O;\F^DV^E W#VLV@WOJIQJ>4^$>EK=H/+)1]R@W(,@3[VD*41I]
M5&/<$Q#B^VCGOD+MD_J2AX)$&27)+_];;$DG/A,H"$8$JA4Y87TQ&<F4&,'!
ML[<1 R'(F D^F^NP+TDLS\^D+EZEUZ:R+6ETS$T'2*7C=V%/#34><UTTWL#)
M#9)/8%&RZY6YW@7Y%N\:!AI;CYP2#'.M(P93I@)?F00GY0[#C_)?A$  (S::
M"5M.+O)#/_:A6WL*%*@QJ5,_C?HFL!H,9V=7I]7+UV8>/TE+JQDQ2RDL:(N<
M'3DTBCVCGO]%!?KA%O 8'-6X'["E$V(HZ,*OZ%7X$3_\7G#[*N1NVL:9J6F>
M AL_]C<<UOJXKN'V-L"?:W)]H+\:'O=^<4(ONK(@KL9^J6&CC2#A2Y4M "KT
MR@(0D0@Z6/-4S:ANN;TMJ[WCN5']Z2Y%LG%,INW@E<9LCW.!O@>O/3ASR]YG
MD7(-;LC_$ %LLB?I/LOU7IE]NWZ-&@M!$)S)3CGN'59'VKQ ?E4&Y7ZQG_$X
M6!Y4OOGDL[Y[E'\!OQ Q4XUK0W%<C-#\?V2UEL_2K=$W61O)E+M]&A/*Y #N
M/YA8/.3L]N7E+?N(%?P/GLH'1_ZG&B'(1_;$CD&5S+D?^-(:S?Q2? !)>@PS
MR9!<?D&7O;'J4#%H;LE&N?6O!AK*VJQ='@X(^(TUG"PI"BD\49,1OAA1[R Z
MY3W&OP.*N5V/ZM #>C1<+%HS[J\0I,HF36@)K(4@9CK_A1"4( 1MQ?LKKHE*
MZ(1D"V(+"D?@Z;-L@A!TV#X;Z\Q/$$" \W1D.UAQ##/*#)G.I9/BX*='BVX/
M"W2!KIL#OTM$%M%O(RW-*2:R;IL0A/SI*R#FRVQ&YYMJ[8,G\U.$H)D1'%@(
M&LL4@FIJUN>A+!OTIA%8##]FV2;Z[B=DTD7^<\3,*!R,'\M"_"W?(H\*I+X)
M04>R:0CN3B!7M*3)0]35<T+0QW]%YT#@OT7,1//\A:!R*[::$'2-[U$+&Z,*
MK*-I!?P$.\J6?8CKZHJ8$'0(RD3Q7Z+BJ5MQ2XK-N XAZ,\]J 1B^4J5$#10
M_QDT@Z"]A?ZY*P0IX7__(P0-OZ(M;J%$BL"+=]LI@H[S(D3;\JD@B=P8NG56
M\ VJA)ILBH,B$S3EH"21,2J^#U?@QS3*+\$AK&H2(E%@>L$XC\[?L76WN/$D
MYKOTM5$SZ[Q^);^::) )(NRMQZ7VP[S#:[P(_G:;N"6^!+P6'*>YO;]1&6-P
MCG4Q)IRTZ 2/#!RIMI_6&B:%\)_0 P-GZG7#B]W*ZAKQ)V<B>N&_CG?NBZ0.
M@MX_.RJ^.<NO%^SN8K4R<04EOAP<,@9WC%_0SKE(S71VQ=X&6KII<LXW#MJ9
MJN,#_O8A>_J2\."^-G2<ZD:L+JZ/3^$$%V%N,&9\-+4&.K<TB).7S!<+N,@6
M&O,@UP>^SC<13.(E/P 5+ ,WP=>*,*HR1CZ]8UHI:OP0UZV _R:0RGJ)\>L_
MZ*B7@=R+>6!M>;FT+'GXT$AOXJ&X>RJD^4<F*9?H:0;SF^.U43@S)G0^*^>G
M_]17@RRW"V_N;/YVCN>HQ%J_H568FSA[L%Y7"C8D=93JCQ."6QDZB7H,;)PI
MO7LZ;N2DJ,/H=GAABD[6<$NT=[*R$6E7E*<.3&;"4+"F/R\O'!DP)VJ?=F_F
MVIWFUZ1\,?VK@6DBC:/'2:*#D]=%>*-C!>9L[\P9 -'NU)E$1M!D[05N5=:P
MEHUJ_#W(",)#E/LXH],]2"XLFO_EW:\OI%3<?D$/[CA[=<6(1HJ#RA55?.2%
ML2^F2\:4^89P F"VP^@(=LRL*)67?PM:"P!G:[/TE/5SCU555-F;9Q3YL;QK
M_'^Q)D'< Q.XOIQMI35/L<=9N$B3%N8IJ]OFUVG.NIPC_.)=$]J8W,"\/+\-
MFDD7:<GFY$EM+GAAOXACVG!0##ZJZSYP[Z)6PC3XF6%]^\S8U4-VTLJ956G:
M)WH:&U(-)_#7FABS%?8"A2UMC'5;EAJ#% ]T=\G'M\Y.[2LCJSW;:GQ]=4DE
M,7WT1(#OJOM]%>=FGV,_197'+'T18.2YV0<DT+I@\;@=;*VHU2/R&F%((>@L
M41!>987ZVZ,J@KLIF[[GP3EQ.<0$IY3LH+Q%^R>X/+'!P+\+OXM7 _IX=3\7
M1+L7P9W?)RJ]"[@_WLA-7]EN+2)<FOC7N?"Z$ 3W^4%[U$=ZLCEYB?^B %CA
M!F#E6 W).5@3MGV[="$PUG1)\'T0KCY!V,.SY*)Y./Y3/X%*Y2#$RM569;2J
M["WK#.G5EB% C*9-3%UO??/[X)B7<E:%2AO@C/_A Z9-PXR;5]$<7H',O_83
MW?>?C$/=_]:R@D\P_<SWMYN?CKA5P8-[1=-X_73*G(%6WYI7S/>@!A1OO_?K
M3[=GIA/U.G2-7E$^P(!#\TU\),UG^3HK_1)[9VT-VSXYX+= "_.L=P9<N9 .
M-ZB#U%TD/ ].AK6>MQIX7;K]7ZU:SRV7)BGQ$+L^#3,9**XJT],_P#- HCCK
M6("O[[9FW^U2G+"P,/^ LDEGB1EP^H_=H(,358_FU?G+G+^DV2GNZ?8@I? L
MGS'J1M+\R8XY3/HX4_\U^:K]YZ1/G0-P/^JHB\%SNJEG+("/9>%_;^ZPBOS.
M$N!M6VQ;+V^,^.6.4"$O%)Y_OJ_?W#3#?VP$3(J<^TT09EX@U8(\Q:_AZ04M
MFTLR=S_!;_&U.588GWT/E3O=3.%3\\0\3&@[(0(E S?Q@\I4H>(%ZJHK&\U"
M$'2"=XFU/?D3=4+#H,,NP_HWP:=0HIQ<Y4S+"'R'(WE]W'P6_#WYLW\@I/O7
MC/G9J)Z@()(S.,YAK"KV,B/@V??@J^J!#=30)>7:FG%7![:IR!KH8VU;QG@$
MO3;WCQ[Z%=\S,(5\.\"<>KQ[%L]-:_ZFK8N>+Z@ZD-6-#'\;?DH(0L1@D"M7
M$4QU.'PMBB(A.!JSND&6+B+,G!:"S+8DWZTS-U.TT]BAL95H50#5A@.S9=\-
M/40H_9I(CPOI@E5:?*D;,.JZ;%ALU]_SQ:[5M^:!WH/+TR?.MMHG/B64?HHM
M'HBYJC-:HIJ_)Q>%4V##"T^T#+73V, 3N\:#TLDM2R6U9"7C#%P"8W"PQI4P
MCZ>C5TX'<T4\V0R&[P9R6S=JGF.MV(UOV!!Z7\MD.-P@Y'--$O8Z&\TX'$^N
MK"QW?S*1DUIPI* P</#\B1'%W4=;R@61@C8*"XEZBI*@>..?"K8#!2P"O2^Q
M\1C^MEX]6ZL-I\7"QV*M/U&2>%>A=B,/$W7]%CN65NKP,1-LK&[>"9^UAQ:J
MQJ:'FSF)>$!+"%JN\'V'%6>5\PQ]R<>X)Y=42?&-NS&/F.V:1VH'*F7#;K&5
MV>&]98_OA."!'"HI?FBQVKI("/+?_GS/S1T3\+X8SR[WQ[?S-@/O2[DUG$#4
MCU*,MF"0H$9IP^9Y91L-QUBQ()AFD"1DOK;H2@H$DI*FK1@?)SN+6*XM)!M?
M3O,HJR5;V<UU,G\.;CV]@[O<G*,ZYZ >>#V),?_OW)"I9P00&H7QD=K+-KUZ
MH(5^ BC1Z?E0AK&_9Q>206=AKNIFBYHI:]=*L,,F3?"-6G%T(HZ#!4Y8^4@*
M%(E/XVR0UH=6F.(?^_[PLD4YK"AJP&,0SG-^EA 4* 3%:NX=,-_/ZM4X@Y7G
M?R"?HFML&[4:P-/%V:Y+X='MHKD3)P\(07=_S:W>'/J^8 ;G^SOVFY]^]RWZ
M>!J?)3][N>-RLY;I5TE1O:H_7')S9_O0+2/AIAA)$7GL:CP$/*"V";:S7[VJ
M)C*LE1;G_HB%^?N&^'X<EZ@KKR]O+*\?7)<^+6M]^++BTQ<EV]^$0!$MZA?@
MT-[[0/=$B6?&'2#+V.!XW\E-#_:M:=C1GONIS7//M"$)[>YV)PU=@M[@](+F
MFIFEF&,7OKEI];,)8K0U7IQ\W+<3FX^N$VE!IN8;L<$Z<+!TK(/>_N]E5HJO
M&-ZLVGOPPW0GSFL=O\2-4M-EC^$/U)F-9EARA: 743._<IAEP+1OT[C(;(96
M-HCV!VZ"Z\;!V)1GJR5DZ,>)1;O_[CUA$>3#^,^NW][]"LQH&'F?X1-KV$$(
MC'O_*PX7T@<N(I+@VNR"&!Z$WH-LSS%@7XRDHZ5\5;%;*64D3-RUBD%#-8WC
M$]]* M'H$+6N1/_35H<KDK.SOBKN<*T%$7,:]PO:H!6P=GQ4#IA/;-S'.SE(
MOLZ:IW,B\S'XICI<;DA8" FPM!ZXMR/5EQ_#B'[,;W#_F'Q\E'N:>\F/R\T1
M4_RC]$H(VN[)?RGWR0N6N(Y(IBB03?)=G5&^.6) )#NNX\E\=''CM^"ZD1^^
MG?8_.;(_/75P+KR9*#"%T'Y?:_>M)N]3*8AX#%XCKJO4T<WKZ7<@3"+C]II7
MFGM>I"BIP<#-+D3YFGFKQ--FO#^-C7=I[M10#S0V70A_W,0^20;'3QVS5/C7
MZPL2[+.).PU)[O[3;>?99DJN@+SL,FHS'U1[Y0WITL=DC1YKFALK\OS&?OU/
M&4GB<%3G[8/:UO?QI;]+J%7$%0KWJF"J475P7<. -@.79_4MK['0KD,!Z(=+
M)(T)P(G#V6AK/%%>2E[(AW^XLA!W<[+H;4#&7#1]=;=L\)D?84A ZX4VUQ7?
M?,.S \DSA$1+WL-_3?#I6QK<&ETD/357I!-!F&!+%C[*W.(#X-F"4RNM'JQ$
M@G\I)>3[/O'.1$>D/3).Z]SP>_TK5^=2K\/+*6@KXC^9WP/T,2@$+)A.7$;M
MY=UCRQ*>-1Y$)=M>^Z+*:<@;DSW>N[9L'QKZZ)%RJ=BETDMG5:;?M(PH_];O
M*J,N):N>PAV$-<VYG&K-@K4ZW&$^2P,?H]\;U6V_/4_HF)3),5&+;F&P';H#
M]ZA3W#I,/W)-,V:FH7.GO +![2.=/[H-U"GQ0$4"0#RY4=JEDAED<^M9"R--
M<F<JZF:S1YGR525IJ:30K91=)U/G7Q%R\ &P,5(+OBHT]F&VO<V(#^#.7J/G
M?159 .S]'^\>L24CC;B7!>,^/AC=C($U9Q:N\&-;\6=?"2$H>;:?7 .;>XQ8
M]N+Z *0.G.X(Q0LZ03H73>]<><&:.Z):_5R#0E<&.NFU 8$EQ8V'L+I#%_)R
MLO'YBZIN.4:ZR*N#WS!?S;J?& 8E/]*07M_Q\/2=_=5*!X,][R^>.!%>2Y/[
M8E$X1TP6.0U4,W("X@3@&7WQC8IUZ1T4::.849XX,T#<;9@'98)W_4SS?CG=
MV3:MVE@Z--UR#OO-\,OA\&-9"K._>X4@+=V^TM=9F7PW!JK8X[XRNL2C7*=3
M2C&^QS18::K,+T=NK96/WM?)4(U%:-VPSSGFC8'ZB 2@NR%I*69-QCA,4,D*
M:Z%78.V'6&21'F>V>IE;O[HXYH9%'X'*K]\3@L1BZK\;A#PEOQ3T=L/KTVOY
MY]?F&?#"O%\4EM-J9$8*Z;/O1" 1S=W-LX1 MF+:\XI+%GA/[(;4NEH:FJ_W
MRHFI2!)']@*Y+/:9@QV-\KJ#=T<KH\ 67^MO&V0Q*7\VZSGQ0E 4'M>%J+)/
M-.Q3YV$ 3\EDLN7[7TJ-BF4-M:-&]3L1I<4PM%%()5<QI=CW;B[7RFXH*\T.
M@9BF!;*.B)[6PS>?<IX3219V<.-)30+/8WRECV=3,<GM9"VX5;D@M\^K(*0'
M>M9P1[LJU./B[K^1TP*GL02W,MS56CT-[OF,>":V^XR96]5U,XK7#_U=SL0I
M26JSU>(,<"?2D/^R< 'I;$DE3]-,J83NVFC#KJ"@%&W)5^Y*2@Y7C<\_:UV#
M?6K U0[^Y-FA\E6]*>^6.,F/WRUNX8H#]@K.U Z6% >N7&AJR;PQ0O$5BS O
M.2\CGDIE^PAV+C$(L@">-K^BN*.&M*#Z3RNG _AIUESD9Y?A]7U2[>>A.^.N
M/W/4DG\^HNT!&6WAN6:"+JHH.;V0._Q0X$8)S$EJDV#O,.]R,"/[_)5J<L/0
MA0[*8U\O]V ,RIY<'^(]6)E\RMZ?^.7Y2=--:1?1/IF+V /.NURTZ"0H8\D-
MWAA>S_:T&T&O:K'MDZ0$0Z,DO=5U9[+L79DJ_F2I\D+423$M]4R-%F5L19*I
MOWZW:6PL*G,.>_I9E\'5([?2/(((7''%# _5SEGEK$'9F!9SOQZ3%L^RZEFK
MWM-L)>M.TV5J!*90M^G^*J?Q;"Q#Q]@_S:/"I4\V&AE_DFRL2)8SD14M8DKZ
M;"6M*!B-:KX[E8JVW-J&T^+![X$!:ZS>NR?0E9_J:7U8-7*)/G6$8BP$T4@Y
M^_O)5B*)G^._TS.W*'+PW]UFKH$VW[K0D_\AH"0NB6P*_VHWL#@?^%:*=CO\
M-S.U%$]+)+)L A7Q/BNFXB]BV29)F?ER#XS:U!_U^H]CC_W/M5YB(2Q;AN3R
M)IT0L]L7*B4XADE'LM')9*, $A"O)TKJ1Q,:Q7F_&LTZ)RO_0%K-[%7OE<4>
MQ8!^NR41(4UD$^*,"@>5%603H%,0_R"I4_%I&TM@_VKM-JN6;*RE- *3)GI0
M)D94X[B'7XETR^Y*UZDF(+5=!:S FO9\<?_1K;A>TV"3KOMC9-C>N3>Y#MTV
M\NXL/X>K-F=CK':R[;8FT6_.5O^;0QB'*_'^86E06OO$6H.82.GVXYC3K6KO
M!-2!!X]^C6"X-3Z!.WF853>"$"2-H$]?%H*>4EO,F0+/B5-:2<&"],EJA"IO
M!<&Z0 &T+JL1EKD%T%4%!E$YS//4R,GPTS^$(-8% J!U%*F#Z\L(M:#0C[)C
MF8 0%( S3YFK+;Q--BMTEK_%1JC@*SU\G@T^_:-5 E,YM20$J<!LPK!ID\6L
MUP3(B=?FQO+W.[=-RL8VTVV%()>U8?SGVZS75@NMQO5;A6'\8@[Z;UB;$S16
M<  X[<@2%.T;XIUF\#77D(TG*A4Z0PK\[$H20[SU'R5=(=8L_ E(E3EPO[CL
M NXT)G"2H96"I^\693,6\UZ:$TVO:>NQ%2A!XR,FY3ZQK%IW]+4URI=.;2QA
M$-7XJO>J-TX0?*+LS^IUHDR18]1M&.U6BAQO/QTMAK%I\W538CV*S -0K1,>
M4ZXV=;BXMQ-.8[Y*5IS\T&T69@.FDT$Z]2"=MM2;*W!US,4NQI$R-GS0LD8$
M$1NQ?PE2?D]J)>[4_OAK-3DYZ7SNO?GN/]/1VDH2(HP4OR>?3(7"MD)JK*B!
MF8^=W_^U7*A%!2Q_#$-[6LJO/V1#[4?&\E/;C]9KM\/O9&YDC%QVZ\H=,3=Y
MYX]3&^(=^[3 &<2$V@_H5:JM'*,$H8/RW"8L7@U_$M\.X^!LQ96O73RSG<18
M3\MF2]L9XUDV%F<65WS>\MSJ,IW8J*X #F'\^Y 0U!+Z(6+$/HQ2:?2H?J 5
MV_[0H+ D,F(:>HK?42(M4%Q]R@1B3-H5!T1@1S>L91471!T>[A47/8?P+71=
M,D[#_+Z8]ZCGQ:"I>(2OAB2R8('SY$),6GK!1'/!PD1(0T-RS*M:KD557G%#
M:7559:5TTO'CGPO.[9#L/D-*Q/NM;NI2RJ#\M!5[(>AZ!>JA?3:FADZ,Q@:7
M8-3:<HX,7,PKQ)J,EIA;TZ4$_2%H_JM"5\=,R_I;U?=A:MXG#DU%/+]"?.,B
MWO_?+SKO4C9-A* 4/,<2)W(MBQI%]I7VIQ@6XE9L5%S5JO126F'8.X!@.41&
M%(VGSO +KPPOEQ2A[_7=UVQ9&7IN&1SY X05@K@:^&]%6*C(-)Q"_"WGD*G_
MM\O D/71*+(BG0K"("U9]C'W;-+I/R61JKAT=TYA?5I5I4H+OWQE>GG=/.V0
MIN79I+XXA*PYA$5HL7.38LF]X$?2BXU*O,H'1Q9_+RWWA&A-!%[R[ZAS3SL8
MU:W_)\GX,JCS__V&T8W-D!7%91^W3I5>>I[8H];VQ*: SK?KAFJM.+D5^X1X
M/;X;EKP5/IE_1A*AW[G/EF4?S;.@@:5_X619Q8F^C1JLWSEUN-3;@7J!3B.]
M)Z_L#ZL.RS^=*)_6ZU@JN5=L38NW5UQ@#67T\;\2M\K)&FX;-,3NNR<P"LW7
MK4I^L;H@3\WUY]KAGWQ>0<=&7,_6@1Z:GMI'"TKRL6) (LR/L4^WJ-9$8@/R
M1380X^\DZ%;-R19MCNW#APUV70[EJ*J)<C=0W:ODI\EE0W3]U)?@;BIKE3 .
M$QF<PFWXY6.% @LT_CAH:W'2M5\O?[?CDJKU<J_D*XGJ7-^@!YV-BH&.\7W[
MCFI^8507SA+CB&7SR^NL@@Y59 I/BL49/<>V2>87\-]\=EXT&3TR'N*L5GR$
M)=%0CXT;+)DY!_HJ&>6(0W_Z^-]-IACA1SC^'6DNEU,!G!5Y,D\F_EFEM*F,
MIB+[\#<V/IKK[+3P9&4!DG&!4)W^20CR78ANU._PWW(,C/N%?X45XS[!BH_@
M=+&F ^;G:3U'F$Y -"W\R=""DW6I$'1IU!"JX.9X=ZLW3<H'P=;1S0>RLIL>
M/SE2H7I4,/$BY=_LO W<6ZQHV>TT0#X/$]T6*@1!>58?G*>M:6G#(N-9SF&,
M!O2^^;3T".7-_EWFS0MH$/2HHF)^QFM'DW)],*1QJJ[Z<<)K[-0#DSUB2SGZ
M$>%+/7 YGOX@;@_6F!77^O/84Q;@;UDY.-^X:^^BTXNS(85^;3/Z@H&A',>O
MMW=.%WX5A[__+/VR<]_NW9X:9R4+S+-"/GZZ46PW:V\?)P0]6GIO'5#<J&N7
M/OP[Q>_AW<&0AN1=>W&EJPFSJ%6]8^Y#>3_Y;MJL*S_QV7V3H;1- ,GNLZ\M
MB[] QXN(S8]-B<M4KJJN_T(6@IZE7Y9.C<SW([*-Q<N7/$_--=:*]/D.[[C#
M0ZH&UF?(X[KQI_MP*&#V (=>;M!/MV.'_]+H*/Q<_2I/(4F<-KS\>,N'PP2@
MC]GIM(:?H['+F=?9\ZU+L^S0Z!5Z9/+(QXL!6$MZNSC_< HIK\(XNZ#@I'^=
M7D116\<V#E7V;Q@U"J<*(%G!E_HU%P=M?@0$K&<[A'^LG,AK-GE2?_%>47*D
M_=#OJF/&M;>YS[[QX^15!Q96\,&B(FS5Q:U]V(HQ@Y+^[MTZ6A2AW2F 8:\/
MP&4Q>F@E/R?P,]ZMH."BNZ(VL1K-4]N1&L0@0#"4=K/VZE1ZG^POK;:,OEB>
MOM*[SXNA_6UUZ0DA/\'GW5".(^\<-CF[-JTXE3]XYS]C3[-2&N@DV26!=B:=
MU(%_"E6L0LMAG)'I-]EV-712G)O%0%6?O",&==$JTW*D:F1@><;,^_6=ZY^K
MO[Z;=KPOUMK'O8-$H[T*$,L-7"M$VR0E*92ZPY;&)8QSD>R(D;_4IX\0:H?8
M*41&L3.S]P4+WP8'P<7K[54IL7 M_R>U[&U+;E*IK84,J!R0^,\/.O"&ZP>.
M@:AZ_??O-&_\Q!Z&,R+:'JJ).W8V?QK7,XIBO6O46*BK+1M=;=R?29K0&Q7L
ML;!LZ9]84NWXE,>30B61CJ2^_YXA-;+^I5)6P9E%29X^,80S=L7N9Z\^@V_'
M#:A*MD#C$)6$!-VB*K 4X,F42V<GML.EZ_EO>%8%!6W.?;&:\OV&^"3XMA\(
M^GV@]2: XA,^^\IL3;^@"4$ \K6H"TDP4."*QP4K&JQ,!K4],1$)X:DF,JL)
MK!SHN+8U$,[$QZF28OXFFW02U1K5D>SCOUL9R&;70"[3)P)KR;9O@>XV0L9:
M?US,41M^^"X7,VGO?7>\MZ'D%WS_CS/P+Z(&&; ".\M&=PA!LD B!\-_:X@'
M\W8"9O#30"Y#=[AOF1M*E\73YPI"V#?ZFK8ZGZX8HB<4;@*Q:-Q^1#-%%2KC
MJWF8A8A;#]@KJ\P[2VC*N2__2*#(_V@$5<-ZL3=:"%*"7J)&50.$'M<&EL6:
ML LZXJN0XTO6@/O;I6DMX#QKE7FC?F&"TID-8RKE%OC"(4 >W?KTM7!MNF;1
M@/\-"D?'K#=!>1392U%OW ULN PCT*?,H33D;K<%Z&X*C0@%P96QAG'+[1<;
MF%"9)43UMQ'L_H+B?O\*AH:V#7L^$E%9\[+9J&'[*JRVY@,/!$B'Y?'"^(6-
MQS'U2/;OF,?%@GZ<W*A 8[X#=V(0NY]!D#G+!0N^$N5"PN\"!T8=HULR,BXP
M$9(8:FO 1S\GD]=U'=%'[9_'Z(BAFZG55<1V61-:;STKE_.0_[;QL"]%!;Z=
M=YS_3K=*=I<0Q+G/FLK9SH)TF 8$\@Q\F&$P4<)5:D49@8%+.H:CF;;L(YDT
M5UC'Q#^[%]QNFLV1#G<D*E51@KCN"\:HO3PKED!$_)2.>O0.S'FF5BQ\NS\1
MF@# @EDO^QA:261]&FPWYD'O[Y8NINQHAP4".6R$2H"KL,XMJ=8T\PTNHM2N
M]$O9GR6>8^^HV5QGB3=!H#MX,.Y>DTYP#+%*MJ2>A@"T1I>3:5++C?+ :28^
MH?@A-$%$SG\;C@*=S4*0_#V!?.(2K'K!J8#CDYZ/R3(,@'#8B1N6KB3_X;\$
ME24<7!2UY 3V)%":L9HB!*$1$4*0\E^2N@OO%%N1U!*&CQ&"Y![BQ[49.ZH8
MZT!NF*\7S:K3&[C%0&Y;F'![4>RO:8)76UG#PNUT[W:(<7PZP1-'T-&X8P":
MEJU *Q"Q3PK<%,A#,XO/MTXK =:/62CKAJI!G*;3+_O& PVC,($1%@6<IF.8
MXFUF=MD%[7F+$XV%VI"3%^.E<Q2N\FL$>Y:@DO"CV >#6 1;D]F,VH7P@<K@
MALQXMG=5O=\P BR;W/2!$ 8E_G^4<J9A2>7_W[?5RI3*DEQI,K-%9?RY5(I0
M.49E#I65ABF5E0L9TZ1)=832W!>F34M'J4S-!<D2+510 ?F5F5N*RR3;E%OH
M.:5T1A9OYG\_N9_>U__!]PG7@8OS_7P^[_?K?:[O=?JONV0^GAC9]*KQ):0N
M**'ZGNCAT$VI)8U8[F8>\A>OZA:WEGN:_=I-\!,(K4[3Y7(HBZC#"G1KQ_;6
M(J3NZ6F((.Q,M7(4!% "05UGNA8'3H@%W.,*;2!H+&2;;"-;)><4NU\@+/]O
MZ$SB[=;RU]IDJ%XF2>>9 IMTY?P+TA322H, 'WP)2S4K8;PZ4L?T:$+M;H+N
M6S%SM%O!2@6^166_'^8K0[Q- JR;K7+*RZGMK7-%Y<II6_I9>)WR'@DR>\..
M]']*OG 3.\4T"' 5UJV^-=17OD.D<5Y"VSA.6M;9)D>V3O)O=T#>)-"9R7!G
M+/M$/ D<;8#%YX9*"Z^%ET;I-_5AS:**3/0CN<ZFC7Z6#^(GX'OJYR RF7^!
ME(WBY)0\AOOI!A-=A-FN^05N$%WW+"B-_('U[JME#U:>@*8>*!M()E%LA7>H
MW9SF6(&<5\M;DQDHB4WNMPA=-7DO,F!3.J*9OH:')",- Y&:R6&NA(W567G*
M^RC.O-'7?R"4')\>&XS=YJO!#FJ]ZGKUZZB^BGFC-"WAN31T$%APEK:4_Z]N
M40M^[?L(?_XCV[AY"\V%?],5*:0VDA5LV%&J4FD<(DG&>L]/P%F(T,*'MQ;6
MWW9RP9K!T[^"\5EQN'3:%EAU#53N!PV"K'(D@!9-S^$O[>(BRSR!U]5'56]=
MJKF55:?;B\F)JQ!O@#V:X,%(O<]'K?,S[1I8;O@WRZAT1=Y-K"G<KL0GS4A3
MYLH$G<;4:84=6\XV&SHYX>4P*K)%*U3Z)'EVD$AOF23F.8+U@@"R+X@AOC4,
MY<__GO@"XE@PI1N+U7>%+=;]J763,]9I=R>%O'D)I0H[%P*N/1<Q'J:<+Q5Q
M".1$I5V-HN U>];4GM +K :9S76T'7 'E"ED5RP!*2V,E# ?Z' 2,69)[#5]
M#"C)!N)!7P5>Q$_-12VF;=;NAAQ%G4/A OTND,8IB<P7,5OSX"AH#3V5AX)&
M,STZ,\OP?8"CW,=?CDMQ)]C KP)!9L:S[KA.Z[K4)U3K9L<0R#B[$=-1H(D"
MEL(E&G_J= O3#'!&W69A;:EDF51LB,+KHNGFC=8*W%HX_ C4*9(N0S<S38?@
M0/UJ=!K?E(W/=,*N@B?5:;V<1QZA43,QUGBH--,JDNWRQN*-O MQ&L[3$,>+
M%D+Q0M-%!V$/J$QQ*1.\*O#KHWE0I?*./$%Y+3JE;FXDA[=1XS.2JD2DAZV"
M&4I5^'[0YS,C9];'46Z<"%"J_)^^C"RRQ6Z AO&RDR=00YT'Z#8CD7< :UCB
M*&#M4#1)6K)#E-^)VEWTY*&(G,<\BIDNX\=>W!I#'+QJNAKX/7;:R&##A_G&
M(8)VUJ0K]1:'#0>55\)3N/L\<^U>^ =X_;NB,T-[ URD8.3H/0&:H2*=Z^$0
M 0T)\M-9&.,J@ A*FYG+M*Y0:A*& J$.@C_2&YU!.H&0'H;H0V@=PG:>>8I.
MC$LP)C$TT>Y4<K=VN8)M!UL?@PM .W0B?XT'!0G@=<]XFR<M1K9Q07Y:+3MI
MB-+*3*=MYAG4SUZJ)=5U<1@+"WT/@$UMS^8(@DW]!6*K']GT%XVF+'JKET<'
M1<A=9GSCJ?XO.SO^&_!39P9VJ38>CI.QTZX3<MB\-=I]4"UNB0O@#)V8;BXR
M@XR%=^1\DW']*EBLD*9=M^ KV"DT!"1A:%T-YN#=4F3<7; 'O-!@U\0:(VKS
M+9+98UJ\CDLS!UQ <0J&5 U3%!XCA0K^(%Z)5J5'F24]ABG'^IQI2"T"MY N
M=^V^I#+.9"TNPGWL5!G+F+#?3+;#;"&2:(5/NP\G(@,6>$S?):1@-P(A8-Y7
M!HC>;X!O4NL(6O?H$LV1C#/W8*-@9#!(%XC(A &#S3)T#VMCD*WT5>Q%U""%
MV1,%WT8;!7YAR5- ,TY59%+SG!V?/<G]DBC8VS4[;^0"E=WD_0R0P+Q;+*T]
M2%%4IU?2.DE@0">#](J1\16(D(626E)/PF+(WV! -1V2%.TN\*_)Y3'G(;-.
M_Y>Z1T <O8):T#I=0;4,[P>6&J?YDR_E_VPL+<+IW@#F,A5:3!Q-P5H H3#G
M//A#CFO!Y=C9HQ!\^>%(E2&*#2M? 8%VZZ%U#Z2&W\]"F5PLM3H,^U4:NNU(
MJ65@<-JDH6]12<*5<086Q-_HB% _ :7)C7C-3MA7;+<$3I6AK&D]7'%Z;"&B
ME=NCW=DWI;=%K*0F<"H[0A2Y]3)F&L\9+$E)*H=SOC?/&ZV<R0YLGIO.;BN'
M%BGH@FG$[6\<27\LO?,A/0*=-;(6!Q[A+Q@$,/TNC3_10;J,+: /OCI6ZTF)
M4/*7&K9!_0=<P;/IKDI6?9XJ> XX&5B7WOHG175XKHU3#+OMAGK>BX6N8UZ.
M-S2_ AMT)3P'[2GHAY"?2L3?QM7H%VGM8<MB+:H&ZKS52*B$RT+A.Q0H1(_L
M%,?!)^FEP'Z0EL6EL4NTNW2/:C]^! **J3T^$6TC*R48[]5=&[L\:A2K$,]C
M4<,A\J ,Z[;^$;LN[,8)JVD#;$2'7E'C)3,$&*_U+IO(AO '>E+>1,6=GF.G
M7W2/\6VVV]+#:^7NR)"<6''WT)!GDYFA6;$;D_:.NA.&,T()K5[3Z;/H0;+Z
M#_"3BB&*U!M@O97+*]<X3]#LX6P(IS>WC6_A\E,:'0QZ3U=Y**2(L1AYC*_@
M>E%9Y033G,-?'.F[;_^4NRWIU!JG"*5JASH6%A<#YV!7R-<?OEQ>B!-)ZQS_
M!5P/SCOBR8GK*('S(G6^[@D_DC3(5!X?;^)?'.>M)QG($*E=X1ZS?51BKG[8
MC?%ENR?)]4F/';M[J2YT4P !WR%#.!DIF[8I,AY7YVAH'!M3\]8ZKFB:@7&3
M!]Q0IJ9C#LC1678KNC'N^,Q9%5ZP]7(9->] #6B_(SL(3W';DQ%NO4^&.@LX
MPG?B(&_!&FK2<?@RM%V.Y82SJ4F[)9@%$&X_J&-GN/L$^GXDOG7Q^W&[T5_)
M7#0Y=X%=,F\4 1<(N#\2@7#V6'Y=)LN/>PQ:PGOS=.Q/EE1E+/='#78&ZTJ?
M=6N/[TAL] &+A?SUEVI-;OC\U'C&\Y:<;A;-V]S4<[%J&N,;\9BYJKULW-PO
MW%9?;Y$Q5+P1^_K.CC^+XC0;F+;LI,;X'>GV, MQDTUSH>:/RE:B;,1IG6T%
MI-L1 IZ9QE>[S\ZE@0^U>I9 %X&0/HQQ&3R;U\;%MR:0FHEV/.[2-\;JE=C0
MRW+":KA>OSQ&B5M$I>_I]V"NIQ:K?X8+Y-GF@ER+>M(PEYF&V0.RA?E8QM.!
MP=5J^?.)Z]F*\;E@S.<_DH;JRO;=:U%L;R?.N 8?PL5=_-5Z+80<)JGCX+@@
MVO%# >?_/ ][AR!(+ATU.YE.)Y#FN4[;^.2SE_T#W'W(OKH76K??N)_+LGE(
M Z&&*&,6"5'&L87^<G&V2F\Q@=VB;X$A14*$@;--&F^<K]*ZPR404OZA6&X:
M+ARQ@TH?;>AMC'',JHT'L=RX3E._ACU>:KX0/53F"^(S,'MDS@BY5#B=-H+K
MPH3("$L&J+B6$T6+Z]Y O]8K^<:3-$QM*/(4-,T ;.4Q.$*WUE7>$7@4<BE3
ML"A[OQ6&=\>:&S3Q0RH9-WKI$2@^18%_Q9P!"7*F:OL54+U4QP3HD-LO\+!A
M/.>-DK.5:$,R6*ZWAY=\!)RZ>)YA*!O2 #50IKZC"%04H@\Z^DHX?!A?2S R
MC1>SV16:"^QU>=EQA"RI->:RQDL; Z$%.$LM"=Y%EH?XTY=0Q:WS1K: 90PX
M+>=,/>3;8M#@E_\.:,-J7O4 40IGW^;^Y<^BK) Y[^G@']0[P*XJP.>N#SU4
M.$NX#C%4K^245/[*"P;?9R1)[1K1Y>-2,WH4.MVJOE5'$F"7HM:X-Q &,_UY
M_4"\G/UR"#C(;"%^:5*0K>,H*41F"N8\&T:VJ>?J4EDBY;$N!_UPN<>\T? ]
M>7+J[5KI>MBWE;E:ORU*OQF,^#JN[%Q$I*(.@2F/KBE9]NI2^-%C8!L<M/3?
MK.0F1B$NNJO\&GT5/NA Z#]492#X^QC1FS$24#6ZC_U!FD-?P8^<SF"^0HNL
M38U;2):8(Q:5&@R]Y1#F)]!%H#C3CZ;M9)@"!V#?"'EG(L\*OA>O\+Y3C;"
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MB>, ..WE($QCT+@N!UZ4C"^\F[RBO#28#7=_1N>7,[K>=@QSE7DJXE( P^/
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MQ?/"*J4<LC%5#KD\;Y]<')/ 4<DB"P_'2A9)-!C8['JP>P!P=A(NYK86^4J
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MO_ZVTVINOXVM1/AB- @#80=D=ZBA^NFG* 3;3B0<H"8N#/0_1<*UJ>)LD%#
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M#-$\T]JH;[=X?%59#+0[EW?(=4[S-LSL6B9786R%$_%C#W:#!CGG*O00;H"
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MH;J5J.%3UD/2HRGP8U:R\GDICEZ4YE614U0!I+#2\WI4ZW,B'X:-XSC"2V7
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M:?P&\FNZ#N1&\AZ$ ;Q0QWJ<E.*NJFU**K4/>*>)MH6=,X-8DJQ7M(-<VYS
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MQZTZ>B <>PC.["Y'7RJ-*[5.$Y*Q\\)@/$)<PE0)I;2AX5"=K35YMGFQH.R
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M(=?%$ 1^DJLGWU(GI*H@&IUWN5L16\JZX2!4T$2'IDHG6BJ0415?RTT!(K-
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MH5!'Q*'O^$PR0%C"YM$$8P4&SIJ=GM\\IWH5P;/*O1SV1JZ%97)\(PM<)+T
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MB6W:XG;\AB^S;Q$A56[9/<)Y=,RM8F PMO:8[AUTE#8&%F%>9DA*,J\NO\]
M[T-AR@21>O]-X(.SZ2^WSA2X4\8&XQQ)9C@7-CO]F%I>^3.'T\0F,B WCBV>
MZ#9'7HVRXGX5=?*9>$8-',6.G4E9TSUU,"-1XLOL.RH6HO2\3Q>O)1(Q"U?:
M8=X@W<ZW@9B0QO>JU'/'O25 T#4K4;WY]M5; JS[.@1@@N:>@*F:H;_U$ BQ
M: =WLUS1%9A64JI3G5R?:_8U)A@+(7C .52R9:<<%,0.-&X5+>SAR..C[%!
MYF)/;7'C370861EH5O<>YIQ\UM61QR'8K9(1]/@J<L<G^E!M C2 OL<3=SV
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M6F%<$[)8%"K1&ZPC W4JL#0WM^ :%NV&=&IANE3=.DR;$5QQ27^OT?,0CM?
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M9?\1,FVRV')L/]W1B /+SN13X?C!II[UT+:TQ>R%F0(,#%M5>;1MS*?'6+D
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MG])+63SP=E'K7[08,!"%D;WS1S-E#VA]/;@-@R1()^)+4DF$X+C@N($36G7
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M"!W_="T@$2-U+RL=@&J(-:M*2*:Z-,[^@%'F",Y4F8KW0S<1X(6_><[PG\7
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MCE61$D\T07I/ZJ'8,**2YH(Q7.S90QK58L_.\[TL]JQ3008.2L&T!7(<N-"
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M(-4X_*15ALO#-F25Y3"I,]K*<19S$@YLM@Y"CS4/C%=6Q$Z&):M2<B-U0'B
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M2AZK@2+R<A(G5\=*S5$P.S=4_2QK0_;,I.ZHN5T5K"I"$O:=L@FR=HC6/I5
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M2<> 4(\$$2!:'88*$NOHORAS BQ;]'RP5=_3ZP7S+$('4!2G2W @"WCQ0'_
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M?Y<JXT4A;1 EF_T!$X*H3XSVCMIY UJI0>A<3<5$-SS7:U6P<4@U\:A/&*]
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MH,A^$A'/$_O(H.N8@L0[]SJH\[;&ZBORJJ,D]J;0)28]2=,O:/EE*>0$EUD
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MQ$[(+85F$BDU1?<,1?^VU\.(&$#):\HVFP(9N&W1(:O7.$A_,C/<\BDN1\8
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MXJ'M(BV2 -(+ /JC76K!(DP0@$@!31F]9I<-8G@72ZT+CXQ9'@$[L5ZZ =<
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M^4M;--%@/KN*DNZ_ML'RJ[)R?;+6?GS(VH]/UMJ/2Y;4S;)R?8< !^X[*:@
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MG(Q0"B)7-\@W7\;GXYENX>KEU G)?^R+-Y6SH8GLI#W."QRW;/0+E*.?G<(
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MVFII_$<%KWW#A/VK7Z5V95"2)7Y"/X3SZCIDS"/&9G@C8LSZ!T'&X* !_.X
M:Y%.5%; ]UH7[\YW!P76&6FX5&87^2B.](3V&.QXY!_&2Z'/39>JG-*RZKOQ
MJ*1 L/[5MFLW%<(0/U1(WN B%XY=1>YA)R@"AOZMFG/CY>N90#*3.<-/>NW
MWUGAG'D$MJ(?X%H7PM>SSR%K0FP=9&FMZ4;E)8WXQ@)5B4 GU<&S7:0E? II
M?O#E21$WXZSO7-+__U/GE.&<9#_)6$PO<<1P/LVEM<]=76P0=!=)_L J@GUM
M$,T"NX.KON@'PI0\$@2N?H>FU8QP<6,#,F\H<SNOU_8U3RB!DJ-&;A822RG>
MB[PPPWFB/R-CVH2UQDIBVNJ.J& D;J6OBU.?T^%HJ-K5"%S=&GG,8E5:S^ E
M5.B:QS9M,B-5T:@Z6#04+/TON30(WFK.M1N*MSZ.*7O$%OI7[6ZG<!OH0@7R
MKNY>1)^]#I_@CLUB*C@A\D"\-RB\@AE!\%7T<B[G=:0DJL0"IAD3%P!]IB*"
M.;LA12V$=@\KN_'5&'1@+G^'EHG[+C;J?@;&C1_DW'WG%0WW__I3]E<P7-J3
M%\'Z6G, ?^O:QV&_VK6_ILOSY<Z)ATJ;A\A A.]T[L 3<(<B8^SHYLP%*0EY
M$!"T(P#A(RXA\T8- P%BUX0A =8NO:+@C^^*A[:C $%?[/P@K(,UF9AD,050
MYV"EI*_!@9TSI?*)_TT@<-TP-AA2"&@F4R-B];>N3%FBOP4/AY<1=YDAM3DR
M+ DZ5W!W(49H!]\C,[ KCE59T_V/<1SD!_?;?2,H,;ERH 79UZ:W H;<M1/>
M4G1UNHJJL9RAL=NCH$Z(HDGDPJO@#+QMVL?:EQCK-%1WY/%%IFZP"N![2%VE
M-'K5P!&D,+X'SW-A@P(CK01J$*-F=B::;CT):SD1R_,;4BJC<#0V51M'G5%8
M_HC!/G2"MF!V@Z-#F/ "I@^_CM V+H#!,R@48]70S^.FYNDQZ89] D/J7,C7
M3) 4F&Y^3A@FO$\X>02=@#4+F//5X3 V9-R -*A1#W(W_;V!-R*6O.(!+!L*
M;"8@1ZL%<L43^MI$ 687FHD0@RPI $B,\<;SI\9O-V",FL(%(KOX%^-%Y*FI
MBL$#K[TEKA_@@.%H)X@D>69(QY2":P(XN,#!27?<(U))WF5O#N K>(JBP+CJ
MTZM^(&BL0 ),<7KP IS09]&E:4/D9G5RPQ-9GP)R*N4!P64N6.UT'0)PL^M$
M!ZQF3%U<*D.]$X9PEWV3;@)A3-%QYLB'+.-4*RM-J3V5Y/8G-WX^,RF(: VC
M<=(X2,N%RB_<%&Q*Z$MSI]BHCQ(;(JC=<_&830\O$H4F*+^BD25PQ=D?28 L
M;'  ;S@;X\UG8CM9L4@PL2A  F-;&1YC%(Z*P*^C[/P@VI*<1+H^S*7AZ-)@
M=#B"C&39X- ,R'8W5H,B7G?!PB=F-N+/,M>9@&)+31 &D'ID<:T)'#.(#-U
M:3=67PW"$*(PVH@9&4@]")=Y>J+8C85;BN##98!5\PHN'DR<+<E8I %O X@:
MPPO+]A!0&TI)N');8;-<"3:XG.&/:SG#ARQG^.-:SO"^AR&IQ+GIPX@.SUM_
M2FQ_"3Z;T"6'!+>:AO(%QL[/Q08GV+%X'];56W1[V3X@YC"D\2VVX+.P+YX[
MOF$Y!Y^#4\%BR#2_8"D,3,)=(A.3ZN@<,P!P*48WAX V\Y1^7+D6\>^$+@F7
MQM:&D-@:T@("Y#8#G^ZX/_7(%";DV]KWD@=Z<[';*V7Z.L^[RAZ20><T/-HS
MN.1GKNAO)[3!42MP&]V"G9;PW9)[S\4A&%X.EAB2IBB19[ "T-::6D-P3[6-
MFD^Q3FB-#EV;0*.R%+I/9 3%DB*-Y;S&+$-))L1GJ/%>;\%KF_#Y8'A'6&E_
MATP/R$PK\-_(P]F/&Y 'M$$*8F!%+?.I"%"/!();;V/?9+H:8LY P/+1GRG7
M\>FWGWWY.D!RDQO*5+:;34=Y;U]&605YVU/M/'QQ#H=O_"/XHV((HXF*.7DP
M0Y@VB69/3AN\YHO/7XM93*#\%!C:^H6'WV7_"-RK,F8<)>*D;Z,I7M@W!XB6
M4*'F8/$.U6"@/.']V0AG"3TBN*:(; -^K.OV46^T,A3C<2>UCE$?CY1,S+41
M)K(YZ<,G>/-T)<AJ,JO2Q?%R>CE&EN-S9= ??Z)#%D^)1]MJ2/*I([YSGW-Z
M:T"0^(\_>85/-6EV_R/(7U\]T*U;-%I.@-XUQZWA8-5UN"-5;<$#34_&\F"J
M79B36 /@;F488LL^_>IUH$.)3PR*MFW4Y2/#X]@V?=N%=H_VL;$!$%R8@B,F
M^ .M5R@S9/+VNGXEO 5XKD+D1)!;J:$^A/[YE6R4("$"7N_,T3B0/8(\Y$,?
MA/<9:;=GIZY_ $O.ALM-6.0L/'B,B!4]'^(I-0AS)14DP_V>@CH<F#@%D4Z/
MF4N/V5WV]_81JZZ47:W"%Q% L.@BJJ$*GX]%*)3C)_(U*9Y*R72+;:B+TL)7
MN@A4PSD\B5QSW#)O274A%,6V^NQ4L^TS.[-4U"+9@?K$UXV>7YL)0_:J!2/\
MK 64?0T>9:N+Q75"5+?&6M!J69@KN0'!\8CKAD62Q+\=L$T=O$YE86&.A)6/
M]R&M'59\QSL/M$1 _->IA#?H==6TX.@NW*.T_*4_$E(S7.&&%LUPY8H/$8)O
MZI"%6YB5<HPRKFKH2DQ>]AJ^&3LG&D:]9M[S7IE33%\1QS<S=,(#.[*$IUML
M;<1<8ZZ?HFAG.W#6*\9#0]1S=1FN3)JETEOJ<%D*J'Z?Y4!XT<!S;) ?/ :R
MM?%!ZYYD__7S!X]JHU<5-OOZ-.D;P^*.:<A%L.AS;[T_6AX3%$431Y<.F(WM
MP%C,E\Y(.<[7CEU>E'WE=Y8J'(-%> 7\%QC,'0P.C.^O_?9MC;\K&/->OF2F
M'+[U-=P4A:^S_[K#?:--^W9_]SEECMR9\XGF8M40X7H\J1</HTPFGLDG;$8T
M!5R248>%7#C;W*Y#I033_IRX'71U\3C3E$E\#,P$/KC#&\2*8!MT%I;ST4JP
MM?Z*2G$]E5;1=#98JT"F!5Y'=4VN$%W/U)HR:]>A5R&?#MV%+2RT?9KVO/0J
M:4[+A*G*D<88BB7%S'F(S![W+65F8J$!^4HQ=ZK^B?@TP8M8BEMR+NE$>5R'
MU0R8K:1F,JH[U++W=E,'2%&R$J7T0%Y!FU.V;&4%WL/0.B6,H/&0*1-H;&=J
M&[%5J63*:U';>LM?\822:F";70W1WMZ&PE-&*U8NL-$#ZWI*@&;IYA,1$[5.
MB$3W0EFK]#5\%[B)]F;&T;D6XV)@DLB9ZC(J)QDFM4Q@Y3'1H' &E*K^S?ML
MDM\MWTL2^\9,*5O'\=MLL\<.NNR='73G&>.$8,XE!',+89O.D]&MRB)9/]VN
M1R%#>6CKM,2#^Q2X4DC[K2ALDE2!T*HY*F]F'4GA(KRR'L)[D[; EAITJ!0Y
M^X(B0-(.@?_E#+Y95(P[,X<M+%4E_H-2TE)R0@F&PR7D\).]RB<Z@[!6A/+5
M$:5+DC"?N"-6NP:FL;BQ6SAP<&0ZZH3$A@?M9K19>WF[F[X=CP@JSD3V$\5,
M-D8U<(D(TF^3V4%/( 7=Z<-/3%99;*641/G><0R#+<5RH4&NZM*\#BSX.!49
MLK?F,XGCF]>PV*A:Q;XU4W;#.]O>%-2XM& EN(UMEQ86A"(RJ47CUXS/_8:X
M7";PI[5,X$.6"?QI+1.XY /_<B4!'Z0=>1F+@,P,\N3X?FJ[>]!3TEJN2GG&
M1,8W$WWAGCHOUJC$E>E6<<"Q\Y**,?6FEP+/M$!;LT&<V<MZ+ HU<<MP2T=?
MW)HFIQ[L6DL CW ='.3LO$/928I#$H"(D2+'-F#/\H0/:*3TTUS5^$<-G,UD
MT':+<!A6*2#&WL$7P)S%RA%D\E8'/]>G)(Z^"92D!@H>'"WQ4UIR*HN=>+#6
M8DVK%YVLEAI,S,?5QT8['3*>2[&_J2HFC&AN<$=35I(3$]_83D=KD;$ 9CFL
M9$,74@&9<O<$L5A:IED),!H_DGXU+V$N>*<VM\$T"*V"B7EMLP15$C6#SS,A
M; E6WYZMX:=NAHHNVF1@2/YS;#B_$L V8CM$(IR$,Z/TYMQ]).Y,:!#UXL8T
M/\F3>4;ZZ-9C_K,>1=1,7X+E5=>PT4B$^2TA& RG]1;\E0V=!50CO7/J4P *
MDLBU=F)1U;_6@)BK,8 GA-3=:NI<F6J!+0_YUFGJ[=QNFQVV)?R236_[".&%
MTB2"06'?6 O8H3@A_WN'E3X]\FP.N<.L-O;S;-OCJ:ON]VPHT&=0B(COFLI:
M=U7)EPL5YL@K+$A(<=]Y&V.8V"))4T4Z52K9"HKI*(J)K:EI.@0$G!MP\%'3
M%52N=1Z=K= )I\5'D-:X[-Q@XOBZ500W6A@=IA#3X]GZQ]V;.QM<0A@QY"CF
M6</->!0DFR<>6;NAE(D2+F7$))$H&6VN#,@WX*Q*<-!D'C:!85XGWP>T,+R[
M1X(((<L!]J4BRX/M9ZYK0\V#>VU#:WBI8XQ0C%,%?7@ &5 3AL9"7^;A]2F,
MPVQ3,Y(Q@]9P9K+3N3AIW:G;+9J\_8BI$.F1T>XUBF:">0@+\K]>@F<"9&$7
M#6P6#A'S@),V)@WV%1F70'/I'N*>^?NB=ES0TG,]H)A.0B@]04,;I4XN]N$L
M+X<]MNKL:F=O:HI)=2^^Q?W,9ERVFG&W,B%306;@ %,8PCRT,H*8]92SYJI(
MT2"FDK7G+H&01WQL$MV41^]WI@Z= 8E9N*<L3B+%A+F"N$6HE F]:DA8(.E'
ML'@D=,XG-^![B9(AD$)2$4Y_94\2S".'&X->@AXAK :W3- G][ZFNEG)@06U
MK,%Z[:5+*\APNGSS[,1Q3/6=L^O 6F[RIORGG$JM>'A')@KK:Y< *FVL06]>
M3L1=TDI8V$J(7*_"?3_-'"B2A$H@-MQ3;5]?'"@_-RDYYG*]OD X-XL;:.?U
MD[)K$V7F,$D9]FJGFT[*^7&/_Y/83*GPBSFAM9GR%"MD,OWM'BODFWNL\FN*
M#MQN_*EJZ*I$%PROT6W5;<<#7@_X1SMY3O=,;,%^:(])WE9P#;13FLN"SRPR
M";6"+.+(,$2P<[#&!Z,)C'%CCP]=+Q,,J/5:N!:':,EQ3,MM8K\TQ<JJ4+S>
M>/R445#12IWC4/ 50MI0ZF'2YN(5G//JY%J$(BF,X^O,IWJ<U!KJEECJ=/#@
M2):D(T=4]!%E\DD6O;:%&"_/J4YASQ&!E7LC@JI@8KG7^2+X4%XVZU03IPLK
M!.)LEQKAG6UMO#036[K%O1NV)IK0&)9Q'SA$OOC'6,159+:Q-7389X3W/084
M4O9><&_!^2[Z_02D0T$\8LN)B:%/46(X.;8MC@&Z>0)-:>H R-&$+WH<W:A%
M]X6YAV+I)5J?=!%Q\<!]8SS<R[+"50S.(O9=D-EX-S]Q!RG* 3>=&H5TQZ+O
M^"A3.B R'_=TD=$&:^DZ#[+7J._$()]4]_J,],-S57A44L!=C0:]!>W"24PJ
MQ&XPX8\2NPCOQ"*X]8RP,LU/+>HL9_N_EO37]Z<C_@V!X3BB8(8F+9<HD>TQ
M%-R:&E$<4./OVZ&B?%\\$*T8\6'L&MU:#JGI^6!3.2@X?I-9-XF)T))1K"2,
M;+GX>FEL^.6J<=PO1^B8Z/_!=NXZ,5JY;\D<5,H !]3\4.NTX,[H2^S=4]@Y
M4, EK$KN)LO$!KSZ*N]45GS]R;66NH6;NMV^5??41G+'KA\YAH..:,>(1EB9
M]LP5RN62J/]82Z(^9$G4?ZPE4>][&)X/<LJ7.S=3E$D95 #I(NNJ? ][*KJ1
M4O6@&(-+WW)J1T_BVL4&[L.V6>J%4-)P49&A;N=?#9916,4]*5SVO+7Q[3CC
MTJBHH8LD&4>EQ[.0E>F0FB:U'HJN0M R<F)+1+O/L[+=CEQ&@\@,U*.<8RP7
M<6XFG0!R0L@Z<]6!N78V)P.9PP@5]"V!_XS%9O.1[FSJ3\*(8$; Z,W,DK!\
M:/ WY3SN[ <E,!GZBY7E >/G& 9L"NTTQC;@Z6*Q/6KGO 9VKNQD?TM]^]76
MT8GP#6T>YR' #_&/*"-2\-B,U-:N>7<]"2S8B0#39]K&)E7^O>T6Q5$331R=
M0,5Z+*J ;/*/ID+Y>C-0Y/!;^3Z\_/M01O -]3YJJ]D_WGS[_3?:969'>>F
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MZK;DI:HK8U.%1I($C(^)LS4=BASAI*:XX:D7'2<.8!Z=0T;;V6%+4L(?-.V
MR9CM5#L:;0&?R=1R^=VD5Y?=WWX+9IP^/>G86>7_YD>U*LJKVY*7JB@++KH[
M;[A93*R *6U@G=M8_5&VOJ=XGFK(!,LTT8@3;<C)W<>&NF17L;WU4:WZ[>JV
MY*7JMVG[!.NXJNL\5N\^@.=YDB9K021$!AMA!CT6 C"@R)"/E7 &UJ< R*@
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MQHT%E )"4'7,*C.C4;A,H:,(L3IC4'IU;5H2V@=$T3#V2'%?(+:IBM>$ISD
M>3O#FD,(M\3V?9;F^YEWN]_TA!#8!?/?2J<>RG J#C1L6SSD/4&,D[JMZ!;!
M2PO4V;XZYAQ(S0DU07XCY$DVK#NK^1$E52DK>^[2NG.B -?<UWLI)@TYD^[H
M#9A32]!A<SR7@MJ\[[(WXW;OPCM[H255W"@%=_(_\H+(K.9E 7Q"DW(FN $]
MT28L,7K@YXG?)5$]N:,+K:WC\[KAJ60?EIMD5#H:B^0^L1UB<_HY?CB7\( @
MWIBB9Q@\G3FLQO1Q,QR8"<#-?85PT02R=D"G+7A>VD_@%-#:*%50<YY11 WE
M6(O<%&!EP$F 9Z"9,6^ABMP[ABJ(*;WF.#:<YO _'F$83M0X-K'NVVZ@U )Z
MF.>^+.1%8?U7N-"?-*&?'RZ4\68<8XB+G8[X=I&RV3(J6O-+<8H4_FQA]PDT
MIHD46*ELKQB95R;.BCTD<'>D]GQ),)#XCEQH*!/+*91L4+\[WI[R-37&4VQ+
M8G,NR!A+83A)4Z!4(+U6494,. _^!"(\LO8)FM?>U1$'ZY./LA/8GJ+]\;I&
M(O0*(;#HQD/O+W3<(W@G&^XHJ9'!, ;SF-3-G9%L@GTCRQ4OM9:A!"*^&JQ8
MM@>[@;4F \=.'XW3D >W"^\P/ $.+MA&(WX)Z$IR'@,D';+#^>X![WSPR^ 7
M<IOG";@NJ.]=6U?MS"X>>^4MB!21E!]V1+_-3 OVIIU>L#,O+KUI"?LE$M*$
ME,X[>00"^5CNV!RPT&VMA#D3760]$(\2J@W.$[RWR0QR-CV$I9QMJIX',/VD
M2QS09Z0,GIUVDZ"4[-Z,%C>AGU\@%E8C5T'.3" I*5T+B+.71-F1_6C,_KOL
M"_04?BP00U)17D/0?]*B_X[VK0F]RHS3?J[.G)Y!@JOLE%A67S\-R1G^3&FS
M"&=X/*(UBST3-GYG^B1LCT3RK?7L7/&$O@:C'Z^M?!E!G>*$64\DOD5/'B3#
MSC/"*3%E;T$,0 SK>%(Z%6P&29U@?&+S--V4T7'MZ3+"0VI@@.%\XL%$P=YU
ME&:@\\NHPOVXP1B@,,W4Q/@%@LF/*\EGU>@I_H;25?6)S +S^D=/@!:E-^ 8
MR0HX^@2"#\-</O7;8C3!)P02&I NZX#>.YLH*/PX=3WI2H+)IQ9-($&V3T/$
MDW,_-FG3IN,)1M=]HC>"=E@P:!)%8<+FJA<2];0X.J*10EH+QJ[DZ#.ZWPRD
M5!P81PG-&/J39C(%X_2G#.ZS2: 9=P)T/7R^&<_Q ] @V%KAH U%]&I$ZCU-
M%TZA35INW9<G%^RZEY6:E#E'&^(?X4 2.8@%%D<3&(.9A";51E80SKKB =ZF
M?6%\9CE@ RMU.$KR%U':E]?KUU>EOWHJZYWYWS]\M.9_/V#^]P\?K?E?^O_;
M-"M8#O[M6=@NWZ.=[6QX79)^:J'B%0IJM6Y/8LQ7YRC9@_%?C/#?3HE!&:T=
M4[WD/.],Y'V)^#6"*J>Y068_C8G$CMU.T?ULC?^<S-Y$$ 0'@=?"T^W2J/D%
M*PN' 2N".)X03"\L#>K;IO&U)1:DZ]),W,Z,(AE<\1,3L <8P( .E;MP\>=+
MUSZ"Y@C3KB#;3YT0<M@Y_1#9L9B#(NY+0'X4[@\%YK<Y;YSY8\0R,R4,94LY
MG+OL6PR:$#-&2/E4X%16&#J!)9\83B8#DW.\)?FJDV@_AFSZ/4%F,V< &(TB
M! U\A;#H/<9J*.[4$F/+%JUO#L[!9A^.NI%A6+[Y9WMB0,K4O(G1+]Y,EW)A
M2RK5YJ<?-7(#!JNUL25,HF%"2F"HW=+8] A+5Z!H69(N%]Q/%E$A2T!22#FF
MLU&9%-&$L2.;,W:,TQ2,V6CZ=@Q_N4@=C&R^77Q_L8UTIY9"7+.'0G2B^?Q]
M6Y<*C8R<I(8]SGI%(GTVL0VKY&8F7\]RC/J*"*=QS?$5&)B3DI10:&!!GHT<
M$_GF--21)&S2%XX-(A^X:E"&82YAI$AH;[A+(UKJC#2HYVH#= 5MX(1#I;^^
MZ7J+U_4ORQ4\484^4@>'$E00XZX0]2_DAV^U^SSY$[4!,)< 6\J@0$BB&OM;
MRD[=9:\;U#DBJ!B,[CTR+JG0]6>KP4ZB%:)G'"MB)>K, FY4E#UCH']+287M
MJTUE,L"P(,VX S4P2E:TJ'W"#P/:=IQIV+!V4OP2SDV.!3)R1#%?H3EW#10@
M@U[UH&2YIK[*%1S-E+JP'@F"DV*X4!LDG, _F/ BJ9ER4M>D%4@EL4Z!4J!8
M^#34SZNGD5"WV+TQT;,5ET!IQECT-R.)#M5]$;2Q&1\&#.N*5FU'H'D-FV9E
M<4#*,COT 58)O'_YBUX_;=?X4R]=)L+T%K<C1"1)\2,  M-]AO*VX(V#$%*]
ME=S,2<,>CW>26G#3%3L?XJ!M$'YU7FV*J(D\Q@*C8,"E5]X[B#K=3Z&HHJ.G
M%1VG"5*BVM&T>(>J-YSPI5Q/\(X=9X# _#7L/72!(<4=QPA#%;U<WYH_BM=X
MG-C/1+[E$ME$P8PL1$Q%-R/ZKIH*J;KUN3;@H]=NE.0GV2-NGF[HBDI23[L1
MTQ-*Z"(7-+V2[^9?ATGLIB_*G[^, LZ'>A#$K2<^G"6*FC;W7DQU;CHDW!B(
M+[ +Y8ECY)$TGB&9V<C]-1XB[>OI9W45UU*-ZS3%)H"SHIF\U3]DH?'50BER
MKGRVU<*4LCQ/T':7?:7B/*D&6@YJB 1+V!]D\#214-&:*+^:;ZS(XS6.9*P4
M,E,!1[FM'VQ ?S'9.AN*6'F;JCWN"[AYMG[D4@38'M@N&&"H(N%B2/M2K?]E
M+U/4>9I7"I4"1AW#002/ALU2/E;8Z"3!"/4F [,#636V6 $=RX=JJ/RT[!,-
MS#Z7RGFQF\H*)E%M1C[#X9NK+W7%$_JR<4631@ 3^Y?Z21Z+CGKPIO8N6EL=
M& 3HY"3\CVIJ@E B%R.5\F=?@"$/9P21IG/X&&<G)3!F!-G%,Z?)SU/4+A5:
M,DVC_7M8'[1\@=E)#/%P=U7_EBU%:]1:NS!A=0RV/_HX8'A5PA].D-HM\=E)
M3V)\WUT6TM1:0'&.\>61K?QIH,=<BAJY36,_Q"]+26",0WEV8E(G@(P M<R'
MTQ$5#>6>>R8UX 2PU-$&[")\2_V Z6/9+98 ,2D>O3:JJ"508*",!""BAG3!
M VD?VK<^!'[$2F\U[BU=H1KPC+9%:%U)+/KH!)$M[T+4\$VRD6>[O7HX4$4H
M39<RJOZREB54=+:-J9^(D_:/NJ,DPEQ#@][%/=&'=F;WPJ;=9?_XB>9\+#,P
M8PUD9SIB]]2PXSS4=D0&95D?5NO'&JZH9ZZ]+R=G/UZ3LQ\R.?OQFIQ=_8Y_
MS=M]/E-!"RP$?FR?U9DBKSRA1CKSH:3L$?] S+GY1<[>7"Z/7;'5&'ELQLKY
MJBQZ)NO>@5F#1S5)?+7'T(N1_+[SKS#S6#7%]&_&<T*;"Z]D!\\87MUWF"7E
M_B&.^H4,DAU3M3/9KGP67>=K51J]^!Z5DFKLPJ9>, F@6D R,GE< DQV?IT_
MT%YH51IF%\*$+RP$]_#5OM=4<]7IRN22\ZZKMU+XNN &LX](R8K0EBQ1&+0'
M*9C#CY%$_1.SIQ%/:9:#?>:&Q>U<#APY_(S@ K$$F]M4U-XL'A4U"\L4JWZO
M6/*CCV8IQ38D>!%31-7A6%2=)AN,M6F#-Z9G80WM79-,OP998*1&K*46E -2
MU9NJ35*:L,T-\82V8] ZZ&WO??& ):/<VD#AYF;96\_9/=R.=='5IU@0\@WE
M)36:S/'#&'>S$34SH!!-XS@=3!H,O[U)0VXE@P->)H6=L2;FQX!]V4M,,">=
M]2K1DW Z4+:I-#KD9^8]$W*"\/IJQ[[&FI=B.TB($U\0ZJLK_ YJ4((UJDK_
M"I/2)K38>:KV18>X9QRF._?FZ+?4(E(3PD4#6W@<_&$#6_/Q'_/LDX\^_IB'
M\94O]J=7;PZX=:\/B!Q29%]2[WB?O=X.N=1MI)_#WS\6W(C"L=B6M  #@U+7
M%4S$-2.]$'WH&>@H>?D3+9)+>5JXP2SM++K2!^-IX\9^3?@-,)G?W65_;Q\]
MQ5,D+4UU[)CVEA[S6,V.Q@DL_+# D+LX4ZT1"AL1'&XR">"?XZ IX*03*TG/
M.0TE8ZD_F!4C9V9E#%@>8%/Z2<0[::.?VQ;X"(F;*U 67<^]7WJ:2YOR<VIQ
M#.7Z[Q,;^-<3-,]& 3X[C9YX&D%-O1GAO,#A^XQ+P^#D=V.-J C8,/. -WJD
MHNZY"09COO!O.G6Y5C]&>SI!]YU#$X1L ]H:<HA2H!R4\D?PZWVCCXN=EUHY
M26@7F7D">!ZCE@F89#IK!3JX^+!X;"/ '5C.CKM!DT8["PC33UPE1LZ JV.C
M7@TB4[!FQ27<4BBP7'H= =5H@<S4CLH=]?!J2^]=]KG7)I<6JX6VJC!/<0,_
M:YO[CHXJ#="7M&>B&56'_./-M]]_DRL4M.:"(K8?PT*;NU6<P8@B/38@)XCW
M0]&J1RQ;8L>&/L?;=68-"?TA%MV95. ,98M 'N1K5>/BDM]J40%;UZI+;MK$
MY:DL5]^=R\?.*@J&/944M"-?T8]M5Y>K[7]E-\47A$F0NV"\2)B (P/6 F^;
MI2JRI4TV?;Q:OD@IE1!ZF/?/C9S+=@LE DE1(>@*BT;6@[V#:3?-'*&HAD>$
M,N%0>&[O)HI^4/I[ 0T.K3RPAS0QQHV&B%]@@.%,.W:HO41=[[L.YT5MG#JX
M9?[RV:"4^\T'P\Y9BU" HM!B'[H6-TK4J859^E[+U'E$!.XD*9\9?-V%Y90.
M!S8AFY.3 OYV ?.-8CU3F*@LUB:]NSG=II2C9X#%K0GZF10ZXE5Q2- HFOO5
M&KWB"7V- A2"!RQ3 2H8!,FZE2 9<,\<2#0-5%2JDB[*$GP14T3PS%2VZ6@X
MC@3TIW[PW*P3S%(<3E<Q5)6)4.C?#12H^:@<DUWQ( YVXL'MDC-RJ6[(ZH"T
MQ/8M01B&]A[*Z'/%+N&/F7+HRR0>,P\TX-43PB15S(<*G]T2+B$LPD/5UH5U
M<&W7FJR_J6P*E07!&,4@ B;Q=8?"4CI92;4N%AYL*\U!7L5'UDY]_"WCJ[):
MC"\,JC$!IA&M'"&KC12Z)TGA^Y2T<6#J'!S>MR9/$DUFJI].E2JO!$,:-:?\
MK*S/\B/3EJG,=.+A:RQ43>R=HG)RZ:%(43<U:+#JW2LQ3!.+?4-(#6*O*Q9:
M'9&+3$T3GH^D'#YJ*GL$3:74:L)?F=Q^V;@ [C#)MRQU% O8)./+YES81R6E
M=.]EU$ 0:^0H6'[?>>F>"B;DMNW 'L;*7_Q60Q!9W-),G2X42Z]1XU#I:.A8
MZBAW,/2(^F6RB%39LL'GH4- *<8C/*%%ZT !?GUGA;,H'RKX>Z\&;QQC\%EM
M-=>RY%\J" P]UA:HS$(+8BBM/*E.%TBP'1X\:=7VI4M?=^Y5DW8E 3KC?M>0
M4:E/H4B2\3YGI_;<>75?1!J(Z(1$&!#S(.L@76C_MB!PH4M(*P)N-7SSWB5C
MGZPE8Q^R9.R3M63LF5Z(-UH>]B'--4NRPX$3K?F)/:\1"3SE4NSS=]$'O ,B
M<+7HKLRB>UTCZ,O]WAFXQ5A)@&%4N.<9E,/4[+^'Q%!8;NPN>:P&<\/D9I9E
ME8*0:'" A"5&H+7J0B0P[>65""/G\Q$Z5SBC[$BI+>*2=UWT_ B>,(.BO=)_
M3JHV9%K2:6"6",RKX\A0NQC?E0!CLZLK]O[;32T%^82F:4S<,$@,H+:*Z$+M
M%5D:.CH#GY9]%8O]M1G?MM]JG9YT3@@42%.*<[X@ '9F"IM#K!HT'@UAA+9X
M;2*ITG3JL2"$HGGWNRPBV+8^]/VX2V&Y6%4:$ 8BCX%6:])'&2_ Y^&YYYH$
MJ6^N0&D9"(J&#%;W88L>IK **7!-6%BG.Y4L[JQ'^WQ\ABUZ8OJE7KLB)"TF
MI9@L .'0/2/C^W8&#Y?Y=U7_MG??8?,U-\;^W1>@Q+<H(U]I%OX;VJNO* *-
M";"ZHOZPKPF.LE\OX%_9%"NZY&Y[@&N@'7N.UDJM14YU8ES>K('7?=SII7J+
M-)X?"LNV<?_IO(N1-G;.D#9:>L8A8+7-*CJTV@NQ0L=N67/QD.>Z;K7]KLSV
M0]#P!>05[A04C&V3RTFPC:1)]@$Y6N[)ZLJM>,+5N8.G$G+L-$:7(H.=\*O8
M=UEQEN6^: 1Z4 ?2@[.,]@ZFQ7O%D*%T1GVR"%QR2O)0K43!/3I$NZX82\F#
MC&S/R'4V.5)N(O 6N% 2W 3MIS7"8?5L@V8* D4/E,>! 1+J&"SA:,-,"0G@
M"7(%*>[/OGWDZ"G')[5%'G0$6"N28)$V><JAQTP:YO#"BR0D%[-ORE>GR  X
M2RG'_<]G).A+)S<&NVQP:QK\>N]))[&OLS&R?[L.SN4PW ^]XC^)ZCB,\9.?
M?9"W1\BLNNTU&/"O_F^U?;O!4.\;+BE7 T!KH?"J/V#U3O"&J76.&ZEZIF\;
M&(B#7-"W#=7:"O1.A K#*/*V&JAZBRCGP<'IB$J$@1H$JH-3%^KL=?XP-J+,
MLM]$789_>RL#SQ%P<D/U-UK\T/D-^JF_1>QQ>#KAW6,P2?^5$R H_, CZ1@L
MG/Z I15%OY=4_=NJ(=@W>")<7PVWQTE9,2.5P"1P*0G6BMX HQ\9'H&*[$=0
MM06ZA[6G_Y"[3Y!QK2+]H0-&V\*A !@BPE280OUSSU PK?NV_?_LO7M3VUBV
M/OR_/H4J9^944B4\&$)(.C-=14CH9DX2,H'NS,Q;;Z5D:=M61Y;<N@#N3_];
MMWV1+0-) [&-3LV9"6!+^[+VVNOZ/%C^!1HH)6Z]I%($+"\<-X&CP.&N)%],
MO';$[*?Y$9^<7@W#*<<@E:$1F.;E/"K"B7&3WV$%+B'WP:[S#PF2GHJ@&#D!
MISQ77!BFL6[9!69W&:4G5?%(QC)L5 ZWRBM-5/I.R/7FXBLN_6 ^30=-GMZ%
MZYM4U/9B2T0Z2ONU']5]6^^=H-SSJ-;WJAV""V,PM]%$;B!R8BLC7!RI?T0?
M.^2/F38P_IN):DX5.$1TX?*#FO=UZW5-8[&WTY77-L)C<]\?TW6$S!.*_I+2
M?T0P5*EOTS/D/@V&,Y=Y,MSY3+>'&6)K' QC/".T*$V9^%+!OZI3>H =S23\
M0B.Q9*6-\1#I#)48XI!">1I>H055_Y+K)C>>1%@)BIH^I^\[^V8>><"_;*P*
MCV/) /1[[=OP)><Y@E3'2F.?4?%&I,BI=*+SO!P4O*8]GBU?V;G*"_R0_>,"
M<G\H/#)6T!*N(C66@0/WP]**<PZ;99/77\#DSB85YR+:]E/&0>)0%^B FT+'
M1;&G@8#H=VIV[4?5W<<KMR7=?<R:C/,=H$XUZMV''%Q'Z0_$._<@HD)K_:N#
MB*KE^B]>//,?_WS\X>#@B;YXDPEKM*A ' H)&;)>0T1N_CXYCG0Q\Z73\*67
MN<SJ4EJ<V%ED;BNY>OAO"N^\,AICFRSG725(.7-]M8'*U#"IM,^&3Z-1+'LO
MJG!8?WJQ7%GZ[M/4K/7435IBM:2 V&OOW ';GKL;@R94(HU$IPP0=CXA7$5)
ML6KS@=9O<4IEL'BG]?Q30<6>NT?I]O(7XQVA^*C:'/@J/W6^(?].O5$I'UOO
M?,?558J[797B758I[G95BNN?Z+N[@L0NH=$E--;8JOLPGI5)E,#3/[#=4/JG
M-69,,R7P062Q&1(QG2]H='P0OG-1HV$6*[(H L1Q(GPF3L5.*+R-#-F8.%84
MZ& SIA%C3US\<@ZEZRAY8$+D.E%P.$[2N%"9P:5;M% EXOZ8C"4]='49*:(R
M*Y^ V-,H"D6MWV&6U61_B1ET2)<(1V5,M/Y_PPE<1&8PISHN\/CPW>F3H-%@
M4MAJH:E>79L#QW'O;+^L8*SE$%ZCX_>$(T)_[+_D8 E^7^\3O AL5FIY9S04
MS!J#Y15Q,0 UGU"U23[%!'Y5\$_3/$Y"_H&M[7&"S20A?0V&K1<'&8+,NVA$
M]"$*G^!2/#9_Q,!)4DIQ0587U)/N?!1C6DE&N\Y_)2,/))O&@^\#BP]FP7\,
M,U7"JLC8Y:>29(A33O9M//[F][<F27P!9C!.A6!25!B-.85?3I,*XW>MQ0?2
M]H.C#;&B&M/ZI5.VR$!96&Z!NR<Q02YC14RTE #$*:&SK I#H[8D!;@]> RH
M,(+Y=R<$]%6^Q,]T+OFZCZJ+W:S<ECS46SX$S9./\IKOE,6*QO8R1IV8UI\'
MWU]7#/"W%S,R?'U;,%P$+4 VD0;: .OO^>HL>8XE8'$T:%O4/9D,4-.3QL5;
MRH;Q,4.Q6-SF!/&G17*.M+"LODNR65XR3 '/E=9#;)QED)@MY9I+P"J-00(S
MPX!8,7.*06D0HSK!L$VF+*B7H9-UZD;Q8Z% ,T_J=$3&A,"%+:8Z3#^KG@B:
M9'.&&K* D:TC:W%36\48*<9 F3-*KKY=F^ 3A!(4)SBD\B5+Z-Q64#+F!OLA
M=EN#_4UH[XLDTD 7&M\#ET-7Z+WD,D7S7I91!!+-T6)9' 7OT8A*]0V]1)/Z
MAR4?QL09OQ"[9YUZ_7L,2QFN[;5PSK]+<>(;QL/P"(V#^K<-:71+$:ZI.%VL
MQFTV.Q$%C*LFG$I9YV1P-S=HI6C66@#+SY$6(Y#I48["O-!#TO./R6F:YF!N
M$AH$SJ&A&:57W1V<^ QFOGIR'MOOJ&YU6[P[$[TLN<$LD0AN&32&3@E?+MYU
MM+M;,3Q7%FSZQNP">6TW%'4Y-:MUFU2; [4 8=,@+&:\&.:^XC<VELJ=!"Z.
MU[C7:ML4U6R1:X ;Z4(#]_JAS$;0S':$,2%PDS*!'7:^9SJPT,DK T08&.6%
MICU/)B V92Y5 ])I)4 N FN43$.A-G.FMX64CZ#>%^O1G(N_M2(M((]G5" _
M+CZNI!8NWAK4OG.-<Y3_H'8F#/J;R<!G:\;CQ:(X4)N! 2%7!&PP3)H01BHD
M"$M[08+X@1I/R0^CFC]8O!KO-5'S<[R5_FO; Z<)CG0OG*;8%BZG.=[#)DQT
MXT9UM]H4GM/9-2CY#D]0UW"Q&JK^#"'OT/0-/'6CYK[E$D,Z4U2 YM.T;%=!
MDU57/L?0^2X/EY>XBLDUHUI48=.*,B5(I)(OQG#J+Q195*R,XMR]J[1N1%5N
M]*-CB\[?4%I!-MR""@G%KE9[6K4%DL5%'=M4<"6\3YYG%:-17Z5'^NM&ZJH#
MI%H1/2$LM8QSA]:P88^3!K<%E\F1M#BLP@8FGK:&R"Q'#G9,*+.3V712P0"*
MPR)V70Y1SQ,'Z_@:IMK6#KJ@:Z%;DW.#.(^C-!^0A=$0)!"9+"ZC<$H<D44X
M3;!=38D5RCLLRI]\4M1JU%ON:+:LGJ@"&T/),VPVMKD1E* I>,MAN,E\R:G!
MG62=FM\M<A0^1P#Y@J;\([XD&18+<%)-B@-S*!QN#:ZJM"8]]=HQ;Q!YS@@/
M93'-*<=!<84<O5?%AKH I,NB@:K'BV2F*K@JP;^<8))("!>PG$4L-UH:K_W0
M<H4**HJI4RV9-(^P16^8Z^7'MD#85=S-VB I,#Q[ YT]F8, \!P=X"*:T\E7
M+O!\$V.1\<UEYW 61'>J8R&^;FDLQW0_M6Q4(" /"848<*G""*=.01TB844Y
MS%C:'"-:ST";TD9CX1]LB10VGE IE:EP-> "L#@U@AF$8+PT_!\D@FGV0,\T
MX"J1;<@ !C,7==X-,HT0EX3 /W#A&2V56%?<R!6!"9<-6(KF7>#-6QV+3=7L
M:Q&#F?-^V_RJ>U7_1F:1%?E0&QKL0%F3Q#A@UMOR)#0XQ\6I(26F]8!:L&9L
M^-WH:OD:N(DF<(G7ZEXNCEH,6%N+9C'?1*DHIW(=D?]BAN%SHA"-F)D4,5.I
MFHH]J>8B9C4!7&40:D&G-NAW<IBE%DL"D]]0)TC)MQ ;N,QC//,8.\PS&P5$
M;?4&UC>?)!$]]%#G&N5[4GVXL[W](EAHIS<$,4Q 6RA.-7/!O99*#@NB;&ZX
MQ7EU==G3KKKL+JO+GG;599T-_/!P\7[5,5H"VB+. ;X/\'IC;:RR\Z3()3:K
M*YG9W@J'2IS#)4@I^OJLA6&=[ ![?YHH"]M*%.N]*:$652X++]XB5';G)J[2
M$5F$_#&NW3=)5[,#$<TLZ^,9'+P98R_'& #AAK,Q/(8Y6,CQ0S<"%"@Z$F!
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MO0UH,3P>>NTD<QJ0L4JR6B%+0%DQVI'# "%7_ONPC,/?_<-P2A"=[\+B"T(
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M"BHAT'LSBEY(MA#T8@E>@C<S8032$W(C*_PP:(=RK#^(?YE0%A5O%XDXH!V
M'XS@GD[P:@"M5^:D>&\P+,>/)/MEB(,\1Y\)O^(,K.<?H'Y?\@29W=SDBA"O
M80UM!;_  $J2U70C#&LLE3'1)*ZX3E-8?D\O!1'.SI8\G!"T0/MJ"!E]31(*
MC28%5\+PK2E^])-+LUQA,_O0G<A[5JO'0\\)QA#,N 0.=2&]'^=TX.B,PF'
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M"V*QP&'0(<AECTV4KE?ZHKP%.Y"BLV%%D*44_,D;)4:=PEPEA2F2I'U[%=]
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M D>%8_U+C=F#5'6'?)4G=%QYV+8J';LF9;XD&G7-(21!L.TF=<FB3G9V \4
MXUA-6\B;CV/IC ^?"'IRK)P[,:/^^0C#7'RDFG]"H 135*L-&C[VTDG*#\8
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M2;QON$ELEIR16-KM+JLG],Y(_8A&=V$@#5TJ/O-"A(DJG;I!;)!V,&5N/,/
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MCS2E6I[,^0L'DQ"]"@\!=Z2:'M&N,F=%Q/'/E '<_ETV'<3_>K5W]I\/_]J
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MDP]9EG*+!FTW>[-H-DS+_$H3S4GQ.]4 QD9R(#OPQ:47ZMX3Z2EO4M?+ S1
M![T1U$="^H L)D)_J%.EF>NU(U7J:L'3-X=!H]U&4)]YB9F8SDO R"[HH=9
M9%!OZLC5C[2+X6J+.3&B#O@6+=-IB=4R1$ZH!_88&\H5LJ%7G=FQ^A,ZD<9E
MWK1,&0*/TG8\(@0_%SS'BD@J=8D2GF>+_,.'-P&?5+  ^)FB  )_I-L(T[QT
MX'C@<PC"7X'M(V7+$3J[CK+6S0JLT+I3OSJG7MKBG%ZYKNMYU?8(,</@!'MO
MVI%7V4XHV!C #_KM']SMM/GJ3PBCJA8@C8+<+AJ_&,LM4&_:*I^! )3+0'I)
M>:,H-('>T$:+L2J>34 DW41U/E*>M$<,5'6A%+>65!<YOV33U?A7=1G<?-(W
MZT>8+["<3XEQ:;[-BID98)+$YGUDY*:2O^].ULT3P2!P[O]X]&R^<6)IKT9K
MOF1=TC&@5DE5TD&94XK^.LW"/>-S\_A:8>CDYF8( Z03UUEF'M-= -8"7@5/
M_JS4+&;ZOU%9T5 O5#(:5_B=%&3EZ^5PY\9RV/*ZMI7'M;K!FK0\;]GA6MEY
M[CZ$>3[^RY.',,V_WL8D;WJTVT@GBM$ ],S38&?W>;"SM_=DL8)GL8'R9"$K
M_8.>1NOR+7U0^TZYGRMPSC?Y8-L#N\&LP6#^C/!^8NC"^1F(@;[[[*]M[;_+
M4$KFARU/V?EKNTYH?JK?^JJ_+'EF?V?NX[)^^W $^\'VB_UEWVM]2_NJ?Y?A
M/]OI!_O;:SK\Q[O[V\&S_O97C7[AEKJ%@5^Y(DM'_[3WXNM&_M?O<7LLN75_
M6IK=_&:?YQO\G*N6_VN>(UOR/.CWGP;/]FYFF-YT(&NU /M[SX+]9PL*X:$L
MP.-G3W= "&YFL=] N:S3U/=[WSSM6]!,2TR#&ZJCLQS1+Q>K+]=X/_I[P>ZS
M/3B0_8=Z&/O/@MW]Y\'3_0>KCQ^#<=G?"?9O&$+8,(7TK+?S'172MSC:;S&!
M3]7+N9/UO5,7[O%R/7&%.-S98)8>V?L?S-*S\YV<[39Y7L6[](3+56SERQKK
MD-VGNR !#_;^>+&W%VQO?^OEL?;3?_RLWP]V]A?<[ =Q>3[M+01&5OKV7-1&
M.[T]8DE7%57&73<;^?C7[@=]S8_S>I"J&T6EOO(ISCV]O;,#_W^M<TW/^B:!
M7/TE>+JS"];!M2[-IB[!T^U^\/3IM??1TNG?3"7?T1I\A7*Z7A9V>L^^70B^
MIXTTIY6P<;-(!G6E&RVQLR''FH(\^C+.4T(>GF*'X3@LP)X:A&42<2HC2>L*
MJV366: ?]WO/'NQIALD_O]:XVM3);_=VKG7/'X >Z^]<;V?=J2*[14OK$U4L
M()@XO![AA2U<-VDOX3Y(,A]&%E'_4S:BW@C2A"NHY6YSJU\$N^!.[2_F&Q^>
MU#\/T)#9?OKMINQM+<5=O+!URM_\_6Z^\^ R:]0FTE+ ?C52_UZ'U+]XZ=P>
M4O]>A]3_W01_?0:_KL/NB-LV94(G]17T8 W:*-U<MKRWC B4N V1\!,NB6TI
MG?E_V>_M^#"^E,!+0GB'!H48-C_I_66[]]1^,B_F'O2T]^*O@>UW9("H^5<]
MTP^XR;!WA=3<#.D"$1C<2(EAE*-Y+1^[_Y=^;W?AU2U4IDU&.8%08[AA8;RF
MUFKO0A%;4Y*E,XVNQCZ-:>"#L2)> [8'#A @S4';6!C<=N^%&5RB(;+:@,W:
MZ;K7%2QJO:^'#AYJ<R:$FO8F4#M_5M<^[_5OK&OWK]"U^[W=ZW3M\][S5="U
MH,Y2-4+(.P*M*N!;=5)9PLH 2>L*\"4$$(>1<RRLS1!Q;F!@RJO"RT""00R)
M@S#(._W]ERXTCOE=&T3.UZOE9^X\-,*.YR#LP!,-GE';[;SI?=AKIJY=$)U.
M+Z_^A%Z3'>9=IW*93#Z?+SFBP[YPIG>M7F50U4)-T<HFE7V-3GYVA4[&6HF_
M!IIE6&-^W$3MJL;0#92I91Z&U<EC3:-<>E83&R @!T7( ?,190@C"DOV(.@?
MZO<Z.0]3QG CS+>2@=H&88HJD\Q=H0M%.S?-X7\0T%4#"..$O&77WU?-?H-D
M==W5X]L$Q").JAD9LQ\U2.4:([BNA#ILR[9=<-G K8)&QKF?Y6!4(?5WAIC<
MXY#0_33JL(HUNB*;+?1GABVV"@<_+@#*7(&L 1D1+;GL^:<)6E2H;/$?4P8\
MO5#\L&&-A]QK8HVZ9J,P, N"(@,/@B(BFI^A0NUB@*%1154SOU0P'X9S? C;
M^' $]CCS_AEF-6+0PSVP%S T*8&$TRVL!6.:AA%1C1L?AG"["2"O1$)R$$>P
MX^N2H;S]<#0JP-T@D?K!?YP\\7>"_O:+8/?YKLX^BX1QA8U'%3;TO,<)?/HB
M+,!K8/#<*>@_BK>T/<(MT.$[7/[&3H8\A:[/,D_I8@[Q2P,B(\?,-GN3=*G'
M<EH0Z0V\I^UG>_2W/).GLD^J'\OHX6:BL%.8-L=0E8K+%C=FI[>SI^V6[AAM
MU$SA&+T'U4XV%1O"<^<(9 1,1H7F&+O-1M4&*-]X@BJ&U&=KCX55'R_!L&5<
M?^/_EGX_>-[?#[;[^R+T7N-,\:$@$/PKWM_SCS,#=!OPI^$PR/VUJ !H:G90
MJ KL@.K,OLAK/</S0[9GF$^O.9KF&S""2,V=P[F#SY$'9$.0DXD.!QS@_OY>
MX#$4')K,,+<;'-+^[H,_I5=GQ9]U6?&[S(H_Z[+BG5MRNT?\(<P1KN"#>@2#
MN,<+.(#K[-G3W>#YKG.=>4V3](YNUW8+V0S'N\I"OM4[]CEZ#5?<L=[B';O;
MVW[H-^R&SA3=R1ID9 >;HU"4Z5:D""HFJS+_H"()?$<D$OZ)'$'_ +FKR+U\
MC"(O1%\'9^_L7X0YZXD^H1A2GG X$T3T5$TK-K\YHKGC42[NY]YAS_\$9_:"
M"B']_PTG<*D?YKW ?_OVD(+$%%$A1D]XN;S8?D._=8F20,HITB/,10/&22!\
M5[!.\$F/_U<"+O:Q0:L3S <-,W&%?XX6%H;)M_MN*?9U+F<]Q?'!"3-92SKR
MGG'27<JMQO%F[QU#1^S?-Q8?">$&"G=J$L:JL184)8(EB"A#*PM8CE4ZU%QG
MK+3$LRXK&#A7>F3^45Y,_-.M77^8I#I]*N0;K9LJQ3=12G%M^];&9U_P9TGS
MFJN M'E_;R?8WMZ^REGZ2I?>J<3I^2<@WGP#/0OLFWEJ&$G)2^0_@45&5I>4
M%P%$!*921XKFS1EKIT+?T?=V9YPGZ6 ,;A;N.XC+-L-6(W<,?$H0K/'OQ-\=
M3@)_4%>+.PS#P#(:Y$,@!CY\M(@+KW.GJ3=JIJ"IC]2@:$;^FMK:;[QMZ9A.
MWWPXX*/[G[SX<@ZG0;4K2PI.$YXZJT"4PRRO**N8#V!90C:24'9!DVI=MK-M
MS84V?:D38J&_^PSIG&$@G*@#)5L/?A/*(<9Q!S641+9D *G"2BPSDY@?TW)D
M;*V5.NV'$^SYOTSAA>I2174E ]%_F[/9["J('.UN[P4OGFW3H*7D@H]WSP>7
M;]Y0DT@H+=8 \>1)==G33Z-Y"!+Z<,[B)^4-5)HH.AXA*^=EF>*V6VC/*3&B
M!]!AB_U0UTO.989O=JZK?*2H3(/.-J;QW8OP+SO.J620'#B7;BY!"/C0PY)-
M9(90Q2RF3)2*N2J7%<^E[^+93Y-*DX+!N:P+Y2$K.[AP3,E#JHKR$0I/KO\[
MO+_B+C<<!+&/T6LSQ<>S0;:F'V^H (VM)HDON%]C-:CL7+A\R;O0=*/\T!C.
M,?X'_",\I;"Z%YJ2UE"3$@=:J=07FK>0$_(@RC$]R;Z=PE>#7')WH,C0? );
M((*G,(T9,;)Z*;AML%9@LL@U7FHC*BEBM".9@>T8# J9'ZR+F0L1$X7G89+B
MCE#IP8R&*J1KH/] @X+%EE4)4:"EK/O$ZG.;HGO>)Y39#%.?F.5,8LEYEKK\
MBP0S@S-A7T_[,G"&@$_&%%+F,,HAJW&$.4[^@"J0=ZG0NIDM)C242";BP$,B
MNPJ7B::]P)S+Q,AX<N#"L$/)==D*+'16\HT0^/.[K-)PALXN&FQ4>0*G=@+/
MJ-0"W;$WQZ*+II>A#X[R&H,+\3FL')[@D"RL)BN?MO*8>C=BD;74D<+&[-Q6
M19C +QH;EM<#-.Q&84'$>/A\(2-NL/ 1T=XHQX]@;$(5&4D1+#'Z^U0W$@XK
MN7]B3NJAB)6.*=I#8]XES$LRL" G<J6#V'OO\PI+ID5X<!\P'$SI;MD')+W3
M[H&A 07[,RW5Q5@1B1:_]B #-9/Z'Q62(](!X^N26$#I$W#3DWJD?!_(X(1R
MY*5'4HA[2JEX' S(WT618QB(,H9*-J=>JB'F3KE-],MY?P@WUH.ZF[E" \0V
MXS."<H7E_H[ZL*8=*NL:54#IIWB0R; #C9%4>(Q'<#O!X:027$,-QW(C=<I6
M$Z2Z#HCX9#TFC+_$J^A<K0:YT,,1M=NO@#V$2]\[2O.+KB]A#2:$)<O:0/4.
M#)TK;]W&S'+CMNV]JCRRKC72A<,A;$F36ZJ3^SLM;6I75SXWFT#077+?[+6^
MN:5E8]=&%&_<+J(6&S],>XNMHX9!-$>%\[95@0O(1\3@5,ZM6EDJJ5L$-X1,
MR16H">S.P-6JZY@RB)WJ6J<)G:'#X^$1!<O3G%MQK6/,UH!RT&HMT1OL*I>;
MJ*T>$E@O/KKM>5Z;FMQW%,U-M%7@9.\<=G;\&CP32XQG'%QZZD278(),.H^J
MR;.ER('30,:4SIJIN46Q/FNV]MH'KE!M\W>MZMKOJKKNLJIKOZOJ>D!571M4
MO'7+MLB1CIETMLC:3,BX4:Z-X&01OL[F:/.WGMH,EFLB-&P2J6#QW J6A5SP
MLOJ51J/*E4]H](U(EL$I+#0U2S0.^7NC]M]\@ERS@CKX;V+$?<N">EWSYNU.
M:'>O]Y10^VY7Z8%8HLA\=#*7G=);[0DA%$E+4EJGCS7(T%/N"9L+XYO4FIMP
M%F4QK#&+S?A"6:8HU6B1A722P>J P*,\+B*T%ABG*6UN>?Y513B98MD,*34-
M3>0F(AW-PNHKPNH]DW"?0SH:)UQ88Y)Z'JQ'B8-.N<!LBOFWA=1G$X!C""JL
M*N?KH"DSFP^HG)I],7H3=<B&*9?A93.MH'7W:P1/IY0A+$IC$7@B)<A',H1)
M$ZB)3B G?U 2TD[3<3P;;;6!'4DP!T#%<"<E1\BHV.^H+C!?/ %;?&XL<WN_
M,*Y63"DGPH:U@MR9&S%Z0*??5WA"\[4[5 Y[F7#T9'D1#_ZR-0:QM&B':C5B
M> 9FM1N5,ZPQ/.=L7U<4LT'KOW$"A?>.7!&V]L I>**BF5A1:6^.RA/4)"HJ
M:D?AF@E28%)=Z6.%"FN['S9HE=JVW<:6W%C2?*SIJR?=B/TT<=UO_I"6,-0B
MM/M7CVF[MW^WZ]J"6?T-@]RY]4&^>+;_XI9&><?A*-#"-+8R@CL^X$HP59:Z
M94JJ',DH .T\+92QV\H*3K(N@VS@3"*XVHNGC?FWD Y\)^%<36E<S5'==S"T
M$Y1['M4:ZZDD1X-4?"?4098^I.%>LD;B[E"JH%WJ"NHJV$Y[;<:H.NVU<EOR
MT+67;: 4]#0*EH%1I;!HEI,#XEQQZP2Y2HUNBZ 9,"/K;#Z41.F!D=MP 4H/
MXS\T"*EP7PQ:=8IO,T;5*;Z5VY*'KOB2R32,N.XIF_GP]%A-DBCPU32A?]D&
M)U%_8Q6FH+>B(D$$/&QH=9N/R)HSS4:=WMJ,475Z:^6VY*'K+1/YFN>!(>")
M2WA=Z;3]&Y7$_85%6%9%C3DZU:FHS1A5IZ)6;DLZ%47T*!5V>G,E0%Y7A/5/
M;N8(F7/S@O"Z$WCXTI*%3D5MQJ@Z%;5R6_+0590&=4  N)+P(KBL58>UJ#8
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M;OR8L;HQ*L!DF=+X?^VE(!:_9WTKT"/,=Y60UP+^*&D)JF;ZI7?:\W\Z./C
MMRA_-'1XLYFY])I[2$(%I5 %3\(ORO!Z2HQ"' XF]\;;"9ZE*6%E89BR*FC8
M$=)<3.FYGG_JP/.&]G1,Y73X"IS4?,9X[=A>8T V\;T>$84.[< "NL*-EC47
M>5YQ81<[M72A?LOMBV2GK,KQ-"/KZ'F8HH?N$?*L'05[:#@6L]/P-/!P*#J$
MLR\2I='PX8_G(3P4'7=RMAW.5!/),#BW%,- 3.M<J)R-ZH^2(JHG2$ +-E7/
MTTJG=5EQ:-4X+Y5EPIQ@+B.9X$2%/)YN+OBQ"&=8T_H-LN[Q7TB4F+:XUO$-
MJ9&=INH2CG(\$DGGQ^!8C1'&?G-3 OUPD-<L>TK\WB&R&('?7MHI)1FZH'BM
M>B;.1IY\*%T%JB"'EV]8\J<QBH"Y&XPPM6\9\A]SRSPM?3H3;C:S961I&A*W
MH+EJWDTT!,8+!LIPG8*@,<2(BN_S5N^NA:N-O07:^&&>IOD% \A?=>3HI$7Z
M>,I!,V> %:01=,U042WJ<A L[UI-ONG PVMS!)AZUEJ 'GJR']UHWVLGVG>(
MQ7P=.^WJ3P@40:'0 N,[N)5AH%3%.04Z7/:9PX\G?-8/WYT0\CQ\?R;7%KF#
M,1IP%+4F-'G$!IWK2[G(BR_T#:F$@GO.V!O(>X &F6G\#?P2<1-0SS M3X+V
MSGF>GK."B14&O9.,E)88.9:W8:"B$*TMB</X0V1/UMYKF%Z$,[RVJH@&ZVE_
M%\FSQ1@R:\!Q?;[92K'79%4H>]$,\=/M"?L0VD&[6:PYJX!Z=>0] CP8DPVB
MZUII/OBJ:5T@(1'9.7:-;!F_WCJVEZE#8$MW"("Z5R%,B6>YA6#PJ'][_FOK
M\;=P!GF6K_;";O)\3&J_MV-B4H1QL8S;0W8F($%@>W.>U\G2.))-@@I'+X_7
M($*"-6Z((^U!&Q-"()".6/2 ?A#>=$6M+"/MK(7^<=L23-$87#X76H/ TX#Y
M,Z:2S&&($B.A.R^)':(4A,/%J*(DD(S-K*HV4M_YEYM (H4IZ>YF3A*0!!-L
M9/'M^2<@OR)=;CFU\RLF>I@3.<KJS$L<YVOX%+%3A:>#+FKS8/K)NW;/K?"@
MC*(/*!Z8/;N!F)?,MJ)WJ6U!-\BDO+IXZ$57/'27Q4,ONN*A>S(D-^:\KL_@
MV7@_Q4J!K5=H8GF'^03U)SECG9V^^A-R]\N3N\]E(Y,J$(GAC)""$NUBL!-4
M6-9DJ+&73W\B@\\&]R@.)58HN.%A4O@8&50:7#&\"(M8>##)?!IE,+38(_N8
M ZA@TY9)98P)N<;U V!9$C#7,&A%[P^LR8_45C:,H+G#M16 <28?VR(0-V,K
M33(:=5)2+%.;_,J[:@)DZ[K+HV=,:P ?X!6I2VT/T<VY=1J-<RRVX1 I?FV2
MQRH56[46SCL3-3,95"]TV YTA)!80VWL$..E>)&4'.,NDO++UA",> (-0?/,
MIVHX-]*. Z/0^%E!&SKS9W@'<*>;7FV,IB0E%@)ZVOIWJ 5AK?1^R$(DF0X_
MBG!@L9_^#"U+SW^COV^KF!H#0R/:R2?@-VW@T7.^A+8M#!3+_8H<B0:'OBG"
MXG5H#M4D[$LG!VD"RE(31T'9ANASA#FO*XPDXX;TO,5GVYW#N5C)L4)0)K!S
MR3"!7TY4-88W(UL\VL1C'<ZB[3AUV-=@D]]<<MC4/\0" TJY2(%9Z9U6X7#H
M.SFT5W6:8O&B?Y9/P5GM/]61]X2G/$G :<M!)F!&U04F3IR]TR>%I)C\:IYE
M(@$V=NG@E%#:A>LL8Q6EF'?QR)%(,%R,3E06ES:9,T=GR]_._6D:\N*"SUSF
MAH\RQRU27(%(SD?//Z0%T/RWI6H<$PP-IRI$E>7Q*6#A<('PM2ZP@/P\G,A1
M@=K\U_X<*:2E^K!+)J^.'?)119S2. :Q@+UR<\I%GN68Z1"2V\XB6>4)'7)"
M"L.'7/J1\(:ZR8/&AG)]$J>B.69'U44[02.+VE)C$&B-<&VVP',SH%2"^;RG
M"S6/S.=/;<845=QI/85+&G_&HO/7817J.LZN=G/%E0D_+(G_\2@L/F_WMXUW
MB7OO[1_T_']AE#2!#=<="_"+5/_\&H0QS=$\ACVFC.P[KMC&HMY>IX!6>T*?
ME$?$MGXY 4>"V,-T$%'8C]T:,U ('VLP4_H[@ZT=;:D:<^T@JDP))09RW2"]
MAM-A1\:4F'/D]B(I,>(IG];5#* S2/N !&[0@K=)T!41R_WM+F)YAQ'+_>TN
M8MF%_K[AENPW;TFPD+["-+KO6W$]]_$.VE8'/QZ_?WWPX>R74^_LYS<?#SZ\
M^>7L^/ T\(_?'][;IMS)O Y/WI^>O#U^?7#VYK5W=/S^X/WA\<%;__0,?O'N
MS?NST_6=W9I+W-G!J[=OO),C'[;H;/-VXN[1/E_Z2PV.VP,"Y8OYSV"!WCLP
MS2U@@O;OF[S^.FOU&^:P#P;Z/1QCM+D:)_?/0@,-8.H8Q,]B%.R\^,'_G\/#
M-V^.COZ,$%YK5M^%<13ZXT(-__'H?\+Z\_8V6$8?WWPX^7CF@\Z#Z_;-AS?P
M7^_/_(]O?CH^/7OS\<UK_\,OK]X>'_H'AX<GO[P_.W[_DW]T_/&=__C#X<')
M*S\C(]T:7)?QY><7VWN?5:R2K:V#.DZJO$!+_G.$]4C;_>W^Y\_XK_[.;O_S
M']/?_OWT_-_#P9>?1MB'>OE#EF?OZPF,GGK+<34^XG"/BGR"W]K:[L-_JIS^
MW=_9VNT_HM=B/_(V_-^SG4<TI'\\@O?_X+S^T8\_'YS^WYNW;_W_#2>PSI]^
M/CY[X[]]^^'O?VN\5<L,0Y"%/_H\S>/7BY-\TYSD45),CN/V:>[U7XW^K<(/
MU8O]VYGF;LLT>0"/?MS9WEXRJ2>KAR%U>XJR_9:X:VUSM+5SAUKF8IQ4ZL_H
M&+G7M]!#YV]\)[TS9_7BA)99OC]T4GK'QN!*7H=_4E3MQ0;WVN[M5J(X29A7
MTN![B@V^5 ;>5G9+L03XQZY9\K 3Y]M4NKL;K'0;DOSTSB39B7R!")_8;C8J
M*L\GTT*-!?CJ;5Z6!G")\:V:I?*=X-^7X#]].$I\[YY$GZI$QWF*]?P:'.O-
M[S56Z70ROPHRO_=0E/VS>Y+XP[ <^T?4$=9)^"I(^+.'H]7W;W/EWFN@"!3A
MAL"W9?@ZZ;T;Z=W?6'3KM1G[S6M4^B_!UB=#_P=\_JDBHCM3N-+O"E>N+%PY
MVOJ6TI5^5[G2'>'KCG R&?EE$<%CD@QS,[W?IJ-'?IA6_WCTZ&_WFH6VLK%.
MZ]>H^Y'LEJP:)[F\KTURW7;V?PT+?NY\R&<Y-;.Y3CBY&Z]R;,'#X&I2* (;
M7JMI'6=Q.*WJ$GNQBG!**-SP\>,LNM4"V4ZBEO7^GDR3#%M'I97P6N? OXNF
MX/N8J]ZA-1OY)\7XB"$FKQ5W\V$G#=6Q<TF[LV,-7%6*8>@#YB\>,/\Q/DRZ
M8 [YB=+A\F0N8\.+M]L/O$:<(Y F7^ZN:XRD;$12\F;8/&J$S=.\A!&5+>%%
M1>%%QOR(,!@SU,$8C[IWI5I?J"3@>1R9"4S?HQX:(R4^1MN86VV1Y,"9_;4-
M1'I=B"N"<9KIW 3>C?J/-'8CM2#CNQ'<)$T-8)!N<2R#J_J9IGF9.("7_J'I
M9O#:]LJ?VRN]*(VG.TA]"?Y/<Z/P5\V%]Z]<> _F!8_'7@C3O4GML+:MF]D(
MYOO!$ICA]+;A?3NMOTSK_Y1C1SHH^T@5=P+ST"U]&^2N\I:K[E:UT0*-2UW3
MW(TNS?E:#1!CBV%J(5Z242[OP7TF]"O39^GI/LO^C;LH@\;KQF'IX(>B)D'P
M)D*N!X6."Y$I1*Y'=AQ'A13YQ-$R@<?-Y*6/;"%TBPBU"2@FT+.18 "4RL"@
M(@>*0M0$;.0G9J,XKP>5 YWJW&788._K9G*7R*9E>;QW!H_-?)7;VV&I&,=!
MELH9#76:I242H)11D0R<!M8^HQ=<O\L"-R<]JAZI]!@%<"(H![#1$P2ZT#PS
MM(C4\U]74:ZA&9+2TBY5LTZ3WHLF?86H(X1Y*9;T6FK3];6/23=<#Q<K,+6*
M#"U$0[&H?FT:8V(T =-XS7TKH60**+\"V8A@)GG3B[I^. VD=++M&;J&&U>G
M]2!-(M="&B:$?#)"%!<-D$>O^L ?U4K9P6%%D+^2M ;'"![_DB4FQUD^\1^+
M[4N5N];NEV97M]%U0$ ]B@#_P(9MP^30[U\$;O<,),I0Q<1K7%IHE#2\*(U=
M&DZG,!4*?A/5@T#]C>I4+%+9K.NA5<PC:6Z=)KQ['U58!%&FC4"WH?@3A X"
M\(!$F@WE74)4V-+]JP98U] ^>!<SU"/CF[/0\*L,\Y_G8,BCJ530N]DVN!@K
M M6\V1'%4T#@2PS!SGX:"IC^2& >&#,SGBH*9/%!F'48%N,+F8-1+O2/,R5*
M!I\G&%,$+\I&H':XN9SG&!".$LY1>V@$!94Q3GU5Y"F#T=H9F&9W,O<0V]73
MK 6T5('F>VMA381W:;S.+!8PWAN_S]=@I[I68EH7TUR8#%A5$@R6T98&88R@
MIL!.9*; =HW\-=.>8S+4>CK+D9MQK%_?J84['C)<G)[1! *_(F(M(##@-A#&
M!H(5H\O \%8(>U8N/75:0&Y$+T+'TVL]GH&K2N;'P_"Y>.>+R8]R3./J^:<H
M0\Z'S=R0>I)PI@6>KD+ -D*E"WQ%>%H10D)H1BT+9<7W6.R CB0WM"/8.I%%
M)C?$CD8 ZO2;VJ(M'J'P$PB=@[1C<:<)2W@P<\PAHF>Z4.!HHO?7? 6>2 QJ
M2:PK=$-5U\_$^^2P@>#Z.Q>)1MH(78806EF'-VT-#S6[$/IHKZ??@*R(A@>*
M+JIW[!JO\836>$?,7K#1X(8I[+^91-9$$33D^/]C[UV[$T=V<.'O_ J?/GN?
M=V8MI\<7KC.S>RU"("&=  FY]A>6P0:<&)O8)@G\^K=4Y2O88!MS2[/7GIGN
M!&R52E))*NF1!:7HN!O1_"3+/=/)".()3(HV"5:X[6%DW G%SJ]M+#_\+C)U
MT91LP$+TP#_8/UT <]MZ&?!4KYUTI_S81\727%;&\,-8_,']Z<X*(+..4%!#
M1M.@H$)1D$.&[;F+T4D'#OCQPXZ*3FY.ERSD('<N"EYQQMJ+PS)77[A7WM3&
MZU1^6N3F,&;/7A8];H9"9"O_,O["5%T(QBOX!5;?,-2+6WW#Z?67I[IK^[E3
M:5)EM7)C4A;:N9>4HAZD(=ISDNU[?$/2W_$M3O!-!6E11^XX9"TXAF,/_X38
M<Y+GX0H8/US!E=;#@4PP8$%V-)S51M<WSZ?%=  +L@& !38)WW[4]7?D7M"9
M"F('"GQ460A!,#BH';B&H3!$<E@>5YCDO/1OB/PC1MGVB(]>=L\=*^PW6F'/
M'2OLOYJ^;J!$W*T/MT B+%C(94"#A[C0@]ZDKJ]U->-'W/BJ@'S+[+7MP_',
M:8=ED7=FW-=S-X,A/[ON(FL^&:'U3/%'_G8+FJD3?\VSGXT),A?1CHOYS(4H
M&V-%0.Q"OIRT&LK/X1+8;/?0L!M0;;/+>AGJ#4H13<#?_WWC7+9E2WF/9]O4
MV^>%N_Y%Z;(T?Q*&'KY!@@%/C$MF>BMB844\6=&9VJV9ZC WN^^NNR(^]HIP
MB+W$(=C8!N?76JNWQ3W9FGU2ODVQ/C"9W8E DLUQU 7%MM+$.!D(PAC%OWCR
M:+D+0[9Z9D<^[<SN9Z."V6RIXGGVV_(M#6JPUP?=/S@F2W-\D>9RN3^#,W<G
M'Q+4+,&#E)#U$LKL%4?EK/=).KQB?ON6_#6]YP:R/;_ ]@JYD7&YS["(_]5R
M[^>@=M[X-(L)^/\8#.&Q&(58+[=FS_Z]E"&A#PE6C97,BOK /2(F<$MKGBT%
M&)&R*L)_ "_G75#@RJAL5@1=ASIP'/"B+>;JG9%0KLSRCU)GIG!5H=M].^L^
MO&Y$URQ?) ^1:X (0,&VTW4CN53/L\9Z#/??8 OG_Q0;^*[_A#R3S<]]W-HC
M*\U6 \6 "@.2+[.X_7<D9G_S)>?*1K,?EI K($4GDSW^]TW^-/]6)R-1,T6I
M)X\$Y1ME_<' _N=$E<D#[]MGWW[DZ$(Q3Q=RO)VBLPG^$;;>0.X$2^078CL?
MR'8^*=M9GN;S',VDR?>51KM%9D]7R>PYQ(<FW/WZ3/F\?G\^:&<7Y5Z[,2IM
MSI:[D#0^/Z 5-'N<S!OO^6Q_8L\F@3>S3-SC/">2N$;8L!@V(I=46(O(K<X5
M"BLE-8#OT9GWVV]:L(7))]VT/,_3;"Z_B4V+&C'%._+WUW7:*V("K7PQS#4'
M>WZ'#+II&71DV6<O[+0SZSUS-79H5*^D_I8->Q  &0!'0#?=;V+7DUKP8F)C
M0.?9(LWSS-&&I[1!P=:ZM(8_6"KE:(XI'0WV[V"P%U-8#4WM!:93E/N;R6B0
M'V1_%C:93D'O/^D=4RJIIE1:.K20F].6(J!M546(.<=PG=.0W$BK,?OYK'5F
ML^IS3JR,3.%#V$@F97$I-G4XKI)LTJ ?WMPPLWW7<">&U#N1/T^&LBA*Z#.(
MC9S\V=45ABEFO_TX\=4 [EQ.5OG^X1L>_1@I)H[4"GQNY?F10*9+'IFVH.75
MP94D&-(M<*79OT>!#MB,>:'./_[JWPRNWIX?V$W:+DS%B=8_F1@2,5X[E8*E
M+(KN[A4+B0-VCF8+ZTK"P3 O6(<2^\IL@4=^V.K .8$>9;UZY&8%W*-_7G\:
MVI.D2O>5BY^;2:]'S,1A6BVO@#I!S,,03Q94LZR+N']7EKYNP!:X6=$UN<0D
MS^+ UK''L"WE;0JT&24V\;F;R](%KKAOL=O< ;J_GO1>$1-HND^7!&QNDHV8
M;2?)=MTMW%_W?];;ZNZL][)TF[H0\WU9T["&\4Y\R5?@&#K+;20%_[ON4+#=
MSB;=H1)7I//YO<NY'>UV:G:;6[#;D%8CUIH8Z8MBG6>8YP>I/]R1E>:^YY;;
MZ6BV&3\FON[CKV%P0D6*5($1\RDQE#^&44Y\+UJ@>;15A00WH]8V)37,7W1[
M@BURXM0%FZ5+'$\7"_&=Z4C[<S3+>V&6O>[TE4R03V7)**NB=W0 F=OG*^ZM
M,KD[::AP'TJ2C&)JQ;T>F@DP42@L^![NR%X1LS)1YF%U<+WQQY"_X%XJK;O'
MC2:9[7ICQ:7G>$.VMDMF(>:TA"DT3SG54KV>/I'$Q:VW$Z17E5GA^JHSJ]<?
M7J^K3/NBL1WG[=L/FV+DKDT)?.-"5:)'0I+MR<*9'O_ CLG7R)X7RR2^G.)I
MGBG1!79U(6&Z$KXGW QRE%@FL1_+T?D"1_/<NMP,5%$F],+/7NPT1"&SS[GW
ME[>[[,WI!HUQV#6%32GZ$"+5T<,I[6*' ?HFH%]_T23*\LV*H>6)K\^*69K-
M9X\YKTUM5[ 925YXQK!T@5E]5WRL.OL"GA>_U*UVKC$L6XZ,^HPY?>W,I'R^
M^G95GEWD>WM8*QS@;7TY.[&.P\8FOM5$#EN)IXO%X_5SJKL4:,'9Q!U\'%TH
M9&F&YXXV_'>PX4RP#0\M'[ZJ_ZJ6+E_U>UW<5OGP,4.RYAY75X=?BS5C5XW9
M]>-G9_;Z-G[5>A]"?LCOM&8L/!A3)8S;_(5BLFCUS"Q;"*]G/AZA2P*B!%4!
M+)LXA"T@QR=[+.;ZNO;U;-49ZH9"Q*@ZH9!<N1;OS]I/LV:24&C+)5U?)#**
M:%PYYFA<(\<G20PJE[P\]FA0O[9!K00;5*?4BEA/9$7+[>J,GTX[L\KC]5OK
M):>\S)*$)5LPI%_$>$8U"-'S25SB>MAC/BG=[0FVTHF+83FZF"W0?'$C( %'
M0[T7ACKG!7S#XXSP8"# Q,(CIP>2VK,,=]UGKZ6STL>]_F[<<4GP0I(46GC(
M(QAO7@*I/_#LZL*?&V:\S_F<0[]- ;PZ@E>;]WJU>]4)O7/6%-9DS=$F[85-
M\M:#+:O^9-C3+9F>=F@UYS&?O>Z=!9AU3<4<]B&*HH/FJ7O5F96KL^%PJBF]
MQPU=-KM3%.8&/5CC.!:G0I"S2 .;A*C^F_I/P#">H/6U!+VI8PAW$2^U)>GM
MH:"C)=?)G!Z"^#VZ+BOC'GL]KB%7SI1-H,C[0AK:JZEW#$VY, >HDNS5%MAX
M3K[+372S_0(W^RM?O1Q:<_7+H\<8?-0BPWJCYG=C6_A-QJ:H#72Y^:C=#N'4
M,M^9H*AHX0?XE,M8_W7VAJ;FQ:(0+!;D=>6).=1T=.**<Y)8+%4J_5_#6;DE
MA(B#@1] "<X3%B62B_=J2Q*'[_S/0:4TDU_#)#'HU5'W>/[E,20Q:F65?V]C
M2V$D"@.E+QLU+1=,(<<P-$/^B2R UG\6MR0CX(G87CQ^& ^7Q0[\_$_Y?Q;$
M-L2:$5KKAC%9$-G"W;C6J+_6^OG^<KF1\;<7Q?5TV2N;$],>,C_WWM.+7_K[
MH%JX_'A9_E[-?41L<2 KCBZLV:BIF52$U<.<&"0FL^PVB2Q',X"5E\!:^N2
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MRJV[^W;F[J)Z6VY5[^_JE39-U1N5[X>YT(/>I.Z/BN>0S+3=HQ&=AQ;*%_H
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M]&MRW9E5C<^RUKNJRN9.)^H C50?*8)MR37UH"UX:G<N*QH' K8ZX7&P?M?
MTG,!WQE%Z>#XDN=#2KNXZHB(D=L)V\/4SXICY\<^'1->N(*&IFI^P;.S.Y[S
MX?IE=,>,JK^D\DZ]?#R3G)(QE7C(V@$;@^6V('17$MKU&*T"<PT=69XN<,>L
MS2:V;94A3YQL*^4 O":UELNCH[]W%MP[/[,AF?,NOF.X[_5!7IG>FP_#70TA
MLNKP$9&4@NN>#KEL?X4'Y]N)1)::8^(4[(=ZX S'H7_BIVM#Z_57^NQ??-^6
MFVJ.B9%&"]^U+,<CGSM^/FW5KAUM]@YM]CX874IX%V0%UVB:&A)O%Q_9:BNB
MD--"4)/PV&(?@')7,*"% XHF9&5B2N)AFX)E4-<V\(*-CWD*2R> <?.%D^?B
M0[%8:E>?GAS,MO2XC4R0(A@&(7$\5,W./7\[%,\?S%^/.:9>808W7&G2XTJ&
M\(A__EJO-9CGIUNE^_@P$2^N!UWN>7#'GRJ]48T1'M%GIZ?#[N@&OF?V+BX5
MX?P!?5_A?K5/K[M\8U8N=SJ+O"DMX<T9$89@[N1OQ\7J\Q-S,QFDRQY+!'?%
MH!7G2*#\)/0#8@'=!YXI$:%B0S8V(=FQP.^7D\U^S\<&C/U='9QD5FVA9/JU
M)%68:_:FG7_YPF:-B6C6%MCS2Q)O?LY&E3;;/YJU)&YRK,$(VS)JJXB.-2IA
ME4D+!,+:J$D[>O^_J??_*,$2 %D:O1XZ.)'D0K,&LCX60.K$D"ST2:4'.&.X
M#=RV9XZYVI\0($86-_:)Z3T4;,Z5">,:F&_-_@*P[I+XX*<^>'C\V:N5H632
M.BI2WI!].4YKJSEGF=]%,.Q WBF-EZ<S[>KQN3+8 .]V?-8N/[=B25XR%YU=
M;YI:(OK#]C_A"M8; E:B^5R.+K"Q@?T3G\0[1:S9I-',KV4T%_SKBZO"K"IH
MN9;*?G6CF5W3:"[PKLQEM;X@/]R*_-%HQC6:*T( =KV1?ILWF:OH7V\@7?QI
M;VD:S&/\LA<WSJ=+;YR%2KW1O)NI=_>=V91_>C.+I5?^(\E\ZR0=OO.7R_%X
MN9""V\G%+QL';&_MB]\E"= ]9-X*\\:E<F<>]?8U2J+%51MO<(3+UWP0)>ZZ
M$1.:_3OALZ7I\-:R:>IR=X)Q5>ZT%K+#JNEKHS]K2Y-\I?7X47Y-KZEZ<6FD
MXJ[G@U4A]7?''OHD5K0841QN)>QHR7VTGU@>1!CT",W'H!+E9J5>T_2VH$C(
MS9%Z$QUC1=HRU)$;'5'NC R/47YXNJD^7;?SE]UM-^?Z>_#]RZ($9UV@P4BT
M #?0,"E)T%48W:,"QM&K1/"%#&>E((/*1"2^J[J6]8\L Q''V'!<;N\F\*PJ
M/-^4("8RYHD[Y+,\0Y=*2<:@+#/@433V7M4E],"9)%YH"@C]N2"KP+VFZC*E
MK,L&^M49^JLZ:$FZK(F.POK\)_5&>BU?*=S#;(-3B&(TSU>&@CH LX_X;:^3
M&J 5AJKG(=?W1M7R8KB6'VNAEUF5=94ED5%)W/K.\UDZEUL]EFJ]4NI@?S&
M>>X1#V6^'J,Q&.?>^J92^'Q) K*3XJV3'X+ORY?\+MFC9'$@GTHIZ;$ >*.[
MN,+<\#&ZM,/W,,>6Z!(3?Y)*U(* (][Z$6]]CQEVR)L='6\]>\1;7W0P4L1;
MSQ[QUH_:&@MO/7?$6]]'VI?CK;<#1CU5K5%/*0"MXZ7)^+A%_I7'SN[!!L;%
M7L]W6#;;F0TUX^7RU\?C2UU.B+WNY?G_1]F3B6+S=BMPZ^LF6U("7"8WZG&I
M6)=@)[MP6NAX)GY:>TDV#B(@Q$FTM>5/V>AX<Q C3<5;?8VQOCLS<WR38QIO
M#WRCMQ8SRB-P4G?'##XV,T+&?-N,R9;ES]JUU/A\'*S%F(I_&/SV.5.*S9GY
MT<4V2TZ?SJZ,Y^N?RI6X%DL2SNU.CR5L?&%QIS>'I4)M+IU7<A_%IMG*,]VU
MN$2>NDN-FA5SU]REK@R&U;56@O$<8R\D[M"%U+BPWF2%BJ<7:-N;%S5][1AM
MQP2B2$B&^]>]I]C5PP,BE?JWJ_]EE5_X+,>6UY#P49&K]HXNVKH$[\:-.CSW
MYO"\CX/S!'9SX*]C96*:O]_FV^%9V0V2%70ASG.![0Z2QQM?'&'>[LP8];K\
M_O;6O6(W<AUN92:RD)@X%11![4DT=2FH$T&?4BQ-!4U62F&ZR9RN.NTD16\[
MR6+#"&)($!.CAC1+LP&,D9U-?PW%XJ?D])TX'"%=)M_FUI9H%,N*1@AK"#9'
MKF-MBCL+!/LO:K-1*X?C-T8$[OV>#,-)M@'1QI#'W $^!N+PW%"*+,VPJ\NU
M?U_.+\U6S>U"XGE0N2R=!8C0"'4*![$3*PI%$FY%<'IL;@]B%+Z&%(UP)2B
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M:M"'T'*(*)QH_9,)^@L^L'T>X!1CH4:X*-U7&)RE <LZ6YW,J.39Q*FT[&I
M[]\%VVB[F[K"F.43]UGG(XQI3["E*Q.FT2L2X%[JKC,R78,V$BJ5ZFUE]GE1
M[<QN=:'X?GMY*;TDN:R.7Z.P!/IQY5W4 8O[Z@O9B-N9T&:E &/'T3S'TVQQ
M=5[R-X"QV^Q^KC)7,8+4L-WDZ2R3HWDV?B-:9-2V=5VE_4T8[14Q*\/9$&&L
MJ^^2L:1ZK7]5D-5J5CLK;6M0PGSUFFQ3>*Q'6/_:QQ&'EC"U!]3VWB:R+H5<
M_+"^Y,9+N=V9G:H?S4]M4GGKE39;V1:0NYSHO2%$.UI_KV]\"OLW'7#%615)
M'I(<4X7$@5*>+N9*=#;1_*.H]6#('/8D231@+6U!0:LV8:U3%$Y4-$61\/N:
M_?90TTU3TD?$7&).^4H^L6)T9;E:_?DV?IUMIM(WBHZ$>-;VNE8JS@%Z89&5
M\@BDO2(+NX8V)#(-B<N1N"Q,2(XT)3FMN)M+Y$OYXVZP$KZX^V4\.&>K[[?C
MRRT?I:L"\+&U-*H[#73 #ED%HIJ+)<-7CN9B27P;H :)K$/BVBFV0+-9AL[E
M4TM2I-60%G[&[V\HL5?$K"SD"9')&L%<"0US9^<_'^XT;O0Y2;%;9W5LV[?)
M.L:V:\H %^+4VQ,#FWT/DJ#?=;^I=6:/#XV/;DYKU#^S.RSGL@FW$A_QAAWN
M]/Y^)<N39:R+B:]D<G2.14= :=T![3M/)1271"UKVDHKYF_V7>NHBLXH--C"
M"HS+7,P"@<;TS_G>I'=^K9V][H7K6O>-^#Q@GRM:HF;5IB74M\2%;X4\1Q>8
M^#B-7_!6*+)FIQM@1&E8CN@:S46M2-U]4>OITZ?>&KSHGZ])HM:-YKD" ]@@
M+^N0Y2M)4!:PRPE-1.))*%FZD"W0Q?2NC@\_O(YJ*6* N6XX@CW>SJ86LGCO
M(4!EX1_ H'T7%,BHWDHH/I5[IB3"+] A[_^!YY-D6.U\P53ULZ=,0#30'W";
MR*U@2M5^7X*0%ZR[QZ+_NKD[;PC]JZO'+5WR@IW^0[0H_9.2+=JAY@>;;PAL
M\!\D=YF[O2#;[@XEL\VE&'=M(24A!3I7R-%\HO+ZW?8P[,$&K<AHEM88Y%+@
M<TBYDK3 '2W_WEG^L[0L/Q)8(J!GLC'6#$$Y1ULV1M] ?P?YE-6))%KU9IJ*
M_/IV9]:[?GF^OWTO\.,DL[U3J_6LA)EY2C"IKC2059@L !DO )D[9"=O<U8K
MYO8'0ML'6ZKD0!$\S><YFHE@JGX;+W^_!8 +%(#$B: 2G>?RD?KSCI'+H9Y?
MN9V=7RA6N?[5^BA?O>M</TGB.8WSRQIXLO0$DZ#5,MK9=<CS4W9NO8+CH,2E
M SFZ4,S3A02GUV\\1&?G0A#LPR0?V9S<AXD[-_-XBNW/*0;X^C8HI%/"I(H!
MF7,0344S)KKD*R)AIN*,J?/,9T/9R,F$8;@_)& #/$@)=%NM%7BK]E1QZ17(
M'NW37A$3!@AM=YB3-E1)E3X$I3D&\U#]E/2>;$BXOF1VU7]Z:ET^#%Z[@VWW
M293;%:J8Y>S6<$(CI6$B*<FB,AG+%TZ4Y/<:629Q;<-&J YO1@[?Z@1YP"R3
MO.Z9S],Y)K\)Z!/&%>P[75 -\F1<2U!7;221%@$2L6%@*@1%Y,H%$2&2_Y!]
M17]]^?BI[1+^UK,,4A0"MPO"%C!1UA2V-=B?Z-H@RR0?HIM'KA*_;E9ZIR:H
MX#%!FYK$M+9RUESE))!O6"8FHXD"PX*(,&BCL2X-)=60WZ4Y8/K9K]9=O_W6
MY8K-)#G?M8XB0J^E>C;%ML9Y:89+0$3T'HC$UN :HU"]#*DQIBPD.:O8&*"-
M(5>*I3R=Y=? 1+,T(MDTG[0.D[WU4O>*&&?J4C""8GLR'BMXJIF@V!%7727B
MA43"'TRIEZ\?>K.@M%)LC?+.RH@437DI)GD^J-ZG1"< W,1@C6#.KQCVL/Q+
M\=]S: M8B<!/[."=\"D9,(<>0+YFW4&S>OE<JCUJFT$WB'A$XH)%P.1$JF =
M@Y0)A&[;__0@QLWQ*IEGR2:^1F+I_-H0CWO+MU5G;G)_/ 6NV8ITG!]^G!^^
MQPP[Y,V./C\\?YP?OFBS4IP?GC_.#S]J:ZSYX86O.S^\ 4=.!ATYODG4->>X
M<6=2'^;Z@H20N$J-R0A]IQ?9QY6,GC &JZ1/I#G?K?AMOB$'0%2D9M]SAPVJ
M;P<I15^$O/CASNSMOO)YQC$EMN3""J7*:9@2)_>G*8]S;S3OJAGV;\I5'[Q<
MKMJ934:?36ED?G)O\K<?Y]4&4I\K9UNV,]]] VO>GHW; /%U513&YL3(W V1
MY(VE"3J?T<=10/,=^Y8R\C$_ANBDGYYH'S!SQYAT#5F4!5V&QYY)/6U*G<J:
M,35@H*+GFS!.ID>UA@(*:*@K4_Q.8X\!P(3>)65*_0$.[O_[OT6.8_ZI$/\7
M_XW]YT\Z(R//ENK*R##UABJ*N@=3RO*141@D(A<"+!2R6)(ZM.^W53S: OT'
M_M:;@!J](^<&.F-1<#T:352<?!;&4QQNC]'OL0?](9M#%$[IDH%(PPX1^NU(
M,@7PLN5>!EM$RIR,--T:KC(=C8>(N6BQ'T.Y-Z0$'>Y:C3'26AF^#X]'GT:Q
M/"*.*C'_!==<4!2;&%$2S*'QG4(LIZR54VC!HH3XHHWQ8E 8@/Y"4Z.)8LHG
M)A(-":TX,]8U<=(SX<$FN=$7(%I [@5<_*OH+YA" ?845B^H\&T@G?P<_OHN
MZ\BF8X8X9$O&5HZNH_+-64OYQZULO!H9V)P)R(8IR"JY@)2/YG 'Q".5S'A4
M$AF[%PGT30.5G. Y]TB7==@TRI#1.P2=Q.H: :=T[[<$52; '?;'X#5P'2;C
M"VD1T:Y/:<CZD3(XFNI.3(C^*05] 93=U&B<!% EB60(C4FO)QE&?Z+8M@*<
M,GB'91>,N2] 4 ?.!,YAXVE6U!_HQTY1T)] >W\"-^&.WT']84@2U45/__B3
M)@,.3?R0# 8G ?./_CY!EL9^*38MAJ2_RX@Z F&B@,'R\(&&#YL$1\ZB=XP.
M$&37II1KXFDPRN0FWI0'F!P:/]Q.:O2D#/K^JP389"A$DL6)H!PMUXXLU[F&
M)"@#HX4E7<7;A+Z((E2023C(V<(_!C56!/5HS/; F T%L#JXU$5TYD!;0\"0
MSZ>@KUD%[2[\/E@#0X:\"/P+ES]]IVK(@("1@0IWJ'9'7T-.H(1-(\_2%(1+
MQ PY=M1Z;49P!U"#0S1&5N!3'B&51][@?_SA0LD'6NR;S=V1&YVQFE/S $W3
M@]<Q+,-V.O GEN/9SFRD&N=:61L9]<$W"ADK8&3#>G,$&(4UI]%GN:A7YR<Y
M%-?U!" OOV12^O>@S#X62 K)A>)820&S=<5F# 5P WTU&:+4EWNR&6%/O*@B
MMQ+X*I((TR*1(3 \M0AGY(%HH^IS.T7VYUG+#6>U7.[MV=F>\B(]JW9J-0&1
M&P>R7-0.W4A;EF>^!Y4]X"W+6%OV'<5'SOE,4^)$![\_GF+A:1DKMJR<<&S(
M*AT;/%5EGF/.+TW6IV,KQW@DQ#%):QA&EHM:A!E-.[GO055P/NW$Z&V+EA6I
M; 9F,8('A=PPN^<!_HPM)GZEC 0916WD^]K$)!B".##'G^E/(&_D=?1LNVY0
M/456(=E.F;J,5D1:EK31" I8T:$S$RQO+..1*??@MB+-'@34(HXR/]!R4,"(
M4<)]Q'G>[KB6_N@6N9,R\E@-'+C2EJ6"U\*3K3]GO+AWZ.]&A.LOY#^;^&@3
M1$07/ LSRO9JP=76U('FET#$.NMZ#47\&OH8^J9N8L\^@Z0F1Y'9WAIQU>WJ
M4%>6P:?Q+P][.3@=\2GUP#7&+_9] ?"(M"Y8+$S,@F,.'C+:4GDL*,H4[8BN
M309#"J="X0N89'SATM4L :(IJ)HQI0'<["%! ]:A'Z+C64&.N K3P :Z9%T3
MXB2'.91U$?G8.N8"VMB__#&"=4T(R1$=9Q8RHM0EX\1@UTT/HA(-P<@0-M(F
M%?CIN7(4D9#TX$SIXP78TJ?:[+3> +SI633BI(;7OD'XH."\!]*<\F2 /"1L
M!7VI(^_/F];;[#R2I2A40WLG=G3AV_[?S'^?G*O6"K&:+) -C[\4U E$,EAX
MO$_W_6+^X>!**4B=+;N/XT>+67XSKPLR-O1(P)"@9%8?T[F >0_-?@# 'S'Q
MP3X4QY]F2Y./LZGBL^\0O#EK1]X^V";TK)4XD4O(2&C'HQ9+^.WXW$F]VGKC
M^7E!RW8+R.U]<T?K(J& '11&<-\>P;'R#??2D(FP)G&3Y]F2 ]SR[%G.V3/T
M)[1G'4^]7=? 5YIF]1W]"ZY"RY^R$?Z):ZP$G9E^*[WKK^94U?/.KC?]:XRR
MV\N7$+C?.:<T!O\)+<=Z6">0U#E9B-KRMTP6V.]!F*$^62#1#Z1VD65$MEP!
M(RQ)%%R@4?D_>LA@Y/\0B=G)_R'].>?D(:FH25W=,0E^-<>V'OM-.-OD"P,7
M:] ^2*%CVT3OZDXS56*?G3DI9=OT(Z.N@Z[A'!9)5_O# 8-8;JAR<E-0\",-
M'09V$@9]UY#0Z3\9PQ\7Q-<++@KS RPMA^M$Y,.1\^H6^;+R.\R5]_0Y^*29
M<Z29XXH>607Q;?;+@'9+L@M$ENW">+)T>^7.P@U+IE/0BNMKGLMIK^JO?M_1
M"G<BC2ZB0Q'M*('J7:4:L=@3IBF<HRG<"6(5X41G!2-BZ!.?+(*=ZUEB5@>N
ME.83<TNV_R_'<CFN].U'L&OJ0T*V'FC%3P+%YT_0+Y&S,\;(3K0WA4M<%-*/
M;+O@E('8;_0%)S5IE5T1G;4M><;2,RI4SUS30 69ACZR!1:I%]H'<H5UK/SH
MT[*!- X&MTYT[/R2JYW%Q"UQUS)N0R=VQ[OHD'E';\/W5M82+7X1YP6]"FEJ
MW_T47%I)V*0CU]E^!EHZS/4P("\@C<V IU&X0M5SJAD9*Q00D97K^Q,^!A(%
M3[(:?8\,G$%4&Y,^Q.9@F3S.)")E)$Q)XAJ]5Y04 =&/GCWI2=BEE2 ICN^W
MP+6&NSI![V$4AHPW%8X.V8$NC)R;N9XV4> Z#/';@(-7P!A>^!G=B2&KB$#X
MCH&C,/RB'NZ<=,.T8W9Y!\27C8P FSQ13#<8]-V/>;0'WTC S292$H R0-K3
M19$R%60ZK$&QOG@;HD>*Q(A6,IL$=][@,Q-8>REJ^+ D5SAPV8H$3 1V6/&,
M5<,IZ#JN[+3TAD1""M)X'#\3,P,N(I[&[1O>+%L1,_4!<IRQ."+[M>U# '6S
M57;9L@Y4&H)$^2]?_<Z/U,MY>&Z^G*?M)CS*3AUM"PD(,F;&'7K;J0)P]_X2
MGYK7,8KT@,YL=E=4V-I8?IKU#J[LAULL^SGMS&3Q9V]0;/;-F8@\UOIYHUZK
M5\J-.ZI<J33O&W?UQCG5:E[5*_5J^VN6 Z4NGMEY\3P5#!E%UW.2-27_#A'/
MK/>.)=H#.K.+=U/HETV9$[G#$4_Y!UY>!E\]H\-$-;'=/5Y,[NYB<G5K@]:?
M"U7?H2X!N;-H"\<""95Q3X,N8L\9YS@]/0Y60E5!I TD%3ET"GB V,$EWP7'
M_EZ%6@M2XHI?6<8Z*E!_6#F\^S9U7BZWG*S=@;+\H.5EP9A*&*!7^K&TAZ)P
M[*'8: ]%X9![*+ ':8O1(>G"3KSA_+R[X78*H&-TN9/A'4:^[&N=V>U#>98M
MW12%:_F07(N6<\YD\)PNSQ*/#L8^.QAVX(Z36C8^$-I"NR;>*8#WUKQ_QX7M
MNEV-WA44?/%*;@K=U*V!_94,]E><Y)5(3<88E,@C(H?J4"#!MT5D7L8W;HX6
M>FWNX8:IBM8(%VQS?399;PF,_X.=64%YXD9OY<K#Z4&9'+0,L#62O9"CG=F=
MG2'1B%U,$V9I%@(5*ZZP"VH,3_4LY/%&PJOD[J]5WV=,1F-B7,@M <EF0QA#
M6L"A2F#DF+&0A"(NJ'9P3,AH21PPS6&@458UAJ=$)Z0&AQ1)!!/A7(E[*MS(
MYW"(AB]IK%:8D6:8OKHB=_FZ!'5]=D95E."R BRJY\ZF+\@Z]0[^/F@&OAPZ
M(84\N(9=-<BG+5H7GT%(.<'XS<[-)ZG,(FEGS":XQW*O'S1](*A6(15:Q+6[
M@Q)0 J1GX/P(WT=,D5.CU(4D!047$P-J**,UZ+A^"WB(CAX0';?H *ZL[(XD
M$!;#EWO^&*)S!SY"ZLQZLMZ;C"!-#D>5*/=@]S#7#9^4(7EPBY]<@![/'5-@
MZ=;J0JU_2+X>_'PZ@\B:"(J5X#>L2QI1AA(!TCY VBD<N@[UB-R%JYYEYL]&
MNSZV)>EMN*)>[JU7/(?EBF]V9O4[8Z@VFM?*]0&EJN4?4-J=02I%KNR/9^=N
MB/?O HV-7\\ZG90),B0TW.Z!\9Z8Q"*!I2$FTC([3CM!WVI*($:<PKU!9 8D
M_)2 ?<&Y]"[I$/^[G5RD:",S/U]9FYA@+'$KJ>?@(H__3IT1 LF[G24 N<1Z
M8B\_TIOG)SOC3L!Y:KPC!KR482./F26_(VM>"?N.'>=XOVNM<^P60MCSI,G5
M>08OB'P1>A-%B7#8A %9$RAWP0\82<A6BW.4'*A ;N/B)KMXK]@;2N($BH+*
MR NS>=C&]1+@AI%99)(([ZM@9<!',HIBYJQSB$4O>;'0TG]99W;W\-G-GW^:
M/UO=@SD$P&_O.]6W'J5<HA50;F E#$7;38';?:4'32>6%RD&6X:NU!,F!LXT
M("]5(GX[N=1WKS5P=[:])W,FS;#OK="S_R#/1,Z6\.??.] U1[1."RB 5C6)
M;^I\L^8&T"BZ&"L"VA:D.E"C6+FHGMU?53/-&E5NW-5/SNI7]W?UARK5KE;N
M;^MWGFO?C2ISK%1]= Y&2^I_BS3Z(73"@_VUR/.O$!&P=M*\$NW"(PB%Y7'N
M!(M+3^2A%WNW\A6-CH?$"&XM1L#)%GNU.R67W]CF)(,#]<+/+M[4-</<LLTC
MM#HEW$6OE["F;U#&V9_ MI).6N\XG08_8*Z@NSH:*]I4DG"]-1G@8!=USV:G
M9S<"^UDH#MTN5-\);#A/_3;/VQ HV^6EWZFP=5FSC.N".L7>H0R8<TNC-D76
M&S5/G7?;*GGGZ!Q;HK-L:24$Z5[@$KM27]F(U/..U//[)O5%77L</*J/_&/I
MX*5^ 4TWMM1';2$+EGJ6+A5*-%M:/98E"9AU[&-H?D+8HQ6YI (7[ZI,]4L>
M%!:S;#51E9^5_'7^Y_VM%%U-]D@UP@\$WT+GU"%J%UVP.O!T"6:5%[DMHW>'
M2FKQ2QKW.4D5N%)MV-;E5T8Y2$D--^)+)#47M3\M3%*9$D,7BH74$=/G;W<\
M>;@RVYDQLU_ET^:]^#C('TRJ;!>76+F%+*DU371NAFCTZO9(W^_,\OW1Y9B1
M7F_KQ8/9H']E/$@B$S21^'BWM7ODK9[5YFM@"- A,K?*E%)DM$FB-:S3 ]$A
M(()-,*]3<L>E2U 7H9I# P-[0+\BOFL96PVHN%VR*RUL_'>J#'=+F0 $(9 3
M,+<T^5+@(&M,LX%1.A #$0OPG=10ZKW:4*N(*&D*W'V53,#GTPS9]$.:NOVZ
M()U.G9STV<-=GOB*GY2QZ!+5ET2K0%]6H2Q%_(<:>OID%X%D9)-TSII0':%9
MC/ AYJ"'H \!5",E3NS:$5\CGRZI \1SNYZ!+$+3,0T8X]#N ';[YL-9!JL8
M2HJ(>*#AVHAYW"U"K2[U-$3D#.#0T(\MM!Y\.X#O*]%A11C@5!9^I>NTC1\<
M"WU1+1UZ><UI2X&^.U4$ZX][A9>?'=XH)^HC.K.R(LD353^_'/"'='S8"\S8
M2#]X=<>S8S?$!^^&4\T'V%LFKK,2"/0..17\@'YC9&9D4EY,G7G^ABLJK!M+
MN-8W[,H&@)*"0.!$D57)OM77D/G%" QV)19\0X*.?D5^EYPJ#$*9'Q%K0K E
M@[[9QU5C\Q BQ2@*=X^?<84>T9'K';'G 15T Z2:(.NX[P<%5$!9!5JMYX*H
MT#<L@(:$?O)TZ@*(.#,Z2;&*;MB36IL =B#-/WTFOF1/JP7#F$Z*3M!6#>+4
MMV4FT@]HZ,1-J]9FH85$H]479\'LS+_%B?ZAZ:(AJ7.F=Z%'),(V?OM!7!RX
M8S,63@<+*P1NPB4KHW="*D%%NRZ(%$!F'!PFM *OSB -FA<T[BL(6FV" FQ
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M#0J;\XZ'"4&\(9FF E,ZH#['@AY QY%HK2JS9%4 (D;UAC!W!Q/FK$0VO (
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M/B/%P'R'*_R?_[=>+A?_:EZ?QG^AWY7^>B]&C]+$ZP$?M0GJ^A4;AMQP$J#
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MX2C@WU@B1FN4P&KJ44:_29#^>&;V/<_,!L(C9%7'(@$!2ZW%:'2PU6$)4LK
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MKZ<K)7E2*F$1M/4VFD*<KL-[;POKGTT4!19ESSB,%X/)Q$7D8,G*U$D]8II
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MFXRNF=P8N-TYB'+A!(O:#(ZB3=+6G'>43?$+VP[5:M:PP.=)R]J9Q ,^^%X
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M=)P5\8II6@(C]3 @V0 Y'?+I(:9*/,!YN)SF@9E90A>VD:@NY38[J7UA9L,
M.&.$"23B0P[<"G(WD;$ 9R&/A6 !0">Y(+2>_0J> Q:T?7N(_\R.BD3MD\/^
M^=<K_]!2&E9B1$6\M4Z\EM*SYNWDG=">&NG>W5-V\-O?(#RLD&0!B8K?Y9W1
M22$/5.$RNIB A; AWA$PE3O%"8B8WL0>U4:6>(CCKO#+R/63=RPC>QL6LP(L
MQJ?,), 9I"N?.9;@(+FW1BQ%OB FM! VP+\LAY*YX GNU^$"S>H KMI!B +^
MCLEW0*I-PZVDE%5(E:;Q(XW&OVA@QV/$ D4X%Q+(IMLY%KN@SDVL@]98Q]-,
ML<</WZ/P_O;ZUT.YI&C_2]ZY%!(3#=19\(BA."Z+?RG=USQI+RYG"R)NV P[
M']VS\T_?6\O>P40[\@E[F#U/OY9T:F+N*5J8]XC3S)V8]/VRT&<&1FN5A:%W
MO0QS.-L^EF:RN#?M(A,4.POA<S><H$:CXS'.Z[G:09P^ *9E=\&:<$-=594*
MB*:S4!(F*?B@ _OX?"J#Q%))FV3#)Z&*T=107$GH^-R>> C-4AF4%C?L;Z3,
M:TN9KNW NV2@Z6;.G>6C.TZ8.QKGD7HJ\9T S;]_*1V6)ZOJ"A<EUZ@(%%8\
MX%- <"4I0HI&MG453YS18V!\_@QBT]GYB?)2=+@?0BX/D+(AS[KPF0Y=/ H5
ME5R1U49C/F)]U["[9MNQX/ HAUA+=X)3@F>Y-:@,58(V"C'+:8"> ["215Q%
M'4*"*KD%R ^<^\+LC",U-*!G.LYB\B,V)_PX*8L[8ZP(<_#$UL?<+X I=W:;
M<JP];.AD!&!J@CYO\H];3D%<#25L>VV\+LU.6%,ZR"+BM*:][)$_M>K8R!_6
M0[2\E-.9#NR@[7AH65VSS/$^B6C;#&_?/)YU#UK]NR#H[?37IK;B?ZV_S\ZO
M#XW&GRF5LEXNWSRRG\<?#W[<?2X5>[_]?77XX?3P[-H\/CLZOSQM7A^?GZE+
M;?V]IL@)^Y?XN;9[4 $+(^!HRAT'TFL+]BBVU/9<)L>88>%&B%J%U?*B4+#:
M@ TMRJ[M &X#LT1YQ'4SD?AKW5G K-"WATR2Q9F>@MVU^S;3$F8-5-YH/O;
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MGIU&4R>Y<,/XW4*M7"KL%I]ZDE-)3906XVSQ1 5-!K%UNQ?[.\-;Z]/^(O-
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M:5_FBN-8N![[3L?&Y]Y?(C2>&T)/#\68??V,B/IX.YQIV0)S;V>G^ONRFS&
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M[MEM:&PAA[_M.+8U(%#VMLV/UH@%JW8;ZT-?U4V,;4-?R2P2R[^5 NR#[;0
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MH63XM/HAL08-A.7C%<R!W?8]@!Z_1-K[O="@CSQ:KA!K7(4\1==('VN^ G;
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M@CI^U--=AA1]#1+N(>4SDCQR5_#(2H$S20-#KXXU(HK$"!RBL(SB(O+KZP/
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M3V-'JHP$5^.RX%)CN6/?,-)GM6T>J?&+>&'"J;(EO#]!J%UJ'&<Y=#O>/>N
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M8IU?,/(0GX6 !F1"$P3HKU 25[VNSLX@WTYH?KXX_4#16!>C(ER]X5S.!C"
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MUI@OOSDK( Z]H7&-P1E0=(,^PR 5^>]$AEN<3$;:8/DO2LPI)'QI!?/,(X^
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MV1B;/[]ZBL;JA(PE'6U4-05]LS?NG35005H>+E\U\&,3</=(ZQ50-0C)?\<
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M8/S:;O^<?E<X2K*CARZQ?GYEXO0Z4*JC!!3U2(S%V$"Y$XHY*(( Q!2D6B4
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MJ!M,DC@))7T65 3E/G&**@):96!>@EGF)83GTM,GGG#49 C93!76E\S\5[M
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MI8"F/LWK]8#_*'C]B*R)?[@>9__D(9]J^^%P$D+'&IZ>";2%(/& $H  5E)
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M4/KV5UD5%>LXG32=-!.8[Y;8YU ^(5<L\@L!>D3E?>VX[Y7BOC&^'\@F^'$
M"0]+4\)N27_]_6,_-?Y<0DQ8Z*!7<W&M3SR#8W)CQ#.#4U]_CG2)8Q#KD:"J
M.D',2%+D PO+C 3\+RNRI3N%*_4UHQ%;S,3Q4TJ-<BLW07043=\*C?'(22A'
M+D?E]KGF[_4$J[:F5-)?P2QDR8&Y=C;N=0=$UY=$1P\3='HG;KJ3#*Q.48BG
M;[@( IZH?T S.NP]D;83/B=\_;,VO&W$OT2EO9M_R_=')_^1!;:I"-EK-PGV
MSA^Q W]MR@(RU-,;MJ<"^>MTGC?^D'DP.$?62ECYAS^H_O3^7+KY;;J[A'1C
MXQ5@O29K8KS]"X9Q)43#/&77-D46>(.=[UP,3)WT]+M-O:W0IO@YSL)LB=YF
M/L(0(.:L?B+.,/TDRC'[J%$_AU3= ZXAUM?A(60XQW9>SN$YD01E<OI;3E&O
MPPH.Y$&-Z8TR#4&_24/F>SI1S<ST%;,'2?>&U:"89@3&4T-QP=1TT)'!;SZZ
M^1OZH%N[G[94J9E^@RN;1B,NL]PFLGD_Z5%5!^(UI5H1(I$LO&Y*(UVB*A<:
MPM2;;>906Q\YTQ$+N.'6:_^0(%+N=MD,"7*0M%&$M8(2?!0>N9X^+)Q7UQ0L
M-H[,XP\+<HB>MGU-A.JHG-M=C$I%QW([CD<[FHQ Z+<MBR'GKI4QUM F,<6G
MU8)U)9<[ M3""&WZ#@ WA>>])$JP 7M8W6FL4V/41O"=V#>3Z][OT40*-8XO
MM!Y>G 2E8:;Z#<:NP_MS&^IO[7@"Q!Q_;S1-C\5SHWQ(6NQV77S!@EV(.;VP
M8^_*$PN0_VI?,VA:W?D^1L&9P"O%/8@//QI;K).$<,3%+9_WO)V%D!#D/U5:
MC-F[E;*&.CI&^0K(6AKUHCG+WWW,1",P6.0]6'EW*D\_7T,L(F.3OI?,4A"0
MGV"AC G9L\K(L5^1&W;/\4FTT>$Q^LG1&4&@T?H\3ZVZRKN:A<.^H.<ZI,;F
ME2=>E^%199ZH0"YH+L-QL?Q)$EF!49"4<E$@Q(\69C\\,_4NL$;?>@R5VL90
M$1ON2-7_QZU=:*= WR:B'X.>T9.DK:G^+/O<H(,<[J.( J^S?#F+XCXJM:%@
M@J$'VRN &=$,?1"*<G8)11D4)YQ[:N/-1M"<<_'&PJJJYHB.JI!!#"R^^LKR
MOA3!.M[S1$93X7O 0^22Z9S=!8?M^65U26OSEZ0!RG$38JILYX1YUYMJ(MLU
ML\.-;J%Y_Z^Y5&"I&H7B[A\/.2 @4E5[]OY>C$<E-3;9[>=8#ZQA .FQJ8:/
MP.P-.T8?.75FE1'[1K7-5T(2=PQZ>88$7<0+,PQ?^7Q6N+E9ZIX0A&)Z090,
M,Q[@ZM%[FV18=IX!+&[[,MQE%6:>,^O-_*$P.A8WWA\>[JFRA"=\8;TVLM#M
M0)#TAK$6E"G^WF^>RYK_(3=4G +H[L>WB-[5]#N_9+5S42<L?J++B<%Q"B%P
MHR%3(^;G3-B/8AW1CK6G"Z@H"98-XF4KKI2;>2(<Z125EY.W#K9H9WOS+->5
M5>"U^,W1W,H'"M_4CTPP)OH4-W[G*_BVFRE55F$:#'#U:.87MKP]2H*X/%!*
MLF:2A%<QMK5#0P?G,;YHAI\1[I[;Z6QW(0RC&J9K"+G(M"U?LS;%>5*R\QL!
M[D1AKAJ8;D%J1NZ4=P59=G,-[O/*@E# "(#BH!8?KXQG)!C6E@K-8$^#;MBU
MBN8DI\NY]&2&QU? ?GI2P@66ER#2)<]>:]VPH(>SO7,VU#6VB7UHLB7R.RTL
MR=)6I?+$A+3M4;P8D>(NS<;,C1C1-3KXW'@DK!L+1C D3MB<L:K0GJ;6T8*Q
MO^F9H!(=Y%[YAX(^Y[YF;ONO$##M\T(TT%J3<:NE2E"-1\TNI'$1-(*7W!4[
M+8L+7*()\<9\JOP0/"V.[>$^8$!<5Z*WNH;:Y"$:=;S7:B[6"]9.]3EDH+1L
MP#G;WB+*L8J2BIT5H@U%P*J*#A=M^%,+B.8GDO5?H7(T*4*6=<[M3V:G%171
M>TYY$JL\O74><V0Y<NS=.53^WF&\1OK4E*& =O]3EW2W!;EC$\V'&7(9=$/4
M-5NETC0:L</>(X33X+_TCE=BHMKM!W;N;$ K+Z#,XSA2>$8&P)<6.H+<^6$X
MMSXMQ,=[5R3;7#/U0(5>/87C1@T;M]K*VR4=;XWR:70+@#V+@-UTP9@@3X@.
M"%J<^;ZC5_A)OE ]//(](3: Z,O_REN;H3/E9:G#*9N'[(325F+&*>MF/<E"
MFVXSW6VVG]$_1AET1)0F_G&YHJL-P!5=E(KYI8;>-7J;S\AHH5Q44/-[Z=-2
M%:\\OO?CHR%JD2/YQ%\57;4>P";)"*[I>^_1ATTIP**;]<QZ./I$7TJ1VWRB
MXKHCDO++UGD'(]"9@F!LA> S_9H(T^AQQC0D+=J5,\S+>"F4_4FH[/0+V-V7
M3B^RN+71_B==HJY$QY\QB_O ;=T:&Z!ZXO(PGY:;58=G\%.&VP4<",6>Q.,%
M?.X:<?G]HBBF16D[DPDE<?H0B7@_W/D]F8,#84)+:TU@MY@!.*^C S(2?L;K
M A@K,]*WQ8O>2E.^!./XF+F6N92D3(H5N8E9;$631^H% R3W7 X*&MHB_Z#:
MT:98!EG@R]%1AFJ-TCY&-LW[$2%GX[##XB D R82'<)9BW7+IYXZCS[J]/<A
MJKJ_8_H4),4$X.7,38SS?<@6NPEA88/DW=E;OB+ZK8M[^"?"J8$^BU=&W-?O
MP#K+I2NDNO,B@;1XUT5O)&G-^9++APVRM:&N996,^5=@C_Y;AE6!H*?/0$8I
MTCF!0Z@</712"0L4*VIQL"D_?>'#^-W#U][D$T\OCD[0BI)=O!N'XF&+]=V!
M;5Y2W&PZGCO ,:<PQ_H3;XLP8_I"\O>$"0^4[9<4R"M [I$XFS)1@;?:V=73
ME3'3T5W$Z<_X\_*+I,-[P9I.VF$O+5PFL<#K<@1,5Z(*A>^>DVTBM0#LY/>C
M0Q1+\^I&"&-$TO1_/GEQBA<MI?CXPYQ1XIXD"DMOZ4X%=!ZJ*[E3:4?L#W $
M&' 5ST]8%Z6FZ!*2J0>@Q18HDW[BD(U\[YWT"Q^5K1A3P]F>AIV6Z<9)^"OW
M6]M9Q=ZZ!'W1%HOE?FD'^/H_'C7T@UY6P[G$*R?-7M7-Y8[>MI5RC"O?HZ0K
M1(?1V AB*LSQ;->I#=E3=S,>:8?;MFA4D:@UX;&QY<A&! LED<*12*>4=]=F
M1XAGY42O)D7==I+G )]#2D"*1B^\ZO#/7EJ8UKJEJLD/3/#%-UD".G'VHDKL
MG17FB=S<9(9!J-=]0J",\Q=2C[C^7'0?E6(/PP'[_(U-$^.U2?9BJ&%:2RR$
MVW#DMT+BIE<E,^DHV4%W#CUO"%&L8UPQP"=B1T5DN#EU>MF'8T;T ^2TOV7)
MJ;]! 4/%F6J7[8N0YDITCG'M\S&36V7KFF)L=_'C>P^M06H"2 [HZXZAKR(K
MJ(55[EVI1";#.)VDD9,D4C E]B$5 &3)%;!RWWI(ZY=>6L&$@) W!. J6'/2
MI<NE]%93QE$TD)@R !C9"E9UN5%,Q(A[7#\NS-6L?1$I#9?'?3@7)9^;0DY_
ME#H1NF!".)QD[=-]!5 T32K#*DT7^$P1@',8@KS[/_16K:\X'U8L\)YF/U+L
MHZMB8WF5M-EM &#^7MV$D'EW'KU5V[EK)=)9PD35!! I>IN0^7'&B;D,G*PN
MF2# 3+N*6(9%C?20L"IGU\E=E+7/O[XE^+R3X&W<7SWEZS[HE>\]::Z5_/)'
MJ5SU'M$^JX!91)N3%&&CLV58HM:EDE[BAZAB+3CIC[X-DQ'M-7:IX$/D(\6$
MB601A2P<WZ3P^\P%ZE@:GJ%M4SZAAJN63\\)?LS'=H\N2F(* $%^]T@$7X0O
MW97/*;+5!4]\+9"I<)>5:U]SA90=&Z4 \6\1X\)X YPF,M[\/'.YBF-0DK#"
MI>OC-P137YWCUC8,^5<^VZM[/^,@9XN*,G<,49&NK1+$%9/J-M359WH*]I4#
M4%X!U2;FD%53J-'#T$74#L4ZR\6A\KCJ(K132[$T?1_MSF$ U*-X/?_8-#TK
M:JBGSJ44R<RC.(HT1%JTAJ,*_%8/&"(MB&0+X))E*HBBQ=2(9"H812#4D"&6
M_'M31T(I)J1.AOL-VQU"V^I!MVY?F^X:U_]H))W%^R.>T,_"&=SIK];4<05R
M9=>1:5MLHDLT4D*]Q]/VNR#M>\'+Z6X3.UUSM>7>-*AMJ^T(5[-QII!ALYU)
MCL8S0=MZAAZGZ21.W2[S/K:=V8)X7MJ95JWK[A#V7P$!CTMN^"R:\[N#[V8%
M)<+]5PH'TT8&H?W3S-''&#ZS&!K?<*W,*#TW+,]7]OZ:<9P6:-8#[ZR!-;DR
M.<_ZY'-B^U#GK/%SG$0[=[RLJG.0YVJ )]$1('65(H1%=8OJ T[9Z"YU002C
M6>+DOMA E1I3""EQ2G\B/?69=."E<7??L.J75'KPG';R]R6MW-FF&!6^5EXQ
M+Q&))F-#)4<K[](&7A[4R(CX2J?H_)3VK8/FDA:ELG<A1:Q4@S@8/!8Q-47.
MYSF.)A*WU1_4Y\Y\?-^U.+47=\?Q[7%4]:PLGFSK5SUUM[[5P/;[,F'2]9DM
MS:UYUA/K^]P0X<;'TH/H=OA/<67'BBGR"RIZ6:K4-32I*M4JKX"@;O;/I< 7
MG 7;=W,WU1R3&CZSY"*M\6=7!8YW8<JQJ""=82_=F"?NV=5!/^&.I4RNE2,_
MRS3K+G*%=.:?X6<HZ"A^36=!G9$5<T J[<QDNU]JI%-\+:%\E5%N+FV1_>X1
MA61F._PLDA?.D?=$W0)/'R'4N;@][4DZ\]6\(OQ8_M\F['WI+^/'4FA8ZP/2
MS^2Z?(OI[%&BH1MYB?U"R.2D1924W/#<PN:S>?/W&A) 3I(C+Y.6M[.&UN0A
M@S$</ZUOG4*E+0X @/O;-SI3)L -5MCQ;H2/#&,8'6XOO9*I\$O_^F"$8,9"
M\2<4H9A%2[+K#\>F6IEON2-\6I]ZG2CSUA.YLAYV'S1'+,/W?VA<TE/<8D*G
MK5H)X;9,J7R .^L(.Q\7,X#=4?U*A0:3E:9Z>< S(A"Z:"TSC8@M.D5[C9YN
M]IJ/$RSX<\V$KSTER-)VJ--!#4,LI=X>O45U$'X O10$75I.7$79*Q,+'T'R
M#KXIX:OHE.4AE$$_9U$WBY,68P[<SJ&"I>Q.$<!01LAS;VVKA$LR[7'G;/-D
MG?ZDMW1FQF%C.^7YLH:WP\8J8"+*37]EGH3>O*CI[=@;P]-S+S:#XRO"";D#
M,]S?FQR;6Z#*@D!S!&L6  !.DG2$JJNUS% E:N);-!?ISQ;2I[K&K$,&EZDN
M6E'[6P^H7,23W X."0V>D;&HPP192Y!+_X?6KRG8R)+'&7=L!Y4R>)@>Z,)9
MCI-Z&H&2&#*$ZG#_&93C,:/CBL4S3CNH@S, ]X6[[I$W8CP[=M6V.)%\8M0V
MMN1HU]X84NDU-;]:O[(V7H[NDFWI&/>,3$605SV$%!F8_"Q13;-<DW,E3%2P
MQ*/*_"5SVF.%DK=NJC'QF7"6?HS021@G)1ONJ_A(61$Q4WUG%*5CQ_/M)XK,
MM9Q70 S )\X>^CCR\@8:^\/,4.4=<">1[!J-_:U5T[KHMP;E=52+B7=<,6MS
M5>+BL)/93<VN5,(L[DHIH+,]QSJW! ?<P63@3UPRJD>:U.YF?OFW0&E9J@#,
M;>0=%*F<QLVZRDOLA.TE\Z?@E&M1Y^MK7KBM%U&HZ\U"6F"N-E0TPRK$_GM-
MR;RH0@&]]+OVC]2*-5),,5>U*)>X2 X9AR.<U*8C%4 O'UU<O56]C[=+5WW[
M)TFEJ56<F'J/-0J:>0ZR-J?\<_D>/S@157"'Z2V0D(4!(G C][R[G\ER?Z^0
M)=?,,4NUQBG?#'NK(Y,,&*YV*?6*TW3,4VT\>),6_=PSKC*J4:"O.VB710%2
M>9Q+R]5BPW9R*,0\\KZ-F6(O<[2#^\%,\WL_#+M&MS.X1K4,ZJ(YNS ?O371
M= 4O)?G#\%$,@)]S.A^T24A84=V=\ @M&N(!5+_5/ILR^1C^71M^P.3Z,IH.
M$K:-N>U)3<!UL89E17A@UN"@_*F-81%M1<>PP<FC[9,=&G:FM8=Y0>I@2JV4
M,.5KT-0SQ0OZYQHY-VS0E@B074HD=?B..^1V[;U:D^]7B.YM$,1_1(58Z1+;
MI,%8$M ^5T/R=;+M%0#$^7Y7'J.GLL)C#<.4)3*I4E.;(LS;TT83_'HD=2'&
M\LE!QMKA7?H),]PD.\*_SA/].W 4F<2P )ZO@&$<0NL7 DBF$9!?0#=)C7MU
M3"Q+W 8LZW>]*MR,(LDZ)<KPH P6ZR0GFG=O?L\!/[C5SJ]@S^55B>_DQ+HY
M[A6;<M@M"I,IA$6.7URI-:BP#F)0=%4_YU[D_A[6=1,T4^7)."K47>%!CS^4
MBS[)X5ZXP=(YH2*_F%*M;>ZTE?#=KU1Y^^LTX FG]>=XX!*"V*F2' RT_=CQ
MX5U^!?C;0Y4 /G@#S)/XI35B7% '(>6M4Y&WEX[SRG'[T[D_9W@1)+6-\^+&
M&]6N("3C6!+;0."Q-#J,2I;5IA]<&F)7V#3=R%S-H<-@W] _D[M))/2E7CB0
MGB KA2'I-VM-MF*:;1=2N$NQBFS&@IW3K9= :*<6%'])9Z8J]52MJ;DM32,;
M;W;6IH7YUHE>4#?>UCS^/;=WQC6[UJ?&63:KKIXL*7B _BC'4,06$F4#P3"2
MI1%L0B7H8)LA<?>,^,(L21?//Z]/PD-_1!:A$C/ X[='<>T\FZCS+@ZZ_K>[
M^)-*^W*.4O>WE21*'CLQS6F"O6N# %83#ZW@_?4L!>V*I<8C=U-$-GOV,[Y)
MV9/9G6$J0RWO#F_OXE7ND3IM'I#MD,*0EV,9G50\K*]\R!/?/8WK1,: 7WI&
M]EO1>WK>3,ES)1D 2H+*ZJ5J00" 2XJL(!(@"?C[D/#?,\/_-? 2%)I3(P%,
M?ULPHYV"4S/V;@GA)CUV1PQ, QIUYYN G:T#WV-)AX_?^8U&K65 :/#]IJG9
MEZC25&)7!W1B[CYP9KO&#O6$J+7P%3^J&*Y)[>3B6.M2+"GI?0UEUML1Y$#;
M:C'3<T #L8NUP*._ KPCMT$:0RLT*JEFWY:,KA9R3!_E/5X!!@V0H9IL\:Z*
M]?53'-I4G7;69B0$#S@O.T8:Q?MXV@!$27R^\0H0),[Z[A4 ]I=+59$8 ,_2
MBQ+7*]BP,FT+/(T;KM(3;6&ZN]$^Z$9IVMGK^$4%%\JFB$CS4X-F'$?*;ZHW
M$6&;6C#WG76)00.9LP?7A<[(!@7K1W(]GJM"KVC*9\DJO*EFEF_?WRW8L9^Q
MS_DNK%7:$YI7\CA(3#5])6'J&,K6BW0H5TNU/CS:#'L1]AB0=O'D8']2,AMG
MT*M)_B"^")>&+<B(Z IR@_E#)91@425CCN;=X OD/Q??[4CP>S=^N*/44>J.
M+=[*+J+:4AS:>!0&I-P'LN0YB!=T_-5?"<:F/EJ)!Q/OP+-#V_-6:NVD"?N#
M:M*]5[$K(*<0H(*!W,%]#G((PXF4WD,*92W-Q&P1$2+67-G#_$"Q%X;6GGJC
MA@Q7R#_G"@$'\;7#SI&Q"D'0S2.@$9H3TKLM59ZI8BN5JF4I=Z2J)8</[N_%
ME?%'B?9&C"L\!6]K;(9-B47YMCJ2F^;M#0SOR(S%AWD<G5LZ"-45RTZ3C)JX
MM(&5XT"?Z;/?2P[T(.KY: 0.;%8>N26V3JG2OC+@DH:I_N^.Q&]Z1/9??&5,
MK]3K-+VM$B+!?/1\DU0*]Z3@TJ!K+.OS&LYK0XJ)T&&+G'7]3.HJ.3Z<\">$
M/(\6.156W5E;$!M>,,-;_A_T[;OQW@XVA:,C5%RRVHN1S_WKW[\"Q6GF7'SI
MJ#A^CV/XBK\%IU84FNW=4/UQ<O)*TF%G8V>+\B2&&)(,7S+#6YU&0N-B-RGY
MU$),.!H;6EKJ?=]TBI59NZ>1& 8;*I')M,3'0NU]).ZD4(JM/.1N*UJ6;HCJ
M6J</OCXJ\V.5R='*Q_1^(O ,A. B?\\;6Q,:Y7U;4\763B-=R *1ISI1.>&9
M4FVZX@A[U#?=[/]C!)->][D_4.)D_*19(SI#2*>INV]IGC@20D1=_*B_026@
MGCC5/V;%WN$;P@%R14Q0S1,>I--H'>J#_Q[@A,T<_>#P*U*2#4X,[E(-*^/^
MLL^_\5W^SE2$,$WHJFJ<2HX&FU=VQZ^D'RZ2_JZT^Z%J4/2[HQ;4>6S?(WCE
MF?_&]/X_$=WK*EC$@>*O%?D]#-$Y]!!A?J=3[A,LJ68#-C?88[5PS8[P\:\W
MQ\YDCZTDX[:6E1^XT%TK5M7_:&;ES'I8#/ .RTC_O1UG!%4XX'CN"+U4O?FS
M#CK'V_%'.R)^B OG8.,;N[''4:E:&2(J#SECU(5[DR6K=R\G<8HZRK*P]L0)
M>Q*G5=GVQ;ONV#SW-9=4,5"Q46MPG]68&A]/Y.<)_<TC25U7<Y0J3E^;,Z#1
M%/HP[KKZUXR3&7D'F[P%^?VJ!M(K;1L[K!H>.AT_9/S<H9YXYUYV.ZG1 !O:
MH<'PT!UZ".VIT?>(TVKJRIA2J8]3?639$?C$+7\R^2=FQ4Y.L:[RR7/>C\S$
MX)O7_FWNKJWU??0,1W@HFGD 74-EQ06U_2]^; &X1!DK)EG#0J]/%1HPLCY8
MX99IU T6QYW*0B<C=D/)FJS.M[^6FI7V$.G#5BA*J;W7O>EP;GWIH#WF9MNL
M#WW-*=B9\N/,:BF8CBI5DL+&O$2NV"_,!Q&67^ZCV@ E^EU)E:'RV?_6(W42
M]0UZ$ *\ M:4Z,VD%QB$4$9CTC3%QBY$O4]Y1R2C;^TG:O#R.Y>X9@^W=, >
MC[5NNR14<)ZFW [)>[,O;@5G.(>\*TIOOI/_W9(D'9Z[2X*A/OQ[/=NU7X=+
M+=;/6*NQP9O5 F:,)7)=BOU2(H6*/U\X*AKJQ=VG_2U]=1Z^[4,YVIMOGTAJ
M9^+S_9:!F0=]U.D/2\TPPWXOT^#&].MUNG$15L'N,\?8TC;&<O&BO46HNN00
MK7K>PY(V\S %-=9W&8-7  4N!RI]#HN4/&IQY?(!.M,D6<D_RA<E Y:YFQJS
M?>YT*=<R=Z/BKMX YB11:L%_V\!](>-F"> R<0M2%:+K?!SQI[E14F&Y4L?Y
MO"6&/B-@9)U#-_#[QYW>0B2H>6?EK,EJE]!!"BJ@IF>.UW%T->DR\0K@I.GZ
M&/?K;-7!06U.$!3W"MC*>S@O#NNMEE!,+@7?^-HAM42))D?;6;'VK:[.]I"-
M''JF,DK$*BC)*X \[=)^G6O/O[^H7+NXGHK+1?(!5G4EYXC.^$A5F\B7W7GU
MYPJ[G3?+JA-B]_&7/57.FS7/^O"Q=V5Q [VT[\[3WSP:L*[G?GH;I7"?\629
MR/#3X:B&(I$_=LVE9 )^=$:T6F2,#%F(W/T=M[ MP[X_^EW="ZD<F?BWG4/"
M&^!I^8 :WZV7(N,YHDZ:L,K^?(9L>;F'DTU25-GU"I%Y^MV7Z"+6V[4 FFJ7
M#7Q8894'_9UPPQHL:N"4\<E/2?SQ\;W7)>"+!<T&J9D(.4SW5NFYIL95I$NB
M-Q?7'K&%YPL6HVFK_<\I2)^0V",*J,'0AT!\2Z.O3UJ(L?45<*J[ZW%FZ=LG
M>+0-):+,:SZ;.=?T\+$0RF^['DZK,+0AKC76_Y7&WU P03CJ5//# M<[6#=R
M#R^VT]F$'8)A%*62J0-I#"G$4[QK=^*Z5VG(^>0[\P?U#!5DI2" F1#K:#JK
MKVJ..8>B1H "9?=58W%PV=OYY6O>[R7;PJ-0!G33G17K3(U=TCEF]J!!VA$)
M'.?ZQ$#=2A3C#8GK\TH&)Z?Y$<S8J18EC'@?Z!5BA"A_Q^8:,\(DF*.R::2E
M!CJ:S/P<S@TQP7ZDNBE]HO.B6;$OP%V7YH5UMLT]UG0XR"&T6/^>%4>&T4@N
MV=]$<6(")WR]\0T[%*RCZ_JCFKY$.(;/44F>;G2A7A>2GM]/HX@!MV(0U'I(
M%L$<F;9>:)^=L0K8 A*"/L#ER!'UD/9SUA:#)835WS/!?2OXET!B*OCGO/Y_
MX?3^!0))),*?DTQ">?"13'G(M6Q>6[XV/Q>ZJ6 V^E"LG [_[6?N1\,&A+.'
MF*$B)S54*OX&#JF]K=NQFH+XW._3*,S;4Z'=))# #G*2,-[J-_8DMJ,-#?)/
MTZJ*\2C2"@SNDW9Z0'[PIRK^Q?<R5K;PX3NAI L:N/[H 8)4)["^<Z55TCS,
M,A<*PJ;V9B76;^<748W0(A9BZ8'#T2-W[.ZFR=4G$HBH@?0Q<.L978R/ PD,
M+OYA0YKED@;PW3[QK-FU%T_/BXY61[9,V5X7D;X*S2P%ZZ%M_DHVZ*V+H%@(
M./$]54!> &3M@K-S%PL]X0F28J_3L5%X+>OY+HF ?L2U E[-A38EJX'9=_A(
M-*$VOUTEP&H#;GT]#6Q-8JX-(=XB7Q+JSL-\< 8_]6<K/'&U954,TQ"(N=/>
M%;&)V>S3$/NMLQ89=Y6D;"TM7- +IH06XP^1-+P?93S..#2]O8#R?$WK!1O*
M+=& #R4>.(E6*3N(^%P1$O7 >%ZCCQ_YO:&2;^)0BGW2MDU7O2Y-.B-_'_83
M@]WRF5<I-:T_?-\8W9=D7*WVD@D[Y[&HJJSTL-&I%;K/H6I![3&B?$DAZ-,M
MA<H.R1')^F.(M0@6\@W#K'8.0WQ,WP>K+++OM;\"<O4;,#?O!LQR^]OGTXDE
MQEN+BJD88LO&N74_=G2] A19>#IXM4^,I]!@2Z4*YKOK]/J.+Q&^I6/%GJ4%
MRO5H>&HET%8<!];MJ57.6PNHW! .'MACJ:_?V.Z$5::^;3I'FOQ]9X092A"I
M[_YIQC,Z[!XYWQ5R8B-"Q6&K8&?W.7;?=LXG%7(YH1BU5H,,.#:1$F\A=(<[
M;)[_CE?TAH.3G9J!(9ZKHX[A&M0/2]1["A/1[S96&8?>@5J>$&:"0JRQH]>;
M))@[Q2!R0[I^(C.B(CMB& :0ZJ[G/;<KTRFSLS<Z@APH'^(^F,K!6E[0NO@B
M)QA#1?V)UB+EB1^&\L,E9N;C>2Y-[2:\G9L2+M(+@E1OQ\LNQXZUS]EOJG7@
M7(M@5EKSU[?;=OFH49S?R[Z@4=\<3,7!XH0JT?:3#1QA[?'U9WP,\^M3O];]
M;]_"9HI,Y&QQ0I#+% ;=#6S!2N0Y%2NCPQ+"S_@P5QO0<0^.CP!PIZT@:; Y
M%8VXD-?)SOCDO5Y+F3K/-=_&<2YFITWE+KEM3C VMT57UO@KX*[?,6.Q&T:Q
M@Z&D8\/NAZ7I)EV_LFD8ONL33:1CHNV\R3>3O2V8%O4^OC@ZG_1/QV:YGK_Y
M#]LY(5.,JHRXV"<RJNB?61M\EQFEI,UZX?'!ZWKUF-Z6W=EQ"3F#2XD^%#!.
MFZV_VTOG?&/K&RA5$:?]H8S#GRK'I%5&,EJ  ^L2O6:%DQ CWX,]QM[<* 0#
M2\CXPGFI_-SJ5X34)$JD#"EAT99E]R3EKG%MZ6+;.OT.3MA-#_%)-UGM0O6E
MZR0+0^K#+/':XLDKP-U-$'&WU*!G1PU7W\-\X"&VNNQ7[?*RX9BK:*P#$2Z^
M?XK/ZB.N#TWS]/4F[I->SJ(-EO<.U7Q&=*JL],R0M<4[;)PWD=MQC_.]#YF\
MC0N(6F6 @DBT(0#B3GP\,UE0K#Q1)@@6K )9C/&L.&FI!8)MLRQMHCK2T"B9
MA-@&IY&#%0GW8Z>%DZ:U6M!AE::0N]A7@*TIZ9'?N^DF8ZU>?]3KS*(_*?N)
M&[N#=95!?Q!)F4E70Q@OX6W.&:)9F$P I&37YY+X_S=QJJVE4.=N!Q;.5=9:
M#NC,0O\C 5;:F<_%%$6FFSTGT8':=0G<Z@07Y?@MN-+VLDFT!J2:+Z,#3GT8
MH;K]W6*+39., ^#]YCKO N&A,O;,,%P1S! VP:DF5VCS/G*GVJW1<T:CQ$I'
MG];Q@R.P*<9 IG/1SCDY]2PN"^20EPBX)CJOZ) 55H?_IXNZ63[NL.WMGI6K
MWEE8RY N)_)/2@@XD!BC871;%J6%X9$9) ?">:[W(U&"NF]QAE^+4&%3^1MI
MQ_KR@[^B$%0&QZL!MMX_D -N50346^;/;&O.+O!/%G?X,LAVA?3Q0C\%7M,N
M].F+4\X5SC6R<X,I],X^!X&9%A?Q?OQ 0C"C#BZV^=?6$6N3#$O9B? AVU*Q
M-PS:/-=:-A2%#JHAA0(8EPF2KFMJRC?TB\_P^WB!;/C,NK%2;<9JB'B;D<31
M/TW -"1&OJ4:\[^+*XV;ZRI[V'V=W&O\[BZ2G\J")3B0U:J=:(AO3J.PT#$,
MO2/H6A>*OU%_]1&61CX ^P7@#"Y-O[Q[SN)D>YMHBF[*N#QA9\RJ;AX>=O<E
MJ8SJ/8Z4"0DT;=L_VGQF*V>W_^[%+Y,K*U.2,6;W*\L6WF\4%.J@[@ZDB($-
MKAD:H<A\4YTF43'ZF#<?0Q URGIEC@I77P$@54KL4AH#"^PDN7;&*P)!1+<1
M\R-K&:-K4'UT<LIVW1\M6Z7--1O9FIIZK)D6!N_8L--KD#GL:XU*C<<7'J>S
M.QUN"H5WC.]4.BL)K@5!E)[$B)OOI ^MR\C8? $7?BGG_NA/%-4K'E](\Z>;
ME"9.#VW*Z2-7DN4Z+LK- [-T?\: %#$V@-0U^-D*UH4N]NNK0^7O5M,3OWAB
M#F"6SK_O0]GHRKWUA*96EAF?4E/.VY7,%\YMA1XLGNQ=I/+&O\<=W1R4(D/\
M(T4T_DT"4=2\)CWC5L0>VY 8*<>28,W,#57<Z#')Y!#RN+V1 KE22)Q0B5D_
M\.<^N-BZR-A1-FO(G0 XB.@.[=816G/HV?GR$Z?(3_P\BJWBWFV[*XAG'F$X
MB(3<FSHOM^.P[6Y2V7 .&E"U1/ :3G*?(Z;><:5G.OR&HY)K/=??Q!.G/\K%
M>!+EJ_8#LC<NMK<T7'V)'@O+D"*WP(YJ"U63TF\V)7MZXUYEDZ&_^*:Y8^:&
MZ3H3U&3)\*@US* W$X?I5CM&B3[N4JC)P:/;XVA<'4LC_9S+]]9&GN\50,"1
M7V(8$&-C\YU.@*5T#U_ )/VW\$Y7!7C%+$BP0":6J?>3#"EZ80"@QL%' Y)D
MJF(A*E/R7,,\V2!S&S*:S/RE1QV.D8I+76*8!JD(5[[[W>RA )X"&]Z(4_&^
M-@W_PF]5+B-!T0:,P(.'+CZ*6^;?FNO9L;\()I'%!LEW73BC<["@'-DE)LL>
M46JI6 I/E=]_(8B\ IRI,I?G@W<.@S-$TM3PC^U2ES!L6-E'1=[:MY=237H9
M57^+$-X*;A)IXF+ !V@'%<&CBEE_&"(V@T]H1:$"6O.GT:C>5QK"796>?_66
MB.[9QH9)E2A.>.[:0%K.23:"E7Y$<-"L"F*\ N!!>=>GI+P=2MXB\JD8AAZI
MI 4: >%Y )1F -%52R^2!(DXS],'6!/_V]GS$G%"R"ZU[MFTQ(/RQ,M3&QE5
M8G="C/PM:0EBLH:48![\3X8H<F+S &0G9OW^<KN!')NI%ZXG.\AF'R>F3.7I
MU?CLNG)SAEO*5YI,WW*CEO66EG"G"U6Q,$U9)@3#'8%!$+8/&R3E,*+S4[E,
MT=&BTD^K]+V&'&)>C8D.:OCH)!.T[4L +/.V8JG:1Q_Z;M@79;NI,<HQ#X;M
MW&QXYKO:]1&[;:N*,7#81FU[LX\&ST<+&IH-%=@5U:@IMQC>'>A&BI1Z&QN
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M>-JV\>M/+FR]W)53"7,<U^"Y!&F!F]A8LPG[RI%G5)'P\?XY))@/D52Y ]<
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M,)%+RTKO_ANZ5[((YAJ7+_&3&]02MZ19-U"N"YC3?0BFO$\Q:&D_/68#0AX
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M9S"EYGUTQF82/F)$4T."CB;@]K^P85?<Q.I*&(++]5R_=)V#CD/7"%WPS^V
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M<!E<!A(<9M#!E_?;[^PYUU[GQ]FM[OK5W<]5=S_==5=U]_/2\Q: 0%E>21Z
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MQ(&QY%&&F>I9S%55]!E>?C_X,#F=OS9#&,>],82>CH)\:E4&5CXT-XRZ" _
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M L?B@*\M:DJ;\9??P$[:YU,\W(]S0-DO?+J';.(OX]>Q;J^P&Z"Q0$[UNV>
M5.:B/P>)HH<]4WR7KG^2[&M);KK+Y28U$=09E\]YJA%R/T2<RQQ*S3"A<WN:
MJLI3\V&8E!)I\Z.P,7SL0XQ^D3]>*V2)[DPW?H\1?]0^4,&'/M:-:8PL4[)!
M9EN[T;[ )*++$S$1P?U4:1G1382DD=&L H)$*W+G(\?4&3;#6N9F7QQJ]8,B
M0H:$E/1C.Q/BD:\H)&63%&K]9QZDPH3V.8"Z")4:'_T5X4OLS\&?#NG4:$L>
M3ZJ2+]ZI!]U=;2W*I<=# RTM.#1@3<=?B9 RM#APE*Z$F796P"U1/\RC]G^X
M!_ ;JSOKB^*'H5+CDQ_\YG)\T\;Y]XK"YWSGXE_G,V#K8\HH#-1?ZEA/X&2V
M+A/Y.EC5(,+0QSDXZHDXXV/DEH5/PX!VH]4(Q7CKBI&"M=R9A3K"0,8"S\=?
M;>Z-9$=CZ!L," HER!V?G((C+WZOZ6!Q0%AJ'864)IS).J]$4417A\WQDQW=
MU49 V]C*@RJLZ>_.BFSMLOBLF9*U)5%\GX?9Y#>_T G@"B)6I0N</HLKLV+R
M,]G:1UO32/=2"*-@T(?^>[?-NOZ17M>\1X[SXM#A^>GYX:=I9R.J3\CTMEK)
MN5L0%N"]P%$W?J,6\W!L8ZP!]F[3W^N_MZ_<ZIJW<PI^BP\" F7+@7<">4#Q
MA8F_A=+(?..,(CF5$G!)Y82C@3N)E'0B4W,3$[G P884C$ROTQT8*F0\\QEP
MO.[&&16U%SM,958:#421O8[\6B7:YK2;LREQG%#6Y(\QZ!+^/D =%ASIX9^C
MN^1PIUL_P?F'R-?I3;5-D %&: I^)P>#J*$$BX^EE25ZO2/N903GUZ6+[T]G
M-1[Z*SDE \FW!CQ*_Y!U@.%@E/#$DH#-P'N>HPVV[VJ"L?G$@4NUU="A><,^
M-G/7XAT6NM+VL[!G #(_?A15SWP3IQRWD1/5BM#"\L#'+B7M=:1A5<^)]^*]
MBI\A0F4ZC#1T/!,2(51+9Z9ISX"!;ER'W+=14JT+^8EZ/T(X1X51+U_*%L3P
M@:YUI\9'(48"'9%[,T@5,10+,C$\@-P<E8]<R)O;KRG4#2<D1*& U.>1CFMJ
M'$X(W'V=WSB6)XT!F&@(L^_F3/3GY$<VSI<:K)"*+7[2_?S793L;;-VI/#FT
M]T2$3V"\+I,J/J!\?RW=_M%;+#GN&^,3FIY'WG*'Q@(GOVBKF$G9%ZY$5Z)3
M-FQLO4]B=>JG DY"-)X5;JKX%84=C<DV]B71BV)1/$E>R1"A ]/-R"<.A,Y@
M"_G[@_:)IOY54.:M4SZ76RMQKVD8+\>8!$$ +>0#*_]1ZX.+2R!=#;OHA'68
MXN:7-)O=+;N$;(APX#T_<(,3!C96[7HS5[,[LT66'E^6@C-FX8Z958X*X+DJ
M+LR0DHAOA$.B:IM,.D4X+4=!3@ ^V3W<F?#I9 1$EKH*((N.P_O>W8+E,/CW
MVS;FR"*TA"8[FLSX:OT&C3<\.7IX7K<YBJ.'@6B!S%M.Z'O]YL0S'E5M3\MN
M5@XT1*:[3[#*T(Y<WT%#6DP&*M5063RV.*D>X=$I::G(#H"Z NE.<)-\(K#R
M@0A.V!K]5J#^=H;LL!I?Z\P\"VI!ZB!!,%?<O<B]7=<@I91NBXU FL^\U=B)
M&G2A"#""#15]WGH&O#I\CU"L ,9;'M+FV4N/LM:$MR0TQ=MV9JG1)5BH:P_J
M.*R:+</RHM^D<#3]"+-B1S^]K:3Z_+E\M3'81Y#)S[OV'+JQ\?0^#H7#%=O[
M&4 5"9%I:K1ZPX!Z,4=Z_KM=;>EQ)=OW9 PRTN0L:^*Z:J3NG;=] P(%D7\Q
M?MM4<$!N\/N0'E=,SXWJ.S^%A JM7'WO2I \RW0(<%=>\TT PXJ"*N0@]]>6
M.-]@-Y:'&MWA.M6\40_L=X@Q.=8K&XE\2$%ZZ:H$=:QU$98;4&>\28WH3+O-
M%ZRS70R/_]4>H[#X('2<2J:1IIJ4.H>!X<"0L'#X]8$ YER&G%HBIGYO;:!@
MXR%T[ >B,7 I6%(I/DB_3IFZKK"4BA?6+(&OA6XTZGKLD)X=!]FNKR<(/;##
MUC))<[_?Z6H?D'V]G5Y12D\,%JL3]^7_D8<D1HG6%DG+."++J/*]V*;7!2ST
M1+<$4CF3QRCAH6/>WEP.[FO7.[E:/W8I![=P?L#:*F^.J]UD4[AQFUKLU.GO
M(J^#-36FWSFUMD0:&=M)N6>(JSEN^6F%L")3,A)5(>='CO12HK>>D3RPP:9B
M&A%;';#K##?F\HF"MD8#0YK 6701E$F.EB$'BH!B38R>)P'88@<L\HG2\U?C
MJDF-#-RI9)&?7(//-'G(S'"/Q_ACR-.Q%;.\^%,_PF'G$7NX75NM8+UD0/\9
MT&:#9<7H0HFU=B*T=5,6((OP+T.LJKA(:M2W+CA9)3<>98V@%B[::J.$R//-
M=GU]S'H&V"62(SB@:.F=%7O*,:@_OP _;#C>W."\-S*EH< 3C'#637EA^.M7
MG_RTY^U+3"][*_[G\73QBCB;?3YR4C:R Y!^0.2!CG86Y$G=AFR\,F3]-1##
MI2(?6] X6T#K0PL1$P'HK1(->^AFYMZ#*%RV/Y=]GNO=ATYMCJIR7N/WKLKA
M\>-YX"XH.%*%<0>9/X]8WGE#[\*R+F>DN2%NSYXC"=NJ0KB<N;NA.TNC"Q:_
MD>==:9\2I0)TD(G\%O=!(8'D[G*2HVA)PFS26\>,\4(BGMA5B$7\4"ZP#TRO
MM_"@!>TKTNEZZJG'B,5EUW[+TGS;31=[.W]G$0]VV*Z2+359-@8FR2NU++B<
M!;2P/2Z3HZ;3\HI<5=QUJICA\5O>B/=<7EV7MD?*X/M!']#@6!;DM#*+UR,'
MF<VYAQD"'?VU%#:TAI[H'2%?\Q=%!I<S]_]P$_IHJ,'-LY@3:NQ(KXK#<6FJ
MLOW#ER#Q7S8;LE<$:JPJ?;XZ2=R9X$(G-TU"%)WTVK__H["A-X5,XTC(ZJGV
MU,M(?W(+"U:>U(QK45!C7V!]P('M-<)/PDG;8=GDL[F@LLUR6800>EHU.+!*
MI!>X;?BAC;IFL<"G-CE1LV+<H UI=*07 X#%,^F6?I;05S"7^-$3'*A?[6J.
M@M#!CW N76BB;ED44_@J,!XLM*WP<!'O]\8?KVD_N9; 6Z+)8NI5/KP%\J'P
MQ#"I-HJ&ABYJ[LB$V<9J*CM[\T/LIT]:<?.<'&B34@\BNBI^E'_\?XRTCJ'O
M!M$ZI!BS\JVT@F*#B%.'S%$7/7YR?NYH;PLI9G-%TEQ/%.< "=(+3/<SUHO-
MI:&&LZ1*T2%!7:+HF")W9-J>^N? *J4'UXGV[42M$00B^40"/DRDGWOV@;%9
M6Y"!^YQ@K83S,Z\,\2KF:K(,$Z<"M9]D?S'ORT);<>*;KO*2BNFV9K&MU[.S
MIS$H8=[]+4\$"._"_;O,=][-,X[)C$X]-+F/1\T,Z4,\RO5HC-->9=/(K"L\
M*G(D@)\DA$,OZQ@K8_% #)<FIH8:-B8O31?9%? ,B."'JF@@'?JII37GN="T
M_V@!??I69):?+3)DZDI2*\]C(2^"0<%/;5+EJK33"0BH@M)'=A.X7(EBU]!_
M5$-1\+8-9%$'O[J>LPXNYD-&(<)8/QCTL^O)B_+;# 6)Z0C4$L3+G]A&+*K]
MA;1)1&5>P9%W:* _9"I]D$,(K5!1M $DG[  /:6C/2-"@P"AN'M]EEA'JF>
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M,[(5B4IU^>V^"+1CQO)#Y'^YX7FUP;E\DODQRF'2':';J(F,%&/\_[H" NM
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MQC.@QMNY/V&'&!%S][T_X@PBG@9$LL]@AO;DCFAGD4TJ$U0?3\/8LBSS B.
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M(8P2W@VT&&8] "L%5B?@<E"UU32$%6D+K?S/49A[SZ&:G)O7:WVK"#W4!AX
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M;MR0WP@=41:EC%584"8I5<M 8[T;H<2;@E]E20D?B(]]!U2D8> 2K7G H=&
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M3>4,*%P?Q+>P<2\E*2Q'2=L7#*QQ.D(XOLLI5B1(#P=O#9#*K.VA))&10U<
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M/"4]5''%X0X"N'O3<]__K<4'0U/DY(A,A3.'IW6JW*RIM:D%([JA&S_,X^8
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MS"C%; ^&=?@\&K8;48VXUN>I(_ATCD4K<\(O WW1#D] Z+Z3?@K#N"+/"VU
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M+A2Q[._J?<0"JFQL=RW%JEDB/ 6%40NC,SG\O^1(EP,<CJ%=C_"AR)9XF2L
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MI"+DDEZ(C?5"1>''R#*?^E4U6]*M+].^ZELHBNM82A_:-^+*_"2-JU*CYK@
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M^!MU73^N;JS^-WE+LUU]?8$O][T0F^>U>)([@EX,^<0D!Z$98)(2*28)!M5
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MA.%6J9Q7<4;*$QJB%H6PJYVD\6EMBG$(*R4W@/PT>]BQ2(X,TLK/@WY2 Q_
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MFNAA>K\Q71)H&UIZ&^893 <SUT/-[+BK/<2NN>=RQ)0JGR2X3;FKF^*W^X1
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M/0G:AO-+F[(R4[=IF%[[Y56TE$QWZR^ /M,W&I-6>A.V)M6/LBR[,OE%A-8
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MB8.HBM]ZJE<^?J97XWU>[+:KJ?LO]LDLHR=S*#9[X*,,88CBS';1X<]T&<)
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M8,5[[7>\4L1 ,@Q113#$=<"QIP3'W@_><.RYT<SZZ$-O5W1 .6Q4\EDY J?
M%-"D'EJOE+NA+W&R_FN-!7W\)?TD'N#RFP2H335&.;-5H7MZ!0?U] %ET%@T
ME7,XP^C6$#8'6W(7%OB[LC="@73)SHC'X2^[6G5^;L)N%M08I]S@!<F(3IK@
MI;>L;QD<1@LR.RV 1QY;0^+ZUED7L+2O79P?/^5/7^R9'7=2'*%(+GS*#-QP
M5G$+2M@\,/+V@ARQ%1<%P2([/@]86B_:>':W4@'6\_G-<O[>%GOE9E'4T48V
MCU#WLO(&/EJQPA[@GQ5JIL*EGWI04VOA$KXVPJ\TCKB,G+FO(8[_\SOJPIA\
M6(&ZJCDR:5@P7'#XIR#S$3$\-%U1RR@EZ8?O9H__;O83_V-VI[^/O<8)#$^T
M9L'03_^3/"^MAPBDF[K2K4:88#GB#R4%GL.*MI\C>%XBZMY?.%X&M?7,8]I"
M@A<LT1Q#@DMNT(LUM&S9@]TXD7,P<GE4CI"H1D!!?]BT>H&.GP2+$?QMMMNV
MVWNT;4.F>Z-SKX-$XXA=X'^N6FS]04/6),%,,.89<#H,PTJ6'\H1M\B=MATT
MHK@"#)(CFMV2H-I?X<$+^IOIK#R24B-IP?*W*7-D#4^=Z=SK<OY&6>R\RB 6
M/6ZQ!28ME[MKCN5-VPXUGGQ=ML$>DS@Z%-%G[[)@O@QM3ZFKFG_VPK>H?^;
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MA$7XA*&B2/95B5W?'+,2&W7DB//4"ZX=ICG@]+7Q\$#?KH8(W5B;1WD1EAU
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M@<9KGVPU20CF;) C].AI/FGDM0.%V=2ALL]Q2?A0_6'S['Q9MQC=9(V#3K\
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M?I_;,W8I5[UJ]4L?Q#@Z2IC/1VFZ 5,)I&IT0).IJ1G+0@/+%0_8R78MS+=
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M5&3)X>D=8S9W1?E>MV>SAL-8D >#2Z61JALLI6<+,7],60;5>ZK=[+QH]0C
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MM&FNO>CO2W_"?=B)9M_34CXR[6B 2RW]^I*@4A@J"-4_AD\Z1' (O/JR&3)
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M>!VY09+TH.1=I=^4'NJ[E] T>1?^L8<@6)X!E]#@N^K83_T_S2W8:V!UK!F
MY;MX<<.&LE%_4W1^/Q%YKIJ5-<1HD5\T8Z*4N4S1.8)#H?JAD*=TY,UR*H;"
M512>I;*/[@3Q+C[1A1/]A&.VR,.&(R+852=U7J(!?O&<O24E@.N/=BWT=<'%
MZ#^R=UU;A=27PY5]]4ZPRT4I5O^Z-T<\#6;]#DVQ2]8TTUE)YK]D2H;SBC_%
M#R3$T%MH^G_V=.A4QV/XD+1C!#_;NHE@^A)]RBC]3-4]2]/VP5<FGT"QLJ;3
MN6G%H@P;&4Y\Z>/'^]C>XQ2YML[.DA]+72SJVG#--IQ>([**?=1F>KK2JKB4
M9;3Z4B#Z:?G;!,?G9:VE; H:6=*ZVTEWX1\FX8P@$:L>]=<Z H[#(@,V*C"C
M[-3\W2[:IWN>I71</34<:FI?^I&]P) 29=2=$OW4QTY@F_^6"RZFL>)*(LD^
M3S"'.I<D*;JXP?3+<6VC][*#-H7O,'Q+B9JMG'@.;)[:T?@82>$>&SK'01_[
ME?4Z%MP/SJ!.G =M844'R.M;NEW,MK_?C["*Z%@H\]R#:DX(8$*ZGYO@#Y6%
M/X?#,-BTP$'!;'_?YE]W;1D5V>IRZPB;ZDDR,ZP\>XYC)=X6XAO>V=I9F(O#
M1MI%9'D7>,;' 8GA$=V_?L]^YMT !@U26YA1?CB>!F;N$UNM@3765D]((I(=
M^/0/=0?R.;ZM,OS^Q!C!3DQBJ(TD0X8M*03VP*(2&'<61<[(G/>7E=]G'?+X
M6*/NK<0I9S-45NPU"O@Y1<QHHK;VEU?6S+PKR?M\X%&U8V^>YBKYV-*"F[\H
M",8O?*?U&5W!LHO#PX4=97<8+CTT.4;99Z X]MNM&=<W&:<X/6,7_+.JU$]M
M_F'-VD@&?EM<@8TDP57[):QFFK;6#J>>YRG_OG#>]R%]W\?[LTI_5EI2; 7Y
M9-?J@#LN%WKSIFK=U+Q$[_[]F":L3X)[UT:[C;<7O</GGJ6??G4F0A[_I7:J
MRE\@ )>0X:-Y1_N'AS=9\<X\NX4X<#!S_:4S$/KI]6=8T1<W.'V\732,1C<[
MW-]Q(K3#[+L&;-4!3-U[-3?5&T*E\'O16.\BS\7I=U)06D0!:K.E'"*#9UMM
MH-]95.24A=2R2UKU2;KB)\P;1?*X2T?PR-/WAF6Z/6:9NV6">)U_ZH-P8H2\
MK*#@YI%R>X>BD/,/@HIXO##_],\M)72@WCT@6):=&?]XJ-FJK!K;D,@4?V I
MED(M^3M;E;UK?MMS?$LTZ4J*E8]/OLL]UC$;J:<I;DN(+S$3C0Z)_9-;^&[^
M19J;/@[2ETSLL\*,AN!U>IQF Z_<XN'0XW7^%.;S&) I/$@*S%9/%&+PZ'-]
MA5EHD<5'Z7CZOW&O__!_BJCK:^ ?"EZWQOX899,]A1.N8Y[OU?*'9RP0FUN"
M1YWI-Q^G,WO":.:3CR*,4X3K8T)0"JE:7.^OM7--[K:GZ^G-R/4-D4BCTNK2
MKRN_6AC7-ZX%-[_NYO+_?1":H?\!4$L#!!0    ( -([;5HB.1C;.%,  #=4
M   1    9F]R;3$P+6M?,# P-"YJ<&><NG54'%&W/=BXNSO!W=T)P8.[!PG6
MN#;0N+L%")+&@@4/[@Y!@KL[ 0)THYU@D^_-FS=KUOK-K)DY=<]?Y]99=]>M
M<^[>J^IU]747@*^FI*H$0$!  'SX=P%>-P * "1$Q/^,?X;\;Z"@HZ @(Z-@
MHJ&AHF-C8F-C86)AX> 2XN/@$N!B8>&3XA,0$9.0D&#CD9&3$I,3$I,0_R<)
M M*_>Y!1,%!0,(AQL'"(_S_;:S^  !TPB&")A,  0"1 0") >!T&T $ ""@(
M_V6 _S8$Q']K1$5#Q\#$^C>A!1^ B("$A(B,])]5_XL&_XL#D E0"-_PRZ,2
MZ5BC,7@2"X2G%Z,SOFT<(-&=@S()VGA%8&"2DI%34#*SL+*Q<P@)BXB*B4LH
MO%-44E915=/3-S T,C8QM;7[:._@Z.3L[>/KYP\*"(R,BHZ)C8M/R,C\E)6=
M\SDWKZ3T:UEY1675M^]-S2VM;>T=G8-#PR.C8S_&)^87%I>65U;7UO?V#PZ/
MCD]^G9[!KF]N[^X?X'_^_@<7 @ )X?^P_R4N@G^X$)&1D9#1_H,+ ='_/Q,(
MD%'>\*,2RNN@67L2,0B$HQ._32]N',!@%-2%DMAXS6&2,@GM,</^ ^V_D/V_
M Q;Q_PO9_P#[/W&M ["1$/YM'A(!0!;PK%>2P(9 OJ=:9S6Z0P"6A9YKM?:N
MW"%8 STE-KZ64<3L>V8V4[-=:B%V^E'HF8N.6$5#P8;0J4Z<^S+_BM,VG-9+
M2?VDQ,]=I6B& [LDGC&&@$@YC'VKI&T":$SO.D]%=0!EA,F7MRKS9)[4C*7\
MVG*;(,"U%I+0#/:3&]0JT3=?FDYU>?Y$NZOU4=]PG_4MJH!.O#:IG#A_X6?<
MD@Y>HI>??B&"BSX76H8P&OB22_$[]4FQ-_%3Z:T?TC\7^Z%[J D2VP@H.[?M
M7JW-J$#=XPZ6;9?O@M7D_7FJN5L.1HY^5JEUL73;5-90K"2'_28G1PR3]J5V
M0?:I2#AV:5,^H%&3SN!R_8@=E<-LYWJ)@=0F;X'TGL!?=*)OFQ4QW#Q?R,Y6
M?+^I1<-FX=WW]IX^B"2G&*-3.<1A-2Y!8$KK/8(Q+0&\8J^0VJGD076)(9M(
M=*V_'0<I5R(:BP6#R8M_T5MN>DC(CK(_E/H7>P!)\;+0*Z#E?88JM:RSQG3E
M@/G="^$$7D<5(\PMDZ7>M5PYU)W[>6("ID </HF>\*<@)=J_7/E1'Z%#D>%+
M/Z4I@*TDX?_1V?'43!5F9Y&P)Z@HSN<S9]Y?#W;''O14Q'V5>+^N+\/0-:=S
M1';_0MQA+$R65HF//T;79<BE@NS'A(]>Q^_;EY(!E(C)<:H8^FA?A3D64&4\
M)KNVP!G_KHHA,=?<_8;,A@._3/54CDXUX,?JP'2P^$]$?2F\(RNNH7VM=<P-
MN>6Z.I?P;%;<5MBICH8,TR<WTLGCZ#1%<G+# >9\I@N*NZN(\P.1.6'5)W>J
M@6^;E@%5;E.48FFCN<9033*_2P'/&2&$TP\)$OJN+/VJ]+;+Z2S;*F.(9;\X
M,W54*E+53(NCB77D4/XY.JB4(4* ,PN>6WUN2A9V]U-A:!V\7M?F[GB];F(6
M):!!_XM8DB/S!888)O&E?]8">.B^9G2@G!S""UHP_;YXM]&B0<NVH3LO# 3*
M2IMJ]'-0^3VO(>-UJXP$O@+&KA(Z<P:N4,N[*A3*=KJU>H,LE&Y^9#@:H6HU
MU=/:A6MZX'J(X<R'23LV$"<9T2[=% Y?K;O=#%CR4(84.I1NG5XK ZF]MK:;
MO;K;Z/]X7XP]!8Z&+HL:G)3Q#EZMZ^G#3I)]MDC/->=1FC-GRF=8<L +ZLQ3
M'":7Q6]E@"P#!FDWD.,PZ>PE?]"YWAM[A7LV,N_=4O#50S!G(2RG?P<7OE5?
MJ!.LP=3]D>=^_=-<] #:D78_+B2KJZ(5[%OY"JC?'T5X'!D,?GB$]+UT%HZ$
MR$)/PG\?=,%0FSZ6FH[31S/UY-JBOL7 F@%CS_?Q#!X>SQ[S]**!;*Z&_DXG
M38:X^ +UG+R^[TR^V5BM\I,TIJ9.U?0V'XM[!=CWP35QOFXSP>IJJYUU2)6[
M1%KG0@ZC_]@:O'_W"J"7L7G:A,@)G\HPPI83]PJQMN$)EQ=6:DVMP Z[UN=S
M\OYI?=R.'V/+WX5"DUZ(>[,ES7[*P8-T@9\:+40MD]8LA*;RYPSHKCX&H*C2
M)9/U%F4U2^W3K6X,BJRG9'GC7/SV,*[A6 ZR7>,9T39^ZL">"O\<(: JO/ D
M_/SE=B9FFS71(M:XNZ\K1=P:B\E3*9J:'B6";7.7'N7EQHYTFK-.*\D2,?V#
M+RPFQC#H5&BU\ )FH_[O<2V_K?#GZ1ES2?CE4X_OE'>2__PE%!C"P/&=RLE0
M(_J3P G%J'Z$3/.HH_(#BD0:&W$S0$>1^/_6==THSM7-^Q*?=%_(<I21-/->
M 8_J.AIBY%\5K]5CWFQX_A*!%-S(T4C3?]AN3O#^UT^;O&G#*Q*!DXDLP8;3
M(AEK]Y*,:B0Y,E&4@(L\X9,4+1U(2^)7>*G:LN]//97F+J*=4XAQ=R00B<!#
M[3 -X<?M;:W'@#^B4E#22J[3MN!L-S\,;>SF;'VYL.(=Y5!^]=>DD]_/?)K>
M"PDR;SO-() ?_ -C95X2;F7?9(=[W#6S8<SSN]_;(-LK/PSXNP11)0<F<26H
M#57@O7F[[G!%L'0MJ*"PPRO[%6#;)'N_[EJ4ZHMCZ5 !TAN!2,$W]B5#"31]
M7)EO)QTZ&^<=<L@(+MUY>*7"QW"Z[ 7SZLPNU7-L*^"-!QM]9"!W*^A.>&FJ
M02_I%<EQS75<#1>:KR ADEH@BOF%5"N_93CT^_++9+\,7:1N1\SUBR1YMLE%
M/T$C4BMY9'B8"BL3T785:&5HW2T=FC-L:@$I='4M5_BZR>672!BW&.! QZLU
M5NL#P6]+61G\*Z4]G#;:ZA&67FF ].$7FAJ5AK&:Q*86\7DA--G1-*726A3#
M 4G3VDC? ?/K!?8P(/BG^=R=T+)0-2<\/4.R4M?7<%1?( +AZ5QT3(<)@K.R
M_,Y(J2&?HQ\_1&$]?]<!::"7[G=HT^[!QJ1IID))20E1,36=B_]3%7A625E6
M#9"1D#J-5*]EJL/1@&QW4D'CB##:O7,?M^#>4A\!X6M8:$X,#KD.0GNWP)/O
M8J3 Z,6_V?YCQO.N7D6:,Q7>N/>3;I0.3TJA!!1S6N-C=L[^IKM3]9T]VX]Q
MU['P)/_],!GGY\3;R62JL1#V!=?N-VA1/D$X$F+;\Y+U?*,7'A>(GY].5O^=
M2U!QX;N8JKUS&E^&5.V&YMX4=E([]4I2[0SVB?9-7/+ E6FZ[S.QO62G,NS=
MO5#9A&.84EGE+])K#<XAXJ B,D'4K"GGHHGK[+W>LV]A@//;D[Q=A\B-A=,_
MLZCO9-#F&(S'[D4@&_1!'QU:E:R)"L9I5::7F0Y]Q*M)+<GG;\?W\E;>-S;G
MD:-\U37;8!#RP$UG1WJ#<,AVD#='1*C$)W^J,*',"L#%*,)UFST9HTP(J#ER
MH9^R^\!B\9<NI"7R "_,$A&VM/A@NA)SP5//FJ;*/7BI2A,VJHJVP-#)J5XH
M.$:9$7#.FF.+RX@NK_7E\>&G21\,DECV [;MO"PRKZ3\.6.Z.$>F5+C@:\:B
M4\LW<=40)! _6+3FUWI(,FJR:[5)/E65"^KX>SO/&/%#:H+;.L-7P+T*U+[#
ML]SRO,VT+4X8*/ZT)BRM>365=^H!2-!$_&.+A"!WNI)IF1]PT$,X,7K]Y\Y,
M\.-'=^:EQ;F)NH9W"19?H"  ;LM)H,/%QUW.'=13F3=Y]V;"BZ['$$E&@FP[
MO@)5*I>)V&D Q0DCC7/)@BG6E$_?]Y-HMP\+^WDWANTI(ULV)F[R>HY3-5RK
M*,<H=KIHVP?9PBM@!K@U$%H_>%%F-M$FJ.4O?/=SL'Q&P(0Z,SPS6J=%WP\3
MQ2N$X;G<!X=J<#FPYU]SUMNR2'RW$#)'3(:.X:)*GQZ;76&+ET\-6Z[^)=M"
MFU-G9=H(?:FH@(<$[#5*'&V/Q%!5V1)RN>5NHN)B';AK>CB'W9_)>9L[Q,JP
M.FUSP$+J]Q[)CP5.6Y<?7$'Z5$%QQSB-)1XAUM=WIQ:?IU$=$1S_EWPD;19Q
MP>1^/C/!+M>&3^6O-F*\X :=Z=X+6_(\G.\5L#CF'$#W>UP+;E!S!F& 3CWD
M]0R3B8:NBZ8QRJ-]*F$[\9%3TM0DR]S,U &_M[F&2U(?#!L.OP)V!.8JZVT[
MG412HE8P8%X^5KBGEY>5U=4F@H(-!DC3:$P0-!*T.!END['*GU]!?J-6I.=Q
M?BVUD7@LJ*^ \H7"#/XS<9FEDU#B7LHS&<$YGXT^VC,,<*Q^<XHTEII]PCP"
M4[B9]_.??"=&5J19/74+%:\7O:8.V$LM#/<L" ^!@2>/_.L+>T>J[[?T =+)
M5P!W_G-]!^2XPSVR#T=*NAAL  ^#Z)Y39B6NB?<MNN;62:V5\#)>A7[*L2XH
M(M_UJ_=L;H@87*8"@H8]Y"+$#BQ)#.0 "!L)^U)$[AZ%)"$,%.ZF(./3039L
MYQ*"0^HP95:96W&S=YBB2U]@2>GCX[=U6"J0HUY!>)YH$[M+GD&Q>BH?P9L=
M5JK A%M2<G)J^_8O?*$C&S"$,5;UYIGG!V95/\570#PC'6ZWSBO@PV3A,^E2
M]9YG*LZI[-T)WDL8)^^^%1TN^#^QKO_$BO?&1>#NJF+]C]0FLE $U1::L4/E
M@\A7 +%;S_D]Q2O@%LE2Z^"":$R&"VZUAT,V0*:@WIZW355=:SQM>XVL@Y;
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MF%N>M!-)\O6C,;D)PN1X(2\RST[/ DFV#"588_&VZZ=8V7U6G="/-@A3H87
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MU06CS76H7G<RHHQNILS:;]HP&>>(=S X2N#Q6KU*^&"T*&56]JMS.>?K]G:
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M41DQQ1%GCC./N*N21G%=AX.^&FC>$].\0V<NKQ:O:ZLHNKE+UD8( H&[&?\
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ML&XTQ]X:(S*E#3Y;E&9^;LH-CAK[#I8V"/#484L?!'Y7?SC%LFP11CGC2F4
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MSD2,-]W[&.-E&9#9I0<,K M['=.PNGB>\(MO4X)XAHGRNHD-$=83NYZI@;G
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M,ZJO'*4> ">L_*%&*E$69@]M/Q\)6%<ML:LN !#VV.:PMPEKT3(Y#7/KAD>
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M'4%3N_A;^=?&/\RLCDAA)K+,%K_5?(9=668=GXI\B=.:+VY%L:E;:O=[*M2
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MEU9TLX,1*)B("YAQ_IM0)YK34KA8ZC(9RF22S"=28[(NO!KDWK'Q'^K+=4R
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MF7;C. EK_UV&WTJ7\AH1NKAG,0/1@I_?\O,VY7XU V6[D=5B.$%Y+=$65Z"
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MHO#WBQ+/UK3%2'2P"L"6>W-$K%%Y<F@::!5]MDK/9,XG./US@"J.AM/0]"4
MK& &XBY8A&$  K-VK1<39J<G*3H!%.&;.TT1$A_= GL= ]@Y[:S$*NX1$U30
MEW:]C#\ZVK>6+4&@WXR.)F9R1X>,PC_4N+O<X3>36.7,5\N'6FEATM<7GWEE
MO71T!CM"M\J'\D!1<.7RI>9EB&K@O6%U4LM?=@=6 )VNGJ$/(8W[PY=,C(LG
MMYM<EG_?"M1@FJNEB-'E2/19*C-?XJ;J2U'.2 ]NT*D_-$48BN,?-%!$VF'W
MIE!XCAE1TV7;@F![N_03L0^FKT7Q$\NE5IX;H7V)GZF:]NU9JTQ16 @:<F(
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M'X* H^:>"4S5+1T2_YHM^:99WVJ((K]]=YRC/HME!;$%44>@;S&>'-J9.$0
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MM*;UP&;,<(3G;><]WQ01BJLYC:<XA]^2YX3KTXG*L==E\SWE[+4[#+)W[_Y
M;#[VV1>R-CDF[SRYN\_ Y=0-Z$W9O<7I/;$8&H0NRO5?,!*>(WT(%"VUV)_K
M%]*9?N5?5:!6H,I,6TB.=):X@+[MFI9]9K)L_F.-!WY#5S76-3J*E^.9JOX
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M5%?!9(":$(N>ZH[3:#C'^$+AE9)S\P1"\_M:F &QWSRWT1<\"69O_=]WJ^1
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MW *62<2Y%BL YL,HPVX=;*BZMR8%>*QL:$"Y^66@VJ/?5C73WSDTBTN]-;N
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M*K'QOQ1):1QC=>J[VN:4PY69P6-%OLA]MN(#E83N6P!T5M6?$,IT,*% &7K
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M'$K>'[X#M/^3!*=(AW>[\%]02P,$%     @ TCMM6FIB #V$T0  T9D! !
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M.&K5"69\=J,^46*995,5 \!1\'=GLTS8ZD@^E%:17) @2WQ=Z/L2*2U6G<Z
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M]09ZY"+]35167VM.Z#]SU![B,$>\7"%UY)F"ML1:>L3GAE2:/X0<-1GN35Y
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M4\DQ$!^PD;S_S?WQX9?"IJ($ZB2M+LJ4&'?E_&M%)W';).?-:^_=C:WG%.[
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M$'\OSFH31[M31^/H/0X!/DNKO$=ZLMSP:V.)/[GAVGD,>*B"RPOK^>&JB3)
M5=KI';4YV4.4!/'0]< N\HY7D;21 B=?%'+R!<##VJ/Y@PP2I! >Z*N&Q^G7
MG3P*$@>BT2LMT"+A4'A:6S:.0I"(&:=@PIM,@H;] 0%A13:<O(%LZ$##1(S-
MVMN_!.F2+YQ?Z^(2L/;;GASN+9;+."T/G"'30>5;:7+DB0U*&A)?:?K7O1EN
MTFVVNIFX)E2?O]U)I&W*MR#VP'N<[$<HYRLLI/7' Z+-N6?,&0>_/5@:MP*K
M^.]#@_$+^S?#0'608 EQF K+=69:/Z;?>3F-4525-B,="X\3&XOG=_[T$JRC
M"X+,T/MNINW]Q,MUO+4I,X'[ZC_Q-]ZE0$=I6C]L=#M>FC\OAW=$G(*;J28$
MG#+2/S6<FYD5='4:3VPR_R7?P[8B^_2T:4,5"W69(9-Z<MK0_D^P^N[<D8EC
M@"0/MKR!"LQN,((S)Y5T?JY%.XQW=?UPR)/"WJN;*"U\H W9S;HDO@+MG"[R
M&%T_>#3E8N\-_Q"\84R.%:#P+:AT[N<18',H#(>'_/X@OY!_;<05""1!2%(2
MP5D^_,Y4&'MJQX"=-ZLJ7)B95N$GD7R 9_Z,6%-C]V?.),+#D7RTH%AHFOH3
M_]D].],D+>YWZ1EN?>?>7U#CPEU4B7/)IR'C)YEK*OPBAZ@;I%1B:H_T0FK]
M""<O)C]Z!=4V"1'W@%Y&T4C;X([XW7')R"R(\WZ4("JU(RDJD:KQZM5L#/:-
MP!Y?ZM,=\>KOH2M $#Q6X3!1A=&\03U4_K0_[X#2Y+RSQTYNAH>LUH4I48,X
MM6^GB$X>1']Y6QZ+C/:WKE7]-BK?7V)YHON^(:Z"J3B\O:PU# @#M)6J#F[E
M^$?NGY,T\=H&-GZ4K7#P8EP_],^^OZ.4)4>!-@Z<39SM4O>BPM^\M[_11^,W
MY9)PPQV_GXT[\-SH/)BR_V-7*V;QPW/<A7H^A(X&./UY]TL]Q5#!\[NS<2F[
M$2K=O,-!71BNU;Y]&2[<78JC;E82+"1OSW$S@Q/[1&RL4@QBS8T8MP53NCWL
M;#)&<;7H2[=S8UMQ;E7&ML9C.5.WGA_"CK.BBV)STD+BN>T$6!U(G3L3_:A5
MWF@RB+^:3 VC%$Q!__I >BI72JK76.5MA,4M;AR+L3>H\[$9$N$<S8GU<DP0
M4.WN1DWH0L'S?=+/[^PEIMX? V<,^<8#5AS"]VV5[3\(H3!ACPG%&EU37ITK
M[]>9=#=*W[4'E@*&PYG!SIA$15(ZA@+2[_&;OK0:Z^Y.*T>H6YY#2QS"0*@T
M]YE<BK-V]-,;2&*!79M+^[<_Z7/.\2TDEM Y4B\U<:Q&5]-P1EK;OY8;=8<F
MJDS%L;*1VEZ%9**'"K"C+/<[8H1-K(*[$J8_<UGTO7G=;'?[@,U&K&*JJ<@^
MH#'H@[HE$K4:>7DEM.R)-<D7:<!QB/'9E3!P.IZFEG>@B;8CBR[=.3;:CV)L
M!27=?6U0DJ8+.'9U]W<W:NT,7=VL'FWH!)/G\X*,/YH9UD0'7KC^HI<X(!RS
MSWJ2B;@<I>_]9#/J]?HN7-(_S)6LQG6NVH#+-35P3UU 3Q4G%YOJ41/9YWCZ
M,.L/= /UO@3IB%5&E%;4NRN?F6[4.03V8TWN7D9="#148[TA,T*EBI-][:R/
M.YY;:$UP9$*V1=]7T42$0U46C/C9\M8VFX77&@R8L&X?/&*0RZWBJ+?LHQ=Z
M)MH VS"D&:CP+R#*>JH CJ9SS,N60MV/\4QGX*A^G-UH# =J=R,O43I*B'F[
M"*;VA*6L4W('$K/;:7LQ?; AW8T?5RG 2E3'YUS0WYJ-F'5QU&&Z'4*.)+CF
MW]UP-:K3KR9QMDS^);XK/I61LJNI7U%&N5".LO%#/!S!I@7]@*<'&D;F*4TS
MG]XH+'W)>M6!PS*9ME%N=1WTBD\R1V#PB)Y-<#@"9DBTN3!;&JT1@[<J<C]B
MBBCA<NZF<*&9KJ4#'-B4TW;E"G<(97NV&V-'.9]TGOR^$;R[PT,WW="\\7ZD
ML2,Y'6)&Q##SVC.^6$M\50/.&G9F<-GZB_O7B(<R5WWZ5M2Z. CC8S$99[(>
M03-.XUO(3K0C2I$Q)V/6:%#$ 0'!'1>:F.QF0Y873M($+.! ':7C,3#&6SG8
M?0RX]+5"0$&'<>([0;3_9CB[FT<VW>76!QHJ,,QM,??=6!*5\_S30Z4$J*XR
M0WCE%P&!_:(Z:!QT2D3X&"!7DR8+>WKBR)-$[J0\%-,@MH!]2T#E)4Y<0B_D
M%0-]LI?B;FN5;]./4'D\OP<OK].L$$^^'#_]\JYCP%3E<%H74I0\TOO V/L$
MD=T^&4V^M])<WXDZ3Y_N0:<$^2_\%_X_Q[NHA3T\IW4U5;&Q1@,S4T>L'7:4
M/28STUJM)TA/4H=A"0>^UB>IPT?Y/U*'H2++YGJONM1&.O6>;AB_1K-]DZ[?
MU66"N^%PI<PXXD<,XU,NMG8;T ^M1CSRH0WD^9CK. =!7-X5AG+!C\LREMT&
MQ)\T'+4E[-=_EQKWX?/7E6Q.K\U.[[\S0Q+\PG_A_YNXX<^X,O7\C?L"VXZU
MTZYYEE-8KT)W%6:B&$'Z"]_RO;]GF=9Z$^R-,>P7;=:)DZ?)_DCW;G&H/O?#
MJ&9ZS&60O.Z%$]ZWGCG-]SGMITS3D<7J UEDG/!=AY+O:\Y-O=]=-++@^2EV
M[8=@Y^0Z50HIPJ=XD31P]YL:D-U^\/V&I.5%67+"OC0P L8,K/T#,\,;;MO>
M[B$3#;*+O[RNG]ISS<%FOY@JM&@HE)"A_LTE+0IL'Y'*FGAP<5GHB%[CKM2.
MBMNF[O7KGL(DA.5&LJ^SSPY+XWPM&E:_HXI!JZ;4^.(L-VXFQB,9+$"]LFNE
MB,V8L,?H#=<K!SV/<8+EF;O2/0690M6(M0+Y1VC3AB?%A4VEZY5<2G--V88^
MYA+E<('1$S RTP?0,. +P^-L%#4#-R=U6.4=&&UGFSS ;J&"9M&Q4.;?8<6W
MXN_K?"Y-CKG%9PD60A*(6M8(>WU(6#BSL?W 06_9D("#(>)(+.5>^R@3?,T'
ML%.$ VVONZT<6TS>%BO[4H4*]\;<E3?B5"C5FN@-Q..2H)))7)^[55;J>C<,
MV2[.1&8CO7XE(:7Y"F;S47ZKD[N,_%8J$IM)'WF'Z/$;ITJBP24[JSCL-8.M
MMW E@ED?0<Q=H[LAY7K-&GE=EGE=CMG*5T:DK- /)YA[C@?]U7,'MPESZU^B
M](+EIDJ/@8"OG-VFB)OJ)&\?6Q:7O7Z\)1'C#%+7'9:V.AM\&2_)A[ZBP%?U
MG9DUB;Y*1A[W]*3?D_!H_RFY1T=D@F1C(#@,F',4Q]?>]<2O%VE2N=@.&\7%
M"(LG5(1+(!V11,9ZZ]8)N9'L951;1GUO'WA=--]^&V ^$VL^/\<W,J$*86%T
M1N)R6!F]>2*)AZ6VH%SQQO]H%!DCQ;*5K:F*@V6WWEQM_BFLG=%5Q$]$J^_9
MI"(A67'&.-U\JS[U%6QF@.* Q>Q7LO__0K(_VD.F^W9B)_L8^)[M;^']A>!;
MMO]0\<_9_OL(YE6S/%[7@I.\SGNY)]Y]<TSG+OA(YF7E6'Z*K*2A@,OOB/[F
M0]$'M-5H3ULW+O&?_%ZF_RQ@4%[O,%N[07IV*T]V2N4 ?L%;82D$-N-UDO>:
MZ+QY&MV8?#OG<@Q,CZ*%67+(D6A?BNAI;.,R1$U.\K2)W[;<7"E^WXK3ZA%C
MR,9'T;Q=4)1?4-1?WI90DTAZ^8>9>]_2<7H7O_]W3<SO;P!>#/Z1X_KMOVS3
M]%1DGJ3F@/Q_O."Q]D=^#D"]8'[]IY>T_(L 8(;LE "EQ1=.*XN:D8K@_+:P
MA@YN'P-AI96C>:SEB^,D4W?%./^ML^K_#F##"0&-7O$9BM-T]B*;[^GLB]0:
M1Y+1M*N4>^Y:QT#H8?M^?:EE_$.!NZ6+9L@M7BBER, RND_<6I/2$'43I?F?
MC[SEQY;_? #NZW6:=\23Y^',N6T=?V;BR7\ ($+J>5[GQ#-/W?H94$Q'TOB5
MJ4X-N?;BY[QG5,N^:FH.M%6N#VZ4>Z-6BRZMJ#7\@:'S+YKX]B\!:!F.!+I5
M8';H578F'OS[.=45+U:T#!L97^TG,W"R>8KBHCV-$YPF &@8'NH>LO1\3W$R
MN]RQG?_C9.KO9U0W63R8RJ1VS5C,62QE2[/0*O-E]9_]9M(_ E]I;!^6Q82_
MUEA;1']SC$VOJ/WZQ0*]+5Y5-P1;$,V#A^@^Q;#9HO4S=]J_4V+.'X%_\"9:
ME3VI%;4,VXTX!NC]QKO>3_>5TCX3_\*L?\C*^L#4</?!WMC),8W0[8QI--L[
MH97)ADGIY!FTD#E[VL1O_H.!S$\GV(J(GYXX$SE?U;M.?8A0B"ISVC_^]9HX
MZ1#@R51@@@+.+3,DUI]Q1/JO 2W-(0#:6+S%V]WWB*?J]_6EGU]GN'<Q]G!H
M*KLM%T5SA6$:S5AOOKV-\%L@3AAQ#"R.+RACOJ?I77<_DF!:,H@Q,/WMRN_:
MDQTS;T(LCLL<9CM\:*-"@_S/YJ<_ K2HZ< 2_1O=]2'Q;U5<5.F<\4.V^#0X
ML8:T77)K\$=TGRY;HT?QBN:_3R+\'\'9SC%?6;>S+P-^TV!0O=\5F[1RX-(Q
M0)AP_8<:H_JFU@P>%(M<^A<]"Y5B_*@.H)@-%9NE ]=10Z^4M).Y),T.:19T
MRUA334SY\.=M]117Z!KO/*M[P$#+?DZX_[G^X"[<<B;F,QN_ WQ^T_O"N'E_
MP:#%S$;5%1]11C4EN'04GZ.0%@7D*\#<"'DR<;^TPJ$>=C_L(H@.8=<056$&
M3DUA(IN!J006Q4%KX?$VD=:Z3]M3W8;.=6;.RR&Q. +PX0_M^EY[J.0W3!YR
MI5N;B##G8;=-UU-V\=6J\]HFQ'B] "VYDD\CE*>MI5W3PJ9:9>4_G'?+XHD2
M'+'LO!NJC*<4@%?#"Q(4HD@6N1];%HKVWTL7)/!R\.92K_/-Q7.@_&HI [;O
M(_QF%R)7=.0^\+Q[OF*OT$ZK_P*TN#<'L::H=]W,$Z\68Q,>L;$2WG-FMG48
M*^;+5: ^7[=VF>*.( 2409Q11S"@MY7/& !%&3ZSH5$\SSD,KM,I1!&53K:J
MT?5IEW/3D'?@9()#"9F%LOJ<PPR&V==?,TO;B7&B_'IS![H+"]Y/EC2N2%!O
MK]IU!8U,DWW&H*6LL]DN>QY>15A+K+#@03OU-BN@Z/TQ8!" [7.=?4-1F<DL
MF6K6!\(O3[Z@0&2)0-D\@]YX,^+KF-LI;;N]X=*@K>%LQ2!-,L.")-9C@IS#
M,6!KX[UV?EQG<2EM<5Z*1@"Q>3X,JR FEAE[N0/SX]L$%1@(1S#_:K^(?K8%
M(F';Z]E%9BE_(S5E@>>%9(JEL]R2O7T^HMJO\'C:V/!K#.@#] N(4LY([/GQ
MU(E=4L91W'"(B?6# ?-F^0R%):BHM[&QKI_L!$8U8#!9^!8'CY;R=1W/3PT
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M-#5*UPM1)8Y#W% U:&+N8_\F-U28/L1(N'Y/7HY"EBTT/%M[D$GS]#Z$QYO
M2RZ$L;4W0I5_P$.#?_3TL:,[W0YVA_-D%8B40C"D5!%/("ES=WW(52E/]7C@
MWJ7 _ )8?;!%Q^IB_V"A^M6/IB.&L^--7:=7+]GZ9&--1]S=<U"9S$9NBAIF
M7@X5IG"N>Z<</@';8I6PPW7C?91E8Y;$$[FN,KVR#[+3T/T3EM@;CS)? ##L
MO:FT.#A[5CN9W?52K5 F?BI2*BNT?E^&R;/4C<EC\=M"_>Q>VZ?=\T-.)M9[
M]3KN';WI/IPL [>N8[",/7;?Q3$(P4]@0>4**2,['_)DD%YEQI%Q)T^YX9S3
M1PA\T33,;0]K7\>@Y7XW8>YTWT"^NSP)^(:/&I>+3((/@'BI6;TM!0\37]KN
M'PICO8_/]7A^RV-;FJ98JO "R#R5O:4HCKA2($0?!G-\S8RXR:)-Q1Z C'_R
M[CMYBL(;@A#YT@>A*S7*1ZBU:6$:+_:Y";KT0EC0LG;'/AJM)0S7: 1")XIH
M,/-5\:;0SH8,1G_36N]<SNRC1W5O$84O%@,J,N84)RG1-X?.TIW/VB4I^'0$
MI[9;:OW8Q.=<S]J_JV'T$4<<GI1NTWR(JIGQ<SC70JF0,?=IWCP)W<O<.C*9
MEH@'G@T]FK.O/U\XS3OQF3C"7_Z78C(R7G;^,W]2\% T&EDGZG-JWC^&Q<UF
M)@6&9G:S=AH.)['"_D($-97?E66ZYPI:"+#^L+C!'2HC6QK,Q%AA/OC6?YBT
M69"JCG>]V-&->8TN@)\EW6?Y>F7E?J8QSC55XE=K[?OCS3I1SMIE_[FLW,G_
M0HWTB\G_7";1<S/FV^1 4X%?#\_B6;L)E\W<'DW=!> Q,53CGGC+VITB^FS$
M1&CC2765PR/SE1_+'EF8^1F1HNI_KS^I.48V#O]GPVS2*=;75.:75@-]QB<<
M!Q\^5M[I8J__X6=$!<I.\;.P-#\*6@C;$K JLO]9H9^5@>$F_<<T>6A/H5T_
M*R3WLS+ EXRRYA\54O]9&<@O)K^8_$E,3(=F_\B4MDU^,^O9[_JT^,ZZ?M?Y
M$LY7B7AGFIMVN8EM@A2)9'GY9:GTBI9!OP,3*+T?O,E==>>_LMMC_P,-V]!"
MM=C+KXTB['%5(W;=2G5ZW97E_LE^=I')UHT,O[$4C;,?92LY?"YV63S2J^+Q
MM?PH7;[_/^SSDZ02TWQI/ZXH53*ZU?%941SCN60_S@'ZL]?55(1G)I9S-6YB
MK4#H/=KI69E7B)=O31MZV'?9<O2^*;:P-V8?__!-K[XZS+90JOP)Q8D "UIT
MR_C=[8/;)1RYVE(![Y,&$"$M)%6XQ<$!9$_PT.ZM$C^\ %J5Z]/BB3X1I7J6
M3+3/XE<,#5D\4[A#U@O#Y1!5C."SLBTANH?%@Y5%33E<D58N<P%XC]>B4;ID
M8O*AH%=E"815$V$W!V23M1,.I\G+RK*@=9<R:2*H="GM2DT,V?"SG6]YB+#R
M+^1_#Q3N9\]__Y[Z%<JJQ,W*"54N36WFCZ8>Q2WX'@T/1_D^!PT7V4%1>DMB
M]_IO;+H%N.!$3-:^+ T9;&KG(\40ZCV!#6((OJQR+MV(^?QH1?Y;@(P7281-
MO4[8-0;3@F]:?#18>FNYGJ@*?HU@K_D[88WM7;B <YG'HFJ<E@ 0=8]25^:N
M&7QF!/G$T-=U.0;I>R.*N&HF\Y;VN2G[&.S:?<BNY+HDM8*UZP6 E19N$6G!
M;K<U4>5%=,XV_+@2'"5F$+Z%$6>TVYE0_R;F?H\$M*[6ERQ#7LF(1/EL>A!#
M+F@^T03A/5D67L0RQPG.1/IG-_6%3JH[F>^79*H,%U<V6(1\084(T[H6\DYU
M.Q-$:N.$YL'P:%IG.2I$S/0,FWL)(VU"(QNEB#?:<S\+OO[D, 765$>ZVSI[
M658E]F*^*Q3A\K=U^1@'ZEN5>#:(WG)]7=5\88>QBUQFI=:>ST.Z:^=NP8-;
MU*HV!U5&F6C!5.CFF\T4%1-WV'E0F)_"L)80Q@G5L@O,FC$I3VNI4*][2RUB
MMDQZ5]J_&A_VYM-B]!WW;E&>,,FVJIZ4R>BT@]RCK"D&.$L+VC._?!_>1RU8
M$V>LF(B/J*.8*):#U]I:#E-3)'Q_ :^; ZQ:ODSP])$Q"<(A+,B]-C"N!I4>
M45KR"EU],45GDL7*6T+01DEA#U.U*Z[XG&8U^'DP#OZZH>$<SL*WHU8G<VK(
M( 97V $C0B+,=O^$CX/\IEZHXD[)?B972.>;C3+XFW0/G1%9C<_X$D=]]C&I
MHFJ8<4A5PZCVR<9#0=.,LO=,]5M^G2+>Y,K-R@5[]^;15"<:B2V*1#Y 9%A
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MA;=>WD;2FY'*B-;H^?(Q:T:$0'#YWHHU0[C/<K%]*(G\CO-S.@QW,?F2*>T
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MEFWR_V&1%X"+^G+ID0RW6'A4S<SER#3TX_'XWL2@QG?PV9"\.L^/I')3VQ=
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MT0.M,5<-]_0%?8BH*JY!KVWZ5#?S+#:[<1*$+5@=(D2T\;<I/BMVR :OD@S
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M4" =3#8Y01!XOILE$@&[ !)?7  [Z=H?>@]?E,M3^L=),JP45*=;89YZRUT
M/MBD:A66@&'7HT-<.997V_J3BN:@07%M8,^ZX+,9OJ*[L4Y\!&%M04>D+&M+
MYU$+=G8^F"3)D'$U7MH\!YP8!Y>!6AXIR^\3T[K31!!_7/<5''%E^MRW7'9^
M1#PBNTF'$1'(NLT*.?YO>)I &XZC=)1:[[P_<>]N*[DVGE\H'PH79JD^(-9'
M3Q 865O">' F Y+GP%%96BUA0:N9=V"5/,@)65#8D!&R!/V<,ORS[A):?%MH
M4]U0E>AZLRZV6)^PH7S!VA=-2>S<%.K18TGQ9[\Y-)3WO)P0H)I%?YN-]H:M
ME+D.W-*W*FAV=Y:DL!3:E,/5=CE9JZ(0VLZ0H'<I>CY',OEEH]=LSC.2!2VC
MRT X5Y/^,1VF<3BOZG]UKBK&*E+:IRAKS1L(!838H0\A=D6JMS9(24@LBJ,K
MGF.KWK!Q%TE->5)_OPC?49)B^FDT*H4P/)(B"6O;"QO (IN18S@HHF@AFIP$
M7\^MF;.9UM$C$CDB K;EN[TPTT%#:8EB&ZQ,4!R^<G3FT<%K^:G.#[-T\-)?
M+5&')/S1QM+#"1EU;SF*9ZWQB&55  GKF23I]ZM)"]T=34*@_!"SB$AT$8DP
M$L[K>],H&Y<-#'*ALL8@S2_JHS>I&(/CX[R,F^(WUVP)5:X"OQGX4(GB$&U%
MFQI2RXT0;TT)BGB-%NZOD1:F@UW'W3)"A#*U%/DE^UIJ)G'?6BI'H&'BQS R
MWXSZZQ;R=%SLP>K328#G:GK.0MC)&7OLJ"^M];CFZS@>@K-9FW)OQ9%/4'(!
MM>Y8&<!MN;:'C ^VY-Q:X$;^-B<3*W9<^UDD9*PU5O@V'[#Q5[M&^7>@O\:E
M;O3PL!JJMJW<N53-;2%1?'Z;@@V0]03--KDCDYNZN.48%U=DL2/-U%/L(L=O
MVIK/?=N3UVLO )OLT0M@B=_U'%&0F>VUFU7D?;JIH.JDW=R"GU:C[#>O[2?9
MV&1/\"6A,=X_^@FAGL_&!1!ZF>-Q^050$@!]-1SF4BC(3J,JZ^<2= &X:*OH
MG/%-D3$SW\8DMKGS.MJOG#T.&<H:==^AKI0J=9]?&)?F80.BNN[N47EMI>P\
M6J<78VG0_DNK!V"[J$B>MC)QLF 3/%[_7CL5MW!Y[4F10=XP!)?_LZS*V)6/
M+IIY'X+RSFF,;>3+OVS<*<_%4G&W[4<APRR6K1[L6!Z^EULB"4.OK8>.,\5:
M$VO+/E1QJCB5';X3$Z.C)Y!R*Z.NA6+#>4.D0]\BLSS@\S/RS?T6K/4$ ?7"
M]PPQK^P8+). BDQDX</QEL69PYA1"8PJ.T[T1MFG$@WJL>!/IWKIS?XNB>,X
MYO=]385*RMD1>4CA['[Y*%Q)DF*00?:L''TW%T'*33#/(IPSRM9Q6:1W@J)!
MEVH^ LM&<(*K\85T2OB$;0%26B5.Z<T#^D\WVLT@ AD3=YG>&72^]:XF0P.-
MXZ015'KD6KU6Q!+J%RHA;-/7.HXL%DB=P%UZWQT^ 9M%*BG%J43?!F*(3C_#
M<(L%M6O&BKU/+*]Y:>FG-EAG%51]-"6?!Z$Y'9[3IK8[[HVF8#<@>)@2;B_V
M"[K \%(W.R=MBV%U=XWPCVQ2TQ;/Z-7J'A$U/CGR94L,:N0G&,H03&N\O6:3
M%@FBMZJWG'J6V.M1]P$A20TISX2HA6"F$WU,KGVVP-._H.65M.R-4E"U'4X;
M4Z- 0\8?O&@D4WJ0MQ^<_%&X51B&^\67?IU@FN\.HU,N&1IT<OA4SKSPYCMQ
MR@O@>M&,8/LQ57:0H[R9I\#I)\>4"?K2=M*0@UHN#D[,A$\8@U9HHYR<.N,S
M.8G;>;V=3_21#4H-MSR=YG/5; QZ([I#PE??#MF5"NV&!$VF%KK><2I;6E+#
M-!?L,*(F"W_&T",T8+-6N:4SI>EO4>WP01:<-NI-E5,2QU-$^[%FQZRN);24
MO[I8+%F8+1<@E*0.S=L83S(TV'Z"-EG7C8S*8D@&U4754NJ*+D[$\'OX#C5\
M/?G>G>V29%$:LO,LR/'N\S?"#"XPW!E>PXJQ3%Q[VMZO-E^/"*8>/(D/R-L&
M!PV=\C[/]7C97Y,LX-F/ J_V-K=\GK?^E(*9S3G "B6Q67RX*(?[74S/^7R?
M0C9R47&,^9$Y%P7W^[E.C=T+(*2([TS,KU*/L=:NH:X(GT+/^M!I2M7T@0;[
MDRTX1 Q?:^SQ<+%*1T%_VM=OQ@K,T,RX3K.M\#; B:1)6MI^"_?6':<,R8_3
M3QN/G[.[(MK>([A>J2JK8?ID()-&])6E**&2W9_8A%V;&%VU*Q*X#U-V'?43
MZGVJ7DFL#14\<2->J9&DH7XPX["/LA%D1QN9F6VQ,4L_LO^D[Q.LYDBW6+7(
M)$)",6DIA=B8O0_$G_41'J%OT'#T](7 _3A)*OG+QL-06V?;!MT2*DD=/K^Q
M^21U5N;)XQ2TOB<F2%7EAJH]DFE6M!#4V@&\&94,CQP5X6R.FR!6/I0YF^8[
M%<-$% &RJL3Z1YW'%A$%AJ*).F1M>^!X9 )H[;'6HB/E>$G@P@V3KR=Z)0JO
M>- "^P"#D<;G61O.6!F<X0_%?=GSY&ZQ6-#FEW(@9@-)$@9GK->7YY<6H=N-
M[ X3(CAXJ\Q$*%7:I?:PD:U)<"AV0)$NP:(8O>:XL=!\=#=@GP2YJX(@50Q&
M+'_X>#;/KBF+T'E;7*?DQM9>H2U*@[\VGD!@,.WII. ?ZP-^.4$7I8@@I^(_
M9)*5A.$;],L1ORSTR'TXM+2WS?#QF(-Q.^]9HP#GU,[MXY,)] 45.E7"#4V3
M#6&K=F_8(*8F:8</M<(#"PN-YS%&?(*[AGIG.4RSKP>( PL]1%4;WKG6!&MH
MT["BYGD(*HZY?,F"KG^42D6!X4A0>93/RLC#">_(MC\?GPAIM# ;=SO,9N2Y
M*4R7?_I@9.L!*VV$]DL<A$$SZ7 11J+]O6#OOLP4-?0MW8X$$1'ZZ6V*8YV(
M^*_NX_D@/]=CW=13)0UER44[#^+/2"V"A8]2TQR _NB!!U^R,W]O&U2%2Z]Z
M;/Y;<;GN;-W.BY<M#^@2%Y!H[=VF6\>#&+/%<'9<*D%#A83SC8,B!F1<9@,Z
M]R?8$3WT0\UN\=;$2^:&T=4+0)JRH Q>?^.,0BJU2_Y0MI;RWN5_D&N34)\E
M;E$10MSNK:S]),PM?*40R;E>?/K@D%O82JI3#YEPCXX.(A*%A7(!8"V_>[]N
MB!D6C4]M$"LT8^R_@/^=U':@RH&:R0]94KPG 86(46_JU SO+R6IN:%H6GM5
M-1=;'R:;OS[6-M+H8M]"S[3H-U_<*Q%<F$UGC$QWSE"-";E;!\.72[" DL8C
MM<GX$[.1L1]U:F,I;#NCY\=423=P'V>],_ENO3=NV7[&4<R1TQ#C\%3XVB F
M. ZIP[@*?7;7GF323+NWF[_B;8%^8URWNH(KG,)C\4/(%2B[?LS;.M?:P!WC
ME>"1<*ZU,>_P@><#!V$=L>1B7J7=JBR2'CLMY4ZYV97:@=M(3S[VCM%GUZ,X
M4O!8T,:4%DN%U[5<.6Q&%*-</T%HMB.K3-J3 FW(&30E.$DQZE14VW6/$Z'B
M(\[B4U*G# A)<@X$N[PNFUE:)!)>3\5N4#%NV[BI>WM?#"RB0B,E<*XD1];3
M]567=&'/98Y4"8S3LC952W99]3'7&RKBGS]ZP'*]H791?I9Y7[Z/*Y+<>J[#
M%?G"%G=/7$-DS!ZEIWKV9LR ?.^S08SSXM+/5CVX[>? -ST!7_'A';MK\N4L
M!X\-'Z:A=[_TUF873:C2 ;F5/HAK2[*NV8,',4 <WJMAXA:IX'9';:V\"*%T
M*=5\^4(3[5TI%?BZ2PMU)V56^2KT\+;?V)TM**"0<_/^B)"HEB5J8VG7^=T
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MK4H5@TX12/V8] .4GJAW)7M[ SV#2<,$L82H$*&=D M@LV3403"5O6[TR"?
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M5Z6J%6TA"2KZX<#R.)ZE+9SB8ZZK"5FEI[!C*LPX#MC5?.WK]+&&V\<CC4,
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MT$[]&YYTA>*'DQ?]69;ER+\*Z'VP<^VILYN0 N6CQ@=VI<R HY$E):6E\X%
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M8_#7,F\:-IVW_%/CV$P/K'5>TK];WJR3>M#3(DLNFN=&VW/Q:8W@*J<^,MK
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M:^@:0QBL]5O9TTUE%-^\7QF]==Y#/#P\U,3%]Y'8R$>]9%3X+2 MZI&'>C6
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M .N!% 4+;?4\8TG?.DQ9XHC\-1=+1:NHV: =U\@D:I;Z2.4'.#J36+ESLK3
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MI8"2CQNFA97ROO  Y-:3AK(/G73?UF&!KF)/ R<R*DFT\@;H"]BH5F2(DL\
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M;L'IF.\8+OLBKMK2LKASJT?0Y&@*(8&=S[NTPEJ4]/GQ=A.#@:0.EX5U3MA
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M;J)]ATNO?_,TE?ZOI_Y3]E/VKRL+/Q[+/-^\/J>QR#=8&FLG.J_E E^S_',
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MAHBK1T0Y<X =]64<-AN_TH"#&-.LO:G-]H\IUR2EM>Z<3E:T_S@Z]7Y< C_
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MP3^?7*D%X.6 -ST2ZY:,JP:J]30U6+?$(<#)B/J'(54=[$VT>?SX2\.F&<G
M$1<**?]B%@D\<,A+:5^58Q_&*_@76!CCWX);BEQP(6BWU:HBG*LTW2=/]]8K
M>6>?O)4:LA#QY:?#SF*7X/X%/WI5XTP?99GULV@5%GHJ/V./[LL.$53N]@R<
MC*O^04MN:Z*\*[P,6^DJGM.8,NZSME0?DWBTDL)-*>UGN*WY(J=GWGF@WG<P
M8+EN6^61[2M:IJSFGGWMYM>>DUY73QS!3TP$&)M)E_:I'N:][]<M*8)?T=+>
MYL@N[.M>ODM4Z\0\("JXS[];-B1W$%"P-F.; '$:6V[AAQYXY+\G<'I(VI%L
MM7R75%AQ3RI<8RNON."I\8+;C?WN0,6(K=KWUTSX3L\ 7;) Z=I,-[OG+HL&
MS*KI6^*E3^D9QSZ#O]K#C\@B,TER;K*PM?*H\Q$2D/AC7DS7ZE2.9C62BN?V
MP.'<H;>!;DB^^*!$2EA/N69J/D(5IH"GS.6 ^IL]M_]-%RDB VGC:6F":6<V
MU1 "<J3:RN*YQ-5T]Z\#BGX$?0SH'M4P)4A#UF."2$R])>T!H\\A_N.)IC?@
MRJM2*^VG@#GYUKM%Y&89AZFI;^+0FZQ\8=CWR0W?>/('6]W*)0'D#=L*:T-&
M_EFZUGH3+43MI^Q,[.A[VV,^Y7P3I\P6 R7*E,;93#6K,H1;B_Y!JM],B_6=
MO*1=?=H^ZBY95_JT>#*2CPV(,XJ5T:$Q+4UK%GKE7P=LA/WX,Z:9\BY :E3?
M?;$TO=[A'B-D&&=\+Z^@AB=N$(3^5J8AK!FP(>][':2GOY++-8A[%>' "5G[
M3VDU_ZT9VV)L8E5S0\,U>66+BCEF38KX#+C&4:Y:+OPK=[=FXIVPW[.S.3D?
MU^['Y/\/UV?1!.=8 \LA5Q&.HT@ QI4=5SUY/8 1C',<Z:&JR0VY=M@+628H
MP!E+ Y$303PFL!?>&L2+RPLA1< TR1@+<!Q0WO^/JJGX3BPW+W''!X6OW\N.
M?I61'",T7VSY 9H/2_O$YH"Z4+[GI $I:'#);=0?UJ+"$+\4AWW+I#JH<!0J
MC,3]'%50%M5^*E"7<;TF32H;C00VB0_]U\"ZR@,D3FITM^UNX/N_<XH9.[G_
MW?098G1JUN5T _ M35D=3>+95UFN+V7# ,V9;YIJ;U[VV/$P3]8"51ZNR2L(
M(8%D*U)M_9MEMV#;;V$N[9$7FE<8(W31,FP7G[\DFWL9SADS3.37H(?0)1=L
M<01?1ZQ=XV8HI'IW$-YSTV'P4U8T^^EG%/D+3Z6WXB@F#S."_"[[)P;4AG8@
MSC"H[X11Q=K5#@?C2U  YIH\&.*IP<V0KN?*H>:/5!+##6&GV45EB)?1ZQU$
MUB:EEI:2+@4:O*#O=7<4NF ?U9=\!A"CR.NLWGEIT>SF00HJ#G-.ZM\YQ4](
MW<?RJZ2_U'?&", WH%O(BE.\C%_U()QQJ8.GV :/&?9E,>UZB&K^)S8(L(V
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MJ%LCH_%!RR(0BTGA)<%3O,YB=:IZSZ/'S!]YD!% ;R, :1?F$$%JZAEZGD'
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MV#:G.7=O#2L-OB(#5O3 $C:1TY:0 ^?ZH6 0Z]\J6_F1YT\/D^B.@JE*^C1
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M0[,5!&>;=U]#.)MJ4E0TQ^2UM>_FZY>M=]PH[2J,T0D*>-A<(57L_TZ;@7F
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MV_/4V?PBO;)'"UG?O%E%PD/FM_J_^*U]Q\ 9U+K8Y72$S*9>&H3G;W(=T9-
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M85&],X7X4*2M?J2!/)KJQ,OI66.6_%/?D8ZY-/^7S0)T;\ON7 ]%GRD8A)'
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M1F 0]=T;+6@;'_S_V'L/L*:V;6TXB!1!0"4H'94.&Q !Z4VE=Q B746!$*J
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MDW,BJ F:+G+,?*E# 56F7KO=7UB [%$]-L>'BP<;-*A_K,=]O?F2*_IF@DF
MR_S1-"5XC%. =4FB3L+./.E"X8+K%K>+OY !I:J;4341ODP&5.]&90^F)_Y]
M$,9$#I[6?.&B<"E@]/XHR&63-+<ZR4E:HMP]6[)+K=*WZ59W>.J["YQ1FBT9
M;J?>I$R\VZU@E:OC3-@.7S'P:R"!U2U6IX4RR@T_'QWG#DL0Y)^&&@NI+N6
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MX<Q68+Z8D27"8*[TPN:#+IW35/7N7'NT8];)K+HZUH*KUO)(T%."_MT'\$.
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MAI[G'7ZIO@_N_.W56U[D GCUS%M"UIDI1E>UV[>,M,=$@8/]#73$S9J4=TY
M;KENP/27*?LP[YX*GQ=E(F[CR_Z$$X&76N#PR;. VZ7^!NM3NQ-,5)QRY&.W
MNT!!L%$GVGG:;BWTG@@([?50!T2#*9KJH?=#T!LC,RLD-+[S0E\PPGC^ 8,;
M=;T=M?W/7A!_/;N8B@K,!ZUB1E?2LDO.7\.\J,KJNKC*GVJ!E:L0 :!4'[D%
M80&;M$FM7!'MSXHMR38:-WK.;E-W^XXUF3#"EAJ7M).ER'?O8NQE/VD:@;ZN
MSK*D8%'1YLM#FGQ;0LO5>MR59G>T!V4[,Z@W%N<8)C5$ZUC;A%A7D-Q1R_FR
M5\7'*XC?*2?2U'860HWH!8.QDJN3U(+DM*+Z.24Y98WA=W^60/9+./M["V>G
MT-N?GL>MI7BJM+,:U9Q)'GD>7Q3X0"LWPZZZ.1&Q.>K_D#6VLC[_DEUZMWW7
MV%1C"5=_/*OO*(B$YLG&>_HSPE%8K5S0'<OTP:L8I,O2R(9#@%#?:@ZA39>=
ML$5&?4.D/:@:DC3'I3/$,(<W:51P[]4';O=-<];^@M/L$==P5F#(DN>0%Z+#
M.<1<&IXB.9>ABC6C!T"C B8^RBXW'Y[IBJ!U"!K XR]J*TN)WFG'3$N)'6QO
M@0)L@>UU7:2OKSE" >'0NZ;L\V)RSN^KX:>84GQAF&N^RIAI27M@'+568XQN
M-3MK<?YE]"W5N/QMP/@B<M2AJO*)#@6A=6[SA@J  %3)\52;(T"+N:1Z(QF'
M%HV10-R@)3_JB/J]))S+_[H9Z5\WN"4,\K.C[9AR@ZKAI9A,F-R-.G2G9UZE
M?H)7=I:K:W\$GR:\M5<\IZB=>/I^\D+4\[*Q.!JMN;E-,.E#*[U$R",.-MIB
MGS KV"=7MO.;$RH:T%-XR_.LL\MX;X0KGY^0"WI"2;[CR[C2L4)H':.19$X8
MW2ZC5CT>]E2"*N/5^TL20,+0A$ ,N(K$"=3K>/S' %Y^ ;_\3."7'\HY+PGL
MD MBB^@\U$I;"C)?4/V-+<9$[GVSI.5\Q0)<UD.P!;R(0Y*&JDB8,@"/)P^Z
MJ<?GPCVTA[$:]N@W/U%.:A"8;U,<2.ZZI65F[/TV6RLW+!)"*[2K!HI-B!9T
M89:P;][J10A_ ;J^MB#2Q;';LP#+.7)@L>GSDTU<O(H:04A-B^M)%T(YY"M7
M*UD<H.KT,0! Z+^;GC''OY9.WFE'D1.":*3,4T;^<7<:"5XW/L1I!)KX8-#-
M%+ ?6(D1)D3*X BG3P3]N1G.$V&9JJ8I(T0.N#9Q(JKMA7_W4LQ\>%8:PPMC
M<QHX-Z (EIP=^\:<QGPI[![^LVR#<Y(/4\HS$ =L_DB#*S?OTW85V(C@(Q4J
M>B(+HY^-P%L CUH?41X"""[6C@:4R0\&W>R4GGCW$3;)(TI3:R H88835[2;
MCS&P)LD5W4>2Z'S#2SFNL<1K8<&M0C=8/A@QS4H0B:*ECR;F9#.**AZ6COAE
MK:?+7TF-G7C=ZQJ!/*.K\\E.(^6,TDFD&-6(FG03I6T:_(6Y ;'D:/QTR?(9
M^_H123[?4SINN'#"Z+O83&0D;SXX2VM>?[%X^E* XT+F,K%*@6:\.2X<G][3
M=EF6U @8):X?%<P<HD!Y)K_5$JB,V71Z(^G.+>?R/A(G)!Z?D?WBHF^9"TO]
M\XDT6^VXR[?+P[?@A,572''2X6FMU@K@,Y(/&*<P^;-OJ"(7KMFQG3SSJ;DR
M%*,_4-U^VKT?TTYK?+WJ&:?>,+[#8O-OBE<AKV7.26]YXDWPPW%>>[4P#)Z&
M3MD&4+Q)&22E#6BQZM=PB:N[#UN\$]N-*)Y@<!?,I_.7$$@HBF&_I$E[Y\U3
M^W3C?U4_.D'Q(S\P^I%E? VJ/P8/XYEP"75AU$"M*BEE-&53=[D1.X %5.7%
MK;,ED='UD;C 0'"U86N%X$I>:4@/)+C'8DFD'62E0UZ1H#LXB.T7&:0M2YY8
MF_BB)MGB?IO1BEE!$DQO[<3YC<NE\!-I> !JSY* DW %VFP%VXM6^G+>&BD!
MQ,#@+%;<JV#[A) *T_?-?"HR,"TQH+(QB=C/-OC_\H/YJ7XP!.B<EYB?=UEX
M&#]G0@#'5SW^Y/-=RH.J[[9>G("%(H9N=?=0HLVK2-2+X'YN[(RB -97=L#R
MS:&Q;ULSF\RIH=.@J#.:.;&H,[S\45L"M#WU)8K]7W/;4OCJ[Q*@_L7?Y?.^
MRF?&<![%&!*@1ZFST"K0[U-G;:84R=JA+9!'B2Q5/F<^<,CYS!S6MVG&:">X
M:";0+12OU?Q7RH*7Q*4YL;.-E^G,:"TO9*GF]YIQI%RI^73WM@@CTJ4PZF1A
MA_OJ64\LRTIJI,JK'OE.L3>:9>TX>3/1A-V9DBRQ4>GB+[6?Q]]YR$]B%F$/
M!\2%L%P%I[4< MBP[FR'(!X-4_HY5^-3]XAXY$CE##Q7N08%#-!"=4YK&.9E
MODG2(GMP-Z@=1.G*$#-XFU-I>;0=)]Y#,=.%2*^HU^SQLVK>+<B]/\?O;\1V
MY_>^G50^8=;&G\TXKCX8./N.'/.IN95ND"2CE:FZ+DC&&Y1W11$^::D <'!^
MU'MF-E . Q3FW4R@*,3H9 ?!FO)@V7U]O8?HK+W&QQM1-M8A9$*G>R.\G>\Z
M)2=H#XDY>UJ20@%+/*R"C7L,9I<8%_5NDVUE*N'8BV?27IUGHHN,CJDIHY"K
M*R^4212ZTG(!]-S(?$U>3)ULIQTG>D^R<S&KA]W,'2HFA8^PN697/U)]79-T
M>?49SG")[O7IB7K'U0\29-HVYEJE ><^L$>-;N7IR:9BN_-7G0"+#O"&Z VY
MKIA/V/$4352<.YM<,50.H9#D6H4:U2Q_ LB5[^U^3$2*C&Q+L6_Y7U/&$1YM
M><@U!KJ:RT$J[!K6LJW8O.U=!P*=FYKPV^&5M7N2I+1 D5OD#U$;<PNGJ_HP
M5)4%,+?/JRTL$I KYV01@@3E:X!J790+,GM#<MG]/'0+$_/GBNB]]_)$F\K;
MQD8Y,O4$;0B-,7M(%%>5;NCD!-ARY!HK49H]OST*4J6,J*9T[(O=4]31DAP]
M!)R!XXM@M-\"CYB6^0K*M36S,C8XRG2RW^LVDZP;:1U8$F*QLS=L#UC28*P;
MI"%D6JYTIW(8)XUX(V*2NR9_>P]".[;IRZ&RP9I,5!QM_O*< *^'Y-0;?%V[
MVGJ",7OD_CR@ ;GI3965NNGW\N1]T1J63>]QT@"OTZ\YUS2NBE)J1/B323TU
MQ[3+9KQA_Z&&*UWO1*PQQ@%.E[9V#V,WN^0Z:)1\MAPRMDTC%[PTS"/US&B*
M1'_,Z6GGDMC"1O?V<\]97J=24VZ,-F>!'O)E2>.I>[H4E'V06-86$8K3+SSW
MAZ8KF +YX)C\2:H.+>Q7P,=LM84!3#IJDT8]UI=@Z/Y;IS4,;O$ 9U^7QCSB
MP($<T#[M#Q%=[#P$M+&(#''LK<()"(VG\P[0AXG'U7^W2PIL#P'4KX\V-2T:
M]N31IO\*$T@Z74'$0X,IGDD[4\7XKQN=+US7C2E5J?.).R,H07Z;*NLQMU$"
MKY2*#:;T50DVEHV4GOY@A7EN[#;NU7)U LD]K13(U3Z]<\W$P@I@(Z=H'DYE
M/R7#]XYK4D5E(4Z6)G+"PJ9>#@99>F)D-QRAE(N2"%[&9J_YV_:WU*#=ZW$G
MT\E5&$H=)YTIN X!]Z/Q1G9-$P,X>#;X[';SG2LY9%<YQGW5B8I0=%<H;=>F
M:JVI,+=9'T%RX[OW3<':8?'^D'P(B+WE4JK_:4J,G+*CQ6@??2AU7(T1WT+9
MZ_;KDE^7_.E+Z)6/9EO \<P[@=S]/3!2QW-K6APL05#+ 5M8FP][I?XX3X^X
M4T-<P+8\O%:HLQ-[)BPY1^4XRH7IOS&0*N%)=VQG=V.A2._L(:#@;3Q ?B^A
M?%"K>_.*VZE'&2;'5@*:#W2H1S/,&-85"N?"EG<NF.G9)IM3!<&$$B;=4M#[
M/)0JK,1V'+O=C_N^F IPLH 5Z=\YX6#TQC28F#$!R+$/SOIFBN>HK!C32NKT
M14A/W1JOH*VY6K5YY2(H]4@VE'!DFO>C["$J;.);G=TU174%&C:IT5EU3?,0
M@":3*IMS;C-A9_O_@=C<,;:6XHD[^N\1/57&]N:V_MU-@%]7_+]]A<PMD>^Y
M4Y7XRV/.*_(!5<L=67IA][-17!U=LY:X>)7[ZI3HXQX)'8LQTT]E=08'+$ZU
M!QV9H[5"/<MGFAKJ^AR4QGG$M6,U*ARU:;@XQCF-$RM^4 +TQK2'OV"88Q?N
M$;,R^F15ZZRRDG\@;W_T8CW;GD862\VIA,3]U$#(XNN)?5V'<U(=.4\G"L0/
M >>.W$,I0]V2&@^0.9I5)0[<C5OL(EJKDO>,0O;GC_*AW0C>,WW$ER1LS C3
M ?U#^/*1IY64K"20%TB,^)+TAV@[LL!1RG&-YJ2T9-+&+($3T[V3MNO]:,7
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M"QN?$!PBO+8B]ARTY7G%C?SM"F%FJ;.9P<,Q@#DO^;KU.=+RUXF&G-") @O
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MR[&7'-!^BW>_\B&-.Y+_HYS>RV-O"65Y.Y0D[AGYQ;DE=PP;$Z&12%/'.O<
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MD-YIP'.\%?KGC!\R$B?.0V69\'TDZ(%1I/FJ*O)8"<%0@!8SBNLPPI3!N"V
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M-V@83$H&NAV*N08<Y 5C9*CSBF*5I3BY=]QMR] [&FB1<N8T#3Q3GG#PU8-
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MR,^9M)CJ6_E0TNF%=C<A>\Y3ZL6&5 W,<Q<MEV6Z&:I$KF>)!;W!>I/3SZU
M[X!<P85D74C)]O40]4"@0=F0 AB'ZD17WKE.6<?T)$"E,DB02%_AD+P4H>:&
M %YF1]M'N0,] 33]TN1#:BVPRIB@,BXK/?!B$OP.XEKIXLW.K!O>Y.!U.;!5
M*)2**A/OKW(1R<U.@M]*[< 6TNP&S>"M/&\K3O<I"^0+-1Z=VUMNLS'>V77_
M_"I[Y;UR6G2"W?LG1<I4JB37G?TL3X2>X$N/J/X$"!]/7SYS',-7YR4K99AZ
MVK$Q>LZ@?Q7M<!4-HYS'5#7:>,6M6Y2&;JI;Q84JUF6XGM5*=R<RAE(L'_.,
M<P0MJ$W?3FK$^,=)\.=(CM'KZM<-E4:-5)P]CG&27CAT>!HC]1,(DW!,._W!
M4;KK_+ENP0TQ*W/+27(VX[%[Z]RV.6G<(I<4S-C2E8XT)6=ZH*&E&"<D?GZL
M!$Y6HW?FTZX:0'*?-LNMH<L=SY]D;,;?J=C,3 2[D2OCY?@-)7VGK['^I:J%
M;,+WP=O\%,+WW8(1^FJDSRP=&>7W>)):&;]]&K]<WS3YWI]44?.:7^^A":9:
MKT2)$@=AL.R[:>:TTVE*!+O(#5MNZS*H@;12&VWHEK!\]=ZR!Z\UE9$PG1*P
MY<1U<G[O^< <-<'CLX>C6>^M]PK%Z>H]2&#>;39,)^*P?-#* )M*R.;)NR>%
M;()O]-"3RAYDXCB32+\I8<CXRSVV_I1WE]M</&T$?CR!CQ0G!U%)EBX*4,+'
M^B8O;-I/)4E36.B0=/: X<F6=&)_WQYS&^URO7>W&Y2^@!9*G=6P:=3$]Y+[
M<,VHO<TLZ+IPCE2OT52*,Q4@@032"A\3B&(GQK.'FCWZTAE !"/DYF.3*'5<
M:^&HFE#XK-%]N2XYB#_??IAWFB% ++H%JU**[1I6:],/0'[=:;FS/EY/0M@Y
MO/VM>9# .L=^4^E#NF/*4+-'_B;E_1F<V^G!Q=D?8SRJR;B)5^"LYQTX""U^
M?L>$L4 _F[R/E5J]LET4KP>ZQRDU$$-O^H+\X>+ON[T%T,3X"QB!NY0W2N+H
M0C&2Q$M2]E@'?[4+Q9_U%'ZBY0>RI"D."")/D,^U!#*OMR\T0C86RY^Q?)Y4
MK?CPW2.JU-E^CKURW)KD-I[-!>L^E!;/O25A]GD%Z[ JI_S-UPJ$F7;(KUYD
M+^HH!*NN69CG4YL 6P,JCP7%K2L\-2F--N6^_I@.\BKVFS40W&K3\\G$ RO1
M#;^^CG8[R^CD(KFWLW6IJ^(1A3(9N7#)_Z)6N60C\CB3]$W\<*R5+SORL5JJ
M.5DO; N$W5T+D*K$)#R.4Y6QX$(V[G5EN 0=W9<-7"KU]-XO[2<2]+2"WG*E
MI<K7Q877"6C^Y3MR_V6$RM_)Q$7EHGD$*C#"R3[^;J#$>VSS(!N04W8RI..-
MN+8\B+1-78SMK?9\!&M&4B1A>[B.WZ:%W^(/%OUQ8:6EEZ9;"XWELCJH&*I"
ML>THG0KC-P8M5!7J]$[IL\1A8M9B&+_+N.M#@6:#LG?NI.+)^URR[^&*JT<^
MCZ4>P J88)\OI0C :!\Z5CRSB4-RTXT/9G0WY8##>P1H]Y"3NU_":M8.;(6@
MKR6+7QMYECEV">2V@,/O;2EP#1Z\QL^XA04O1G!+S'P_7S-MG^-]> ?Q87O0
MLZP>[5C@8 )QM";;T;-%?-AK+S_*59OU,0S*;G!BGHY9P"[JJ!SPU6S7,EYO
M; FS36E*(N_U?:>B3MD9:V9R#]-)G_U>1F>4::34 I:K]V&>X7#%D>1+Y(52
M,JU2_:NF(\ASKZ9F9-AQV*!QH6#3_!@?OJ^2R?3'>RC"YC)__K)/XWAUP7<L
M$.#&INAA?*0=8:9/)IGP7E>$4^X,VL_Q1<H 8>V4KPZ,?<@&YJY)[P@?RVO<
M\VZET_HZW36KJ'*P2213:=1-&'2-.I/(RA5V$'DLS_.7]]P_ X6+= T\/KGT
MN9I[5/-7 [CO%!AG(!"6M]&4A,+UWNB:J<>8T\<\/]@,N$D7RR*FH4R_9XJJ
M6U!9J1:>]9]6JK9[C-?SP038M^>9?K 7JY16HO$3\#24W:/43Y*2)C**ENRW
M17S:_13G5>;H5#03PDS 2<(@'IP_EJE^(F\I *4G"VOFLD8^$#+KK&J.?&UD
MR%)J0D9\@N+E^6+K?#(E;EA@?Z+./*D(A1N^O5"*?+1<TC@C@@#6 _6:PE$+
MMJ9 X$<0':)\@8] U@FE<!9U7S5IN9YP_<".+V>*G^K'YT*^<JN1[;E%'\(B
M(02PST>]M@<3[Q3Q-HI<H>/Q.J84J6>XH6N/6O'=,_/<]EK2O,T=B\W#XOR4
M:_1):=*G29Y1UQ"X: R!+[1(:J4H1-FXP8!<KAOI]*JT4]VQ3LSWU.#=PYLF
M7[X844'6)0M;WUO8^>0YB"N@<*?Z4A(UKS0B0_P"G\@YA8R(Q/O-)VG\)=N\
M&[0_Q%AKL'2GRCDXPIS5 =7_!OZH_\M0'S#QNM,E70-PX+J9R43S>$D4,H=\
M5%86M98P=.B];^4_O+0,1"&!%8CF-6,36 #O@K'MHX_<XH9$PL7V<R+A7';,
M[$%-XH;YF_[]-,+QJ@)XE>T36 O;TDN=R+TQ>I4'K^*0P/3)RX)F<3-^Z+*M
MQ]3;!3+BJ;<\=LUACWRH3\.L ]5B(U.%8PHL2?PIHC/MCU*#5M^PP27[T 8/
M=V,VD_:G,SA%W!)-MFM7&UMWWXB[L1GHKQ^4D"%40HA$6%Z/C9W QCR5 &I:
M><"CY<8NHMME=2/V)9OSNPB5MKWQ1/PX'_+EU"?62\LFAQ+%/4^VIV!IS,'I
MCGU>' _1Z<S7L6\[EXYZ9I(I#MKZ>7(IT^X(8CL*H9O.8 ;29DXIN1*N7"HB
M,7)#P2EPHV24J[>6^N+.K=1\A7/F>XHHP%W$_U&G^&'M3.>B-9GP]IDJQXBU
M_N6VWT",M;VD7+[BE;AVDZ^=61>M#]$Y]2* FBRM^<-"3E9J,>?:_UE*Y3_B
M+L@&:8+['$.= WJ39Q"RIP!&@\(L<T#645I<%6AAN#/'Y]SI3_9$E5GN]\;)
M7D@JN^28"A(P>(M2E\'Y3.8OM.>I#\];Q9R]B0\P6-Z/ULZ$NQ'"?-M$D_ P
MC?OQ%O%.).]S54%WL:/Y2?RV&(#Q;9:;TQN/M+QG#0]VKCD:U,.XIUYZ$N1M
M$-C:7<A5)TU]Y]'@5\*U(Y\XL3.L:QU<2%#*++KX@'Q7L.[F8!(TF8_5T*7N
M.K"[KQ.N2&&X C8]D=-A"-=H]9647;I;6=7WY)G2ND74\=$90]R-1LN2E\/5
M@4+S/1"QEI$[M\S2RS7V'H8M[UW35ZX#'Z,*4CYJ3%C<&WMN[914-/?><<CS
MO?B$<HW2'?"]*(K#,OR)A:YBR]/:46^R4N.'N">AVYS;1:_A7U^-#L;-S3V4
MM7$>Z9]GHO[DV'^H;G*,;LKX7,)*Y/B.V,/\6>U"WUM#^>B^;5HC8B&[4O>D
M+R3"]%+'QANTUS<Q F_30S.-U[Q[WPVA6)+8ZHR?PV+=N08,VVA^ BF-ASI!
M\_I3:T>W)XU>.*/VS7PR27#7,TR\1%S4///_>BWS)X!#MX2B^K!4*O%KA;!C
MO%G.)<^TP1L;*KK2\)9/K6E/(<_Y6Q[VX#U7=2??G \3-(=M<;S>.-/"R2Z[
MYR;5$1_K1X_R\S:  U6)@ !:KW#Z+)!WN<S)*RMN1_H#XRE:=G*I_%#A-;ZL
M)'6M&J5GCV;'WYG+J4=J5]RK!A0$H-3/J,:<^#S!()6L1/Y)X7;?HIUSW8?A
M7=/'P8P%*[5V)WY!M**5+=_CWN&8,M#LFL!N^1UKL&6<=R.!29'!=1H(FS>A
M ;^ &=[L2M82O>96A1+%*)W @,.6I/9"8^U:NZ)(4J8GQKVNE538%%L]+Z<B
M_6J.XI9M/^Y/G]U&Q+9TG"J)+%]\9;"I/()!5SDSV2XV6LT'W?A&[&43ZW%<
M7!^J/IO+\W9AW]29.L8?Z-E-?IG\L.KQF^<IFDQI!H:=JINZ>6]D#5+K."7*
M 7-%]V%8_3.HS2"=CG&@5..Y":; _/0#@ZQ8)DD00,! K3X?/N"_X2XZ8((8
M'^82I:#2XR0=NX?O 27Z;R '_\M0\T!+QV/#:9Y7?"S!F)I&J-:\-C;"U_[
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MP7F'E$@5_H>]3/D;?P/_O+!O?6?K+8<FYV:FZK=Q4ECEL/E:7T:TV4^@78?
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MYJ-J'E5!R:=AZ?=&^'@Z9C0J&C;RZLM*MG<\Z(;"<?T-I60ZMAE@1+$;FBC
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MC3@O 2TJ$97(/NOI>EN=N 8K7P@6KST[:%#:S Y)0&^/)8OA8>H2S5V'DN9
MWA;T'&;B96<[]?J0RDLD4Z]#R3"@MN VR**K:":0ID4*(V!A0S*R8\-9,:"9
MJUH)NI.!@$4W6=$<EKW< ;I!G&KE!CO08(,8.\*L3$-\$/NKS@HRIPQ&[>,)
M ;Z[*?CF1>-?SSG5P@[''5X%#>-S%#7_V!K$:<-/>J,Q\B%+=D,=D&!.BF>.
M\H 2*<>EZ5#,#]_I83W,)%B)9Z$N^&Z4+JX+9WT,IZ.B$5+#"1'722LZ&\39
MEQ?9X6'23:\!=CWD(15TI#6WT0"'*"JO*&X\Y+-H)AZ&Y^X?OC77 0_E6$5\
M.+T"K#F=PQ<$U*10HR&OQ7)$:2NAI#V@S*^ZU*JD#3E,O$)0T@%(S9B9EUAF
MM/]5K11@@A(T4>'4T@E8;'YH7@?1SU5?HVBTKGV$ !<CQ A&V*92KQDV*7BI
M3% >D(SED,7P'[&%/WV/;X^%AHNB,$)B7Q&$25?<GLQQ_<0I;#/CF1]U\S48
M:_1YL!JG<@^D@:I-\JHBRNF<$#.[%8RH #M5)L'CN#0.X!C510#J=Q:S&H8S
M:'!XJ/=8H<'K4"*E:Y (5@^TR,Z/$2A9#X8'XM0EA&'>_:.L\L(9L"Z.LOP"
M"!:3I3J':!Y >@W%#;YJ:=IP-_79;8T/FPC@^@<,\%5'B/2Y#OF,M"X"\%9P
M4T5:MI-J0O@_"5PQXQ,'+()0:NT1MR@$V-J79:*Q/R601.KX?@)CS19B$: $
M5&6T@^4$Y."BF03Q"!.8E&AFZ!0<="7M2()"%(&D%O9*; 5V"'13$5<+((7!
MHJ;]"763-%4 LWU5;3;9MM6YA#):UD&<8^+%I-1O^/9M5]D,:G"4D.T.?9JS
MQYJ%7160:@D$=XNN 1HQU*N@\4\S2RAF?I8Y.&L.9)C40VFC^XI'=FG:Z; 2
MMV 5@6@R"/ N?,LG]S'1>#RUE%C>UJ./DH.XP<&H@HGS;H2!SM<;OID$0VJL
MJZ!Y=S 63$@)BP!)9>MJC^6AJFXAFA5]E:L/\6(R9.Y:3Z;G%?=CTW1LZ.(5
MYCM"?YD9@V[CH3WS@SB%@AR9Y*MB>=]7A^%W/\%P<-2?42[GT.I*K6%U+B8+
MTWCTZ;8\6:+3POZJ982#4/@D2IT+5/01TP!N5P*)CSL_[.3TXZH<X?A)2%=Q
MG4,0T)@#F5E$]EP) ;#[X0!5$.I10ZQ[1JH.B$>-0(_SXN *?IG7.:ZC!;3A
M7X?S=9& JZ4&F!M/I)"%*@_/=KL)?K<GAT6T((? C>=4+\H[:A%.KZ3!T=RT
MB@(_3/XEZV[JU&CF2G9<+9Q@#!Y\4T&*X][9(/9KX&..:Y?#O9F!>CI=! .!
M ^!>816G9 9HHEC8^\(6<PPW2O@)_(%$,]$>%($P#9@ [%[+*P#%$W']Q!%)
MRQU6;^NOFYRNU)9),/SXC=DJ"5K4YDJ^1Y\OQOO44N-Z0$FS4]O6[#^: -[V
M>2$"RC7I!\"BJZ ][DVUU6=D*C[T>( $A(&CN2"76+D+C-46C,K] ,+ZGW4\
M[9^=,MKN(Q20$ GC#]('RL==7)^:K0IFIC>"F6,+CDHXQ[441L'BKRO7PNV;
M3HM/AU\N_@32(T\G7I5>9C&)-5JM8[!_ EJRH:Y?WOJ5"T99=!=5(5]9K%:=
M#@4-R%^L[5O_G3P(YL"XO_OE+=]14M9/0(;D=*SD$UD6&4?AS)&F^)V?  _E
M?NY^]M^)?P)_IV:<,HFXN!!955[1WM+IY?21BO\4>>G/MZKXEO+BX.&G9I=S
M5:V?0$;XQ=KE\*C,ZD*KN$Q-SN>@27*)](^KZ)^ %.5^SM]26(C\0!4$#70\
M\PSZY[.UMQA_478]_H-"?7_$5YLYHZO9JY9'CH62Y'0\/;+ O*^D/4:,I0$#
MTZ2EKJ9)\2PLKO//\5R,%QNHO>;:\,FW:.+8NK=+N6>-:R2J,>ZKLG$:8U2@
MFP]J]L43OZEG3PRU%YQ,G&R435.NS?@C%B#J_+ZOS[63]#]YU MGS1='C C[
M01K-0M^%967G5*X3OO/W@BP-D(<NFCLX46!)NGW3/BX:#R[I+ETO=F_ W97'
M>1QKK<%AFLZ5OL?W4K=CK4%K6$36$+(-<X98!;GCFMGA!]-L\'-<F^WB&EC=
M6\EBK2*1[NQ'N,5R?GNYY,?'*__^@.'!\R5<:[@$-RYU7I*UPA!:;TSXMHWC
M*MY, \;]]L5]-@Z\9HFO%I\S2?==!I"::?6UUFM3TS-KCR_W).MP1(4Q,[Y'
M9\9S4N(#GPC]@Z$,(;Z@,:9TKN"*DV"WH]KZT=+ <)MH!:YZY'<P=\MH)^YT
MVB!>432TX?0SYSERT3G0R7>$O+)F/\$'1S@B8-%)5;]%E2O,44=#"HPS&DRK
MF/0AQ@;IJD7JF%X]O3 +QGAYK-QJI!;^5!_M!<M_7%TA>)],"XPSZ.ICJQM-
M9=U(<KNKU;GQ7&K+0BUW'@?M]?4KML0@@#_'X881--:Y%O6:#DR'7!1^2/\1
M[V.$9L3 DR7@,5PBFR/"7GBU\D)VE"=%(\?:*BKC/6+[8%OCBW8%I=L-K:@5
M.._1.II/V\S[_V+O/8.:C-IVT0<04*2(TKMTB(#T#A&D]]Y!>@T=I&H *88N
M AHZTCM"Z"!($Y#>0P]=:JA144[\OIGS:\^9_>/L>?<YLR=S9R99ZUG/NM>Z
M[G+-K-*P^:8AI=>9.>?IILO.YT+T<35]3.=T@NZU72/.7C2P-16Q;_;+LYJ@
MLO1/(0$A'KN):%G0T1,!K=K,C#%N/,16GAL8-S=[/E=KL].*<]BUJ&?EZJH2
M?0..# U3**@A-+S.)UVB/5#[2G3^]M5C-^-F(OXJ8I]'U[!YG^(?/FXA02UQ
MQYLB. $$:FXO#1),'E4$78J,]'J@;Q:[*UXR2<VF/Z]SW4;]T%Z=P=G3)) L
MLNI4\NMB0EM*3=SM?M(Y/U4R?Z-"D/B 2%$SA _PFO:F2+,.6I6<R[R.U9+3
ML5H*-=':."'OK>'!PS5BJ"T&('B=F-*T)$'+N2^H](D2Y%"_77/2R;&=D.DB
M+7!!@;-WQ\$NA=LZO7]/3DHJ>G[1Z_&9TYA8+NBEU7S!9'7' $LK,_=E/DF2
M%B%@DE6;+-K*T.;JT"T?[^6V%R:-:KD,%-04T_B#!/;Q^+UY;F;YU/_R"<V6
MID%!;S,'D>_/FJ_"(^"BLN!\LF=A6#;-E?Y"X6B"&(YJK&4:D44MV2S])!W$
M8Z/TZ__5^:?Z+573]FQF&04.HM0] UDUSE@_E'QB;%R)XCD4%8VPMWNS&6'M
MMZ'SP*T-<KCFW"#T46=,<*IMZ>11W'>[L^_W/EQ3X*Q8:/)#IC1?U%4R2O0;
M-+0D_Q:3CL&A]GR5/NRV*NWBF=B518AD\($*@QE;:8N>4,/.OW4$EZNPQO]^
M=,?ASZ&)*T$QR5SF5<M=;P(7W%.=K  >^D3OZ3 %U6/S!67B_'6B4I_-4>LY
MW:G]+?#K9 @0(C":YV9)>IF8?U#O_H!0X=Z)^?>BNGZ >RQH7WL78=S9"1M8
M*4K9=!GUGL;\UH6;6$GU?:>XQ(7*WJE1$9DPI-OP_\(TSC>U]$/LKV)]]QV[
M]B@1#4\N.UQ[R?Q[X@X^JA1YG9;\Q9NMG]K>D0@M'>&'$[AU,#_P*OR)H!<F
MNJ"EP%EVD\JF<R PP^@IYY2IE"_%QP4G7-2*HKW>>B)DN7]ZD]]C#J58(PA*
M,XG529H"L9X>#]SH$E94>MTANF//<%EC8X$V<)FR*$C>2:.EG'"]?NW58%:?
M,(%? ]XL9GEQ8P)",5.+O2WO=]_V-!D4G5A8Y9M-:64#L#5R/DA2E$J''\#F
M9+SG,CGO<W?LXPP(PD>9'P18O"2XUA9\_CH.!ESPL#]=:J_;PG6/GNK0*[/&
M)!YNW0+ZI/@!;:\^4=47B0Z_J.3Y:[3;1DXX\)#T@SV8KBT3)E!UH_W$[W>D
MC]5*O8!G\DJ,^\AE2]@X7<GF@%) R"T0MWUZF4U:[YD,/((!^U<9\N+J0<SI
M3JY2D0=2#B:J/NT(!TQ6OXJ"?XS(&AN#+J%>-I-KD=Q)9K'!M*?U+: %VQZ8
MLWW'T];_VQ49W**7TXB3[TN(F]1!#ENWQ\3,\PY!"'YF8L!EU3?AY4K>!%A_
M$I?MR0J5O5N7#+,DV)VK6+!9^A%X(/*$AMQTE16M&<)/KKQ/]@S,2)=O_1Y&
M[S.N?EZ*7FVF?2CVX;G\ZI*5>$R'>MM9,XZ5"BOT\7R8^B_'J;[Z!H?-"(NY
M9F:7>IC=77XI$QY4N-.:QHS!:--#A\U4"]^#C"9S7FNU-_B^E6!ZHH(0$VIL
MH'ZPMG>=.NAU;3KG?/.$T3AX?-%_DYWESQ$B'B7PH*DV&%>+.6,] 09<DE#]
M<!\5Y,PZ>5JYY:%/75ZU1L:_0L<?:M2^N-7<&&RG=4R("^6Q/L@(L:SO]_8^
M8R":UJ439+VPA:/)* ^DTN<:B-.6WG.O<0^:7Y 0]K4E#N=W-3[]6B%G)YC+
MC5=/XS.=JK KK5I#IH_>V@^;< U<<^G9Q1-9$F"RCN]/UFU\RG-)DT]Z"]"L
MZU((B)(4+YO45=4_98%]2-'FQA'?6B<R6EEM0$#LYE6:A=2[Q20H^X<V5\S5
M:*M%SMG9,$T3A 6M]T>(C""]VS7R8'3;#Q-FI\XX10%-)MY;X*V,JC^%LFDO
M2)?@I]Z-E:N]=(.AB*S.;QL=BW<MXVXC:/FW],_@E(;?7C7B3*Y3]10[RA*J
M]V99LBE;K+=\&_5K"%-XS?X'SBPXR,B-U^%DU.WFPY<K9=?0:+$HJL4O_7%S
MX0C9:/CN+EN"+B$\:'#@^A=34:I%\LKN3G^@-</<M.74U(O>[X.L'0?]3?O!
M-5F!EB<2%$><%K7WW":?<2JU;\*QXV\<S.=?7J+3%0_?EN% 2:\8'VUF22O:
MM<FJ;_!W2,M\\ZUF]+X%R+;&2H6.NHF#\\FTD3QR)VX[,BJHA<:/5* P-<&_
MY*;RISD'JHHC)93Q[9 C,%-<X!=K;GG>!&/MV-HE]\"E5&A*@/FW61F7-J--
MB^$<*5U":TD&F!3:.M1G,\<T66A)1X#ZNNFJ.H\4\Y71JJ,<K-9>#02PX%/T
MQ'+F)&=)YD-Q!LV!/K1R@4^)*T2T>97RZS[\2WS 0M&[A6R>FL&!CKT$863#
M*P8>*RDL\0=LFYI1*SS--C&"28@9TZ#B #Y2M4_R77J_YF)AYM]=IN-+= ,9
M$3NKM*1PHPW-PZ&>_/N!\.OX />?MI^Y[!Z9"S G+>%Q49KT2,W&9 7[7;7V
M.38DS$/^+>6/S0Y'N. *D-8T/D@TJ+:<"W /IYH9!Q%?47J.Z"%F'H4W%LR$
MF'P(VCG3P)K!8 F!M*(O-^XTIMEBCDMPWZ57EN3QS(U],56F+O$D:5#-B>(4
MQ/]("H>"E]EEQ!X^T=*<M,.9Y$A:9$\ E:PEPC0Q>@I3Y#WIK:_)B?ENWQE,
MLO7Z-#D(*4QSMNGTN[#3%VGKY_DN*4$83!&P-.3AW\H5>U)6*SLAQ[)F[2[O
MT"Z!7R=L=?+6YT_J8ZX$DY1%EX=K&CZO(2GHA\K<>,OO@V&E+.6TJ)83VJ"8
M:Z762)!V<L)4$'T?23!M0ZO76BV-J J*K<)ZR2&@'P@,X9AIACOXZ5PO^)D3
MRD:_V*=^:[\QZ</SM6++1&Q5;H;?(<74]*,1J1 ^$,+LZ?KI#MJ2/WUS:*?3
M(EQY;<A)@I:FID'_RV_*3*2>KR <Z'HFR^.3.NK]^K1.,V&RA_2GRC-8*74?
MB39HI7F.DSM<-9],A9"0IIB+L?)M"WID..JW%)GD'V#4:%J.95RLD$_@*"R#
MBP$+_>!.RZ-2=ELI0SO5CE1)%GYA^*9H'L,HR6+S-,OY,E.O",[2T=!.0IE$
M#>GT8&8Y:\TGYRV\Y003B%< 93]\A0=??5<$YX53N=OT$*1$2^1UL+)[VNQ-
MR-Q+Y=4I,C&P3\2H\W+0M'ZF1K:-Z0>C3  %%<%:BMJEQFZ,Y:F/U= N[%P@
M-I+GA,GAV,\:'I1/+$#Q0Z?$-<:TZQ9P6[\8M1B ]\ID%/U4+ ZTE@0C08\6
MZ';#"%%:0B/:&?19*4GT!?EW!#&G$BS9)I""URY99)@/MT!-&77_+S:QR9#6
MLLLOY.%16K\="X.'UG"A8M_N#1WH$&Z/@<C : KS.?C\<WQNH=ZISWPWKGP[
MC7.!IYZ)VO>Q:3;[BYECOR/+FL[-NXW5]=V%:N.&52+HG7J&B&-_5,KK4"\W
MX$*2W8B%7)L0E&H&YZ_WJD;^G%S?++NH@)^\/;J(7B@2Z<R BD.'Q@2U')<7
M1'>=!^%S+Q.?_L2&"F0;,S&F@C%01?%LN-,8*F6=3>1$H,$T.^S^Z@D$9&:A
MFQ7/8&+@+H"$V+]/H*9EA3*_6TYZ3ZT;/7XZSU6.Z6Q<<?2_C/?FHJU\Q3KK
MQ2?2GS&%NSW/A0L5,'>_:KX>=_;TXPW_\1TM_I9C\I@M1F(QWCZ_]ND$8E2_
MM\_ <LF"UC$E92@I?<DZ*+NOG/_3"^+J!%RL5X&46(K.Y3$<%PF3*EGLSQ?[
MF;QZ',I'(+T'.7OC[,+(NQ9SN35_J-F-_R*8 N>S!@-D7Y&*IDK^85"T__T
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MK%-NO9?BX&#B5XH/P7TJ894]GQ&4;)9GB":62/AP3<Q@4LK:<OHI#DN*WON
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M]GV&!@GU=O*7SZ!I(\UHM.ZK%F; ^WD+.M/BBN)[]6^[T,_&E"IH#SVEZY>
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MLQHSM/A_%'VN0SAUX6=-X2U/O;E^G0=Z6/N,Z!/@&RN'*(0_PGK3;]VH#SS
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M\9IDR.2F87Q+(EG/V8]!U9$,>4V[UNWOKVJ'OO^=\E!YU2&*/P^3_I_O'O#
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M<Y:@VM1QJ9?.$<0Z)H=M\5BH7'AD,/)MYR'E4_/W$JJY#>[EFU.5R$/WGW
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M<,3:]_FJK:+[#,I";LPC^8^4#.%/_@M02P,$%     @ TCMM6CU2]RS9'0
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MY+_X7O#M,_W/(PBA0?05A)]?0N_+&1TW'?;YW1N$9Q=7;]]>7OS>ZXZ=.5R
M<R^@>G/@V8:*]E)&=_GITZ>+^*^;IH66+X_8WXSQ[F+#SK9G\E<WVA)D&W^X
M2/Z8;>IQNLXP'7J?PUB2+G) %%N(D".#V8+^=+YI=DY_=7YY=?[N\LU+Z)YM
M<(J5C9$/1W!JT/\G0&]']8@-+@E6^(6B>T'_?-%!Q'H)KS'A',/IES/2;$GZ
MOWI_>97T_M][C:+UDEAQZ%$C/#,N#A[Y&OA43^,YA%$HXJ"T<2.<# &&032'
MD>< OQ);I91U\4B_,K@@_8>#Z6!)9P9B3Z$9N'0VP' .@]![@ET4"E59O:<F
M9!A'R/DV1[Y+IC#KSY47K:OPS:9N@M<.".>W/GJNI-H"T2&<Q3- ")TW,_1T
MX:S=])M=/Q*YH;/"1/"1%W[K@0#,XH$)C..(0 IGZQLO='P4KC#<9WLSW1?Z
MIJ+0?\0R)=_]@0/5)VJ/C( ]X.]Q8@>.YQ(>:I"P8O]U65?BW(732ZY9;;;M
MS0)O2F8I J/CH%40D>7*$/F>XT&QC<L0U\7I$,,E\%SK94EF)4@GJ0&98'%G
MA>E4:X:AA.NHTD==?*>:(2YA#1Y]F!NSZX%'S_<B"6U7[JB^^8_,L.=TJ1'[
M!:*ZV$^(9T N65W<=<#2BX#O_27%5'GKVGA!BX47Q;-^[$3C#X)L B30E2"M
MBTLRIZ$%G( 7,5<E36NS*CBCTM+M U[(&123HC:>5H\A_'-%!K&>*!)"CACM
M6YF=:YFEFYJMN8-.Z/QU'-_[7;3I8^28K]Y3Z_Y&3I #NVO8]TA:D QQ"W._
M'+?2'33@!^0X9!(TYQ,D@1;0U;Q6OX$1\/RP#S#=,3]!$7L"LMJTY\RAN_+A
M8&H2VSEW/7]%AQDG6QEB1BD#0FU6[*<5GU%5YP=U5C\2^WZ@U U41J5ZGPU8
MF*Q;J&YS!_9<OXRQ^Q@LZ71B.L1,O&A=61IQ'PWQ?9WW>INER&$BR'97OS2_
M06\VCZ!K/I$Y= ;M8+F*PGO"S03U(* 1F3C;0 .8<?3R#I-/'KJ5Q:QGG/KE
MMUX@=KP0#K'GT-$)5S2#1&:SC&U51_6@;A5+5RD>7^<8#:]F*_NV:MTT$VFI
MRK0<=7T[^<4"X/5@VO,";[%:=,DG#(E+B9?7LA]+A3Y:V$545GCUKII8_Z G
MCR:F;Q'.;!\.6//(]%,__WT8W< I)&L/EPQXX()-HI,&]G15[46"M'[]CN 2
MX8@N]-(]'$TV5E:P3"_-[5$K3]_2/1R=/(-.FCP;/BUW*:S?O&ANNJY'AP9^
MNKK)J;LT<4:[BQ-GY!^[Q%F%OFL5*-[C'\/U7@>ULF:Z_UJ%R=P[0>RD235V
MA9W6)P+1S,H'N.N%47B])@LH)PX!=&B2%^'UP5)(]MN(($?;.:>O6HVGC@^R
M40;SN)$5Q2#P#[<*<9=-?9S'LLWHJCYV;;)/>?+<%?"/XY713RV,FL\ NQ/2
MTU$<EO92XT2  =WQF<3#!C-X//A[_35H &2].T,!(7#HP;M"NJ\"Q\R>ZF,V
ML[6N@6%N;_4Q'1M>V"'+%SA!O6#IT<7,<6;,ZJW.>2'T7(A+K/IZ3;[U(^:)
M\G[#:*_?^@0A&R.P\O.I]@H<YSO@L0:PL^&NK'&>@Y*SMYLCP/30[8=X_#GI
M CNK1WCN>E11\7HL':@@/NW%"Z(+TO0B;7-1VD'S?&\'.W?1 G@5F2Y2M\!Q
M/-+Y BX>Z1'D2NSNDS;/*_#]:AS&!,WS%:#(K,K:AJ95FTR^ZH.-<D.^SS/Y
MM1?$6],N^7&/;_@2P<"%VQF.=BA_6C[R(MH\O>UP:9S3JQ$K.A^3?Z8MFV.E
M_$3\'DM7A(_MD>28IR!$ON>2W[A&2F]L.FB)T_)0^Q[;[^39-G[8Z^]O38IQ
MP+GY/;'>\\3:=6Z@J;'KWB!+(6-O ",9H1TY.>?L]V3[("];MLO_ 4L4_FRD
M/:<2;63RD;,GB$\OT2#,63-,0?@8SQ&K\'P&P#)=.)!UPN8WNQ5$^HN'+7-$
M<= F_]RBYX-'Z,?#/J2-R]I>J.5Z+YK%X3AME^=V9S<FWO"=3JR2WBN9S3\[
M*(B(I5E^/!KQ"$FX<\/9%*.%4)6IVA!7@JQN"2-G!L+$DKZ<7;[=\4+7X>Z7
MLPBO2D1N&:#$MND73+9A-"OSXLE86#E9K?"5+D%%<.VCP("*)W,)<JHPRK%Y
MDZYI6=@PFM>*27&%+0*$JVLD(P +EZNWIPS,PV4)^W5ALUEH'COY'0M>+"0+
MOW?*\*-):!3$CKZ7;KY8V!6:/M0.V_XND $)_]M 8IZUF]UV^;@A\%P[2(]B
MB #ADC7P4=6.CE@ )E3*L!K15'  70O@P MFH0BD\O8/93.V9NAP.&?Z(76?
MD$.V\RN?;F*2XZC9?5AR<D+X.<EV\5 V76L&7C5AF'Y)&9[LW6S92CS?]N&C
M&H0J;)5*6=;.,XWG ,,PD^CAH)!OJC\(I1PSYS9UJX/,L1*&RXQ%*1PX'4%B
M6J$7P3'$3YX#AQ![R*6YNEF"07QBFK? :'9D[2VD%04P)U]5!L=R&#2:223P
M01C&-W=BC+8:NB5:-@<=^Q;A,8CO)6SO(_5A-)A.P O;TAH;4GL3:U9REFV]
MU\VV[@,,Z>%SZ/Y*O"*9B^^(DJD.!L%.-!.33RJ8W9 ?@UGR11UN6L>.>+*6
M58O@+,/ZH,JP"'>[#X=M#7O-M(>PR"U+[Q^5+M3M,%Q!-VLLL7OKP^?X+]PH
MN@2Y]CC)2\'"[T?-\$O6QH<#F*,_503+Q&!!^-.!$);<].C?#.4^K$%0MGRG
M]++D^B)360H6,)]: 29G*I61*=*?)#0,,7BYX-:_FLDS.N:K(>0G"4VY%+6'
MV(_Z;"I#4Z0_26P88C#!R42C?KG(24C&_];*D:-BW<R]DT8?Y4\:T9Z,M*MZ
MCDO56XYS3[!+>EAOUX9*ENW6H/T:NX[C<V&;KHULWTU*6K5:YIZ [_(";GK+
M2;KIKP&I)$IQICQ_^O3I[>7[/,=W5M\:F=U&3]])E=?,,/DAS^38ONO;MW;'
M[$\,L],9W/<G=O_.& ZZ=L>VQDTR7ZG49D:&CWD9AB-K:-HWAO7[T.J/K;%A
M]F^,P>17:V1T[D<CBXHV'EN31J6I7GLS(]*/>9%2*,;&T/S#O.Y:)2)U;?/:
M[MJ3AE$2U>C,2/%3P;@F@\X_SJ_-L75C= 8]BHXYL0?]1@]=EY?OS+#YJ3!W
MFD-[8G;M?S;/G$0)SQVG5V\+G YZ/7O2LZAE4(OH#.+/U>HW_:V65?G,,'J9
M9]3N$U8M8V+^WK!UL@M^9M@K>,NQ=4>52-B\'8QZC</.+ *:X;'@\,;WUV/K
M_^XIF]97BK@R1\)Q*%<%KR=P*,8/F]Z:/7Y?H3)H1IJJ[M'X(>FK45D.*!2:
M$>EP;]F*<(<6#\U(>*3S;$5,N3JC&:&D?6DK[,L7'LV(4/2S/._5BASL\J0[
MOM\5O&[6F;5C+:)BI1EN"ZZWQ+>UPK2HA&F&YX(_3K=*Q@\IM;$E_YN:BSX=
MY/O@$24\9.].$_/O(V)%Y7^>D'^%P(DO8Q5B,&7GF>L<15'V9EMBJ09I1!>4
M&AA+FTM.39A</L74&%;Z7[':7X+3*B*"RU4L G77JII##\F)SL1:(U1%]W\X
M)(HN9PFT+<1&WZM9=<*C]16M>B#4]()6CE_1)8;2YJINFX@_%RXV6E\XB2MA
M33/S.]^A,9I__^Z,JR>=3MD7) ?EP@JO$57M2(WCX^."CA-)/V>H"EZ='6>#
M)M",,V6<+$DN4 U7V)F#$)HS#!,^F5!2*CZ1JBM^AWYIJ))@3&"4>=.#3F]_
M4(-1"Z&"HIPLR)1-J/G;P9D+IS<$ \>+V#"*:;]C;"6%UVZW3VR2GM**"_V[
MT+U>T[=7[""M?Q7,TN=S/-YA<?D^OF,#J*@$[5;*FQ<VTI)C], B+?/606'$
M@9Y']1V#+12;Z8N5?>>(3$L1Q#",TJ3W8#J%]*0J99KS;7/IOF.()01G@:SL
M&F9Z:92:)#V52TL*I]>6'4@TX0Z"C 8XT:8JW7S')E!=#RR+R-R?;/E<=]5'
M)3,9Y>+IJ<ZOULU]US(&MX;9G]CG-W;W?F)_M8RQU;D?I2<_TAX5)9FIF$4I
MK1?'7Q&]T0O6]*S(*HJ!'$PWR[4AQ/%9_8))E(0*:AM!=7+Y2$FD$\OUC*--
M4KEN$V,FE.O$1_MD\I'"7J_+.^#'[QL=5(,L0*T6A-I3G7;;Y')F^V A3+Z*
M*=5D"MK 3\9BBCK4*L'0&.XZIQ#TLPU-T_C68NFC-829%VU%F28FB:*ZJ])?
M)9(70[OI^[<XWR(\9K'73-7QB@,!*?*NW^F*(^<5<T&O-32VFDNZ5Q7/:'A7
M49]N)')6+<<X>/>29([.5[]OI<N1^B%&9%L0K8<^B*^ZTRSQ4O(M#1E:U1$*
M)H_2L0=1#]I$%>2A9,8+Y+2E?23@%G@X+FI"UI'T(EZ'5DOD[^,Y)!KLPB5Q
M0;(B:;>\VO*:7)Q,7\%U!S12OL(T9W(-0B^\#]!C"/$3E=H.B+.AA5,#Q_.]
MV.MD!17MKIH;4<UN7(PVPSH:TKA.>_#OQ[ITWO/K8H&:[O29<[AH3RD@5+3K
M;WS^0%65H)U38_)\O1;?=),B/M6E207-Z'3 B2FJQ!4J*6(U2X<J:$CBJ/<-
MN*:!U-E+-PIVJ\?[DW 3Q-O:*X/IU'.@V*]2:CEB1;ZURF>%#I&I[JF5@=#M
M"A--D64!%XI<*U4/E!VH]#+NF2L1_5S7?0BG*[_K33FQ, EB5?=B#HYYR<JD
M7ZPZL_+*5J J+4#%.9M7+*J5.9N7JT;%*4:U/:O79.&=W6D4V;I4',$+I;?V
M#B56+%+5KOB95&EZ&6#-$;10@2LK:%RXRA@,XT)$9F=B?[4G?RB1YSI??FM3
M4HTC6K$.5T&TDII<V]IJBD^8;C/?R1-0R8F'O!9,/QX\SJ6EST/]!=VD*'1\
M2Z PPW%."M0UD.IL3CT"2:=^:AU.FSQ10^;'3"HU )KV&:CDEN:N\GLJ&S_D
MPR72(-33!)!(7@/:Q?<8W(H"" (R-3$@&<U+8:5OU*<)N'2.]-0,J:9IE1$,
M(>%D3O8"-_ )^BC>Q:5K2/$CW$)B12$@N:\K?X-<2AKMYM&T1BEAVW071+%A
ME!R)D@11BES56<Q#<)07B#G)JGT8NK HX"RV2]L__*CH)?5VEL9LF34.-_T&
MO=D\@J[Y1(QSEB1S0UJB8(+2Y&^<#AY,DP!%>$</$]/:%<Q=?*$4=787_YME
MW_TZ(5MX\ZLU,N\LP^X/[R=CXYYNZR<#HV>9X_N197PUN_<Q01++&!MW([-/
MZ5J.95@O9$7MA7"(B>$0)>Q>#\]$;3@QC?>% M=9;5B_6Z../;:,X<CN).(2
M94S,_@T]5IH-YBB/;I1;=_*.E;F*Y@C3S^6>J!EG-$/CL.&>#D?TPK5$D*.I
M\53'.HZ0ZWI=E$PZZ-',N-I$/YHU3V80I$DTM8^&U"R\H$1T$X-I$'UIU()D
M%BBUX*71MJ/6F4!80;F)P125QF[0.FJS0Q%".@6F3MT0=0Z"G;2QMELMM<#$
M(. ?W.%0*(J:-3EA(&G!Z_9TTH!-GE%%P+84JDY=*4-L7W(F9,UC1MI7_<PR
M-,I*^"O#+2?[J81 #U1-?T4EW8LGI:&DEEP\FP%5]]S;W<&WJ$N-@[^5HIM#
M0$_CS6'D.:6/<K\OOHYW;*C3^&%OT-?0YVOH\S7T^1KZ? U]OH8^7T.?WU_$
MZ37T^1KZU,(07T.?KZ'/U]#G:^CSI!![#7V>*&[_7J'/+GJ&.-UK+GC/AC4Y
MZL/[[\#(6@UREBE0(K)YPH9ZOUPJ,-3<J*^&6H<")=8O+8?@J1CGCWF1)8K2
MOK\J1-EI[/R\Y&)T637:!@]-=\#2BX#O_24M2N$AH8XYM"=FU_XG6P U\\KV
MHH=$]+ZDK:+9<,.)*%*>:Z=/9)NI]OP$4BJI_E'D#=O)([YT)D!!_%09/Q[,
M)U,7V2U'@0$53V:-8JHY-D7!*$9S17%-*5TC&0'TBS'6 8S6<;ZZP-/TAN\I
M/;W!_RA.[[T-(LF"++#I(E2D_T+3AZN/^H/ X)J)Q$=E3[/2,G2#:>8A4K[O
M9S37V^=S9=2H$FSQM5A0_D"LZ*.IW)&:]0$?%W2<2/JM&%3!J_,JHT$3:#77
M9T:3.>P!_ U&F^>XS1F&4%@Q5DRH*@1WZ!>'*@O' NE]S;FB,3U<^KA.'/EP
MA9TY".&6(?9G1XFE:!^N5#W2=3Q6%01D3JT?:J[T:[T0+H@4'; 4)/1R[1ZN
M%)7ZJ $(AC!,I?]8RS(^A,Z;&7JZ<*&7^#+RCYT+(S\\=.$,^%80$?-@K!%)
MJT(C35>&9:PR?44[^DU88<812)/]%BVOV3@:0PP.FUV"U:U1+9=)E;7>ZJKG
MU\YO9,AG3$OXD-FN@[K=#G>B9A.TOLIA62N2YI:Y;*G9"_Z!\+<GS_?YAUIR
MK=I?BD@HM)1']FI"67QJ!'WB/-PAP-$ZZ[2OU]F_\",E5?K0U$D>( GSF] !
M2E&,OJRMFLC( 2IG8Z9O#N4X<+1TV,T!J&D>Q0Z>8$BZ%06M]MNI*L7(^2[R
M16L+[+)T7\\&[* $_NHQ]%P/X/48;%\^$"3OV21Z>R&AK$5@/BC#9<=A'RS(
M/S-3@/ ZB02MHG2^$ %461+]?%*SV.GLL^K'5U.7-<3>$YEQACYP^ 'ZE*"\
M_<,G14=CY3^K_.-43#%8&'U2E@NEQ@C_7-'S)T_I:VEBQU9*H+];X\A9A.2C
M1H@(YT,VB3H7QM.V$!N-_5:-\.CNI6J 4%/7E.-7Y)E*FS]<_J3(,PF_%RXX
M6>Y9R%S^5*]'"G&4@87\M(.$_/# JXY!_JY%/0NNE]EGDKF#;5VG3,/>,*SH
M9%*IOE Y:RWY@!K5J>6\+J_R-N=L@=9[X,5;K!8\O>\U>;AJ>[? L%;$XX]I
MT9]JR8$?>50X?R&/[18Y1 _O5-W+E[U,)&2>A9*R14N!8SL,5Y7P20A.$)LL
MX\PUBS:X9 HL5@ G0W6""!6X9TYRZL)1< HQAF[%68Y/IS]4,OPSO;U.8(FF
M.S;-:8(D,^DI2_B7,2PU[PD(3Q,JZ=E/6:ZLXX,P'$S3:VL#/**GK38EC<?0
M66&B7AAV@.]#]WJ=M@O3AIR \)$=ZX]W+0+J%V8N?QUQ=XKZ>KUK,@3K^-+(
M,\!N<G+=#L((K^+SUX-H#O%D#H*TCG0?Q3E]Z.;>'(R?%+PA2K\%'HY?&^0$
MW#3@3G_+U$=+[42\M##OS%2?4\X(4G3)[SLHB#!PHA7P)Q!7KP&NB,U_9X,_
M6%TLR_])@]WH$. !CI7KQM_J$.)8/5*;4A:Q_E8B+00S':^N4@SA.5GVWZSH
M-;[D7>)DC=F'S_&?N"5C9.CU1["*',QPD,)S+\B!T UOB?R44Q#05S<R5LG;
M' E(]<=.4@0F;&K+7PJ##*<55J@0/55W!"G#8US?3^RFF"2GA4@)ZTQXU&6&
MRK:_N1>%\GO>RXKA E%W^L-ZA%A,R)7%]C:,FH&;<)I9'=.E+QM=$:7^0,I)
MP,1,67R/[-B)9B"96XC9T:T1W)2"Z*"04]663Z<_7C+\,]%2&WV+IP6!DXO;
MZ(]"GE>FQI4%A$HG:+E$K8!2?W3D)&!BIBR4P=@&QCOYPW?#^^3ZHU=!#":$
MAT8T&%?E-]F/$0R!#S-[.QJ6PV3%4[:!HI1B0HWQJ"( \_1#S:4A-OQ03KR(
MLI]L, 3ZSS<_$:V7L\W4=<UUK5A<3- U3+[/^R4*.A!'1/ .(E-K'%JN"(6@
MMQ-%2DHJ)I"9V$3+!?Q7BP7 Z\&T1[I<K!9=",AV+DDL;![,W?*=*7G_OE"]
M_[[7,T=_T =Q>W;?[MWWC*YETG=RS3]Z5G^2>0VWT>+]6UC"N-)*$!%_ @/'
M@Z%,)?\/A4K^@U[/GB0"F'WZ,$%_8O?OK'['ML;Z%/8?8N2N'&*YX-'SX^JR
M&\'7!6LN#<I*4"N+-;-X$SP'(*;4YH& *O 5H]%2^BG/'S3]B(#@]/MVRKV#
M:(;!<DY?QV9?D^$T5W9M1EK_2$8,)E:MHI)8:Y8[Y@U *@Z[>?N7;L2Z13*,
MU[ZZ50J$KM=U:@&KA<L\FPJ!8;3$"5[T7QFLR$\/';,,%?*7CMGVFYM2MHWR
M'+8S]U1P_=R:SOJ7E*_J&?AB,&>D?[<JY*]%YK]K>+7T5<V;0*OE5B?/Z \(
M<+S7EZLNSZ%0]*!T#06R!4)I..-",)AV0< YO;-KHZHRWA%[V1SS+ "4S8F)
MI03NB-@)\--L+!N+TN8G" M;CKJ7C(SY:D2V"8.I'3B8<F(',4.CS$R=FZV8
M[4])^6)!M)N@NC ,(1R0)3*@XL7<)L?/)\B*([F\CT5$>TK@51.*Z?=5 ;G/
M\59R-GH,@A.$C"<)"R=EY]C*[(NF+] JB.C<4>USRU*>(')2(K$@5':L;9-K
MNT68X=$VFMEO>(( E4G PD/9P;5]^]FP+#OS;=J?(#H<05@@9<ZZM9RU=N;0
M7='RI43@)X]N[HE1D7426L )>(&\S/7'0N:Z\ZMU<]^U:.IZ.!I\M<?TS?;;
MP<BP^YU!SS(FYN]62^GKG6!]&-VDU_")1":9VKCY^!]Y4O6MB7%CW5JCD75#
MI3',\=AJ*R-?1(6;@?\I+T@I",H3[M9T"ATZ_E8\ZF)&T$&!0[X\D.I.E'FO
MV(V:*5&&24$NOD(7VB3E#X(X_Y!U5=6I2=-7,(:M(&F%'='S-:SVRM(RU2')
M/^C 4X!&Z;,BHZ(ZOFP*-2D7@:I%N.A;8[D^:'1.E]0"7ZN)D5M(N@4^-Q6R
MU^:AS(9:6.<+C1WQ&&9^$/6_DQOQ'YO+M'@H U,S5>;99=JENC,3X"6Y/2$X
M*['?[&2=<:FX&D7$M_R)YO="0T6''$KUR="YOO[U4+7K[$T/@*95WVF]+#U,
MON/),YK,T2H$@3N9>SA:C[T7P:/;(D)5+]>S+!U59IZ9.:C9X]I!JA:8,,Y5
M?'GC!T5/STLHF\,P,ZY?LX*9>-\2)W:8F>\H'SYJJWI9[IGQ_'9/L)_^O8*#
M5T:'73"H-]7\>L'@]8*!\G73"5XPB'/5>)U EOZP0RS]Q8/=+8$G_:/=;3WU
M6.6VP3Z7S+RBLNTSK3F0E-ST??1,*[OEDW"=.3UD:@?F@HK"WEE4[>GA4M&U
MYSK2'(<)RX)?V;9QEP)'8=@!&*^G"-/JJE+Y_SS-22,J$DO?;(?U A9>$ MY
M T,'>_%Y.XG(>CGA2:,H)9MV0;/[ !,I9P%]O8/P?@T#HNTHW HSA 'P:45Z
M,W#MM#26Z3B86];RB$Y/V@2.EEMBQZ#J\,\(+A&.Z"8H78#0R8IS2.83[Y#,
MR!H.1A/SFOPTMNYHQ0>C.QAG#\DH*A'%JDI25@^JV%958:NRQR0Y'.MV^*-"
M\:K29S-/XQC'3DHZ"-6RQ%D.!I&R2(G4\]@2\FJWF"EP*W=(@$FF\A '7_-2
M6.F;;FH"+BU#*LU VG*:BJQQR))G!$-(QIF39<\-?((^6@HOP<J0*KH-*_?)
MH.JRU#TU,O-6"3M#B$,4!-"GM6W95\N39!";1.VQG HP"(5@3G;*?%.YQ0@O
MPW+)5%V7D%[EB;G7+IAU1W9Z&/B$8],E>W\OC)(#\T*D!(3:8R7#OW8KOOBY
MIFW0+9E'4H;[D!-FYM-ICY4$^]J%IPAC":,TVL!&9J^9]D 4N=4O[I.L2NU@
MBO B#64*[Q-]>%N(^:3!';M_.QCUS F][%5VK:BF*U%[^3WHN(DLPZ>E]0*=
M%1VJ0R":(>S!<!#XZ\;'-=U_K<*D0FKSX]F!ZSUY[@KXS0X6OX$7E^=I7*0)
M!K2D?+;^S&[0](N@_WD$(22_^7]02P,$%     @ TCMM6A)I>L^+7@  MV %
M !4   !I;F1P+3(P,C0Q,C,Q7VQA8BYX;6SEO6USZS:6+OK]5MW_@).Y=2JI
MLI/LG>Z927KZG-*6Y1W=\;9\;.VD^Z1.I6@2LCF;(A60LJV^?_X"X(M(XI62
M""R[IVHZWN):P+. !\#"V\)__,^7=8*>,,GC+/WK5^^^_?XKA-,PB^+TX:]?
M?;X[G]Q-Y_.O4%X$:10D68K_^E6:??4__\?__7\A^G__\=_.S]%EC)/H)W21
MA>?S=)7]!5T':_P3^HA33((B(W]!OP3)EOV27<8))FB:K3<)+C#]4&;\$_KS
MM^__?(_.SRW2_06G448^W\Z;=!^+8I/_]-UWS\_/WZ;94_"<D2_YMV&VMDOP
MK@B*;=ZD]OW+]]7_E>K_D<3IEY_8_]P'.4:TO-+\IY<\_NM7+-\JV^<?OLW(
MPW?OO__^W7=_^W1U%S[B=7 >IZS<0OQ5K<52D>F]^_'''[_C7VM10?+EGB1U
M'C]\5\-I4J9?8XU\"TD>_Y1S>%=9&!2\VHW9(*4$^]=Y+7;.?CI_]_[\AW??
MON315W7A\Q(D68)O\0IQ,W\J=AM*I3QF3/BJ^NV1X)4<3$+(=TS_NQ0_! 6.
M6$8_LHS>_2O+Z%^JGZ^">YQ\A9@DY8?2KA\[:55*W[D&>X-)G$6S]##4?6U/
M\&G;(<41!K3UG9NPS(H@.0A\6],Y[&M\6(GO]=R7-.WG\6$EW=(<!78A0AY<
MO/)R3=B/5_2O#D3\4M !#$<U2):$I@?F.?"!H4J[23T+.^DFK#?/B&@[&QEY
MFJL@O^<);_/SAR#8T S>_^D[G!1Y_<LY^X470O7#[VQLQ&N<%K,_MG&Q8R,W
M]0'2(I^\Q'F=%S?TKU]9ZGS7-X1I3TAM34!"0Y%4$M^%&1W0-L5Y4A9^J;XB
MV=H:2E5^F:7"[\E]DT]9Z!2*PJ".&,%YMB4A'E3G;:N&E'"%<IU0+>;$X?3\
M\]U7_Z,417M9]!N3_C__\=T^!R\4HXC667I79.&73WA]CXG":(F<2RHI8;;I
M(PB!H8P*69\FI1SB@NBW4M0_1R91%#-7-4AN@CB:I]-@$],16,L7@XY+[EC!
M;_-(JP"&4S8H^_S:ZR"F1*=(J%*#P[9;7 1QBJ-90%(Z#\ZU-%,)N^27'G";
M6')),(S2PNM3J19&M30<!DW"<+O>)LR!712/F+!1E^!'G.;Q$YZG8;;&^K[+
M7M]I/S;4K$Z?9JL,AHU#$0M]W6(Z1Y.B(/']M@CN$XR*C/9ZA'I?<*AZM[W/
M\1];YDP^T?]9TJQTOKU*VJE7KX?<\>?EHF HIL?7)]1>&G%QQ.2A^/$]4[3]
MFT+6(XG4_994$"J!M/V10!\PG1#C\6(U(83"Y1-;31>DD'7)'2W<-G>D@F"X
MHT,GS@L3JIV1H*!C'VKIH""-.O_F0R4J'@/JV7>43M-/Q6E4$NC=^W*7X5_F
MUQ<WOY?+&S>T>!Z#'$\>".9HY+Z[E88+0@V SFAE(>Z=7/88%2M4M1;:J\'I
MJ"9I$4=QLF6$OL/AEM#)+,YG+V&RC7!T22N5.8G4VV-SW,6JGIG<8'+W2!V_
M#SMY IKN;M0<G4X>QB^ZSG1CO.R\MS%W-@I3FI8"VFM \4%GZTV2[3#FRY>+
M#3-;ZX=JY%TV#2/L-K&5PF!H:4(H^*6,C.<?:)\?T>GQCGL1+8_B#)5IP!D%
M?@T8.OT4IR?CDDY2>&T*=03 T$:&JD^52@8.%2Z#F/"#0[0SS7-<3),@UPWG
M&GF7%#'";M-%*0R&.B:$PC#&A!"7@C)TW9!L@PEUFBG08I)&S!O>K$T+*48M
MEZ2R-*%-+8,*&(+9X>S3K-8Z0UR/3Y4;33A]F-*X#SO#<K"5)@@*BJ98T7"O
M!I^* M8^':^R].'\BGKN$5K2WV.V(U'VA*,NS91S$$QR"I8O#BU6JSC$^@YN
MD*:SI9IAIC1+-G9JWADV'*OD]$BIS+NZ<B6PU!^AWU/0[7)+9[G%ELAW6.4B
MS@BD -<PI?<=!B7DH/IUWTC!&=C*/=KFM%Q]X%TSH&DU7 YD%M#; YA&W#N'
M[#$*"P.U+,I6J%1'M=H9^A D[$H#% ?^%N>8ENPC[3<O\!-.,M[;S5XV.,WU
MISVL--V>)[(VI7NXR*@&AHSV6,5C1Z4F'^):NJA2AM/]E3>P$FKB)%K':9P7
MY4Z<#2<M=5VR<I Y;5Y:*8)AYA"T?6Y6NN6>;$<;'CO++0BVZ,N\1HJ-=^O\
MUWRR+1XS$O\#1Y_3")/60C*;]>0?=K,73,(XQS>$^I:W;*58=VAIC)R<GE49
MKZ@Z)UU.GPV85C6>;<(V=B6,N#3BXB.??1#@+5+-[$<K[N[4@QGT_LB#6M8[
MP2P!6K&$*HT].Q:1+I^S(5QIB7ODB@!:PY5&%BI7^@"MN$*5/'"%R@_J63H*
M/ODB M<Q9B\-EC,"1#O6,+6Q>3,IEH_X4T"^X&*Q6F$2IP_-62XU>6RTG#'(
MWH2&1F85&%RRQBELFA:4/AB5JJC6W1_3&V=JD>/PVX?LZ;L(Q^6L@OZQGTS0
M?_Q^A1^"9)86<;&33 *D$BYXI('&."/Y[)T?:DS"5A*30J78N,[MS]-?@SA]
M)O'#(]OMFF975U-U)Z*3=M9YF"$WG89:U#L9[/#UB?'S%.TU^#K$-$-4"<ZZ
MPRWF-[IN E+LEH3.[X*03?7H-*_]1;.<,"0!MZNV0PWK+M[::GMGYL&0Q:5<
M+L9I>IVEI/HG4P-TJ'6>/N&<)JM=K^T+N=VKD@'L;D^U)< 02 JK3Y):"$X/
MQNYQQ5$<D-U=D.#%BB]8&2YM*N1=W[C3PN[?NI,*@R&/":&PF4FEV#YF%5H#
M1M]"YX9/M,^[28)0/3TS";L]X*4#W#W3)9,$0Q\M//$@(1=&C?384_B_9^3+
M4YPDFL4>0<29?ZT USC5O>_>JUP#JE_1C=38%7S' GK>[X9?F[14=$:&088T
M%+'2@D&<(5 E!VB8+G)PM5*YADQS3!_P--CHUHT%(8=KQ0J K?7AG@0,7JA@
MB>O I1R+LS2R#YN3HN5TT'_M'0[ZC]]5^_2];RZJ7@J'U7CG@_>*EJ&1'9*+
M\R(.@P1]PD&^)96',**'::CH3\%+O-ZNI0U>\MU5A4MAU97>^0BBXF6(^I5?
MR?AMU\TQS8\X>R#!YI%Q4='.-;*N:&"$6U-"*0B"'B9TXMFPO=@8G4.]49,7
M&U*RA?W58@K]U^_32=^2^E<GM=^%P.NY_,E_C79P"/<J)E?SR\7M]7PRDINV
M?,[^C@-RA=N^I=IATXH[<]TL0#=.G$;6>]U; NR3@IT 82J(ZXR]#WOX_8ME
M\%*=L--NJZB$W=^Z4 $6+UST);U3R0J>N,+-;U90:?3_;DF<1W%8QEL8<U_W
M$D?LJ++FDE97P-T5+1FP_06M]E?OU:V$)%S.*F4<K"H5FB7#SF>7*T1]4.UU
MH +4,J$(2'HI"DX?3WN-\BD/7<B^KHS34'TR>)T0?6T![QS0H1+&?]I?ET)C
M'R_?Q 3/4^IO+!^S;1ZDT?(Q)L7N+G[1K>F9M1PN\MF:T%KU,ZEX)\LPG.*Z
M(%-$\Q2]__Z'?QU[9)BG$5[%:5S@DK)JXJ@DG9%%#[4AB%P,!BFTV$3WKQ9N
MNI.Q]P04E+V,G[2GRRW4_'<IHA'F/F6O X,_]D"UO<J?QST2'&;;M""[TDNI
M_K%W4*H??I]?]2QL?W!!%Q$((\3^5^]5+D 1>HB[V\GL:K3>H, D#1+YC6Q=
M=V"CY[ _L#>CU2&8E;S38RA2L4LH59'RYOSHOD<)@(YN>9:F.)EFN>Z(@U[>
MH1]BAMWR1M3",!AD@5#T3"KF-#J(*_FZ:3+-GC"9W+,[]6'1LU'RW=4M$RFL
M^HY)YZ-W)J@0B8&DJ R=UE92KBOZ(@NWZ^H]#HD%W<^NJED&JJ[E]C<0E2P!
MU*_C6H2_8N*X@B<TXXAE?ID$#Q+XO>^NJE@*JZ[CSD<0E2Q#)-P:K&40$_)5
MS1<X#TG,8SKH[.B(.:]T"4BA[ELRL"@@ E,SH27KJ6._Q0]5:!SV*&9UD$+3
MC2GD77?]6MC]L4 J#((T-@B5HT5;"35:GG@T2=,MFQ1M,J*C3U?,-6MD(/MD
M:<N XH@$F)(:I2PJA3TQXG]M T)G+<G.2 I!TC4O%%#[U.B)@6*'')N2((VX
M7X[PRZK\&5PC2411Y],-!5AAZM&3 \43!3CUE*21]\N4NT><)"QB69":.Q29
ML&NVJ 'W^2)*@F*,$IZ2,UP#52IP:,.?>KR@;I*EL2UYG^018.OXTPB#I5 ?
MH26+RG<ZF9XG)I4[PM3-)B8."9*NV:. VN=-3PP48^38E%RIMNNYO'^2S-+(
MBB*-G!^"]&#*Z5$) 21'%YF)&C.VT^:/&)=Q'O(='XKEDOXF"\ZED75-$"7<
M/DD$05!$4:%3DJ54J#G#5;P2AMUJL*-+2](/602H<JHT8@")TL=FH@F_<^*#
M)-,M(1W4ZA%'+>IL4]8 MMF?5<B!((H!G+!K6XIWB.)I!"I#$U[&";[>2LYY
MR$5<<4,%KN9$_SL(+BA ":=]RIB03 Z5@EYJOMXE2(OK8"WK(>1B;AD@!]EE
M05<&$!.DP!1LV,LB)NR%$5/:,Y$@8:>=7_X3[Y1V"7)N.:& V25%3P@0*^3(
M%+2HA!&71E3<"S%N2+QF4=SBT#!4B()NJ:$"VN5&7PH0.130%.RHI-'=?.IS
M)%D&+_.($C5>Q>7+8P:6*.7=DL4 N\L9A3 @ZN@1*AC$;LAUM7P2B5VS)INL
M==QA6AZ\GV:1VD,Q:+DEE94)76II50 1S :G@F8=U;/R3 K*"*H20"P%+XR;
M1!$MJ+SZSU6<XG=*^Z6R;MFE@=OEE$00$)/4Z!3\J23/ZC\0TV&/ 0$AS?L!
MIK[W3YKWMJ1Y#YHT[P\AS?(Y T*:'P:8^H-_TOQ@2YH?0)/FAX-(PQX%\DF;
M*?US09;9L^QPME+2"V5$J%+"[,7@T47 9B(+4V#^#%/Q21/N6"W(#<F>XC14
MN\PJ<2^$48"6LJ8G"X\Z<H F_C0.<:WGM:\IG7)C(ZG%_/0R79#R+J:ZM0V.
M)%U@QLZEE/9)B9LL+X+D?\<;[41<+NR%'E+ 4I)T).%110;/1)A2!U$E'Q/K
MBJYL0T-ZE:SWW=T58 FL_17@UD<0)) A$J\ EZLGI9#K:F8<)3A0] C=S\XJ
M60*JJ>/6-QA5+ (2:IBW:RKCHR%?9>R,U&.6J@\(B"+.WHU4@&L>CNQ]!U'C
M"E#"TY$9/VO&Y#RMQK\4.,WEW7?KF[.1O0^G&<CK#R!JMX]&%N6%?W=<F[^2
MN* Y3[/U>IM6NSRR<X,*.5>UK(59U[A4"$3MZY#UF5#)HJZP8UK<94D<QD6<
M/GRBDT\2!S*K9$*N"*$&6+-!E !!!24L(5!M(XAJ2<<DN"&8D1"GY:-I2YQ&
MF/"'JR5VZ81=D<(,N":'6A($28SPQ!?N\'G8TD"E2OG,N%_:S/-\B\D@\DA4
M/%%("5Y!)$$>(IU4((VD*A5]<NL.AUL6CO_=^_ME7"2RR:4HXFQ,4H!K1J3>
M=Q#<4( 2HF6S;^S]U7?OO[[_!M5:CJO_.EN2(*)#XMUN?9\EBNA34BE7)-!
MK'D@$0%!!36N/ANN,U2)HE+61W2J#EB).;WOK@@@A557?><CB$J7(1(:?Z>N
M/77Y]4.,B@L)<C'77;\,9+_[;\N H( &F# IJ411\RRFAPL)^R'KP>P$/'AS
M AX,3L #1"?@P=8)>/#F!-39EB%":+^TN$_BAT 1G% K[9H4&LA]?DA$05%%
MC4_99S0J:*_C.J(E#W$V3U<96?/\+^D?$BL5<LYB6NI@-D$M94(@.*)#)H2U
M+(/.M801DW;-BVT4%S@JP5S&:9"&<9 TX1%E*^)F%6=LL03?$,<@#X-#=B %
M.I5J=2S#1G$?ZM+U4GIY .-7G"3_F6;/Z1T.\BS%4;F6(MLITLN[/3%C@-T]
M-*,0!D$G&X2*HS-,Z?P+TT*U6K42YH5)OV3)-BT"PN^2$UG/I)!SRQP%S"YC
M>D* F")'IF!((XQ*:3\7M,OH$8V3Q3H\:0@8O;CCZ]I:T+U;VU)90)S1 E3=
MX:YB?NQ]XU++TQ7+ K/W(N(G?!$4085-::]*W/6E2AWH_FU*F2P@"FD!*N]/
M-CHL5$Q0<\I;R!@RI:[60Z8Y)=Z3<A\X1H HQHYI1 #10X9+$T&&H%K6"Q?N
MUD&2?-CF<8IS]4#4DW++!2G$+A<Z(H"X(,.EX (71;6L%R[,UI@\T.'M(\F>
MB\<J/JO2-H6T6VYH(7<Y(A4%Q!4=/@5G:A54ZM0A=?V0YV4?4+R,LJBV5"+J
MF#9*L#W."'*0"*,")[ EP2%;;[G."K3,T.<<H^(1(WZ<-:*_MR+!E^GX>FDD
MY,]TEEYY&@5$1B&=L/-71Y2 A;='!$D01#+"4[]#TFB@6L4Q:Q:4PZ0]C^,@
MY@5>*V\[F%5<,<@6?,TCDSP(-EF"['.*JW4GUUP1,4V?T8S:P>W5+EY'R+%G
M+ '8<XQ;$B XHH2E<HO;;P7XB9VWO4_B\#+) O4J2T?&<<0\$5XO6-Y> ! #
M1%2J$'E<$'%)+_7_(4B_D.VF"'<W) LQ9J>L\J:W,JV_66J[Y<P@D[ILLE(%
MQ+,A>!4,W">!6FF<M48LGXMY[- XB^:6A5_N'@-:@(MMD;,1E )3KX)KE1QO
M+U@8T-MDT&@ HIX%3-6& ]=$7/4,E<JHI>UI?I;OHP#BZ,/N%J\P8?<.EOBE
M^$ S^J*985CHNIZ]69O3G\P9%4&0<"A:U50O1^T$T#T[(U8EX9B'\W!%^-F1
MC$R* M/6P,\MR2\8Z(1=,<T,N*:66A($EXSP^N293R]O4:6!6BH^[B#LGP*A
MG?&ZF!&2D6E&1^Q00Q\;)??/L9@,$%]F46F H)4U3,U[+<+9,<230?MTT&\L
MI?_CX[1B1A0W(3I?G9Y![$+J'#<L/X%@AHA'>HB0UK.'NPU5UI<Q6<]E2]2]
M[XZKMPNK5\'E1TA5W$&DJF0FA.87?NJ917-17%P0)!S7=1]:K[;KSY#JNX=)
M5>.UV$FK?!7D]QSM-C]_"()-6>\X*?+ZEST!JA]^;\:5Q:H9;&ZR<KML<L]>
M? G[JS_#5%U0YA!C&)>&Z'DGV0%@A6LPC1.1K5J^1:V-?JOU3^M-',++29[C
M(C<PL"_DDFMR@&U6=27 \$<*2^BGN! 0%E3KCU9D$&3=<T(!5Z1&3Q 80^3H
M5 \&!ESG)^^,F0;YXR2-V']F?VSCIR!A:SR38AH0LHO3AU^"9-N?L0S4=<FH
M0>:T&6:E"(9Q0] *#*1**$@C%+(_\%[=.Q=O"-X$<31[V> TQ]0^?A2@T[H4
MY6&EZ9*' TQIL]!"#0P'[;%*@A0Q381+U9RS,>/'/L).]^B=D3;<\\@R(Y_\
M,:?(BB"YLATT5<$+6"(P.7%-:V> FR43=\\4-6B1-*(LF)[' %",?)2>A\#<
MKAN2;3 I=C<4:4'[3C:*;]A,\QJKQSB=BMO!S0R^.ZJIY<&0R@*D.(Z5*GS\
MPK7\&4KQ:<]^'$*P!446L-,H5SC(\6W\\%@L5I_I.,T:@*((##HN*68%O\TQ
MK0(8DMF@[+.,2YUGJ_-MCLO^RS^Y]I[>OA=6F2R7=4HF'=P.B62"<,BC02<_
M1%V.=N@<17C#UBQS5&2H>(Q)A#8!*6(,SYNR'/+]>D\V7A-$;]M(F]+A3@6'
M"0A-M,;YH(2:"!"K7UOI0"KZ*@[NXR1F?1-UPOB1Q\<LB3#)F4-6[ RS+7MU
MEV09:E2;3K:Z8(:I@8"%QU+VZMROSEL)_/=_^??W[_[M+]S7/G$,PR.Y:K?E
MHE/PQ$>+S1>U-$3.#=N&2?:*_A<%JDN4^4VP"^Z3_9)J&)(MCD0;59W]X&2<
M#IP'&MD98@>F 8:G!P(7=INK9*@7S].1+*"WB.V=U]U9;VWE3L]BDY*_U0B5
M >KEB+X&&#Y:P13FEK422IA60[7=6<,^?A,*P&DMZS[3=Z]HU^]Y[MF,TPSK
M#JR[L0.IKVJ98+W%8]#QQ".[S1ZM IA^R@:E;ML'E)NGZ'3-*ZEF/0"#HF&%
MU:0$AG*V2 >,CBGF!TD!#Y)&#BIDO7=QUET;V 'S@+59H..FV59OA#'0!"PY
MM)2 1 -V53TN^#UA=CXQXR&A<!JJ::'5<'ITU R]<V!4+0YF##-C%)^@;S3*
M,Z)M'?3U=59@]&_?>*?9X'T!*#L!P];^7\%J_^#U_3OE>KY_S[P5HD-[[ET0
M<]U/R4#V.Z>V#!BZ*(#)NJ$L+?=^?D+_S_???O^.G5A 3TSG#-&\SKXO_Q_E
M93B48%L\9B3^!XY0D#,O^P*'F(6*0S^\8PKO_\3[L_ZO/_P%O7M_]OV['\Y^
MI%E4:<7LI8BH7%3=1UG1IOOO9W_Z_MW9]W_ZMX/2^,$[\V\("^)!<&0DOU32
M\=%Z%=3>4?J^&)A6H,8F.2I?2BK;PI]/UQ+2K,?>C+3)ZYVDDRCB]RZ#Y":(
MHWDZ#39Q(3QS;Y1VNMNEA]S9U)*+@B&M'I^P1=5((W[7(TY16"IXI]$M+H(X
MQ=$L("D+W38)P^UZF[!P1A=X%8>QRHFT471)+GM#VCPS:X&AG#54R09I+8BB
M4M([[41/V=JE]CU'L9N;P%H]4>*3+Z*\CF-&T@-5!Y[#@G4$[I"C;[ (9XG6
MN(8'_=1;:PIW$Y %X4$R(N[$WF#"HU.:)W]J34]3:9,IBMFU2@W,$&J/53<'
M/]O/."#QKPR%.FDF/.8R$#4\\4T%7<&SOCA$?BDPZGDE3%KA\8L_'&K-K5K:
M*Z^ZD+6<*D7A\JF#SXI+Y>(%/!ZI(W';J7AEE"(*MXT\7&Z9(W!+"09I3:R[
ME#C0(;-5]K>\.\0ML],$P\9!< WKPI#\LZY=EBZ:2<D? VT<-;T&4,99NFL"
MT^!Y;#*[M$Z;3L$WT]2NFUH:-,.T#IR*74!\.)D]9C?.J.6;8P9GSJ "FFUF
METY%.4A>'7MB8XV;\+.&PTU*:9<\,T!N\TLA"H97>GS"VQ9<NO7@ *"HP,UA
M]"I*GRE L$;>R]4"%6SIE8*^,!@^F1"JKQ#4$1+]'XV[Q3FFQ<>BCE[@)YQD
M/-9599!R^U:KXW:KW )^=Y=<HP"&638HA7A2E0[?9XKV6MXI]A&GE/<)M642
MK>,T9FVDB)^PGF1&+9<TLS2A332#"ABJV>'LDZW2XEP+.GK>Z2;TRK:]M^>Q
MT&H,A+4UKH(GWPO/A.$/#E=*9^\JRXUL:4MZX8L(5<J8O1A0S@@ A8A!]!-B
MA5 S)TO],^8Z2[.N!?IA3"/ODCU&V&T.*87!#%HFA/*PB3&7A!'']1H7QCZG
M)^.4+S)X'8ZT!6#U,#)H0A !7*"$?O;.@_H(;+TO]"'(XU!AF$+6)2^T<-O\
MD J"Z3]TZ%140<%3$"<\+%.1H;"U@5R=YT.T1RH7'7DT@,X.\SW+ !S9+N)D
M6RAW4Y32/@G7@ZRC7"4*EG1=?*/0+BJS\$Z\7S$+=HVCR1,=M!_P]9;=4%JL
MA*5]7>\W, V7)#W(O#9U!R4 AM"'H.[3O$Z#TIPG@E*>"J-RM7^SS7%US2@)
MV=4/-H%,Z\;1<!]*%ZLHDZJMV^XT#DX% -M-)EKP794$=,8;<(_'>2C].Y]?
M3;/UAN!'.@V+G_#> Z<#V6*U#%YNRK!(DZ(@\?VV8"/:,KL)+.*PG2QUYX\3
MG*Y(A.<,CD\:3*LZK3WRN7_83KY:"?"_^Z:S_!:'29#G\2HNGTB>1/^US7D(
METM*M,EB.K_,R%V08#KBXG!+RFA357$=4-)'Y@>E;9VDV&Q;VU&9N6E_/Y;M
M+\4/[ RJ=F5V9$/%#<MNFBAH$D6KC"W7%9B:6B!,)TXL:D&*U@'Y@GGC1WF3
M#6O-R38J1\P4RL*.JC0_IP0'"3M?^3.=O]&!_6,0IZR(%^F^Y"8DSNFG"_K/
M]('.%^,L.K!E'Y\=A(9]JD*S:=?'Y@5^6#V1@<*5BD?Z+S:THFV3 7J@22L;
MKO<V*BD<0S/3:CB^R&."WKO'HQ*'M7AO!BJYRM/R[$#T_<V9P25CO,+2OI#;
M4! R@-TP$&T),'V:%)88BJXYLLG%_)_7;!!=Q2F>TS]56WXR02_$$(!*R=%(
MP2-('YJ&)$P4<5DM4T8M]@-#L[QW6O ;[@?0DB.%K@_7X.S7PH> _C/T?VC,
M=F'6\]*KU>*JW^536XY8KI56!*EO<W@GRG[BFR\S1>@T;MM]D..(^2;4,>'3
MVUL6YR6/"WR'R5,<XM*III/@["'EJ>BB,XZ?K=OH>6X*L1N&;]P\P8R C@R5
MQO\]YVGRQ=8Z44\CZL #3&['4>W1-BDNL.>7>+675T';:P6<*=?XF7]1.[M6
MNLYCY-F:(_AF)D4P)!N"5K@71S^R(;FU72F<.ZE>1(EKT3#+BSK,_+_> XDS
M+]I?.B4'TE90!L!;A4$6Q.UI0F>N'.X(U#V5(QJG4<G+=^]_>,>Y.;^^N+%K
MF(NT[R8.U'7!S(/,8<0<I.B=EX>@'4Y+?L_J.2 DH%Z=@:/AT=WK,&[VFMXP
M<LJ4?;-3;9")GJ(F:'XJX8Y-4 B=Z/(Y.[@I<UW?-%6:,ZP3I8J@2:I".RY'
M([^=Z#!RRI1]LU-MT,!.%#H_E7#')JA-)PIQR^('#\O1LU1[\DF#\H -"WCK
M_SYVB4Q%K@0)?0>@V3A<K*9!_GB99,^F\#MZ%2_[NQKPTIU>B;SW;GD 2/7N
M+^UAF1+B6I!B/%WC@@&[(=E3'.'HP^YSCJ-YVMR?GX1%_%2>U=*S[Y"$'-\U
M/M#0WGK^P%3 \/=@Z,)1*$;D%2=R.VX">Y^N2<+_H??6!A5[')EBYF<OEAG;
M:4K#.,&=/9!E=IIF,'ZVGK901RU$Q1;J*'F":9".#!7?5FNR97=]29W9_NH7
M_97]S1 U=\1@-O(+O*'X8[X%K"CEKHC+QB,#UR9Z^SL84DI ]0G4%O'.@#JP
M0O>,@6XZ(!%V?KA*"5B880F23IGRA,E]EF/C%$N%\A3'-XY8!IM7=WMF_&K/
M(OW4W _87T&0+<+8Z3E;_!IB1K/N9:,$Y6[84,!B$%V[.US>>RLZFA-,V7^!
MR_^VQN_JS)0Y6+-U H[C-P\TK!?2V5(;S#@Y&++\(E/>\ZWR'!?E&WZM-_W\
M^UFBM3<$LY=Y+ZIHZ%5@M$D:\?M@$VZ'=='9)>:7ST,,UG/;)B4H/?-)K)#$
MT.>O.M<!.LMW[LL+]%O"+MOS7](L/6_^S=,#V ZXM?M)V##>RY4]]]L:@PQ]
MMD03/H\UJ"7O0F=;-FW>!#ON68B\;?7:H_FTRH'GBOW[ED5]6:P^T[;(;*$-
MLGY:=G>-^V[%25)TZ >?PO26AWQ,<MX]D=/9H'Y!(&%I(,(2.<]6YUOZ#]X3
M=SR4'9A8IY8+9$<OD$/=N3ANQP+6%>W!N&67%XQ+F%!9.T^?Z'SV!/MOVH0
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M-I6/'5:D*<$D]5$#@R295TCO4W7M;8Z#[+27CS&=206DV,W2!_K; 5VV(@D
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M.4)+,WX]#?R$UAI=Z+?2E"\SLL)QL:6559?,2,4OS>DU-5--49VR44JR@1;
M<SP3+;SG5:G,AMDT0B&;O";):VB))O]#4BH^7.K!,$"UX9$*^:3.]4 ,KV<
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M2-K($&HY=%9MZ;.M_)Q]\$XJZ<I.Y^!"\[%9SE%M]!V8EO<U/EMSC2M[IH3
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M\?VV/---9\HW 0QV3]+(KD),.C#;@1ZJIG'P!?Q2W%,E-?>XJH"*^J<D:B%
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M;;5_NJ)_T9_KG^C_L"UF^LO_#U!+ P04    " #2.VU:ML\@8HY!  !]'@0
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M Q'_*^K"0R(C$N2+1^*Z8N]F>2 M+RH/A/UOF+#+Y>P \%$TTS6?6N#8IZH
MX?][5^#/28O$P(PPZCM\2F< ['.%@:A_QD1=(B$JWD//@:)]+ K>_^"#G1$/
M">H;&MB6&_?HAO\N4,-=4!P*.<J>4RLF*NR_$8N!04\5AD*.L@W5B-@RX$ET
MRJDS2JLB+PV%'&4#JA.R9<R'7DC#O;C<.MEM'DZ.TW.L\Z6@&*-L.F5"H6![
M\#1XH;BSJ\(W6Q**,<I>4R4<"LX#+@^SW)'GD)?_('L5T+FB4*11]IA*\5"@
MGC$J8CH6U-8;C7Q9*-@H.TNU@"AH+ZV7D;@]&07B"I#TH$NK0+%'V5:"Q$6A
M0$1UL*V?<A</1'@MVP]\1VG2-16A=*#L-PU$1R&E[S@<KB#YSYAZY(.*BL+B
MX#,B/ (48G8$]H]FL'^$PXZR#]6*V1'8/YG!_@D..\I>5"LF)NP#_N.4+?UG
MR0FTM# 4<I2]J$9$3,"CF6;*HHC5./F/#O5<#2CTB%M4M;"H"A]/\A!M/Y2$
MXHVX72T6#A/GF1^$EOM?=*M;21:7AV*.N'%5"=JV@S'F73@M9*%$F2)0?%'V
MJH7BM VI8)@12ZZ^YR6@@*)L0(N$:1G/L2_./AY]3^F/S9>"XHJRDY0)U;;A
M%:'$@73HI_X,CF!#,:M9,5J&\5=&0]X#<3-JYR4^&LFIF*0H%%Z4[9]2O):A
M7D21].+*V2&O6C'.1>6@(*-L]N2"M8SPC!'!-.'+[BB.2]PU8-/52F9Y5>6A
MB*/L]?2"XB(_"H(=8:;X%]2"LH"R[8,*W;:=21(U?OCXL!0W9B16)E<*BC7*
MED\F5,O83OSD6M1BOWGP7?GUD,*"4(11-G@*T5H&^:P?Q?!FBD"!1=G9%8J#
M9!.&+_:CN(THCUXH+@D%&&6GIQ(.S?:N0;9W;6A[479\,J&0L(UCP_F(FCZX
M='V6];(8YL(*X'LVF(@K1&W[_EYTY2=U0?^&_U ,NZ0H%'"<*Y(J\=J&>N=0
MD74IZM(-]2S/YENJ4_9T">K:6E "<.Y0 H5&<>__2ESW/SS_V5L0*_ ]XL1+
M?96'7UH%R@+B&:)&7!0*OOCNCJ/$HD!0)AD#DJ)0R!'/#B7BX<1>QD'-Q[DG
M?I=&A;BL!A1XQ$-$M;!(\6DA$7VF3^3:"JVDARK\936@^",>**J%18N?9P/Q
M>(>O/C//%(2BC1@*6R@:"LB+C>6Z5[N >B10VI9,02C(B#&OA:*A@#S<$+;F
M1NV6^<_A8W*W4P6VI (4=,3(5J6H.."_G.Z1Q_??E,@7E 9G)T"$72HD5MJ-
M8V;K1?14().@KBH/Q1WU8J5<T):1CW)1I]=/46=&?-^F"GK0UX*R@+)=A0J-
M,[>F;O(KI]:S<E"\$3>F18+AW)G:/;C4OG%]2[DN/RL&Q1=Q%UH@%@J\5Y;W
ME>VVH;T760<)$<<GP7&T 39$P :@E"#N3XV@P'$7^)N-N$SDVU\7CUSH()5-
M7.DT4-:#4H-YB1,@.-(J*#A=]"+.U7XN4BV+,(4E>0FO^(>^JA=%@.I0?E S
M"H%A:)FFD;UBD</;9_TP)$$,FSR80%4>2@3*AE@O*%H:$#YP-^&0,9\-?&Y$
M;34#D'I0)E#S#>D%QSCM\ID\(.&L #A]'-H9UKDH.&#>4+8923:^F2)00'%.
M98O$P8%TG#Q2KP3U5 @**]Y9:UZD F#_\3[7^S'_Q>&OA7\\:\TXX7?Q4_9G
MB;\_]M[UC@?#4>9O+_!=ZHA)OI?4[R4-5%:0E14\1!3L@G=KR]HF^=+=,#C\
MYJ0NR2]^/W9NNCJ>9,_\V$FF2!R>5(?5KJ[Z922+'^K0RY MAY5MW C2\W$B
MD:0!&U2>B,,#=T ^<L71DI:KP2UB0"(J.A$#*W@4;PGQ_PS_V-$GRQ7[CGXX
ML!C;\XU@]$*:G!A@=;3LYR ._#(B=82_XI<CS^25LP>JC)9 O01W!FB@,P?D
MJ!P;]3MA2["APYWW/7Y":QQ++>UAU+W0#RTW*HG+V,3W;+-YJZ@&6N9V\ZE+
M+C#Z&)HQ?TM8N)^YXE%@SQ$&>RL62A.B-'NJ6F@9WJ&@9TV>'@)TGJ:\BY9P
M^$</+L[%LZS3U3VWT$)6.5&::FA)X<LQ!0(!GZK3C'F23$%1<7&TA/$EJ5$)
MC4X)G(W21-3OTRU'!("#RUPUZ#C#S$!OOB1X!;2DGIWGLV9T"OKHNQSB0,R@
MX5Z_N(.W@)?IOKH#R10G=&N9ZC#8OZ2J@Y<SORP#4@*[ZH1*8@&#F;47+_X>
M]^VVS7;<H.0$4!A3XY;P\O/#^?$KRM@1FL\7P(>.[K6DZNKAI?\O2R$,"73"
M3$9>E;'5F)?#F!C0Z+G@I8Z)\TI3#>^9@MKGQ0Y[N"26 K0UUU?%>_W B 20
M\>S@QKU0.L,!A_E,0@62E**_#EL*(A+S687:[>0KX$\$/=,P"JX5A[Q^= .)
M\ VQBD]E);Q7&^KA%X (NB$MXYZIP2'3P),/]7!V 6Z8U.T"70Q)KB3>TQ!P
M?/.#J$A:=!IF!_L,8:*P,-ZC$67)4,B,SD??<2*OJ^7.+.J,O(&UI6%A)MV#
MMT=6 >]%B;*\:&1'YV9.0HMZQ!E:S!/7U/JVO=OL7!&7>TU6(D6PG"9(7;PW
M*<HR!D<$G;R\;"9+ \S'*\J2(Y?X@M?GNH51^>,XS/<S:M^)*;&IE7[D*Q2S
M"-='$E([-5.<W:?X!+]/T?O+67O_]G:_HK%%/P=ZRJ*^.M$*;$98=,L8M ^0
M5[[<FQ@&V*!/IKFKX?U=^.@S^N=I&"OYRU?"OJI1#W$R,+I'6)3RTH2L0P7L
MJQIU$G4.0O=(4F>:D$E5)L]$@YOS^NAJ.O]$=?^)^:0&K8]]KZ,"CV80=8Q1
M^/2FJX=]HZ,V!CL[R15U4S?/J>I@W_2HF;&.S79%701->-J*V/<^:N8--NVU
MOP\_):^?KI*8"[ZSCLX(-_Q+C^+=OR<R]@-)GH,?5?OR4^,]?]4[-=_C0/3.
M/M"+OH"BPB+]TH8<NZK?FTLK( </)1=B 9D/%%60M]X:,F1!0C+1T>WCG*/'
M/R_NFE^3)^+ZT:V]I+NJ@P9E->Q]MA[W[ D#  5TKFZ)Q\5R>2?[SH9Z5(@D
M4KYKV=)6Q-YNF_(%1 *=L9Q<!B8/?U=MRHI4V@L^"3K*%!O^]#I#P6&Z,/:>
MNN2,E9?W@EF<^)Y_+IC69BJJ8.^QS1C5RHYN)2<DA(RN3#'L?;,A"T4R7O"(
M.L1B'!QK5U9 ;3EWDN+8>V@S#I4RHX^B;.^NJ;L+54XI:07LM G56,G(C<[+
MKT3DV"!._XD;X36)7S:8KG)>%\T(,FP&.^."&8>E,.HJLXD"&O@:C1M"S])0
M"[TZH- )CFXTG[D!3W,XG]"GJZ7U,A-O"'#4PY#1AUTH[D(O_3B^!^#GJNL#
MZ+D=#'<9]0+;:469$]NU@H"N:)PHN._\]RZ(;KK<<!#[T\'HQF<+RR7<WL4/
M%HO;:@D(Y52GXB?1<TW4ITRU@&^^3/\<+],]LA;'#+@.# DZ]QXCEBM.5G_Q
M76%U;RWJ"<BFW@F)/J,!_],U_Z>WCE\F*Z^9U;^(GB6C'L6L"WITLU<@FUX]
ME)70DVB8,0P X,+#H-/'KXI8[[,CUY_@1Z[I)O^/M?6#?^\E+6/'1)>[[ FJ
MCG4U)>G<4BRE $(DY71#,J?F34<[E+BB<BY1>G>$S 4?H$2\=ZAP>Q:5[1@G
M9QHE S_5_?1E=&0"8@42=MSWHLOG+Q3"17&U2Z2E6)+4 3V2-_.\6]?^AJ^1
M%+[,XN(=(T2E;%FO9K% J:,E].CQ.R)YF/:T.,H6Q8X+*<.$5&+TY;?D)K..
M%TTU[%B0,AR!D$#G*WN/64>4K#QV7$@9AM2RHU.3NE(NV[5KAQ6\">R0D%)#
MS!0A=$Y;NHO?_&25VR0T?P5_&SF<> ]8B.J]-#A$*W],UOQ4IF40< 1VF02>
M'.[!TI=,TY'T#U9 HIA^;E$B@N:$JW) 0[(@[(G:)/:!SHGMK[VH%4T:H>:_
MW)EY6*=>;9& ;O*_R7.XYI<).OUZ.X%[.X%K^7II695\-6=OEQDT"^9/%R^+
MN*6(;[BFE2.:!"?D.?J+TGT,JHX=%6NV\8#"T57RXK5W>?9R];'#9ZO2)P&D
M*G_4<V)2/GS\]"$B9C2YGL&&U-0K6NB+^O#JV!&Q>EK,Y,%@):,:QK04U4>/
M9:U$C!P1S/&R?/:KC)>H.GI(:8T#)H4'ZH QYJ6H/GIX9IT#ID9FD!W&OW_L
M0(!B!9^QZ'\M3L>AA[O?KN(S-B$1W^]2V/V&.,0-/1Q8P>.-ZS]+DKS\%1YQ
M*%KJQ4UAAQ@>A3**+"RHA>:!$'V9,?^)<EZO]O<!<4;>\09YWP[I4^Q/T<I7
MIJWN)&&5$IEW:I1$#'UN;-3=U-@2L@+@E^".2IWKB.>MN*31;+'TQ0&-9U.7
MG/5[Z=<V7IO_,O;9;6VJTQ9)Z-IX33A'-HT8DFO.>2GL(]36R/$5('2$OT-.
M@_,38,WBN: \]K$E$J=J^$JOQY\(>_ #4F5')7%9C+R0<&I"$9)'G*EW9[&O
M)+IG>SH)DW@K8%6Q#PO;5@0X,J_@5)OCQL3+I]<D_F\*J22B!)2H$MP&]LDE
MDE4QAQE]'LEW><;(UJ+BL:9(QY/\4\<GXX. A(H]1=GVL(]12U"GX]X$R-=F
M782$I_%CK#/%];'/:AO0$150F#HA785($8A>UIZ+U#'3%;>?D2A<UT]O;9.B
MN26>A:LUBGU67%XMZI"^(_,(? =>AU^Q P?1=7JK#)&[X$R$$F%'WA-?AM?C
MAE:VU9US\LJ.: !FZ%9A9NT/@>SV'SO*"'#;FM0'5D<_8Z_ D%]&8/SU00U/
M??@V(4X@XLI%0/F=%0KQ]M%;$:Y+;$&>2"KHLY!OTC<QEA$X"GVITBAZ.$!]
M6E0=6W3+ 0>CC@FB W$$M;%OCMSK6T\D;^S4LIY0M@55FS:>\*JXG@!@AFX5
MTI9-A*2)=WJYX*>D#["Y05(52F9C;LL*S,AG "5.^(S&*Y[CLUA<R.2=ZD._
M!WZ@G/.A#4#9;<S%6!^[9IA=]#H1#EH=AAVN)8TY&6O3$G/D+G@=("05_R>B
M8Y_XDI<O9>=\N<.HS158_(&/D/-?I$K&L<Y91]SPQ79W3O1 COUH>6LRYX-A
MN%H1U1JB[7Y U;7YBS+P]0<.5]^J<G.H8FBN:;#U \N]9?YN*]Y.HX'M>WQ'
ML"/.Z3'%AE3;N!?@B++7HM@E>;KXG"/?GG(;7%OXV"4_=-L8U:+@V/=;#N >
MPE".7AC/*5B)"3!</]@QHG=75&\9JH3-WTTS4\(Z\&SH9F%\9$L\\FRYTZT
M<OA"F$T+'Z\3-505H/PTYI&N#6P?)G"CU"R9Y056Y/N.ML<CKV_;_DZL*:V]
M.&$Y1.8,=HQ%][GB8W9Y8&6E%J'D-N9P;H+<&C!NB/U!M"V(^J/+C"BY-".:
M,6X%RG)C_N$F6"Z));JO<;';;MUHOK'< RXC;^6S3<R'_F(?M $H[<VG[H'/
MK(;HH+,9*]C2>B&!R(U7'%]V"M'*E85RU'SF'CA'<ID+Z&CV$G D>$#L[]?^
MTWMB._&B>_:T/=F08]_BZ[^?/__TXX<?>N]ZIQ+\'WQBZ#T%O1EAD:IY-DG]
MO?JMWW0/8Z6RG9,N\7^($X@O0>KSIZ^/%>\]\)J@BM7'!D""IZWLF1#1S>-?
MD1/L0R$[U_PS">I]#$2/+%^:VCOQ5OV #]6US_:2%R=X64G1#F">T8X4L)(^
MU_J>A![DONMF.\*7(M(,WKR*N@8^Y$JU2>&OEN-T);X-%D:>PQ>!SLYRY3J>
M+8./M$*YLYU-W4%N2:M//=!I<T%)?&R+->)<?0LZWJ[:]IW_7OIBXR'7VDP1
M?& 52IOI:^I&=4LZ>^R 1F-SY?!A+52%<W7-];I=9;TC5K2WEJKJ60%\1!6*
M>M;3U"7Q-M>[2[Y!N7*+H[Y2O4\5@Y\JUK[IJ[SZS4E;ZPY<C_K 7Q 1.TP.
MW$^LC63+(2D*1K_^4R\ECKZNXRAXBT^?5I+3U8K:A 4WGD;K =7 /-1_\*/%
MV#<1!(67&2$L.KR,<B("&%%6 '-1_R&/ 1< F=NV1I$/^M0Q+0O*"F 6ZC^-
M,6 !('/K8\%?BO"H:-6U*7+ 1LJ3*01&N_Y3$2.=+Y2M?83[=LCW5^Y>>'QU
M0!>6!>-=_W&$&=X*25N&/=HH\!Z)7FA-B[0P&/CZSQ@,@-?(VO:RQ_=X7R9<
M&9[6>MLB+PW&OOY(;N!B4R<I(O!13U*#$81_824P#?5'*)>@02$WA@$Z=@UN
MAN15X"&'33 !1=F'BH/"2IQ\6Z2KCV'CJ^%-%,-T35<KPB&PB98FTS; O#6R
M:S;GK1Q&K3LSSD7Y$D06.$H+&"=:GX?:'85A&V B&]EVFQ-9#B-T(H^9W8SI
M*ZH))JV1_7D=I,GQ0*<JMT(UIDS5 IBZ1C;U=5"GQZ=E"@L,@/!H)_X(#7O@
MRF#B&O$/F!-GB KZL(N"-<N..$EE,&>-^!CJ&&Q*5-H>9];#SK78F 8AY*1+
M41S,2R,NB!)C22<YOL63;H9E9<$<-.**J,6>83I #W;4@ EM)3 EC;@ES"D!
MHH >E-WHRR,?&[CM"W$2%7<ZAWCKJ>*K'N!+AT]Q23!+3;X04\" XO@>SVQ%
MJPD1ZZ'#NK @&.HF4QHJH5;(A^$I51X2G)< 8]MDHC\EMD42M7_L* _O.?X1
M#&636?.44&;D:!E%;:!4J?"H!BX+DK+!:1T(D_*]6ZX(24>N26 S&KF;=7%2
M@'I@1AK9U&K"H\!RMVZ/'2KZ8;D__O#QZ:1&VM,K;34P'8WL9<L-$# :;1MX
M+_"NO%48\,E&'\$F*PQFI)E#]G+QM&K).W*1<LBBZ]3*RY0_YBY3BN=M^,9B
M+]Y.Y2WX'O%W@;OO]9\MSH33.WOLJ@4M._1GNLK)DZ/H7.5@-5LY\XV_?^B0
MXJ9E<4G\,'X3%M('N87BM'T%4V042NY)7_/_RN].%!;$!U^E/BFP"WO?\D7,
MR[P"" 3X[3K@MW =,#V,B,AM3[T((C&F]&8C7P/WPE!)PPT!H>U-P7H=)C+(
MW329,KC7A4 @^M+.HZ!\Z #?;>P#&N@"T:2E<2\(2:#,+4RD8K:,^B+\.F/V
ME"T#-@Q"&J?+N2/AH^]H&(#5Q+TBI&7#1/RVG?"[D ]B3Z2=A!@@17'<"T):
M#K2"XIG[B1_^1HXFE.B&!*PF[@TB+1TFXK?,S T7U_?(867!%VQR[[2L+.Y]
M(BWZ:A$OZ, V(\CUCBS]Y!59OB(4J=GL:'TB-6A&#>!>5C)E%0(&[M"*>OB%
M^JX5/[?UB[\A Y$+D^W'UK,19^I6<&\Z&:Z3RX+4 2[YYNL/OK.E*VHGO5U:
M+U?$(RL:!D9\ZEO"O395 Z=0L'!YY0;$M;RD@Z/-5J1>Y!V.G]?5K%1*-H5[
M#:L255+&S6#$VP2 5CVJ\KAWL6HB3P_(!:V1"H2![O%RY7$O:#7'+NY>,#V9
M^"3@&Z(YB=ZV/7KLU7;6I#[N;:V:&#0'K"-GUM$I\Y)NXE<^%.?6G[+GUE'-
M7ERUY?2_<:<W48_'ZC-I2=%6'"KBT\& P\)UZL[;4M$'Q5&TJCS^49(2\[0?
M12%%V^?0EWDXJM<;_1%IBWF WXY(,2YMQ,.1?T"BV4FY3#%\N.'*72Q!K2$
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M@%XL* KFU[NX(RJT3V7 ^ZJ. )V5KI-.G)GO4IN28,;\8^A5VHGS-YT3Y]!
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MH1X-R9@^D3CM]U[E-]1614O<598_,!SHQ,TYDOSSPNA<DR?B^I&:)4%H.NI
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M6W]FPB/,Q]? 'X\'2B.AJH VK^; REL!O: -6=_??/;UB;JN.MXO5PIO\@.
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ML-<P9DXCO?1&CM?D+^+_/5@!X;_Y_U!+ 0(4 Q0    ( -([;5H""\I*#"\
M .:& 0 *              "  0    !E>#$Y+3$N:'1M4$L! A0#%     @
MTCMM6OSVE^[Y!   ;1P   H              ( !-"\  &5X,C,M,2YH=&U0
M2P$"% ,4    " #2.VU:* K[K5<(  !#1   "@              @ %5-
M97@S,2TQ+FAT;5!+ 0(4 Q0    ( -([;5I87M.<.0@  #)$   *
M      "  =0\  !E>#,Q+3(N:'1M4$L! A0#%     @ TCMM6JZK%I1R!
M_1P   H              ( !-44  &5X,S(M,2YH=&U02P$"% ,4    " #2
M.VU:WM8Z[&8$  !?'   "@              @ '/20  97@S,BTR+FAT;5!+
M 0(4 Q0    ( -([;5HZ%D9,D&$  *MD   +              "  5U.  !F
M:6Y?,# Q+FIP9U!+ 0(4 Q0    ( -([;5KX"E75D@0#  LF&P ,
M      "  1:P  !F;W)M,3 M:RYH=&U02P$"% ,4    " #2.VU:[4"(@>=P
M  ![<@  $0              @ '2M , 9F]R;3$P+6M?,# P,2YJ<&=02P$"
M% ,4    " #2.VU:SGG8I))C  "X9   $0              @ 'H)00 9F]R
M;3$P+6M?,# P,BYJ<&=02P$"% ,4    " #2.VU:R]VD$J.P  ":N0  $0
M            @ &IB00 9F]R;3$P+6M?,# P,RYJ<&=02P$"% ,4    " #2
M.VU:(CD8VSA3   W5   $0              @ %[.@4 9F]R;3$P+6M?,# P
M-"YJ<&=02P$"% ,4    " #2.VU:NCOS73E@   .8@  $0
M@ 'BC04 9F]R;3$P+6M?,# P-2YJ<&=02P$"% ,4    " #2.VU::F( /831
M  #1F0$ $               @ %*[@4 9F]R;3$P+6M?,# V+FIP9U!+ 0(4
M Q0    ( -([;5J)K^O-_V<! (.$ @ 0              "  ?R_!@!F;W)M
M,3 M:U\P,#<N:G!G4$L! A0#%     @ TCMM6F\NW5MA#0  IG\  !$
M         ( !*2@( &EN9' M,C R-#$R,S$N>'-D4$L! A0#%     @ TCMM
M6NZ3S%BO$   ",,  !4              ( !N34( &EN9' M,C R-#$R,S%?
M8V%L+GAM;%!+ 0(4 Q0    ( -([;5H]4O<LV1T  ,"E 0 5
M  "  9M&" !I;F1P+3(P,C0Q,C,Q7V1E9BYX;6Q02P$"% ,4    " #2.VU:
M$FEZSXM>  "W8 4 %0              @ &G9 @ :6YD<"TR,#(T,3(S,5]L
M86(N>&UL4$L! A0#%     @ TCMM6K;/(&*.00  ?1X$ !4
M ( !9<,( &EN9' M,C R-#$R,S%?<')E+GAM;%!+!08     %  4 ,4$   F
%!0D    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:INDP="http://indaptusrx.com/20241231"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="indp-20241231.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-03-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
        </entity>
        <period>
            <instant>2025-03-12</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-01-31_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="From2025-02-012025-02-28_custom_EquityPurchaseAgreementsMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">INDP:EquityPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PropertyPlantAndEquipmentMember_custom_ComputersAndOtherOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">INDP:ComputersAndOtherOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PropertyPlantAndEquipmentMember_custom_FurnitureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">INDP:FurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExercisePriceRangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">INDP:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExercisePriceRangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">INDP:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExercisePriceRangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">INDP:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ExercisePriceRangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">INDP:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ExercisePriceRangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">INDP:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ExercisePriceRangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">INDP:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember9626531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-01_custom_AtTheMarketOfferingAgreementMember_custom_HCWainwrightAndCoLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">INDP:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">INDP:HCWainwrightAndCoLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-01</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_AtTheMarketOfferingAgreementMember_custom_HCWainwrightAndCoLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">INDP:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">INDP:HCWainwrightAndCoLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-08-06_custom_AtTheMarketOfferingAgreementMember_custom_HCWainwrightAndCoLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">INDP:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">INDP:HCWainwrightAndCoLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-06</instant>
        </period>
    </context>
    <context id="AsOf2024-08-08_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-08</instant>
        </period>
    </context>
    <context id="AsOf2024-08-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
        </entity>
        <period>
            <instant>2024-08-08</instant>
        </period>
    </context>
    <context id="AsOf2024-08-08_us-gaap_WarrantMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-08</instant>
        </period>
    </context>
    <context id="AsOf2024-08-08_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-08</instant>
        </period>
    </context>
    <context id="From2024-08-082024-08-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
        </entity>
        <period>
            <startDate>2024-08-08</startDate>
            <endDate>2024-08-08</endDate>
        </period>
    </context>
    <context id="AsOf2024-11-22_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-22</instant>
        </period>
    </context>
    <context id="AsOf2024-11-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
        </entity>
        <period>
            <instant>2024-11-22</instant>
        </period>
    </context>
    <context id="AsOf2024-11-22_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-22</instant>
        </period>
    </context>
    <context id="From2024-11-222024-11-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
        </entity>
        <period>
            <startDate>2024-11-22</startDate>
            <endDate>2024-11-22</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-01-16_us-gaap_InvestorMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-16</instant>
        </period>
    </context>
    <context id="AsOf2025-01-16_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-16</instant>
        </period>
    </context>
    <context id="AsOf2025-01-16_us-gaap_WarrantMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-16</instant>
        </period>
    </context>
    <context id="From2025-01-162025-01-16_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-16</startDate>
            <endDate>2025-01-16</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-11_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-11</instant>
        </period>
    </context>
    <context id="AsOf2025-02-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
        </entity>
        <period>
            <instant>2025-02-11</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-02-122025-02-12_custom_YorkvilleMember_custom_StandbyEquityPurchaseAgreementsMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">INDP:StandbyEquityPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">INDP:YorkvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-12</startDate>
            <endDate>2025-02-12</endDate>
        </period>
    </context>
    <context id="From2025-02-122025-02-12_custom_YorkvilleMember_custom_StandbyEquityPurchaseAgreementsMember_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">INDP:StandbyEquityPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">INDP:YorkvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-12</startDate>
            <endDate>2025-02-12</endDate>
        </period>
    </context>
    <context id="From2025-02-122025-02-12_custom_ExchangeCapMember_custom_YorkvilleMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">INDP:ExchangeCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">INDP:YorkvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-12</startDate>
            <endDate>2025-02-12</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-12_custom_StandbyEquityPurchaseAgreementsMember_custom_YorkvilleMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">INDP:StandbyEquityPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">INDP:YorkvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-12</instant>
        </period>
    </context>
    <context id="From2025-02-122025-02-12_custom_YorkvilleMember_custom_StandbyEquityPurchaseAgreementsMember_srt_MaximumMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">INDP:StandbyEquityPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">INDP:YorkvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-12</startDate>
            <endDate>2025-02-12</endDate>
        </period>
    </context>
    <context id="AsOf2021-10-01_stpr_CA_custom_TwoYearLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">INDP:TwoYearLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="From2021-10-012021-10-01_stpr_CA_custom_TwoYearLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">INDP:TwoYearLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="From2023-04-192023-04-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
        </entity>
        <period>
            <startDate>2023-04-19</startDate>
            <endDate>2023-04-19</endDate>
        </period>
    </context>
    <context id="AsOf2023-04-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
        </entity>
        <period>
            <instant>2023-04-19</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_FederalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">INDP:FederalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_StateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">INDP:StateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExpireInTwoThousandThirtySixMember_custom_FederalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">INDP:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">INDP:ExpireInTwoThousandThirtySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_IndefinitePeriodMember_custom_FederalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">INDP:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">INDP:IndefinitePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExpireInTwoThousandThirtyFiveMember_custom_StateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">INDP:StateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">INDP:ExpireInTwoThousandThirtyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_country_IL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ExternalResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">INDP:ExternalResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ExternalResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">INDP:ExternalResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_InternalPersonnelCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">INDP:InternalPersonnelCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_InternalPersonnelCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">INDP:InternalPersonnelCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-012024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001857044</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Integer">
        <measure>INDP:Integer</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-01-01to2024-12-31" id="Fact000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-12-31" id="Fact000005">0001857044</dei:EntityCentralIndexKey>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0037">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0038">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0039">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0040">Yes</dei:EntityInteractiveDataCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0084"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0117"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0120"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0126"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0127"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0151"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0152"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0225"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0228"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0242"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0244"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0245"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0248"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0249"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0250"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0254"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0255"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0256"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0260"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0261"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0263"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0269"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0282"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0285"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0290"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0291"
      unitRef="USD"
      xsi:nil="true"/>
    <INDP:StockIssuedDuringPeriodValueNewIssuesOne
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <INDP:StockIssuedDuringPeriodValueNewIssuesOne
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0299"
      unitRef="USD"
      xsi:nil="true"/>
    <INDP:StockIssuedDuringPeriodValueNewIssuesTwo
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <INDP:StockIssuedDuringPeriodValueNewIssuesTwo
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0307"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0312"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0321"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0329"
      unitRef="USD"
      xsi:nil="true"/>
    <INDP:InterestEarnedOnMarketableSecurities
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0349"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0373"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0376"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <INDP:LeaseRenewalOptionExercise
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <INDP:TransactionCostsInAccountsPayableAndOtherCurrentLiabilities
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0407"
      unitRef="USD"
      xsi:nil="true"/>
    <INDP:ChangeInAccumulatedOtherComprehensiveIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0409"
      unitRef="USD"
      xsi:nil="true"/>
    <INDP:DelawareFranchiseTaxesPayableCurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0514"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0539"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0543"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0551"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0559"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0567"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0770"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0840"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0841"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="xdx2ixbrl0867"
      unitRef="Integer">1</us-gaap:NumberOfReportableSegments>
    <dei:DocumentType contextRef="From2024-01-01to2024-12-31" id="Fact000014">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2024-01-01to2024-12-31" id="Fact000015">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000016">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000017">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2024-01-01to2024-12-31" id="Fact000018">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2024-01-01to2024-12-31" id="Fact000019">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-01-01to2024-12-31" id="Fact000020">001-40652</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-12-31" id="Fact000021">INDAPTUS THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-01-01to2024-12-31" id="Fact000022">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-01-01to2024-12-31" id="Fact000023">86-3158720</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-01-01to2024-12-31" id="Fact000024">3 Columbus Circle</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2024-01-01to2024-12-31" id="Fact000025">15th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2024-01-01to2024-12-31" id="Fact000026">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-01-01to2024-12-31" id="Fact000027">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-01-01to2024-12-31" id="Fact000028">10019</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-01-01to2024-12-31" id="Fact000029">(646)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-01-01to2024-12-31" id="Fact000030">427-2727</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2024-01-01to2024-12-31" id="Fact000032">Common     stock, par value $0.01</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2024-01-01to2024-12-31" id="Fact000034">INDP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2024-01-01to2024-12-31" id="Fact000036">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityFilerCategory contextRef="From2024-01-01to2024-12-31" id="Fact000041">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-01-01to2024-12-31" id="Fact000042">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-01-01to2024-12-31" id="Fact000043">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2024-01-01to2024-12-31" id="Fact000044">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2024-01-01to2024-12-31" id="Fact000045">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2024-01-01to2024-12-31" id="Fact000046">false</dei:EntityShellCompany>
    <dei:EntityShellCompany contextRef="From2024-01-01to2024-12-31" id="Fact000047">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000048"
      unitRef="USD">15039986</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-03-12"
      decimals="INF"
      id="Fact000049"
      unitRef="Shares">14429244</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000051">None.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000054">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cybersecurity
Risk Management and Strategy&lt;/b&gt;&lt;/span&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90C_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240101__20241231_zLEfoXgEJ78j"&gt;We,
through our third party service provider that manages our information technology systems and networks, have developed and implemented
a cybersecurity risk management program intended to protect the confidentiality, &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_ztltpBYvAQz5"&gt;integrity&lt;/span&gt;, and availability of our critical systems
and information.&lt;/span&gt; Our cybersecurity risk management program includes a cybersecurity incident response plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



    &lt;div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;&lt;td style="text-align: center; width: 100%"&gt;61&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
    &lt;div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"&gt;&lt;p style="margin: 0pt"&gt;&#160;&lt;/p&gt;&lt;/div&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
design and assess our program based on the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF). This does
not imply that we meet any particular technical standards, specifications, or requirements, only that we use the NIST CSF as a guide
to help us identify, assess, and manage cybersecurity risks relevant to our business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
cybersecurity risk management program includes:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_c20240101__20241231_zc0EMY0WcsEi"&gt;risk
    assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and
    our broader enterprise IT environment;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20240101__20241231_zcncos9boFdc"&gt;designated
    team members are responsible for managing (1) our cybersecurity risk assessment processes, (2) our security controls, and (3) our
    response to cybersecurity incidents;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls;
    and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a
    cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

We
have not identified risks from known cybersecurity threats, that have &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_906_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbT_c20240101__20241231_zcoKyztoAs1d"&gt;materially&lt;/span&gt; affected or are reasonably likely to materially affect
us, including our operations, business strategy, results of operations, or financial condition. See Item 1A. &#x201c;Risk Factors &#x2013;
Our Risks Related to Our Business - &lt;i&gt;Our business and operations may suffer in the event of information technology system failures,
cyberattacks or deficiencies in our cybersecurity.&lt;/i&gt;&#x201d;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000055">We,
through our third party service provider that manages our information technology systems and networks, have developed and implemented
a cybersecurity risk management program intended to protect the confidentiality, &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_ztltpBYvAQz5"&gt;integrity&lt;/span&gt;, and availability of our critical systems
and information.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000056">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000057">risk
    assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and
    our broader enterprise IT environment;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000058">designated
    team members are responsible for managing (1) our cybersecurity risk assessment processes, (2) our security controls, and (3) our
    response to cybersecurity incidents;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="From2024-01-01to2024-12-31" id="Fact000059">true</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000060">Our
Board considers cybersecurity risk as part of its risk oversight function and oversees our cybersecurity and other information technology
risks and management&#x2019;s implementation of our cybersecurity risk management program.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000061">Our
management team, including our Chief Operating Officer, is responsible for assessing and managing our material risks from cybersecurity
threats. Our Chief Operating Officer has primary responsibility for our overall cybersecurity risk management program and supervises
our retained provider of IT services and external cybersecurity consultants. Our Chief Operating Officer has experience supervising and
managing company security and privacy departments.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <dei:AuditorName contextRef="From2024-01-01to2024-12-31" id="Fact000062">HASKELL &amp; WHITE LLP</dei:AuditorName>
    <dei:AuditorFirmId contextRef="From2024-01-01to2024-12-31" id="Fact000063">200</dei:AuditorFirmId>
    <dei:AuditorLocation contextRef="From2024-01-01to2024-12-31" id="Fact000064">Irvine, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000072"
      unitRef="USD">5786753</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000073"
      unitRef="USD">13362053</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000075"
      unitRef="USD">831577</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000076"
      unitRef="USD">633156</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000078"
      unitRef="USD">6618330</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000079"
      unitRef="USD">13995209</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000085"
      unitRef="USD">735</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000087"
      unitRef="USD">82175</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000088"
      unitRef="USD">173206</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000090"
      unitRef="USD">638251</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000091"
      unitRef="USD">754728</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000093"
      unitRef="USD">720426</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000094"
      unitRef="USD">928669</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000096"
      unitRef="USD">7338756</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000097"
      unitRef="USD">14923878</us-gaap:Assets>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000105"
      unitRef="USD">3309717</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000106"
      unitRef="USD">2672327</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000108"
      unitRef="USD">84164</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000109"
      unitRef="USD">101705</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000111"
      unitRef="USD">3393881</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000112"
      unitRef="USD">2774032</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000118"
      unitRef="USD">73348</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000121"
      unitRef="USD">73348</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000123"
      unitRef="USD">3393881</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000124"
      unitRef="USD">2847380</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000135"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000137"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000139"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000141"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000143"
      unitRef="Shares">12013901</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000145"
      unitRef="Shares">12013901</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000147"
      unitRef="Shares">8401047</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000149"
      unitRef="Shares">8401047</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000132"
      unitRef="USD">120139</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000133"
      unitRef="USD">84011</us-gaap:CommonStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000154"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000156"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000158"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000160"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000162"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000164"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000166"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000168"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000170"
      unitRef="USD">64263919</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000171"
      unitRef="USD">57409643</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000173"
      unitRef="USD">-60439183</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000174"
      unitRef="USD">-45417156</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000176"
      unitRef="USD">3944875</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000177"
      unitRef="USD">12076498</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000179"
      unitRef="USD">7338756</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000180"
      unitRef="USD">14923878</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000185"
      unitRef="USD">7251097</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000186"
      unitRef="USD">7621707</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000188"
      unitRef="USD">8114654</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000189"
      unitRef="USD">8756767</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000191"
      unitRef="USD">15365751</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000192"
      unitRef="USD">16378474</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000194"
      unitRef="USD">-15365751</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000195"
      unitRef="USD">-16378474</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000197"
      unitRef="USD">343724</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000198"
      unitRef="USD">955003</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000200"
      unitRef="USD">-15022027</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000201"
      unitRef="USD">-15423471</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000203"
      unitRef="USDPShares">-1.61</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000205"
      unitRef="USDPShares">-1.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000207"
      unitRef="USDPShares">-1.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000209"
      unitRef="USDPShares">-1.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000211"
      unitRef="Shares">9355710</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000213"
      unitRef="Shares">9355710</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000215"
      unitRef="Shares">8401047</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000217"
      unitRef="Shares">8401047</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000219"
      unitRef="USD">-15022027</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000220"
      unitRef="USD">-15423471</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000226"
      unitRef="USD">430993</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000229"
      unitRef="USD">334559</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000231"
      unitRef="USD">-15022027</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000232"
      unitRef="USD">-15519905</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000240"
      unitRef="Shares">8401047</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000234"
      unitRef="USD">84011</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000235"
      unitRef="USD">54443705</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000236"
      unitRef="USD">-29993685</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000237"
      unitRef="USD">96434</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000238"
      unitRef="USD">24630465</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000243"
      unitRef="USD">2965938</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000246"
      unitRef="USD">2965938</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000251"
      unitRef="USD">430993</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000252"
      unitRef="USD">430993</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000257"
      unitRef="USD">334559</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000258"
      unitRef="USD">334559</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000262"
      unitRef="USD">-15423471</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000264"
      unitRef="USD">-15423471</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000272"
      unitRef="Shares">8401047</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000266"
      unitRef="USD">84011</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000267"
      unitRef="USD">57409643</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000268"
      unitRef="USD">-45417156</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000270"
      unitRef="USD">12076498</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000280"
      unitRef="Shares">8401047</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000274"
      unitRef="USD">84011</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000275"
      unitRef="USD">57409643</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000276"
      unitRef="USD">-45417156</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000278"
      unitRef="USD">12076498</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000283"
      unitRef="USD">2305849</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000286"
      unitRef="USD">2305849</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000294"
      unitRef="Shares">152000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000288"
      unitRef="USD">1520</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000289"
      unitRef="USD">352591</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000292"
      unitRef="USD">354111</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <INDP:StockIssuedDuringPeriodSharesNewIssuesOne
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000302"
      unitRef="Shares">1643837</INDP:StockIssuedDuringPeriodSharesNewIssuesOne>
    <INDP:StockIssuedDuringPeriodValueNewIssuesOne
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000296"
      unitRef="USD">16438</INDP:StockIssuedDuringPeriodValueNewIssuesOne>
    <INDP:StockIssuedDuringPeriodValueNewIssuesOne
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000297"
      unitRef="USD">2445532</INDP:StockIssuedDuringPeriodValueNewIssuesOne>
    <INDP:StockIssuedDuringPeriodValueNewIssuesOne
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000300"
      unitRef="USD">2461970</INDP:StockIssuedDuringPeriodValueNewIssuesOne>
    <INDP:StockIssuedDuringPeriodSharesNewIssuesTwo
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000310"
      unitRef="Shares">1817017</INDP:StockIssuedDuringPeriodSharesNewIssuesTwo>
    <INDP:StockIssuedDuringPeriodValueNewIssuesTwo
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000304"
      unitRef="USD">18170</INDP:StockIssuedDuringPeriodValueNewIssuesTwo>
    <INDP:StockIssuedDuringPeriodValueNewIssuesTwo
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000305"
      unitRef="USD">1750304</INDP:StockIssuedDuringPeriodValueNewIssuesTwo>
    <INDP:StockIssuedDuringPeriodValueNewIssuesTwo
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000308"
      unitRef="USD">1768474</INDP:StockIssuedDuringPeriodValueNewIssuesTwo>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000314"
      unitRef="USD">-15022027</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000316"
      unitRef="USD">-15022027</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000324"
      unitRef="Shares">12013901</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000318"
      unitRef="USD">120139</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000319"
      unitRef="USD">64263919</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000320"
      unitRef="USD">-60439183</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000322"
      unitRef="USD">3944875</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000332"
      unitRef="Shares">12013901</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000326"
      unitRef="USD">120139</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000327"
      unitRef="USD">64263919</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000328"
      unitRef="USD">-60439183</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000330"
      unitRef="USD">3944875</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000337"
      unitRef="USD">-15022027</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000338"
      unitRef="USD">-15423471</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000343"
      unitRef="USD">735</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000344"
      unitRef="USD">1284</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000346"
      unitRef="USD">2305849</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000347"
      unitRef="USD">2965938</us-gaap:ShareBasedCompensation>
    <INDP:InterestEarnedOnMarketableSecurities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000350"
      unitRef="USD">430993</INDP:InterestEarnedOnMarketableSecurities>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000355"
      unitRef="USD">81944</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000356"
      unitRef="USD">-161800</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000358"
      unitRef="USD">-474057</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000359"
      unitRef="USD">680520</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <INDP:IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000361"
      unitRef="USD">142</INDP:IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet>
    <INDP:IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000362"
      unitRef="USD">647</INDP:IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000364"
      unitRef="USD">-12323188</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000365"
      unitRef="USD">-13405315</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000371"
      unitRef="USD">6859432</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000374"
      unitRef="USD">24000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000377"
      unitRef="USD">17140568</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000382"
      unitRef="USD">5510591</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000385"
      unitRef="USD">762703</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000388"
      unitRef="USD">4747888</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000391"
      unitRef="USD">-7575300</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000392"
      unitRef="USD">3735253</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000394"
      unitRef="USD">13362053</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000395"
      unitRef="USD">9626800</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000397"
      unitRef="USD">5786753</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000398"
      unitRef="USD">13362053</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <INDP:LeaseRenewalOptionExercise
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000404"
      unitRef="USD">236506</INDP:LeaseRenewalOptionExercise>
    <INDP:TransactionCostsInAccountsPayableAndOtherCurrentLiabilities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000406"
      unitRef="USD">163333</INDP:TransactionCostsInAccountsPayableAndOtherCurrentLiabilities>
    <INDP:ChangeInAccumulatedOtherComprehensiveIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000410"
      unitRef="USD">-96434</INDP:ChangeInAccumulatedOtherComprehensiveIncomeLoss>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000415"
      unitRef="USD">1600</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000416"
      unitRef="USD">1600</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:NatureOfOperations contextRef="From2024-01-01to2024-12-31" id="Fact000418">&lt;p id="xdx_800_eus-gaap--NatureOfOperations_zqUCxD209197" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
1: &lt;span id="xdx_82E_zumxOemtx2qi"&gt;GENERAL&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Indaptus
Therapeutics, Inc. and its wholly-owned subsidiaries, Decoy Biosystems, Inc. and Intec Pharma Ltd., collectively (the &#x201c;Company&#x201d;),
is a biotechnology company dedicated to enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic
solid tumors and lymphomas, which are responsible for more than 90% of all cancer deaths. The Company is developing a novel, multi-targeted
product that activates both innate and adaptive anti-tumor and anti-viral immune responses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Risks
and uncertainties&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to a number of risks similar to those of other companies of similar size in its industry, including, but not limited
to, the need for successful development of products, the need for additional capital (or financing) to fund operations (see below), competition
from substitute products and services from larger companies, protection of proprietary technology, patent litigation, and dependence
on key individuals.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Going
concern and management&#x2019;s plans&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has incurred net losses and utilized cash in operations since inception. For the year ended December 31, 2024, the Company incurred
a net loss of approximately $&lt;span id="xdx_906_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20240101__20241231_zmnsGoAomsIg" title="Net loss"&gt;15.0&lt;/span&gt; million, and as of December 31, 2024, the Company had an accumulated deficit of approximately $&lt;span id="xdx_903_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20241231_zYo5hzF55qY" title="Accumulated deficit"&gt;60.4&lt;/span&gt;
million. In addition, during the year ended December 31, 2024, the Company used approximately $&lt;span id="xdx_90A_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20240101__20241231_zgXEi320GJt1" title="Net cash used in operating activities"&gt;12.3&lt;/span&gt; million of cash in operations and
expects to continue to incur significant cash outflows and incur future additional losses as clinical trials and commercialization of
the Company&#x2019;s product candidates will require significant additional financing. The Company believes that, as of the date of the
issuance of these consolidated financial statements, it has adequate cash to fund its ongoing activities into the second quarter of
2025 based on its current operating plan. The Company plans to execute its operating plan by obtaining additional capital, principally
through entering into collaborations, strategic alliances, or license agreements with third parties and/or additional public or private
debt and equity financing, such as through the registered direct offerings and concurrent private placements that the Company completed
in August 2024 (the &#x201c;August 2024 Offering&#x201d;) and in November 2024 (the &#x201c;November 2024 Offering&#x201d;), and through
the private placement in January 2025 (the &#x201c;January 2025 Offering&#x201d;). Following these offerings, the Company raised a total
of approximately $&lt;span id="xdx_905_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20240101__20241231_zm23B49uwDyl" title="Net of placement agent cost"&gt;6.3&lt;/span&gt; million, net of placement agent and other offering expenses in the amount of approximately $&lt;span id="xdx_90D_eus-gaap--NoninterestExpenseOfferingCost_pn5n6_c20250101__20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrRevrktynr6" title="Other offering cost"&gt;1.1&lt;/span&gt; million. For more
details, see Note 6(c), 6(d) and 6(e). In addition, in February 2025, the Company entered into a &lt;span style="background-color: white"&gt;Standby
Equity Purchase Agreement pursuant to which the Company has the right, but not the obligation, to sell up to $&lt;span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20250201__20250228__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zMM325oknZff" title="Purchase ordinary shares"&gt;20.0&lt;/span&gt; million o&lt;span style="color: #212529"&gt;f
the Company&#x2019;s common stock &lt;/span&gt;during a 36-month period, subject to the restrictions and satisfaction of the conditions in the
Standby Equity Purchase Agreement. For more details, see Note 6(f). &lt;/span&gt;However, there is no assurance that additional capital and/or
financing will be available to the Company, and even if available, whether it will be on terms acceptable to the Company or in the amounts
required. If the Company is unsuccessful in securing sufficient financing, it may need to delay, reduce, or eliminate its research and
development programs, which could adversely affect its business prospects, or cease operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of these uncertainties, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern. The consolidated
financial statements do not include any adjustments to the carrying amounts and classifications of assets and liabilities that would
result if the Company was unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact000420"
      unitRef="USD">-15000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000422"
      unitRef="USD">-60400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact000424"
      unitRef="USD">-12300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact000426"
      unitRef="USD">6300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NoninterestExpenseOfferingCost
      contextRef="From2025-01-012025-01-31_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact000428"
      unitRef="USD">1100000</us-gaap:NoninterestExpenseOfferingCost>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-02-012025-02-28_custom_EquityPurchaseAgreementsMember_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact000430"
      unitRef="USD">20000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000432">&lt;p id="xdx_80F_eus-gaap--SignificantAccountingPoliciesTextBlock_zzT8l1FpiXzc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2: &lt;span id="xdx_82B_zidKcg8Oftzd"&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zHvtafAti2d2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Basis
of presentation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#x201c;US GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_zRVAz49Q8aMi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Principles
of consolidation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements include the accounts of Indaptus and its subsidiaries. Intercompany balances and transactions have
been eliminated upon consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--UseOfEstimates_z7lX2mqACVBi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Use
of estimates&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in accordance with US GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements, and the
reported amounts of expenses during the reporting periods. The most significant estimates relate to the determination of the fair value
of stock-based compensation and the determination of period-end obligations to certain contract research organizations. Management evaluates
its estimates and assumptions on an ongoing basis using historical experience and other factors and makes adjustments when facts and
circumstances dictate. These estimates are based on information available as of the date of the consolidated financial statements; therefore,
actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zITshnNOMlMc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Loss
per share&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss
per share, basic and diluted, is computed on the basis of the net loss for the period divided by the weighted average number of shares
of common stock outstanding during the period. Diluted loss per share is based upon the weighted average number of shares of common stock
and of common stock equivalents outstanding when dilutive. Common stock equivalents include outstanding stock options and warrants which
are included under the treasury stock method when dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zTVxb6GxtKPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following number of stock options and warrants were excluded from the calculation of diluted loss per share because their effect would
have been anti-dilutive for the periods presented (share data):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B7_z7noe3Or3OFi" style="display: none"&gt;SCHEDULE
OF ANTI-DILUTIVE SECURITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted average&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Outstanding stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zzzBDQa1x78h" style="width: 16%; text-align: right" title="Anti-dilutive securities"&gt;2,519,419&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z8roWgWnW3W9" style="width: 16%; text-align: right" title="Anti-dilutive securities"&gt;1,979,196&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_znlKC6M6KURe" style="text-align: right" title="Anti-dilutive securities"&gt;3,935,282&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_za29FhSrik0l" style="text-align: right" title="Anti-dilutive securities"&gt;3,090,787&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_z0zZABOUdWg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6fmJp0ekRI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Cash
and cash equivalents&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. As of
December 31, 2024, and 2023, cash and cash equivalents consist primarily of checking and money market deposits. The Company&#x2019;s cash
balances exceed those that are federally insured; however, the Company believes it is not exposed to significant credit risk due to the
financial strength of the depository institutions in which the cash and cash equivalents are held. To date, the Company has not recognized
any losses caused by uninsured balances.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zAleiunrGJg3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Property
and equipment&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment assets are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over
the estimated useful lives of the assets. The Company uses an estimated useful life of &lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersAndOtherOfficeEquipmentMember_zdj4BE7ssyu8" title="Estimated useful life"&gt;three years&lt;/span&gt; for employee-related computers and
other office equipment and &lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureMember_zt1TZj9uzmx5" title="Estimated useful life"&gt;five years&lt;/span&gt; for furniture. Leasehold improvements are amortized over the shorter of the lease-term or the estimated
useful life of the related asset.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zrMB8XORfTug" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Patents&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company expenses patent costs, including related legal costs, as incurred and records such costs within general and administrative expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zF7nDBVoI5zc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Research
and development expenses&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses include costs directly attributable to the conduct of research and development programs, including the cost
of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research
and development activities, including clinical trials and professional services. All costs associated with research and development are
expensed as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accrues for expenses resulting from obligations under agreements with contract research organizations (&#x201c;CROs&#x201d;), contract
manufacturing organizations (&#x201c;CMOs&#x201d;), and other outside service providers for which payment flows do not match the periods
over which services or materials are provided to the Company. Accruals are recorded based on estimates of services received and efforts
expended pursuant to agreements with CROs, CMOs, and other outside service providers. These estimates are typically based on contracted
amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers
as to the progress or stage of completion of the services. In the event advance payments are made to a CRO, CMO, or outside service provider,
the payments will be recorded as a prepaid expense, which will be amortized or expensed as the contracted services are performed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_z8xuuJUtuue8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;General
and administrative expenses&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative expenses include compensation, employee benefits, and stock-based compensation for executive management, finance,
administration and human resources, facility costs (including rent), professional service fees, and other general overhead costs to support
the Company&#x2019;s operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zdqqlKEERcNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Income
taxes&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences
attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective
tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred
tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation
allowance is recorded for deferred tax assets if it is more likely than not that some portion or all of the deferred tax assets will
not be realized in the foreseeable future. As of December 31, 2024, and 2023, the Company has recorded a full valuation allowance against
its deferred tax assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized
income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or
measurement are reflected in the period in which the change in judgment occurs. The Company records interest related to unrecognized
tax benefits in interest expense and penalties in general and administrative expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zF62OiizdLR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock-based
compensation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company measures and records the expense related to stock-based payment awards based on the fair value of those awards as determined
using the Black-Scholes-Merton (&#x201c;Black-Scholes&#x201d;) model as of the date of grant. The Company recognizes stock-based compensation
expense over the requisite service period of the individual grant, generally equal to the vesting period, on a straight-line basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Black-Scholes model requires the use of highly subjective and complex assumptions, which determine the fair value of stock-based payment
awards, including the option&#x2019;s expected term and the price volatility of the underlying stock. The Company estimates the fair value
of options granted by using the Black-Scholes model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
Volatility&lt;/i&gt;&#x2014;The Company estimates volatility for option grants by evaluating the historical volatility of a peer group of companies
for the period immediately preceding the option grant for a term that is approximately equal to the options&#x2019; expected term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
Term&lt;/i&gt;&#x2014;The expected term of the Company&#x2019;s options represents the period that the stock-based payment awards are expected
to be outstanding. The expected term is estimated using the simplified method for employee stock options since the Company does not have
adequate historical exercise data to estimate the expected term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Risk-Free
Interest Rate&lt;/i&gt;&#x2014;The risk-free interest rate is based on the implied yield currently available on U.S. Treasury zero-coupon issues
with a term that is equal to the options&#x2019; expected term at the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Dividend
Yield&lt;/i&gt;&#x2014;The Company has not declared or paid dividends to date and does not anticipate declaring dividends. As such, the dividend
yield has been estimated to be zero.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has elected to recognize forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z7gde9Bxbz2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Fair
value measurements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability
in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the
measurement date. The Company follows the established framework for measuring fair value and providing disclosures about fair value measurements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Quoted prices in active
    markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs other than Level
    1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unobservable inputs which
    are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or
    similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
820, &lt;i&gt;Fair Value Measurement&lt;/i&gt;, requires all entities to disclose the fair value of financial instruments, both assets and liabilities,
for which it is practicable to estimate fair value, and defines the fair value of a financial instrument as the amount at which the instrument
could be exchanged in a current transaction between willing parties. As of December 31, 2024, and 2023, the recorded values of cash and
cash equivalents, prepaid expenses, and accounts payable and other current liabilities approximate their fair values due to the short-term
nature of these items.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--NewAdoptedAccountingPronouncementsPolicyPolicyTextBlock_zAcWFfnPQO1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;Recently
adopted accounting pronouncements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;In
November 2023, the FASB issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures. The FASB amended the guidance in ASC
280, Segment Reporting (&#x201c;ASC 280&#x201d;), to require a public entity to disclose significant segment expenses and other segment
items on an annual and interim basis and to provide in interim periods all disclosures about a reportable segment&#x2019;s profit or loss
and assets that are currently required annually. Public entities with a single reportable segment are required to provide the new disclosures
and all the disclosures required under ASC 280. The guidance is applied retrospectively to all periods presented in financial statements
unless it is impracticable. This new guidance is effective for public business entities for annual periods beginning after December 15,
2023, and for interim periods beginning after December 15, 2024. The Company adopted this new standard effective December 31, 2024. See
Note 9, Segment Information, for disclosures related to the adoption of ASU 2023-07.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_znDn13vSn9X1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span id="xdx_86B_zps4ItJ4JNDf"&gt;Recently
issued accounting pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;In
November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense &lt;span style="background-color: white"&gt;Disaggregation &lt;/span&gt; Disclosures.
This ASU will require entities to provide enhanced disclosures, in a tabular format, related to certain expense categories included in
the statement of operations. The ASU aims to increase transparency and provide investors with more detailed information about the nature
of expenses reported on the face of the income statement. The new ASU is effective for annual reporting periods beginning after December
15, 2026 and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating
the impact of the adoption of this standard on the related disclosures&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;In
December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures. This ASU does not change accounting for income
taxes but requires new disclosures focusing on two areas, the effective rate reconciliation and taxes paid. This new standard is effective
for public business entities for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently
evaluating the impact of the adoption of this standard on the related disclosures.&lt;/span&gt;&lt;/p&gt;
&lt;p id="xdx_85A_zrHdvVzL6ima" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000434">&lt;p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zHvtafAti2d2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Basis
of presentation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#x201c;US GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000436">&lt;p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_zRVAz49Q8aMi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Principles
of consolidation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements include the accounts of Indaptus and its subsidiaries. Intercompany balances and transactions have
been eliminated upon consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2024-01-01to2024-12-31" id="Fact000438">&lt;p id="xdx_84A_eus-gaap--UseOfEstimates_z7lX2mqACVBi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Use
of estimates&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in accordance with US GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements, and the
reported amounts of expenses during the reporting periods. The most significant estimates relate to the determination of the fair value
of stock-based compensation and the determination of period-end obligations to certain contract research organizations. Management evaluates
its estimates and assumptions on an ongoing basis using historical experience and other factors and makes adjustments when facts and
circumstances dictate. These estimates are based on information available as of the date of the consolidated financial statements; therefore,
actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000440">&lt;p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zITshnNOMlMc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Loss
per share&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss
per share, basic and diluted, is computed on the basis of the net loss for the period divided by the weighted average number of shares
of common stock outstanding during the period. Diluted loss per share is based upon the weighted average number of shares of common stock
and of common stock equivalents outstanding when dilutive. Common stock equivalents include outstanding stock options and warrants which
are included under the treasury stock method when dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zTVxb6GxtKPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following number of stock options and warrants were excluded from the calculation of diluted loss per share because their effect would
have been anti-dilutive for the periods presented (share data):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B7_z7noe3Or3OFi" style="display: none"&gt;SCHEDULE
OF ANTI-DILUTIVE SECURITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted average&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Outstanding stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zzzBDQa1x78h" style="width: 16%; text-align: right" title="Anti-dilutive securities"&gt;2,519,419&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z8roWgWnW3W9" style="width: 16%; text-align: right" title="Anti-dilutive securities"&gt;1,979,196&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_znlKC6M6KURe" style="text-align: right" title="Anti-dilutive securities"&gt;3,935,282&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_za29FhSrik0l" style="text-align: right" title="Anti-dilutive securities"&gt;3,090,787&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_z0zZABOUdWg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000442">&lt;p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zTVxb6GxtKPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following number of stock options and warrants were excluded from the calculation of diluted loss per share because their effect would
have been anti-dilutive for the periods presented (share data):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B7_z7noe3Or3OFi" style="display: none"&gt;SCHEDULE
OF ANTI-DILUTIVE SECURITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted average&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Outstanding stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zzzBDQa1x78h" style="width: 16%; text-align: right" title="Anti-dilutive securities"&gt;2,519,419&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z8roWgWnW3W9" style="width: 16%; text-align: right" title="Anti-dilutive securities"&gt;1,979,196&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_znlKC6M6KURe" style="text-align: right" title="Anti-dilutive securities"&gt;3,935,282&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_za29FhSrik0l" style="text-align: right" title="Anti-dilutive securities"&gt;3,090,787&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000444"
      unitRef="Shares">2519419</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000446"
      unitRef="Shares">1979196</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000448"
      unitRef="Shares">3935282</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000450"
      unitRef="Shares">3090787</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000452">&lt;p id="xdx_846_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6fmJp0ekRI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Cash
and cash equivalents&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. As of
December 31, 2024, and 2023, cash and cash equivalents consist primarily of checking and money market deposits. The Company&#x2019;s cash
balances exceed those that are federally insured; however, the Company believes it is not exposed to significant credit risk due to the
financial strength of the depository institutions in which the cash and cash equivalents are held. To date, the Company has not recognized
any losses caused by uninsured balances.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000454">&lt;p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zAleiunrGJg3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Property
and equipment&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment assets are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over
the estimated useful lives of the assets. The Company uses an estimated useful life of &lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersAndOtherOfficeEquipmentMember_zdj4BE7ssyu8" title="Estimated useful life"&gt;three years&lt;/span&gt; for employee-related computers and
other office equipment and &lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureMember_zt1TZj9uzmx5" title="Estimated useful life"&gt;five years&lt;/span&gt; for furniture. Leasehold improvements are amortized over the shorter of the lease-term or the estimated
useful life of the related asset.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_PropertyPlantAndEquipmentMember_custom_ComputersAndOtherOfficeEquipmentMember"
      id="Fact000456">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_PropertyPlantAndEquipmentMember_custom_FurnitureMember"
      id="Fact000458">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000460">&lt;p id="xdx_84A_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zrMB8XORfTug" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Patents&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company expenses patent costs, including related legal costs, as incurred and records such costs within general and administrative expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2024-01-01to2024-12-31" id="Fact000462">&lt;p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zF7nDBVoI5zc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Research
and development expenses&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses include costs directly attributable to the conduct of research and development programs, including the cost
of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research
and development activities, including clinical trials and professional services. All costs associated with research and development are
expensed as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accrues for expenses resulting from obligations under agreements with contract research organizations (&#x201c;CROs&#x201d;), contract
manufacturing organizations (&#x201c;CMOs&#x201d;), and other outside service providers for which payment flows do not match the periods
over which services or materials are provided to the Company. Accruals are recorded based on estimates of services received and efforts
expended pursuant to agreements with CROs, CMOs, and other outside service providers. These estimates are typically based on contracted
amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers
as to the progress or stage of completion of the services. In the event advance payments are made to a CRO, CMO, or outside service provider,
the payments will be recorded as a prepaid expense, which will be amortized or expensed as the contracted services are performed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000464">&lt;p id="xdx_84D_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_z8xuuJUtuue8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;General
and administrative expenses&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative expenses include compensation, employee benefits, and stock-based compensation for executive management, finance,
administration and human resources, facility costs (including rent), professional service fees, and other general overhead costs to support
the Company&#x2019;s operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000466">&lt;p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zdqqlKEERcNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Income
taxes&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences
attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective
tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred
tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation
allowance is recorded for deferred tax assets if it is more likely than not that some portion or all of the deferred tax assets will
not be realized in the foreseeable future. As of December 31, 2024, and 2023, the Company has recorded a full valuation allowance against
its deferred tax assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized
income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or
measurement are reflected in the period in which the change in judgment occurs. The Company records interest related to unrecognized
tax benefits in interest expense and penalties in general and administrative expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000468">&lt;p id="xdx_84C_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zF62OiizdLR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock-based
compensation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company measures and records the expense related to stock-based payment awards based on the fair value of those awards as determined
using the Black-Scholes-Merton (&#x201c;Black-Scholes&#x201d;) model as of the date of grant. The Company recognizes stock-based compensation
expense over the requisite service period of the individual grant, generally equal to the vesting period, on a straight-line basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Black-Scholes model requires the use of highly subjective and complex assumptions, which determine the fair value of stock-based payment
awards, including the option&#x2019;s expected term and the price volatility of the underlying stock. The Company estimates the fair value
of options granted by using the Black-Scholes model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
Volatility&lt;/i&gt;&#x2014;The Company estimates volatility for option grants by evaluating the historical volatility of a peer group of companies
for the period immediately preceding the option grant for a term that is approximately equal to the options&#x2019; expected term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
Term&lt;/i&gt;&#x2014;The expected term of the Company&#x2019;s options represents the period that the stock-based payment awards are expected
to be outstanding. The expected term is estimated using the simplified method for employee stock options since the Company does not have
adequate historical exercise data to estimate the expected term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Risk-Free
Interest Rate&lt;/i&gt;&#x2014;The risk-free interest rate is based on the implied yield currently available on U.S. Treasury zero-coupon issues
with a term that is equal to the options&#x2019; expected term at the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Dividend
Yield&lt;/i&gt;&#x2014;The Company has not declared or paid dividends to date and does not anticipate declaring dividends. As such, the dividend
yield has been estimated to be zero.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has elected to recognize forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000470">&lt;p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z7gde9Bxbz2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Fair
value measurements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability
in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the
measurement date. The Company follows the established framework for measuring fair value and providing disclosures about fair value measurements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Quoted prices in active
    markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs other than Level
    1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unobservable inputs which
    are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or
    similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
820, &lt;i&gt;Fair Value Measurement&lt;/i&gt;, requires all entities to disclose the fair value of financial instruments, both assets and liabilities,
for which it is practicable to estimate fair value, and defines the fair value of a financial instrument as the amount at which the instrument
could be exchanged in a current transaction between willing parties. As of December 31, 2024, and 2023, the recorded values of cash and
cash equivalents, prepaid expenses, and accounts payable and other current liabilities approximate their fair values due to the short-term
nature of these items.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <INDP:NewAdoptedAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000472">&lt;p id="xdx_84E_ecustom--NewAdoptedAccountingPronouncementsPolicyPolicyTextBlock_zAcWFfnPQO1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;Recently
adopted accounting pronouncements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;In
November 2023, the FASB issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures. The FASB amended the guidance in ASC
280, Segment Reporting (&#x201c;ASC 280&#x201d;), to require a public entity to disclose significant segment expenses and other segment
items on an annual and interim basis and to provide in interim periods all disclosures about a reportable segment&#x2019;s profit or loss
and assets that are currently required annually. Public entities with a single reportable segment are required to provide the new disclosures
and all the disclosures required under ASC 280. The guidance is applied retrospectively to all periods presented in financial statements
unless it is impracticable. This new guidance is effective for public business entities for annual periods beginning after December 15,
2023, and for interim periods beginning after December 15, 2024. The Company adopted this new standard effective December 31, 2024. See
Note 9, Segment Information, for disclosures related to the adoption of ASU 2023-07.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</INDP:NewAdoptedAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000474">&lt;p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_znDn13vSn9X1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span id="xdx_86B_zps4ItJ4JNDf"&gt;Recently
issued accounting pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;In
November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense &lt;span style="background-color: white"&gt;Disaggregation &lt;/span&gt; Disclosures.
This ASU will require entities to provide enhanced disclosures, in a tabular format, related to certain expense categories included in
the statement of operations. The ASU aims to increase transparency and provide investors with more detailed information about the nature
of expenses reported on the face of the income statement. The new ASU is effective for annual reporting periods beginning after December
15, 2026 and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating
the impact of the adoption of this standard on the related disclosures&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;In
December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures. This ASU does not change accounting for income
taxes but requires new disclosures focusing on two areas, the effective rate reconciliation and taxes paid. This new standard is effective
for public business entities for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently
evaluating the impact of the adoption of this standard on the related disclosures.&lt;/span&gt;&lt;/p&gt;
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <INDP:PrepaidExpenseAndOtherCurrentAssetsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000476">&lt;p id="xdx_808_ecustom--PrepaidExpenseAndOtherCurrentAssetsDisclosureTextBlock_zTYE2Mf9JAXa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3: &lt;span id="xdx_821_zlYPptFFlEOg"&gt;PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_ecustom--ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock_z8ENLd2sfC94" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
expenses and other current assets are comprised of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zHZ1PU09hW0d" style="display: none"&gt;SCHEDULE
OF PREPAID EXPENSE AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20241231_zz8S2HWxhMPc" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231_zrwsaLIdXohl" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PrepaidInsurance_iI_pp0p0_maPEAOAz50c_z689fbTuzGWc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;506,489&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;554,097&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--PrepaidResearchAndDevelopment_iI_pp0p0_maPEAOAz50c_zsmHvMGxPZNl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,309&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPEAOAz50c_z103lWxDYz5e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other prepaid expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;175,088&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;61,750&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPEAOAz50c_zv7GQh85FQw2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;831,577&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;633,156&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPEAOAz50c_ztbE9QjeH7J5" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; text-align: left; padding-bottom: 2.5pt"&gt;Prepaid expenses and other current assets&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; display: none; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; display: none; text-align: right"&gt;831,577&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; display: none; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; display: none; text-align: right"&gt;633,156&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AE_zhng3EtopIif" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</INDP:PrepaidExpenseAndOtherCurrentAssetsDisclosureTextBlock>
    <INDP:ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000478">&lt;p id="xdx_892_ecustom--ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock_z8ENLd2sfC94" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
expenses and other current assets are comprised of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zHZ1PU09hW0d" style="display: none"&gt;SCHEDULE
OF PREPAID EXPENSE AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20241231_zz8S2HWxhMPc" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231_zrwsaLIdXohl" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PrepaidInsurance_iI_pp0p0_maPEAOAz50c_z689fbTuzGWc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;506,489&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;554,097&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--PrepaidResearchAndDevelopment_iI_pp0p0_maPEAOAz50c_zsmHvMGxPZNl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,309&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPEAOAz50c_z103lWxDYz5e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other prepaid expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;175,088&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;61,750&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPEAOAz50c_zv7GQh85FQw2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;831,577&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;633,156&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPEAOAz50c_ztbE9QjeH7J5" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; text-align: left; padding-bottom: 2.5pt"&gt;Prepaid expenses and other current assets&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; display: none; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; display: none; text-align: right"&gt;831,577&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; display: none; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; display: none; text-align: right"&gt;633,156&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</INDP:ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000480"
      unitRef="USD">506489</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000481"
      unitRef="USD">554097</us-gaap:PrepaidInsurance>
    <INDP:PrepaidResearchAndDevelopment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000483"
      unitRef="USD">150000</INDP:PrepaidResearchAndDevelopment>
    <INDP:PrepaidResearchAndDevelopment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000484"
      unitRef="USD">17309</INDP:PrepaidResearchAndDevelopment>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000486"
      unitRef="USD">175088</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000487"
      unitRef="USD">61750</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000489"
      unitRef="USD">831577</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000490"
      unitRef="USD">633156</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000492"
      unitRef="USD">831577</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000493"
      unitRef="USD">633156</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000495">&lt;p id="xdx_806_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zMaNMhjaQ4g9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4: &lt;span id="xdx_821_zwCUHTUaTl7i"&gt;ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z7Ghfw9tcRD3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
payable and other current liabilities are comprised of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zrXQEarVuofe" style="display: none"&gt;SCHEDULE
OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20241231_zJNuo2kqCPZ5" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20231231_zgmpYP5DlDhi" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AccountsPayableCurrent_iI_pp0p0_maAPAOAzxRP_ztpjmkFOSvNd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;870,229&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;806,004&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pp0p0_maAPAOAzxRP_znSBd8T5lr0c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued employee costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,371,498&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,213,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maAPAOAzxRP_zlKXwDdYWWy9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;39,165&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--AccruedResearchAndDevelopmentCurrent_iI_pp0p0_maAPAOAzxRP_z8rk0yw8NkD8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;860,958&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;439,024&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--AccruedBoardFeesCurrent_iI_pp0p0_maAPAOAzxRP_zfAV4Uc2wuli" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued board fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DelawareFranchiseTaxesPayableCurrent_iI_pp0p0_maAPAOAzxRP_zJiRSqpQT0ah" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Delaware franchise taxes payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0514"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maAPAOAzxRP_z0rTZzcNdzia" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;17,228&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;17,330&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_pp0p0_mtAPAOAzxRP_zMpVQCMEKC6c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total accounts payable and other current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,309,717&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,672,327&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zYgsqK7PcsUj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000497">&lt;p id="xdx_899_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z7Ghfw9tcRD3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
payable and other current liabilities are comprised of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zrXQEarVuofe" style="display: none"&gt;SCHEDULE
OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20241231_zJNuo2kqCPZ5" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20231231_zgmpYP5DlDhi" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AccountsPayableCurrent_iI_pp0p0_maAPAOAzxRP_ztpjmkFOSvNd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;870,229&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;806,004&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pp0p0_maAPAOAzxRP_znSBd8T5lr0c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued employee costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,371,498&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,213,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maAPAOAzxRP_zlKXwDdYWWy9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;39,165&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--AccruedResearchAndDevelopmentCurrent_iI_pp0p0_maAPAOAzxRP_z8rk0yw8NkD8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;860,958&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;439,024&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--AccruedBoardFeesCurrent_iI_pp0p0_maAPAOAzxRP_zfAV4Uc2wuli" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued board fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DelawareFranchiseTaxesPayableCurrent_iI_pp0p0_maAPAOAzxRP_zJiRSqpQT0ah" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Delaware franchise taxes payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0514"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maAPAOAzxRP_z0rTZzcNdzia" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;17,228&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;17,330&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_pp0p0_mtAPAOAzxRP_zMpVQCMEKC6c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total accounts payable and other current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,309,717&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,672,327&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000499"
      unitRef="USD">870229</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000500"
      unitRef="USD">806004</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000502"
      unitRef="USD">1371498</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000503"
      unitRef="USD">1213054</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000505"
      unitRef="USD">72054</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000506"
      unitRef="USD">39165</us-gaap:AccruedProfessionalFeesCurrent>
    <INDP:AccruedResearchAndDevelopmentCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000508"
      unitRef="USD">860958</INDP:AccruedResearchAndDevelopmentCurrent>
    <INDP:AccruedResearchAndDevelopmentCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000509"
      unitRef="USD">439024</INDP:AccruedResearchAndDevelopmentCurrent>
    <INDP:AccruedBoardFeesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000511"
      unitRef="USD">117750</INDP:AccruedBoardFeesCurrent>
    <INDP:AccruedBoardFeesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000512"
      unitRef="USD">117750</INDP:AccruedBoardFeesCurrent>
    <INDP:DelawareFranchiseTaxesPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000515"
      unitRef="USD">40000</INDP:DelawareFranchiseTaxesPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000517"
      unitRef="USD">17228</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000518"
      unitRef="USD">17330</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000520"
      unitRef="USD">3309717</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000521"
      unitRef="USD">2672327</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000523">&lt;p id="xdx_807_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zib1MN8LgiC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
5: &lt;span id="xdx_82E_zXq2nXHnYhh9"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has an equity incentive plan for grants to employees, officers, consultants, directors, and other service providers that was
approved in 2021 (the &#x201c;2021 Plan&#x201d;). The 2021 Plan provides for the grant of non-qualified stock options, incentive stock
options, restricted stock awards, restricted stock units, unrestricted stock awards, stock appreciation rights and other forms of stock-based
compensation. The 2021 Plan permits the Company&#x2019;s board to change the type, terms, and conditions of awards as circumstances may
change. This flexibility to adjust the type of compensation to be granted is particularly important given current economic and world
events.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zXAmXgmZyVk1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the stock option activity during the year ended December 31, 2024, is presented in the table below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_zeyGQStcEPA6" style="display: none"&gt;SCHEDULE
OF STOCK OPTION ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted average&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of &lt;br/&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Exercise &lt;br/&gt; price&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Remaining &lt;br/&gt; contractual &lt;br/&gt; life &lt;br/&gt; (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Intrinsic value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Outstanding as of January 1, 2024&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zwDRGNlhFQP6" style="width: 10%; text-align: right" title="Number of options, outstanding balance"&gt;2,050,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zqPGJvNypWcd" title="Weighted average exercise price, outstanding, balance"&gt;10.90&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zQuVqRd6KOq" title="Weighted average remaining contractual life (in years)"&gt;7.9&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20241231_z9qeWdsE2tSj" style="width: 10%; text-align: right" title="Intrinsic value, outstanding balance"&gt;36,363&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_z5dyblhUVj47" style="text-align: right" title="Number of options, granted"&gt;838,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zNpvhPhY6vHb" title="Weighted average exercise price, granted"&gt;1.54&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_pp0p0_c20240101__20241231_zpqtrVNV8h6c" style="text-align: right" title="Intrinsic value, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0539"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left; padding-left: 10pt"&gt;Forfeited and cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231_zJcVASGjDmMe" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, forfeited and cancelled"&gt;(625&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20241231_zzfIWwR9soo6" title="Weighted average exercise price, forfeited and cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0543"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_z9SBzHGDYs37" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, outstanding balance"&gt;2,887,822&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_zx4o6cMRJQme" title="Weighted average exercise price, balance"&gt;8.06&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zmUbwefKtb3k" title="Weighted average remaining contractual life (in years)"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240101__20241231_zH1kDjUIjIS4" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, Outstanding, balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0551"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_zfYJzxb1YpKb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, exercisable"&gt;1,854,764&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zyCcs0JmxGdb" title="Weighted average exercise price, exercisable"&gt;11.54&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_z1y98MsH2l68" title="Weighted average remaining contractual life, Exercisable"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20240101__20241231_zv137HlKlX57" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, outstanding balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0559"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Vested and expected to vest as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20240101__20241231_zYfkN4Z22mm" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, vested and expected to vest"&gt;2,887,822&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_zRkr1D4wLpql" title="Weighted average exercise price, vested and expected to vest"&gt;8.06&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zFuPTSGFqAoh" title="Weighted average remaining contractual life (in years), vested and expected to vest"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240101__20241231_zRHIFEfKL8g2" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, vested and expected to vest balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0567"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zzi5cqrNmD9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zSATXzgUajvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the total stock-based compensation expense included in the consolidated statements of operations for the periods
presented:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zDPSQrTLhZff"&gt;SCHEDULE
OF STOCK BASED COMPENSATION EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240101__20241231_zEowYqIwHx3e" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20230101__20231231_zersO87Crwo2" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zwS6iSu3ZWL8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;624,480&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;792,273&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zTQbkhyUTQQj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,681,369&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,173,665&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ShareBasedCompensation_zohOI9W2FCq3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total stock-based compensation expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,305,849&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,965,938&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zvl7kNmXeEZa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, total compensation cost not yet recognized related to unvested stock options was approximately $&lt;span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20241231_zex7hvOGfFih" title="Share-based compensation, not yet recognized"&gt;1.0&lt;/span&gt; million, which
is expected to be recognized over a weighted-average period of approximately &lt;span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231_zBQmLdCRC5Mc" title="Share-based compensation, not yet recognized, term"&gt;1.5&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company estimates the fair value of stock options on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes
option-pricing model requires estimates of highly subjective assumptions, which affect the fair value of each stock option. The weighted
average inputs used to measure the value of the options granted during the years ended December 31, 2024 and 2023 are presented in the
table below. The weighted average fair value of stock options issued during the years ended December 31, 2024 and 2023 was $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231_zZZVhQl1go7a" title="Weighted average fair value of stock options issued"&gt;1.31&lt;/span&gt; and
$&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zuV1qMdADOFc" title="Weighted average fair value of stock options issued"&gt;1.43&lt;/span&gt; per share, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zrcCTPEa0VWk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B5_z5EeR8Fixg7a" style="display: none"&gt;SCHEDULE
OF WEIGHTED AVERAGE INPUTS USED TO MEASURE VALUE OF OPTIONS GRANTED&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Exercise price&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20241231_zlukEmmEsRN4" style="width: 16%; text-align: right" title="Exercise price"&gt;1.54&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20231231_zlWom0vDGvO2" style="width: 16%; text-align: right" title="Exercise price"&gt;1.70&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231_zNSCGk9H5jf5" title="Expected term (in years)"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zDz1s1bSj666" title="Expected term (in years)"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231_zEMj6Ynoddpg" title="Volatility"&gt;114.78&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231_zY9sburtLfT7" title="Volatility"&gt;110.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231_zUc1dIbbB9o" title="Risk free rate"&gt;4.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231_zEAYfPdAp7dl" title="Risk free rate"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231_zYYuY7UHS391" title="Dividend yield"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_zporOTsZbj21" title="Dividend yield"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zdWOOj9D8ms" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zISc1R7Vjvle" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the exercise price of outstanding stock options as of December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zRHySXYFx62c" style="display: none"&gt;SCHEDULE
OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="text-decoration: underline"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Options &lt;br/&gt; outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;$0.01 - $8.00&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zAb9sL5u7fgi" style="text-align: right" title="Options outstanding"&gt;1,861,499&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;$&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVYRVJDSVNFIFBSSUNFIE9GIE9VVFNUQU5ESU5HIFNUT0NLIE9QVElPTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zKEYUUqRU9C7" title="Exercise price range lower range limit"&gt;0.01&lt;/span&gt; - $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVYRVJDSVNFIFBSSUNFIE9GIE9VVFNUQU5ESU5HIFNUT0NLIE9QVElPTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zFPPL2xF8cse" title="Exercise price range upper range limit"&gt;8.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zFlofZCEAqhd" style="width: 16%; text-align: right" title="Options outstanding"&gt;1,861,499&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;$&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVYRVJDSVNFIFBSSUNFIE9GIE9VVFNUQU5ESU5HIFNUT0NLIE9QVElPTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zvcnbSm68Xx2" title="Exercise price range lower range limit"&gt;8.01&lt;/span&gt; - $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVYRVJDSVNFIFBSSUNFIE9GIE9VVFNUQU5ESU5HIFNUT0NLIE9QVElPTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zS0Jv3U0bKp5" title="Exercise price range upper range limit"&gt;16.00&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zAqwWC07acxk" style="text-align: right" title="Options outstanding"&gt;992,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;$&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVYRVJDSVNFIFBSSUNFIE9GIE9VVFNUQU5ESU5HIFNUT0NLIE9QVElPTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zIKCOXNfzFOa" title="Exercise price range lower range limit"&gt;16.01&lt;/span&gt; or higher&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zJ3TqrSUYHf7" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding"&gt;34,073&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231_zD6QVuk5SHfl" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding"&gt;2,887,822&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zZlu8LxJak8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000525">&lt;p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zXAmXgmZyVk1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the stock option activity during the year ended December 31, 2024, is presented in the table below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_zeyGQStcEPA6" style="display: none"&gt;SCHEDULE
OF STOCK OPTION ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted average&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of &lt;br/&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Exercise &lt;br/&gt; price&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Remaining &lt;br/&gt; contractual &lt;br/&gt; life &lt;br/&gt; (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Intrinsic value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Outstanding as of January 1, 2024&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zwDRGNlhFQP6" style="width: 10%; text-align: right" title="Number of options, outstanding balance"&gt;2,050,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zqPGJvNypWcd" title="Weighted average exercise price, outstanding, balance"&gt;10.90&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zQuVqRd6KOq" title="Weighted average remaining contractual life (in years)"&gt;7.9&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20241231_z9qeWdsE2tSj" style="width: 10%; text-align: right" title="Intrinsic value, outstanding balance"&gt;36,363&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_z5dyblhUVj47" style="text-align: right" title="Number of options, granted"&gt;838,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zNpvhPhY6vHb" title="Weighted average exercise price, granted"&gt;1.54&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_pp0p0_c20240101__20241231_zpqtrVNV8h6c" style="text-align: right" title="Intrinsic value, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0539"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left; padding-left: 10pt"&gt;Forfeited and cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231_zJcVASGjDmMe" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, forfeited and cancelled"&gt;(625&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20241231_zzfIWwR9soo6" title="Weighted average exercise price, forfeited and cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0543"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_z9SBzHGDYs37" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, outstanding balance"&gt;2,887,822&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_zx4o6cMRJQme" title="Weighted average exercise price, balance"&gt;8.06&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zmUbwefKtb3k" title="Weighted average remaining contractual life (in years)"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240101__20241231_zH1kDjUIjIS4" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, Outstanding, balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0551"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_zfYJzxb1YpKb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, exercisable"&gt;1,854,764&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zyCcs0JmxGdb" title="Weighted average exercise price, exercisable"&gt;11.54&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_z1y98MsH2l68" title="Weighted average remaining contractual life, Exercisable"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20240101__20241231_zv137HlKlX57" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, outstanding balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0559"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Vested and expected to vest as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20240101__20241231_zYfkN4Z22mm" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, vested and expected to vest"&gt;2,887,822&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_zRkr1D4wLpql" title="Weighted average exercise price, vested and expected to vest"&gt;8.06&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zFuPTSGFqAoh" title="Weighted average remaining contractual life (in years), vested and expected to vest"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240101__20241231_zRHIFEfKL8g2" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, vested and expected to vest balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0567"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000527"
      unitRef="Shares">2050197</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000529"
      unitRef="USDPShares">10.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2023-01-012023-12-31" id="Fact000531">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000533"
      unitRef="USD">36363</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000535"
      unitRef="Shares">838250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000537"
      unitRef="USDPShares">1.54</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000541"
      unitRef="Shares">625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000545"
      unitRef="Shares">2887822</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000547"
      unitRef="USDPShares">8.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2024-01-01to2024-12-31" id="Fact000549">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000553"
      unitRef="Shares">1854764</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000555"
      unitRef="USDPShares">11.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2024-01-01to2024-12-31" id="Fact000557">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000561"
      unitRef="Shares">2887822</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000563"
      unitRef="USDPShares">8.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2024-01-01to2024-12-31" id="Fact000565">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000569">&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zSATXzgUajvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the total stock-based compensation expense included in the consolidated statements of operations for the periods
presented:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zDPSQrTLhZff"&gt;SCHEDULE
OF STOCK BASED COMPENSATION EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240101__20241231_zEowYqIwHx3e" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20230101__20231231_zersO87Crwo2" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zwS6iSu3ZWL8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;624,480&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;792,273&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zTQbkhyUTQQj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,681,369&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,173,665&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ShareBasedCompensation_zohOI9W2FCq3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total stock-based compensation expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,305,849&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,965,938&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact000571"
      unitRef="USD">624480</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact000572"
      unitRef="USD">792273</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact000574"
      unitRef="USD">1681369</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact000575"
      unitRef="USD">2173665</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000577"
      unitRef="USD">2305849</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000578"
      unitRef="USD">2965938</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000580"
      unitRef="USD">1000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2024-01-01to2024-12-31" id="Fact000582">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000584"
      unitRef="USDPShares">1.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000586"
      unitRef="USDPShares">1.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000588">&lt;p id="xdx_897_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zrcCTPEa0VWk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B5_z5EeR8Fixg7a" style="display: none"&gt;SCHEDULE
OF WEIGHTED AVERAGE INPUTS USED TO MEASURE VALUE OF OPTIONS GRANTED&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Exercise price&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20241231_zlukEmmEsRN4" style="width: 16%; text-align: right" title="Exercise price"&gt;1.54&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20231231_zlWom0vDGvO2" style="width: 16%; text-align: right" title="Exercise price"&gt;1.70&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231_zNSCGk9H5jf5" title="Expected term (in years)"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zDz1s1bSj666" title="Expected term (in years)"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231_zEMj6Ynoddpg" title="Volatility"&gt;114.78&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231_zY9sburtLfT7" title="Volatility"&gt;110.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231_zUc1dIbbB9o" title="Risk free rate"&gt;4.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231_zEAYfPdAp7dl" title="Risk free rate"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231_zYYuY7UHS391" title="Dividend yield"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_zporOTsZbj21" title="Dividend yield"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000590"
      unitRef="USDPShares">1.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000592"
      unitRef="USDPShares">1.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2024-01-01to2024-12-31" id="Fact000594">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2023-01-012023-12-31" id="Fact000596">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000598"
      unitRef="Pure">1.1478</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000600"
      unitRef="Pure">1.109</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000602"
      unitRef="Pure">0.040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000604"
      unitRef="Pure">0.037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000606"
      unitRef="Pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000608"
      unitRef="Pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000610">&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zISc1R7Vjvle" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the exercise price of outstanding stock options as of December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zRHySXYFx62c" style="display: none"&gt;SCHEDULE
OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="text-decoration: underline"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Options &lt;br/&gt; outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;$0.01 - $8.00&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zAb9sL5u7fgi" style="text-align: right" title="Options outstanding"&gt;1,861,499&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;$&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVYRVJDSVNFIFBSSUNFIE9GIE9VVFNUQU5ESU5HIFNUT0NLIE9QVElPTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zKEYUUqRU9C7" title="Exercise price range lower range limit"&gt;0.01&lt;/span&gt; - $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVYRVJDSVNFIFBSSUNFIE9GIE9VVFNUQU5ESU5HIFNUT0NLIE9QVElPTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zFPPL2xF8cse" title="Exercise price range upper range limit"&gt;8.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zFlofZCEAqhd" style="width: 16%; text-align: right" title="Options outstanding"&gt;1,861,499&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;$&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVYRVJDSVNFIFBSSUNFIE9GIE9VVFNUQU5ESU5HIFNUT0NLIE9QVElPTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zvcnbSm68Xx2" title="Exercise price range lower range limit"&gt;8.01&lt;/span&gt; - $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVYRVJDSVNFIFBSSUNFIE9GIE9VVFNUQU5ESU5HIFNUT0NLIE9QVElPTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zS0Jv3U0bKp5" title="Exercise price range upper range limit"&gt;16.00&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zAqwWC07acxk" style="text-align: right" title="Options outstanding"&gt;992,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;$&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVYRVJDSVNFIFBSSUNFIE9GIE9VVFNUQU5ESU5HIFNUT0NLIE9QVElPTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zIKCOXNfzFOa" title="Exercise price range lower range limit"&gt;16.01&lt;/span&gt; or higher&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zJ3TqrSUYHf7" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding"&gt;34,073&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231_zD6QVuk5SHfl" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding"&gt;2,887,822&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceRangeOneMember"
      decimals="INF"
      id="Fact000612"
      unitRef="Shares">1861499</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2024-01-012024-12-31_custom_ExercisePriceRangeOneMember"
      decimals="INF"
      id="Fact000614"
      unitRef="USDPShares">0.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-01-012024-12-31_custom_ExercisePriceRangeOneMember"
      decimals="INF"
      id="Fact000616"
      unitRef="USDPShares">8.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceRangeOneMember"
      decimals="INF"
      id="Fact000618"
      unitRef="Shares">1861499</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2024-01-012024-12-31_custom_ExercisePriceRangeTwoMember"
      decimals="INF"
      id="Fact000620"
      unitRef="USDPShares">8.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-01-012024-12-31_custom_ExercisePriceRangeTwoMember"
      decimals="INF"
      id="Fact000622"
      unitRef="USDPShares">16.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceRangeTwoMember"
      decimals="INF"
      id="Fact000624"
      unitRef="Shares">992250</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2024-01-012024-12-31_custom_ExercisePriceRangeThreeMember"
      decimals="INF"
      id="Fact000626"
      unitRef="USDPShares">16.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2024-12-31_custom_ExercisePriceRangeThreeMember"
      decimals="INF"
      id="Fact000628"
      unitRef="Shares">34073</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000630"
      unitRef="Shares">2887822</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <INDP:CapitalizationTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000632">&lt;p id="xdx_802_ecustom--CapitalizationTextBlock_zQDr6vbLxSPf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
6: &lt;span id="xdx_827_zd4DzPIxkPF5"&gt;CAPITALIZATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
    of December 31, 2024 and December 31, 2023, the Company had &lt;span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zlGPvMVUFSt5" title="Common stock, shares authorized"&gt;&lt;span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_zCn6Ojz7eTGa" title="Common stock, shares authorized"&gt;200,000,000&lt;/span&gt;&lt;/span&gt;
    shares of common stock authorized and &lt;span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231_zpa5gZcgoJQ" title="Common stock, shares issued"&gt;&lt;span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zwuk79Q4j3ub" title="Common stock, shares outstanding"&gt;12,013,901&lt;/span&gt;&lt;/span&gt;
    and &lt;span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_zybpOiObkan4" title="Common stock, shares issued"&gt;&lt;span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_zhIxN9rFWqb8" title="Common stock, shares outstanding"&gt;8,401,047&lt;/span&gt;&lt;/span&gt;
    shares issued and outstanding, respectively. As of December 31, 2024 and December 31, 2023, the Company had &lt;span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_zH1QrIk6Atsg" title="Preferred stock, shares authorized"&gt;&lt;span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231_zRihT3jroly4" title="Preferred stock, shares authorized"&gt;5,000,000&lt;/span&gt;&lt;/span&gt;
    shares of preferred stock authorized. There were &lt;span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20241231_zwai1cDwmOH8" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20231231_zPaXnSHWCqm2" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20241231_ztTEv39Awwha" title="Preferred stock, shares outstanding"&gt;&lt;span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20231231_zfqiuOXVW4j4" title="Preferred stock, shares outstanding"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; shares of preferred stock issued or outstanding as of December 31, 2024 and
    2023. As of December 31, 2024 and December 31, 2023, there were warrants outstanding to purchase an aggregate of &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231_zGbw15QBQfX5" title="Warrants outstanding to purchase"&gt;6,675,853&lt;/span&gt;
    and &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231_zWKGIVW8YPFd" title="Warrants outstanding to purchase"&gt;3,090,787&lt;/span&gt;
    shares of common stock, respectively. As of December 31, 2024, these warrants are exercisable at a weighted average price of $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmfnXT32AZt" title="Weighted average exercise price"&gt;6.52&lt;/span&gt;
    and their weighted average remaining contractual term is &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z99qsiitKYna" title="Weighted average, remaining contractual life"&gt;3.5&lt;/span&gt;
    years.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On June 1, 2022, the Company
    entered into an At The Market Offering Agreement (the &#x201c;ATM Agreement&#x201d;) which was amended on September 1, 2022 with a
    sales agent, pursuant to which the Company may offer and sell, from time to time through the sales agent, shares of the Company&#x2019;s
    common stock, par value $&lt;span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20220901__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zD8OFNxMCYm3" title="Common stock, par value"&gt;0.01&lt;/span&gt; per share. The issuance and sale of common stock by the Company under the &lt;span style="background-color: white"&gt;ATM
    Agreement&lt;/span&gt; is being made pursuant to the Company&#x2019;s effective &#x201c;shelf&#x201d; registration statement on Form S-3 filed
    with the SEC on September 1, 2022 and declared effective on September 9, 2022. &lt;span style="background-color: white"&gt;In 2024, the
    Company sold &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zxCOyrv5Rnp8" title="Shares issued"&gt;152,000&lt;/span&gt; shares of the Company&#x2019;s common stock for aggregate gross proceeds of approximately $&lt;span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zWBOeAH44Ir1" title="Proceeds from issuance of common stock"&gt;0.4&lt;/span&gt; million. &lt;/span&gt;The
    Company&#x2019;s ability to issue shares under the shelf registration statement on Form S-3 is limited by General Instruction I.B.6
    to Form S-3. On August 6&lt;span style="background-color: white"&gt;, 2024, the Company filed a prospectus supplement to reduce the amount
    of shares registered under the prospectus for the ATM to $&lt;span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240806__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zvuNyxGQ4UD7" title="Common stock, par value"&gt;0.00&lt;/span&gt; and to suspend the ATM program, but the ATM Agreement remains in full
    force and effect&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    August 8, 2024, the Company completed a registered direct offering, pursuant to which the Company sold and issued to certain investors,
    including an officer of the Company, &lt;span id="xdx_902_eus-gaap--SharesIssued_iI_pid_c20240808__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zelDhdzt93F4" title="Shares issued"&gt;1,643,837&lt;/span&gt; shares of the Company&#x2019;s common stock at a purchase price per share of $&lt;span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240808_zXFr5mqby50l" title="Shares issued, price per share"&gt;1.825&lt;/span&gt;.
    In addition, in a concurrent private placement, the Company also issued to the purchasers in the August 2024 Offering unregistered
    warrants to purchase &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240808__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_ztIxvFUnmOY" title="Class of warrant or right, number of securities called by warrants or rights"&gt;1,643,837&lt;/span&gt; shares of the Company&#x2019;s common stock (the &#x201c;August 2024 Warrants&#x201d;). The August 2024
    Warrants are immediately exercisable at an exercise price of $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240808__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTLaIQ9mVkAa" title="Class of warrant or right, exercise price of warrants or rights"&gt;1.70&lt;/span&gt; per share and expire &lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20240808__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyCK8qXJziT2" title="Warrants and rights outstanding, term"&gt;five years&lt;/span&gt; from the date of issuance. The
    total net proceeds were approximately $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240808__20240808_z74O81jkPrEc" title="Proceeds from issuance of common stock"&gt;2.5&lt;/span&gt; million, after deducting placement agent and other offering expenses in the amount of
    approximately $&lt;span id="xdx_906_eus-gaap--NoninterestExpenseOfferingCost_pn5n6_c20240808__20240808_zisvYsmJA2P" title="Noninterest expense offering cost"&gt;0.5&lt;/span&gt; million. In September 2024, the Company filed a registration statement to register the resale by the investors
    of the shares of common stock issuable upon exercise of the August 2024 Warrants. The registration statement was declared effective
    on September 20, 2024.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On November 22, 2024, the
    Company completed a registered direct offering, pursuant to which the Company sold and issued to certain investors, including an
    officer of the Company, &lt;span id="xdx_901_eus-gaap--SharesIssued_iI_pid_c20241122__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zpPaub8IlHyg" title="Shares issued"&gt;1,817,017&lt;/span&gt; shares of the Company&#x2019;s common stock at a purchase price per share of $&lt;span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241122_zLZnRgBSmDP8" title="Shares issued, price per share"&gt;1.175&lt;/span&gt;. In addition,
    in a concurrent private placement, the Company also issued to the purchasers in the November 2024 Offering unregistered warrants
    to purchase &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241122__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3tH7DlmCpUc" title="Class of warrant or right, number of securities called by warrants or rights"&gt;1,817,017&lt;/span&gt; shares of the Company&#x2019;s common stock (the &#x201c;November 2024 Warrants&#x201d;). The November 2024 Warrants
    are immediately exercisable at an exercise price of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241122__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTlEiDZ8Zn1" title="Class of warrant or right, exercise price of warrants or rights"&gt;1.05&lt;/span&gt; per share and expire &lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20241122__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaWIxo0Xyihl" title="Warrants and rights outstanding, term"&gt;five years&lt;/span&gt; from the date of issuance. The total net
    proceeds were approximately $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20241122__20241122_zssE98fAhfS4" title="Proceeds from issuance of common stock"&gt;1.8&lt;/span&gt; million, after deducting placement agent and other offering expenses in the amount of approximately
    $&lt;span id="xdx_903_eus-gaap--NoninterestExpenseOfferingCost_pn4n6_c20241122__20241122_z1Od3HuxhA4a" title="Noninterest expense offering cost"&gt;0.35&lt;/span&gt; million. In December 2024, the Company filed a registration statement to register the resale by the investors of the shares
    of common stock issuable upon exercise of the November 2024 Warrants. The registration statement was declared effective on December
    31, 2024. In addition, in connection with the November 2024 Offering, the Company issued to the placement agent and its designees
    warrants to purchase an aggregate of &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zMvS2HFrdTZ5" title="Warrants to purchase aggregate shares"&gt;124,212&lt;/span&gt; shares of common stock at an exercise price of $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231_z86TXieDX3xa" title="Warrants exercise price"&gt;1.3125&lt;/span&gt;. The placement agent warrants
    are exercisable six months from the date of issuance and expire on the fifth anniversary of the issue date. The fair value of a warrant
    to purchase &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_dc_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_ze9SNHpHHqIf" title="Fair value of a warrant to purchase"&gt;one&lt;/span&gt; share of common stock that was issued to the placement agent was $&lt;span id="xdx_903_eus-gaap--SharePrice_iI_pid_c20241231_z3LMabN6EdTe" title="Share price"&gt;0.93&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On January 16, 2025, the
    Company completed a private placement offering pursuant to which the Company sold and issued to certain investors an aggregate of
    &lt;span id="xdx_90C_eus-gaap--SharesIssued_iI_pid_c20250116__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z6qmcF7ObzLi" title="Shares issued"&gt;2,109,383&lt;/span&gt; shares of common stock and warrants to purchase &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250116__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zbtOnOmhtoXf" title="Warrants purchase shares"&gt;2,109,383&lt;/span&gt; shares of common stock (the &#x201c;January 2025 Warrants&#x201d;).
    The shares and January 2025 Warrants were sold on a combined basis for consideration of $&lt;span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250116__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z89ZL6bXm0Bi" title="Shares issued, price per share"&gt;1.065&lt;/span&gt; for one share and one January 2025
    Warrant. The January 2025 Warrants are immediately exercisable at an exercise price of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250116__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0l8YbSRAU1c" title="Class of warrant or right, exercise price of warrants or rights"&gt;0.94&lt;/span&gt; per share and expire &lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250116__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLPiR2Q0oVo2" title="Warrants and rights outstanding, term"&gt;five years&lt;/span&gt; from
    the date of issuance. The total net proceeds were approximately $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250116__20250116__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zh1argJvdXa" title="Proceeds from issuance of common stock"&gt;2.0&lt;/span&gt; million, after deducting placement agent and other offering
    expenses in the amount of approximately $&lt;span id="xdx_90C_eus-gaap--NoninterestExpenseOfferingCost_pn4n6_c20250116__20250116__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1trsDX6pLYb" title="Noninterest expense offering cost"&gt;0.25&lt;/span&gt; million. In February 2025, the Company filed a registration statement to register the
    resale by the investors of the shares of common stock and shares of common stock issuable upon exercise of the January 2025 Warrants.
    The registration statement was declared effective on February 11, 2025. In addition, in connection with the January 2025 Offering,
    the Company issued to the placement agent and its designees warrants to purchase an aggregate of &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250211__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zrmgqXaeK144" title="Warrants to purchase aggregate shares"&gt;147,656&lt;/span&gt; shares of common stock at
    an exercise price of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250211_zps1i9rlWV2i" title="Warrants exercise price"&gt;1.175&lt;/span&gt;. The placement agent warrants are exercisable six months from the date of issuance and expire on the
    fifth anniversary of the issue date. The fair value of a warrant to purchase &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_dc_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zeztbEJsflDl" title="Fair value of a warrant to purchase"&gt;one&lt;/span&gt; share of common stock that was issued to the placement
    agent was $&lt;span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zC5XhSrpBj1h" title="Share price"&gt;0.74&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0"&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 12, 2025, the
    Company &lt;span style="background-color: white"&gt;entered into a Standby Equity Purchase &lt;/span&gt;Agreement (the &#x201c;SEPA&#x201d;) with
    YA II PN, LTD., a Cayman Islands exempt limited company (&#x201c;Yorkville&#x201d;), which provides that, upon the terms and subject
    to the restrictions and satisfaction of the conditions in the SEPA, Yorkville is committed to purchase up to an aggregate of $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20250212__20250212__dei--LegalEntityAxis__custom--YorkvilleMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpKf5biUcyj4" title="Purchase ordinary shares"&gt;20.0&lt;/span&gt;
    million of the Company&#x2019;s shares of common stock over a 36-month period. At the Company&#x2019;s option, the shares of common
    stock would be purchased by Yorkville from time to time at a price equal to 97% of the lowest of the three daily VWAPs during a three
    consecutive trading day period commencing on the date that the Company, subject to certain limitations, delivers a notice to Yorkville
    that the Company is committing Yorkville to purchase such shares of common stock. The Company may also specify a certain minimum
    acceptable price per share in each advance. The Company will control the timing and amount of sales of the Company&#x2019;s shares
    to Yorkville. As consideration for Yorkville&#x2019;s irrevocable commitment to purchase shares of the Company&#x2019;s common stock
    upon the terms of and subject to restrictions and satisfaction of the conditions set forth in the SEPA, upon execution of the SEPA,
    the Company issued to Yorkville &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250212__20250212__dei--LegalEntityAxis__custom--YorkvilleMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zI7PfwYmxaTc" title="Commitment shares issued"&gt;305,960&lt;/span&gt; shares of common stock, as commitment shares. &lt;span style="background-color: white"&gt;Under
    the applicable Nasdaq Rules and pursuant to the SEPA, in no event may the Company issue or sell to Yorkville more than &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250212__20250212__us-gaap--TypeOfArrangementAxis__custom--ExchangeCapMember__dei--LegalEntityAxis__custom--YorkvilleMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zSWuwsbgPitk" title="Shares issued"&gt;2,823,244&lt;/span&gt;
    shares of common stock (the &#x201c;Exchange Cap&#x201d;), which is 19.99% of the shares of common stock outstanding immediately prior
    to the execution of the SEPA, unless (i) the Company obtains stockholder approval to issue shares of common stock in excess of the
    Exchange Cap, or (ii) the average price of all applicable sales of common stock under the SEPA equals or exceeds $&lt;span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250212__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementsMember__dei--LegalEntityAxis__custom--YorkvilleMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zMNAUoxt3hL" title="Shares issued, price per share"&gt;0.81722&lt;/span&gt; per share
    (which represents the lower of (i) the Nasdaq Official Closing Price (as reflected on Nasdaq.com) on the trading day immediately
    preceding the effective date or (ii) the average Nasdaq Official Closing Price of the common stock (as reflected on Nasdaq.com) for
    the five trading days immediately preceding the effective date). &lt;/span&gt;On February 12, 2025, the Company filed a Form S-1 covering
    the resale of up to &lt;span id="xdx_901_ecustom--NumberOfResaleCommonStockComprised_pid_c20250212__20250212__dei--LegalEntityAxis__custom--YorkvilleMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNjHk7M2Kdah" title="Number of resale common stock comprised"&gt;10,000,000&lt;/span&gt; shares of common stock comprised of (i) &lt;span id="xdx_904_ecustom--NumberOfCommitmentShares_pid_c20250212__20250212__dei--LegalEntityAxis__custom--YorkvilleMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zvYCCsv9gbf2" title="Commitment shares issued"&gt;305,960&lt;/span&gt; commitment shares, and (ii) up to &lt;span id="xdx_90D_ecustom--NumberOfCommitmentSharesToBeIssuedUponCertainConditions_pid_c20250212__20250212__dei--LegalEntityAxis__custom--YorkvilleMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementsMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4ocMnv8ECwj" title="Commitment shares to be issued upon certain conditions"&gt;9,694,040&lt;/span&gt; shares
    of common stock reserved for issuance and sale to Yorkville under the SEPA. The Form S-1 was declared effective on February 13, 2025.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</INDP:CapitalizationTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000634"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000636"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000638"
      unitRef="Shares">12013901</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000640"
      unitRef="Shares">12013901</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000642"
      unitRef="Shares">8401047</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000644"
      unitRef="Shares">8401047</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000646"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000648"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000650"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000652"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000654"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000656"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000658"
      unitRef="Shares">6675853</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000660"
      unitRef="Shares">3090787</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000662"
      unitRef="USDPShares">6.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember9626531"
      id="Fact000664">P3Y6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-09-01_custom_AtTheMarketOfferingAgreementMember_custom_HCWainwrightAndCoLLCMember"
      decimals="INF"
      id="Fact000666"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_custom_AtTheMarketOfferingAgreementMember_custom_HCWainwrightAndCoLLCMember"
      decimals="INF"
      id="Fact000668"
      unitRef="Shares">152000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-012024-12-31_custom_AtTheMarketOfferingAgreementMember_custom_HCWainwrightAndCoLLCMember"
      decimals="-5"
      id="Fact000670"
      unitRef="USD">400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-08-06_custom_AtTheMarketOfferingAgreementMember_custom_HCWainwrightAndCoLLCMember"
      decimals="INF"
      id="Fact000672"
      unitRef="USDPShares">0.00</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-08-08_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact000674"
      unitRef="Shares">1643837</us-gaap:SharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-08-08"
      decimals="INF"
      id="Fact000676"
      unitRef="USDPShares">1.825</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-08-08_us-gaap_WarrantMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000678"
      unitRef="Shares">1643837</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-08-08_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000680"
      unitRef="USDPShares">1.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-08-08_us-gaap_WarrantMember"
      id="Fact000682">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-08-082024-08-08"
      decimals="-5"
      id="Fact000684"
      unitRef="USD">2500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NoninterestExpenseOfferingCost
      contextRef="From2024-08-082024-08-08"
      decimals="-5"
      id="Fact000686"
      unitRef="USD">500000</us-gaap:NoninterestExpenseOfferingCost>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-11-22_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact000688"
      unitRef="Shares">1817017</us-gaap:SharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-11-22"
      decimals="INF"
      id="Fact000690"
      unitRef="USDPShares">1.175</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-11-22_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000692"
      unitRef="Shares">1817017</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-11-22_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000694"
      unitRef="USDPShares">1.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-11-22_us-gaap_WarrantMember"
      id="Fact000696">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-11-222024-11-22"
      decimals="-5"
      id="Fact000698"
      unitRef="USD">1800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NoninterestExpenseOfferingCost
      contextRef="From2024-11-222024-11-22"
      decimals="-4"
      id="Fact000700"
      unitRef="USD">350000</us-gaap:NoninterestExpenseOfferingCost>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact000702"
      unitRef="Shares">124212</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000704"
      unitRef="USDPShares">1.3125</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000706"
      unitRef="Shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000708"
      unitRef="USDPShares">0.93</us-gaap:SharePrice>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-01-16_us-gaap_InvestorMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000710"
      unitRef="Shares">2109383</us-gaap:SharesIssued>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-01-16_us-gaap_InvestorMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000712"
      unitRef="Shares">2109383</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2025-01-16_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000714"
      unitRef="USDPShares">1.065</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-01-16_us-gaap_WarrantMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000716"
      unitRef="USDPShares">0.94</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-01-16_us-gaap_WarrantMember_us-gaap_SubsequentEventMember"
      id="Fact000718">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-01-162025-01-16_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact000720"
      unitRef="USD">2000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NoninterestExpenseOfferingCost
      contextRef="From2025-01-162025-01-16_us-gaap_SubsequentEventMember"
      decimals="-4"
      id="Fact000722"
      unitRef="USD">250000</us-gaap:NoninterestExpenseOfferingCost>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-02-11_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact000724"
      unitRef="Shares">147656</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-02-11"
      decimals="INF"
      id="Fact000726"
      unitRef="USDPShares">1.175</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000728"
      unitRef="Shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharePrice
      contextRef="AsOf2024-12-31_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000730"
      unitRef="USDPShares">0.74</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-02-122025-02-12_custom_YorkvilleMember_custom_StandbyEquityPurchaseAgreementsMember_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact000732"
      unitRef="USD">20000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-02-122025-02-12_custom_YorkvilleMember_custom_StandbyEquityPurchaseAgreementsMember_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000734"
      unitRef="Shares">305960</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-02-122025-02-12_custom_ExchangeCapMember_custom_YorkvilleMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000736"
      unitRef="Shares">2823244</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2025-02-12_custom_StandbyEquityPurchaseAgreementsMember_custom_YorkvilleMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000738"
      unitRef="USDPShares">0.81722</us-gaap:SharesIssuedPricePerShare>
    <INDP:NumberOfResaleCommonStockComprised
      contextRef="From2025-02-122025-02-12_custom_YorkvilleMember_custom_StandbyEquityPurchaseAgreementsMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000740"
      unitRef="Shares">10000000</INDP:NumberOfResaleCommonStockComprised>
    <INDP:NumberOfCommitmentShares
      contextRef="From2025-02-122025-02-12_custom_YorkvilleMember_custom_StandbyEquityPurchaseAgreementsMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000742"
      unitRef="Shares">305960</INDP:NumberOfCommitmentShares>
    <INDP:NumberOfCommitmentSharesToBeIssuedUponCertainConditions
      contextRef="From2025-02-122025-02-12_custom_YorkvilleMember_custom_StandbyEquityPurchaseAgreementsMember_srt_MaximumMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000744"
      unitRef="Shares">9694040</INDP:NumberOfCommitmentSharesToBeIssuedUponCertainConditions>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000746">&lt;p id="xdx_80C_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z0miqQVsBwpc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
7: &lt;span id="xdx_82F_zX8L3OIVyEa"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Litigation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business.
These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. Periodically,
the Company reviews the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential
loss from any claim or legal claim is considered probable and the amount of such potential loss can be estimated, the Company accrues
liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because
of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available,
the Company reassesses the potential liability related to pending claims and litigation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 1, 2021, the Company entered into a noncancelable two-year operating lease agreement for approximately &lt;span id="xdx_907_eus-gaap--AreaOfLand_iI_usqft_c20211001__srt--StatementGeographicalAxis__stpr--CA__us-gaap--TypeOfArrangementAxis__custom--TwoYearLeaseAgreementMember_z2gOvU5k7aw6" title="Area of land"&gt;2,000&lt;/span&gt; square feet of office
space in San Diego, California. The base rent was $&lt;span id="xdx_900_eus-gaap--LeaseAndRentalExpense_c20211001__20211001__srt--StatementGeographicalAxis__stpr--CA__us-gaap--TypeOfArrangementAxis__custom--TwoYearLeaseAgreementMember_z4k8zWNsWg6l" title="Base rent"&gt;7,999&lt;/span&gt; per month with an increase of &lt;span id="xdx_90C_ecustom--RateOfIncreaseInLeaseRent_pid_dp_uPure_c20211001__20211001__srt--StatementGeographicalAxis__stpr--CA__us-gaap--TypeOfArrangementAxis__custom--TwoYearLeaseAgreementMember_zeHwO7qa6F03" title="Rate of increase in lease rent"&gt;3&lt;/span&gt;% after the first anniversary of the lease term
commencement, which was November 1, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 19, 2023, the Company executed an amendment to &lt;span id="xdx_901_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20230419__20230419_zSuzqnVwWydf" title="Operating lease, extend description"&gt;the lease agreement to extend the lease through October 31, 2025.&lt;/span&gt; Accordingly, the
Company remeasured its operating lease liability under the agreement and recognized an incremental lease liability and right-of-use asset
of $&lt;span id="xdx_901_eus-gaap--OperatingLeaseLiability_iI_c20230419_zhf2HlUv8eG7" title="Operating lease liability"&gt;236,506&lt;/span&gt;. The remeasurement was based on a &lt;span id="xdx_902_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_c20230419_zlpHQycvTJ6c" title="Incremental borrowing rate"&gt;9&lt;/span&gt;% incremental borrowing rate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z3RisQPkGIXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
minimum annual lease payments and a reconciliation to the Company&#x2019;s operating lease liability under the Company&#x2019;s noncancelable
operating lease as of December 31, 2024 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_zyf7vEqKPT65" style="display: none"&gt;SUMMARY OF MINIMUM LEASE PAYMENTS&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_492_20241231_z2PZRMxwOvqh" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_mtLOLLPzSwn_zQCoRnEkG5E" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Total minimum lease payments in 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;86,862&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zEnBsCwROf7f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: amount representing interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,698&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zAXm3aw0rwBj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Present value of operating lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;84,164&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zAEZ8rsZSrOa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: current portion&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(84,164&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_z7fwp61UXO37" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Operating lease liability, net of current portion&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0770"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zDUqlJEt6m32" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognized rent expense of $&lt;span id="xdx_907_eus-gaap--PaymentsForRent_c20240101__20241231_znp3ac0wfoOd" title="Rental expense"&gt;101,847&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--PaymentsForRent_c20230101__20231231_z0EOnlGOGHVa" title="Rental expense"&gt;100,742&lt;/span&gt; during the years ended December 31, 2024 and 2023, respectively. Total cash
payments for the operating lease totaled $&lt;span id="xdx_907_eus-gaap--OperatingLeasePayments_c20240101__20241231_zUetMXs1F68c" title="Operating lease payments"&gt;101,705&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--OperatingLeasePayments_c20230101__20231231_zIuNVfWHen93" title="Operating lease payments"&gt;99,254&lt;/span&gt; during the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfLand
      contextRef="AsOf2021-10-01_stpr_CA_custom_TwoYearLeaseAgreementMember"
      decimals="INF"
      id="Fact000748"
      unitRef="sqft">2000</us-gaap:AreaOfLand>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2021-10-012021-10-01_stpr_CA_custom_TwoYearLeaseAgreementMember"
      decimals="0"
      id="Fact000750"
      unitRef="USD">7999</us-gaap:LeaseAndRentalExpense>
    <INDP:RateOfIncreaseInLeaseRent
      contextRef="From2021-10-012021-10-01_stpr_CA_custom_TwoYearLeaseAgreementMember"
      decimals="INF"
      id="Fact000752"
      unitRef="Pure">0.03</INDP:RateOfIncreaseInLeaseRent>
    <us-gaap:LesseeOperatingLeaseOptionToExtend contextRef="From2023-04-192023-04-19" id="Fact000754">the lease agreement to extend the lease through October 31, 2025.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2023-04-19"
      decimals="0"
      id="Fact000756"
      unitRef="USD">236506</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="AsOf2023-04-19"
      decimals="INF"
      id="Fact000758"
      unitRef="Pure">0.09</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000760">&lt;p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z3RisQPkGIXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
minimum annual lease payments and a reconciliation to the Company&#x2019;s operating lease liability under the Company&#x2019;s noncancelable
operating lease as of December 31, 2024 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_zyf7vEqKPT65" style="display: none"&gt;SUMMARY OF MINIMUM LEASE PAYMENTS&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_492_20241231_z2PZRMxwOvqh" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_mtLOLLPzSwn_zQCoRnEkG5E" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Total minimum lease payments in 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;86,862&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zEnBsCwROf7f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: amount representing interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,698&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zAXm3aw0rwBj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Present value of operating lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;84,164&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zAEZ8rsZSrOa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: current portion&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(84,164&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_z7fwp61UXO37" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Operating lease liability, net of current portion&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0770"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000762"
      unitRef="USD">86862</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000764"
      unitRef="USD">2698</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000766"
      unitRef="USD">84164</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000768"
      unitRef="USD">84164</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:PaymentsForRent
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000772"
      unitRef="USD">101847</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000774"
      unitRef="USD">100742</us-gaap:PaymentsForRent>
    <us-gaap:OperatingLeasePayments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000776"
      unitRef="USD">101705</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000778"
      unitRef="USD">99254</us-gaap:OperatingLeasePayments>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000780">&lt;p id="xdx_80A_eus-gaap--IncomeTaxDisclosureTextBlock_zrZN08W838b4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
8: &lt;span id="xdx_82E_zrtFde83fKSb"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the Company had net operating loss carry forwards that may be available to reduce future years&#x2019; taxable income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zTUhivYeNtv9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s provision for income taxes consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_z242BAKEQzPd" style="display: none"&gt;SCHEDULE
OF PROVISION FOR INCOME TAXES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20241231_zLCL4eNfPQE6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230101__20231231_znfb9i2Tirvk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzSdz_zT9WXNRuxvpd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Computed &#x201c;expected&#x201d; tax benefit&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(3,154,290&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(3,238,593&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzSdz_zHBWzLXsEXdj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State taxes, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,768&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,304&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_maITEBzSdz_z8QXT9poXWoe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Non-deductible items&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;230,890&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;61,842&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzSdz_zkmuv7KMfY3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Change in deferred tax asset valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,454,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,509,496&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_maITEBzSdz_zd2Vst94TdV5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;482,045&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;613,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmountReturnToProvisionAdjustments_maITEBzSdz_zyynnugD7Cgi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Return-to-provision adjustments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;41,316&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzSdz_zIGJRcb3CRIg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;621&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;13,918&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzSdz_zFKUFZFpa7C7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,700&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,450&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zvB6mdalE6E8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zTZ3FR6D4M28" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s net deferred tax assets were comprised of the following as of December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zgbOpEyrc719" style="display: none"&gt;SCHEDULE
OF NET DEFERRED TAX ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20241231_zSXUmyXbCTaa" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20231231_zPRpDyGVFAnc" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_zWysNROiBnZc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Net operating losses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;53,447,116&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;51,846,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_z8ThOyPpXaTg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Capitalized research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,959,591&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,162,872&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_zF0phi160nWh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;288,756&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;261,052&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_iI_znJ534kLTMp9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;249,495&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;220,923&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsFrequentFlierLiability_iI_zCqjP36GDjka" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,760&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36,761&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsOther_iI_zQs0zjhFqFxi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;616&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;559&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzCTx_maDTALNzH2X_zZEfUKkg0W1c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total gross deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;56,963,334&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;54,528,167&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_iNI_di_maDITLzRZ0_zFirxZXVNsc9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Right-of-use asset&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(17,340&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(36,373&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzRZ0_msDTALNzH2X_zpMKSOQ73S11" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Gross deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(17,340&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(36,373&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzH2X_zkcee1TRsfmf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: Deferred tax asset valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(56,945,994&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(54,491,794&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzH2X_zl5cYOCzlixj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0840"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0841"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zpBQcQhW3nEf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
income tax assets and liabilities are recorded for differences between the financial statement and tax basis of the assets and liabilities
that will result in taxable or deductible amounts in the future based on enacted laws and rates applicable to the periods in which the
differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets
to the amount expected to be realized&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to
the extent that management assesses that realization is &#x201c;more likely than not.&#x201d; Realization of the future tax benefits is
dependent on the Company&#x2019;s ability to generate sufficient taxable income within the carryforward period. Because of the Company&#x2019;s
recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned
future tax benefits is currently not likely to be realized and, accordingly, has provided a full valuation allowance for the years ended
December 31, 2024 and 2023. The net change in total valuation allowance for the years ended December 31, 2024 and 2023 was an increase
of $&lt;span id="xdx_900_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20240101__20241231_z0XcFPhK3gI5" title="Valuation allowance change amount"&gt;2.5&lt;/span&gt; million and increase of $&lt;span id="xdx_90B_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20230101__20231231_zI4DoyCjUOC5" title="Valuation allowance change amount"&gt;2.5&lt;/span&gt; million respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2024, the Company has United States federal and state net operating loss (NOL) carryforwards of $&lt;span id="xdx_909_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_z8HnJvHrsef7" title="Net operating loss (NOL) carryforwards"&gt;35.3&lt;/span&gt; million and $&lt;span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__custom--StateMember_zea56iQfLLvb" title="Net operating loss (NOL) carryforwards"&gt;7.6&lt;/span&gt; million,
respectively. The federal NOL carryforwards generated in pre-2018 tax years of $&lt;span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--TaxPeriodAxis__custom--ExpireInTwoThousandThirtySixMember__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_z3SVfRchMs0c" title="Operating loss carryforwards"&gt;0.8&lt;/span&gt; million will begin to expire in 2036 while federal
NOLs generated after 2017 of $&lt;span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--TaxPeriodAxis__custom--IndefinitePeriodMember__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_zBShpWSjvE9i" title="Operating loss carryforwards"&gt;34.4&lt;/span&gt; million will carry forward indefinitely. The state NOL carryforwards of $&lt;span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--TaxPeriodAxis__custom--ExpireInTwoThousandThirtyFiveMember__us-gaap--IncomeTaxAuthorityAxis__custom--StateMember_zer61JGsbbm" title="Operating loss carryforwards"&gt;7.6&lt;/span&gt; million will begin to
expire in 2035 unless previously utilized. At December 31, 2024, the Company also had Israel NOL carryforwards of $&lt;span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__srt--StatementGeographicalAxis__country--IL_zFColA0xLhZ4" title="Operating loss carryforwards"&gt;197.9&lt;/span&gt; million. The
Israel NOLs carry forward indefinitely.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s ability to utilize its net operating losses may be limited under Section 382 and 383 of the Internal Revenue Code. The
limitations apply if an ownership change, as defined by Section 382, occurs. Generally, an ownership change occurs when certain shareholders
increase their aggregate ownership by more than 50 percentage points over their lowest ownership percentage in a testing period (typically
three years). Although the Company has not undergone a Section 382 analysis, it is possible that the utilization of the net operating
losses, could be substantially limited. Additionally, U.S. tax laws limit the time during which these carryforwards may be utilized against
future taxes. As a result, the Company may not be able to take full advantage of these carryforwards for federal and state tax purposes.
Future changes in stock ownership may also trigger an ownership change and, consequently, a Section 382 limitation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes the benefit of tax positions taken or expected to be taken in its tax returns in the consolidated financial statements
when it is more likely than not that the position will be sustained upon examination by authorities. Recognized tax positions are measured
at the largest amount of benefit that is &lt;span id="xdx_90B_eus-gaap--IncomeTaxExaminationDescription_c20240101__20241231_zucLEhOVSrEa" title="Income tax examination description"&gt;greater than 50% likely of being realized upon settlement&lt;/span&gt;. As of December 31, 2024 and 2023
the Company has not recorded any unrecognized tax benefits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records interest related to unrecognized tax benefits in interest expense and penalties in general and administrative expenses.
As of December 31, 2024 and 2023, the Company recorded &lt;span id="xdx_90F_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_iI_do_c20241231_zGXutwkTqx21" title="Unrecognized tax benefits, income tax penalties and interest accrued"&gt;&lt;span id="xdx_906_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_iI_do_c20231231_zAtdHnNOJXb" title="Unrecognized tax benefits, income tax penalties and interest accrued"&gt;no&lt;/span&gt;&lt;/span&gt; accrued interest and penalties related to unrecognized tax benefits. The Company
does not expect any significant changes in its tax positions that would warrant recognition of a liability for unrecognized income tax
benefits during the next 12 months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company files U.S. federal and various state income tax returns and is subject to the examination for tax years back to 2021 and 2020
for federal and state purposes, respectively, and its NOL&#x2019;s dating back to inception are subject to adjustment by the taxing authorities
if claimed on future tax filings for which the statute remain open to examination. The Company also files Israeli tax returns and is
subject to examination for tax years back to 2020. The Company is not currently under audit by the Internal Revenue Service or other
similar national, state and local authorities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000782">&lt;p id="xdx_89B_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zTUhivYeNtv9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s provision for income taxes consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_z242BAKEQzPd" style="display: none"&gt;SCHEDULE
OF PROVISION FOR INCOME TAXES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20241231_zLCL4eNfPQE6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230101__20231231_znfb9i2Tirvk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzSdz_zT9WXNRuxvpd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Computed &#x201c;expected&#x201d; tax benefit&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(3,154,290&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(3,238,593&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzSdz_zHBWzLXsEXdj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State taxes, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,768&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,304&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_maITEBzSdz_z8QXT9poXWoe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Non-deductible items&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;230,890&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;61,842&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzSdz_zkmuv7KMfY3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Change in deferred tax asset valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,454,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,509,496&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_maITEBzSdz_zd2Vst94TdV5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;482,045&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;613,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmountReturnToProvisionAdjustments_maITEBzSdz_zyynnugD7Cgi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Return-to-provision adjustments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;41,316&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzSdz_zIGJRcb3CRIg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;621&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;13,918&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzSdz_zFKUFZFpa7C7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,700&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,450&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000784"
      unitRef="USD">-3154290</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000785"
      unitRef="USD">-3238593</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000787"
      unitRef="USD">-11768</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000788"
      unitRef="USD">1304</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000790"
      unitRef="USD">230890</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000791"
      unitRef="USD">61842</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000793"
      unitRef="USD">2454200</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000794"
      unitRef="USD">2509496</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000796"
      unitRef="USD">482045</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000797"
      unitRef="USD">613167</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <INDP:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmountReturnToProvisionAdjustments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000799"
      unitRef="USD">2</INDP:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmountReturnToProvisionAdjustments>
    <INDP:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmountReturnToProvisionAdjustments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000800"
      unitRef="USD">41316</INDP:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmountReturnToProvisionAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000802"
      unitRef="USD">621</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000803"
      unitRef="USD">13918</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000805"
      unitRef="USD">1700</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000806"
      unitRef="USD">2450</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000808">&lt;p id="xdx_89E_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zTZ3FR6D4M28" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s net deferred tax assets were comprised of the following as of December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zgbOpEyrc719" style="display: none"&gt;SCHEDULE
OF NET DEFERRED TAX ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20241231_zSXUmyXbCTaa" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20231231_zPRpDyGVFAnc" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_zWysNROiBnZc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Net operating losses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;53,447,116&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;51,846,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_z8ThOyPpXaTg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Capitalized research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,959,591&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,162,872&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_zF0phi160nWh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;288,756&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;261,052&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_iI_znJ534kLTMp9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;249,495&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;220,923&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsFrequentFlierLiability_iI_zCqjP36GDjka" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,760&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36,761&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsOther_iI_zQs0zjhFqFxi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;616&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;559&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzCTx_maDTALNzH2X_zZEfUKkg0W1c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total gross deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;56,963,334&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;54,528,167&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_iNI_di_maDITLzRZ0_zFirxZXVNsc9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Right-of-use asset&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(17,340&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(36,373&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzRZ0_msDTALNzH2X_zpMKSOQ73S11" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Gross deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(17,340&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(36,373&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzH2X_zkcee1TRsfmf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: Deferred tax asset valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(56,945,994&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(54,491,794&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzH2X_zl5cYOCzlixj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0840"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0841"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000810"
      unitRef="USD">53447116</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000811"
      unitRef="USD">51846000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000813"
      unitRef="USD">2959591</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000814"
      unitRef="USD">2162872</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000816"
      unitRef="USD">288756</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000817"
      unitRef="USD">261052</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000819"
      unitRef="USD">249495</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000820"
      unitRef="USD">220923</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsFrequentFlierLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000822"
      unitRef="USD">17760</us-gaap:DeferredTaxAssetsFrequentFlierLiability>
    <us-gaap:DeferredTaxAssetsFrequentFlierLiability
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000823"
      unitRef="USD">36761</us-gaap:DeferredTaxAssetsFrequentFlierLiability>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000825"
      unitRef="USD">616</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000826"
      unitRef="USD">559</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000828"
      unitRef="USD">56963334</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000829"
      unitRef="USD">54528167</us-gaap:DeferredTaxAssetsGross>
    <INDP:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000831"
      unitRef="USD">17340</INDP:DeferredTaxLiabilitiesRightOfUseAsset>
    <INDP:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000832"
      unitRef="USD">36373</INDP:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000834"
      unitRef="USD">17340</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000835"
      unitRef="USD">36373</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000837"
      unitRef="USD">56945994</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000838"
      unitRef="USD">54491794</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact000843"
      unitRef="USD">2500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2023-01-012023-12-31"
      decimals="-5"
      id="Fact000845"
      unitRef="USD">2500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31_custom_FederalMember"
      decimals="-5"
      id="Fact000847"
      unitRef="USD">35300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31_custom_StateMember"
      decimals="-5"
      id="Fact000849"
      unitRef="USD">7600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31_custom_ExpireInTwoThousandThirtySixMember_custom_FederalMember"
      decimals="-5"
      id="Fact000851"
      unitRef="USD">800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31_custom_IndefinitePeriodMember_custom_FederalMember"
      decimals="-5"
      id="Fact000853"
      unitRef="USD">34400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31_custom_ExpireInTwoThousandThirtyFiveMember_custom_StateMember"
      decimals="-5"
      id="Fact000855"
      unitRef="USD">7600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31_country_IL"
      decimals="-5"
      id="Fact000857"
      unitRef="USD">197900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:IncomeTaxExaminationDescription contextRef="From2024-01-01to2024-12-31" id="Fact000859">greater than 50% likely of being realized upon settlement</us-gaap:IncomeTaxExaminationDescription>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000861"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000863"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000865">&lt;p id="xdx_808_eus-gaap--SegmentReportingDisclosureTextBlock_zNfDbhvssg4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
9: &lt;span id="xdx_822_zeZIHDYvK10g"&gt;SEGMENT INFORMATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating
decision maker in deciding how to allocate resources in assessing performance. The Company operates as a &lt;span id="xdx_901_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20240101__20241231_zOBWekpOhlp9" title="Number of reportable segments::XDX::1"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0867"&gt;single&lt;/span&gt;&lt;/span&gt; reporting segment, focusing
on the development of a novel and patented systemically administered anti-cancer and anti-viral immunotherapy. The Company&#x2019;s chief
operating decision maker (&#x201c;CODM&#x201d;) is the chief executive officer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM assesses
performance for the segment based on operating expenses as reported in the accompanying consolidated statement of operations. The Company
expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances the development of its
product candidates through pre-clinical and clinical trials. In addition, the measure of segment assets is reported on the accompanying
consolidated balance sheet as total assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
such, the CODM uses cash forecast models in deciding how to invest into the segment. Such cash forecast models are reviewed to assess
the entity-wide operating results and performance. Net loss is used to monitor budget versus actual results. Monitoring budgeted versus
actual results is used in assessing performance of the segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z0dognWGcGM3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents reportable segment loss, including significant expenses regularly provided to the CODM, attributable to the
Company&#x2019;s reportable segment for the years ended December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zl3YUgJxanE2"&gt;SCHEDULE
OF REPORTABLE SEGMENT LOSS&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231_zsOxoeSs6ydl" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20231231_zEZZk0RK9w59" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ResearchAndDevelopmentExpense_hus-gaap--IncomeStatementLocationAxis__custom--ExternalResearchAndDevelopmentMember_zepfhC2OeXt" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 10pt"&gt;External research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,355,449&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,683,828&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ResearchAndDevelopmentExpense_hus-gaap--IncomeStatementLocationAxis__custom--InternalPersonnelCostsMember_zVnbDcks6oOk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Internal personnel costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,895,648&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,937,879&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_msNILz3BM_z0uL5JaqY5t9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,251,097&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,621,707&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_msNILz3BM_zffPC4pkaJCc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,114,654&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,756,767&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OtherOperatingIncomeExpenseNet_iN_di_maNILz3BM_zyLSWk6AqGU1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other income, net&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(343,724&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(955,003&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--NetIncomeLoss_iN_di_mtNILz3BM_zbZuKzFYFBB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;15,022,027&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;15,423,471&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zUpo773nd4Bk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000869">&lt;p id="xdx_897_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z0dognWGcGM3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents reportable segment loss, including significant expenses regularly provided to the CODM, attributable to the
Company&#x2019;s reportable segment for the years ended December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zl3YUgJxanE2"&gt;SCHEDULE
OF REPORTABLE SEGMENT LOSS&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231_zsOxoeSs6ydl" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20231231_zEZZk0RK9w59" style="border-bottom: Black 1pt solid; display: none; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ResearchAndDevelopmentExpense_hus-gaap--IncomeStatementLocationAxis__custom--ExternalResearchAndDevelopmentMember_zepfhC2OeXt" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 10pt"&gt;External research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,355,449&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,683,828&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ResearchAndDevelopmentExpense_hus-gaap--IncomeStatementLocationAxis__custom--InternalPersonnelCostsMember_zVnbDcks6oOk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Internal personnel costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,895,648&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,937,879&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_msNILz3BM_z0uL5JaqY5t9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,251,097&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,621,707&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_msNILz3BM_zffPC4pkaJCc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,114,654&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,756,767&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OtherOperatingIncomeExpenseNet_iN_di_maNILz3BM_zyLSWk6AqGU1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other income, net&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(343,724&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(955,003&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--NetIncomeLoss_iN_di_mtNILz3BM_zbZuKzFYFBB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;15,022,027&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;15,423,471&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_ExternalResearchAndDevelopmentMember"
      decimals="0"
      id="Fact000871"
      unitRef="USD">4355449</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_ExternalResearchAndDevelopmentMember"
      decimals="0"
      id="Fact000872"
      unitRef="USD">4683828</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_InternalPersonnelCostsMember"
      decimals="0"
      id="Fact000874"
      unitRef="USD">2895648</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_InternalPersonnelCostsMember"
      decimals="0"
      id="Fact000875"
      unitRef="USD">2937879</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000877"
      unitRef="USD">7251097</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000878"
      unitRef="USD">7621707</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000880"
      unitRef="USD">8114654</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000881"
      unitRef="USD">8756767</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000883"
      unitRef="USD">343724</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000884"
      unitRef="USD">955003</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000886"
      unitRef="USD">-15022027</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000887"
      unitRef="USD">-15423471</us-gaap:NetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000889">&lt;p id="xdx_803_eus-gaap--SubsequentEventsTextBlock_zOMMw51kkpg4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
10: &lt;span id="xdx_82F_zzd3KEJcCJ7a"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluated subsequent events from December 31, 2024, the date of these consolidated financial statements, through March 13, 2024,
which represents the date the consolidated financial statements were issued, for events requiring recognition or disclosure in the consolidated
financial statements for the year ended December 31, 2024. The Company concluded that no events have occurred that would require recognition
or disclosure in the consolidated financial statements, except for the January 2025 Offering that was completed on January 16, 2025,
as described in Note 6(e) and for the SEPA that was entered with Yorkville on February 12, 2025, as described in Note 6(f).&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2024-10-012024-12-31" id="Fact000890">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2024-10-012024-12-31" id="Fact000891">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2024-10-012024-12-31" id="Fact000892">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2024-10-012024-12-31" id="Fact000893">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
